PT	AU	BA	BE	GP	AF	BF	CA	TI	SO	SE	BS	LA	DT	CT	CY	CL	SP	HO	DE	ID	AB	C1	C3	RP	EM	RI	OI	FU	FP	FX	CR	NR	TC	Z9	U1	U2	PU	PI	PA	SN	EI	BN	J9	JI	PD	PY	VL	IS	PN	SU	SI	MA	BP	EP	AR	DI	DL	D2	EA	PG	WC	WE	SC	GA	PM	OA	HC	HP	DA	UT
J	Torgerson, D; Raftery, J				Torgerson, D; Raftery, J			Economics notes - Measuring outcomes in economic evaluations	BMJ-BRITISH MEDICAL JOURNAL			English	Article									Univ York, Ctr Hlth Econ, Natl Primary Care Res & Dev, York YO1 5DD, N Yorkshire, England; Univ Birmingham, Hlth Serv Management Ctr, Birmingham B15 2RT, W Midlands, England	University of York - UK; University of Birmingham	Torgerson, D (corresponding author), Univ York, Ctr Hlth Econ, Natl Primary Care Res & Dev, York YO1 5DD, N Yorkshire, England.	J.P.RAFTERY@bham.ac.uk	Torgerson, David/L-4566-2019	Torgerson, David/0000-0002-1667-4275				EuroQol Group, 1991, HLTH POLICY, V16, P199; GARRATT AM, 1993, BMJ-BRIT MED J, V306, P1440, DOI 10.1136/bmj.306.6890.1440; Palmer S, 1999, BRIT MED J, V318, P1349, DOI 10.1136/bmj.318.7194.1349; ROLAND M, 1983, SPINE, V8, P141, DOI 10.1097/00007632-198303000-00004; Ryan M, 1996, HEALTH ECON, V5, P543, DOI 10.1002/(SICI)1099-1050(199611)5:6<543::AID-HEC230>3.0.CO;2-R; Ryan M, 1995, Qual Health Care, V4, P207, DOI 10.1136/qshc.4.3.207	6	26	26	0	5	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	MAY 22	1999	318	7195					1413	1413		10.1136/bmj.318.7195.1413	http://dx.doi.org/10.1136/bmj.318.7195.1413			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	200DQ	10334758	Green Published			2022-12-28	WOS:000080524700038
J	Keppler, OT; Hinderlich, S; Langner, J; Schwartz-Albiez, R; Reutter, W; Pawlita, M				Keppler, OT; Hinderlich, S; Langner, J; Schwartz-Albiez, R; Reutter, W; Pawlita, M			UDP-GlcNAc 2-epimerase: A regulator of cell surface sialylation	SCIENCE			English	Article							DIFFERENTIATION-DEPENDENT EXPRESSION; ACETYLNEURAMINIC ACID BIOSYNTHESIS; BIFUNCTIONAL ENZYME CATALYZES; FIRST 2 STEPS; SIALIC-ACID; ADHESION MOLECULE; RAT-LIVER; T-CELLS; B-CELLS; 2-EPIMERASE/N-ACETYLMANNOSAMINE KINASE	Modification of cell surface molecules with sialic acid is crucial for their function in many biological processes, including cell adhesion and signal transduction, Uridine diphosphate-N-acetylglucosamine 2-epimerase (UDP-GLcNAc 2-epimerase) is an enzyme that catalyzes an early, rate-limiting step in the sialic acid biosynthetic pathway. UDP-GlcNAc 2-epimerase was found to be a major determinant of cell surface sialylation in human hematopoietic cell Lines and a critical regulator of the function of specific cell surface adhesion molecules.	Deutsch Krebsforschungszentrum, Appl Tumor Virol Program, D-69120 Heidelberg, Germany; Free Univ Berlin, Inst Mol Biol & Biochem, D-14195 Berlin, Germany	Helmholtz Association; German Cancer Research Center (DKFZ); Free University of Berlin	Pawlita, M (corresponding author), Deutsch Krebsforschungszentrum, Appl Tumor Virol Program, Neuenheimer Feld 280, D-69120 Heidelberg, Germany.	M.Pawlita@dkfz-heidelberg.de	Pawlita, Labor/C-9720-2011	Pawlita, Michael/0000-0002-4720-8306				Abe M, 1996, PATHOL INT, V46, P977, DOI 10.1111/j.1440-1827.1996.tb03577.x; AMINOFF D, 1961, BIOCHEM J, V81, P384, DOI 10.1042/bj0810384; BAST BJEG, 1992, J CELL BIOL, V116, P423, DOI 10.1083/jcb.116.2.423; Baum LG, 1996, J BIOL CHEM, V271, P10793, DOI 10.1074/jbc.271.18.10793; Bergmann M, 1998, GLYCOBIOLOGY, V8, P963, DOI 10.1093/glycob/8.10.963; BEVILACQUA MP, 1993, J CLIN INVEST, V91, P379, DOI 10.1172/JCI116210; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Chigorno V, 1996, J BIOL CHEM, V271, P21738, DOI 10.1074/jbc.271.36.21738; CHRETIEN S, 1988, P NATL ACAD SCI USA, V85, P6, DOI 10.1073/pnas.85.1.6; COLL MJ, 1986, FEBS LETT, V208, P418, DOI 10.1016/0014-5793(86)81060-2; COLLARD JG, 1986, CANCER RES, V46, P3521; DallOlio F, 1996, GLYCOCONJUGATE J, V13, P115, DOI 10.1007/BF01049687; ERBE DV, 1993, J CELL BIOL, V120, P1227, DOI 10.1083/jcb.120.5.1227; FORT P, 1985, NUCLEIC ACIDS RES, V13, P1431, DOI 10.1093/nar/13.5.1431; FOXALL C, 1992, J CELL BIOL, V117, P895, DOI 10.1083/jcb.117.4.895; Fritsch M, 1996, J CHROMATOGR A, V727, P223, DOI 10.1016/0021-9673(95)01157-9; GILLESPIE W, 1993, J BIOL CHEM, V268, P3801; Giordanengo V, 1997, EUR J BIOCHEM, V247, P558, DOI 10.1111/j.1432-1033.1997.00558.x; HarduinLepers A, 1995, GLYCOBIOLOGY, V5, P741, DOI 10.1093/glycob/5.8.741; HAUN G, 1993, J VIROL, V67, P7482, DOI 10.1128/JVI.67.12.7482-7492.1993; Hennet T, 1998, P NATL ACAD SCI USA, V95, P4504, DOI 10.1073/pnas.95.8.4504; Hinderlich S, 1997, J BIOL CHEM, V272, P24313, DOI 10.1074/jbc.272.39.24313; Horstkorte R, 1999, EUR J BIOCHEM, V260, P923, DOI 10.1046/j.1432-1327.1999.00253.x; KANEKO Y, 1995, J HISTOCHEM CYTOCHEM, V43, P945, DOI 10.1177/43.9.7642967; Kelm S, 1996, GLYCOCONJUGATE J, V13, P913, DOI 10.1007/BF01053186; Keppler OT, 1999, GLYCOBIOLOGY, V9, P557, DOI 10.1093/glycob/9.6.557; KEPPLER OT, 1992, EUR J IMMUNOL, V22, P2777, DOI 10.1002/eji.1830221104; KEPPLER OT, UNPUB; KIJIMASUDA I, 1988, CANCER RES, V48, P3728; KIKUCHI K, 1971, BIOCHIM BIOPHYS ACTA, V252, P357, DOI 10.1016/0304-4165(71)90017-1; KNIBBS RN, 1993, J BIOL CHEM, V268, P18524; Kniep B, 1996, J BIOCHEM-TOKYO, V119, P456; KORNFELD S, 1964, P NATL ACAD SCI USA, V52, P371, DOI 10.1073/pnas.52.2.371; LAI R, 1994, BRIT J HAEMATOL, V87, P251, DOI 10.1111/j.1365-2141.1994.tb04906.x; LAW CL, 1995, J IMMUNOL, V155, P3368; LOWE JB, 1990, CELL, V63, P475, DOI 10.1016/0092-8674(90)90444-J; LUCKA L, UNPUB; MartinezPomares L, 1996, IMMUNOBIOLOGY, V195, P407, DOI 10.1016/S0171-2985(96)80012-X; Maru I, 1996, J BIOL CHEM, V271, P16294, DOI 10.1074/jbc.271.27.16294; Matic M, 1998, INVEST OPHTH VIS SCI, V39, P905; MENDLA K, 1988, BIOCHEM J, V250, P261, DOI 10.1042/bj2500261; NAKAMORI S, 1993, CANCER RES, V53, P3632; OKAMOTO Y, 1980, BIOCHEM J, V188, P905, DOI 10.1042/bj1880905; PILATTE Y, 1993, GLYCOBIOLOGY, V3, P201, DOI 10.1093/glycob/3.3.201; POWELL LD, 1993, J BIOL CHEM, V268, P7019; POWELL LD, 1987, J IMMUNOL, V139, P262; POWELL LD, 1995, J BIOL CHEM, V270, P14243, DOI 10.1074/jbc.270.24.14243; ROSEN SD, 1994, CURR OPIN CELL BIOL, V6, P663, DOI 10.1016/0955-0674(94)90092-2; SAMMAR M, 1994, INT IMMUNOL, V6, P1027, DOI 10.1093/intimm/6.7.1027; SGROI D, 1993, J BIOL CHEM, V268, P7011; Shanmugam V, 1997, BIOCHEMISTRY-US, V36, P5729, DOI 10.1021/bi961687w; Spivak C. T, 1966, METHOD ENZYMOL, V9, P612; STAMENKOVIC I, 1991, CELL, V66, P1133, DOI 10.1016/0092-8674(91)90036-X; Stasche R, 1997, J BIOL CHEM, V272, P24319, DOI 10.1074/jbc.272.39.24319; Tedder TF, 1997, ANNU REV IMMUNOL, V15, P481, DOI 10.1146/annurev.immunol.15.1.481; VARKI A, 1984, ANAL BIOCHEM, V137, P236, DOI 10.1016/0003-2697(84)90377-4; Varki A, 1997, FASEB J, V11, P248, DOI 10.1096/fasebj.11.4.9068613; Varki A, 1997, J CLIN INVEST, V99, P158, DOI 10.1172/JCI119142; Wagers AJ, 1998, J IMMUNOL, V160, P5122; YEDNOCK TA, 1989, ADV IMMUNOL, V44, P313; YOGEESWARAN G, 1981, SCIENCE, V212, P1514, DOI 10.1126/science.7233237	61	269	287	2	19	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAY 21	1999	284	5418					1372	1376		10.1126/science.284.5418.1372	http://dx.doi.org/10.1126/science.284.5418.1372			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	198NN	10334995				2022-12-28	WOS:000080430600058
J	Devinsky, O				Devinsky, O			Patients with refractory seizures	NEW ENGLAND JOURNAL OF MEDICINE			English	Review							JUVENILE MYOCLONIC EPILEPSY; NONEPILEPTIC SEIZURES; MANAGEMENT; NEUROLOGY; DIAGNOSIS; DRUGS		NYU Med Ctr, Dept Neurol, Comprehens Epilepsy Ctr, New York, NY 10016 USA; St Barnabas Hlth Care Syst, Inst Neurol & Neurosurg, Livingston, NJ USA	New York University	Devinsky, O (corresponding author), NYU Med Ctr, Dept Neurol, Comprehens Epilepsy Ctr, 560 1st Ave Rivergate,4th Fl, New York, NY 10016 USA.	od4@is4.nyu.edu		Devinsky, Orrin/0000-0003-0044-4632				ALPER K, 1993, NEUROLOGY, V43, P1950, DOI 10.1212/WNL.43.10.1950; [Anonymous], 1981, Epilepsia, V22, P489; [Anonymous], 1989, EPILEPSIA, V30, P389, DOI 10.1111/j.1528-1157.1989.tb05316.x; Barry E, 1998, EPILEPSIA, V39, P427, DOI 10.1111/j.1528-1157.1998.tb01395.x; BAZIL CW, 1994, EPILEPSIA, V35, P768, DOI 10.1111/j.1528-1157.1994.tb02509.x; Buchanan N, 1996, SEIZURE, V5, P149; CALLAGHAN N, 1988, NEW ENGL J MED, V318, P942, DOI 10.1056/NEJM198804143181502; Callaghan N, 1988, NEW ENGL J MED, V319, P188; CASCINO GD, 1990, MAYO CLIN PROC, V65, P1578, DOI 10.1016/S0025-6196(12)62193-4; CASCINO GD, 1998, EPILEPSY COMPREHENSI, V1, P937; Cramer J. A., 1991, PATIENT COMPLIANCE M, P123; CRAMER JA, 1995, NEUROLOGY, V45, pS25; DEVINSKY O, 1995, ANN NEUROL, V37, P141, DOI 10.1002/ana.410370202; DEVINSKY O, 1994, CURRENT DIAGNOSIS NE, P1; Dichter MA, 1996, NEW ENGL J MED, V334, P1583, DOI 10.1056/NEJM199606133342407; Ebersole JS, 1996, EPILEPSIA, V37, P386, DOI 10.1111/j.1528-1157.1996.tb00577.x; Engel J, 1996, NEW ENGL J MED, V334, P647, DOI 10.1056/NEJM199603073341008; FERRENDELLI JA, 1995, NEUROLOGY, V45, pS12; Fisher RS, 1997, NEUROLOGY, V49, P293, DOI 10.1212/WNL.49.1.293; FISHER RS, 1994, IMITATORS EPILEPSY; FRENCH JA, 1993, NON-EPILEPTIC SEIZURES, P101; GEORGE R, 1995, NEUROLOGY, V45, P224, DOI 10.1212/wnl.45.2.224; Hauser W, 1990, EPILEPSY FREQUENCY C; Herzog AG, 1997, EPILEPSIA, V38, P1082, DOI 10.1111/j.1528-1157.1997.tb01197.x; ISOJARVI JIT, 1993, NEW ENGL J MED, V329, P1383, DOI 10.1056/NEJM199311043291904; Kochiadakis GE, 1997, AM HEART J, V134, P459, DOI 10.1016/S0002-8703(97)70082-6; Langtry HD, 1997, DRUGS, V54, P752, DOI 10.2165/00003495-199754050-00009; Luciano D., 1996, Epilepsia, V37, P29; Macdonald R L, 1996, Epilepsy Res Suppl, V11, P79; Mattson R H, 1991, Adv Neurol, V55, P453; MATTSON RH, 1985, NEW ENGL J MED, V313, P145, DOI 10.1056/NEJM198507183130303; Morrell MJ, 1996, EPILEPSIA, V37, pS34, DOI 10.1111/j.1528-1157.1996.tb06037.x; MORRELL MJ, 1993, NEUROL CLIN, V11, P737, DOI 10.1016/S0733-8619(18)30121-X; Motte J, 1997, NEW ENGL J MED, V337, P1807, DOI 10.1056/NEJM199712183372504; MOTTE J, 1998, NEW ENGL J MED, V339, P851; OTTMAN R, 1994, NEUROLOGY, V44, P2105, DOI 10.1212/WNL.44.11.2105; RAMSAY RE, 1993, NON-EPILEPTIC SEIZURES, P47; RESOR SR, 1990, NEUROLOGY, V40, P1677, DOI 10.1212/WNL.40.11.1677; REUTENS DC, 1995, NEUROLOGY, V45, P1469, DOI 10.1212/WNL.45.8.1469; Rowan AJ, 1993, NONEPILEPTIC SEIZURE; Sackellares JC, 1996, PSYCHOL DISTURBANCES; SATO S, 1982, NEUROLOGY, V32, P157, DOI 10.1212/WNL.32.2.157; SHARPE C, 1995, MED J AUSTRALIA, V162, P133, DOI 10.5694/j.1326-5377.1995.tb138476.x; VINING EPG, 1997, EPILEPSY COMPREHENSI, V2, P1339; 1990, EPILEPSIA S1, V31, pS1	45	172	180	0	1	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	MAY 20	1999	340	20					1565	1570		10.1056/NEJM199905203402008	http://dx.doi.org/10.1056/NEJM199905203402008			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	197HG	10332020				2022-12-28	WOS:000080358900008
J	Magee, LA; Ornstein, MP; von Dadelszen, P				Magee, LA; Ornstein, MP; von Dadelszen, P			Management of hypertension in pregnancy	BMJ-BRITISH MEDICAL JOURNAL			English	Review							RANDOMIZED CONTROLLED TRIAL; SEVERE PREECLAMPSIA; EXPECTANT MANAGEMENT; WEEKS GESTATION; METHYLDOPA; DIHYDRALAZINE; ISRADIPINE; LABETALOL; HYDRALAZINE; NIFEDIPINE		Univ Toronto, Dept Med, Toronto, ON, Canada; Univ Toronto, Dept Obstet & Gynaecol, Toronto, ON, Canada	University of Toronto; University of Toronto	Magee, LA (corresponding author), Mt Sinai Hosp, Dept Med, Toronto, ON M5G 1X5, Canada.	laura.magee@utoronto.ca	von Dadelszen, Peter/AAP-7480-2021	von Dadelszen, Peter/0000-0003-4136-3070				ALES K, 1990, AM J OBSTET GYNECOL, V162, P288, DOI 10.1016/0002-9378(90)90867-7; [Anonymous], 1990, AM J OBSTET GYNECOL, V163, P1691; ARIAS F, 1979, OBSTET GYNECOL, V53, P489; BARTON JR, 1990, AM J OBSTET GYNECOL, V162, P788, DOI 10.1016/0002-9378(90)91011-Z; BHORAT IE, 1993, AM J OBSTET GYNECOL, V168, P1292, DOI 10.1016/0002-9378(93)90383-T; BOTTKANNER G, 1992, CLIN EXP HYPERTENS B, V11, P207, DOI 10.3109/10641959209031044; Briggs GG., 2008, DRUGS PREGNANCY LACT, P431; Brown MA, 1997, MED J AUSTRALIA, V166, P640, DOI 10.5694/j.1326-5377.1997.tb123300.x; BUTTERS L, 1990, BMJ-BRIT MED J, V301, P587, DOI 10.1136/bmj.301.6752.587; Calder A, 1982, INT C SERIES, V591, P148; COCKBURN J, 1982, LANCET, V1, P647; COLLINS R, 1994, COCHRANE LIB; CROWTHER CA, 1993, COCHRANE LIB; *DEP HLTH, 1991, CONF ENQ MAT DEATH U; DULEY L, 1993, COCHRANE LIB; ELQARMALAWI AM, 1995, INT J GYNECOL OBSTET, V49, P125, DOI 10.1016/0020-7292(95)02351-C; FIDLER J, 1982, BRIT J OBSTET GYNAEC, V89, P1031; GIANNINA G, 1997, J SOC OBSTET GYNAECO, V19, P1249; GRIFFIS KR, 1989, AM J PERINAT, V6, P437, DOI 10.1055/s-2007-999634; Gulmezoglu AM, 1997, BRIT J OBSTET GYNAEC, V104, P689, DOI 10.1111/j.1471-0528.1997.tb11979.x; HJERTBERG R, 1993, J PERINAT MED, V21, P69, DOI 10.1515/jpme.1993.21.1.69; HORVATH JS, 1985, OBSTET GYNECOL, V66, P634; Howarth GR, 1997, HYPERTENS PREGNANCY, V16, P213, DOI 10.3109/10641959709031638; Jegasothy R, 1996, J Obstet Gynaecol Res, V22, P21; LARDOUX H, 1988, ARCH MAL COEUR VAISS, V81, P137; MARLETTINI MG, 1990, CURR THER RES CLIN E, V48, P684; MATHEWS DD, 1982, BRIT J OBSTET GYNAEC, V89, P128, DOI 10.1111/j.1471-0528.1982.tb04678.x; MENZIES DN, 1964, BMJ-BRIT MED J, V1, P739, DOI 10.1136/bmj.1.5385.739; Montan S, 1996, J PERINAT MED, V24, P177, DOI 10.1515/jpme.1996.24.2.177; MOODLEY J, 1992, BRIT J OBSTET GYNAEC, V99, P727, DOI 10.1111/j.1471-0528.1992.tb13872.x; ODENDAAL HJ, 1990, OBSTET GYNECOL, V76, P1070; OLAH KS, 1993, EUR J OBSTET GYN R B, V51, P175, DOI 10.1016/0028-2243(93)90032-8; Oumachigui A, 1992, Indian Heart J, V44, P39; PARAN E, 1995, INT J CLIN PHARM TH, V33, P119; RAMANATHAN J, 1988, AM J OBSTET GYNECOL, V159, P650, DOI 10.1016/S0002-9378(88)80027-9; Rey E, 1997, CAN MED ASSOC J, V157, P1245; REYNOLDS B, 1984, ARCH DIS CHILD, V59, P1061, DOI 10.1136/adc.59.11.1061; ROTHBERG AD, 1991, PEDIAT REV COMMUNICA, V6, P13; Sibai BM, 1996, NEW ENGL J MED, V335, P257, DOI 10.1056/NEJM199607253350407; SIBAI BM, 1994, AM J OBSTET GYNECOL, V171, P818, DOI 10.1016/0002-9378(94)90104-X; SOMERS PJ, 1989, BIOFEEDBACK SELF-REG, V14, P309, DOI 10.1007/BF00999122; Steyn DW, 1997, LANCET, V350, P1267; TUFFNELL DJ, 1992, LANCET, V339, P224, DOI 10.1016/0140-6736(92)90017-W; VOTO LS, 1987, J CARDIOVASC PHARM, V10, pS101, DOI 10.1097/00005344-198700103-00025; WALLACE DH, 1995, OBSTET GYNECOL, V86, P193, DOI 10.1016/0029-7844(95)00139-I; WALTERS BNJ, 1986, CLIN SCI, V71, P589, DOI 10.1042/cs0710589; WIDESWENSSON D, 1993, AM J OBSTET GYNECOL, V169, P1581, DOI 10.1016/0002-9378(93)90440-T; WIDESWENSSON DH, 1995, AM J OBSTET GYNECOL, V173, P872, DOI 10.1016/0002-9378(95)90357-7	48	168	173	0	8	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	MAY 15	1999	318	7194					1332	1336		10.1136/bmj.318.7194.1332	http://dx.doi.org/10.1136/bmj.318.7194.1332			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	198HR	10323823	Green Published, Green Accepted			2022-12-28	WOS:000080418400033
J	DeLucia, EH; Hamilton, JG; Naidu, SL; Thomas, RB; Andrews, JA; Finzi, AC; Lavine, M; Matamala, R; Mohan, JE; Hendrey, GR; Schlesinger, WH				DeLucia, EH; Hamilton, JG; Naidu, SL; Thomas, RB; Andrews, JA; Finzi, AC; Lavine, M; Matamala, R; Mohan, JE; Hendrey, GR; Schlesinger, WH			Net primary production of a forest ecosystem with experimental CO2 enrichment	SCIENCE			English	Article							RISING ATMOSPHERIC CO2; LOBLOLLY-PINE; ELEVATED CO2; GROWTH TRENDS; UNITED-STATES; TREE GROWTH; SODA-LIME; RESPONSES; BIOMASS; CLIMATE	The concentration of atmospheric carbon dioxide was increased by 200 microliters per Liter in a forest plantation, where competition between organisms, resource Limitations, and environmental stresses may modulate biotic responses. After 2 years the growth rate of the dominant pine trees increased by about 26 percent relative to trees under ambient conditions. Carbon dioxide enrichment also increased Litterfall and fine-root increment. These changes increased the total net primary production by 25 percent. Such an increase in forest net primary production globally would fix about 50 percent of the anthropogenic carbon dioxide projected to be released into the atmosphere in the year 2050. The response of this young, rapidly growing forest to carbon dioxide may represent the upper Limit for forest carbon sequestration.	Univ Illinois, Dept Plant Biol, Urbana, IL 61801 USA; W Virginia Univ, Dept Biol, Morgantown, WV 26506 USA; Duke Univ, Inst Stat & Decis Sci, Durham, NC 27708 USA; Brookhaven Natl Lab, Div Biosyst, Upton, NY 11973 USA	University of Illinois System; University of Illinois Urbana-Champaign; West Virginia University; Duke University; United States Department of Energy (DOE); Brookhaven National Laboratory	DeLucia, EH (corresponding author), Univ Illinois, Dept Plant Biol, Urbana, IL 61801 USA.	delucia@uiuc.edu	Finzi, Adrien/A-7017-2016	Finzi, Adrien/0000-0003-2220-4533; Mohan, Jacqueline/0000-0002-6697-6204				BAZZAZ FA, 1990, ANNU REV ECOL SYST, V21, P167, DOI 10.1146/annurev.es.21.110190.001123; COMINS HN, 1993, ECOL APPL, V3, P666, DOI 10.2307/1942099; Crawley M.J., 1983, Studies in Ecology, V10, P1; Curtis PS, 1998, OECOLOGIA, V113, P299, DOI 10.1007/s004420050381; DeAngelis D. L., 1981, Dynamic properties of forest ecosystems., P567; Drake BG, 1997, ANNU REV PLANT PHYS, V48, P609, DOI 10.1146/annurev.arplant.48.1.609; EDWARDS NT, 1982, PEDOBIOLOGIA, V23, P321; GRAUMLICH LJ, 1991, ECOLOGY, V72, P1, DOI 10.2307/1938895; Grogan P, 1998, ECOLOGY, V79, P1467, DOI 10.1890/0012-9658(1998)079[1467:CFMUSL]2.0.CO;2; GUNDERSON CA, 1994, PHOTOSYNTH RES, V39, P369, DOI 10.1007/BF00014592; Hall Ralph C., 1944, JOUR FOREST, V42, P742; Hattenschwiler S, 1997, GLOB CHANGE BIOL, V3, P463, DOI 10.1046/j.1365-2486.1997.00105.x; He Y, 1996, T ASAE, V39, P1551, DOI 10.13031/2013.27650; Hendrey GR, 1999, GLOBAL CHANGE BIOL, V5, P293, DOI 10.1046/j.1365-2486.1999.00228.x; Idso SB, 1999, GLOBAL CHANGE BIOL, V5, P493, DOI 10.1046/j.1365-2486.1999.00240.x; INNES JL, 1991, HOLOCENE, V1, P168, DOI DOI 10.1177/095968369100100210; KEELAND BD, 1993, CAN J FOREST RES, V23, P2454, DOI 10.1139/x93-304; LUXMOORE RJ, 1993, WATER AIR SOIL POLL, V70, P309, DOI 10.1007/BF01105004; McLeod AR, 1999, ADV ECOL RES, V28, P1, DOI 10.1016/S0065-2504(08)60028-8; McNulty SG, 1996, FOREST ECOL MANAG, V86, P241, DOI 10.1016/S0378-1127(96)03744-9; MELILLO JM, 1993, NATURE, V363, P234, DOI 10.1038/363234a0; MONK CD, 1970, OIKOS, V21, P138, DOI 10.2307/3543848; Naidu SL, 1998, CAN J FOREST RES, V28, P1116, DOI 10.1139/cjfr-28-8-1116; NORBY RJ, 1992, NATURE, V357, P322, DOI 10.1038/357322a0; Pan YD, 1998, OECOLOGIA, V114, P389, DOI 10.1007/s004420050462; PEET RK, 1987, BIOSCIENCE, V37, P586, DOI 10.2307/1310669; Persson H., 1979, Vegetatio, V41, P101, DOI 10.1007/BF00121422; SANTANTONIO D, 1987, CAN J FOREST RES, V17, P900, DOI 10.1139/x87-141; Schlesinger WH., 1997, BIOGEOCHEMISTRY; SHARKEY TD, 1985, BOT REV, V51, P507; STRAIN BR, 1994, WATER AIR SOIL POLL, V64, P45; Tissue DT, 1997, PLANT CELL ENVIRON, V20, P1123, DOI 10.1046/j.1365-3040.1997.d01-140.x; VANDEUSEN PC, 1992, CAN J FOREST RES, V22, P660, DOI 10.1139/x92-088; Vogt KA, 1998, PLANT SOIL, V200, P71, DOI 10.1023/A:1004313515294; Whittaker RH., 1975, PRIMARY PRODUCTIVITY, P55, DOI 10.1007/978-3-642-80913-2_4; [No title captured]; [No title captured]	37	367	410	9	118	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	MAY 14	1999	284	5417					1177	1179		10.1126/science.284.5417.1177	http://dx.doi.org/10.1126/science.284.5417.1177			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	197HJ	10325230				2022-12-28	WOS:000080359100040
J	Sookhai, S; Redmond, HP; Deasy, JM				Sookhai, S; Redmond, HP; Deasy, JM			Impervious wound-edge protector to reduce postoperative wound infection: a randomised, controlled trial	LANCET			English	Article									Royal Coll Surg Ireland, Beaumont Hosp, Dept Surg, Dublin 2, Ireland; Natl Univ Ireland Univ Coll Cork, Cork Univ Hosp, Cork, Ireland	Royal College of Surgeons - Ireland; University College Cork	Redmond, HP (corresponding author), Royal Coll Surg Ireland, Beaumont Hosp, Dept Surg, Dublin 2, Ireland.							Davey PG, 1998, NEW HORIZ-SCI PRACT, V6, pS64; MEAKINS JL, 1989, AM COLLEGE SURG CARE, V2, P8; NYSTROM PO, 1984, DIS COLON RECTUM, V27, P451, DOI 10.1007/BF02555535; OLSON MM, 1990, ARCH SURG-CHICAGO, V125, P794; Zoutman D, 1998, INFECT CONT HOSP EP, V19, P254	5	45	47	0	1	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	MAY 8	1999	353	9164					1585	1585		10.1016/S0140-6736(99)00950-2	http://dx.doi.org/10.1016/S0140-6736(99)00950-2			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	195XW	10334259				2022-12-28	WOS:000080278300016
J	Heithoff, DM; Sinsheimer, RL; Low, DA; Mahan, MJ				Heithoff, DM; Sinsheimer, RL; Low, DA; Mahan, MJ			An essential role for DNA adenine methylation in bacterial virulence	SCIENCE			English	Article							COMPLETE GENOME SEQUENCE; ESCHERICHIA-COLI; SALMONELLA VIRULENCE; PHASE VARIATION; GENES; INFECTION; PATTERNS; PYELONEPHRITIS; EXPRESSION	Salmonella typhimurium lacking DNA adenine methylase (Dam) were fully proficient in colonization of mucosal sites but showed severe defects in colonization of deeper tissue sites. These Dam(-) mutants were totally avirulent and were effective as live vaccines against murine typhoid fever. Dam regulated the expression of at least 20 genes known to be induced during infection; a subset of these genes are among those activated by the PhoP global virulence regulator. PhoP, in turn, affected Dam methylation at specific genomic sites, as Evidenced by alterations in DNA methylation patterns. Dam inhibitors are likely to have broad antimicrobial action, and Dam- derivatives of these pathogens may serve as Live attenuated vaccines.	Univ Calif Santa Barbara, Dept Mol Cellular & Dev Biol, Santa Barbara, CA 93106 USA	University of California System; University of California Santa Barbara	Mahan, MJ (corresponding author), Univ Calif Santa Barbara, Dept Mol Cellular & Dev Biol, Santa Barbara, CA 93106 USA.				NIAID NIH HHS [AI36373, AI23348] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R29AI036373, R21AI023348, R01AI023348] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BANDYOPADHYAY R, 1994, GENE, V140, P67, DOI 10.1016/0378-1119(94)90732-3; Blattner FR, 1997, SCIENCE, V277, P1453, DOI 10.1126/science.277.5331.1453; BRAATEN BA, 1994, CELL, V76, P577, DOI 10.1016/0092-8674(94)90120-1; Conner CP, 1998, P NATL ACAD SCI USA, V95, P4641, DOI 10.1073/pnas.95.8.4641; EARTHART C, 1996, ESCHERICHIA COLI SAL, P1075; FLEISCHMANN RD, 1995, SCIENCE, V269, P496, DOI 10.1126/science.7542800; Fraser CM, 1998, SCIENCE, V281, P375, DOI 10.1126/science.281.5375.375; GROISMAN EA, 1995, 2 COMPONENT SIGNAL T, P319, DOI DOI 10.1128/9781555818319; GULIG PA, 1993, MOL MICROBIOL, V7, P825, DOI 10.1111/j.1365-2958.1993.tb01172.x; HALE WB, 1994, J BACTERIOL, V176, P3438, DOI 10.1128/jb.176.11.3438-3441.1994; Heithoff DM, 1999, J BACTERIOL, V181, P799, DOI 10.1128/JB.181.3.799-807.1999; Heithoff DM, 1997, P NATL ACAD SCI USA, V94, P934, DOI 10.1073/pnas.94.3.934; HEITHOFF DM, UNPUB; Julio SM, 1998, MOL GEN GENET, V258, P178, DOI 10.1007/s004380050721; LeClerc JE, 1996, SCIENCE, V274, P1208, DOI 10.1126/science.274.5290.1208; MAHAN MJ, 1995, P NATL ACAD SCI USA, V92, P669, DOI 10.1073/pnas.92.3.669; MAHAN MJ, 1993, SCIENCE, V259, P686, DOI 10.1126/science.8430319; Marinus M.G., 1996, E COLI SALMONELLA CE, P782; MARINUS MG, 1984, GENE, V28, P123, DOI 10.1016/0378-1119(84)90095-7; NEWMAN EB, 1996, CELLULAR MOL BIOL, P1513; ROBERTS JA, 1985, J UROLOGY, V133, P1068, DOI 10.1016/S0022-5347(17)49382-7; ROLAND KL, 1993, J BACTERIOL, V175, P4154, DOI 10.1128/JB.175.13.4154-4164.1993; SLAUCH JM, 1991, J BACTERIOL, V173, P4039, DOI 10.1128/jb.173.13.4039-4048.1991; SMITH CL, 1987, METHOD ENZYMOL, V155, P449; Tavazoie S, 1998, NAT BIOTECHNOL, V16, P566, DOI 10.1038/nbt0698-566; van der Woude M, 1998, J BACTERIOL, V180, P5913, DOI 10.1128/JB.180.22.5913-5920.1998; vanderWoude M, 1996, TRENDS MICROBIOL, V4, P5, DOI 10.1016/0966-842X(96)81498-3; Vescovi EG, 1996, CELL, V84, P165, DOI 10.1016/S0092-8674(00)81003-X	28	385	403	0	56	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAY 7	1999	284	5416					967	970		10.1126/science.284.5416.967	http://dx.doi.org/10.1126/science.284.5416.967			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	194MU	10320378				2022-12-28	WOS:000080198800047
J	Rueter, SM; Dawson, TR; Emeson, RB				Rueter, SM; Dawson, TR; Emeson, RB			Regulation of alternative splicing by RNA editing	NATURE			English	Article							PRE-MESSENGER-RNA; ADENOSINE-DEAMINASE; SEQUENCES; CLONING; INOSINE; ENZYME; FORMS	The enzyme ADAR2 is a double-stranded RNA-specific adenosine deaminase which is involved in the editing of mammalian messenger RNAs by the site-specific conversion of adenosine to inosine(1-3) Here we identify several rat ADAR2 mRNAs produced as a result of two distinct alternative splicing events. One such splicing event uses a proximal 3' acceptor site, adding 47 nucleotides to the ADAR2 coding region, changing the predicted reading frame of the mature ADAR2 transcript. Nucleotide-sequence analysis of ADAR2 genomic DNA revealed the presence of adenosine-adenosine (AA) and adenosine-guanosine (AG) dinucleotides at these proximal and distal alternative 3' acceptor sites, respectively. Use of the proximal 3' acceptor depends upon the ability of ADAR2 to edit its own pre-mRNA, converting the intronic AA to an adenosine-inosine (Al) dinucleotide which effectively mimics the highly conserved AG sequence normally found at 3' splice junctions. Our observations indicate that RNA editing can serve as a mechanism for regulating alternative splicing and they suggest a novel strategy by which ADAR2 can modulate its own expression.	Vanderbilt Univ, Sch Med, Dept Pharmacol, Nashville, TN 37232 USA	Vanderbilt University	Emeson, RB (corresponding author), Vanderbilt Univ, Sch Med, Dept Pharmacol, 221 Kirkland Hall, Nashville, TN 37232 USA.		Dawson, Toni/P-8599-2016					Ausubel FM, 1988, MOL REPROD DEV; Bass BL, 1997, RNA, V3, P947; Burns CM, 1997, NATURE, V387, P303, DOI 10.1038/387303a0; CALLIGARIS R, 1995, P NATL ACAD SCI USA, V92, P11598, DOI 10.1073/pnas.92.25.11598; Deirdre A, 1995, EMBO J, V14, P3236; EMESON RB, 1989, NATURE, V341, P76, DOI 10.1038/341076a0; Farabaugh PJ, 1996, MICROBIOL REV, V60, P103, DOI 10.1128/MMBR.60.1.103-134.1996; Gerber A, 1997, RNA, V3, P453; JACKSON IJ, 1991, NUCLEIC ACIDS RES, V19, P3795; KIM U, 1994, P NATL ACAD SCI USA, V91, P11457, DOI 10.1073/pnas.91.24.11457; KOZAK M, 1991, J CELL BIOL, V115, P887, DOI 10.1083/jcb.115.4.887; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; Lai F, 1997, MOL CELL BIOL, V17, P2413, DOI 10.1128/MCB.17.5.2413; LAI F, 1995, J BIOL CHEM, V270, P17096; Maas S, 1996, J BIOL CHEM, V271, P12221, DOI 10.1074/jbc.271.21.12221; Melcher T, 1996, J BIOL CHEM, V271, P31795, DOI 10.1074/jbc.271.50.31795; Melcher T, 1996, NATURE, V379, P460, DOI 10.1038/379460a0; MOUNT SM, 1982, NUCLEIC ACIDS RES, V10, P459, DOI 10.1093/nar/10.2.459; OCONNELL MA, 1995, MOL CELL BIOL, V15, P1389; OConnell MA, 1997, J BIOL CHEM, V272, P473; Rechsteiner M, 1996, TRENDS BIOCHEM SCI, V21, P267, DOI 10.1016/S0968-0004(96)10031-1; REED R, 1989, GENE DEV, V3, P2113, DOI 10.1101/gad.3.12b.2113; Rueter S.M., 1998, MODIFICATION EDITING, P343; RUETER SM, 1995, SCIENCE, V267, P1491, DOI 10.1126/science.7878468; SCHREIBER E, 1989, NUCLEIC ACIDS RES, V17, P6419, DOI 10.1093/nar/17.15.6419; Tarn WY, 1996, BIOCHIMIE, V78, P1057, DOI 10.1016/S0300-9084(97)86730-2; Zuker M, 1994, Methods Mol Biol, V25, P267	27	476	499	3	31	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	MAY 6	1999	399	6731					75	80		10.1038/19992	http://dx.doi.org/10.1038/19992			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	194BK	10331393				2022-12-28	WOS:000080172100058
J	Schultz, SK; Andreasen, NC				Schultz, SK; Andreasen, NC			Schizophrenia	LANCET			English	Article							GRAY-MATTER VOLUME; OBSTETRIC COMPLICATIONS; METAANALYSIS; SYMPTOMS; TRIAL; HALLUCINATIONS; TRANSMISSION; HALOPERIDOL; DIAGNOSIS; PSYCHOSIS	Schizophrenia is among the most severe and debilitating of psychiatric disorders. Diagnosis is currently by criterion-based systems, including positive leg, hallucinations and delusions) acid negative leg, avolition and alogia) symptoms. The importance of negative symptoms in the course and outcome of the illness is increasingly being studied. Current research seeks to detect causal mechanisms in schizophrenia through studies of neural connectivity and function, as well as models of genetic transmission, such as polygenic models of inheritance in genetic research. Potential genes have been identified that may confer vulnerability to the illness, perhaps in conjunction with environmental factors. Neuroimaging research with magnetic resonance imaging and positron emission tomography has investigated differences in volumes and functional dysregulation in specific neural subregions. Areas studied include the frontal and temporal cortex, the hippocampus, the thalamus, and the cerebellum. Despite these advances, treatment of symptoms and psychosocial and cognitive impairments remains only partially successful for many patients.	Univ Iowa, Dept Psychiat, Mental Hlth Clin Res Ctr, Iowa City, IA 52242 USA	University of Iowa	Andreasen, NC (corresponding author), Univ Iowa, Dept Psychiat, Mental Hlth Clin Res Ctr, 2911-JPP,200 Hawkins Dr, Iowa City, IA 52242 USA.	susan-schultz@uiowa.edu	Ojopi, Elida Benquique/A-6773-2012; AbrahÃo, Ana AmÃ©lia Carraro/V-9843-2019; Gattaz, Wagner F/C-4456-2012; Barlati, Stefano/M-2992-2017; Fitzgerald, Paul B/A-1225-2008; Frodl, Thomas/D-8118-2012; McIntosh, Andrew M/B-9379-2008; Schultz, Susan K./M-3516-2019; Frodl, Thomas Stefan/GQZ-9107-2022; van Os, Jim/I-9496-2012; Murray, Robin M/F-8658-2012; Vita, Antonio/K-4345-2018; Peer, Jason/N-7177-2019; Cannon, Mary/D-8227-2012	Ojopi, Elida Benquique/0000-0001-5824-5199; Barlati, Stefano/0000-0002-1784-3915; Fitzgerald, Paul B/0000-0003-4217-8096; Frodl, Thomas/0000-0002-8113-6959; McIntosh, Andrew M/0000-0002-0198-4588; Frodl, Thomas Stefan/0000-0002-8113-6959; van Os, Jim/0000-0002-7245-1586; Murray, Robin M/0000-0003-0829-0519; Cannon, Mary/0000-0002-0910-299X; , Susan/0000-0001-5846-8288				Abi-Dargham A, 1998, AM J PSYCHIAT, V155, P761; American Psychiatric Association, 2000, DSM 4 DIAGN STAT MAN, V4th ed., DOI DOI 10.1001/JAMA.1994.03520100096; Andreasen NC, 1997, SCIENCE, V275, P1586, DOI 10.1126/science.275.5306.1586; Arnold SE, 1998, ARCH GEN PSYCHIAT, V55, P225, DOI 10.1001/archpsyc.55.3.225; Arnold SE, 1996, ACTA NEUROPATHOL, V92, P217, DOI 10.1007/s004010050512; Beasley CM, 1996, NEUROPSYCHOPHARMACOL, V14, P111, DOI 10.1016/0893-133X(95)00069-P; Buchanan RW, 1998, AM J PSYCHIAT, V155, P751; Buchanan RW, 1996, INT CLIN PSYCHOPHARM, V11, P3, DOI 10.1097/00004850-199605002-00002; BUCHSBAUM MS, 1992, ARCH GEN PSYCHIAT, V49, P935; Buchsbaum MS, 1996, AM J PSYCHIAT, V153, P191; Davis JM, 1996, PSYCHIAT ANN, V26, P78, DOI 10.3928/0048-5713-19960201-08; Deicken RF, 1998, BIOL PSYCHIAT, V43, p25S, DOI 10.1016/S0006-3223(98)90530-3; DOLAN RJ, 1995, NATURE, V378, P180, DOI 10.1038/378180a0; Drury V, 1996, BRIT J PSYCHIAT, V169, P593, DOI 10.1192/bjp.169.5.593; Earnst KS, 1997, CLIN PSYCHOL REV, V17, P167, DOI 10.1016/S0272-7358(96)00052-9; Essock SM, 1996, PSYCHOPHARMACOL BULL, V32, P683; Falkai P, 1996, INT CLIN PSYCHOPHARM, V11, P13, DOI 10.1097/00004850-199605002-00003; Flaum M, 1996, ANN MED, V28, P525, DOI 10.3109/07853899608999116; Fleischhacker WW, 1997, DRUGS, V53, P915, DOI 10.2165/00003495-199753060-00002; FRANGOU S, 1996, BR MED B, V3, P587; Freedman R, 1998, BIOL PSYCHIAT, V43, p1S, DOI 10.1016/S0006-3223(98)00102-4; Geddes JR, 1995, BRIT J PSYCHIAT, V167, P786, DOI 10.1192/bjp.167.6.786; Green MF, 1996, AM J PSYCHIAT, V153, P321; GUR RC, 1995, LANCET, V345, P1383, DOI 10.1016/S0140-6736(95)92591-0; Hogarty GE, 1997, AM J PSYCHIAT, V154, P1504, DOI 10.1176/ajp.154.11.1504; Hull JW, 1997, SCHIZOPHR RES, V24, P17, DOI 10.1016/S0920-9964(97)82046-4; Jeste DV, 1996, J CLIN PSYCHIAT, V57, P39; KANE J, 1988, ARCH GEN PSYCHIAT, V45, P789; Kindermann SS, 1997, SCHIZOPHR RES, V27, P143, DOI 10.1016/S0920-9964(97)00063-7; Knapp M, 1997, BRIT J PSYCHIAT, V171, P509, DOI 10.1192/bjp.171.6.509; KOPAIA LC, 1997, INT CLIN PSYCHOP S11, V4, pS11; Lawrie SM, 1998, BRIT J PSYCHIAT, V172, P110, DOI 10.1192/bjp.172.2.110; Lehman AF, 1998, SCHIZOPHRENIA BULL, V24, P1; Levinson DF, 1998, AM J PSYCHIAT, V155, P741; Lim KO, 1998, BIOL PSYCHIAT, V43, p11S, DOI 10.1016/S0006-3223(98)90485-1; Lim KO, 1996, AM J PSYCHIAT, V153, P1548; MALLA AK, 1995, CAN J PSYCHIAT, V40, pS55; MCGUFFIN P, 1995, LANCET, V346, P678, DOI 10.1016/S0140-6736(95)92285-7; McGuire PK, 1996, BRIT J PSYCHIAT, V169, P148, DOI 10.1192/bjp.169.2.148; Meats P, 1997, Int J Psychiatry Clin Pract, V1, P231, DOI 10.3109/13651509709024734; Moldin SO, 1997, SCHIZOPHRENIA BULL, V23, P547, DOI 10.1093/schbul/23.4.547; Mowry BJ, 1997, AUST NZ J PSYCHIAT, V31, P704, DOI 10.3109/00048679709062684; ODonovan MC, 1996, ANN MED, V28, P541, DOI 10.3109/07853899608999118; PEUSKENS J, 1996, EUR NEUROPSYCHOPHA S, V2, pS7; Portin P, 1997, ACTA PSYCHIAT SCAND, V95, P73, DOI 10.1111/j.1600-0447.1997.tb00377.x; Rosenheck R, 1997, NEW ENGL J MED, V337, P809, DOI 10.1056/NEJM199709183371202; Salit SA, 1998, NEW ENGL J MED, V338, P1734, DOI 10.1056/NEJM199806113382406; SCHLAEPFER TE, 1994, AM J PSYCHIAT, V151, P842; Schooler NR, 1997, SCHIZOPHR RES, V27, P249, DOI 10.1016/S0920-9964(97)00089-3; SHENTON ME, 1997, BRAIN IMAGING CLIN P; SILBERSWEIG DA, 1995, NATURE, V378, P176, DOI 10.1038/378176a0; Stefan MD, 1997, ACTA PAEDIATR, V86, P112; Tamminga CA, 1998, CRIT REV NEUROBIOL, V12, P21, DOI 10.1615/CritRevNeurobiol.v12.i1-2.20; Turecki G, 1997, AM J MED GENET, V74, P195, DOI 10.1002/(SICI)1096-8628(19970418)74:2<195::AID-AJMG16>3.3.CO;2-T; Verdoux H, 1997, AM J PSYCHIAT, V154, P1220; Ward KE, 1996, SCHIZOPHR RES, V22, P197, DOI 10.1016/S0920-9964(96)00076-X; Williamson P, 1998, BIOL PSYCHIAT, V43, p7S, DOI 10.1016/S0006-3223(98)90471-1; World Health Organization, 2022, INT CLASS DIS, V11th; YurgelunTodd DA, 1996, AM J PSYCHIAT, V153, P200	59	187	199	0	15	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	APR 24	1999	353	9162					1425	1430		10.1016/S0140-6736(98)07549-7	http://dx.doi.org/10.1016/S0140-6736(98)07549-7			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	191KD	10227239				2022-12-28	WOS:000080020800044
J	Geller, G				Geller, G			Weighing burdens and benefits rather than competence - Commentary	BRITISH MEDICAL JOURNAL			English	Editorial Material							CHILDREN		Johns Hopkins Med Inst, Baltimore, MD 21205 USA	Johns Hopkins University; Johns Hopkins Medicine	Geller, G (corresponding author), Johns Hopkins Med Inst, 550 N Broadway, Baltimore, MD 21205 USA.							BINEDELL J, 1998, GENETIC TESTING CHIL, P123; Chapple Alison, 1996, Eur J Genet Soc, V2, P28; CLAYTON EW, 1995, AM J MED GENET, V57, P630, DOI 10.1002/ajmg.1320570423; COHEN CB, 1998, GENETIC TESTING CHIL, P133; FRYER A, 1995, ARCH DIS CHILD, V73, P97, DOI 10.1136/adc.73.2.97; HARPER PS, 1990, LANCET, V335, P1205, DOI 10.1016/0140-6736(90)92713-R; MARTEAU TM, 1994, J MED GENET, V31, P743, DOI 10.1136/jmg.31.10.743; WERTZ DC, 1994, JAMA-J AM MED ASSOC, V272, P875, DOI 10.1001/jama.272.11.875; WILFOND BS, 1995, AM J HUM GENET, V57, P1233	9	2	2	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	APR 17	1999	318	7190					1065	1066						2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	193ML	10336286				2022-12-28	WOS:000080140000037
J	Ben-Shlomo, Y; Smith, GD				Ben-Shlomo, Y; Smith, GD			Commentary: Socioeconomic position should be measured accurately	BRITISH MEDICAL JOURNAL			English	Editorial Material									Univ Bristol, Dept Social Med, Bristol BS8 2PR, Avon, England	University of Bristol	Ben-Shlomo, Y (corresponding author), Univ Bristol, Dept Social Med, Bristol BS8 2PR, Avon, England.		Davey Smith, George/A-7407-2013; Ben-Shlomo, Yoav/ABD-2004-2021	Davey Smith, George/0000-0002-1407-8314; Ben-Shlomo, Yoav/0000-0001-6648-3007				BENSHLOMO Y, 1995, J EPIDEMIOL COMMUN H, V49, P200, DOI 10.1136/jech.49.2.200; Blane D, 1997, EUR J PUBLIC HEALTH, V7, P385, DOI 10.1093/eurpub/7.4.385; Geronimus AT, 1998, AM J EPIDEMIOL, V148, P475; Law MR, 1998, J EPIDEMIOL COMMUN H, V52, P344, DOI 10.1136/jech.52.6.344; PIANTADOSI S, 1988, AM J EPIDEMIOL, V127, P893, DOI 10.1093/oxfordjournals.aje.a114892	5	16	16	0	2	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	MAR 27	1999	318	7187					844	+						2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	185DM	10223795				2022-12-28	WOS:000079652900026
J	Hamilton, P				Hamilton, P			ABC of labour care - Care of the newborn in the delivery room	BRITISH MEDICAL JOURNAL			English	Review									St George Hosp, London, England	St Georges University London	Hamilton, P (corresponding author), St George Hosp, London, England.							*BRIT PAED ASS, 1993, NEON RES; *DEP HLTH, 1998, VIT K NEWB BAB; LINDER N, 1988, J PEDIATR-US, V112, P613, DOI 10.1016/S0022-3476(88)80183-5; *ROYAL COLL OBST G, 1990, WORK PART REP MAT CA; SIMS DG, 1994, ARCH DIS CHILD-FETAL, V70, pF3, DOI 10.1136/fn.70.1.F3; 1998, DRUG THER B, V36, P17	6	5	6	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	MAY 22	1999	318	7195					1403	1406		10.1136/bmj.318.7195.1403	http://dx.doi.org/10.1136/bmj.318.7195.1403			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	200DQ	10334755	Green Published			2022-12-28	WOS:000080524700033
J	McKelvie, RS; Benedict, CR; Yusuf, S				McKelvie, RS; Benedict, CR; Yusuf, S			Evidence based cardiology - Prevention of congestive heart failure and management of asymptomatic left ventricular dysfunction	BRITISH MEDICAL JOURNAL			English	Review							SYSTOLIC DYSFUNCTION; MYOCARDIAL-INFARCTION; PLASMA-CONCENTRATIONS; NATRIURETIC FACTOR; FRAMINGHAM; DISEASE; EPIDEMIOLOGY; DILATATION; POPULATION; PEPTIDE		McMaster Univ, Hamilton Hlth Sci Corp, Gen Div, Dept Med,Div Cardiol, Hamilton, ON L8L 2X2, Canada; Univ Texas, Hlth Sci Ctr, Div Cardiol, Houston, TX 77030 USA	McMaster University; University of Texas System; University of Texas Health Science Center Houston	McKelvie, RS (corresponding author), McMaster Univ, Hamilton Hlth Sci Corp, Gen Div, Dept Med,Div Cardiol, 237 Barton St E, Hamilton, ON L8L 2X2, Canada.			Yusuf, Salim/0000-0003-4776-5601				Benedict CR, 1996, CIRCULATION, V94, P690, DOI 10.1161/01.CIR.94.4.690; BENEDICT CR, 1993, J AM COLL CARDIOL, V22, pA146, DOI 10.1016/0735-1097(93)90480-O; CODY RJ, 1986, J CLIN INVEST, V78, P1362, DOI 10.1172/JCI112723; COWIE MR, 1997, LANCET, V350, P1347; FRANCIS GS, 1984, ANN INTERN MED, V101, P370, DOI 10.7326/0003-4819-101-3-370; FRANCIS GS, 1990, CIRCULATION, V82, P1724, DOI 10.1161/01.CIR.82.5.1724; GERSTEIN HC, 1997, CIRCULATION S, V96, P225; KANNEL WB, 1974, AM J CARDIOL, V34, P29, DOI 10.1016/0002-9149(74)90089-7; Kjekshus J, 1997, J Card Fail, V3, P249, DOI 10.1016/S1071-9164(97)90022-1; LAUER MS, 1992, AM J CARDIOL, V70, P1180, DOI 10.1016/0002-9149(92)90052-Z; McDonagh TA, 1997, LANCET, V350, P829, DOI 10.1016/S0140-6736(97)03033-X; McDonagh TA, 1998, LANCET, V351, P9, DOI 10.1016/S0140-6736(97)03034-1; MCKEE PA, 1971, NEW ENGL J MED, V285, P1441, DOI 10.1056/NEJM197112232852601; McKelvie Robert S., 1997, P597; McKelvie RS, 1998, EVIDENCE BASED CARDI, P703; Mindlen F, 1996, CAN J CARDIOL, V12, P127; NICKLAS JM, 1992, NEW ENGL J MED, V327, P685; POULEUR H, 1993, CIRCULATION, V87, P14; POULEUR HG, 1993, J AM COLL CARDIOL, V22, pA43, DOI 10.1016/0735-1097(93)90462-A; Psaty BM, 1997, JAMA-J AM MED ASSOC, V277, P739, DOI 10.1001/jama.277.9.739; REMES J, 1992, EUR HEART J, V13, P588, DOI 10.1093/oxfordjournals.eurheartj.a060220; RICHARDS AM, 1993, BRIT HEART J, V69, P414; RUTHERFORD JD, 1994, CIRCULATION, V90, P1731, DOI 10.1161/01.CIR.90.4.1731; Shindler DM, 1996, AM J CARDIOL, V77, P1017, DOI 10.1016/S0002-9149(97)89163-1; SMITH WM, 1985, AM J CARDIOL, V55, pA3, DOI 10.1016/0002-9149(85)90789-1; STRUTHERS AD, 1993, BRIT HEART J, V70, P397; SUSKIN N, 1997, CAN J CARDIOL, V13, pC103; VANHOEVEN KH, 1990, CIRCULATION, V82, P848, DOI 10.1161/01.CIR.82.3.848; Vasan RS, 1997, NEW ENGL J MED, V336, P1350, DOI 10.1056/NEJM199705083361903; WHO Int Soc Hyperten Blood Press Lower, 1998, J HYPERTENS, V16, P127; YAMANI M, 1993, MAYO CLIN PROC, V68, P1214, DOI 10.1016/S0025-6196(12)60078-0; YUSUF S, 1992, LANCET, V340, P1178	32	21	21	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	MAY 22	1999	318	7195					1400	1402		10.1136/bmj.318.7195.1400	http://dx.doi.org/10.1136/bmj.318.7195.1400			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	200DQ	10334754	Green Published			2022-12-28	WOS:000080524700032
J	Nienaber, CA; Fattori, R; Lund, G; Dieckmann, C; Wolf, W; von Kodolitsch, Y; Nicolas, V; Pierangeli, A				Nienaber, CA; Fattori, R; Lund, G; Dieckmann, C; Wolf, W; von Kodolitsch, Y; Nicolas, V; Pierangeli, A			Nonsurgical reconstruction of thoracic aortic dissection by stent-graft placement	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							LEFT-HEART BYPASS; ANEURYSM REPAIR; PARAPLEGIA; RISK; MANAGEMENT; OPERATIONS; PROGNOSIS; SURVIVAL	Background The treatment of thoracic aortic dissection is guided by prognostic and anatomical information. Proximal dissection requires surgery, but the appropriate treatment of distal thoracic aortic dissection has not been determined, because surgery has failed to improve the prognosis. Methods We prospectively evaluated the safety and efficacy of elective transluminal endovascular stent-graft insertion in 12 consecutive patients with descending (type B) aortic dissection and compared the results with surgery in 12 matched controls. In all 24 patients, aortic dissection was diagnosed by magnetic resonance angiography. In each group, the dissection involved the aortic arch in 3 patients and the descending thoracic aorta in all 12 patients. With the patient under general anesthesia, either surgical resection was undertaken or a custom-designed endovascular stent-graft was placed by unilateral arteriotomy. Results Stent-graft placement resulted in no morbidity or mortality, whereas surgery for type B dissection was associated with four deaths (33 percent, P=0.09) and five serious adverse events (42 percent, P=0.04) within 12 months. Transluminal placement of the stent-graft prosthesis was successful in all patients, with no leakage; full expansion of the stents was ensured by balloon inflation at 2 to 3 atm. Sealing of the entry tear was monitored during the procedure by transesophageal ultrasonography and angiography, and thrombosis of the false lumen was confirmed in all 12 patients after a mean of three months by magnetic resonance imaging. There were no deaths or instances of paraplegia, stroke, embolization, side-branch occlusion, or infection in the stent-graft group; nine patients had postimplantation syndrome, with transient elevation of C-reactive protein levels and body temperature plus mild leukocytosis. All the patients who received stent-grafts recovered, as did seven patients who underwent surgery for type B dissection (58 percent) (P=0.04). Conclusions These preliminary observations suggest that elective, nonsurgical insertion of an endovascular stent-graft is safe and efficacious in selected patients who have thoracic aortic dissection and for whom surgery is indicated. Endoluminal repair may be useful for interventional reconstruction of thoracic aortic dissection. (N Engl J Med 1999;340:1539-45.) (C)1999, Massachusetts Medical Society.	Univ Hamburg, Hosp Eppendorf, Dept Cardiol, D-20246 Hamburg, Germany; Univ Hamburg, Hosp Eppendorf, Dept Diagnost Radiol, D-20246 Hamburg, Germany; Univ Hamburg, Hosp Eppendorf, Dept Vasc Surg, D-20246 Hamburg, Germany; St Orsola Marcello Malpighi Hosp, Dept Radiol, Bologna, Italy; St Orsola Marcello Malpighi Hosp, Dept Cardiothorac Surg, Bologna, Italy	University of Hamburg; University of Hamburg; University of Hamburg; IRCCS Azienda Ospedaliero-Universitaria di Bologna; IRCCS Azienda Ospedaliero-Universitaria di Bologna	Nienaber, CA (corresponding author), Univ Hamburg, Hosp Eppendorf, Dept Cardiol, Martinistr 52, D-20246 Hamburg, Germany.	nienaber@uke.uni-hamburg.de	Fattori, Rossella/L-1017-2016; Lund, Gunnar/L-1110-2019					ACHER CW, 1994, J VASC SURG, V19, P236, DOI 10.1016/S0741-5214(94)70099-0; ANAGNOSTOPOULOS CE, 1972, AM J CARDIOL, V30, P263, DOI 10.1016/0002-9149(72)90070-7; Blum U, 1997, NEW ENGL J MED, V336, P13, DOI 10.1056/NEJM199701023360103; BORST HG, 1994, J THORAC CARDIOV SUR, V107, P126; Chavan A, 1997, CIRCULATION, V96, P2124; Coselli JS, 1997, ANN THORAC SURG, V63, P28, DOI 10.1016/S0003-4975(96)01029-6; DAGAMA AD, 1991, J CARDIOVASC SURG, V32, P141; DAKE MD, 1994, NEW ENGL J MED, V331, P1729, DOI 10.1056/NEJM199412293312601; DINSMORE RE, 1972, RADIOLOGY, V105, P567, DOI 10.1148/105.3.567; DOROGHAZI RM, 1984, J AM COLL CARDIOL, V3, P1026, DOI 10.1016/S0735-1097(84)80363-0; DRIPPS RD, 1961, JAMA-J AM MED ASSOC, V178, P261, DOI 10.1001/jama.1961.03040420001001; ERGIN MA, 1994, ANN THORAC SURG, V57, P820, DOI 10.1016/0003-4975(94)90182-1; FUSTER V, 1994, J CARDIAC SURG, V9, P713, DOI 10.1111/j.1540-8191.1994.tb00906.x; GLOWER DD, 1990, CIRCULATION, V82, P39; Hagan P, 1998, J AM COLL CARDIOL, V31, p217A, DOI 10.1016/S0735-1097(97)84646-3; HEINEMANN MK, 1994, J CARDIAC SURG, V9, P748, DOI 10.1111/j.1540-8191.1994.tb00910.x; KATO M, 1995, CIRCULATION, V92, P107, DOI 10.1161/01.CIR.92.9.107; Kazui T, 1992, Nihon Geka Gakkai Zasshi, V93, P1028; Kouchoukos NT, 1997, NEW ENGL J MED, V336, P1876, DOI 10.1056/NEJM199706263362606; MASUDA Y, 1991, CIRCULATION, V84, P7; MATTHEWS DE, 1988, USING UNDERSTANDING; Miller D C, 1993, Semin Thorac Cardiovasc Surg, V5, P33; MILLER DC, 1998, P 6 AORT SURG S NEW, P34; Mitchell RS, 1996, J THORAC CARDIOV SUR, V111, P1054, DOI 10.1016/S0022-5223(96)70382-3; NEYA K, 1992, CIRCULATION, V86, P1; NIENABER CA, 1993, NEW ENGL J MED, V328, P1, DOI 10.1056/NEJM199301073280101; NIENABER CA, 1992, HERZ, V17, P398; Panneton J, 1995, ANN VASC SURG, V9, P596, DOI 10.1007/BF02018836; Prince MR, 1996, AM J ROENTGENOL, V166, P1387, DOI 10.2214/ajr.166.6.8633452; RIZZOLI G, 1990, EUR J CARDIO-THORAC, V4, P575, DOI 10.1016/1010-7940(90)90015-R; SCHEPENS MAAM, 1995, ANN VASC SURG, V9, P327, DOI 10.1007/BF02139403; Schor JS, 1996, ANN THORAC SURG, V61, P1339, DOI 10.1016/0003-4975(96)00105-1; Svensson LG, 1997, J CARDIAC SURG, V12, P279; SVENSSON LG, 1994, J VASC SURG, V20, P255, DOI 10.1016/0741-5214(94)90013-2; SVENSSON LG, 1990, CIRCULATION, V82, P24; SVENSSON LG, 1993, CHEST, V104, P1248, DOI 10.1378/chest.104.4.1248; SVENSSON LG, 1992, CURR PROB SURG, V29, P915; SVENSSON LG, 1993, J VASC SURG, V17, P357, DOI 10.1016/0741-5214(93)90421-H	38	746	863	1	39	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	MAY 20	1999	340	20					1539	1545		10.1056/NEJM199905203402003	http://dx.doi.org/10.1056/NEJM199905203402003			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	197HG	10332015	Bronze			2022-12-28	WOS:000080358900003
J	Petersen, BE; Bowen, WC; Patrene, KD; Mars, WM; Sullivan, AK; Murase, N; Boggs, SS; Greenberger, JS; Goff, JP				Petersen, BE; Bowen, WC; Patrene, KD; Mars, WM; Sullivan, AK; Murase, N; Boggs, SS; Greenberger, JS; Goff, JP			Bone marrow as a potential source of hepatic oval cells	SCIENCE			English	Article							WHOLE-ORGAN TRANSPLANTATION; LIVER-REGENERATION; STEM-CELLS; ADULT-RAT; ACTIVATION; COMPARTMENT; EXPRESSION; TISSUE; DAMAGE; CDNA	Bone marrow stem cells develop into hematopoietic and mesenchymal Lineages but have not been known to participate in production of hepatocytes, biliary : cells, or oval cells during Liver regeneration. Cross-sex or cross-strain bone marrow and whole Liver transplantation Were used to trace the origin of the repopulating Liver cells. Transplanted rats were treated with 2-acetylaminofluorene, to block hepatocyte proliferation, and then hepatic injury, to induce oval cell proliferation. Markers for Y chromosome, dipeptidyl peptidase IV enzyme, and L21-6 antigen were used to identify Liver cells of bone marrow origin. From these cells, a proportion of the regenerated hepatic cells were shown to be, donor-derived. Thus, a stem cell associated with the bone marrow has epithelial cell Lineage capability.	Univ Pittsburgh, Sch Med, Dept Pathol, Div Transplantat Pathol, Pittsburgh, PA 15261 USA; Univ Pittsburgh, Sch Med, Dept Radiat Oncol, Pittsburgh, PA 15261 USA; McGill Univ, Dept Hematol Oncol, Montreal, PQ H3A 2T5, Canada	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; McGill University	Petersen, BE (corresponding author), Univ Pittsburgh, Sch Med, Dept Pathol, Div Transplantat Pathol, Pittsburgh, PA 15261 USA.							An J, 1997, J ANDROL, V18, P289; Asahara T, 1997, SCIENCE, V275, P964, DOI 10.1126/science.275.5302.964; EVARTS RP, 1989, CANCER RES, V49, P1541; FAUSTO N, 1994, LIVER BIOL PATHOBIOL, pCH78; Ferrari G, 1998, SCIENCE, V279, P1528, DOI 10.1126/science.279.5356.1528; FUJIO K, 1994, LAB INVEST, V70, P511; GRISHAM JW, 1997, STEM CELLS, pCH8; Hagios C, 1998, PHILOS T R SOC B, V353, P857, DOI 10.1098/rstb.1998.0250; HIXSON DC, 1992, ROLE CELL TYPES HEPA, pCH8; LOJDO Z, 1979, HISTOCHEMISTRY, V57, P107; MURASE N, 1995, TRANSPLANTATION, V60, P158, DOI 10.1097/00007890-199507270-00009; Murase N, 1996, TRANSPLANTATION, V61, P1, DOI 10.1097/00007890-199601150-00001; Novikoff PM, 1996, AM J PATHOL, V148, P1473; Omori M, 1997, AM J PATHOL, V150, P1179; Omori N, 1997, HEPATOLOGY, V26, P720, DOI 10.1002/hep.510260325; Petersen BE, 1997, AM J PATHOL, V151, P905; Petersen BE, 1998, HEPATOLOGY, V27, P1030, DOI 10.1002/hep.510270419; Petersen BE, 1998, HEPATOLOGY, V27, P433, DOI 10.1002/hep.510270218; Taniguchi H, 1996, NAT MED, V2, P198, DOI 10.1038/nm0296-198; THORGEIRSSON SS, 1993, P SOC EXP BIOL MED, V204, P253; YAGIHASHI A, 1995, TRANSPLANT P, V27, P1519	21	1901	2276	3	116	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	MAY 14	1999	284	5417					1168	1170		10.1126/science.284.5417.1168	http://dx.doi.org/10.1126/science.284.5417.1168			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	197HJ	10325227				2022-12-28	WOS:000080359100037
J	Kramer, EM; Irish, VF				Kramer, EM; Irish, VF			Evolution of genetic mechanisms controlling petal development	NATURE			English	Article							MADS-BOX; FLOWER DEVELOPMENT; MOLECULAR EVOLUTION; HOMEOBOX GENE; ARABIDOPSIS; EXPRESSION; DIVERSIFICATION; PISTILLATA; APETALA3; PLANTS	Molecular genetic studies in Arabinopsis thaliana and other higher-eudicot flowering plants have led to the development of the 'ABC' model of the determination of organ identity in flowers, in which three classes of gene, A, B and C, are thought to work together to determine organ identity(1,2). According to this model, the B-class genes APETALA3 (AP3) and PISTILLATA (PI) act to specify petal and stamen identity, Here we test whether the roles of these genes are conserved throughout the angiosperms by analysing the expression of AP3 and PI orthologues in the lower eudicot subclass Ranunculidae, We show that, although expression of these orthologues in the stamens is conserved, the expression patterns in the petals differ from those found in the higher eudicots, The differences between these expression patterns suggest that the function of AP3 and PI homologues as R-class organ-identity genes is not rigidly conserved among all angiosperms. These observations have important implications for understanding the evolution of both angiosperm petals and the genetic mechanisms that control the identities of floral organs.	Yale Univ, Dept Mol Cellular & Dev Biol, New Haven, CT 06520 USA	Yale University	Irish, VF (corresponding author), Yale Univ, Dept Mol Cellular & Dev Biol, POB 208104, New Haven, CT 06520 USA.	vivian.irish@yale.edu						Bowman JL, 1997, J BIOSCIENCE, V22, P515, DOI 10.1007/BF02703197; BOWMAN JL, 1989, PLANT CELL, V1, P37, DOI 10.1105/tpc.1.1.37; Carr SM, 1997, PLANTA, V201, P179, DOI 10.1007/s004250050117; CHASE MW, 1993, ANN MO BOT GARD, V80, P528, DOI 10.2307/2399846; COEN ES, 1991, NATURE, V353, P31, DOI 10.1038/353031a0; DECRAENE LPR, 1992, CAN J BOT, V70, P1765, DOI 10.1139/b92-219; DRINNAN AN, 1994, EARLY EVOLUTION FLOW, P93; GOTO K, 1994, GENE DEV, V8, P1548, DOI 10.1101/gad.8.13.1548; HARDENACK S, 1994, PLANT CELL, V6, P1775, DOI 10.1105/tpc.6.12.1775; Irish VF, 1998, ADV BOT RES, V28, P197; JACK T, 1992, CELL, V68, P683, DOI 10.1016/0092-8674(92)90144-2; KELLY AJ, 1995, PLANT CELL, V7, P225, DOI 10.1105/tpc.7.2.225; KOSUGE K, 1994, PLANT SYST EVOL, P185; Kramer EM, 1998, GENETICS, V149, P765; LINCOLN C, 1994, PLANT CELL, V6, P1859, DOI 10.1105/tpc.6.12.1859; MEYEROWITZ EM, 1991, DEVELOPMENT, P157; PURUGGANAN MD, 1995, GENETICS, V140, P345; SMITH LG, 1992, DEVELOPMENT, V116, P21; SOMMER H, 1991, DEVELOPMENT, P169; Takhtajan A, 1991, EVOLUTIONARY TRENDS; THEISSEN G, 1995, CURR OPIN GENET DEV, V5, P628, DOI 10.1016/0959-437X(95)80032-8; ZACHGO S, 1995, DEVELOPMENT, V121, P2861	22	196	213	1	30	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	MAY 13	1999	399	6732					144	148		10.1038/20172	http://dx.doi.org/10.1038/20172			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	196XU	10335842				2022-12-28	WOS:000080335700048
J	Rao, RB; Ely, SF; Hoffman, RS				Rao, RB; Ely, SF; Hoffman, RS			Deaths related to liposuction	NEW ENGLAND JOURNAL OF MEDICINE			English	Article; Proceedings Paper	North-American-Congress-of-Clinical-Toxicology Annual Meeting	SEP 10-15, 1998	ORLANDO, FL	Toxicol Hist Soc, N Amer Congress Clin Toxicol			TUMESCENT TECHNIQUE; LOCAL-ANESTHESIA; SUCTION LIPECTOMY; NATIONAL SURVEY; BLOOD-LOSS; LIDOCAINE; COMPLICATIONS; EPINEPHRINE; SAFETY; MG/KG	Background The technique of tumescent liposuction involves the subcutaneous infusion of a solution containing lidocaine, followed by the aspiration of fat through microcannulas, Although the recommended doses of lidocaine are as high as 55 mg per kilogram of body weight, few safety data are available. Since reporting of adverse events associated with tumescent liposuction is not mandatory, the incidence of complications and deaths is unknown, Methods We identified 5 deaths after tumescent liposuction among 48,527 deaths referred to the Office of Chief Medical Examiner of the City of New York between 1993 and 1998. The patients' records and postmortem examination results were reviewed to identify common contributory factors: Results The five patients had received lidocaine in doses ranging from 10 to 40 mg per kilogram. Other drugs, such as midazolam, were also administered. Three patients died as a result of precipitous intraoperative hypotension and bradycardia with no definitively identified cause. Postmortem blood lidocaine concentrations in two of the patients were 5.2 and 2 mg per liter. One patient died of fluid overload, and one died of deep venous thrombosis of calf veins with pulmonary thromboembolism after tumescent liposuction of the legs. Conclusions Tumescent liposuction can be fatal, perhaps in part because of lidocaine toxicity or lidocaine-related drug interactions. (N Engl J Med 1999; 340:1471-5.) (C) 1999, Massachusetts Medical Society.	NYU, Med Ctr, New York City Poison Control Ctr, Dept Surg Emergency Med, New York, NY 10016 USA; Bellevue Hosp Ctr, New York, NY 10016 USA; NYU, Med Ctr, Dept Forens Med, New York, NY 10016 USA	New York University; Bellevue Hospital Center; New York University	Rao, RB (corresponding author), NYU, Med Ctr, New York City Poison Control Ctr, Dept Surg Emergency Med, 455 1st Ave,Rm 123, New York, NY 10016 USA.	raorama@pol.net		Hoffman, Robert/0000-0002-0091-9573				ALLEN JE, 1997, STAR LEDGER     0826, P20; *AM AC PED, 1997, 1997 RED BOOK REP CO, P1; Am Soc Dermatologic Surg, 1997, DERMATOL SURG, V23, P1127; BERNSTEIN G, 1988, J DERMATOL SURG ONC, V14, P1112, DOI 10.1111/j.1524-4725.1988.tb03467.x; BRYSON HM, 1995, DRUGS, V50, P513, DOI 10.2165/00003495-199550030-00008; Burk RW, 1996, PLAST RECONSTR SURG, V97, P1379, DOI 10.1097/00006534-199606000-00009; Catterall W, 1996, GOODMAN GILMANS PHAR, P331; CHASE M, 1999, WALL STREET J   0118, pB1; Christie J L, 1976, J Forensic Sci, V21, P671; CHRISTMAN KD, 1986, PLAST RECONSTR SURG, V78, P428, DOI 10.1097/00006534-198609000-00040; Dolsky RL, 1997, DERMATOL SURG, V23, P1192, DOI 10.1111/j.1524-4725.1997.tb00472.x; DRAKE LA, 1991, J AM ACAD DERMATOL, V24, P489, DOI 10.1016/S0190-9622(08)80075-8; Gilliland MD, 1997, PLAST RECONSTR SURG, V99, P215, DOI 10.1097/00006534-199701000-00032; GOLDFRANK LR, 1994, GOLDFRANKS TOXICOLOG, P717; Grazer FM, 1997, PLAST RECONSTR SURG, V100, P1893, DOI 10.1097/00006534-199712000-00040; Hanke CW, 1996, DERMATOL SURG, V22, P595; Klein JA, 1997, DERMATOL SURG, V23, P1169, DOI 10.1111/j.1524-4725.1997.tb00467.x; KLEIN JA, 1990, DERMATOL CLIN, V8, P425, DOI 10.1016/S0733-8635(18)30474-1; KLEIN JA, 1993, PLAST RECONSTR SURG, V92, P1085, DOI 10.1097/00006534-199311000-00014; KLEIN JA, 1990, J DERMATOL SURG ONC, V16, P248, DOI 10.1111/j.1524-4725.1990.tb03961.x; Klein JA, 1998, DERMATOL SURG, V24, P691; KLEIN JA, 1995, DERMATOL SURG, V21, P449, DOI 10.1111/j.1524-4725.1995.tb00212.x; Knize DM, 1997, PLAST RECONSTR SURG, V100, P1867, DOI 10.1097/00006534-199712000-00035; LASSWELL M, 1997, ALLURE           AUG, P151; LASSWELL M, 1997, ALLURE           AUG, P128; LILLIS PJ, 1988, J DERMATOL SURG ONC, V14, P1145, DOI 10.1111/j.1524-4725.1988.tb03472.x; McShane RH, 1997, PLAST RECONSTR SURG, V100, P281, DOI 10.1097/00006534-199707000-00058; *MED EC, 1998, PHYS DESK REF, P582; Ostad A, 1996, DERMATOL SURG, V22, P921, DOI 10.1111/j.1524-4725.1996.tb00634.x; Parkinson A, 1996, TOXICOLOGY BASIC SCI, P113; PEAT MA, 1985, J FORENSIC SCI, V30, P1048; Pitman GH, 1996, CLIN PLAST SURG, V23, P633; PITMAN GH, 1993, LIPOSUCTION ANESTHET, P67; *PLAST SURG INF SE, 1998, NUMB LIP PROC INCR 2; PROUTY RW, 1990, J FORENSIC SCI, V35, P243; SAMDAL F, 1994, PLAST RECONSTR SURG, V93, P1217, DOI 10.1097/00006534-199405000-00017; STONE A, 1995, PLAST RECONSTR SURG, V95, P603, DOI 10.1097/00006534-199503000-00046; TEIMOURIAN B, 1989, PLAST RECONSTR SURG, V84, P628, DOI 10.1097/00006534-198984040-00012; 1997, NY TIMES        1129, P10	39	181	192	0	12	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	MAY 13	1999	340	19					1471	1475		10.1056/NEJM199905133401904	http://dx.doi.org/10.1056/NEJM199905133401904			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Conference Proceedings Citation Index - Science (CPCI-S)	General & Internal Medicine	194MT	10320385				2022-12-28	WOS:000080198700004
J	Albrecht, T; Blomley, MJK; Cosgrove, DO; Taylor-Robinson, SD; Jayaram, V; Eckersley, R; Urbank, A; Butler-Barnes, J; Patel, N				Albrecht, T; Blomley, MJK; Cosgrove, DO; Taylor-Robinson, SD; Jayaram, V; Eckersley, R; Urbank, A; Butler-Barnes, J; Patel, N			Non-invasive diagnosis of hepatic cirrhosis by transit-time analysis of an ultrasound contrast agent	LANCET			English	Article							LIVER-DISEASE; BLOOD-FLOW; US; ULTRASONOGRAPHY; EXPERIENCE	Background Hepatic cirrhosis is accompanied by several haemodynamic changes including arterialisation of the liver, intrahepatic shunts, pulmonary arteriovenous shunts, and a hyperdynamic circulatory state. We postulated that the hepatic first pass of a bolus of an ultrasound contrast agent injected into a peripheral Vein is accelerated in patients with cirrhosis. We investigated this first pass in patients with diffuse liver disease and in normal controls to assess whether it provides useful differential diagnostic information. Methods We enrolled 15 patients with biopsy-proven cirrhosis, 12 patients with biopsy-proven non-cirrhotic diffuse liver disease, and 11 normal controls. We carried out continuous spectral doppler ultrasonography of a hepatic vein from 20 s before to 3 min after a peripheral intravenous bolus injection of 2.5 g Levovist. The intensity of the doppler signal was measured and used to plot time-intensity curves. Findings Patients with cirrhosis showed a much earlier onset of enhancement (arrival time; mean 18.3 s) and peak enhancement (mean 55.5 s) than controls (49.8 s and 97.5 s) or patients with non-cirrhotic diffuse liver disease (35.8 s and 79.7 s). All patients with cirrhosis had an arrival time of the bolus of less than 24 s, whereas the arrival time was 24 s or more in 22 of the 23 other participants. Peak enhancement was higher in patients with cirrhosis (mean 48.7 units) than in the other two groups (12.5 and 12.3 units, respectively). We found highly significant differences between the patients with cirrhosis and each of the other two groups for all variables (p<0.005), whereas we found no significant differences between non-cirrhotic patients and controls. Interpretation Our preliminary study suggests that analysis of liver transit time of a bolus of ultrasound contrast agent provides useful information about haemodynamic changes in patients with cirrhosis. Measurement of the arrival time of the bolus allows discrimination of patients with cirrhosis from controls and from patients with noncirrhotic diffuse river disease, and has potential as a non-invasive test for cirrhosis.	Free Univ Berlin, Klinikum Benjamin Franklin, Dept Radiol, D-12200 Berlin, Germany; Univ London Imperial Coll Sci Technol & Med, Hammersmith Hosp, Dept Imaging, London, England; Schering AG, Clin Dev Diagnost, D-1000 Berlin, Germany	Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; Imperial College London; Schering AG	Albrecht, T (corresponding author), Free Univ Berlin, Klinikum Benjamin Franklin, Dept Radiol, D-12200 Berlin, Germany.		Eckersley, Robert J/A-7366-2010	Eckersley, Robert/0000-0001-9247-5350				AGUSTI AGN, 1990, J HEPATOL, V10, P251, DOI 10.1016/0168-8278(90)90061-U; Albrecht T, 1998, ACAD RADIOL, V5, pS195, DOI 10.1016/S1076-6332(98)80104-9; Albrecht T, 1998, RADIOLOGY, V207, P339, DOI 10.1148/radiology.207.2.9577478; ALBRECHT T, 1997, RADIOLOGY, V205, P337; BERTHELO.P, 1966, NEW ENGL J MED, V274, P291, DOI 10.1056/NEJM196602102740601; Biersack H J, 1977, Rofo, V126, P47; Blomley M, 1998, LANCET, V351, P568, DOI 10.1016/S0140-6736(05)78554-8; Blomley M, 1997, LANCET, V349, P1855, DOI 10.1016/S0140-6736(05)63872-X; Blomley MJK, 1998, RADIOLOGY, V209, P862, DOI 10.1148/radiology.209.3.9844688; CREUTZIG H, 1981, NUKLEARMED, V20, P25; GOSINK BB, 1979, AM J ROENTGENOL, V133, P19, DOI 10.2214/ajr.133.1.19; HALES MR, 1959, AM J PATHOL, V35, P909; KASHITANI N, 1995, ABDOM IMAGING, V20, P197, DOI 10.1007/BF00200392; Kedar RP, 1996, RADIOLOGY, V198, P679, DOI 10.1148/radiology.198.3.8628854; KONTOS HA, 1964, AM J MED, V37, P526, DOI 10.1016/0002-9343(64)90066-X; MERGO PJ, 1994, RADIOGRAPHICS, V14, P1291, DOI 10.1148/radiographics.14.6.7855342; MORIYASU F, 1986, AM J ROENTGENOL, V146, P735, DOI 10.2214/ajr.146.4.735; MOSER E, 1985, Nuclear Medizin, V24, P185; MURRAY JF, 1958, AM J MED, V24, P358, DOI 10.1016/0002-9343(58)90322-X; Nanda N.C., 1997, ADV ECHO IMAGING USI, P115, DOI [10.1007/978-94-011-5704-9_6, DOI 10.1007/978-94-011-5704-9_6]; NORD HJ, 1982, GASTROINTEST ENDOSC, V28, P102; Oberti F, 1997, GASTROENTEROLOGY, V113, P1609, DOI 10.1053/gast.1997.v113.pm9352863; OHNISHI K, 1986, AM J GASTROENTEROL, V81, P975; POPPER H, 1952, AM J CLIN PATHOL, V22, P717; PUGH RNH, 1973, BRIT J SURG, V60, P646, DOI 10.1002/bjs.1800600817; ROFSKY NM, 1995, SEMIN ULTRASOUND CT, V16, P16, DOI 10.1016/0887-2171(95)90012-8; RYPINS EB, 1981, AM J SURG, V142, P574, DOI 10.1016/0002-9610(81)90429-3; SANDFORD NL, 1985, GASTROENTEROLOGY, V89, P186, DOI 10.1016/0016-5085(85)90761-9; SCHWARTZ K, 1993, ULTRASOUND MED BIOL, V4, P289; Sherlock S, 1993, DIS LIVER BILIARY SY, P33; SYROTA A, 1976, GASTROENTEROLOGY, V71, P652; Villeneuve JP, 1996, HEPATOLOGY, V23, P24, DOI 10.1053/jhep.1996.v23.pm0008550044; WOLFE JD, 1977, AM J MED, V63, P746, DOI 10.1016/0002-9343(77)90161-9; ZOLI M, 1995, J HEPATOL, V23, P129, DOI 10.1016/0168-8278(95)80326-2	34	198	239	1	10	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	MAY 8	1999	353	9164					1579	1583		10.1016/S0140-6736(98)06373-9	http://dx.doi.org/10.1016/S0140-6736(98)06373-9			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	195XW	10334257				2022-12-28	WOS:000080278300014
J	Dillner, L; Hutchinson, L; Kerr, J; Leinster, S; Matheson, K; Peterson, S; Rake, M; Richards, T; Smith, R; Wood, D; Cantillon, P; Abbasi, K				Dillner, L; Hutchinson, L; Kerr, J; Leinster, S; Matheson, K; Peterson, S; Rake, M; Richards, T; Smith, R; Wood, D; Cantillon, P; Abbasi, K		Educ Grp Guidelines Evaluation	Guidelines for evaluating papers on educational interventions	BRITISH MEDICAL JOURNAL			English	Article							RANDOMIZED CONTROLLED TRIALS; CONSORT STATEMENT		BMJ, London WC1H 9JR, England		Abbasi, K (corresponding author), BMJ, London WC1H 9JR, England.							Altman DG, 1996, BRIT MED J, V313, P570; ALTMAN DG, 1991, BRIT MED J, V292, P810; Begg C, 1996, JAMA-J AM MED ASSOC, V276, P637, DOI 10.1001/jama.276.8.637; Docherty M, 1999, BRIT MED J, V318, P1224	4	45	47	0	2	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	MAY 8	1999	318	7193					1265	1267						3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	195XT	10231261				2022-12-28	WOS:000080278000030
J	McCarthy, M; Wilkinson, ML				McCarthy, M; Wilkinson, ML			Recent advances - Hepatology	BMJ-BRITISH MEDICAL JOURNAL			English	Review							PEDIATRIC LIVER-TRANSPLANTATION; HEPATITIS-C; INTERFERON-ALPHA; WILSON DISEASE; CIRRHOSIS; GENE		Guys Hosp, Guys Kings Coll & St Thomas Hosp Med & Dent Sch, Gastroenterol Unit, London SE1 9RT, England	Guy's & St Thomas' NHS Foundation Trust; University of London; King's College London	Wilkinson, ML (corresponding author), Guys Hosp, Guys Kings Coll & St Thomas Hosp Med & Dent Sch, Gastroenterol Unit, London SE1 9RT, England.							[Anonymous], 1997, HEPATOLOGY, V26, pS2; Brewer GJ, 1996, ARCH NEUROL-CHICAGO, V53, P1017, DOI 10.1001/archneur.1996.00550100103019; BULL PC, 1993, NAT GENET, V5, P327, DOI 10.1038/ng1293-327; CHEMELLO L, 1995, J VIRAL HEPATITIS, V2, P91, DOI 10.1111/j.1365-2893.1995.tb00012.x; ChenardNeu MP, 1996, HEPATOLOGY, V23, P1119; COX DW, 1996, PROGR LIVER DIS; Desmet V. J., 1997, Journal of Hepatology, V26, P31, DOI 10.1016/S0168-8278(97)82330-6; DYKHUIZEN RS, 1995, GUT, V36, P939, DOI 10.1136/gut.36.6.939; Feder JN, 1996, NAT GENET, V13, P399, DOI 10.1038/ng0896-399; Gane EJ, 1996, GASTROENTEROLOGY, V110, P167, DOI 10.1053/gast.1996.v110.pm8536853; KANE JA, 1995, GUT, V36, P146, DOI 10.1136/gut.36.1.146; Lee KJ, 1997, ELECTRON LETT, V33, P1, DOI 10.1049/el:19970045; MAKIN AJ, 1995, GASTROENTEROLOGY, V109, P1907, DOI 10.1016/0016-5085(95)90758-0; McCarthy M, 1996, GUT, V39, P870, DOI 10.1136/gut.39.6.870; NISHIGUCHI S, 1995, LANCET, V346, P1051, DOI 10.1016/S0140-6736(95)91739-X; OTTE JB, 1990, ANN SURG, V211, P146, DOI 10.1097/00000658-199002000-00006; OZAWA K, 1992, ANN SURG, V216, P547, DOI 10.1097/00000658-199211000-00004; Poynard T, 1997, LANCET, V349, P825, DOI 10.1016/S0140-6736(96)07642-8; POYNARD T, 1995, NEW ENGL J MED, V332, P1457, DOI 10.1056/NEJM199506013322201; Robson KJH, 1997, GUT, V41, P841; Silva EES, 1996, J PEDIATR-US, V128, P285	21	7	7	0	0	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	MAY 8	1999	318	7193					1256	1259						4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	195XT	10231259				2022-12-28	WOS:000080278000028
J	Sasieni, P; Adams, J				Sasieni, P; Adams, J			Effect of screening on cervical cancer mortality in England and Wales: Analysis of trends with an age period cohort model	BRITISH MEDICAL JOURNAL			English	Article									Imperial Canc Res Fund, Dept Math Stat & Epidemiol, London WC2A 3PX, England	Cancer Research UK	Sasieni, P (corresponding author), Imperial Canc Res Fund, Dept Math Stat & Epidemiol, 44 Lincolns Inn Fields, London WC2A 3PX, England.			Sasieni, Peter/0000-0003-1509-8744				BERAL V, 1974, LANCET, V1, P1037; *OFF POP CENS SURV, 1998, MON POP HLTH SER; Rooney C, 1996, Popul Trends, P29; Sasieni PD, 1996, BRIT J CANCER, V73, P1001, DOI 10.1038/bjc.1996.196	4	121	129	0	7	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	MAY 8	1999	318	7193					1244	1245						2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	195XT	10231253				2022-12-28	WOS:000080278000024
J	Diefenbach, A; Schindler, H; Rollinghoff, M; Yokoyama, WM; Bogdan, C				Diefenbach, A; Schindler, H; Rollinghoff, M; Yokoyama, WM; Bogdan, C			Requirement for type 2 NO synthase for IL-12 signaling in innate immunity	SCIENCE			English	Article							NITRIC-OXIDE SYNTHASE; NATURAL-KILLER-CELLS; LEISHMANIA-MAJOR; INTERFERON-GAMMA; TYROSINE KINASE; T-CELLS; ACTIVATION; MICE; INTERLEUKIN-12; INFECTION	Interleukin-12 (IL-12) and type 2 NO synthase (NOS2) are crucial for defense against bacterial and parasitic pathogens, but their relationship in innate immunity is unknown. in the absence of NOS2 activity, IL-12 was unable to prevent spreading of Leishmania parasites, did not stimulate natural killer (NK) cells for cytotoxicity or interferon-gamma (IFN-gamma) release, and failed to activate Tyk2 kinase and to tyrosine phosphorylate Stat4 (the central signal transducer of IL-12) in NK cells. Activation of Tyk2 in NK cells by IFN-alpha/beta also required NOS2. Thus, NOS2-derived NO is a prerequisite for cytokine signaling and function in innate immunity.	Univ Erlangen Nurnberg, Inst Klin Mikrobiol Immunol & Hyg, D-91054 Erlangen, Germany; Washington Univ, Sch Med, Howard Hughes Med Inst, Div Rheumatol, St Louis, MO 63110 USA	University of Erlangen Nuremberg; Howard Hughes Medical Institute; Washington University (WUSTL)	Bogdan, C (corresponding author), Univ Erlangen Nurnberg, Inst Klin Mikrobiol Immunol & Hyg, Wasserturmstr 3, D-91054 Erlangen, Germany.		Diefenbach, Andreas/T-2589-2018	Diefenbach, Andreas/0000-0002-9176-9530; Bogdan, Christian/0000-0002-2300-0631				BACON CM, 1995, J EXP MED, V181, P399, DOI 10.1084/jem.181.1.399; BARBIERI G, 1994, EUR J BIOCHEM, V223, P427, DOI 10.1111/j.1432-1033.1994.tb19010.x; Bingisser RM, 1998, J IMMUNOL, V160, P5729; Bogdan C, 1997, Behring Inst Mitt, P58; Bogdan C, 1998, J EXP MED, V187, P1361, DOI 10.1084/jem.187.9.1361; COLAMONICI OR, 1994, J BIOL CHEM, V269, P3518; Denkers EY, 1998, IMMUNOLOGIST, V6, P116; Diefenbach A, 1998, IMMUNITY, V8, P77, DOI 10.1016/S1074-7613(00)80460-4; Duhe RJ, 1998, P NATL ACAD SCI USA, V95, P126, DOI 10.1073/pnas.95.1.126; Fearon DT, 1996, SCIENCE, V272, P50, DOI 10.1126/science.272.5258.50; GEIGER J, 1992, P NATL ACAD SCI USA, V89, P1031, DOI 10.1073/pnas.89.3.1031; Hierholzer C, 1998, J EXP MED, V187, P917, DOI 10.1084/jem.187.6.917; Huang FP, 1998, EUR J IMMUNOL, V28, P4062, DOI 10.1002/(SICI)1521-4141(199812)28:12<4062::AID-IMMU4062>3.0.CO;2-K; KARLHOFER FM, 1995, J EXP MED, V181, P1785, DOI 10.1084/jem.181.5.1785; Lander HM, 1997, FASEB J, V11, P118, DOI 10.1096/fasebj.11.2.9039953; LASKAY T, 1995, EUR J IMMUNOL, V25, P2220, DOI 10.1002/eji.1830250816; MacMicking J, 1997, ANNU REV IMMUNOL, V15, P323, DOI 10.1146/annurev.immunol.15.1.323; MACMICKING JD, 1995, CELL, V81, P641, DOI 10.1016/0092-8674(95)90085-3; Robinson D, 1997, IMMUNITY, V7, P571, DOI 10.1016/S1074-7613(00)80378-7; Rothe H, 1996, BIOCHEM BIOPH RES CO, V224, P159, DOI 10.1006/bbrc.1996.1000; SCHARTON TM, 1993, J EXP MED, V178, P567, DOI 10.1084/jem.178.2.567; SCHARTONKERSTEN T, 1995, J IMMUNOL, V154, P5320; SCHMIDT HHHW, 1994, CELL, V78, P919, DOI 10.1016/0092-8674(94)90267-4; Sousa CRE, 1997, J EXP MED, V186, P1819, DOI 10.1084/jem.186.11.1819; STOUT RD, 1993, CURR OPIN IMMUNOL, V5, P398, DOI 10.1016/0952-7915(93)90059-2; Tarrant TK, 1999, J EXP MED, V189, P219, DOI 10.1084/jem.189.2.219; Thierfelder WE, 1996, NATURE, V382, P171, DOI 10.1038/382171a0; Thuring H, 1995, EUR J IMMUNOL, V25, P3229, DOI 10.1002/eji.1830251205; Trinchieri G, 1996, J LEUKOCYTE BIOL, V59, P505, DOI 10.1002/jlb.59.4.505; Yu CR, 1996, J IMMUNOL, V157, P126	30	156	160	0	1	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	MAY 7	1999	284	5416					951	955		10.1126/science.284.5416.951	http://dx.doi.org/10.1126/science.284.5416.951			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	194MU	10320373				2022-12-28	WOS:000080198800042
J	Hiraishi, H; Terano, A				Hiraishi, H; Terano, A			Rupture of a pancreatic pseudocyst into the duodenum	NEW ENGLAND JOURNAL OF MEDICINE			English	Article									Dokkyo Univ, Sch Med, Tochigi 3210293, Japan	Dokkyo Medical University	Hiraishi, H (corresponding author), Dokkyo Univ, Sch Med, Tochigi 3210293, Japan.								0	5	5	0	0	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	MAY 6	1999	340	18					1411	1411		10.1056/NEJM199905063401806	http://dx.doi.org/10.1056/NEJM199905063401806			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	192QN	10228192				2022-12-28	WOS:000080090600006
J	Horowitz, HS				Horowitz, HS			Proper use of fluoride products in fluoridated communities	LANCET			English	Editorial Material							RISK-FACTORS; DENTAL FLUOROSIS; ENAMEL FLUOROSIS; CHILDREN				Horowitz, HS (corresponding author), 6307 Herkos Court, Bethesda, MD 20817 USA.							BARNHART WE, 1974, J DENT RES, V53, P1317, DOI 10.1177/00220345740530060301; Dean HT., 1954, INT DENT J, V4, P311; HOROWITZ HS, 1992, J PUBLIC HEALTH DENT, V52, P216, DOI 10.1111/j.1752-7325.1992.tb02276.x; Horowitz HS, 1996, J PUBLIC HEALTH DENT, V56, P253, DOI 10.1111/j.1752-7325.1996.tb02448.x; HOROWITZ HS, 1986, J PUBLIC HEALTH DENT, V46, P179, DOI 10.1111/j.1752-7325.1986.tb03139.x; OSUJI OO, 1988, J DENT RES, V67, P1488, DOI 10.1177/00220345880670120901; Pendrys DG, 1998, AM J EPIDEMIOL, V148, P967, DOI 10.1093/oxfordjournals.aje.a009573; Pendrys DG, 1996, AM J EPIDEMIOL, V143, P808	8	8	8	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	MAY 1	1999	353	9163					1462	1462		10.1016/S0140-6736(99)90026-0	http://dx.doi.org/10.1016/S0140-6736(99)90026-0			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	195XV	10232310				2022-12-28	WOS:000080278200007
J	Michaelsson, K; Baron, JA; Farahmand, BY; Persson, I; Ljunghall, S				Michaelsson, K; Baron, JA; Farahmand, BY; Persson, I; Ljunghall, S			Oral-contraceptive use and risk of hip fracture: a case-control study	LANCET			English	Article							BONE-MINERAL DENSITY; DISTAL FOREARM; WOMEN; AGE; OSTEOPOROSIS; MASS; DETERMINANTS; PREVENTION; MENOPAUSAL; CALCIUM	Background Epidemiological studies indicate a protective effect of postmenopausal oestrogen therapy on the risk of osteoporotic fractures. Whether premenopausal oestrogen exposure in the form of oral contraceptives also reduces the risk of osteoporotic fractures remains uncertain. Method We did a population-based case control study of hip fracture among Swedish postmenopausal women, 50-81 years of age, through mailed questionnaires and telephone interviews. Of those women who were eligible, 1327 (82.5%) cases and 3312 (81.6%) randomly selected controls responded. Findings 130 (11.6%) cases and 562 (19.1%) controls reported ever-use of oral contraceptives. Ever-use of oral contraceptives was associated with a 25% reduction in hip fracture risk (odds ratio 0.75 [95% CI 0.59-0.96]). Women who had ever used a high-dose pill (equivalent to greater than or equal to 50 pg ethinylestradiol per tablet) had a 44% lower risk for hip fracture than never-users (0.56 [0.42-0.75]). No overall trend was observed with duration of oral-contraceptive use, or time since last use. However, when making comparisons with women who have never used oral contraceptives, the odds ratios for hip-fracture were 0.69 (0.51-0.94) for use after age 40, 0.82 (0.57-1.16) for use at ages 30-39, and 1.26 (0.76-2.09) for use before age 30. Interpretation Our results imply that in postmenopausal women, oral-contraceptive use late in reproductive life may reduce the risk of hip fracture, although we recognise the limitations of the case-control method.	Univ Uppsala Hosp, Dept Orthopaed, S-75185 Uppsala, Sweden; Univ Uppsala Hosp, Dept Internal Med, S-75185 Uppsala, Sweden; Dartmouth Coll, Hitchcock Med Ctr, Dartmouth Med Sch, Dept Med, Hanover, NH 03756 USA; Dartmouth Coll, Hitchcock Med Ctr, Dartmouth Med Sch, Dept Community & Family Med, Hanover, NH 03756 USA; Stockholm Cty Council, Dept Epidemiol, Stockholm, Sweden; Karolinska Inst, Dept Med Epidemiol, Stockholm, Sweden	Uppsala University; Uppsala University Hospital; Uppsala University; Uppsala University Hospital; Dartmouth College; Dartmouth College; Stockholm County Council; Karolinska Institutet	Michaelsson, K (corresponding author), Univ Uppsala Hosp, Dept Orthopaed, S-75185 Uppsala, Sweden.	Karl.Michaelsson@ortopedi.uu.se	Michaelsson, Karl/AAM-9094-2021	Michaelsson, Karl/0000-0003-2815-1217	NINR NIH HHS [NR 1 RO 1 CA58427] Funding Source: Medline	NINR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Nursing Research (NINR))		BARAN DT, 1994, OSTEOPOROSIS INT, V4, P31; Christiansen C, 1990, Osteoporos Int, V1, P7; COOPER C, 1993, BONE, V14, P41, DOI 10.1016/8756-3282(93)90254-8; CORSON SL, 1993, J REPROD MED, V38, P1015; DeCherney A, 1996, AM J OBSTET GYNECOL, V174, P15, DOI 10.1016/S0002-9378(96)70366-6; ENZELSBERGER H, 1988, MATURITAS, V9, P375, DOI 10.1016/0378-5122(88)90103-X; FORTNEY JA, 1994, J REPROD MED, V39, P105; GAMBACCIANI M, 1994, OBSTET GYNECOL, V83, P392; GOLDSMITH NF, 1975, J BONE JOINT SURG AM, V57, P657, DOI 10.2106/00004623-197557050-00014; GOULDING A, 1977, CLIN ENDOCRINOL, V6, P449, DOI 10.1111/j.1365-2265.1977.tb03328.x; Hansen M A, 1991, Osteoporos Int, V1, P95; HEANEY RP, 1992, J INTERN MED, V231, P169, DOI 10.1111/j.1365-2796.1992.tb00520.x; HILLARD TC, 1991, CALCIFIED TISSUE INT, V49, pS55, DOI 10.1007/BF02555090; HRESCHYSHYN MM, 1998, AM J OBSTET GYNECOL, V159, P318; Johansson C, 1996, MATURITAS, V24, P97, DOI 10.1016/0378-5122(95)01024-6; KLEEREKOPER M, 1991, ARCH INTERN MED, V151, P1971, DOI 10.1001/archinte.151.10.1971; LINDSAY R, 1986, CONTRACEPTION, V34, P333, DOI 10.1016/0010-7824(86)90086-7; Magnusson C, 1998, INT J CANCER, V76, P29, DOI 10.1002/(SICI)1097-0215(19980330)76:1<29::AID-IJC6>3.3.CO;2-1; MALLMIN H, 1994, OSTEOPOROSIS INT, V4, P298, DOI 10.1007/BF01622186; MAZESS RB, 1991, AM J CLIN NUTR, V53, P132, DOI 10.1093/ajcn/53.1.132; Michaelsson K, 1998, BMJ-BRIT MED J, V316, P1858; MUSEY VC, 1987, AM J OBSTET GYNECOL, V157, P312, DOI 10.1016/S0002-9378(87)80159-X; NAESSEN T, 1989, AM J EPIDEMIOL, V130, P289, DOI 10.1093/oxfordjournals.aje.a115335; NILAS L, 1987, J CLIN ENDOCR METAB, V65, P697, DOI 10.1210/jcem-65-4-697; NISCHAN P, 1993, AM J EPIDEMIOL, V138, P697, DOI 10.1093/oxfordjournals.aje.a116907; Norell SE, 1998, INT J EPIDEMIOL, V27, P1033, DOI 10.1093/ije/27.6.1033; ONeill TW, 1996, J EPIDEMIOL COMMUN H, V50, P288, DOI 10.1136/jech.50.3.288; ONeill TW, 1997, OSTEOPOROSIS INT, V7, P72, DOI 10.1007/BF01623464; PRIOR JC, 1990, ENDOCR REV, V11, P386, DOI 10.1210/edrv-11-2-386; RECKER RR, 1992, JAMA-J AM MED ASSOC, V268, P2403, DOI 10.1001/jama.268.17.2403; Rizzoli R, 1997, LANCET, V349, pS20, DOI 10.1016/S0140-6736(97)90007-6; STEINBERG KK, 1987, J CLIN ENDOCR METAB, V65, P697; STEVENSON JC, 1989, BRIT MED J, V298, P924, DOI 10.1136/bmj.298.6678.924; TUPPURAINEN M, 1994, OSTEOPOROSIS INT, V4, P93, DOI 10.1007/BF01623231	34	101	103	0	4	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	MAY 1	1999	353	9163					1481	1484		10.1016/S0140-6736(98)09044-8	http://dx.doi.org/10.1016/S0140-6736(98)09044-8			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	195XV	10232314				2022-12-28	WOS:000080278200011
J	Rye, HS; Roseman, AM; Chen, SX; Furtak, K; Fenton, WA; Saibil, HR; Horwich, AL				Rye, HS; Roseman, AM; Chen, SX; Furtak, K; Fenton, WA; Saibil, HR; Horwich, AL			GroEL-GroES cycling: ATP and nonnative polypeptide direct alternation of folding-active rings	CELL			English	Article							CHAPERONIN GROEL; PROTEIN; BINDING; RELEASE; SUBSTRATE; COMPLEXES; DYNAMICS; CONSEQUENCES; INTERMEDIATE; NUCLEOTIDES	The double-ring chaperonin GroEL mediates protein folding in the central cavity of a ring bound by ATP and GroES, but it is unclear how GroEL cycles from one folding-active complex to the next. We observe that hydrolysis of ATP within the cis ring must occur before either nonnative polypeptide or GroES can bind to the trans ring, and this is associated with reorientation of the trans ring apical domains. Subsequently, formation of a new cis-ternary complex proceeds on the open trans ring with polypeptide binding first, which stimulates the ATP-dependent dissociation of the cis complex (by 20- to 50-fold), followed by GroES binding. These results indicate that, in the presence of nonnative protein, GroEL alternates its rings as folding-active cis complexes, expending only one round of seven ATPs per folding cycle.	Yale Univ, Sch Med, Howard Hughes Med Inst, New Haven, CT 06510 USA; Yale Univ, Sch Med, Dept Genet, New Haven, CT 06510 USA; Univ London Birkbeck Coll, Dept Crystallog, London WC1E 7HX, England	Howard Hughes Medical Institute; Yale University; Yale University; University of London; Birkbeck University London	Horwich, AL (corresponding author), Yale Univ, Sch Med, Howard Hughes Med Inst, 333 Cedar St, New Haven, CT 06510 USA.		Roseman, Alan/AAE-6689-2019	Roseman, Alan/0000-0002-4783-2619; Rye, Hays/0000-0002-9420-3137	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		BADCOE IG, 1991, BIOCHEMISTRY-US, V30, P9195, DOI 10.1021/bi00102a010; BRUNGER AT, 1992, X PLOY V 3 1 MANUAL; Buckle AM, 1997, P NATL ACAD SCI USA, V94, P3571, DOI 10.1073/pnas.94.8.3571; BURSTON SG, 1995, J MOL BIOL, V249, P138, DOI 10.1006/jmbi.1995.0285; CHEN S, 1994, NATURE, V371, P261, DOI 10.1038/371261a0; Corrales FJ, 1996, FOLD DES, V1, P265, DOI 10.1016/S1359-0278(96)00040-5; FENTON WA, 1994, NATURE, V371, P614, DOI 10.1038/371614a0; Frank J, 1996, J STRUCT BIOL, V116, P190, DOI 10.1006/jsbi.1996.0030; Goldberg MS, 1997, P NATL ACAD SCI USA, V94, P1080, DOI 10.1073/pnas.94.4.1080; Gutfreund H, 1995, KINETICS LIFE SCI; Inbar E, 1997, BIOCHEMISTRY-US, V36, P12276, DOI 10.1021/bi9714870; ITZHAKI LS, 1995, BIOCHEMISTRY-US, V34, P14581, DOI 10.1021/bi00044a037; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Kad NM, 1998, J MOL BIOL, V278, P267, DOI 10.1006/jmbi.1998.1704; Katsumata K, 1996, J MOL BIOL, V258, P827, DOI 10.1006/jmbi.1996.0290; LIN ZL, 1995, J BIOL CHEM, V270, P1011, DOI 10.1074/jbc.270.3.1011; LLORCA O, 1994, FEBS LETT, V345, P181, DOI 10.1016/0014-5793(94)00432-3; Lorimer G, 1997, NATURE, V388, P720, DOI 10.1038/41892; Lorimer GH, 1996, FASEB J, V10, P5, DOI 10.1096/fasebj.10.1.8566548; Murai N, 1996, J BIOL CHEM, V271, P28229, DOI 10.1074/jbc.271.45.28229; Ranson NA, 1997, J MOL BIOL, V266, P656, DOI 10.1006/jmbi.1996.0815; Roseman AM, 1996, CELL, V87, P241, DOI 10.1016/S0092-8674(00)81342-2; ROY H, 1992, PROTEIN SCI, V1, P925, DOI 10.1002/pro.5560010711; Rye HS, 1997, NATURE, V388, P792, DOI 10.1038/42047; SMITH KE, 1995, J BIOL CHEM, V270, P21517, DOI 10.1074/jbc.270.37.21517; Sparrer H, 1996, J MOL BIOL, V258, P74, DOI 10.1006/jmbi.1996.0235; Sparrer H, 1997, J BIOL CHEM, V272, P14080, DOI 10.1074/jbc.272.22.14080; STANIFORTH RA, 1994, BIOCHEM J, V300, P651, DOI 10.1042/bj3000651; TAGUCHI H, 1995, FEBS LETT, V359, P195, DOI 10.1016/0014-5793(95)00041-7; TODD MJ, 1994, SCIENCE, V265, P659, DOI 10.1126/science.7913555; Torok Z, 1996, J BIOL CHEM, V271, P16180, DOI 10.1074/jbc.271.27.16180; Van Der Meer B. W., 1994, RESONANCE ENERGY TRA; vanHeel M, 1996, J STRUCT BIOL, V116, P17, DOI 10.1006/jsbi.1996.0004; WEISSMAN JS, 1994, CELL, V78, P693, DOI 10.1016/0092-8674(94)90533-9; Weissman JS, 1996, CELL, V84, P481, DOI 10.1016/S0092-8674(00)81293-3; WEISSMAN JS, 1995, CELL, V83, P577, DOI 10.1016/0092-8674(95)90098-5	36	272	274	0	23	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	APR 30	1999	97	3					325	338		10.1016/S0092-8674(00)80742-4	http://dx.doi.org/10.1016/S0092-8674(00)80742-4			14	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	192VP	10319813	hybrid			2022-12-28	WOS:000080100500006
J	Naar, AM; Beaurang, PA; Zhou, S; Abraham, S; Solomon, W; Tjian, R				Naar, AM; Beaurang, PA; Zhou, S; Abraham, S; Solomon, W; Tjian, R			Composite co-activator ARC mediates chromatin-directed transcriptional activation	NATURE			English	Article							RNA-POLYMERASE-II; CREB-BINDING PROTEIN; COMPLEX; RECEPTOR; COACTIVATOR; INTERACTS; ACETYLATION; MECHANISMS; DOMAIN; YEAST	Gene activation in eukaryotes is regulated by complex mechanisms in which the recruitment and assembly of the transcriptional machinery is directed by gene- and cell-type-specific DNA-binding proteins(1). When DNA is packaged into chromatin, the regulation of gene activation requires new classes of chromatin-targeting activity(2), In humans, a multisubunit cofactor functions in a chromatin-selective manner to potentiate synergistic gene activation by the transcriptional activators SREBP-1a and Sp1 (ref, 3). Here we show that this activator-recruited cofactor (ARC) interacts directly with several different activators, including SREBP-1a, VP16 and the p65 subunit of NF-kappa B, and strongly enhances transcription directed by these activators in vitro with chromatin-assembled DNA templates. The ARC complex consists of 16 or more subunits; some of these are novel gene products, whereas others are present in other multisubunit cofactors, such as CRSP4, NAT(5) and mammalian Mediator(6). Detailed analysis indicates that the ARC complex is probably identical to the nuclear hormone-receptor cofactor DRIP7. Thus, ARC/DRIP is a large composite coactivator that belongs to a family of related cofactors and is targeted by different classes of activator to mediate transcriptional stimulation.	Univ Calif Berkeley, Howard Hughes Med Inst, Dept Mol & Cell Biol, Berkeley, CA 94720 USA; SUNY Hlth Sci Ctr, Dept Microbiol & Immunol, Morse Inst Mol Genet, Brooklyn, NY 11203 USA	Howard Hughes Medical Institute; University of California System; University of California Berkeley; State University of New York (SUNY) System; State University of New York (SUNY) Downstate Medical Center	Tjian, R (corresponding author), Univ Calif Berkeley, Howard Hughes Med Inst, Dept Mol & Cell Biol, 401 Barker Hall, Berkeley, CA 94720 USA.							DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; Drane P, 1997, ONCOGENE, V15, P3013, DOI 10.1038/sj.onc.1201492; Fondell JD, 1996, MOL CELL BIOL, V16, P281; Gerritsen ME, 1997, P NATL ACAD SCI USA, V94, P2927, DOI 10.1073/pnas.94.7.2927; Grant PA, 1998, CELL, V94, P45, DOI 10.1016/S0092-8674(00)81220-9; Gu W, 1999, MOL CELL, V3, P97, DOI 10.1016/S1097-2765(00)80178-1; Jiang YW, 1998, P NATL ACAD SCI USA, V95, P8538, DOI 10.1073/pnas.95.15.8538; KAMAKAKA RT, 1993, GENE DEV, V7, P1779, DOI 10.1101/gad.7.9.1779; KIM YJ, 1994, CELL, V77, P599, DOI 10.1016/0092-8674(94)90221-6; LEE JK, 1995, EXPERT SYST APPL, V9, P3, DOI 10.1016/0957-4174(94)00043-U; LILLIE JW, 1989, NATURE, V338, P39, DOI 10.1038/338039a0; Myers LC, 1998, GENE DEV, V12, P45, DOI 10.1101/gad.12.1.45; Naar AM, 1998, GENE DEV, V12, P3020, DOI 10.1101/gad.12.19.3020; Ogryzko VV, 1998, CELL, V94, P35, DOI 10.1016/S0092-8674(00)81219-2; Oliner JD, 1996, GENE DEV, V10, P2903, DOI 10.1101/gad.10.22.2903; Perkins ND, 1997, SCIENCE, V275, P523, DOI 10.1126/science.275.5299.523; Rachez C, 1999, NATURE, V398, P824, DOI 10.1038/19783; Rachez C, 1998, GENE DEV, V12, P1787, DOI 10.1101/gad.12.12.1787; REGIER JL, 1993, P NATL ACAD SCI USA, V90, P883, DOI 10.1073/pnas.90.3.883; Ryu SJ, 1999, NATURE, V397, P446, DOI 10.1038/17141; Sauer F, 1997, CURR OPIN GENET DEV, V7, P176, DOI 10.1016/S0959-437X(97)80126-8; Struhl K, 1998, GENE DEV, V12, P599, DOI 10.1101/gad.12.5.599; Sun XQ, 1998, MOL CELL, V2, P213, DOI 10.1016/S1097-2765(00)80131-8; Yuan CX, 1998, P NATL ACAD SCI USA, V95, P7939, DOI 10.1073/pnas.95.14.7939; Zhu YJ, 1997, J BIOL CHEM, V272, P25500, DOI 10.1074/jbc.272.41.25500	25	356	366	0	10	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	APR 29	1999	398	6730					828	832		10.1038/19789	http://dx.doi.org/10.1038/19789			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	192BL	10235267				2022-12-28	WOS:000080058100063
J	Greenspan, SL				Greenspan, SL			A 73-year-old woman with osteoporosis	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material							BONE-MINERAL DENSITY; POSTMENOPAUSAL OSTEOPOROSIS; ELDERLY WOMEN; HIP FRACTURE; RISK-FACTORS; ESTABLISHED OSTEOPOROSIS; VERTEBRAL FRACTURES; REPLACEMENT THERAPY; RANDOMIZED TRIAL; DOUBLE-BLIND		Beth Israel Deaconess Med Ctr, Div Gen Med, Osteoporosis Prevent & Treatment Ctr, Boston, MA 02215 USA; Beth Israel Deaconess Med Ctr, Bone Dens Testing Ctr, Boston, MA 02215 USA; Beth Israel Deaconess Med Ctr, Harvard Thorndike Gen Clin Res Ctr, Boston, MA 02215 USA; Harvard Univ, Sch Med, Boston, MA USA	Harvard University; Beth Israel Deaconess Medical Center; Harvard University; Beth Israel Deaconess Medical Center; Harvard University; Beth Israel Deaconess Medical Center; Harvard University; Harvard Medical School	Greenspan, SL (corresponding author), Beth Israel Deaconess Med Ctr, Div Gen Med, Osteoporosis Prevent & Treatment Ctr, 330 Brookline Ave,LY318, Boston, MA 02215 USA.							Baran DT, 1997, CALCIFIED TISSUE INT, V61, P433, DOI 10.1007/s002239900362; Black DM, 1996, LANCET, V348, P1535, DOI 10.1016/S0140-6736(96)07088-2; Bush TL, 1996, JAMA-J AM MED ASSOC, V276, P1389, DOI 10.1001/jama.276.17.1389; CAULEY JA, 1995, ANN INTERN MED, V122, P9, DOI 10.7326/0003-4819-122-1-199501010-00002; CHAPUY MC, 1992, NEW ENGL J MED, V327, P1637, DOI 10.1056/NEJM199212033272305; CHRISTIANSEN C, 1990, J CLIN ENDOCR METAB, V71, P836, DOI 10.1210/jcem-71-4-836; Col NF, 1997, JAMA-J AM MED ASSOC, V277, P1140, DOI 10.1001/jama.277.14.1140; Cummings SR, 1998, JAMA-J AM MED ASSOC, V280, P2077, DOI 10.1001/jama.280.24.2077; CUMMINGS SR, 1995, NEW ENGL J MED, V332, P767, DOI 10.1056/NEJM199503233321202; CUMMINGS SR, 1993, LANCET, V341, P72, DOI 10.1016/0140-6736(93)92555-8; CUMMINGS SR, 1986, ANN INTERN MED, V104, P817, DOI 10.7326/0003-4819-104-6-817; DawsonHughes B, 1997, NEW ENGL J MED, V337, P670, DOI 10.1056/NEJM199709043371003; DAWSONHUGHES B, 1990, CALCIFIED TISSUE INT, V46, P280, DOI 10.1007/BF02555008; Delmas PD, 1997, NEW ENGL J MED, V337, P1641, DOI 10.1056/NEJM199712043372301; Eastell R, 1998, NEW ENGL J MED, V338, P736, DOI 10.1056/NEJM199803123381107; ENSRUD K, 1998, BONE, V23, pS174; ETTINGER B, 1987, ANN INTERN MED, V106, P40, DOI 10.7326/0003-4819-106-1-40; FINKELSTEIN JS, 1989, J CLIN ENDOCR METAB, V69, P776, DOI 10.1210/jcem-69-4-776; GENANT HK, 1990, OBSTET GYNECOL, V76, P579; Genant HK, 1997, ARCH INTERN MED, V157, P2609, DOI 10.1001/archinte.157.22.2609; Genant HK, 1996, J BONE MINER RES, V11, P707; GREENSPAN S, 1998, BONE S, V23, pS174; Greenspan SL, 1998, J BONE MINER RES, V13, P1431, DOI 10.1359/jbmr.1998.13.9.1431; GREENSPAN SL, 1994, JAMA-J AM MED ASSOC, V271, P128, DOI 10.1001/jama.271.2.128; Greenspan SL, 1997, J BONE MINER RES, V12, P1303, DOI 10.1359/jbmr.1997.12.8.1303; GREENSPAN SL, 1994, J BONE MINER RES, V9, P1959, DOI 10.1002/jbmr.5650091216; GRISSO JA, 1991, NEW ENGL J MED, V324, P1326, DOI 10.1056/NEJM199105093241905; Hulley S, 1998, JAMA-J AM MED ASSOC, V280, P605, DOI 10.1001/jama.280.7.605; Institute of Medicine, 1997, DIETARY REFERENCE IN; JOHNSTON CC, 1992, NEW ENGL J MED, V327, P82, DOI 10.1056/NEJM199207093270204; Kanis J, 1998, OSTEOPOROSIS INT, V8, pS1; KANIS JA, 1994, OSTEOPOROSIS INT, V4, P368, DOI 10.1007/BF01622200; KANIS JA, 1994, J BONE MINER RES, V9, P1137, DOI 10.1002/jbmr.5650090802; KELLIE SE, 1992, JAMA-J AM MED ASSOC, V267, P286; LIBERMAN UA, 1995, NEW ENGL J MED, V333, P1437, DOI 10.1056/NEJM199511303332201; Lindsay R, 1997, OSTEOPOROSIS INT, V7, P1; LINDSAY R, 1990, OBSTET GYNECOL, V76, P290; Lindsay R, 1997, LANCET, V350, P550, DOI 10.1016/S0140-6736(97)02342-8; LINDSAY R, 1984, OBSTET GYNECOL, V63, P759; Looker AC, 1997, J BONE MINER RES, V12, P1761, DOI 10.1359/jbmr.1997.12.11.1761; LUFKIN EG, 1992, ANN INTERN MED, V117, P1, DOI 10.7326/0003-4819-117-1-1; LYRITIS GP, 1991, CALCIFIED TISSUE INT, V49, P369, DOI 10.1007/BF02555844; Marshall D, 1996, BRIT MED J, V312, P1254, DOI 10.1136/bmj.312.7041.1254; McClung M, 1998, ANN INTERN MED, V128, P253, DOI 10.7326/0003-4819-128-4-199802150-00001; MELTON LJ, 1993, J BONE MINER RES, V8, P1227; MELTON LJ, 1992, J BONE MINER RES, V7, P1005, DOI 10.1002/jbmr.5650070902; MELTON LJ, 1983, OSTEOPOROTIC SYNDROM, P45; MELTON LJ, 1988, OSTEOPOROSIS ETIOLOG, P111; *NAT OST FDN, 1998, PHYS GUID PREV TREAT, P1; ORWOLL ES, 1990, J CLIN ENDOCR METAB, V70, P1202, DOI 10.1210/jcem-70-4-1202; OVERGAARD K, 1992, BRIT MED J, V305, P556, DOI 10.1136/bmj.305.6853.556; PAK CYC, 1995, ANN INTERN MED, V123, P401, DOI 10.7326/0003-4819-123-6-199509150-00001; PRAEMER A, 1992, MUSCULOSKELETAL COND, P143; Ray NF, 1997, J BONE MINER RES, V12, P24, DOI 10.1359/jbmr.1997.12.1.24; RIGGS BL, 1990, NEW ENGL J MED, V322, P802, DOI 10.1056/NEJM199003223221203; RIGGS BL, 1986, NEW ENGL J MED, V314, P1676, DOI 10.1056/NEJM198606263142605; Ross PD, 1996, CALCIFIED TISSUE INT, V59, P339, DOI 10.1007/s002239900137; STOCK JL, 1997, J BONE MINER RES  S1, V12, pS149; STORM T, 1992, J BONE MINER RES, V7, pS117; TINETTI ME, 1994, NEW ENGL J MED, V331, P821, DOI 10.1056/NEJM199409293311301; WATTS NB, 1990, NEW ENGL J MED, V323, P73, DOI 10.1056/NEJM199007123230201; WIMALAWANSA SJ, 1995, AM J MED, V99, P36, DOI 10.1016/S0002-9343(99)80102-8; 1998, FED REG, V63, P34321	64	7	7	0	4	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	APR 28	1999	281	16					1531	1540		10.1001/jama.281.16.1531	http://dx.doi.org/10.1001/jama.281.16.1531			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	188PP	10227324				2022-12-28	WOS:000079857400036
J	Landick, R				Landick, R			Transcription - Shifting RNA polymerase into overdrive	SCIENCE			English	Editorial Material							ELONGATION; TERMINATION; MECHANISM; DNA; HAIRPIN; PROTEIN; COMPLEX; PAUSE; MODEL		Univ Wisconsin, Dept Bacteriol, Madison, WI 53706 USA	University of Wisconsin System; University of Wisconsin Madison	Landick, R (corresponding author), Univ Wisconsin, Dept Bacteriol, Madison, WI 53706 USA.							BENTLEY DL, 1995, CURR OPIN GENET DEV, V5, P210, DOI 10.1016/0959-437X(95)80010-7; Chan CL, 1997, J MOL BIOL, V268, P54, DOI 10.1006/jmbi.1997.0935; Chang CH, 1997, J BIOL CHEM, V272, P23427, DOI 10.1074/jbc.272.37.23427; Chedin S, 1998, GENE DEV, V12, P3857, DOI 10.1101/gad.12.24.3857; DEMERCOYROL L, 1990, BIOCHEM J, V269, P651, DOI 10.1042/bj2690651; Ebright RH, 1998, COLD SPRING HARB SYM, V63, P11, DOI 10.1101/sqb.1998.63.11; Guajardo R, 1997, J MOL BIOL, V265, P8, DOI 10.1006/jmbi.1996.0707; Gusarov I, 1999, MOL CELL, V3, P495, DOI 10.1016/S1097-2765(00)80477-3; Jones KA, 1997, GENE DEV, V11, P2593, DOI 10.1101/gad.11.20.2593; KASHLEV M, 1993, CELL, V75, P147, DOI 10.1016/S0092-8674(05)80091-1; KORNISSAROVA N, 1997, J BIOL CHEM, V272, P15329; KRUMM A, 1993, BIOESSAYS, V15, P659, DOI 10.1002/bies.950151005; McCracken S, 1997, NATURE, V385, P357, DOI 10.1038/385357a0; Mooney RA, 1998, J BACTERIOL, V180, P3265, DOI 10.1128/JB.180.13.3265-3275.1998; Nudler E, 1999, J MOL BIOL, V288, P1, DOI 10.1006/jmbi.1999.2641; Nudler E, 1997, CELL, V89, P33, DOI 10.1016/S0092-8674(00)80180-4; Nudler E, 1996, SCIENCE, V273, P211, DOI 10.1126/science.273.5272.211; Reeder TC, 1996, CELL, V87, P767, DOI 10.1016/S0092-8674(00)81395-1; RTSIMOVITCH I, 1998, GENE DEV, V12, P3110; Shilatifard A, 1997, CURR OPIN GENET DEV, V7, P199, DOI 10.1016/S0959-437X(97)80129-3; Uptain SM, 1997, ANNU REV BIOCHEM, V66, P117, DOI 10.1146/annurev.biochem.66.1.117; von Hippel PH, 1998, SCIENCE, V281, P660, DOI 10.1126/science.281.5377.660; Wang DG, 1997, P NATL ACAD SCI USA, V94, P8433, DOI 10.1073/pnas.94.16.8433; Yarnell WS, 1999, SCIENCE, V284, P611, DOI 10.1126/science.284.5414.611	24	30	31	0	2	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	APR 23	1999	284	5414					598	599		10.1126/science.284.5414.598	http://dx.doi.org/10.1126/science.284.5414.598			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	190FH	10328742				2022-12-28	WOS:000079951100031
J	Wheeler, MH				Wheeler, MH			Total thyroidectomy for benign thyroid disease	LANCET			English	Editorial Material							CANCER		Univ Wales Hosp, Dept Endocrine Surg, Cardiff CF4 4XW, S Glam, Wales	Cardiff University	Wheeler, MH (corresponding author), Univ Wales Hosp, Dept Endocrine Surg, Cardiff CF4 4XW, S Glam, Wales.							BEAHRS OH, 1963, SURG GYNECOL OBSTET, V117, P535; CADY B, 1979, CANCER, V43, P810, DOI 10.1002/1097-0142(197903)43:3<810::AID-CNCR2820430306>3.0.CO;2-B; CADY B, 1986, WORLD J SURG, V10, P786; CATZ B, 1969, AM J SURG, V118, P434, DOI 10.1016/0002-9610(69)90151-2; CLARK OH, 1982, ANN SURG, V196, P361, DOI 10.1097/00000658-198209000-00016; DEGROOT L, 1973, JAMA-J AM MED ASSOC, V225, P487, DOI 10.1001/jama.225.5.487; GOUGH IR, 1992, AUST NZ J SURG, V62, P87; HARNESS JK, 1986, WORLD J SURG, V10, P781, DOI 10.1007/BF01655238; KHADRA M, 1992, AUST NZ J SURG, V62, P91; Kocher T, 1903, TXB OPERATIVE SURG, P133; Liu Q, 1998, SURGERY, V123, P2, DOI 10.1067/msy.1998.83301; REEVE TS, 1987, ANN SURG, V206, P782, DOI 10.1097/00000658-198712000-00016; SMEDS S, 1997, TXB ENDOCRINE SURG, P205; Stephenson B M, 1994, Curr Opin Gen Surg, P53; WINSA B, 1995, EUR J ENDOCRINOL, V132, P406, DOI 10.1530/eje.0.1320406	15	44	47	0	2	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	MAY 23	1998	351	9115					1526	1527		10.1016/S0140-6736(05)61116-6	http://dx.doi.org/10.1016/S0140-6736(05)61116-6			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZQ497	10326531				2022-12-28	WOS:000073868000004
J	Cogoni, C; Macino, G				Cogoni, C; Macino, G			Gene silencing in Neurospora crassa requires a protein homologous to RNA-dependent RNA polymerase	NATURE			English	Article							DOUBLE-STRANDED-RNA; TRANSGENIC PLANTS; SEQUENCE; EXPRESSION; DNA; INTERFERENCE; INACTIVATION; SUPPRESSION; DEGRADATION; CLONING	In plants and fungi, the introduction of transgenes can lead to post-transcriptional gene silencing(1,2). This phenomenon, in which expression of the transgene and of endogenous genes containing sequences homologous to the transgene can be blocked, is involved in virus resistance(3-5) and genome maintenance(6,7). Transgene-induced gene silencing has been termed quelling in Neurospora crassa and co-suppression in plants. Quelling-defective (qde) mutants of N. crassa, in which transgene-induced gene silencing is impaired, have been isolated(8). Here we report the cloning of qde-1, the first cellular component of the gene-silencing mechanism to be isolated, which defines a new gene family conserved among different species including plants, animals and fungi. The qde-1 gene product is similar to an RNA-dependent RNA polymerase found in the tomato(9). The identification of qde-1 strongly supports models that implicate an RNA-dependent RNA polymerase in the post-transcriptional gene-silencing mechanism. The presence of qde-1 homologues in a variety of species of plants and fungi indicates that a conserved gene-silencing mechanism may exist, which could have evolved to preserve genome integrity and to protect the genome against naturally occurring transposons and viruses.	Univ Rome La Sapienza, Dipartimento Biotecnol Cellulari & Ematol, Sez Genet Mol, I-00161 Rome, Italy	Sapienza University Rome	Macino, G (corresponding author), Univ Rome La Sapienza, Dipt Biotecnol Cellulari & Ematol, Sez Genet Mol, Viale Regina Elena 324, I-00161 Rome, Italy.							ASSAAD FF, 1993, PLANT MOL BIOL, V22, P1067, DOI 10.1007/BF00028978; Baulcombe DC, 1996, PLANT MOL BIOL, V32, P79, DOI 10.1007/BF00039378; Bingham PM, 1997, CELL, V90, P385, DOI 10.1016/S0092-8674(00)80496-1; CABIBBO A, 1991, FUNGAL GENET NEWSL, V38, P68; Cogoni C, 1997, TRENDS PLANT SCI, V2, P438, DOI 10.1016/S1360-1385(97)90028-5; Cogoni C, 1997, P NATL ACAD SCI USA, V94, P10233, DOI 10.1073/pnas.94.19.10233; Cogoni C, 1996, EMBO J, V15, P3153, DOI 10.1002/j.1460-2075.1996.tb00678.x; Davis R.H., 1970, METHODS ENZYMOL, V17, P79, DOI [10.1016/0076-6879(71)17168-6, DOI 10.1016/0076-6879(71)17168-6]; Depicker A, 1997, CURR OPIN CELL BIOL, V9, P373, DOI 10.1016/S0955-0674(97)80010-5; Fire A, 1998, NATURE, V391, P806, DOI 10.1038/35888; FLAVELL RB, 1994, P NATL ACAD SCI USA, V91, P3490, DOI 10.1073/pnas.91.9.3490; Kasschau KD, 1998, CELL, V95, P461, DOI 10.1016/S0092-8674(00)81614-1; LINDBO JA, 1993, PLANT CELL, V5, P1749, DOI 10.1105/tpc.5.12.1749; MANIATIS ST, 1982, MOL CLONING LAB MANU; Matzke MA, 1996, TRENDS PLANT SCI, V1, P382, DOI 10.1016/S1360-1385(96)80313-X; Metzlaff M, 1997, CELL, V88, P845, DOI 10.1016/S0092-8674(00)81930-3; Montgomery MK, 1998, TRENDS GENET, V14, P255, DOI 10.1016/S0168-9525(98)01510-8; MORELLI G, 1993, METHOD ENZYMOL, V214, P412; Palauqui JC, 1997, EMBO J, V16, P4738, DOI 10.1093/emboj/16.15.4738; Ratcliff F, 1997, SCIENCE, V276, P1558, DOI 10.1126/science.276.5318.1558; ROMANO N, 1992, MOL MICROBIOL, V6, P3343, DOI 10.1111/j.1365-2958.1992.tb02202.x; Schiebel W, 1998, PLANT CELL, V10, P2087, DOI 10.1105/tpc.10.12.2087; SCHMIDHAUSER TJ, 1990, MOL CELL BIOL, V10, P5064, DOI 10.1128/MCB.10.10.5064; Staben C, 1989, FUNGAL GENET NEWSL, V36, P79, DOI DOI 10.4148/1941-4765.1519; Stam M, 1997, ANN BOT-LONDON, V79, P3, DOI 10.1006/anbo.1996.0295; Timmons L, 1998, NATURE, V395, P854, DOI 10.1038/27579; Voinnet O, 1997, NATURE, V389, P553, DOI 10.1038/39215; Voinnet O, 1998, CELL, V95, P177, DOI 10.1016/S0092-8674(00)81749-3; VOLLMER SJ, 1986, P NATL ACAD SCI USA, V83, P4869, DOI 10.1073/pnas.83.13.4869; Wassenegger M, 1998, PLANT MOL BIOL, V37, P349, DOI 10.1023/A:1005946720438	30	491	592	3	47	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	MAY 13	1999	399	6732					166	169		10.1038/20215	http://dx.doi.org/10.1038/20215			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	196XU	10335848				2022-12-28	WOS:000080335700054
J	Lowance, D; Neumayer, HH; Legendre, CM; Squifflet, JP; Kovarik, J; Brennan, PJ; Norman, D; Mendez, R; Keating, MR; Coggon, GL; Crisp, A; Lee, IC				Lowance, D; Neumayer, HH; Legendre, CM; Squifflet, JP; Kovarik, J; Brennan, PJ; Norman, D; Mendez, R; Keating, MR; Coggon, GL; Crisp, A; Lee, IC		Int Valacyclovir Cytomegalovirus Prophylaxis Tr	Valacyclovir for the prevention of cytomegalovirus disease after renal transplantation	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							SOLID-ORGAN TRANSPLANTATION; ORAL ACYCLOVIR PROPHYLAXIS; ALLOGRAFT RECIPIENTS; MYCOPHENOLATE MOFETIL; REJECTION EPISODES; CONTROLLED TRIAL; HIGH-RISK; INFECTION; GANCICLOVIR; IMPACT	Background Cytomegalovirus (CMV) disease is a major complication of organ transplantation. We hypothesized that prophylactic treatment with valacyclovir would reduce the risk of CMV disease. Methods A total of 208 CMV-negative recipients of a kidney from a seropositive donor and 408 CMV-positive recipients were randomly assigned to receive either 2 g of valacyclovir or placebo orally four times daily for 90 days after transplantation, with the dose adjusted according to renal function. The primary end point was laboratory-confirmed CMV disease in the first six months after transplantation. Results Treatment with valacyclovir reduced the incidence or delayed the onset of CMV disease in both the seronegative patients (P<0.001) and the seropositive patients (P=0.03). Among the seronegative patients, the incidence of CMV disease 90 days after transplantation was 45 percent among placebo recipients and 3 percent among valacyclovir recipients. Among the seropositive patients, the respective values were 6 percent and 0 percent. At six months, the incidence of CMV disease was 45 percent among seronegative recipients of placebo and 16 percent among seronegative recipients of valacyclovir; it was 6 percent among seropositive placebo recipients and 1 percent among seropositive valacyclovir recipients. At six months, the rate of biopsy-confirmed acute graft rejection in the seronegative group was 52 percent among placebo recipients and 26 percent among valacyclovir recipients (P=0.001). Treatment with valacyclovir also decreased the rates of CMV viremia and viruria, herpes simplex virus disease, and the use of inpatient medical resources. Hallucinations and confusion were more common with valacyclovir treatment, but these events were not severe or treatment limiting. The rates of other adverse events were similar among the groups. Conclusions Prophylactic treatment with valacyclovir is a safe and effective way to prevent CMV disease after renal transplantation. (N Engl J Med 1999; 340:1462-70.) (C) 1999, Massachusetts Medical Society.	Piedmont Hosp, Dept Internal Med, Atlanta, GA 30367 USA; Univ Erlangen Nurnberg, Med Klin, Dept Nephrol, D-8520 Erlangen, Germany; Hop Necker Enfants Malad, Serv Reanimat & Transplantat, Paris, France; Univ Catholique Louvain, Clin Univ St Luc, Dept Transplantat, B-1200 Brussels, Belgium; Univ Clin 3, Dept Nephrol & Dialysis, Vienna, Austria; Hosp Univ Penn, Infect Control Off, Philadelphia, PA USA; Oregon Hlth Sci Univ, Dept Immunogenet, Portland, OR USA; Natl Inst Transplantat, Los Angeles, CA USA; Mayo Clin, Rochester, MN USA; Glaxo Wellcome Res & Dev Ltd, Dept Infect Dis Clin Res, Greenford, Middx, England; Glaxo Wellcome Res & Dev Ltd, Dept Clin Studies, Greenford, Middx, England	University of Erlangen Nuremberg; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Necker-Enfants Malades - APHP; UDICE-French Research Universities; Universite Paris Cite; Universite Catholique Louvain; Cliniques Universitaires Saint-Luc; University of Pennsylvania; Pennsylvania Medicine; Oregon Health & Science University; Mayo Clinic; GlaxoSmithKline; GlaxoSmithKline	Lowance, D (corresponding author), Piedmont Hosp, Dept Internal Med, Suite 610,Piedmont Prof Bldg,35 Collier Rd NW, Atlanta, GA 30367 USA.							BALFOUR HH, 1989, NEW ENGL J MED, V320, P1381, DOI 10.1056/NEJM198905253202105; CANDINAS D, 1994, SCHWEIZ MED WSCHR, V124, P1789; CHATTERJEE SN, 1978, JAMA-J AM MED ASSOC, V240, P2446, DOI 10.1001/jama.240.22.2446; CHITWOOD KK, 1993, CLIN TRANSPLANT, V7, P320; COLE NL, 1987, DIAGN MICR INFEC DIS, V6, P255, DOI 10.1016/0732-8893(87)90020-4; CONTI DJ, 1995, ARCH SURG-CHICAGO, V130, P1217; Couchoud C, 1998, TRANSPLANTATION, V65, P641, DOI 10.1097/00007890-199803150-00007; COX DR, 1972, J R STAT SOC B, V34, P187; DUNN DL, 1994, TRANSPLANTATION, V57, P876, DOI 10.1097/00007890-199403270-00019; DUNN DL, 1991, TRANSPLANTATION, V51, P98, DOI 10.1097/00007890-199101000-00015; FLETCHER CV, 1991, ANTIMICROB AGENTS CH, V35, P938, DOI 10.1128/AAC.35.5.938; FRYD DS, 1980, TRANSPLANTATION, V30, P436, DOI 10.1097/00007890-198012000-00010; Gavalda J, 1997, TRANSPL INT, V10, P462; GULANIKAR AC, 1992, TRANSPLANTATION, V53, P323, DOI 10.1097/00007890-199202010-00013; HIBBERD PL, 1992, TRANSPLANTATION, V53, P68, DOI 10.1097/00007890-199201000-00013; HO M, 1991, TRANSPLANT P, V23, P2; JORDAN ML, 1992, J UROLOGY, V148, P1388, DOI 10.1016/S0022-5347(17)36918-5; Kletzmayr J, 1996, J AM SOC NEPHROL, V7, P325; LINDHOLM A, 1993, TRANSPLANTATION, V56, P307, DOI 10.1097/00007890-199308000-00010; MARKER SC, 1981, SURGERY, V89, P660; Mayer AD, 1997, TRANSPLANTATION, V64, P436, DOI 10.1097/00007890-199708150-00012; MCCARTHY JM, 1993, TRANSPLANTATION, V55, P1277, DOI 10.1097/00007890-199306000-00013; METSELAAR HJ, 1989, J ANTIMICROB CHEMOTH, V23, P37, DOI 10.1093/jac/23.suppl_E.37; MORRIS DJ, 1994, DRUG SAFETY, V10, P281, DOI 10.2165/00002018-199410040-00002; Murray BM, 1997, IMMUNOL INVEST, V26, P243, DOI 10.3109/08820139709048930; NAIMARK DMJ, 1994, TRANSPLANT REV, V8, P93; Neyts J, 1998, ANTIMICROB AGENTS CH, V42, P216; NICHOLSON ML, 1990, TRANSPLANT P, V22, P1811; POUTEILNOBLE C, 1993, TRANSPLANTATION, V55, P851, DOI 10.1097/00007890-199304000-00032; RAMOS EL, 1991, KIDNEY, P2361; Reusser P, 1996, BAILLIERE CLIN INF D, V3, P357; RUBIN RH, 1990, REV INFECT DIS    S7, V12, P754; SALIBA F, 1993, TRANSPLANT P, V25, P1444; SCHWARZ A, 1991, AM J KIDNEY DIS, V17, P524, DOI 10.1016/S0272-6386(12)80493-8; SOLLINGER HW, 1995, TRANSPLANTATION, V60, P225, DOI 10.1097/00007890-199508000-00003; THE TH, 1994, NETH J MED, V45, P309; VASQUEZ EM, 1993, TRANSPLANTATION, V55, P448, DOI 10.1097/00007890-199302000-00046; Wagner JA, 1995, TRANSPLANTATION, V60, P1473, DOI 10.1097/00007890-199560120-00018; WELLER S, 1993, CLIN PHARMACOL THER, V54, P595, DOI 10.1038/clpt.1993.196; WINSTON DJ, 1995, LANCET, V346, P1380, DOI 10.1016/S0140-6736(95)92401-9	40	527	539	0	9	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	MAY 13	1999	340	19					1462	1470		10.1056/NEJM199905133401903	http://dx.doi.org/10.1056/NEJM199905133401903			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	194MT	10320384				2022-12-28	WOS:000080198700003
J	Berger, M; Muhlhauser, I				Berger, M; Muhlhauser, I			Diabetes care and patient-oriented outcomes	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material							INTENSIFIED INSULIN THERAPY; SEVERE HYPOGLYCEMIA; TEACHING PROGRAM; BLOOD-GLUCOSE; SURVIVAL; MELLITUS; COMPLICATIONS; METAANALYSIS; HYPERTENSION; EDUCATION		Univ Dusseldorf, Dept Metab Dis & Nutr, WHO Collaborating Ctr Diabet Treatment & Prevent, D-40225 Dusseldorf, Germany; Univ Hamburg, Unit Hlth Sci & Educ, Hamburg, Germany	Heinrich Heine University Dusseldorf; University of Hamburg	Berger, M (corresponding author), Univ Dusseldorf, Dept Metab Dis & Nutr, WHO Collaborating Ctr Diabet Treatment & Prevent, Moorenstr 5, D-40225 Dusseldorf, Germany.	bergermi@uni-duesseldorf.de						Amer Diabet Assoc, 1999, DIABETES CARE, V22, pS42; [Anonymous], 1990, Diabet Med, V7, P360; [Anonymous], 1982, Diabetes, V31 Suppl 5, P1; Berger M, 1996, DIABETOLOGIA, V39, P749, DOI 10.1007/s001250050507; Berger M, 1997, DIABETOLOGIA, V40, pS91, DOI 10.1007/s001250051416; BERGER M, 1995, DIABETIC MED, V12, P201, DOI 10.1111/j.1464-5491.1995.tb00459.x; Bott S, 1997, DIABETOLOGIA, V40, P926, DOI 10.1007/s001250050769; Brunelle RL, 1998, DIABETES CARE, V21, P1726, DOI 10.2337/diacare.21.10.1726; Engler RL, 1996, CIRCULATION, V94, P2297, DOI 10.1161/01.CIR.94.9.2297; Estacio RO, 1998, NEW ENGL J MED, V338, P645, DOI 10.1056/NEJM199803053381003; Hansson L, 1998, LANCET, V351, P1755, DOI 10.1016/S0140-6736(98)04311-6; Hayward RA, 1997, JAMA-J AM MED ASSOC, V278, P1663, DOI 10.1001/jama.278.20.1663; KOHNER EM, 1993, BRIT MED J, V307, P1195, DOI 10.1136/bmj.307.6913.1195; Kotsanos JG, 1997, DIABETES CARE, V20, P948, DOI 10.2337/diacare.20.6.948; KRONSBEIN P, 1988, LANCET, V2, P1407; Malmberg K, 1997, BRIT MED J, V314, P1512, DOI 10.1136/bmj.314.7093.1512; Mayfield JA, 1998, DIABETES CARE, V21, P2161, DOI 10.2337/diacare.21.12.2161; MUHLHAUSER I, 1995, J INTERN MED, V237, P591; Muhlhauser I, 1998, DIABETOLOGIA, V41, P1139, DOI 10.1007/s001250051043; MUHLHAUSER I, 1993, J INTERN MED, V233, P321; MUHLHAUSER I, 1987, DIABETOLOGIA, V30, P681, DOI 10.1007/BF00296989; Muller UA, 1999, DIABETES CARE, V22, pB29; Nathan DM, 1998, LANCET, V352, P832, DOI 10.1016/S0140-6736(98)22937-0; Pahor M, 1998, LANCET, V351, P689, DOI 10.1016/S0140-6736(05)78489-0; Parving HH, 1998, DIABETOLOGIA, V41, P745, DOI 10.1007/s001250050983; PIEBER TR, 1995, DIABETES CARE, V18, P625, DOI 10.2337/diacare.18.5.625; Pyorala K, 1997, DIABETES CARE, V20, P614, DOI 10.2337/diacare.20.4.614; Sackett D. L., 1997, EVIDENCE BASED MED P; SAWICKI PT, 1995, J HYPERTENS, V13, P933, DOI 10.1097/00004872-199508000-00015; SHAMOON H, 1995, DIABETES CARE, V18, P361; SHAMOON H, 1993, NEW ENGL J MED, V329, P977, DOI 10.1056/nejm199309303291401; STAROSTINA EG, 1994, DIABETOLOGIA, V37, P170, DOI 10.1007/s001250050089; Stearne MR, 1998, BMJ-BRIT MED J, V317, P703; Tuomilehto J, 1999, NEW ENGL J MED, V340, P677, DOI 10.1056/NEJM199903043400902; Turner RC, 1998, LANCET, V352, P854, DOI 10.1016/s0140-6736(98)07037-8; Turner RC, 1998, LANCET, V352, P837, DOI 10.1016/s0140-6736(98)07019-6; WANG PH, 1993, LANCET, V341, P1306, DOI 10.1016/0140-6736(93)90816-Y; WASSERMAN DH, 1994, DIABETES CARE, V17, P924, DOI 10.2337/diacare.17.8.924	38	51	52	0	0	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAY 12	1999	281	18					1676	1678		10.1001/jama.281.18.1676	http://dx.doi.org/10.1001/jama.281.18.1676			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	193WR	10328053				2022-12-28	WOS:000080161200001
J	Loeser, JD; Melzack, R				Loeser, JD; Melzack, R			Pain: an overview	LANCET			English	Article							PHANTOM	Until the 1960s, pain was considered an inevitable sensory response to tissue damage. There was little room for the affective dimension of this ubiquitous experience, and none whatsoever for the effects of genetic differences, past experience, anxiety, or expectation. In recent years, great advances have been made in our understanding of the mechanisms that underlie pain and in the treatment of people who complain of pain. The roles of factors outside the patient's body have also been clarified. Pain is probably the most common symptomatic reason to seek medical consultation. All of us have headaches, burns, cuts, and other pains at some time during childhood and adult life. Individuals who undergo surgery are almost certain to have postoperative pain. Ageing is also associated with an increased likelihood of chronic pain. Healthcare expenditures for chronic pain are enormous, rivalled only by the costs of wage replacement and welfare programmes for those who do not work because of pain. Despite improved knowledge of underlying mechanisms and better treatments, many people who have chronic pain receive inadequate care.	Univ Washington, Dept Neurol Surg, Seattle, WA 98195 USA; McGill Univ, Dept Psychol, Montreal, PQ, Canada	University of Washington; University of Washington Seattle; McGill University	Loeser, JD (corresponding author), Univ Washington, Dept Neurol Surg, Box 356470, Seattle, WA 98195 USA.							CASSEL EJ, 1982, NEW ENGL J MED, V306, P639, DOI 10.1056/NEJM198203183061104; CHROUSOS GP, 1992, JAMA-J AM MED ASSOC, V267, P1244, DOI 10.1001/jama.267.9.1244; CODERRE T, 1992, PAIN, V42, P259; DUBNER R, 1992, TRENDS NEUROSCI, V15, P96, DOI 10.1016/0166-2236(92)90019-5; GRACELY RH, 1992, PAIN, V51, P175, DOI 10.1016/0304-3959(92)90259-E; Levine J.D., 1994, TXB PAIN, P45; LOESER JD, 1980, P 1 WORLD C CLIN PHA, P316; MELZACK R, 1990, TRENDS NEUROSCI, V13, P88, DOI 10.1016/0166-2236(90)90179-E; MELZACK R, 1978, PAIN, V4, P195, DOI 10.1016/0304-3959(77)90133-6; MELZACK R, 1965, SCIENCE, V150, P971, DOI 10.1126/science.150.3699.971; MELZACK R, 1998, PSYCHOL FACTORS PAIN; Merskey H, 1994, CLASSIFICATION CHRON, P210; RAINVILLE P, 1996, NEUR ABSTR, V614, P2	13	309	329	1	40	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	MAY 8	1999	353	9164					1607	1609		10.1016/S0140-6736(99)01311-2	http://dx.doi.org/10.1016/S0140-6736(99)01311-2			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	195XW	10334273				2022-12-28	WOS:000080278300044
J	Sookhai, S; Redmond, HP; Deasy, JM				Sookhai, S; Redmond, HP; Deasy, JM			Impervious wound-edge protector to reduce postoperative wound infection: a randomised, controlled trial	LANCET			English	Article									Aristotelian Univ Salonika, Sch Med, Dept Microbiol, GR-54006 Salonika, Greece; AHEPA Univ Hosp, Salonika 54006, Greece; Cent Publ Hlth Lab, PHLS, Resp & Systemat Infect Lab, London NW9 5HT, England	Aristotle University of Thessaloniki; Aristotle University of Thessaloniki; Ahepa University Hospital; Public Health England	Redmond, HP (corresponding author), Aristotelian Univ Salonika, Sch Med, Dept Microbiol, GR-54006 Salonika, Greece.							BARRETT NJ, 1986, J INFECTION, V12, P265, DOI 10.1016/S0163-4453(86)94320-3; GALLO G, 1992, EUR J EPIDEMIOL, V8, P292; HILL HR, 1969, NEW ENGL J MED, V17, P917; MAYONWHITE RT, 1982, J HYG-CAMBRIDGE, V88, P439, DOI 10.1017/S0022172400070303	4	45	47	0	1	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	MAY 8	1999	353	9164					1585	1586		10.1016/S0140-6736(99)00950-2	http://dx.doi.org/10.1016/S0140-6736(99)00950-2			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	195XW	10334259				2022-12-28	WOS:000080278300017
J	Rachez, C; Lemon, BD; Suldan, Z; Bromleigh, V; Gamble, M; Naar, AM; Erdjument-Bromage, H; Tempst, P; Freedman, LP				Rachez, C; Lemon, BD; Suldan, Z; Bromleigh, V; Gamble, M; Naar, AM; Erdjument-Bromage, H; Tempst, P; Freedman, LP			Ligand-dependent transcription activation by nuclear receptors requires the DRIP complex	NATURE			English	Article							THYROID-HORMONE RECEPTOR; COACTIVATOR COMPLEX; PROTEIN; INTERACTS; IDENTIFICATION; SPECIFICITY; CHROMATIN; MEDIATOR; BINDING; MOTIF	Nuclear receptors modulate the transcription of genes in direct response to small, lipophilic ligands. Binding to ligands induces conformational changes in the nuclear receptors that enable the receptors to interact with several types of cofactor that are critical for transcription activation (transactivation)(1). We previously described a distinct set of ligand-dependent proteins called DRIPs, which interact with the vitamin D receptor (VDR); together, these proteins constitute a new cofactor complex(2). DRIPs bind to several nuclear receptors and mediate ligand-dependent enhancement of transcription by VDR and the thyroid-hormone receptor in cell-free transcription assays(2,3). Here we report the identities of thirteen DRIPs that constitute this complex, and show that the complex has a central function in hormone-dependent transactivation by VDR on chromatin templates. The DRIPs are almost indistinguishable from components of another new cofactor complex called ARC, which is recruited by other types of transcription activators to mediate transactivation on chromatin-assembled templates(4,5). Several DRIP/ARC subunits are also components of other potentially related cofactors, such as CRSP6, NAT(7), SMCC8 and the mouse Mediator(9), indicating that unique classes of activators may share common sets or subsets of cofactors. The role of nuclear-receptor ligands may, in part, be to recruit such a cofactor complex to the receptor and, in doing so, to enhance transcription of target genes.	Cornell Univ, Grad Sch Med Sci, Sloan Kettering Div, Cell Biol Program, New York, NY 10021 USA; Cornell Univ, Grad Sch Med Sci, Sloan Kettering Div, Program Mol Biol, New York, NY 10021 USA; Univ Calif Berkeley, Howard Hughes Med Inst, Dept Mol Biol & Cell Biol, Berkeley, CA 94720 USA	Cornell University; Memorial Sloan Kettering Cancer Center; Cornell University; Memorial Sloan Kettering Cancer Center; Howard Hughes Medical Institute; University of California System; University of California Berkeley	Freedman, LP (corresponding author), Cornell Univ, Grad Sch Med Sci, Sloan Kettering Div, Cell Biol Program, 1275 York Ave, New York, NY 10021 USA.	l-freedman@ski.mskcc.org	Rachez, Christophe/GLR-0102-2022	Erdjument-Bromage, Hediye/0000-0003-0224-3594; Rachez, Christophe/0000-0001-8502-4738				Darimont BD, 1998, GENE DEV, V12, P3343, DOI 10.1101/gad.12.21.3343; Drane P, 1997, ONCOGENE, V15, P3013, DOI 10.1038/sj.onc.1201492; Erdjument-Bromage H, 1998, J CHROMATOGR A, V826, P167, DOI 10.1016/S0021-9673(98)00705-5; Fondell JD, 1996, P NATL ACAD SCI USA, V93, P8329, DOI 10.1073/pnas.93.16.8329; Geromanos S, 1998, RAPID COMMUN MASS SP, V12, P551, DOI 10.1002/(SICI)1097-0231(19980515)12:9<551::AID-RCM198>3.3.CO;2-P; Gu W, 1999, MOL CELL, V3, P97, DOI 10.1016/S1097-2765(00)80178-1; Heery DM, 1997, NATURE, V387, P733, DOI 10.1038/42750; Jiang YW, 1998, P NATL ACAD SCI USA, V95, P8538, DOI 10.1073/pnas.95.15.8538; KAMAKAKA RT, 1993, GENE DEV, V7, P1779, DOI 10.1101/gad.7.9.1779; Kraus WL, 1998, GENE DEV, V12, P331, DOI 10.1101/gad.12.3.331; LeDouarin B, 1996, EMBO J, V15, P6701, DOI 10.1002/j.1460-2075.1996.tb01060.x; LEE JW, 1995, MOL ENDOCRINOL, V9, P243; Lemon BD, 1997, MOL CELL BIOL, V17, P1923, DOI 10.1128/MCB.17.4.1923; LI Y, 1995, P NATL ACAD SCI USA, V92, P10864, DOI 10.1073/pnas.92.24.10864; Lui M, 1996, ANAL BIOCHEM, V241, P156, DOI 10.1006/abio.1996.0393; MANN M, 1994, ANAL CHEM, V66, P4390, DOI 10.1021/ac00096a002; McInerney EM, 1998, GENE DEV, V12, P3357, DOI 10.1101/gad.12.21.3357; Moras D, 1998, CURR OPIN CELL BIOL, V10, P384, DOI 10.1016/S0955-0674(98)80015-X; Naar AM, 1999, NATURE, V398, P828, DOI 10.1038/19789; Naar AM, 1998, GENE DEV, V12, P3020, DOI 10.1101/gad.12.19.3020; Nagase T, 1995, DNA Res, V2, P167, DOI 10.1093/dnares/2.4.167; Rachez C, 1998, GENE DEV, V12, P1787, DOI 10.1101/gad.12.12.1787; Ryu SJ, 1999, NATURE, V397, P446, DOI 10.1038/17141; Sun XQ, 1998, MOL CELL, V2, P213, DOI 10.1016/S1097-2765(00)80131-8; Torchia J, 1997, NATURE, V387, P677, DOI 10.1038/42652; Torchia J, 1998, CURR OPIN CELL BIOL, V10, P373, DOI 10.1016/S0955-0674(98)80014-8; Yoshikawa H, 1998, GENOMICS, V49, P237, DOI 10.1006/geno.1998.5246; Yuan CX, 1998, P NATL ACAD SCI USA, V95, P7939, DOI 10.1073/pnas.95.14.7939; Zhu YJ, 1997, J BIOL CHEM, V272, P25500, DOI 10.1074/jbc.272.41.25500	29	596	624	0	11	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	APR 29	1999	398	6730					824	828		10.1038/19783	http://dx.doi.org/10.1038/19783			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	192BL	10235266				2022-12-28	WOS:000080058100062
J	Johnstone, P; Zolese, G				Johnstone, P; Zolese, G			Systematic review of the effectiveness of planned short hospital stays for mental health care	BRITISH MEDICAL JOURNAL			English	Article							2-YEAR FOLLOW-UP; LONG HOSPITALIZATION; PSYCHIATRIC-CARE; FAMILIES; SCHIZOPHRENICS	Objective To determine the effectiveness of planned short hospital stays versus standard care for people with serious mental illness. Design Systematic review of all randomised controlled trials comparing planned short hospital stay versus long hospital stay or standard care for people with serious mental illness. Subjects Four trials enrolled 628 patients. Main outcomes measures Relapse; readmission; death (suicides and all causes); violent incidents (self, others, property); lost to follow up; premature discharge; delayed discharge; mental state (not improved); social functioning; patient satisfaction, quality of life, self esteem, and psychological wellbeing; family burden; imprisonment; employment status; independent living; total cost of care; and average length of hospital stay. Results Patients allocated to planned short hospital stays had no more readmissions (in four trials, odds ratio 0.93, 95% confidence interval 0.66 to 1.29 with no heterogeneity between trials), no more losses to follow up (in three trials of 404 patients, 1.09, 0.62 to 1.91 with no heterogeneity between trials), and more successful discharges on time (in three trials of 404 patients, 0.47, 0.27 to 0.85) than patients allocated long hospital stays or standard care. Some evidence showed that patients allocated planned short hospital stay were no more likely to leave hospital prematurely and had a greater chance of being employed than those allocated long hospital stay or standard care. Data on mental, social, and family outcomes could not be summated, and there were few or no data on patient satisfaction, deaths, violence, criminal behaviour, and costs. Conclusion The effectiveness of care in mental hospitals is important to patients, carers, and policy makers. Despite inadequacies in the data, this review suggests that planned short hospital stays do not encourage a "revolving door" pattern of care for people with serious mental illness and may be more effective than standard care. Further pragmatic trials are needed on the most effective organisation and delivery of care in mental hospitals.	Berkshire Hlth Author, Reading RG30 2BA, Berks, England; Pathfinder Mental Hlth Serv NHS Trust, London SW17 7DJ, England		Johnstone, P (corresponding author), Berkshire Hlth Author, Reading RG30 2BA, Berks, England.							ADAMS CE, 1998, COCHRANE COLLABORATI; Beck A, 1997, BRIT J PSYCHIAT, V170, P247, DOI 10.1192/bjp.170.3.247; BURHAN AS, 1969, HOSP COMMUNITY PSYCH, V20, P369; CAFFEY EM, 1971, ARCH GEN PSYCHIAT, V24, P81; *DEP HLTH, 1994, REP INQ CAR TREATM C; GLICK ID, 1976, AM J PSYCHIAT, V133, P515; GLICK ID, 1974, ARCH GEN PSYCHIAT, V30, P363; GLICK ID, 1976, AM J PSYCHIAT, V133, P509; GLICK ID, 1975, AM J PSYCHIAT, V132, P385; GLICK ID, 1976, ARCH GEN PSYCHIAT, V33, P78; GLICK ID, 1977, ARCH GEN PSYCHIAT, V34, P314; Goffman E., 1961, ASYLUM ESSAYS SOCIAL; HARGREAVES WA, 1977, ARCH GEN PSYCHIAT, V34, P305; HERZ MI, 1976, AM J PSYCHIAT, V133, P795; HERZ MI, 1975, AM J PSYCHIAT, V132, P413; HERZ MI, 1979, ARCH GEN PSYCHIAT, V36, P701; HERZ MI, 1977, AM J PSYCHIAT, V134, P502; HIRSCH SR, 1979, BRIT MED J, V1, P442, DOI 10.1136/bmj.1.6161.442; KNIGHTS A, 1980, BRIT J PSYCHIAT, V137, P170, DOI 10.1192/bjp.137.2.170; MATTES JA, 1977, J NERV MENT DIS, V165, P387, DOI 10.1097/00005053-197712000-00004; MATTES JA, 1979, J NERV MENT DIS, V167, P175, DOI 10.1097/00005053-197903000-00007; REBEL S, 1976, AM J PSYCHIAT, V133, P518; ROSEN B, 1976, ARCH GEN PSYCHIAT, V33, P1316; Sackett D, 1994, COCHRANE COLLABORATI; TODD NA, 1976, BRIT J PSYCHIAT, V129, P424, DOI 10.1192/bjp.129.5.424; Wing JK, 1970, I SCHIZOPHRENIA; 1998, TIMES            JUL, P4	27	48	48	0	5	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	MAY 22	1999	318	7195					1387	1390		10.1136/bmj.318.7195.1387	http://dx.doi.org/10.1136/bmj.318.7195.1387			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	200DQ	10334748	Green Submitted, Green Published, Bronze			2022-12-28	WOS:000080524700026
J	Alexandroff, AB; Jackson, AM; O'Donnell, MA; James, K				Alexandroff, AB; Jackson, AM; O'Donnell, MA; James, K			BCG immunotherapy of bladder cancer: 20 years on	LANCET			English	Review							BACILLUS-CALMETTE-GUERIN; CYTOTOXIC T-LYMPHOCYTES; CARCINOMA-CELLS; TUMOR; INDUCTION; CYTOKINE; ANTIGEN; HELPER; EXPRESSION; THERAPY		Univ Edinburgh, Dept Surg, Edinburgh, Midlothian, Scotland; St James Univ Hosp, Imperial Canc Res Fund, Canc Med Res Unit, Leeds LS9 7TF, W Yorkshire, England; Beth Israel Deaconess Med Ctr, Div Urol, Boston, MA USA	University of Edinburgh; Saint James's University Hospital; Harvard University; Beth Israel Deaconess Medical Center	James, K (corresponding author), Royal Infirm, Lister Res Labs, Dept Clin & Surg Sci, Edinburgh EH3 9YW, Midlothian, Scotland.		Jackson, Andrew M/I-5929-2013	Jackson, Andrew M/0000-0003-4739-4804; O'Donnell, Michael/0000-0001-7202-6427	NCI NIH HHS [R29 CA64230] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R29CA064230] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Alexandroff AB, 1998, IMMUNOL TODAY, V19, P247, DOI 10.1016/S0167-5699(98)01265-1; Alexandroff AB, 1996, INT J ONCOL, V9, P179; Bennett SRM, 1998, NATURE, V393, P478, DOI 10.1038/30996; Bohle A, 1996, J UROLOGY, V155, P1892, DOI 10.1016/S0022-5347(01)66040-3; CASSATELLA MA, 1995, IMMUNOL TODAY, V16, P21, DOI 10.1016/0167-5699(95)80066-2; Crispen R, 1989, Prog Clin Biol Res, V310, P35; Cui JQ, 1997, SCIENCE, V278, P1623, DOI 10.1126/science.278.5343.1623; Dunbar PR, 1998, CURR BIOL, V8, P413, DOI 10.1016/S0960-9822(98)70161-7; Gong JL, 1997, NAT MED, V3, P558, DOI 10.1038/nm0597-558; Gueguen M, 1998, J IMMUNOL, V160, P6188; Haley JL, 1999, IMMUNOLOGY, V96, P114; HERR HW, 1992, J CELL BIOCHEM, P112; Jackson AM, 1998, J UROLOGY, V159, P1054, DOI 10.1016/S0022-5347(01)63835-7; JACKSON AM, 1995, CLIN EXP IMMUNOL, V99, P369, DOI 10.1111/j.1365-2249.1995.tb05560.x; JACKSON AM, 1998, CURR RES MOL THERAP, V1, P256; JACKSON AM, 1994, IMMUNOLOGIST, V2, P208; Kadhim SA, 1997, J UROLOGY, V158, P646, DOI 10.1016/S0022-5347(01)64576-2; Kaempfer R, 1996, J CLIN ONCOL, V14, P1778, DOI 10.1200/JCO.1996.14.6.1778; KURODA K, 1993, J CLIN INVEST, V91, P69, DOI 10.1172/JCI116202; Lamm D L, 1989, Prog Clin Biol Res, V310, P335; LAMM DL, 1994, J UROLOGY, V151, P21, DOI 10.1016/S0022-5347(17)34863-2; LAMM DL, 1995, J UROLOGY, V153, P1444, DOI 10.1016/S0022-5347(01)67427-5; LAMM DL, 1980, J UROLOGY, V124, P38, DOI 10.1016/S0022-5347(17)55282-9; LATTIME EC, 1992, CANCER RES, V52, P4286; MATHE G, 1969, LANCET, V1, P697, DOI 10.1016/S0140-6736(69)92648-8; MCAVENEY KM, 1994, CANCER IMMUNOL IMMUN, V39, P401, DOI 10.1007/BF01534428; MISRA N, 1995, IMMUNOLOGY, V86, P97; MORALES A, 1976, J UROLOGY, V116, P180, DOI 10.1016/S0022-5347(17)58737-6; O'Donnell M A, 1995, Surg Oncol Clin N Am, V4, P189; O'Donnell M.A, 1997, J UROL 2, V157, P383; ODonnell MA, 1997, TRENDS BIOTECHNOL, V15, P512, DOI 10.1016/S0167-7799(97)01134-7; Parker SL, 1998, CA-CANCER J CLIN, V48, P31, DOI 10.3322/canjclin.48.1.31; PATARD JJ, 1995, INT J CANCER, V64, P60, DOI 10.1002/ijc.2910640112; Patel A, 1998, J UROLOGY, V159, P71, DOI 10.1016/S0022-5347(01)64015-1; Pawinski A, 1996, J UROLOGY, V156, P1934, DOI 10.1016/S0022-5347(01)65396-5; PRESCOTT S, 1992, J UROLOGY, V147, P1636, DOI 10.1016/S0022-5347(17)37668-1; RATLIFF TL, 1994, J UROLOGY, V152, P2147, DOI 10.1016/S0022-5347(17)32340-6; RATLIFF TL, 1993, J UROLOGY, V150, P1018, DOI 10.1016/S0022-5347(17)35678-1; Ridge JP, 1998, NATURE, V393, P474, DOI 10.1038/30989; Schoenberger SP, 1998, NATURE, V393, P480, DOI 10.1038/31002; SHAPIRO A, 1988, WORLD J UROL, V6, P61, DOI 10.1007/BF00326845; THANHAUSER A, 1995, CANCER IMMUNOL IMMUN, V40, P103, DOI 10.1007/s002620050150; UTZ DC, 1980, UROL CLIN N AM, V7, P533; van der Meijden A P, 1989, Prog Clin Biol Res, V310, P11; Wang RD, 1996, J IMMUNOL, V157, P2961; WYNDER EL, 1977, CANCER-AM CANCER SOC, V40, P1246, DOI 10.1002/1097-0142(197709)40:3<1246::AID-CNCR2820400340>3.0.CO;2-5; Zlotta AR, 1997, CLIN EXP IMMUNOL, V109, P157, DOI 10.1046/j.1365-2249.1997.4141313.x	47	352	371	3	25	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	MAY 15	1999	353	9165					1689	1694		10.1016/S0140-6736(98)07422-4	http://dx.doi.org/10.1016/S0140-6736(98)07422-4			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	198DT	10335805				2022-12-28	WOS:000080408000046
J	Lonn, EM; Yusuf, S				Lonn, EM; Yusuf, S			Evidence based cardiology - Emerging approaches in preventing cardiovascular disease	BRITISH MEDICAL JOURNAL			English	Review							CORONARY HEART-DISEASE; ANGIOTENSIN-CONVERTING-ENZYME; VITAMIN-E CONSUMPTION; MYOCARDIAL-INFARCTION; BETA-CAROTENE; ANTIOXIDANT VITAMINS; PLASMA HOMOCYSTEINE; VASCULAR-DISEASE; ARTERY DISEASE; RISK FACTOR		Hamilton Hlth Sci Corp, Div Cardiol, Hamilton, ON L8L 2X2, Canada	McMaster University	Lonn, EM (corresponding author), Hamilton Hlth Sci Corp, Div Cardiol, Gen Site, Hamilton, ON L8L 2X2, Canada.			Yusuf, Salim/0000-0003-4776-5601				ALDERMAN MH, 1991, NEW ENGL J MED, V324, P1098, DOI 10.1056/NEJM199104183241605; BALL SG, 1993, LANCET, V342, P821; BERLINER JA, 1995, CIRCULATION, V91, P2488, DOI 10.1161/01.CIR.91.9.2488; BLOT WJ, 1993, JNCI-J NATL CANCER I, V85, P1483, DOI 10.1093/jnci/85.18.1483; BOUSHEY CJ, 1995, JAMA-J AM MED ASSOC, V274, P1049, DOI 10.1001/jama.274.13.1049; CAMBIEN F, 1992, NATURE, V359, P641, DOI 10.1038/359641a0; Danesh J, 1998, J Cardiovasc Risk, V5, P229, DOI 10.1097/00043798-199808000-00004; GOLDMAN L, 1984, ANN INTERN MED, V101, P825, DOI 10.7326/0003-4819-101-6-825; GORDON T, 1974, J CHRON DIS, V27, P329, DOI 10.1016/0021-9681(74)90013-7; Graham IM, 1997, JAMA-J AM MED ASSOC, V277, P1775, DOI 10.1001/jama.277.22.1775; Greenberg ER, 1996, JAMA-J AM MED ASSOC, V275, P699, DOI 10.1001/jama.275.9.699; HEINONEN OP, 1994, NEW ENGL J MED, V330, P1029; Hennekens CH, 1996, NEW ENGL J MED, V334, P1145, DOI 10.1056/NEJM199605023341801; JHA P, 1995, ANN INTERN MED, V123, P860, DOI 10.7326/0003-4819-123-11-199512010-00009; KANNEL WB, 1979, ANN INTERN MED, V90, P85, DOI 10.7326/0003-4819-90-1-85; KOBER L, 1995, NEW ENGL J MED, V333, P1670, DOI 10.1056/NEJM199512213332503; Kushi LH, 1996, NEW ENGL J MED, V334, P1156, DOI 10.1056/NEJM199605023341803; Lonn EM, 1997, CAN J CARDIOL, V13, P957; LONN EM, 1994, CIRCULATION, V90, P2056, DOI 10.1161/01.CIR.90.4.2056; Mancini GBJ, 1996, CIRCULATION, V94, P258, DOI 10.1161/01.CIR.94.3.258; Mayer EL, 1996, J AM COLL CARDIOL, V27, P517, DOI 10.1016/0735-1097(95)00508-0; MCCULLY KS, 1975, ATHEROSCLEROSIS, V22, P215, DOI 10.1016/0021-9150(75)90004-0; MEADE TW, 1993, NEW ENGL J MED, V329, P616, DOI 10.1056/NEJM199308263290905; Nygard O, 1997, NEW ENGL J MED, V337, P230, DOI 10.1056/NEJM199707243370403; Omenn GS, 1996, NEW ENGL J MED, V334, P1150, DOI 10.1056/NEJM199605023341802; Rapola JM, 1997, LANCET, V349, P1715, DOI 10.1016/S0140-6736(97)01234-8; Rapola JM, 1996, JAMA-J AM MED ASSOC, V275, P693, DOI 10.1001/jama.275.9.693; Rimm EB, 1998, JAMA-J AM MED ASSOC, V279, P359, DOI 10.1001/jama.279.5.359; Rimm EB, 1996, JAMA-J AM MED ASSOC, V275, P447, DOI 10.1001/jama.275.6.447; RIMM EB, 1993, NEW ENGL J MED, V328, P1450, DOI 10.1056/NEJM199305203282004; Robinson K, 1998, CIRCULATION, V97, P437; Rodes J, 1998, CIRCULATION, V97, P429; RUTHERFORD JD, 1994, CIRCULATION, V90, P1731, DOI 10.1161/01.CIR.90.4.1731; Samani NJ, 1996, CIRCULATION, V94, P708, DOI 10.1161/01.CIR.94.4.708; STAMPFER MJ, 1993, NEW ENGL J MED, V328, P1444, DOI 10.1056/NEJM199305203282003; STEINBERG D, 1992, CIRCULATION, V85, P2338, DOI 10.1161/01.CIR.85.6.2337; Stephens NG, 1996, LANCET, V347, P781, DOI 10.1016/S0140-6736(96)90866-1; VERSCHUREN WMM, 1995, JAMA-J AM MED ASSOC, V274, P131, DOI 10.1001/jama.274.2.131; WALLDIUS G, 1994, AM J CARDIOL, V74, P875, DOI 10.1016/0002-9149(94)90579-7; WILSON T S, 1973, Age and Ageing, V2, P163, DOI 10.1093/ageing/2.3.163; WRIGHT RA, 1994, J AM COLL CARDIOL, V24, P67, DOI 10.1016/0735-1097(94)90543-6; Yusuf S, 1998, EUR HEART J, V19, pJ36; YUSUF S, 1992, LANCET, V340, P1173, DOI 10.1016/0140-6736(92)92889-N	43	25	26	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	MAY 15	1999	318	7194					1337	1341		10.1136/bmj.318.7194.1337	http://dx.doi.org/10.1136/bmj.318.7194.1337			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	198HR	10323824	Green Published			2022-12-28	WOS:000080418400034
J	Zhao, YU; Sheng, HZ; Amini, R; Grinberg, A; Lee, E; Huang, SP; Taira, M; Westphal, H				Zhao, YU; Sheng, HZ; Amini, R; Grinberg, A; Lee, E; Huang, SP; Taira, M; Westphal, H			Control of hippocampal morphogenesis and neuronal differentiation by the LIM homeobox gene Lhx5	SCIENCE			English	Article							EMBRYONIC CEREBRAL-CORTEX; DENTATE GYRUS; C-ELEGANS; MICE; EXPRESSION; FOREBRAIN; HOMEODOMAIN; MULTIPLE; REELER; CELLS	The mammalian hippocampus contains the neural circuitry that is crucial for cognitive functions such as Learning and memory. The development of such circuitry is dependent on the generation and correct placement of the appropriate number and types of neurons. Mice Lacking function of the LIM homeobox gene Lhx5 showed a defect in hippocampus development. Hippocampal neural precursor cells were specified and proliferated, but many of them failed to either exit the cell cycle or to differentiate and migrate properly. Lhx5 is therefore essential for the regulation of precursor cell proliferation and the control of neuronal differentiation and migration during hippocampal development.	NICHHD, Lab Mammalian Genes & Dev, Bethesda, MD 20892 USA; NICHHD, Genet Mol Lab, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD); National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)	Westphal, H (corresponding author), NICHHD, Lab Mammalian Genes & Dev, Bethesda, MD 20892 USA.				EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [ZIAHD000071] Funding Source: NIH RePORTER; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [Z01HD000071] Funding Source: NIH RePORTER	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		BAYER SA, 1980, J COMP NEUROL, V190, P115, DOI 10.1002/cne.901900108; Bertuzzi S, 1996, GENOMICS, V36, P234, DOI 10.1006/geno.1996.0458; BOURGOUIN C, 1992, NEURON, V9, P549, DOI 10.1016/0896-6273(92)90192-G; CAVINESS VS, 1973, J COMP NEUROL, V151, P113, DOI 10.1002/cne.901510203; CAVINESS VS, 1979, J COMP NEUROL, V185, P423; Chae T, 1997, NEURON, V18, P29, DOI 10.1016/S0896-6273(01)80044-1; DARCANGELO G, 1995, NATURE, V374, P719, DOI 10.1038/374719a0; Dawid IB, 1998, TRENDS GENET, V14, P156, DOI 10.1016/S0168-9525(98)01424-3; DelRio JA, 1997, NATURE, V385, P70, DOI 10.1038/385070a0; FREYD G, 1990, NATURE, V344, P876, DOI 10.1038/344876a0; Furuta Y, 1997, DEVELOPMENT, V124, P2203; GAVIN BJ, 1990, GENE DEV, V4, P2319, DOI 10.1101/gad.4.12b.2319; Grove EA, 1998, DEVELOPMENT, V125, P2315; Hirotsune S, 1998, NAT GENET, V19, P333, DOI 10.1038/1221; Hobert O, 1997, NEURON, V19, P345, DOI 10.1016/S0896-6273(00)80944-7; Hobert O, 1998, J NEUROSCI, V18, P2084; Howell BW, 1997, NATURE, V389, P733, DOI 10.1038/39607; NAGY A, 1993, P NATL ACAD SCI USA, V90, P8424, DOI 10.1073/pnas.90.18.8424; Nakajima K, 1997, P NATL ACAD SCI USA, V94, P8196, DOI 10.1073/pnas.94.15.8196; Ohshima T, 1996, P NATL ACAD SCI USA, V93, P11173, DOI 10.1073/pnas.93.20.11173; Pellegrini M, 1996, DEVELOPMENT, V122, P3893; Pfaff SL, 1996, CELL, V84, P309, DOI 10.1016/S0092-8674(00)80985-X; Porter FD, 1997, DEVELOPMENT, V124, P2935; ROBINSON GW, 1991, NEW BIOL, V3, P1183; Sharma K, 1998, CELL, V95, P817, DOI 10.1016/S0092-8674(00)81704-3; Sheldon M, 1997, NATURE, V389, P730, DOI 10.1038/39601; Sheng HZ, 1997, DEV DYNAM, V208, P266, DOI 10.1002/(SICI)1097-0177(199702)208:2<266::AID-AJA13>3.0.CO;2-1; Sheng HZ, 1996, SCIENCE, V272, P1004, DOI 10.1126/science.272.5264.1004; SIMEONE A, 1993, EMBO J, V12, P2735, DOI 10.1002/j.1460-2075.1993.tb05935.x; SIMEONE A, 1992, EMBO J, V11, P2541, DOI 10.1002/j.1460-2075.1992.tb05319.x; SORIANO E, 1994, J COMP NEUROL, V342, P571, DOI 10.1002/cne.903420406; TOYAMA R, 1995, DEV BIOL, V170, P583, DOI 10.1006/dbio.1995.1238; WAY JC, 1988, CELL, V54, P5, DOI 10.1016/0092-8674(88)90174-2; XU Y, 1993, P NATL ACAD SCI USA, V90, P227, DOI 10.1073/pnas.90.1.227; Yoshida M, 1997, DEVELOPMENT, V124, P101	35	128	134	0	5	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	MAY 14	1999	284	5417					1155	1158		10.1126/science.284.5417.1155	http://dx.doi.org/10.1126/science.284.5417.1155			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	197HJ	10325223				2022-12-28	WOS:000080359100033
J	Jacques, PF; Selhub, J; Bostom, AG; Wilson, PWF; Rosenberg, IH				Jacques, PF; Selhub, J; Bostom, AG; Wilson, PWF; Rosenberg, IH			The effect of folic acid fortification on plasma folate and total homocysteine concentrations	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							NEURAL-TUBE DEFECTS; CORONARY HEART-DISEASE; SERUM TOTAL HOMOCYSTEINE; MYOCARDIAL-INFARCTION; VASCULAR-DISEASE; RISK FACTOR; MICROBIOLOGICAL ASSAY; LACTOBACILLUS-CASEI; SUPPLEMENTATION; PREVENTION	Background In 1996, the Food and Drug Administration issued a regulation requiring all enriched grain products to be fortified with folic acid to reduce the risk of neural-tube defects in newborns. Fortification (140 mu g per 100 g) began in 1996, and the process was essentially complete by mid-1997. Methods To assess the effect of folic acid fortification on folate status, we measured plasma folate and total homocysteine concentrations (a sensitive marker of folate status) using blood samples from the fifth examination (January 1991 to December 1994) of the Framingham Offspring Study cohort for baseline values and the sixth examination (January 1995 to August 1998) for follow-up values. We divided the cohort into two groups on the basis of the date of their follow-up examination: the study group consisted of 350 subjects who were seen after fortification (September 1997 to March 1998), and the control group consisted of 756 subjects who were seen before fortification (January 1995 to September 1996). Results Among the subjects in the study group who did not use vitamin supplements, the mean folate concentrations increased from 4.6 to 10.0 ng per milliliter (11 to 23 nmol per liter) (P<0.001) from the baseline visit to the follow-up visit, and the prevalence of low folate concentrations (<3 ng per milliliter [7 nmol per liter]) decreased from 22.0 to 1.7 percent (P< 0.001). The mean total homocysteine concentration decreased from 10.1 to 9.4 mu mol per liter during this period (P<0.001), and the prevalence of high homocysteine concentrations (>13 mu mol per liter) decreased from 18.7 to 9.8 percent (P<0.001). In the control group, there were no statistically significant changes in concentrations of folate or homocysteine. Conclusions The fortification of enriched grain products with folic acid was associated with a substantial improvement in folate status in a population of middle-aged and older adults. (N Engl J Med 1999;340:1449-54.) (C) 1999, Massachusetts Medical Society.	Tufts Univ, USDA, Jean Mayer Human Nutr Res Ctr Aging, Boston, MA 02111 USA; Mem Hosp Rhode Isl, Div Gen Internal Med, Providence, RI USA; NHLBI, Framingham Heart Study, Framingham, MA USA	Tufts University; United States Department of Agriculture (USDA); Framingham Heart Study; National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI)	Rosenberg, IH (corresponding author), Tufts Univ, USDA, Jean Mayer Human Nutr Res Ctr Aging, 711 Washington St, Boston, MA 02111 USA.		Wilson, Peter W.F./J-2455-2016		DIVISION OF EPIDEMIOLOGY AND CLINICAL APPLICATIONS [N01HC038038] Funding Source: NIH RePORTER; NHLBI NIH HHS [N01-HC-38038] Funding Source: Medline	DIVISION OF EPIDEMIOLOGY AND CLINICAL APPLICATIONS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Afman L, 1999, FASEB J, V13, pA891; [Anonymous], 1992, MMWR MORB MORTAL WKL, V41, P1; ARAKI A, 1987, J CHROMATOGR-BIOMED, V422, P43, DOI 10.1016/0378-4347(87)80438-3; ARNESEN E, 1995, INT J EPIDEMIOL, V24, P704, DOI 10.1093/ije/24.4.704; BOUSHEY CJ, 1995, JAMA-J AM MED ASSOC, V274, P1049, DOI 10.1001/jama.274.13.1049; BOWER C, 1989, MED J AUSTRALIA, V150, P613, DOI 10.5694/j.1326-5377.1989.tb136723.x; BRATTSTROM LE, 1988, SCAND J CLIN LAB INV, V48, P215, DOI 10.3109/00365518809167487; CZEIZEL AE, 1993, BRIT MED J, V306, P1645, DOI 10.1136/bmj.306.6893.1645; DAWBER T. R., 1957, AMER JOUR PUBL HEALTH, V47, P4, DOI 10.2105/AJPH.47.4_Pt_2.4; FEINLEIB M, 1975, PREV MED, V4, P518, DOI 10.1016/0091-7435(75)90037-7; Food and Drug Administration, 1996, FED REGISTER, V61, P8781; Graham IM, 1997, JAMA-J AM MED ASSOC, V277, P1775, DOI 10.1001/jama.277.22.1775; Gregory JF, 1998, FASEB J, V12, pA511; HERBERT V, 1994, MODERN NUTR HLTH DIS, V1, P402; HOPKINS PN, 1995, ARTERIOSCL THROM VAS, V15, P1314, DOI 10.1161/01.ATV.15.9.1314; HORNE DW, 1988, CLIN CHEM, V34, P2357; LANDGREN F, 1995, J INTERN MED, V237, P381, DOI 10.1111/j.1365-2796.1995.tb01190.x; LAURENCE KM, 1981, BRIT MED J, V282, P1509, DOI 10.1136/bmj.282.6275.1509; Malinow MR, 1998, NEW ENGL J MED, V338, P1009, DOI 10.1056/NEJM199804093381501; MILUNSKY A, 1989, JAMA-J AM MED ASSOC, V262, P2847, DOI 10.1001/jama.262.20.2847; Morrison HI, 1996, JAMA-J AM MED ASSOC, V275, P1893, DOI 10.1001/jama.275.24.1893; MULINARE J, 1988, JAMA-J AM MED ASSOC, V260, P3141, DOI 10.1001/jama.260.21.3141; Nygard O, 1997, NEW ENGL J MED, V337, P230, DOI 10.1056/NEJM199707243370403; Oakley GP, 1998, NEW ENGL J MED, V338, P1060, DOI 10.1056/NEJM199804093381509; PERRY IJ, 1995, LANCET, V346, P1395, DOI 10.1016/S0140-6736(95)92407-8; RIMM EB, 1992, AM J EPIDEMIOL, V135, P1114, DOI 10.1093/oxfordjournals.aje.a116211; Rimm EB, 1998, JAMA-J AM MED ASSOC, V279, P359, DOI 10.1001/jama.279.5.359; *SAS I, 1989, SAS US GUID VERS 6; Schorah CJ, 1998, EUR J CLIN NUTR, V52, P407, DOI 10.1038/sj.ejcn.1600576; SELHUB J, 1993, JAMA-J AM MED ASSOC, V270, P2693, DOI 10.1001/jama.270.22.2693; SHIN YS, 1983, CLIN CHIM ACTA, V127, P77, DOI 10.1016/0009-8981(83)90077-3; SMITHELLS RW, 1983, LANCET, V1, P1027; STAMPFER MJ, 1992, JAMA-J AM MED ASSOC, V268, P877, DOI 10.1001/jama.268.7.877; TAMURA T, 1990, CLIN CHEM, V36, P1993; Tucker KL, 1997, JAMA-J AM MED ASSOC, V277, P714; UBBINK JB, 1994, J NUTR, V124, P1927, DOI 10.1093/jn/124.10.1927; VERGEL RG, 1990, PRENATAL DIAG, V10, P149, DOI 10.1002/pd.1970100303; Verhoef P, 1996, AM J EPIDEMIOL, V143, P845, DOI 10.1093/oxfordjournals.aje.a008828; WALD N, 1991, LANCET, V338, P131; WERLER MM, 1993, JAMA-J AM MED ASSOC, V269, P1257, DOI 10.1001/jama.269.10.1257; WILCKEN DEL, 1988, METABOLISM, V37, P697, DOI 10.1016/0026-0495(88)90093-5; 1993, FED REG, V58, P53305	42	856	879	0	34	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	MAY 13	1999	340	19					1449	1454		10.1056/NEJM199905133401901	http://dx.doi.org/10.1056/NEJM199905133401901			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	194MT	10320382				2022-12-28	WOS:000080198700001
J	Swift, RM				Swift, RM			Drug therapy - Drug therapy for alcohol dependence	NEW ENGLAND JOURNAL OF MEDICINE			English	Review							PLACEBO-CONTROLLED TRIAL; COMPULSIVE DRINKING SCALE; DOUBLE-BLIND; CLINICAL-TRIAL; PSYCHIATRIC-DISORDERS; DISULFIRAM TREATMENT; RELAPSE PREVENTION; NUCLEUS-ACCUMBENS; LITHIUM TREATMENT; ETHANOL INTAKE		Vet Affairs Med Ctr, ACOS Res & Educ, Providence, RI 02908 USA; Brown Univ, Sch Med, Ctr Alcohol & Addict Studies, Providence, RI 02912 USA; Brown Univ, Sch Med, Dept Psychiat, Providence, RI 02912 USA	US Department of Veterans Affairs; Veterans Health Administration (VHA); Providence VA Medical Center; Brown University; Brown University	Swift, RM (corresponding author), Vet Affairs Med Ctr, ACOS Res & Educ, 830 Chalkstone Ave, Providence, RI 02908 USA.							American Psychiatric Association, 2000, DSM 4 DIAGN STAT MAN, V4th ed., DOI DOI 10.1001/JAMA.1994.03520100096; ANTON RF, 1995, ALCOHOL CLIN EXP RES, V19, P92, DOI 10.1111/j.1530-0277.1995.tb01475.x; Anton RF, 1996, ARCH GEN PSYCHIAT, V53, P225; ANTON RF, 1995, ARCH GEN PSYCHIAT, V53, P576; BENJAMIN D, 1993, BRAIN RES, V621, P137, DOI 10.1016/0006-8993(93)90309-B; Berg BJ, 1996, DRUG SAFETY, V15, P274, DOI 10.2165/00002018-199615040-00005; BROADBENT J, 1995, PSYCHOPHARMACOLOGY, V120, P475, DOI 10.1007/BF02245821; BRUNO F, 1989, PSYCHOPATHOLOGY, V22, P49, DOI 10.1159/000284626; CHICK J, 1992, BRIT J PSYCHIAT, V161, P84, DOI 10.1192/bjp.161.1.84; Chick J, 1995, ALCOHOL ALCOHOLISM, V30, P785; Chick J, 1996, ALCOHOL CLIN EXP RES, V20, P391, DOI 10.1111/j.1530-0277.1996.tb01658.x; CHICK J, 1996, 10 WORLD PSYCH C AUG; CIRAULO DA, 1988, AM J PSYCHIAT, V145, P1501; COLLINS DM, 1987, ALCOHOL, V4, P49, DOI 10.1016/0741-8329(87)90060-7; Cornelius JR, 1997, ARCH GEN PSYCHIAT, V54, P700; Croop RS, 1997, ARCH GEN PSYCHIAT, V54, P1130; *CTR SUBST AB TREA, 1998, DHHS PUBL; DAOUST M, 1992, PHARMACOL BIOCHEM BE, V41, P669, DOI 10.1016/0091-3057(92)90210-7; Davidson D, 1996, ALCOHOL CLIN EXP RES, V20, P732, DOI 10.1111/j.1530-0277.1996.tb01679.x; DORUS W, 1989, JAMA-J AM MED ASSOC, V262, P1646, DOI 10.1001/jama.262.12.1646; Finney JW, 1996, ADDICTION, V91, P1773, DOI 10.1046/j.1360-0443.1996.911217733.x; FINNEY JW, 1996, ADDICTION, V91, P1803; FROEHLICH JC, 1990, PHARMACOL BIOCHEM BE, V35, P385, DOI 10.1016/0091-3057(90)90174-G; FULLER RK, 1986, JAMA-J AM MED ASSOC, V256, P1449, DOI 10.1001/jama.256.11.1449; GALLIMBERTI L, 1992, ALCOHOL CLIN EXP RES, V16, P673, DOI 10.1111/j.1530-0277.1992.tb00658.x; Geerlings PJ, 1997, EUR ADDICT RES, V3, P129, DOI 10.1159/000259166; GEORGE SR, 1995, J PHARMACOL EXP THER, V273, P373; GESSA GL, 1985, BRAIN RES, V348, P201, DOI 10.1016/0006-8993(85)90381-6; Gorelick D A, 1993, Recent Dev Alcohol, V11, P413; HELZER JE, 1988, J STUD ALCOHOL, V49, P219, DOI 10.15288/jsa.1988.49.219; Hersh D, 1998, PSYCHOPHARMACOLOGY, V139, P44, DOI 10.1007/s002130050688; HOFFMAN PL, 1990, ALCOHOL, V7, P229, DOI 10.1016/0741-8329(90)90010-A; HUBBELL CL, 1986, ALCOHOL, V3, P39, DOI 10.1016/0741-8329(86)90070-4; Hughes JC, 1997, ADDICTION, V92, P381; Institute of Medicine Division of Mental Health and Behavioral Medicine, 1990, BROAD BAS TREATM ALC; Jaffe AJ, 1996, J CONSULT CLIN PSYCH, V64, P1044, DOI 10.1037/0022-006X.64.5.1044; Johnson BA, 1996, PSYCHOPHARMACOLOGY, V128, P206, DOI 10.1007/s002130050126; JUDD LL, 1977, ARCH GEN PSYCHIAT, V34, P463; Kessler RC, 1997, ARCH GEN PSYCHIAT, V54, P313; KHANTZIAN EJ, 1985, AM J PSYCHIAT, V142, P1259; KNAPP DJ, 1992, PHARMACOL BIOCHEM BE, V41, P847, DOI 10.1016/0091-3057(92)90237-A; Koob G F, 1992, Recent Dev Alcohol, V10, P201; KRANZLER HR, 1994, ARCH GEN PSYCHIAT, V51, P720; KRANZLER HR, 1994, J CONSULT CLIN PSYCH, V62, P1116; KRANZLER HR, 1995, AM J PSYCHIAT, V152, P391; Ladewig D, 1993, Ther Umsch, V50, P182; LAWFORD BR, 1995, NAT MED, V1, P337, DOI 10.1038/nm0495-337; LEJOYEUX M, 1993, ALCOHOL ALCOHOLISM, V28, P273; LEMARQUAND D, 1994, BIOL PSYCHIAT, V36, P395, DOI 10.1016/0006-3223(94)91215-7; LHUINTRE JP, 1990, ALCOHOL ALCOHOLISM, V25, P613, DOI 10.1093/oxfordjournals.alcalc.a045057; LINNOILA M, 1987, ANN INTERN MED, V107, P875, DOI 10.7326/0003-4819-107-6-875; LINNOILA M, 1987, PSYCHOPHARMACOL BULL, V23, P452; Litten RZ, 1996, ALCOHOL CLIN EXP RES, V20, P859, DOI 10.1111/j.1530-0277.1996.tb05264.x; LITTLETON J, 1994, ADDICTION, V89, P1397, DOI 10.1111/j.1360-0443.1994.tb03736.x; LITTLETON J, 1995, ADDICTION, V90, P1179, DOI 10.1046/j.1360-0443.1995.90911793.x; MALCOLM R, 1992, ALCOHOL CLIN EXP RES, V16, P1007, DOI 10.1111/j.1530-0277.1992.tb00691.x; MALCOLM R, 1989, AM J PSYCHIAT, V146, P617; Malec E, 1996, ALCOHOL CLIN EXP RES, V20, P307, DOI 10.1111/j.1530-0277.1996.tb01644.x; MASON BJ, 1994, ALCOHOL CLIN EXP RES, V18, P1162, DOI 10.1111/j.1530-0277.1994.tb00098.x; Mason BJ, 1996, ALCOHOL CLIN EXP RES, V20, pA10, DOI 10.1111/j.1530-0277.1996.tb01184.x; Mason BJ, 1996, JAMA-J AM MED ASSOC, V275, P761, DOI 10.1001/jama.275.10.761; MASON BJ, 1996, ALCOHOL CLIN EXP R S, V20, pA16; MCCAUL ME, IN PRESS ALCOHOL CLI; MCGINNIS JM, 1993, JAMA-J AM MED ASSOC, V270, P2207, DOI 10.1001/jama.270.18.2207; McGrath PJ, 1996, ARCH GEN PSYCHIAT, V53, P232; MONTI PM, IN PRESS ALCOHOL CLI; MORSE RM, 1992, JAMA-J AM MED ASSOC, V268, P1012, DOI 10.1001/jama.268.8.1012; Mueller TI, 1997, ALCOHOL CLIN EXP RES, V21, P86; NALPAS B, 1990, Encephale, V16, P175; NARANJO CA, 1987, CLIN PHARMACOL THER, V41, P266, DOI 10.1038/clpt.1987.27; NARANJO CA, 1994, EXS, V71, P209; NARANJO CA, 1994, INT CLIN PSYCHOPHARM, V9, P163, DOI 10.1097/00004850-199409000-00004; Naranjo CA, 1997, ADDICTION, V92, P969, DOI 10.1111/j.1360-0443.1997.tb02976.x; NIE ZG, 1994, J PHARMACOL EXP THER, V271, P1566; OMALLEY SS, 1992, ARCH GEN PSYCHIAT, V49, P881; PEACHEY JE, 1989, BRIT J ADDICT, V84, P877; PEACHEY JE, 1989, HUMAN METABOLISM ALC, V1, P157; PETERS DH, 1994, DRUGS, V47, P1010, DOI 10.2165/00003495-199447060-00009; Poldrugo F, 1997, ADDICTION, V92, P1537; REGIER DA, 1990, JAMA-J AM MED ASSOC, V264, P2511; Rice RD, 1993, ALCOHOL HEALTH RES W, V17, P10; ROBINSON TE, 1993, BRAIN RES REV, V18, P247, DOI 10.1016/0165-0173(93)90013-P; ROHSENOW DJ, 1992, ADV BEHAV RES THER, V14, P195, DOI 10.1016/0146-6402(92)90008-C; SALVATO FR, 1994, ALCOHOL CLIN EXP RES, V18, P1187, DOI 10.1111/j.1530-0277.1994.tb00102.x; Samson H H, 1993, Alcohol Alcohol Suppl, V2, P469; SAMSON HH, 1992, TRENDS PHARMACOL SCI, V13, P206, DOI 10.1016/0165-6147(92)90065-E; Sass H, 1996, ARCH GEN PSYCHIAT, V53, P1097; SCHUCKIT MA, 1994, EXS, V71, P341; SELLERS EM, 1992, TRENDS PHARMACOL SCI, V13, P69, DOI 10.1016/0165-6147(92)90026-3; SELLERS EM, 1994, ALCOHOL CLIN EXP RES, V18, P879, DOI 10.1111/j.1530-0277.1994.tb00054.x; SHAW GK, 1994, BRIT J PSYCHIAT, V165, P515, DOI 10.1192/bjp.165.4.515; Soyka M, 1994, Alcohol Alcohol Suppl, V2, P531; Spanagel R, 1996, EUR J PHARMACOL, V305, P39, DOI 10.1016/0014-2999(96)00174-4; SUZDAK PD, 1986, P NATL ACAD SCI USA, V83, P4071, DOI 10.1073/pnas.83.11.4071; SWIFT RM, 1994, AM J PSYCHIAT, V151, P1463; TSAI GC, 1995, AM J PSYCHIAT, V152, P332; Volpicelli JR, 1997, ARCH GEN PSYCHIAT, V54, P737; VOLPICELLI JR, 1992, ARCH GEN PSYCHIAT, V49, P876; VOLPICELLI JR, 1995, AM J PSYCHIAT, V152, P613; Whitworth AB, 1996, LANCET, V347, P1438, DOI 10.1016/S0140-6736(96)91682-7; WISE RA, 1987, PSYCHOL REV, V94, P469, DOI 10.1037/0033-295X.94.4.469; ZEISE ML, 1993, EUR J PHARMACOL, V231, P47, DOI 10.1016/0014-2999(93)90682-8	102	170	175	1	12	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	MAY 13	1999	340	19					1482	1490		10.1056/NEJM199905133401907	http://dx.doi.org/10.1056/NEJM199905133401907			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	194MT	10320388				2022-12-28	WOS:000080198700007
J	Tunstall-Pedoe, H; Kuulasmaa, K; Mahonen, M; Tolonen, H; Ruokokoski, E; Amouyel, P				Tunstall-Pedoe, H; Kuulasmaa, K; Mahonen, M; Tolonen, H; Ruokokoski, E; Amouyel, P		WHO MONICA Project	Contribution of trends in survival and coronary-event rates to changes in coronary heart disease mortality: 10-year results from 37 WHO MONICA Project populations	LANCET			English	Article							MYOCARDIAL-INFARCTION; CASE-FATALITY	Background The WHO MONICA (monitoring trends and determinants in cardiovascular disease) Project monitored, from the early 1980s, trend over 10 years in coronary heart disease (CHD) across 37 populations in 21 countries. We aimed to validate trends in mortality, partitioning responsibility between changing coronary-event rates and changing survival. Methods Registers identified non-fatal definite myocardial infarction and definite, possible, or unclassifiable coronary deaths in men and women aged 35-64 years, followed up for 28 days in or out of hospital. We calculated rates from population denominators to estimate trends in age-standardised rates and case fatality (percentage of 28-day fatalities=[100-survival percentage]). Findings During 371 population-years, 166 000 events were registered. Official CHD mortality rates, based on death certification, fell (annual changes: men -4.0% [range -10.8 to 3.2]; women -4.0% [-12.7 to 3.0]). By MONICA criteria, CHD mortality rates were higher, but felt less (-2.7% [-8.0 to 4.2] and -2.1% [-8.5 to 4.1]). Changes in non-fatal rates were smaller (-2.1%, [-6.9 to 2.8] and -0.8% [-9.8 to 6.8]). MONICA coronary-event rates (fatal and non-fatal combined) fell more (-2.1% [-6.5 to 2.8] and -1.4% [-6.7 to 2.8]) than case fatality (-0.6% [-4.2 to 3.1] and -0.8% [-4.8 to 2.9]). Contribution to changing CHD mortality varied, but in populations in which mortality decreased, coronary-event rates contributed two thirds and case fatality one third. Interpretation Over the decade studied, the 37 populations in the WHO MONICA Project showed substantial contributions from changes in survival, but the major determinant of decline in CHD mortality is whatever drives changing coronary-event rates.	Univ Dundee, Ninewells Hosp & Med Sch, Cardiovasc Epidemiol Unit, MONICA Qual Control Ctr Event Registrat, Dundee DD1 9SY, Scotland; KTL, Natl Publ Hlth Inst, Dept Epidemiol & Hlth Promot, MONICA Data Ctr, Helsinki, Finland; Inst Pasteur, INSERM, U508, F-59019 Lille, France	University of Dundee; Finland National Institute for Health & Welfare; Institut National de la Sante et de la Recherche Medicale (Inserm); Le Reseau International des Instituts Pasteur (RIIP); Universite de Lille - ISITE; Institut Pasteur Lille	Tunstall-Pedoe, H (corresponding author), Univ Dundee, Ninewells Hosp & Med Sch, Cardiovasc Epidemiol Unit, MONICA Qual Control Ctr Event Registrat, Dundee DD1 9SY, Scotland.			Tolonen, Hanna/0000-0003-3121-4303; Paluzie, Guillermo/0000-0002-5808-6041; Kuulasmaa, Kari/0000-0003-2165-1411; Amouyel, Philippe/0000-0001-9088-234X				BRESLOW NE, 1984, APPL STAT-J ROY ST C, V33, P38; Chambless L, 1997, CIRCULATION, V96, P3849; DOBSON AJ, 1991, STAT MED, V10, P457, DOI 10.1002/sim.4780100317; Fuller W.A., 2009, MEASUREMENT ERROR MO; GRIMM RH, 1987, CIRCULATION, V75, P6; HAVLIK RJ, 1978, NIH PUBLICATION; KUUASMAA K, 1997, B INT STAT I VOORBUR; Rosamond WD, 1998, NEW ENGL J MED, V339, P861, DOI 10.1056/NEJM199809243391301; Salomaa V, 1997, J Clin Epidemiol, V50, P3, DOI 10.1016/S0895-4356(96)00317-4; Sans S, 1997, EUR HEART J, V18, P1231; TUNSTALL-PEDOE H, 1988, Journal of Clinical Epidemiology, V41, P105; TUNSTALLPEDOE H, 1989, INT J EPIDEMIOL, V18, pS169; TUNSTALLPEDOE H, 1994, CIRCULATION, V90, P583, DOI 10.1161/01.CIR.90.1.583; UEMURA K, 1988, World Health Statistics Quarterly, V41, P155; WATERHOUSE J, 1976, CANC INCIDENCE 5 CON, P456; *WHO MONICA PROJ, 1989, WORLD HLTH STAT ANN, P27	16	1082	1114	0	29	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	MAY 8	1999	353	9164					1547	1557		10.1016/S0140-6736(99)04021-0	http://dx.doi.org/10.1016/S0140-6736(99)04021-0			11	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	195XW	10334252				2022-12-28	WOS:000080278300009
J	Zemlin, F; Schuster, R; Beckmann, E; Carrascosa, JL; Valpuesta, JM; Ertl, G				Zemlin, F; Schuster, R; Beckmann, E; Carrascosa, JL; Valpuesta, JM; Ertl, G			Stress-induced recrystallization of a protein crystal by electron irradiation	NATURE			English	Article							SELF-ORGANIZED CRITICALITY; AVALANCHE DYNAMICS; MICROSCOPE; NOISE; DNA	Ordering of a system of particles into its thermodynamically stable state usually proceeds by thermally activated mass transport of its constituents. Particularly at low temperature, the activation barrier often hinders equilibration-this is what prevents a glass from crystallizing(1) and a pile of sand from flattening under gravity. But if the driving force for mass transport (that is, the excess energy of the system) is increased, the activation barrier can be overcome and structural changes are initiated(2). Here we report the reordering of radiation-damaged protein crystals under conditions where transport is initiated by stress rather than by thermal activation, After accumulating a certain density of radiation-induced defects during observation by transmission electron microscopy, the distorted crystal recrystallizes, The reordering is induced by stress caused by the defects at temperatures that are low enough to suppress diffusive mass transport. We propose that this defect-induced reordering might be a general phenomenon.	Max Planck Gesell, Fritz Haber Inst, D-14195 Berlin, Germany; Univ Autonoma Madrid, CSIC, Natl Biotechnol Ctr, E-28049 Madrid, Spain	Max Planck Society; Fritz Haber Institute of the Max Planck Society; Autonomous University of Madrid; Consejo Superior de Investigaciones Cientificas (CSIC)	Schuster, R (corresponding author), Max Planck Gesell, Fritz Haber Inst, Faradayweg 4-6, D-14195 Berlin, Germany.		Valpuesta, José M/T-1977-2017; Valpuesta, Jose M/AAA-6002-2019	Valpuesta, José M/0000-0001-7468-8053; 				BAK P, 1988, PHYS REV A, V38, P364, DOI 10.1103/PhysRevA.38.364; BAK P, 1987, PHYS REV LETT, V59, P381, DOI 10.1103/PhysRevLett.59.381; Bragg L., 1942, J SCI INSTRUM, V19, P148; BRAGG WL, 1947, P ROY SOC LOND A MAT, V190, P474; CARAZO JM, 1986, J MOL BIOL, V192, P853, DOI 10.1016/0022-2836(86)90033-1; Debenedetti P.G., 1996, METASTABLE LIQUIDS C; DUBOCHET J, 1988, Q REV BIOPHYS, V21, P129, DOI 10.1017/S0033583500004297; Frette V, 1996, NATURE, V379, P49, DOI 10.1038/379049a0; KNAPEK E, 1982, ULTRAMICROSCOPY, V10, P71, DOI 10.1016/0304-3991(82)90189-9; MASSOBRIO C, 1989, PHYS REV LETT, V62, P1142, DOI 10.1103/PhysRevLett.62.1142; Paczuski M, 1996, PHYS REV E, V53, P414, DOI 10.1103/PhysRevE.53.414; SYMONS MCR, 1995, RADIAT PHYS CHEM, V45, P837, DOI 10.1016/0969-806X(94)E0035-H; SYMONS MCR, 1982, ULTRAMICROSCOPY, V10, P41, DOI 10.1016/0304-3991(82)90185-1; Tadic B, 1996, PHYS REV LETT, V77, P3843, DOI 10.1103/PhysRevLett.77.3843; VALPUESTA JM, 1994, J MOL BIOL, V240, P281, DOI 10.1006/jmbi.1994.1445; VALPUESTA JM, 1994, Q REV BIOPHYS, V27, P107, DOI 10.1017/S0033583500004510; Zemlin F, 1996, ULTRAMICROSCOPY, V63, P227, DOI 10.1016/0304-3991(96)00038-1	17	11	11	0	12	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	MAY 6	1999	399	6731					51	54		10.1038/19947	http://dx.doi.org/10.1038/19947			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	194BK	10331388				2022-12-28	WOS:000080172100051
J	Spiess, C; Beil, A; Ehrmann, M				Spiess, C; Beil, A; Ehrmann, M			A temperature-dependent switch from chaperone to protease in a widely conserved heat shock protein	CELL			English	Article							PERIPLASMIC ALPHA-AMYLASE; ESCHERICHIA-COLI; BETA-GALACTOSIDASE; DISULFIDE BONDS; DEGP PROTEASE; GENE; SYSTEM; HTRA; DEGRADATION; MALS	Misfolding or unfolding of polypeptides can occur as a consequence of environmental stress and spontaneous mutation. The abundance of general chaperones and proteases suggests that cells distinguish between proteins that can be refolded and "hopeless" cases fated to enter the proteolytic pathway. The mechanisms controlling this key metabolic decision are not well understood. We show here that the widely conserved heat shock protein DegP (HtrA) has both general molecular chaperone and proteolytic activities. The chaperone function dominates at low temperatures, while the proteolytic activity is present at elevated temperatures. These results show that a single cellular factor can switch between two key pathways, controlling protein stability and turnover. Implications of this finding for intracellular protein metabolism are discussed.	Univ Konstanz, Fak Biol, D-78457 Constance, Germany	University of Konstanz	Ehrmann, M (corresponding author), Univ Konstanz, Fak Biol, D-78457 Constance, Germany.	michael.ehrmann@uni-konstanz.de	Taylor, Graham/A-4027-2012; Ehrmann, Michael/A-7307-2012	Ehrmann, Michael/0000-0002-1927-260X; Spiess, Christoph/0000-0002-0570-9700				Arslan E, 1998, BIOCHEM BIOPH RES CO, V251, P744, DOI 10.1006/bbrc.1998.9549; BANEYX F, 1991, J BACTERIOL, V173, P2696, DOI 10.1128/jb.173.8.2696-2703.1991; BARDWELL JCA, 1991, CELL, V67, P581, DOI 10.1016/0092-8674(91)90532-4; Betton JM, 1998, J BIOL CHEM, V273, P8897, DOI 10.1074/jbc.273.15.8897; Buchner J, 1998, METHOD ENZYMOL, V290, P323, DOI 10.1016/S0076-6879(98)90029-5; Bukau B, 1998, CELL, V92, P351, DOI 10.1016/S0092-8674(00)80928-9; CAVARD D, 1995, FEMS MICROBIOL LETT, V125, P173; CHANG ACY, 1978, J BACTERIOL, V134, P1141, DOI 10.1128/JB.134.3.1141-1156.1978; DANESE PN, 1995, GENE DEV, V9, P387, DOI 10.1101/gad.9.4.387; DONG JM, 1993, GENE, V136, P227; FREUNDLIEB S, 1986, J BIOL CHEM, V261, P2946; Geme JWS, 1998, MOL MICROBIOL, V27, P617; Glover JR, 1998, CELL, V94, P73, DOI 10.1016/S0092-8674(00)81223-4; Gottesman S, 1997, GENE DEV, V11, P815, DOI 10.1101/gad.11.7.815; Gottesman S, 1996, ANNU REV GENET, V30, P465, DOI 10.1146/annurev.genet.30.1.465; Guigueno A, 1997, J BACTERIOL, V179, P3260, DOI 10.1128/jb.179.10.3260-3269.1997; GUZMAN LM, 1995, J BACTERIOL, V177, P4121, DOI 10.1128/jb.177.14.4121-4130.1995; Hu SI, 1998, J BIOL CHEM, V273, P34406, DOI 10.1074/jbc.273.51.34406; Kihara A, 1998, J BIOL CHEM, V273, P29770, DOI 10.1074/jbc.273.45.29770; KUO MS, 1986, CARBOHYD RES, V156, P173, DOI 10.1016/S0008-6215(00)90109-5; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Levchenko I, 1997, CELL, V91, P939, DOI 10.1016/S0092-8674(00)80485-7; LINDQUIST S, 1988, ANNU REV GENET, V22, P631, DOI 10.1146/annurev.ge.22.120188.003215; LIPINSKA B, 1988, NUCLEIC ACIDS RES, V16, P10053, DOI 10.1093/nar/16.21.10053; Missiakas D, 1998, MOL MICROBIOL, V28, P1059, DOI 10.1046/j.1365-2958.1998.00865.x; NEU HC, 1965, J BIOL CHEM, V240, P3685; NEUHOFF V, 1988, ELECTROPHORESIS, V9, P255, DOI 10.1002/elps.1150090603; Nichtl A, 1998, J MOL BIOL, V282, P1083, DOI 10.1006/jmbi.1998.2075; Pallen MJ, 1997, MOL MICROBIOL, V26, P209, DOI 10.1046/j.1365-2958.1997.5601928.x; Pogliano J, 1997, GENE DEV, V11, P1169, DOI 10.1101/gad.11.9.1169; Prinz WA, 1996, EMBO J, V15, P5209, DOI 10.1002/j.1460-2075.1996.tb00906.x; RAWLINGS ND, 1994, METHOD ENZYMOL, V244, P19; Savel'ev AS, 1998, J BIOL CHEM, V273, P20596, DOI 10.1074/jbc.273.32.20596; SCHNEIDER E, 1992, J BIOL CHEM, V267, P5148; SKORKOGLONEK J, 1995, J BIOL CHEM, V270, P11140, DOI 10.1074/jbc.270.19.11140; SNYDER WB, 1995, J BACTERIOL, V177, P953, DOI 10.1128/jb.177.4.953-963.1995; Sone M, 1997, J BIOL CHEM, V272, P6174, DOI 10.1074/jbc.272.10.6174; Spiess C, 1997, J BIOL CHEM, V272, P22125, DOI 10.1074/jbc.272.35.22125; STRAUCH KL, 1988, P NATL ACAD SCI USA, V85, P1576, DOI 10.1073/pnas.85.5.1576; Suzuki CK, 1997, TRENDS BIOCHEM SCI, V22, P118, DOI 10.1016/S0968-0004(97)01020-7; Waller PRH, 1996, J BACTERIOL, V178, P1146, DOI 10.1128/jb.178.4.1146-1153.1996; Zumbrunn J, 1996, FEBS LETT, V398, P187, DOI 10.1016/S0014-5793(96)01229-X	42	620	646	1	50	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	APR 30	1999	97	3					339	347		10.1016/S0092-8674(00)80743-6	http://dx.doi.org/10.1016/S0092-8674(00)80743-6			9	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	192VP	10319814	Bronze			2022-12-28	WOS:000080100500007
J	Hirsh, J; Bates, SM				Hirsh, J; Bates, SM			Prognosis in acute pulmonary embolism	LANCET			English	Editorial Material							HEPARIN		Hamilton Civ Hosp, Res Ctr, Hamilton, ON L8V 1C3, Canada	McMaster University	Hirsh, J (corresponding author), Hamilton Civ Hosp, Res Ctr, Hamilton, ON L8V 1C3, Canada.							BARRITT DW, 1960, LANCET, V1, P1309; Dalen JE, 1997, ARCH INTERN MED, V157, P2550, DOI 10.1001/archinte.157.22.2550; GOLDHABER SZ, 1993, LANCET, V341, P507, DOI 10.1016/0140-6736(93)90274-K; Ribeiro A, 1997, AM HEART J, V134, P479, DOI 10.1016/S0002-8703(97)70085-1; Simonneau G, 1997, NEW ENGL J MED, V337, P663, DOI 10.1056/NEJM199709043371002; tenCate JW, 1997, NEW ENGL J MED, V337, P657	6	15	15	0	1	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	APR 24	1999	353	9162					1375	1376		10.1016/S0140-6736(99)90053-3	http://dx.doi.org/10.1016/S0140-6736(99)90053-3			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	191KD	10227212				2022-12-28	WOS:000080020800003
J	Gu, LQ; Braha, O; Conlan, S; Cheley, S; Bayley, H				Gu, LQ; Braha, O; Conlan, S; Cheley, S; Bayley, H			Stochastic sensing of organic analytes by a pore-forming protein containing a molecular adapter	NATURE			English	Article							SYNTHETIC RECEPTORS; ALPHA-HEMOLYSIN; STAPHYLOCOCCUS-AUREUS; CHANNEL; RECOGNITION; THERMODYNAMICS; CYCLODEXTRINS; COMPLEXATION; BIOSENSORS; MEMBRANES	The detection of organic molecules is important in many areas, including medicine, environmental monitoring and defence(1-5) Stochastic sensing is an approach that relies on the observation of individual binding events between analyte molecules and a single receptor(6). Engineered transmembrane protein pores are promising sensor elements for stochastic detection(6), and in their simplest manifestation they produce a fluctuating binary ('on/off') response in the transmembrane electrical current. The frequency of occurrence of the fluctuations reveals the concentration of the analyte, and its identity can be deduced from the characteristic magnitude and/or duration of the fluctuations. Genetically engineered versions of the bacterial pare-forming protein alpha-haemolysin have been used to identify and quantify divalent metal ions in solution(6). But it is not immediately obvious how versatile binding sites for organic ligands might be obtained by engineering of the pore structure. Here we show that stochastic sensing of organic molecules can be procured from alpha-haemolysin by equipping the channel with an internal, non-covalently bound molecular 'adapter' whim mediates channel blocking by the analyte. We use cyclodextrins as the adapters because these fit comfortably inside the pore and present a hydrophobic cavity suitable for binding a variety of organic analytes. Moreover, at single sensing element of this sort can be used to analyse a mixture of organic molecules with different binding characteristics. We envisage the use of other adapters, so that the pore could be 'programmed' for a rang of sensing functions.	Texas A&M Univ, Univ Hlth Sci Ctr, Dept Med Biochem & Genet, College Stn, TX 77843 USA; Texas A&M Univ, Dept Chem, College Stn, TX 77843 USA	Texas A&M University System; Texas A&M University College Station; Texas A&M University System; Texas A&M University College Station	Braha, O (corresponding author), Texas A&M Univ, Univ Hlth Sci Ctr, Dept Med Biochem & Genet, 440 Reynolds Med Bldg, College Stn, TX 77843 USA.	obraha@medicine.tamu.edu; bayley@tamu.edu	Conlan, Sean/B-4401-2008	Conlan, Sean/0000-0001-6848-3465; Bayley, Hagan/0000-0003-2499-6116				Arduini A, 1997, CURR OPIN CHEM BIOL, V1, P467, DOI 10.1016/S1367-5931(97)80040-3; Bayley H, 1997, SCI AM, V277, P62, DOI 10.1038/scientificamerican0997-62; Beer PD, 1997, CURR OPIN CHEM BIOL, V1, P475, DOI 10.1016/S1367-5931(97)80041-5; Bezrukov SM, 1996, MACROMOLECULES, V29, P8517, DOI 10.1021/ma960841j; BHAKDI S, 1981, P NATL ACAD SCI-BIOL, V78, P5475, DOI 10.1073/pnas.78.9.5475; Blanchet MA, 1996, NAT STRUCT BIOL, V3, P934, DOI 10.1038/nsb1196-934; Braha O, 1997, CHEM BIOL, V4, P497, DOI 10.1016/S1074-5521(97)90321-5; Chen HD, 1997, CURR OPIN CHEM BIOL, V1, P458, DOI 10.1016/S1367-5931(97)80039-7; COLQUHOUN D, 1982, PHILOS T ROY SOC B, V300, P1, DOI 10.1098/rstb.1982.0156; Cornell BA, 1997, NATURE, V387, P580, DOI 10.1038/42432; CROOKS RM, 1998, ACCOUNTS CHEM RES, V31, P199; Czarnik AW, 1998, NATURE, V394, P417, DOI 10.1038/28728; Dickinson TA, 1996, NATURE, V382, P697, DOI 10.1038/382697a0; Gouaux E, 1998, J STRUCT BIOL, V121, P110, DOI 10.1006/jsbi.1998.3959; Hartgerink JD, 1998, CHEM-EUR J, V4, P1367, DOI 10.1002/(SICI)1521-3765(19980807)4:8<1367::AID-CHEM1367>3.0.CO;2-B; Hellinga HW, 1998, TRENDS BIOTECHNOL, V16, P183, DOI 10.1016/S0167-7799(98)01174-3; INOUE Y, 1993, J AM CHEM SOC, V115, P475, DOI 10.1021/ja00055a017; Kasianowicz JJ, 1996, P NATL ACAD SCI USA, V93, P13770, DOI 10.1073/pnas.93.24.13770; KRASILNIKOV OV, 1992, FEMS MICROBIOL IMMUN, V105, P93; Lonergan MC, 1996, CHEM MATER, V8, P2298, DOI 10.1021/cm960036j; Lu HP, 1998, SCIENCE, V282, P1877, DOI 10.1126/science.282.5395.1877; LUCCHESI K, 1989, J MEMBRANE BIOL, V109, P269, DOI 10.1007/BF01870284; MONTAL M, 1972, P NATL ACAD SCI USA, V69, P3561, DOI 10.1073/pnas.69.12.3561; Oberhauser AF, 1998, NATURE, V393, P181, DOI 10.1038/30270; Rekharsky MV, 1998, CHEM REV, V98, P1875, DOI 10.1021/cr970015o; Schmid B, 1998, PROTEIN SCI, V7, P1603, DOI 10.1002/pro.5560070714; Song LZ, 1996, SCIENCE, V274, P1859, DOI 10.1126/science.274.5294.1859; WALKER B, 1992, J BIOL CHEM, V267, P10902; [No title captured]	29	593	680	10	165	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	APR 22	1999	398	6729					686	690		10.1038/19491	http://dx.doi.org/10.1038/19491			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	189RP	10227291				2022-12-28	WOS:000079920100044
J	Kennedy, J; Auclair, K; Kendrew, SG; Park, C; Vederas, JC; Hutchinson, CR				Kennedy, J; Auclair, K; Kendrew, SG; Park, C; Vederas, JC; Hutchinson, CR			Modulation of polyketide synthase activity by accessory proteins during lovastatin biosynthesis	SCIENCE			English	Article							MYCOCEROSIC ACID SYNTHASE; DIELS-ALDER REACTION; ASPERGILLUS-TERREUS; MYCOBACTERIUM-TUBERCULOSIS; OXYGEN-ATOMS; ACYL-COA; ORIGIN; MEVINOLIN; GENE; BIOCHEMISTRY	Polyketides, the ubiquitous products of secondary metabolism in microorganisms, are made by a process resembling fatty acid biosynthesis that allows the suppression of reduction or dehydration reactions at specific biosynthetic steps, giving rise to a wide range of often medically useful products. The Lovastatin biosynthesis cluster contains two type I polyketide synthase genes. Synthesis of the main nonaketide-derived skeleton was found to require the previously known iterative Lovastatin nonaketide synthase (LNKS), plus at least one additional protein (LovC) that interacts with LNKS and is necessary for the correct processing of the growing polyketide chain and production of dihydromonacolin L. The noniterative lovastatin diketide synthase (LDKS) enzyme specifies formation of 2-methylbutyrate and interacts closely with an additional transesterase (LovD) responsible for assembling Lovastatin from this polyketide and monacolin J.	Univ Wisconsin, Sch Pharm, Madison, WI 53706 USA; Univ Wisconsin, Dept Bacteriol, Madison, WI 53706 USA; Univ Alberta, Dept Chem, Edmonton, AB T6G 2G2, Canada	University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison; University of Alberta	Vederas, JC (corresponding author), Univ Wisconsin, Sch Pharm, 425 N Charter St, Madison, WI 53706 USA.		Kennedy, Jonathan/G-5621-2010	Kennedy, Jonathan/0000-0002-9126-1198; Vederas, John/0000-0002-2996-0326	NIAID NIH HHS [AI43031] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI043031] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Ahn JH, 1998, MOL GEN GENET, V260, P462, DOI 10.1007/s004380050917; AUCLAIR K, SCIENCE; AUCLAIR K, UNPUB; Cane DE, 1998, SCIENCE, V282, P63, DOI 10.1126/science.282.5386.63; CHAN JK, 1983, J AM CHEM SOC, V105, P3334, DOI 10.1021/ja00348a062; Cole ST, 1998, NATURE, V393, P537, DOI 10.1038/31159; DONADIO S, 1991, SCIENCE, V252, P675, DOI 10.1126/science.2024119; Fitzmaurice AM, 1998, J BIOL CHEM, V273, P8033, DOI 10.1074/jbc.273.14.8033; Guenzi E, 1998, J BIOL CHEM, V273, P32857, DOI 10.1074/jbc.273.49.32857; HARDMAN JG, 1996, GOODMAN GILMANS PHAR, P885; HENDRICKSON L, UNPUB; Hutchinson CR, 1997, CHEM REV, V97, P2525, DOI 10.1021/cr960022x; Ichihara A, 1998, CURR ORG CHEM, V2, P365; JACOBS M, 1995, MYCOTA, V2, P155; Katayama K, 1998, BBA-PROTEIN STRUCT M, V1384, P387, DOI 10.1016/S0167-4838(98)00040-5; Katz L, 1997, CHEM REV, V97, P2557, DOI 10.1021/cr960025+; KENNEDY JD, UNPUB; Kolattukudy PE, 1997, MOL MICROBIOL, V24, P263, DOI 10.1046/j.1365-2958.1997.3361705.x; KONO Y, 1979, BIOORG CHEM, V8, P391, DOI 10.1016/0045-2068(79)90064-6; Konz D, 1999, CHEM BIOL, V6, pR39, DOI 10.1016/S1074-5521(99)80002-7; Liu YQ, 1998, TETRAHEDRON, V54, P15937, DOI 10.1016/S0040-4020(98)01003-5; MONAGHAN RL, 1990, ANNU REV MICROBIOL, V44, P271; MOORE RN, 1985, J AM CHEM SOC, V107, P3694, DOI 10.1021/ja00298a046; NAKAMURA T, 1990, J ANTIBIOT, V43, P1597, DOI 10.7164/antibiotics.43.1597; OHagan D., 1991, POLYKETIDE METABOLIT; OIKAWA H, 1994, J AM CHEM SOC, V116, P3605, DOI 10.1021/ja00087a059; RAINWATER DL, 1985, J BIOL CHEM, V260, P616; Rangaswamy V, 1998, P NATL ACAD SCI USA, V95, P15469, DOI 10.1073/pnas.95.26.15469; SMITH S, 1994, FASEB J, V8, P1248, DOI 10.1096/fasebj.8.15.8001737; Staunton J, 1997, CHEM REV, V97, P2611, DOI 10.1021/cr9600316; TREIBER LR, 1989, J ANTIBIOT, V42, P30, DOI 10.7164/antibiotics.42.30; Vinci VA, 1998, US, Patent No. [5744350 A, 5744350]; Wagschal K, 1996, J CHEM SOC PERK T 1, P2357, DOI 10.1039/p19960002357; Witter DJ, 1996, J ORG CHEM, V61, P2613, DOI 10.1021/jo952117p; YAMAMOTO Y, 1985, J AM CHEM SOC, V107, P2471, DOI 10.1021/ja00294a045; YANG G, 1996, PLANT CELL, V8, P139; YOSHIZAWA Y, 1994, J AM CHEM SOC, V116, P2693, DOI 10.1021/ja00085a089	37	503	556	3	127	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	MAY 21	1999	284	5418					1368	1372		10.1126/science.284.5418.1368	http://dx.doi.org/10.1126/science.284.5418.1368			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	198NN	10334994				2022-12-28	WOS:000080430600057
J	Houdusse, A; Kalbokis, VN; Himmel, D; Szent-Gyorgyi, AG; Cohen, C				Houdusse, A; Kalbokis, VN; Himmel, D; Szent-Gyorgyi, AG; Cohen, C			Atomic structure of scallop myosin subfragment S1 complexed with MgADP: A novel conformation of the myosin head	CELL			English	Article							PHOSPHATE-RELEASE STEPS; SMOOTH-MUSCLE MYOSIN; X-RAY STRUCTURES; MOTOR DOMAIN; SKELETAL-MUSCLE; REGULATORY DOMAIN; ACTIN; RESOLUTION; NUCLEOTIDE; ACTOMYOSIN	The crystal structure of a proteolytic subfragment from scallop striated muscle myosin, complexed with MgADP, has been solved at 2.5 Angstrom resolution and reveals an unusual conformation of the myosin head. The converter and the lever arm are in very different positions from those in either the pre-power stroke or near-rigor state structures; moreover, in contrast to these structures, the SH1 helix is seen to be unwound. Here we compare the overall organization of the myosin head in these three states and show how the conformation of three flexible "joints" produces rearrangements of the four major subdomains in the myosin head with different bound nucleotides. We believe that this novel structure represents one of the prehydrolysis ("ATP") states of the contractile cycle in which the myosin heads stay detached from actin.	Brandeis Univ, Rosenstiel Basic Med Sci Res Ctr, Waltham, MA 02254 USA; Brandeis Univ, Dept Biol, Waltham, MA 02254 USA; Brandeis Univ, Biophys & Struct Biol Program, Waltham, MA 02254 USA	Brandeis University; Brandeis University; Brandeis University	Cohen, C (corresponding author), Brandeis Univ, Rosenstiel Basic Med Sci Res Ctr, Waltham, MA 02254 USA.			houdusse, anne/0000-0002-8566-0336	NIAMS NIH HHS [AR 17346, AR 15963, AR 41808] Funding Source: Medline; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR041808, R01AR015963, R37AR015963, R37AR017346, R01AR017346] Funding Source: NIH RePORTER	NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		BAGSHAW CR, 1974, BIOCHEM J, V141, P331, DOI 10.1042/bj1410331; Berger CL, 1996, BIOPHYS J, V71, P3330, DOI 10.1016/S0006-3495(96)79526-7; BIVIN DB, 1993, P NATL ACAD SCI USA, V90, P6791, DOI 10.1073/pnas.90.14.6791; BRENNER B, 1982, P NATL ACAD SCI-BIOL, V79, P7288, DOI 10.1073/pnas.79.23.7288; Brunger AT, 1992, XPLOR VERSION 3 1 MA; CHALOVICH JM, 1983, P NATL ACAD SCI-BIOL, V80, P4909, DOI 10.1073/pnas.80.16.4909; Cope MJTV, 1996, STRUCTURE, V4, P969, DOI 10.1016/S0969-2126(96)00103-7; Dominguez R, 1998, CELL, V94, P559, DOI 10.1016/S0092-8674(00)81598-6; Evans P. R., 1993, P CCP4 STUD WEEK DAT, P114; FISHER AJ, 1995, BIOCHEMISTRY-US, V34, P8960, DOI 10.1021/bi00028a004; Goldman YE, 1998, CELL, V93, P1, DOI 10.1016/S0092-8674(00)81137-X; Grinband J, 1998, BIOPHYS J, V74, pA263; Gulick AM, 1997, BIOESSAYS, V19, P561, DOI 10.1002/bies.950190707; Gulick AM, 1997, BIOCHEMISTRY-US, V36, P11619, DOI 10.1021/bi9712596; HIRATSUKA T, 1992, J BIOL CHEM, V267, P14949; HOLMES KC, 1997, NOVARTIS FDN S, V213, P76; Houdusse A, 1996, STRUCTURE, V4, P21, DOI 10.1016/S0969-2126(96)00006-8; HUSTON EE, 1988, BIOCHEMISTRY-US, V27, P8945, DOI 10.1021/bi00425a011; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Kalabokis VN, 1997, BIOCHEMISTRY-US, V36, P15834, DOI 10.1021/bi971932r; Kinose F, 1996, J CELL BIOL, V134, P895, DOI 10.1083/jcb.134.4.895; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; Liang WC, 1998, P NATL ACAD SCI USA, V95, P12844, DOI 10.1073/pnas.95.22.12844; Linari M, 1998, BIOPHYS J, V74, P2459, DOI 10.1016/S0006-3495(98)77954-8; LYMN RW, 1971, BIOCHEMISTRY-US, V10, P4617, DOI 10.1021/bi00801a004; Nitao LK, 1998, BIOPHYS J, V74, pA259; OSTAP EM, 1995, BIOPHYS J, V69, P177, DOI 10.1016/S0006-3495(95)79888-5; OTWINOWSKI Z, 1993, DATA COLLECTION PROC, P59; Patterson B, 1997, J BIOL CHEM, V272, P27612, DOI 10.1074/jbc.272.44.27612; RAYMENT I, 1993, SCIENCE, V261, P58, DOI 10.1126/science.8316858; RAYMENT I, 1993, SCIENCE, V261, P50, DOI 10.1126/science.8316857; REISLER E, 1974, BIOCHEMISTRY-US, V13, P3837, DOI 10.1021/bi00716a001; Ruppel KM, 1996, MOL BIOL CELL, V7, P1123, DOI 10.1091/mbc.7.7.1123; Smith CA, 1996, BIOCHEMISTRY-US, V35, P5404, DOI 10.1021/bi952633+; Suzuki Y, 1998, NATURE, V396, P380, DOI 10.1038/24640; Vale RD, 1996, J CELL BIOL, V135, P291, DOI 10.1083/jcb.135.2.291; Van Dijk J, 1998, BIOCHEMISTRY-US, V37, P8385, DOI 10.1021/bi980139a; WELLS JA, 1980, BIOCHEMISTRY-US, V19, P1711, DOI 10.1021/bi00549a030; White HD, 1997, BIOCHEMISTRY-US, V36, P11828, DOI 10.1021/bi970540h; WHITTAKER M, 1995, NATURE, V378, P748, DOI 10.1038/378748a0; XIE X, 1994, NATURE, V368, P306, DOI 10.1038/368306a0	41	307	307	0	12	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	MAY 14	1999	97	4					459	470		10.1016/S0092-8674(00)80756-4	http://dx.doi.org/10.1016/S0092-8674(00)80756-4			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	196FV	10338210	Bronze			2022-12-28	WOS:000080299100007
J	Banavar, JR; Maritan, A; Rinaldo, A				Banavar, JR; Maritan, A; Rinaldo, A			Size and form in efficient transportation networks	NATURE			English	Article							POPULATION	Many biological processes, from cellular metabolism to population dynamics, are characterized by allometric scaling (power-law) relationships between size and rate(1-10). An outstanding question is whether typical allometric scaling relationships-the power-law dependence of a biological rate on body mass-can be understood by considering the general features of branching networks serving a particular volume. Distributed networks in nature stern from the need for effective connectivity(11), and occur both in biological systems such as cardiovascular and respiratory networks(1-8) and plant vascular and root systems(1,9,10), and in inanimate systems such as the drainage network of river basins(12), Here we derive a general relationship between size and flow rates in arbitrary networks with local connectivity. Our theory accounts in a general way for the quarter-power allometric scaling of living organisms(1-10), recently derived(8) under specific assumptions for particular network geometries. It also predicts scaling relations applicable to all efficient transportation networks, which we verify from observational data on the river drainage basins. Allometric scaling is therefore shown to originate from the general features of networks irrespective of dynamical or geometric assumptions.	Penn State Univ, Dept Phys, Davey Lab 104, University Pk, PA 16802 USA; Penn State Univ, Ctr Phys Mat, Davey Lab 104, University Pk, PA 16802 USA; SISSA, I-34014 Trieste, Italy; Abdus Salam Int Ctr Theoret Phys, I-34014 Trieste, Italy; MIT, Dept Civil & Environm Engn, Ralph M Parsons Lab, Cambridge, MA 02139 USA; Univ Padua, Dipartimento Ingn Idraul Marittina & Geotecn, Padua, Italy	Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Pennsylvania State University - University Park; Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Pennsylvania State University - University Park; International School for Advanced Studies (SISSA); Abdus Salam International Centre for Theoretical Physics (ICTP); Massachusetts Institute of Technology (MIT); University of Padua	Banavar, JR (corresponding author), Penn State Univ, Dept Phys, Davey Lab 104, University Pk, PA 16802 USA.							BONNER JT, 1983, EVOLUTION COMPLEXITY; Brown J.H., 1995, MACROECOLOGY; Calder WA., 1984, SIZE FUNCTION LIFE H; Damuth JD, 1998, NATURE, V395, P115, DOI 10.1038/25843; Enquist BJ, 1998, NATURE, V395, P163, DOI 10.1038/25977; FELDMAN HA, 1983, RESP PHYSIOL, V52, P149, DOI 10.1016/0034-5687(83)90002-6; McMahon T.A., 1983, SIZE LIFE; Rodriguez-Iturbe I., 1997, FRACTAL RIVER BASINS; SCHMIDT NK, 1984, SCALING IS ANIMAL SI; STEVENS PS, 1974, PATTERNS NATURE; West GB, 1997, SCIENCE, V276, P122, DOI 10.1126/science.276.5309.122; WILSON EO, 1997, CONSILIENCE UNITY KN	12	571	587	3	116	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	MAY 13	1999	399	6732					130	132		10.1038/20144	http://dx.doi.org/10.1038/20144			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	196XU	10335841				2022-12-28	WOS:000080335700043
J	Raju, TNK				Raju, TNK			The Nobel chronicles - 1953: Hans Adolf Krebs (1900-81) and Fritz Albert Lipmann (1899-1986)	LANCET			English	Article									Univ Illinois, Chicago, IL 60607 USA	University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital	Raju, TNK (corresponding author), Univ Illinois, Chicago, IL 60607 USA.								0	3	3	1	4	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	MAY 8	1999	353	9164					1628	1628		10.1016/S0140-6736(05)75758-5	http://dx.doi.org/10.1016/S0140-6736(05)75758-5			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	195XW	10334294				2022-12-28	WOS:000080278300067
J	Cooper, JS; Guo, MD; Herskovic, A; Macdonald, JS; Martenson, JA; Al-Sarraf, M; Byhardt, R; Russell, AH; Beitler, JJ; Spencer, S; Asbell, SO; Graham, MV; Leichman, LL				Cooper, JS; Guo, MD; Herskovic, A; Macdonald, JS; Martenson, JA; Al-Sarraf, M; Byhardt, R; Russell, AH; Beitler, JJ; Spencer, S; Asbell, SO; Graham, MV; Leichman, LL			Chemoradiotherapy of locally advanced esophageal cancer - Long-term follow-up of a prospective randomized trial (RTOG 85-01)	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							SQUAMOUS-CELL CARCINOMA; SOUTHWEST ONCOLOGY GROUP; CHEMOTHERAPY; RADIOTHERAPY; EXPERIENCE; CISPLATIN; RADIATION; SURGERY; THERAPY	Context Carcinoma of the esophagus traditionally has been treated by surgery or radiation therapy (RT), but 5-year overall survival rates have been only 5% to 10%, We previously reported results of a study conducted from January 1986 to April 1990 of combined chemotherapy and RT vs RT alone when an interim analysis revealed significant benefit for combined therapy. Objective To report the long-term outcomes of a previously reported trial designed to determine if adding chemotherapy during RT improves the survival rate of patients with esophageal carcinoma. Design Randomized controlled trial conducted 1985 to 1990 with follow-up of at least 5 years, followed by a prospective cohort study conducted between May 1990 and April 1991. Setting Multi-institution participation, ranging from tertiary academic referral centers to general community practices. Patients Patients had squamous cell or adenocarcinoma of the esophagus, T1-3 N0-1 M0, adequate renal and bone marrow reserve, and a Karnofsky score of at least 50. Interventions Combined modality therapy (n = 134). 50 Gy in 25 fractions over 5 weeks, plus cisplatin intravenously on the first day of weeks 1, 5, 8, and 11, and fluorouracil, 1 g/m(2) per day by continuous infusion on the first 4 days of weeks 1, 5, 8, and 1 1, In the randomized study, combined therapy was compared with RT only (n = 62): 64 Gy in 32 fractions over 6.4 weeks. Main Outcome Measures Overall survival, patterns of failure, and toxic effects. Results Combined therapy significantly increased overall survival compared with RT alone. In the randomized part of the trial, at 5 years of follow-up the overall survival for combined therapy was 26% (95% confidence interval [CI], 15%-37%) compared with 0% following RT. In the succeeding nonrandomized part, combined therapy produced a 5-year overall survival of 14% (95% CI, 6%-23%). Persistence of disease (despite therapy) was the most common mode of treatment failure; however, it was less common in the groups receiving combined therapy (34/130 [26%]) than in the group treated with RT only (23/62 [37%]). Severe acute toxic effects also were greater in the combined therapy groups. There were no significant differences in severe fate toxic effects between the groups. However, chemotherapy could be administered as planned in only 89 (68%) of 130 patients (10% had life-threatening toxic effects with combined therapy vs 2% in the RT only group). Conclusion Combined therapy increases the survival of patients who have squamous cell or adenocarcinoma of the esophagus, T1-3 N0-1 M0, compared with RT alone.	NYU, Dept Radiat Oncol, New York, NY USA; Radiat Therapy Oncol Grp Headquarters, Philadelphia, PA USA; Wayne State Univ, Dept Radiat Oncol, Detroit, MI 48202 USA; St Vincents Canc Ctr, Dept Med Oncol, New York, NY USA; Mayo Clin, Dept Radiat Oncol, Rochester, MN USA; Providence Canc Ctr, Dept Med Oncol, Southfield, MI USA; Med Coll Wisconsin, Dept Radiat Oncol, Milwaukee, WI 53226 USA; Radiat Oncol Ctr, Dept Radiat Oncol, Sacramento, CA USA; Albert Einstein Coll Med, Dept Radiat Oncol, New York, NY USA; Univ Alabama, Dept Radiat Oncol, Birmingham, AL USA; Albert Einstein Med Ctr, Dept Radiat Oncol, Philadelphia, PA 19141 USA; Washington Univ, Dept Radiat Oncol, St Louis, MO USA; Roswell Pk Canc Inst, Dept Med Oncol, Buffalo, NY USA	New York University; Radiation Therapy Oncology Group (RTOG); Wayne State University; Saint Vincents Hospital Manhattan; Mayo Clinic; Medical College of Wisconsin; Yeshiva University; University of Alabama System; University of Alabama Birmingham; Yeshiva University; Washington University (WUSTL); Roswell Park Cancer Institute	Cooper, JS (corresponding author), 566 1st Ave, New York, NY 10016 USA.				NATIONAL CANCER INSTITUTE [U10CA021661, U10CA032115, U10CA032102] Funding Source: NIH RePORTER; NCI NIH HHS [CA32115, CA32102, CA21661] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AlSarraf M, 1997, J CLIN ONCOL, V15, P277, DOI 10.1200/JCO.1997.15.1.277; ALSARRAF M, 1990, INT J RADIAT ONCOL, V19, P813, DOI 10.1016/0360-3016(90)90519-P; Begg C, 1996, JAMA-J AM MED ASSOC, V276, P637, DOI 10.1001/jama.276.8.637; EARLAM R, 1980, BRIT J SURG, V67, P457, DOI 10.1002/bjs.1800670702; EARLAM R, 1980, BRIT J SURG, V67, P381, DOI 10.1002/bjs.1800670602; FORASTIERE AA, 1992, SEMIN ONCOL, V19, P57; GRAY RJ, 1988, ANN STAT, V16, P1141, DOI 10.1214/aos/1176350951; Harras A., 1996, NIH PUBLICATION; HERSKOVIC A, 1992, NEW ENGL J MED, V326, P1593, DOI 10.1056/NEJM199206113262403; KAPLAN EL, 1958, J AM STAT ASSOC, V53, P457, DOI 10.2307/2281868; KELSEN DP, 1982, CANCER, V49, P1174, DOI 10.1002/1097-0142(19820315)49:6<1174::AID-CNCR2820490618>3.0.CO;2-W; LEICHMAN L, 1991, SEMIN ONCOL, V18, P64; LEICHMAN L, 1984, SEMIN ONCOL, V11, P178; MANTEL N, 1959, J NATL CANCER I, V22, P719; OBRIEN PC, 1979, BIOMETRICS, V35, P549, DOI 10.2307/2530245; POPLIN E, 1987, J CLIN ONCOL, V5, P622, DOI 10.1200/JCO.1987.5.4.622; SEYDEL HG, 1988, INT J RADIAT ONCOL, V14, P33, DOI 10.1016/0360-3016(88)90047-8; SWISHER SG, 1995, AM J SURG, V169, P609, DOI 10.1016/S0002-9610(99)80231-1; Walsh TN, 1996, NEW ENGL J MED, V335, P462, DOI 10.1056/NEJM199608153350702	19	1411	1568	0	37	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAY 5	1999	281	17					1623	1627		10.1001/jama.281.17.1623	http://dx.doi.org/10.1001/jama.281.17.1623			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	191MJ	10235156				2022-12-28	WOS:000080025900027
J	Kandela, P				Kandela, P			Clitoridectomy	LANCET			English	Editorial Material											Kandela, P (corresponding author), 23 Greenlands Rd, Staines TW18 4LR, Middx, England.							BANTOCK G, 1866, LANCET          0616, P663; BANTOCK G, 1866, LANCET          0714, P51; BROWN B, 1866, LANCET          1103, P495; BROWN B, 1866, LANCET          0630, P719; BROWN B, 1866, LANCET          0609, P639; HARRIS FH, 1866, LANCET          0623, P699; *LOND SURG HOM, 1967, LANCET          1209, P175; MOORE G, 1866, LANCET          0623, P699; *OBST SOC, 1967, LANCET          0406, P425; PICKOP J, 1886, LANCET          0714, P51; SISSON RS, 1866, LANCET          0728, P114; WEST C, 1866, LANCET          1117, P560; 1966, LANCET          1222, P697; 1886, LANCET          1208, P639; 1867, LANCET          0216, P230	15	3	3	0	1	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	APR 24	1999	353	9162					1453	1453		10.1016/S0140-6736(05)75985-7	http://dx.doi.org/10.1016/S0140-6736(05)75985-7			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	191KD	10227263				2022-12-28	WOS:000080020800068
J	Sharp, D				Sharp, D			Trends in cancer survival in England and Wales	LANCET			English	Article									The Lancet, London WC1B 3SL, England		Sharp, D (corresponding author), The Lancet, 42 Bedford Sq, London WC1B 3SL, England.							BERRINO F, IN PRESS IARC SCI PU, V151; *CANC RES CAMP, 1999, 2 CRC; Coebergh JXW, 1998, EUR J CANCER, V34, P2137; Coleman MP., 1999, CANC SURVIVAL TRENDS; Selby P, 1996, LANCET, V348, P313, DOI 10.1016/S0140-6736(96)02482-8	5	9	9	0	1	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	APR 24	1999	353	9162					1437	1438		10.1016/S0140-6736(99)03340-1	http://dx.doi.org/10.1016/S0140-6736(99)03340-1			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	191KD	10227241				2022-12-28	WOS:000080020800046
J	Covacci, A; Telford, JL; Del Giudice, G; Parsonnet, J; Rappuoli, R				Covacci, A; Telford, JL; Del Giudice, G; Parsonnet, J; Rappuoli, R			Helicobacter pylori virulence and genetic geography	SCIENCE			English	Review							CAG PATHOGENICITY ISLAND; HEAT-LABILE ENTEROTOXIN; PEPTIC-ULCER DISEASE; VACUOLATING CYTOTOXIN; GNOTOBIOTIC PIGLETS; INTRAGASTRIC VACCINATION; MONGOLIAN GERBILS; IMMUNE-RESPONSES; EPITHELIAL-CELLS; GENOME SEQUENCE	Isolated for the first time in 1982 from human gastric biopsy, Helicobacter pylori is responsible for gastritis, peptic ulcer, and gastric cancer. A pathogenicity island acquired by horizontal transfer, coding for a type IV secretion system, is a major determinant of virulence. The infection is now treated with antibiotics, and vaccines are in preparation. The geographic distribution suggests coevolution of man and Helicobacter pylori.	Chiron SpA, IRIS, I-53100 Siena, Italy; Stanford Univ, Dept Med Infect Dis Hrp T152, Stanford, CA 94305 USA	Novartis; Stanford University	Rappuoli, R (corresponding author), Chiron SpA, IRIS, Via Fiorentina 1, I-53100 Siena, Italy.	rappuoli@iris02.biocine.it	Telford, John Laird/ABG-8144-2020	Parsonnet, Julie/0000-0001-7342-5366				Achtman M, 1999, MOL MICROBIOL, V32, P459, DOI 10.1046/j.1365-2958.1999.01382.x; Akopyants NS, 1998, MOL MICROBIOL, V28, P37, DOI 10.1046/j.1365-2958.1998.00770.x; Alm RA, 1999, NATURE, V397, P176, DOI 10.1038/16495; Andersson SGE, 1998, NATURE, V396, P133, DOI 10.1038/24094; Angstrom J, 1998, GLYCOBIOLOGY, V8, P297, DOI 10.1093/glycob/8.4.297; Appelmelk BJ, 1997, TRENDS MICROBIOL, V5, P70, DOI 10.1016/S0966-842X(96)10084-6; Atherton JC, 1996, J INFECT DIS, V174, P552, DOI 10.1093/infdis/174.3.552; Bitzan MM, 1998, J INFECT DIS, V177, P955, DOI 10.1086/515256; BLANCOLABRA A, 1981, J FOOD BIOCHEM, V5, P1, DOI 10.1111/j.1745-4514.1981.tb00658.x; Blaser MJ, 1998, BRIT MED J, V316, P1507, DOI 10.1136/bmj.316.7143.1507; Campbell S, 1997, INFECT IMMUN, V65, P3708, DOI 10.1128/IAI.65.9.3708-3712.1997; CAVALLI-SFORZA L.L., 1996, GENI POPOLI LINGUE; Censini S, 1996, P NATL ACAD SCI USA, V93, P14648, DOI 10.1073/pnas.93.25.14648; Chow WH, 1998, CANCER RES, V58, P588; Christie PJ, 1997, TRENDS MICROBIOL, V5, P264, DOI 10.1016/S0966-842X(97)88833-6; CLEMENS J, 1995, J INFECT DIS, V171, P1653, DOI 10.1093/infdis/171.6.1653; Corthesy-Theulaz IE, 1998, INFECT IMMUN, V66, P581; COVACCI A, 1993, P NATL ACAD SCI USA, V90, P5791, DOI 10.1073/pnas.90.12.5791; Covacci A, 1997, TRENDS MICROBIOL, V5, P205, DOI 10.1016/S0966-842X(97)01035-4; Covacci A, 1998, CURR OPIN MICROBIOL, V1, P96, DOI 10.1016/S1369-5274(98)80148-3; COVER TL, 1994, J BIOL CHEM, V269, P10566; Cover TL, 1997, J CELL BIOL, V138, P759, DOI 10.1083/jcb.138.4.759; Cuenca R, 1996, GASTROENTEROLOGY, V110, P1770, DOI 10.1053/gast.1996.v110.pm8964402; DElios MM, 1997, J IMMUNOL, V158, P962; Diamond J., 2010, RUZHYA MIKROBY STALI; Dubois A, 1998, INFECT IMMUN, V66, P4340; Eaton KA, 1998, J INFECT DIS, V178, P1399, DOI 10.1086/314463; EATON KA, 1994, INFECT IMMUN, V62, P3604, DOI 10.1128/IAI.62.9.3604-3607.1994; Eaton KA, 1996, INFECT IMMUN, V64, P2445, DOI 10.1128/IAI.64.7.2445-2448.1996; Ermak TH, 1998, J EXP MED, V188, P2277, DOI 10.1084/jem.188.12.2277; EVANS DJ, 1995, INFECT IMMUN, V63, P2213, DOI 10.1128/IAI.63.6.2213-2220.1995; Falkow S, 1998, EMERG INFECT DIS, V4, P495, DOI 10.3201/eid0403.980342; Finlay BB, 1997, MICROBIOL MOL BIOL R, V61, P136, DOI 10.1128/.61.2.136-169.1997; Galan JE, 1999, SCIENCE, V284, P1322, DOI 10.1126/science.284.5418.1322; Ghiara P, 1997, INFECT IMMUN, V65, P4996, DOI 10.1128/IAI.65.12.4996-5002.1997; Giuliani MM, 1998, J EXP MED, V187, P1123, DOI 10.1084/jem.187.7.1123; Glocker E, 1998, INFECT IMMUN, V66, P2346, DOI 10.1128/IAI.66.5.2346-2348.1998; Graham DY, 1998, GASTROENTEROLOGY, V115, P1272, DOI 10.1016/S0016-5085(98)70100-3; Guy B, 1998, VACCINE, V16, P850, DOI 10.1016/S0264-410X(97)00258-2; Hamlet A, 1999, GASTROENTEROLOGY, V116, P259, DOI 10.1016/S0016-5085(99)70121-6; Hansson LE, 1996, NEW ENGL J MED, V335, P242, DOI 10.1056/NEJM199607253350404; Ilver D, 1998, SCIENCE, V279, P373, DOI 10.1126/science.279.5349.373; Ito Y, 1997, J CLIN MICROBIOL, V35, P1710, DOI 10.1128/JCM.35.7.1710-1714.1997; Kersulyte D, 1999, MOL MICROBIOL, V31, P31, DOI 10.1046/j.1365-2958.1999.01140.x; Kleanthous H, 1998, INFECT IMMUN, V66, P2879, DOI 10.1128/IAI.66.6.2879-2886.1998; Lanzavecchia S, 1998, J STRUCT BIOL, V121, P9, DOI 10.1006/jsbi.1997.3941; Lupetti P, 1996, J CELL BIOL, V133, P801, DOI 10.1083/jcb.133.4.801; Maeda S, 1998, GUT, V42, P338, DOI 10.1136/gut.42.3.338; Marchetti M, 1998, VACCINE, V16, P33, DOI 10.1016/S0264-410X(97)00153-9; MARCHETTI M, 1995, SCIENCE, V267, P1655, DOI 10.1126/science.7886456; MARSHALL BJ, 1984, LANCET, V1, P1311; Marshall DG, 1998, MICROBIOL-SGM, V144, P2925, DOI 10.1099/00221287-144-11-2925; McGee DJ, 1999, CURR TOP MICROBIOL, V241, P155; MENOZZI P, 1994, HIST GEOGRAPHY HUMAN; MEYERTERVEHN AT, UNPUB; Miehlke S, 1999, J CLIN MICROBIOL, V37, P245, DOI 10.1128/JCM.37.1.245-247.1999; Mohammadi M, 1996, J IMMUNOL, V156, P4729; Molinari M, 1997, J BIOL CHEM, V272, P25339, DOI 10.1074/jbc.272.40.25339; Moran AP, 1997, J BACTERIOL, V179, P6453, DOI 10.1128/jb.179.20.6453-6463.1997; Pagliaccia C, 1998, P NATL ACAD SCI USA, V95, P10212, DOI 10.1073/pnas.95.17.10212; Pan ZJ, 1998, J INFECT DIS, V178, P220, DOI 10.1086/515601; Papini E, 1998, J CLIN INVEST, V102, P813, DOI 10.1172/JCI2764; Papini E, 1997, EMBO J, V16, P15, DOI 10.1093/emboj/16.1.15; Pappo J, 1999, INFECT IMMUN, V67, P337, DOI 10.1128/IAI.67.1.337-341.1999; Park SM, 1998, SCAND J GASTROENTERO, V33, P923, DOI 10.1080/003655298750026921; Parsonnet J, 1998, GUT, V43, pS6, DOI 10.1136/gut.43.2008.S6; Peek RM, 1998, P ASSOC AM PHYSICIAN, V110, P531; PELICIC V, IN PRESS MICROBIOLOG; REPLOGLE ML, 1995, AM J EPIDEMIOL, V142, P856, DOI 10.1093/oxfordjournals.aje.a117725; Rossi G, 1999, INFECT IMMUN, V67, P3112, DOI 10.1128/IAI.67.6.3112-3120.1999; Rothenbacher D, 1999, J INFECT DIS, V179, P398, DOI 10.1086/314595; Saga G, 1998, TRENDS MICROBIOL, V6, P253, DOI 10.1016/S0966-842X(98)01308-0; Saldinger PF, 1998, GASTROENTEROLOGY, V115, P891, DOI 10.1016/S0016-5085(98)70261-6; Scoarughi GL, 1999, J BACTERIOL, V181, P552, DOI 10.1128/JB.181.2.552-555.1999; Segal ED, 1996, P NATL ACAD SCI USA, V93, P1259, DOI 10.1073/pnas.93.3.1259; Segal ED, 1997, P NATL ACAD SCI USA, V94, P7595, DOI 10.1073/pnas.94.14.7595; Simon PM, 1997, INFECT IMMUN, V65, P750, DOI 10.1128/IAI.65.2.750-757.1997; SMITH KL, 1998, BACTERIAL INFECT HUM, P337; SONNENBERG A, 1993, AM J PUBLIC HEALTH, V83, P1006, DOI 10.2105/AJPH.83.7.1006; Suerbaum S, 1998, P NATL ACAD SCI USA, V95, P12619, DOI 10.1073/pnas.95.21.12619; SUERBAUM S, 1995, TRENDS MICROBIOL, V3, P168, DOI 10.1016/S0966-842X(00)88913-1; TELFORD JL, 1994, TRENDS BIOTECHNOL, V12, P420, DOI 10.1016/0167-7799(94)90031-0; TELFORD JL, 1994, J EXP MED, V179, P1653, DOI 10.1084/jem.179.5.1653; Telford JL, 1996, DRUGS, V52, P799, DOI 10.2165/00003495-199652060-00002; Tomb JF, 1997, NATURE, V388, P539, DOI 10.1038/41483; van der Ende A, 1998, INFECT IMMUN, V66, P1822, DOI 10.1128/IAI.66.5.1822-1826.1998; vanderEnde A, 1996, GASTROENTEROLOGY, V111, P638, DOI 10.1053/gast.1996.v111.pm8780568; Watanabe T, 1998, GASTROENTEROLOGY, V115, P642, DOI 10.1016/S0016-5085(98)70143-X; Weltzin R, 1997, VACCINE, V15, P370, DOI 10.1016/S0264-410X(97)00203-X; Winans SC, 1996, TRENDS MICROBIOL, V4, P64, DOI 10.1016/0966-842X(96)81513-7; Wirth HP, 1998, INFECT IMMUN, V66, P4856, DOI 10.1128/IAI.66.10.4856-4866.1998; Yang JC, 1998, SCAND J GASTROENTERO, V33, P1152, DOI 10.1080/00365529850172494	92	876	928	2	67	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAY 21	1999	284	5418					1328	1333		10.1126/science.284.5418.1328	http://dx.doi.org/10.1126/science.284.5418.1328			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	198NN	10334982				2022-12-28	WOS:000080430600045
J	Bouts, BA				Bouts, BA			Argyria	NEW ENGLAND JOURNAL OF MEDICINE			English	Article									Blanchard Valley Med Associates, Findlay, OH 45840 USA		Bouts, BA (corresponding author), Blanchard Valley Med Associates, Findlay, OH 45840 USA.		Parekh, Utsav/AAQ-6583-2020	Parekh, Utsav/0000-0002-0548-7810					0	21	22	0	1	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	MAY 20	1999	340	20					1554	1554		10.1056/NEJM199905203402006	http://dx.doi.org/10.1056/NEJM199905203402006			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	197HG	10332018				2022-12-28	WOS:000080358900006
J	Dworkin, RH				Dworkin, RH			Prevention of postherpetic neuralgia	LANCET			English	Editorial Material							PLACEBO-CONTROLLED TRIAL; ACUTE HERPES-ZOSTER; RANDOMIZED TRIAL; DOUBLE-BLIND; DIABETIC NEUROPATHY; ORAL ACYCLOVIR; PAIN; AMITRIPTYLINE; METAANALYSIS; THERAPY		Univ Rochester, Sch Med & Dent, Dept Anesthesiol, Rochester, NY 14642 USA	University of Rochester	Dworkin, RH (corresponding author), Univ Rochester, Sch Med & Dent, Dept Anesthesiol, Rochester, NY 14642 USA.							BEUTNER KR, 1995, ANTIMICROB AGENTS CH, V39, P1546, DOI 10.1128/AAC.39.7.1546; Bowsher D, 1997, J PAIN SYMPTOM MANAG, V13, P327, DOI 10.1016/S0885-3924(97)00077-8; BYASSMITH MG, 1995, PAIN, V60, P267, DOI 10.1016/0304-3959(94)00121-T; DWORKIN RH, 1994, LANCET, V343, P1648, DOI 10.1016/S0140-6736(94)93106-2; Dworkin RH, 1998, J INFECT DIS, V178, pS76, DOI 10.1086/514260; DWORKIN RH, 1998, HDB PAIN SYNDROMES B; Harati Y, 1998, NEUROLOGY, V50, P1842, DOI 10.1212/WNL.50.6.1842; Jackson JL, 1997, ARCH INTERN MED, V157, P909, DOI 10.1001/archinte.157.8.909; JOHNSON R, 1995, J INFECTION, V30, P193; McQuay HJ, 1996, PAIN, V68, P217, DOI 10.1016/S0304-3959(96)03140-5; Rowbotham M, 1998, JAMA-J AM MED ASSOC, V280, P1837, DOI 10.1001/jama.280.21.1837; TYRING S, 1995, ANN INTERN MED, V123, P89, DOI 10.7326/0003-4819-123-2-199507150-00002; Watson CPN, 1998, NEUROLOGY, V51, P1166, DOI 10.1212/WNL.51.4.1166; Watson CPN, 1998, NEUROLOGY, V50, P1837; Whitley RJ, 1996, ANN INTERN MED, V125, P376, DOI 10.7326/0003-4819-125-5-199609010-00004; WOOD MJ, 1994, NEW ENGL J MED, V330, P896, DOI 10.1056/NEJM199403313301304; Wood MJ, 1996, CLIN INFECT DIS, V22, P341, DOI 10.1093/clinids/22.2.341; WOOD MJ, 1995, MANAGEMENT STRATEGIE	18	27	28	0	6	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	MAY 15	1999	353	9165					1636	1637		10.1016/S0140-6736(99)00003-3	http://dx.doi.org/10.1016/S0140-6736(99)00003-3			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	198DT	10335778	hybrid			2022-12-28	WOS:000080408000003
J	Sabatini, DM; Barrow, RK; Blackshaw, S; Burnett, PE; Lai, MM; Field, ME; Bahr, BA; Kirsch, J; Betz, H; Snyder, SH				Sabatini, DM; Barrow, RK; Blackshaw, S; Burnett, PE; Lai, MM; Field, ME; Bahr, BA; Kirsch, J; Betz, H; Snyder, SH			Interaction of RAFT1 with gephyrin required for rapamycin-sensitive signaling	SCIENCE			English	Article							P70 S6 KINASE; ATAXIA-TELANGIECTASIA GENE; PHOSPHATIDYLINOSITOL 3-KINASE; MAMMALIAN PROTEIN; CELL-LINE; EARLY G1; YEAST; PHOSPHORYLATION; HOMOLOG; TARGET	RAFT1 (rapamycin and FKBP12 target 1; also called FRAP or mTOR) is a member of the ATM (ataxia telangiectasia mutated)-related family of proteins and functions as the in vivo mediator of the effects of the immunosuppressant rapamycin and as an important regulator of messenger RNA translation. In mammalian cells RAFT1 interacted with gephyrin, a widely expressed protein necessary for the clustering of glycine receptors at the cell membrane of neurons. RAFT1 mutants that could not associate with gephyrin failed to signal to downstream molecules, including the p70 ribosomal 56 kinase and the eIF-4E binding protein, 4E-BP1. The interaction with gephyrin ascribes a function to the Large amino-terminal region of an ATM-related protein and reveals a role in signal transduction for the clustering protein gephyrin.	Johns Hopkins Univ, Sch Med, Dept Neurosci, Baltimore, MD 21205 USA; Univ Connecticut, Dept Pharmaceut Sci, Storrs, CT 06269 USA; Max Planck Inst Brain Res, Dept Neurochem, D-60528 Frankfurt, Germany	Johns Hopkins University; University of Connecticut; Max Planck Society	Snyder, SH (corresponding author), Johns Hopkins Univ, Sch Med, Dept Neurosci, 725 N Wolfe St, Baltimore, MD 21205 USA.			/0000-0002-1446-7256	NIDA NIH HHS [DA-00074, DA-00266] Funding Source: Medline; NIGMS NIH HHS [GM-07309] Funding Source: Medline; NATIONAL INSTITUTE ON DRUG ABUSE [P50DA000266] Funding Source: NIH RePORTER	NIDA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission)		ALBERS MW, 1993, J BIOL CHEM, V268, P22825; Barbet NC, 1996, MOL BIOL CELL, V7, P25, DOI 10.1091/mbc.7.1.25; Beretta L, 1996, EMBO J, V15, P658, DOI 10.1002/j.1460-2075.1996.tb00398.x; Blackshaw S, 1997, J NEUROSCI, V17, P8074; BROWN EJ, 1994, NATURE, V369, P756, DOI 10.1038/369756a0; BROWN EJ, 1995, NATURE, V377, P441, DOI 10.1038/377441a0; Brunn GJ, 1997, SCIENCE, V277, P99, DOI 10.1126/science.277.5322.99; Burnett PE, 1998, P NATL ACAD SCI USA, V95, P8351, DOI 10.1073/pnas.95.14.8351; Burnett PE, 1998, P NATL ACAD SCI USA, V95, P1432, DOI 10.1073/pnas.95.4.1432; CAFFERKEY R, 1993, MOL CELL BIOL, V13, P6012, DOI 10.1128/MCB.13.10.6012; CHEVRAY PM, 1992, P NATL ACAD SCI USA, V89, P5789, DOI 10.1073/pnas.89.13.5789; CHIU MI, 1994, P NATL ACAD SCI USA, V91, P12574, DOI 10.1073/pnas.91.26.12574; CHUNG J, 1992, CELL, V69, P1227, DOI 10.1016/0092-8674(92)90643-Q; Gao FB, 1998, BIOESSAYS, V20, P70, DOI 10.1002/(SICI)1521-1878(199801)20:1<70::AID-BIES10>3.0.CO;2-5; HARTLEY KO, 1995, CELL, V82, P849, DOI 10.1016/0092-8674(95)90482-4; HEITMAN J, 1991, SCIENCE, V253, P905, DOI 10.1126/science.1715094; JAYARAMAN T, 1993, J BIOL CHEM, V268, P25385; Kawasaki BT, 1997, J NEUROSCI RES, V49, P381, DOI 10.1002/(SICI)1097-4547(19970801)49:3<381::AID-JNR13>3.0.CO;2-2; KEITH CT, 1995, SCIENCE, V270, P50, DOI 10.1126/science.270.5233.50; KIRSCH J, 1995, MOL CELL NEUROSCI, V6, P450, DOI 10.1006/mcne.1995.1033; KRUPPA J, 1977, J CELL BIOL, V74, P414, DOI 10.1083/jcb.74.2.414; KUNZ J, 1993, CELL, V73, P585, DOI 10.1016/0092-8674(93)90144-F; KUO CJ, 1992, NATURE, V358, P70, DOI 10.1038/358070a0; MEYER G, 1995, NEURON, V15, P563, DOI 10.1016/0896-6273(95)90145-0; MORROW DM, 1995, CELL, V82, P831, DOI 10.1016/0092-8674(95)90480-8; PRIOR P, 1992, NEURON, V8, P1161, DOI 10.1016/0896-6273(92)90136-2; SABATINI DM, 1995, J BIOL CHEM, V270, P20875, DOI 10.1074/jbc.270.36.20875; SABATINI DM, 1994, CELL, V78, P35, DOI 10.1016/0092-8674(94)90570-3; SABATINI DM, UNPUB; SABERS CJ, 1995, J BIOL CHEM, V270, P815, DOI 10.1074/jbc.270.2.815; SAVITSKY K, 1995, SCIENCE, V268, P1749, DOI 10.1126/science.7792600; SEHGAL SN, 1975, J ANTIBIOT, V28, P727, DOI 10.7164/antibiotics.28.727; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; STEWARD O, 1992, TRENDS NEUROSCI, V15, P180, DOI 10.1016/0166-2236(92)90170-D; vonManteuffel SR, 1996, P NATL ACAD SCI USA, V93, P4076, DOI 10.1073/pnas.93.9.4076; WALENSKY LD, 1995, J CELL BIOL, V130, P857, DOI 10.1083/jcb.130.4.857; Walensky LD, 1998, J CELL BIOL, V141, P143, DOI 10.1083/jcb.141.1.143; Watters D, 1997, ONCOGENE, V14, P1911, DOI 10.1038/sj.onc.1201037	38	152	158	1	9	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	MAY 14	1999	284	5417					1161	1164		10.1126/science.284.5417.1161	http://dx.doi.org/10.1126/science.284.5417.1161			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	197HJ	10325225				2022-12-28	WOS:000080359100035
J	Annas, GJ				Annas, GJ			Waste and longing - The legal status of placental-blood banking	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material							TRANSPLANTATION; FUTURE		Boston Univ, Sch Publ Hlth, Hlth Law Dept, Boston, MA 02215 USA	Boston University	Annas, GJ (corresponding author), Boston Univ, Sch Publ Hlth, Hlth Law Dept, Boston, MA 02215 USA.			Annas, George/0000-0001-5836-7831				*AM COLL OBST GYN, 1997, COMM OP ROUT STOR UM; ANNAS GJ, 1989, NEW ENGL J MED, V320, P1079, DOI 10.1056/NEJM198904203201610; ANNAS GJ, 1993, JAMA-J AM MED ASSOC, V270, P2346, DOI 10.1001/jama.270.19.2346; Annas GJ, 1995, J LAW MED ETHICS, V23, P360, DOI 10.1111/j.1748-720X.1995.tb01378.x; ANNAS GJ, 1993, STANDARD CARE LAW AM, P167; BARON CH, 1975, BOSTON U LAW REV, V55, P159; Curran William J., 1959, NEW YORK U LAW REV, V34, P891; DeLillo Don, 1997, UNDERWORLD; FOX RC, 1974, COURAGE FAIL; GRADY D, 1998, NY TIMES        1201, pD6; GRADY D, 1998, NY TIMES        0415, pA1; *I MED COMM ASS GE, 1994, ASS GEN RISKS IMPL H; Kulynych Jennifer, 1998, Univ Richmond Law Rev, V32, P407; LIND SE, 1994, TRANSFUSION, V34, P828, DOI 10.1046/j.1537-2995.1994.34994378287.x; Parkman R, 1998, NEW ENGL J MED, V339, P1628, DOI 10.1056/NEJM199811263392209; Rubinstein P, 1998, NEW ENGL J MED, V339, P1565, DOI 10.1056/NEJM199811263392201; Schenk Jennifer L., 1997, MD J CONT LEGAL ISSU, V8, P151; Starr Douglas, 1998, BLOOD EPIC HIST MED; Sugarman J, 1997, JAMA-J AM MED ASSOC, V278, P938, DOI 10.1001/jama.278.11.938; SUGARMAN J, 1995, JAMA-J AM MED ASSOC, V274, P1783, DOI 10.1001/jama.274.22.1783; Titmuss R., 1970, GIFT RELATIONSHIP HU; Zilberstein M, 1997, LANCET, V349, P642, DOI 10.1016/S0140-6736(96)05267-1	22	79	81	0	1	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	MAY 13	1999	340	19					1521	1524		10.1056/NEJM199905133401923	http://dx.doi.org/10.1056/NEJM199905133401923			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	194MT	10320393	Green Published			2022-12-28	WOS:000080198700031
J	Drucker, E; Vlahov, D				Drucker, E; Vlahov, D			Controlled clinical evaluation of diacetyl morphine for treatment of intractable opiate dependence	LANCET			English	Editorial Material									Montefiore Med Ctr, Albert Einstein Coll Med, Dept Epidemiol & Social Med, Bronx, NY 10467 USA; Johns Hopkins Univ, Sch Publ Hlth, Baltimore, MD USA; New York Acad Med, Ctr Urban Epidemiol Studies, New York, NY USA	Montefiore Medical Center; Yeshiva University; Albert Einstein College of Medicine; Johns Hopkins University; New York Academy of Medicine	Drucker, E (corresponding author), Montefiore Med Ctr, Albert Einstein Coll Med, Dept Epidemiol & Social Med, Bronx, NY 10467 USA.							*WHO, 1999, REP EXT PAN EV SWISS	1	10	10	0	1	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	MAY 8	1999	353	9164					1543	1544		10.1016/S0140-6736(99)90110-1	http://dx.doi.org/10.1016/S0140-6736(99)90110-1			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	195XW	10334249				2022-12-28	WOS:000080278300005
J	[Anonymous]				[Anonymous]			BMA launches consultation on Helsinki Declaration	BMJ-BRITISH MEDICAL JOURNAL			English	Editorial Material																			0	0	0	0	0	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	MAY 8	1999	318	7193					1293	1293						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	195XT	10231285				2022-12-28	WOS:000080278000069
J	Pinhas-Hamiel, O; Zeitler, P				Pinhas-Hamiel, O; Zeitler, P			The importance of a name	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							DEPENDENT DIABETES-MELLITUS; INSULIN-SECRETION; AFRICAN-AMERICANS; KETOACIDOSIS; ADOLESCENTS; AUTOANTIBODIES; SENSITIVITY		Maccabi Juvenile Diabet Ctr, IL-47117 Ramat Hasharon, Israel; Univ Colorado, Hlth Sci Ctr, Dept Pediat, Div Endocrinol, Denver, CO 80262 USA	University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver	Pinhas-Hamiel, O (corresponding author), Maccabi Juvenile Diabet Ctr, 5 Usishkin St,POB 1773, IL-47117 Ramat Hasharon, Israel.	c12502@coop.co.il	Pinhas-Hamiel, Orit/K-5198-2013	Zeitler, Philip/0000-0001-5756-7858				Arslanian S, 1996, J PEDIATR-US, V129, P440, DOI 10.1016/S0022-3476(96)70078-1; Despres JP, 1996, NEW ENGL J MED, V334, P952, DOI 10.1056/NEJM199604113341504; Diaz RAG, 1996, ARCH MED RES, V27, P177; EFENDIC S, 1979, ACTA ENDOCRINOL-COP, V90, P5; FERRANNINI E, 1987, NEW ENGL J MED, V317, P350, DOI 10.1056/NEJM198708063170605; KASSIRER JP, 1989, ANN INTERN MED, V110, P893, DOI 10.7326/0003-4819-110-11-893; Osei K, 1997, DIABETES CARE, V20, P396, DOI 10.2337/diacare.20.3.396; PinhasHamiel O, 1996, J PEDIATR-US, V128, P608, DOI 10.1016/S0022-3476(96)80124-7; PinhasHamiel O, 1997, DIABETES CARE, V20, P484, DOI 10.2337/diacare.20.4.484; ROWLEY MJ, 1992, DIABETES, V41, P548, DOI 10.2337/diabetes.41.4.548; SCHIFFRIN A, 1994, DIABETES RES CLIN PR, V23, P95, DOI 10.1016/0168-8227(94)90016-7; Scott CR, 1997, PEDIATRICS, V100, P84, DOI 10.1542/peds.100.1.84; Stearne MR, 1998, BMJ-BRIT MED J, V317, P703; UMPIERREZ GE, 1995, DIABETES, V44, P790, DOI 10.2337/diabetes.44.7.790; WiestLadenburger U, 1997, DIABETES, V46, P565, DOI 10.2337/diabetes.46.4.565; Wroblewski M, 1998, DIABETES CARE, V21, P250, DOI 10.2337/diacare.21.2.250	16	13	14	0	7	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	MAY 6	1999	340	18					1418	1421		10.1056/NEJM199905063401808	http://dx.doi.org/10.1056/NEJM199905063401808			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	192QN	10228194				2022-12-28	WOS:000080090600008
J	de Vries, F				de Vries, F			To make a drama out of trauma is fully justified	LANCET			English	Article											de Vries, F (corresponding author), Dintelstr 91-3, NL-1079 BB Amsterdam, Netherlands.								0	14	14	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON WC1B 3SL, ENGLAND	0140-6736			LANCET	Lancet	MAY 23	1998	351	9115					1579	1580		10.1016/S0140-6736(98)11524-6	http://dx.doi.org/10.1016/S0140-6736(98)11524-6			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZQ497	10326557				2022-12-28	WOS:000073868000049
J	McCauliffe, DP				McCauliffe, DP			Distinguishing subacute cutaneous from other types of lupus erythematosus	LANCET			English	Editorial Material									Univ N Carolina, Sch Med, Dept Dermatol, Chapel Hill, NC 27599 USA	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina School of Medicine	McCauliffe, DP (corresponding author), Univ N Carolina, Sch Med, Dept Dermatol, Chapel Hill, NC 27599 USA.							BIELSA I, 1994, ARCH DERMATOL, V130, P54, DOI 10.1001/archderm.130.1.54; Chlebus E, 1998, J AM ACAD DERMATOL, V38, P405, DOI 10.1016/S0190-9622(98)70497-9; Crowson AN, 1997, HUM PATHOL, V28, P67, DOI 10.1016/S0046-8177(97)90281-1; LEHMANN P, 1990, J AM ACAD DERMATOL, V22, P181, DOI 10.1016/0190-9622(90)70020-I; McCauliffe Daniel P., 1993, P302; McCauliffe DP, 1997, LUPUS, V6, P158, DOI 10.1177/096120339700600211; REED BR, 1985, ANN INTERN MED, V103, P49, DOI 10.7326/0003-4819-103-1-49; SONTHEIMER RD, 1989, MED CLIN N AM, V73, P1073, DOI 10.1016/S0025-7125(16)30620-4; SONTHEIMER RD, 1979, ARCH DERMATOL, V115, P1409, DOI 10.1001/archderm.115.12.1409; Sontheimer Richard D., 1993, P285; TAN EM, 1982, ARTHRITIS RHEUM, V25, P1271, DOI 10.1002/art.1780251101; WOLSKA H, 1989, INT J DERMATOL, V28, P98, DOI 10.1111/j.1365-4362.1989.tb01327.x	12	5	6	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON WC1B 3SL, ENGLAND	0140-6736			LANCET	Lancet	MAY 23	1998	351	9115					1527	1528		10.1016/S0140-6736(05)61117-8	http://dx.doi.org/10.1016/S0140-6736(05)61117-8			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZQ497	10326532				2022-12-28	WOS:000073868000005
J	Pal, B				Pal, B			Email contact between doctor and patient	BRITISH MEDICAL JOURNAL			English	Editorial Material																			0	17	17	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	MAY 22	1999	318	7195					1428	1428		10.1136/bmj.318.7195.1428	http://dx.doi.org/10.1136/bmj.318.7195.1428			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	200DQ	10334782	Green Published			2022-12-28	WOS:000080524700081
J	Ridker, PM; Manson, JE; Buring, JE; Shih, J; Matias, M; Hennekens, CH				Ridker, PM; Manson, JE; Buring, JE; Shih, J; Matias, M; Hennekens, CH			Homocysteine and risk of cardiovascular disease among postmenopausal women	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							CORONARY HEART-DISEASE; METHYLENETETRAHYDROFOLATE REDUCTASE GENE; SERUM TOTAL HOMOCYSTEINE; PLASMA HOMOCYST(E)INE; MYOCARDIAL-INFARCTION; VASCULAR-DISEASE; US PHYSICIANS; FOLIC-ACID; POPULATION; MUTATION	Context Individuals with elevated levels of homocysteine tend to have higher prevalence of cardiovascular disease. However, prospective studies of homocysteine are inconsistent and data among women are limited. Objective To determine whether elevated homocysteine levels in healthy postmenopausal women predict risk of developing cardiovascular disease. Design Prospective, nested case-control study with a mean 3-year follow-up. Setting The Women's Health Study, an ongoing US primary prevention trial initiated in 1993. Participants From a total cohort of 28 263 postmenopausal women with no history of cardiovascular disease or cancer at baseline, 122 women who subsequently experienced cardiovascular events were defined as cases, and 244 age- and smoking status-matched women who remained free of disease during follow-up were defined as controls. Main Outcome Measures Incidence of death due to cardiovascular disease, nonfatal myocardial infarction (MI), stroke, percutaneous transluminal coronary angioplasty, or coronary artery bypass graft by baseline homocysteine level, Results Of the 122 cases, there were 85 events of MI or stroke and 37 coronary revascularizations. Case subjects had significantly higher baseline homocysteine levels than controls (14.1 vs 12.4 mu mol/L; P = .02). Subjects with homocysteine levels in the highest quartile had a 2-fold increase in risk of any cardiovascular event (relative risk [RR], 2.0; 95% confidence interval [CI], 1.1-3.8). This effect was largely due to an excess of cases with high levels of homocysteine; the RR for those with homocysteine levels at or higher than the 95th percentile (20.7 mu mol/L) was 2.6 (95% CI, 1.1-5.7), Risk estimates were independent of traditional risk factors and were greatest for the end points of MI and stroke (RR for those with baseline homocysteine levels in the top quartile, 2.2; 95% CI, 1.1-4.6). Self-reported multivitamin supplement use at study entry was associated with significantly reduced levels of homocysteine (P<.001). However, the association between increasing quartile of homocysteine level and risk of MI or stroke remained significant in analyses controlling for baseline multivitamin supplement use (P = .003 for trend), and subgroup analyses limited to women who were (P = .02 for trend) or were not (P = .04 for trend) taking multivitamin supplements. Conclusions Among healthy postmenopausal US women, elevated levels of homocysteine moderately increased the risk of future cardiovascular disease. Whether lowering the homocysteine level reduces risk of cardiovascular events requires testing in randomized controlled trials.	Brigham & Womens Hosp, Div Cardiovasc Dis, Boston, MA 02115 USA; Brigham & Womens Hosp, Div Prevent Med, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Ambulatory Care & Prevent, Boston, MA USA; Abbott Labs, Abbott Pk, IL 60064 USA	Harvard University; Brigham & Women's Hospital; Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School; Abbott Laboratories	Ridker, PM (corresponding author), Brigham & Womens Hosp, Div Cardiovasc Dis, 75 Francis St, Boston, MA 02115 USA.	pmridker@bics.bwh.harvard.edu						Alfheim I, 1998, CLIN CHEM, V44, pA170; ALFTHAN G, 1994, ATHEROSCLEROSIS, V106, P9, DOI 10.1016/0021-9150(94)90078-7; ARNESEN E, 1995, INT J EPIDEMIOL, V24, P704, DOI 10.1093/ije/24.4.704; BOUSHEY CJ, 1995, JAMA-J AM MED ASSOC, V274, P1049, DOI 10.1001/jama.274.13.1049; Brattstrom L, 1998, CIRCULATION, V98, P2520, DOI 10.1161/01.CIR.98.23.2520; Buring JE, 1992, J MYOCARDIAL ISCHEMI, V4, P27; ChasanTaber L, 1996, J AM COLL NUTR, V15, P136; Egerton W, 1996, AM J CARDIOL, V77, P759, DOI 10.1016/S0002-9149(97)89213-2; Evans RW, 1997, ARTERIOSCL THROM VAS, V17, P1947, DOI 10.1161/01.ATV.17.10.1947; Folsom AR, 1998, CIRCULATION, V98, P204, DOI 10.1161/01.CIR.98.3.204; LINDGREN A, 1995, STROKE, V26, P795, DOI 10.1161/01.STR.26.5.795; Ma J, 1996, CIRCULATION, V94, P2410, DOI 10.1161/01.CIR.94.10.2410; Malinow MR, 1998, NEW ENGL J MED, V338, P1009, DOI 10.1056/NEJM199804093381501; MCCULLY KS, 1969, AM J PATHOL, V56, P111; Nygard O, 1997, NEW ENGL J MED, V337, P230, DOI 10.1056/NEJM199707243370403; PERRY IJ, 1995, LANCET, V346, P1395, DOI 10.1016/S0140-6736(95)92407-8; Ridker PM, 1998, CIRCULATION, V98, P731, DOI 10.1161/01.CIR.98.8.731; SELHUB J, 1993, JAMA-J AM MED ASSOC, V270, P2693, DOI 10.1001/jama.270.22.2693; SHIPCHANDLER MT, 1995, CLIN CHEM, V41, P991; STAMPFER MJ, 1992, JAMA-J AM MED ASSOC, V268, P877, DOI 10.1001/jama.268.7.877; TAYLOR LM, 1991, J VASC SURG, V13, P128, DOI 10.1016/0741-5214(91)90020-U; Verhoef P, 1997, AM J CARDIOL, V79, P799, DOI 10.1016/S0002-9149(96)00874-0; Verhoef P, 1998, J AM COLL CARDIOL, V32, P353, DOI 10.1016/S0735-1097(98)00244-7; Wald NJ, 1998, ARCH INTERN MED, V158, P862, DOI 10.1001/archinte.158.8.862; Welch GN, 1998, NEW ENGL J MED, V338, P1042, DOI 10.1056/NEJM199804093381507; WILLETT WC, 1994, STROKE, V25, P1924	26	188	197	1	6	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAY 19	1999	281	19					1817	1821		10.1001/jama.281.19.1817	http://dx.doi.org/10.1001/jama.281.19.1817			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	196BH	10340369	Bronze			2022-12-28	WOS:000080288800035
J	Conn, GL; Draper, DE; Lattman, EE; Gittis, AG				Conn, GL; Draper, DE; Lattman, EE; Gittis, AG			Crystal structure of a conserved ribosomal protein-RNA complex	SCIENCE			English	Article							FACTOR EF-G; TERTIARY STRUCTURE; ESCHERICHIA-COLI; GTPASE CENTER; THIOSTREPTON INTERACT; SUBUNIT; BINDING; DOMAIN; L11; THERMODYNAMICS	The structure of a highly conserved complex between a 58-nucleotide domain of Large subunit ribosomal RNA and the RNA-binding domain of ribosomal protein L11 has been solved at 2.8 angstrom resolution. It reveals a precisely folded RNA structure that is stabilized by extensive tertiary contacts and contains an unusually Large core of stacked bases. A bulge Loop base from one hairpin of the RNA is intercalated into the distorted major groove of another helix; the protein Locks this tertiary interaction into place by binding to the intercalated base from the minor groove side. This direct interaction with a key ribosomal RNA tertiary interaction suggests that part of the role of L11 is to stabilize an unusual RNA fold within the ribosome.	Johns Hopkins Univ, Dept Chem, Baltimore, MD 21218 USA; Johns Hopkins Univ, Dept Biophys, Baltimore, MD 21218 USA	Johns Hopkins University; Johns Hopkins University	Draper, DE (corresponding author), Johns Hopkins Univ, Dept Chem, Charles & 34Th St, Baltimore, MD 21218 USA.	draper@jhunix.hcf.jhu.edu; lattman@jhu.edu	Lattman, Eaton/D-6681-2018		NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM029048] Funding Source: NIH RePORTER; NIGMS NIH HHS [R37 GM29048] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Abrahams JP, 1996, ACTA CRYSTALLOGR D, V52, P30, DOI 10.1107/S0907444995008754; Battiste JL, 1996, SCIENCE, V273, P1547, DOI 10.1126/science.273.5281.1547; BRUNGER AT, 1992, NATURE, V355, P472, DOI 10.1038/355472a0; BRUNGER AT, 1987, SCIENCE, V235, P458, DOI 10.1126/science.235.4787.458; Bukhman YV, 1997, J MOL BIOL, V273, P1020, DOI 10.1006/jmbi.1997.1383; Cate JH, 1996, SCIENCE, V273, P1678, DOI 10.1126/science.273.5282.1678; Conn GL, 1998, BIOCHEMISTRY-US, V37, P11980, DOI 10.1021/bi980825+; CUNDLIFFE E, 1979, NATURE, V278, P859, DOI 10.1038/278859a0; Cundliffe E., 1986, STRUCTURE FUNCTION G, P586; DRAPER DE, 1995, J MOL BIOL, V249, P231, DOI 10.1006/jmbi.1995.0291; ELBARADI TTAL, 1987, J MOL BIOL, V195, P909, DOI 10.1016/0022-2836(87)90494-3; EVANS SV, 1993, J MOL GRAPHICS, V11, P134, DOI 10.1016/0263-7855(93)87009-T; Fountain MA, 1996, BIOCHEMISTRY-US, V35, P6539, DOI 10.1021/bi952697k; Gopalan V, 1997, J MOL BIOL, V267, P765, DOI 10.1006/jmbi.1997.0907; GuhaThakurta D, 1999, BIOCHEMISTRY-US, V38, P3633, DOI 10.1021/bi9826411; GUTELL R, COMMUNICATION; Hinck AP, 1997, J MOL BIOL, V274, P101, DOI 10.1006/jmbi.1997.1379; Huang SG, 1996, J MOL BIOL, V258, P308, DOI 10.1006/jmbi.1996.0252; HUMMEL H, 1987, BIOCHIMIE, V69, P857, DOI 10.1016/0300-9084(87)90212-4; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; JUCKER FM, 1995, RNA, V1, P219; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; LAING LG, 1994, J MOL BIOL, V237, P560, DOI 10.1006/jmbi.1994.1255; LEAHY DJ, 1992, SCIENCE, V258, P987, DOI 10.1126/science.1279805; Legault P, 1998, CELL, V93, P289, DOI 10.1016/S0092-8674(00)81579-2; LU M, 1994, J MOL BIOL, V244, P572, DOI 10.1006/jmbi.1994.1753; Merritt EA, 1997, METHOD ENZYMOL, V277, P505, DOI 10.1016/S0076-6879(97)77028-9; Munishkin A, 1997, P NATL ACAD SCI USA, V94, P12280, DOI 10.1073/pnas.94.23.12280; NOLLER HF, 1991, ANNU REV BIOCHEM, V60, P191, DOI 10.1146/annurev.biochem.60.1.191; Otwinowski Z., 1991, ISOMORPHOUS REPLACEM, P80; READ RJ, 1986, ACTA CRYSTALLOGR A, V42, P140, DOI 10.1107/S0108767386099622; ROSENDAHL G, 1994, NUCLEIC ACIDS RES, V22, P357, DOI 10.1093/nar/22.3.357; ROSENDAHL G, 1993, J MOL BIOL, V234, P1013, DOI 10.1006/jmbi.1993.1655; RYAN PC, 1991, P NATL ACAD SCI USA, V88, P6308, DOI 10.1073/pnas.88.14.6308; Terwilliger TC, 1997, METHOD ENZYMOL, V276, P530; THOMPSON J, 1993, EMBO J, V12, P1499, DOI 10.1002/j.1460-2075.1993.tb05793.x; Weeks KM, 1996, SCIENCE, V271, P345, DOI 10.1126/science.271.5247.345; Wilson KS, 1998, CELL, V92, P131, DOI 10.1016/S0092-8674(00)80905-8; XING YY, 1995, J MOL BIOL, V249, P319, DOI 10.1006/jmbi.1995.0299; Xing YY, 1997, NAT STRUCT BIOL, V4, P24, DOI 10.1038/nsb0197-24; Xing YY, 1996, BIOCHEMISTRY-US, V35, P1581, DOI 10.1021/bi952132o	41	242	247	0	6	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAY 14	1999	284	5417					1171	1174		10.1126/science.284.5417.1171	http://dx.doi.org/10.1126/science.284.5417.1171			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	197HJ	10325228				2022-12-28	WOS:000080359100038
J	Premaratne, UN; Sterne, JAC; Marks, GB; Webb, JR; Azima, H; Burney, PGJ				Premaratne, UN; Sterne, JAC; Marks, GB; Webb, JR; Azima, H; Burney, PGJ			Clustered randomised trial of an intervention to improve the management of asthma: Greenwich asthma study	BRITISH MEDICAL JOURNAL			English	Article							QUALITY-OF-LIFE; SELF-MANAGEMENT; GENERAL-PRACTICE; EDUCATION-PROGRAM; ADULTS; QUESTIONNAIRE; MORBIDITY; GUIDELINES; PLANS; FLOW	Objectives To evaluate the effectiveness of an asthma resource centre in improving treatment and quality of life for asthmatic patients. Design Community based randomised controlled trial. Setting 41 general practices in Greenwich with a practice nurse. Subjects All registered patients aged 15-50 years. Intervention Nurse specialists in asthma who educated and supported practice nurses,who in turn educated patients in the management of asthma according to the British Thoracic Society's guidelines. Main outcome measures Quality of life of asthmatic patients, attendance at accident and emergency departments, admissions to local hospitals, and steroid prescribing by general practitioners. Results Of 24 400 patients randomly selected and surveyed in 1993, 12 238 replied; 1621 were asthmatic of whom 1291 were sent a repeat questionnaire in 1996 and 780 replied. Of 24 400 patients newly surveyed in 1996, 10 783 (1616 asthmatic) replied. No evidence was found for an improvement in asthma related quality of life among newly surveyed patients in intervention practices compared with control practices, Neither was there evidence of an improvement in other measures of the quality of asthma care. Weak evidence was found for an improvement in quality of life in intervention practices among asthmatics registered with study practices in 1993 and followed up in 1996. Neither attendances at accident and emergency departments nor admissions for asthma showed any tendency to diverge in intervention and control practices over the study period. Steroid prescribing rates rose steadily during the study period. The average annual increase in steroid prescribing was 3% per year higher in intervention than control practices (95% confidence interval - 1% to 6%, P = 0.10). Conclusions This model of service delivery is not effective in improving the outcome of asthma in the community. Further development is required if cost effective management of asthma is to be introduced.	Univ London Kings Coll, Dept Publ Hlth Sci, London SE1 3QD, England; Univ Sydney, Inst Resp Med, Sydney, NSW 2006, Australia; Greenwich Dist Hosp, Asthma Res Ctr, London SE10 9HE, England	University of London; King's College London; University of Sydney	Burney, PGJ (corresponding author), Univ London Kings Coll, Dept Publ Hlth Sci, Capital House, London SE1 3QD, England.		Sterne, Jonathan/Z-3106-2019; Marks, Guy B./F-5058-2013	Sterne, Jonathan/0000-0001-8496-6053; Marks, Guy B./0000-0002-8976-8053; Burney, Peter/0000-0001-8635-5678				ALLEN RM, 1995, THORAX, V50, P731, DOI 10.1136/thx.50.7.731; BAILEY WC, 1990, ARCH INTERN MED, V150, P1664, DOI 10.1001/archinte.150.8.1664; *BRIT THOR SOC, 1993, THORAX, V48, pS1; CHARLTON I, 1991, BRIT J GEN PRACT, V41, P227; CHARLTON I, 1992, FAM PRACT, V9, P154, DOI 10.1093/fampra/9.2.154; Cote J, 1997, AM J RESP CRIT CARE, V155, P1509, DOI 10.1164/ajrccm.155.5.9154850; *DEP HLTH, 1990, TERMS SERV DOCT GEN; FEDER G, 1995, BRIT MED J, V311, P1473, DOI 10.1136/bmj.311.7018.1473; Gupchup GV, 1997, CLIN THER, V19, P1116, DOI 10.1016/S0149-2918(97)80064-1; IGNACIOGARCIA JM, 1995, AM J RESP CRIT CARE, V151, P353, DOI 10.1164/ajrccm.151.2.7842191; JONES KP, 1995, THORAX, V50, P851, DOI 10.1136/thx.50.8.851; Lahdensuo A, 1996, BRIT MED J, V312, P748; LIANG KY, 1986, BIOMETRIKA, V73, P13, DOI 10.1093/biomet/73.1.13; MARKS GB, 1993, J CLIN EPIDEMIOL, V46, P1103, DOI 10.1016/0895-4356(93)90109-E; MARKS GB, 1992, J CLIN EPIDEMIOL, V45, P461, DOI 10.1016/0895-4356(92)90095-5; Marks GB, 1997, EUR RESPIR J, V10, P1224, DOI 10.1183/09031936.97.10061224; MAYO PH, 1990, ANN INTERN MED, V112, P864, DOI 10.7326/0003-4819-112-11-864; Meijer RJ, 1997, EUR RESPIR J, V10, P1163, DOI 10.1183/09031936.97.10051163; Premaratne UN, 1997, RESP MED, V91, P61, DOI 10.1016/S0954-6111(97)90069-X; PRESCOTTCLARKE P, 1996, HLTH SURVEY ENGLAND, V1, P51; WILSON SR, 1993, AM J MED, V94, P564, DOI 10.1016/0002-9343(93)90206-5; YOON R, 1993, THORAX, V48, P1110, DOI 10.1136/thx.48.11.1110; [No title captured], DOI DOI 10.1136/THX.52.2008.S1]	23	65	65	0	6	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	MAY 8	1999	318	7193					1251	1255						5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	195XT	10231256				2022-12-28	WOS:000080278000027
J	Selnes, OA; Goldsborough, MA; Borowicz, LM; McKhann, GM				Selnes, OA; Goldsborough, MA; Borowicz, LM; McKhann, GM			Neurobehavioural sequelae of cardiopulmonary bypass	LANCET			English	Review							CORONARY-ARTERY BYPASS; OPEN-HEART-SURGERY; CENTRAL-NERVOUS-SYSTEM; CARDIAC SURGICAL PATIENTS; SERUM S-100 PROTEIN; GRAFT-SURGERY; FOLLOW-UP; MYOCARDIAL-INFARCTION; NEUROPSYCHOLOGICAL DYSFUNCTION; CEREBRAL COMPLICATIONS	The development of coronary artery bypass grafting (CABG) and its effect on angina is the product of a series of technical and scientific advances. Despite these advances, however, adverse neurobehavioural outcomes continue to occur. Stroke is the most serious complication of CARS, but studies that have identified demographic and medical risk factors available before surgery are an important advance. Short-term cognitive deficits are common after CABG, but may not be specific to this procedure. However, deficits in some cognitive areas such as visuoconstruction persist over time, and may reflect parieto-occipital watershed area injury secondary to hypoperfusion or embolic factors. Risk factors for cognitive decline may be time dependent, with short-term studies identifying factors that differ from those of long-term studies. Patients with depression before surgery are likely to have persistent depression afterwards. However, depression does not account for the cognitive decline after CARS. Since CARS is increasingly done in older patients with more comorbidity, the challenge is to identify patients at risk of adverse neurocognitive outcomes and to protect them by modification of the surgical procedure or by effective medical therapy.	Zanyl Krieger Mind Brain Inst, Baltimore, MD 21218 USA; Johns Hopkins Univ, Sch Med, Dept Neurol, Baltimore, MD 21205 USA; Johns Hopkins Univ, Sch Med, Dept Surg, Baltimore, MD 21205 USA	Johns Hopkins University; Johns Hopkins University	McKhann, GM (corresponding author), Zanyl Krieger Mind Brain Inst, 338 Krieger Hall,3400 N Charles St, Baltimore, MD 21218 USA.	g.mckhann@hju.edu			NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS035610] Funding Source: NIH RePORTER; NINDS NIH HHS [NS-35610] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ABERG T, 1983, ANN THORAC SURG, V36, P680, DOI 10.1016/S0003-4975(10)60278-0; ABERG T, 1984, J THORAC CARDIOV SUR, V87, P99; Abraha HD, 1997, ANN CLIN BIOCHEM, V34, P546, DOI 10.1177/000456329703400510; Alderman EL, 1997, JAMA-J AM MED ASSOC, V277, P715; ARIS A, 1986, J THORAC CARDIOV SUR, V91, P526; BARBUT D, 1994, STROKE, V25, P2398, DOI 10.1161/01.STR.25.12.2398; BEALL AC, 1993, ANN THORAC SURG, V55, P1382; BENEDICT RHB, 1994, NEUROPSYCHOL REV, V4, P223, DOI 10.1007/BF01874893; BLAUTH CI, 1988, J THORAC CARDIOV SUR, V95, P668; BLUMENTHAL JA, 1995, ANN THORAC SURG, V59, P1345, DOI 10.1016/0003-4975(95)00055-P; Borowicz LM, 1996, J CARDIOTHOR VASC AN, V10, P105, DOI 10.1016/S1053-0770(96)80185-6; BRENER BJ, 1987, J VASC SURG, V5, P269, DOI 10.1067/mva.1987.avs0050269; BREUER AC, 1983, STROKE, V14, P682, DOI 10.1161/01.STR.14.5.682; BRILLMAN J, 1993, NEUROL CLIN, V11, P475, DOI 10.1016/S0733-8619(18)30164-6; Brown W R, 1997, Ann N Y Acad Sci, V826, P386, DOI 10.1111/j.1749-6632.1997.tb48489.x; BUTTERS N, 1992, NEW ISSUES NEUROSCIE, P338; CALABRESE JR, 1987, CLEV CLIN J MED, V54, P29, DOI 10.3949/ccjm.54.1.29; CALIFF RM, 1989, JAMA-J AM MED ASSOC, V261, P2077, DOI 10.1001/jama.261.14.2077; CARNEY RM, 1995, AM J CARDIOL, V76, P562, DOI 10.1016/S0002-9149(99)80155-6; CHANNER KS, 1988, J ROY SOC MED, V81, P629, DOI 10.1177/014107688808101105; CLARK RE, 1995, J THORAC CARDIOV SUR, V109, P249, DOI 10.1016/S0022-5223(95)70386-1; COFFEY CE, 1983, NEUROLOGY, V33, P1416, DOI 10.1212/WNL.33.11.1416; DavilaRoman VG, 1996, J AM COLL CARDIOL, V28, P942, DOI 10.1016/S0735-1097(96)00263-X; Deslauriers R, 1996, J CARDIOTHOR VASC AN, V10, P127, DOI 10.1016/S1053-0770(96)80188-1; Duits AA, 1997, PSYCHOSOM MED, V59, P257, DOI 10.1097/00006842-199705000-00009; Edmonds HL, 1996, J CARDIOTHOR VASC AN, V10, P15, DOI 10.1016/S1053-0770(96)80174-1; EDMONDS HL, 1992, J THORAC CARDIOV SUR, V103, P555; ELSASS P, 1984, SCAND J THORAC CARD, V18, P161, DOI 10.3109/14017438409102399; FAGGIOLI GL, 1990, J VASC SURG, V12, P724, DOI 10.1067/mva.1990.24458; FRASURESMITH N, 1993, JAMA-J AM MED ASSOC, V270, P1819, DOI 10.1001/jama.270.15.1819; FRASURESMITH N, 1995, CIRCULATION, V91, P999, DOI 10.1161/01.CIR.91.4.999; Gao F, 1997, PERFUSION-UK, V12, P171, DOI 10.1177/026765919701200305; GARDNER TJ, 1985, ANN THORAC SURG, V40, P574, DOI 10.1016/S0003-4975(10)60352-9; GROTE CL, 1992, J THORAC CARDIOV SUR, V104, P1405; HAMMEKE TA, 1988, J THORAC CARDIOV SUR, V96, P326; HARRIS DN, 1993, LANCET, V342, P586, DOI 10.1016/0140-6736(93)91412-F; Herlitz J, 1998, THORAC CARDIOV SURG, V46, P20, DOI 10.1055/s-2007-1010178; Heyer EJ, 1996, J CARDIOTHOR VASC AN, V10, P99, DOI 10.1016/S1053-0770(96)80184-4; Hlatky MA, 1997, CIRCULATION, V96, P11; HOWARD R, 1987, ARCH NEUROL-CHICAGO, V44, P934, DOI 10.1001/archneur.1987.00520210036016; Johnsson P, 1995, J CARDIOTHOR VASC AN, V9, P694, DOI 10.1016/S1053-0770(05)80231-9; Johnsson P, 1996, J CARDIOTHOR VASC AN, V10, P120, DOI 10.1016/S1053-0770(96)80187-X; Jonsson H, 1998, ANN THORAC SURG, V65, P1639, DOI 10.1016/S0003-4975(98)00229-X; JUNOD FL, 1987, ANN THORAC SURG, V43, P59, DOI 10.1016/S0003-4975(10)60167-1; JUOLASMAA A, 1981, Journal of Clinical Neuropsychology, V3, P181, DOI 10.1080/01688638108403125; KLONOFF H, 1989, J THORAC CARDIOV SUR, V97, P78; Koolhoven I, 1996, GEN HOSP PSYCHIAT, V18, P448, DOI 10.1016/S0163-8343(96)00089-8; KORNFELD DS, 1978, J THORAC CARDIOV SUR, V76, P93; LANGELUDDECKE P, 1989, J PSYCHOSOM RES, V33, P37, DOI 10.1016/0022-3999(89)90104-9; Libman RB, 1997, ARCH NEUROL-CHICAGO, V54, P83, DOI 10.1001/archneur.1997.00550130063017; Lillehei C. Walton, 1993, P1; Limburg M, 1998, NEUROLOGY, V50, P895, DOI 10.1212/WNL.50.4.895; Lindal E, 1996, SCAND J REHABIL MED, V28, P27; Mahanna EP, 1996, ANN THORAC SURG, V61, P1342, DOI 10.1016/0003-4975(95)01095-5; MARCANTONIO ER, 1994, JAMA-J AM MED ASSOC, V271, P134, DOI 10.1001/jama.271.2.134; MARTIN WRW, 1982, CAN J NEUROL SCI, V9, P21, DOI 10.1017/S0317167100043572; McKhann GM, 1997, ANN THORAC SURG, V63, P516; McKhann GM, 1997, LANCET, V349, P1282, DOI 10.1016/S0140-6736(96)09466-4; Missler U, 1997, STROKE, V28, P1956, DOI 10.1161/01.STR.28.10.1956; Moller JT, 1998, LANCET, V351, P857, DOI 10.1016/S0140-6736(97)07382-0; MOODY DM, 1990, ANN NEUROL, V28, P477, DOI 10.1002/ana.410280403; Murkin JM, 1997, ANN THORAC SURG, V64, P904, DOI 10.1016/S0003-4975(97)00743-1; MURKIN JM, 1995, J THORAC CARDIOV SUR, V110, P349, DOI 10.1016/S0022-5223(95)70230-X; MURKIN JM, 1995, ANN THORAC SURG, V59, P1289, DOI 10.1016/0003-4975(95)00106-U; NEWMAN MF, 1995, ANN THORAC SURG, V59, P1326, DOI 10.1016/0003-4975(95)00076-W; Newman MF, 1996, CIRCULATION, V94, P74; NEWMAN S, 1987, CURR PSYCHOL RES REV, V6, P115, DOI 10.1007/BF02686616; Newman S, 1993, CARDIAC SURG BRAIN, P34; NEWMAN SP, 1995, ANN THORAC SURG, V59, P1351, DOI 10.1016/0003-4975(95)00215-7; Nussmeier NA, 1996, J CARDIOTHOR VASC AN, V10, P31, DOI 10.1016/S1053-0770(96)80176-5; OBRIEN DJ, 1992, J THORAC CARDIOV SUR, V104, P1116; ODwyer C, 1996, J CARDIOTHOR VASC AN, V10, P54, DOI 10.1016/S1053-0770(96)80179-0; OWENS JF, 1982, NURS RES, V31, P60; PADAYACHEE TS, 1987, ANN THORAC SURG, V44, P298, DOI 10.1016/S0003-4975(10)62077-2; PATEL RL, 1993, EUR J CARDIO-THORAC, V7, P457, DOI 10.1016/1010-7940(93)90274-F; PERSSON L, 1987, STROKE, V18, P911, DOI 10.1161/01.STR.18.5.911; Pratt LA, 1996, CIRCULATION, V94, P3123, DOI 10.1161/01.CIR.94.12.3123; PUGSLEY W, 1994, STROKE, V25, P1393, DOI 10.1161/01.STR.25.7.1393; REDMOND JM, 1993, SURGERY, V114, P324; Redmond JM, 1996, ANN THORAC SURG, V61, P42, DOI 10.1016/0003-4975(95)00903-5; Roach GW, 1996, NEW ENGL J MED, V335, P1857, DOI 10.1056/NEJM199612193352501; RORICK MB, 1990, NEUROLOGY, V40, P835, DOI 10.1212/WNL.40.5.835; SAVAGEAU JA, 1982, J THORAC CARDIOV SUR, V84, P585; SAVAGEAU JA, 1982, J THORAC CARDIOV SUR, V84, P595; SCHMIDT R, 1993, NEUROLOGY, V43, P775, DOI 10.1212/WNL.43.4.775; SELLMAN M, 1993, THORAC CARDIOV SURG, V41, P349, DOI 10.1055/s-2007-1013888; SHAW PJ, 1987, Q J MED, V62, P259; SHAW PJ, 1987, STROKE, V18, P700, DOI 10.1161/01.STR.18.4.700; SILVERSTONE PH, 1987, BRIT MED J, V294, P219, DOI 10.1136/bmj.294.6566.219-a; Small DL, 1996, J CARDIOTHOR VASC AN, V10, P139, DOI 10.1016/S1053-0770(96)80189-3; SMITH PL, 1993, CARDIAC SURG BRAIN; Solomon AJ, 1998, ANN INTERN MED, V128, P216, DOI 10.7326/0003-4819-128-3-199802010-00008; SOTANIEMI KA, 1986, STROKE, V17, P410, DOI 10.1161/01.STR.17.3.410; SOTANIEMI KA, 1980, J NEUROL NEUROSUR PS, V43, P127, DOI 10.1136/jnnp.43.2.127; STUMP DA, 1995, ANN THORAC SURG, V59, P1340, DOI 10.1016/0003-4975(95)00108-W; Stump DA, 1996, J CARDIOTHOR VASC AN, V10, P113, DOI 10.1016/S1053-0770(96)80186-8; Svenmarker S, 1997, EUR J CARDIO-THORAC, V11, P957, DOI 10.1016/S1010-7940(97)88351-0; Taggart DP, 1997, EUR J CARDIO-THORAC, V11, P645, DOI 10.1016/S1010-7940(96)01103-7; Tardiff BE, 1997, ANN THORAC SURG, V64, P715, DOI 10.1016/S0003-4975(97)00757-1; Timberlake N, 1997, J PSYCHOSOM RES, V43, P197, DOI 10.1016/S0022-3999(96)00002-5; TONER I, 1994, J NEUROSURG ANESTH, V6, P163; TOWNES BD, 1989, J THORAC CARDIOV SUR, V98, P774; Utley JR, 1996, J CARDIOTHOR VASC AN, V10, P38, DOI 10.1016/S1053-0770(96)80177-7; VANDERLINDEN J, 1991, ANN THORAC SURG, V51, P237, DOI 10.1016/0003-4975(91)90793-P; vanderMast RC, 1996, J PSYCHOSOM RES, V41, P13, DOI 10.1016/0022-3999(96)00005-0; Vingerhoets G, 1998, PSYCHOSOMATICS, V39, P30, DOI 10.1016/S0033-3182(98)71378-7; Vingerhoets G, 1997, EUR J CARDIO-THORAC, V11, P424, DOI 10.1016/S1010-7940(96)01031-7; Vingerhoets G, 1997, J INT NEUROPSYCH SOC, V3, P480, DOI 10.1017/S1355617797004803; WAREING TH, 1993, ANN THORAC SURG, V55, P1400, DOI 10.1016/0003-4975(93)91079-3; Waterloo K, 1997, ACTA NEUROCHIR, V139, P26, DOI 10.1007/BF01850864; WILLIAMSRUSSO P, 1995, JAMA-J AM MED ASSOC, V274, P44, DOI 10.1001/jama.274.1.44; WONG BI, 1992, LANCET, V339, P1383, DOI 10.1016/0140-6736(92)91200-R; YUSUF S, 1994, LANCET, V344, P563, DOI 10.1016/S0140-6736(94)91963-1; ZIVIN JA, 1991, SCI AM, V265, P56, DOI 10.1038/scientificamerican0791-56	114	188	205	0	3	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	MAY 8	1999	353	9164					1601	1606		10.1016/S0140-6736(98)07576-X	http://dx.doi.org/10.1016/S0140-6736(98)07576-X			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	195XW	10334272	hybrid			2022-12-28	WOS:000080278300043
J	Zheng, WM; Knudsen, EI				Zheng, WM; Knudsen, EI			Functional selection of adaptive auditory space map by GABA(A)-mediated inhibition	SCIENCE			English	Article							EXPERIENCE-DEPENDENT PLASTICITY; BARN OWL; VISUAL CALIBRATION; OPTIC TECTUM; CORTICAL-NEURONS; NEURAL MAP; CORTEX; LOCALIZATION; MIDBRAIN; BLOCKADE	The external nucleus of the inferior colliculus in the barn owl contains an auditory map of space that is based on the tuning of neurons for interaural differences in the timing of sound. In juvenile owls, this region of the brain can acquire alternative maps of interaural time difference as a result of abnormal experience. It has been found that, in an external nucleus that is expressing a learned, abnormal map, the circuitry underlying the normal map still exists but is functionally inactivated by inhibition mediated by gamma-aminobutyric acid type A (GABA(A)) receptors. This inactivation results from disproportionately strong inhibition of specific input channels to the network. Thus, experience-driven changes in patterns of inhibition, as well as adjustments in patterns of excitation, can contribute critically to adaptive plasticity in the central nervous system.	Stanford Univ, Sch Med, Dept Neurobiol, Stanford, CA 94305 USA	Stanford University	Zheng, WM (corresponding author), Stanford Univ, Sch Med, Dept Neurobiol, Fairchild Sci Bldg, Stanford, CA 94305 USA.				NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERS [F32DC000307, R01DC000155] Funding Source: NIH RePORTER; NIDCD NIH HHS [5 R01 DC00155-18, F32 DC00307-01] Funding Source: Medline	NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Deafness & Other Communication Disorders (NIDCD)); NIDCD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Deafness & Other Communication Disorders (NIDCD))		Brainard MS, 1998, J NEUROSCI, V18, P3929; BRAINARD MS, 1993, J NEUROSCI, V13, P4589; CARANDINI M, 1994, SCIENCE, V264, P1333, DOI 10.1126/science.8191289; Crair MC, 1998, SCIENCE, V279, P566, DOI 10.1126/science.279.5350.566; DULAC S, 1990, J NEUROPHYSIOL, V63, P131, DOI 10.1152/jn.1990.63.1.131; Feldman DE, 1997, J NEUROSCI, V17, P6820; Galarreta M, 1998, NAT NEUROSCI, V1, P587, DOI 10.1038/2822; Hensch TK, 1996, SCIENCE, V272, P554, DOI 10.1126/science.272.5261.554; Hensch TK, 1998, SCIENCE, V282, P1504, DOI 10.1126/science.282.5393.1504; JACOBS KM, 1991, SCIENCE, V251, P944, DOI 10.1126/science.2000496; Katz LC, 1996, SCIENCE, V274, P1133, DOI 10.1126/science.274.5290.1133; KNUDSEN EI, 1978, SCIENCE, V200, P795, DOI 10.1126/science.644324; KNUDSEN EI, 1991, SCIENCE, V253, P85, DOI 10.1126/science.2063209; KNUDSEN EI, 1993, J NEUROSCI, V13, P2837; KOCH C, 1983, P NATL ACAD SCI-BIOL, V80, P2799, DOI 10.1073/pnas.80.9.2799; Lane RD, 1997, J NEUROPHYSIOL, V77, P2723, DOI 10.1152/jn.1997.77.5.2723; MOISEFF A, 1981, J NEUROSCI, V1, P40, DOI 10.1523/JNEUROSCI.01-01-00040.1981; MOWER GD, 1984, BRAIN RES, V309, P168, DOI 10.1016/0006-8993(84)91024-2; QIAN N, 1990, P NATL ACAD SCI USA, V87, P8145, DOI 10.1073/pnas.87.20.8145; Shadlen MN, 1998, J NEUROSCI, V18, P3870; vanVreeswijk C, 1996, SCIENCE, V274, P1724, DOI 10.1126/science.274.5293.1724	21	102	103	0	4	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	MAY 7	1999	284	5416					962	965		10.1126/science.284.5416.962	http://dx.doi.org/10.1126/science.284.5416.962			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	194MU	10320376				2022-12-28	WOS:000080198800045
J	Ray, LB				Ray, LB			The science of signal transduction	SCIENCE			English	Editorial Material																			0	13	14	0	3	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	APR 30	1999	284	5415					755	756		10.1126/science.284.5415.755	http://dx.doi.org/10.1126/science.284.5415.755			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	192AW	10336400				2022-12-28	WOS:000080056200031
J	Hirsh, J; Weitz, JI				Hirsh, J; Weitz, JI			New antithrombotic agents	LANCET			English	Article							ACUTE MYOCARDIAL-INFARCTION; FACTOR-XA; CORONARY ANGIOPLASTY; THROMBIN INHIBITION; BLOOD-COAGULATION; HEPARIN; ANTICOAGULANT; HIRUDIN; TRIAL; THROMBOLYSIS	The development of new antithrombotic agents has been stimulated by clinical needs and by advances in biotechnology that have made it possible to produce drugs that target specific steps in,thrombogenesis. Heparin has pharmacokinetic and biophysical limitations that are overcome by new anticoagulants. Of these, low-molecular-weight heparin and direct inhibitors of thrombin have been evaluated clinically. Coumarins require careful laboratory monitoring because of concerns about safety. Orally active direct inhibitors of thrombin and factor Xa may replace coumarins. Aspirin is of limited efficacy because it inhibits only one pathway of platelet activation. Inhibitors of adenosine diphosphate receptor and glycoprotein IIb/IIIa antagonists are more effective than aspirin and are used in the clinic.	Hamilton Civ Hosp Res Ctr, Hamilton, ON L8V 1C3, Canada; Dept Med, Hamilton, ON L8V 1C3, Canada	McMaster University; McMaster University	Hirsh, J (corresponding author), Hamilton Civ Hosp Res Ctr, Hamilton, ON L8V 1C3, Canada.		Weitz, Jeffrey/AAD-1929-2019	Weitz, Jeffrey/0000-0002-1092-7550				ANTMAN EM, 1994, CIRCULATION, V90, P1624, DOI 10.1161/01.CIR.90.4.1624; Antman EM, 1996, CIRCULATION, V94, P911, DOI 10.1161/01.CIR.94.5.911; Bazzino O, 1998, NEW ENGL J MED, V338, P1498; Bazzino O, 1998, NEW ENGL J MED, V338, P1488; BITTL JA, 1995, NEW ENGL J MED, V333, P764, DOI 10.1056/NEJM199509213331204; BROZE GJ, 1992, SEMIN HEMATOL, V29, P159; CALIFF RM, 1994, NEW ENGL J MED, V330, P956, DOI 10.1056/nejm199404073301402; Coller BS, 1997, J CLIN INVEST, V99, P1467, DOI 10.1172/JCI119307; EISENBERG PR, 1993, J CLIN INVEST, V91, P1877, DOI 10.1172/JCI116404; Eriksson BI, 1997, NEW ENGL J MED, V337, P1329, DOI 10.1056/NEJM199711063371901; ESMON CT, 1995, TRENDS CARDIOVAS MED, V5, P141, DOI 10.1016/1050-1738(95)00054-D; FURIE B, 1992, NEW ENGL J MED, V326, P800; GENT M, 1989, LANCET, V1, P1215, DOI 10.1016/S0140-6736(89)92327-1; Gent M, 1996, LANCET, V348, P1329, DOI 10.1016/s0140-6736(96)09457-3; Gibson CM, 1998, J AM COLL CARDIOL, V32, P28, DOI 10.1016/S0735-1097(98)00192-2; GOMI K, 1990, BLOOD, V75, P1396; Grip L, 1997, EUR HEART J, V18, P1416; HASS WK, 1989, NEW ENGL J MED, V321, P501, DOI 10.1056/NEJM198908243210804; Herault JP, 1997, J PHARMACOL EXP THER, V283, P16; Herbert JM, 1998, BLOOD, V91, P4197, DOI 10.1182/blood.V91.11.4197.411k09_4197_4205; Herbert JM, 1996, J PHARMACOL EXP THER, V276, P1030; HIRSH J, 1991, NEW ENGL J MED, V324, P1565; HIRSH J, 1991, NEW ENGL J MED, V324, P1865; ITO MK, 1992, CLIN PHARMACY, V11, P603; Kelley RF, 1997, BLOOD, V89, P3219, DOI 10.1182/blood.V89.9.3219; MARAGANORE JM, 1990, BIOCHEMISTRY-US, V29, P7095, DOI 10.1021/bi00482a021; Minford AMB, 1996, BRIT J HAEMATOL, V93, P215, DOI 10.1046/j.1365-2141.1996.4691021.x; More RS, 1997, LANCET, V349, P146, DOI 10.1016/S0140-6736(97)22003-9; NEUHAUS KL, 1993, CIRCULATION, V88, P292; Ortel TL, 1998, SEMIN HEMATOL, V35, P26; PATRONO C, 1994, NEW ENGL J MED, V330, P1287; SERRUYS PW, 1995, NEW ENGL J MED, V333, P757, DOI 10.1056/NEJM199509213331203; Simoons ML, 1997, LANCET, V349, P1429; SPANIER TB, J THORAC CARDIVOASC, V1179, P98; Stanssens P, 1996, P NATL ACAD SCI USA, V93, P2149, DOI 10.1073/pnas.93.5.2149; STONE SR, 1986, BIOCHEMISTRY-US, V25, P4622, DOI 10.1021/bi00364a025; Tcheng JE, 1997, LANCET, V349, P1422; TCHENG JE, 1994, CIRCULATION, V90, P1757, DOI 10.1161/01.CIR.90.4.1757; TOPOL E, 1994, CIRCULATION, V90, P1631; Topol E, 1998, NEW ENGL J MED, V339, P436; Topol E, 1998, CIRCULATION, V97, P2386; Topol EJ, 1998, LANCET, V352, P87, DOI 10.1016/S0140-6736(98)85010-1; Topol EJ, 1999, LANCET, V353, P227, DOI 10.1016/S0140-6736(98)11086-3; Topol EJ, 1997, NEW ENGL J MED, V336, P1689; Topol EJ, 1996, NEW ENGL J MED, V335, P775; VLASUK GP, 1993, THROMB HAEMOSTASIS, V70, P212; WEITZ JI, 1990, J CLIN INVEST, V86, P385, DOI 10.1172/JCI114723; Weitz JI, 1997, NEW ENGL J MED, V337, P688, DOI 10.1056/NEJM199709043371007; White HD, 1997, CIRCULATION, V96, P2155; Yusuf S, 1999, LANCET, V353, P429	50	84	90	0	2	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	APR 24	1999	353	9162					1431	1436		10.1016/S0140-6736(98)09233-2	http://dx.doi.org/10.1016/S0140-6736(98)09233-2			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	191KD	10227240				2022-12-28	WOS:000080020800045
J	Belgrader, P; Benett, W; Hadley, D; Richards, J; Stratton, P; Mariella, R; Milanovich, F				Belgrader, P; Benett, W; Hadley, D; Richards, J; Stratton, P; Mariella, R; Milanovich, F			Infectious disease - PCR detection of bacteria in seven minutes	SCIENCE			English	Article							MICROCHIP PCR; INSTRUMENT		Univ Calif Lawrence Livermore Natl Lab, Biol & Biotechnol Res Program, Livermore, CA 94551 USA	United States Department of Energy (DOE); Lawrence Livermore National Laboratory; University of California System	Belgrader, P (corresponding author), Univ Calif Lawrence Livermore Natl Lab, Biol & Biotechnol Res Program, POB 808, Livermore, CA 94551 USA.							Belgrader P, 1998, CLIN CHEM, V44, P2191; Cheng J, 1998, TOP CURR CHEM, V194, P215; Christel LA, 1999, J BIOMECH ENG-T ASME, V121, P22, DOI 10.1115/1.2798037; FOSTER FK, 1998, P S MICR SYST ASME I; Heid CA, 1996, GENOME RES, V6, P986, DOI 10.1101/gr.6.10.986; Ibrahim MS, 1998, ANAL CHEM, V70, P2013, DOI 10.1021/ac971091u; Kopp MU, 1998, SCIENCE, V280, P1046, DOI 10.1126/science.280.5366.1046; LIVAK KJ, 1995, PCR METH APPL, V4, P357; Niemeyer DM, 1998, MIL MED, V163, P226, DOI 10.1093/milmed/163.4.226; Northrup M.A., 1996, United States Patent, Patent No. 5589136; Northrup MA, 1998, ANAL CHEM, V70, P918, DOI 10.1021/ac970486a; Tang YW, 1997, CLIN CHEM, V43, P2021	12	307	365	5	55	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	APR 16	1999	284	5413					449	450		10.1126/science.284.5413.449	http://dx.doi.org/10.1126/science.284.5413.449			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	187NE	10232992				2022-12-28	WOS:000079792200033
J	Janknecht, R; Hunter, T				Janknecht, R; Hunter, T			Signal transduction - Nuclear fusion of signaling pathways	SCIENCE			English	Editorial Material							LEUKEMIA INHIBITORY FACTOR; TGF-BETA; TRANSCRIPTIONAL ACTIVATION; NERVOUS-SYSTEM; CBP/P300; COACTIVATOR; COOPERATION; P300/CBP; PROTEINS; SMAD3		Mayo Clin, Dept Biochem & Mol Biol, Rochester, MN 55905 USA; Salk Inst Biol Studies, Mol Biol & Virol Lab, La Jolla, CA 92037 USA	Mayo Clinic; Salk Institute	Janknecht, R (corresponding author), Mayo Clin, Dept Biochem & Mol Biol, Rochester, MN 55905 USA.			Janknecht, Ralf/0000-0003-1741-1562				Bhattacharya S, 1996, NATURE, V383, P344, DOI 10.1038/383344a0; Bonni A, 1997, SCIENCE, V278, P477, DOI 10.1126/science.278.5337.477; Bugga L, 1998, J NEUROBIOL, V36, P509, DOI 10.1002/(SICI)1097-4695(19980915)36:4<509::AID-NEU5>3.0.CO;2-#; Darnell JE, 1997, SCIENCE, V277, P1630, DOI 10.1126/science.277.5332.1630; Feng XH, 1998, GENE DEV, V12, P2153, DOI 10.1101/gad.12.14.2153; Giles RH, 1998, TRENDS GENET, V14, P178, DOI 10.1016/S0168-9525(98)01438-3; Janknecht R, 1998, GENE DEV, V12, P2114, DOI 10.1101/gad.12.14.2114; Kamei Y, 1996, CELL, V85, P403, DOI 10.1016/S0092-8674(00)81118-6; Koblar SA, 1998, P NATL ACAD SCI USA, V95, P3178, DOI 10.1073/pnas.95.6.3178; Massague J, 1998, ANNU REV BIOCHEM, V67, P753, DOI 10.1146/annurev.biochem.67.1.753; Mehler MF, 1997, TRENDS NEUROSCI, V20, P309, DOI 10.1016/S0166-2236(96)01046-6; Morrison SJ, 1999, CELL, V96, P737, DOI 10.1016/S0092-8674(00)80583-8; Nakashima K, 1999, SCIENCE, V284, P479, DOI 10.1126/science.284.5413.479; Nishihara A, 1998, GENES CELLS, V3, P613, DOI 10.1046/j.1365-2443.1998.00217.x; Pouponnot C, 1998, J BIOL CHEM, V273, P22865, DOI 10.1074/jbc.273.36.22865; Shen X, 1998, MOL BIOL CELL, V9, P3309, DOI 10.1091/mbc.9.12.3309; Topper JN, 1998, P NATL ACAD SCI USA, V95, P9506, DOI 10.1073/pnas.95.16.9506; Zhang JJ, 1996, P NATL ACAD SCI USA, V93, P15092, DOI 10.1073/pnas.93.26.15092	18	16	16	0	1	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	APR 16	1999	284	5413					443	444		10.1126/science.284.5413.443	http://dx.doi.org/10.1126/science.284.5413.443			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	187NE	10232991				2022-12-28	WOS:000079792200030
J	Soulsby, CT; Morgan, MY				Soulsby, CT; Morgan, MY			Dietary management of hepatic encephalopathy in cirrhotic patients: survey of current practice in United Kingdom	BRITISH MEDICAL JOURNAL			English	Article							LIVER-DISEASE; NUTRITION		Univ London Royal Free Hosp, Sch Med, Dept Med, London NW3 2QG, England; Royal Free Hosp, Dept Nutr & Dietet, London NW3 2QG, England	University of London; University College London; UCL Medical School; University of London; University College London; Royal Free London NHS Foundation Trust; UCL Medical School	Morgan, MY (corresponding author), Univ London Royal Free Hosp, Sch Med, Dept Med, London NW3 2QG, England.		Morgan, Marsha Y/C-5909-2009					KEARNS PJ, 1992, GASTROENTEROLOGY, V102, P200, DOI 10.1016/0016-5085(92)91801-A; MORGAN TR, 1995, J AM COLL NUTR, V14, P152; NIELSEN K, 1995, BRIT J NUTR, V74, P557, DOI 10.1079/BJN19950158; PHILLIPS GB, 1952, NEW ENGL J MED, V247, P239, DOI 10.1056/NEJM195208142470703; Plauth M, 1997, CLIN NUTR, V16, P43, DOI 10.1016/S0261-5614(97)80022-2	5	35	35	0	2	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	MAY 22	1999	318	7195					1391	1391		10.1136/bmj.318.7195.1391	http://dx.doi.org/10.1136/bmj.318.7195.1391			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	200DQ	10334749	Bronze, Green Published, Green Submitted			2022-12-28	WOS:000080524700028
J	Zhang, B; Salituro, G; Szalkowski, D; Li, ZH; Zhang, Y; Royo, I; Vilella, D; Diez, MT; Pelaez, F; Ruby, C; Kendall, RL; Mao, XZ; Griffin, P; Calaycay, J; Zierath, JR; Heck, JV; Smith, RG; Moller, DE				Zhang, B; Salituro, G; Szalkowski, D; Li, ZH; Zhang, Y; Royo, I; Vilella, D; Diez, MT; Pelaez, F; Ruby, C; Kendall, RL; Mao, XZ; Griffin, P; Calaycay, J; Zierath, JR; Heck, JV; Smith, RG; Moller, DE			Discovery of a small molecule insulin mimetic with antidiabetic activity in mice	SCIENCE			English	Article							RECEPTOR TYROSINE KINASE; HAMSTER OVARY CELLS; PHOSPHATIDYLINOSITOL 3-KINASE; GLUCOSE-TRANSPORT; SKELETAL-MUSCLE; CRYSTAL-STRUCTURE; OBESE SUBJECTS; PROTEIN; EXPRESSION; SUBSTRATE	Insulin elicits a spectrum of biological responses by binding to its cell surface receptor. In a screen for small molecules that activate the human insulin receptor tyrosine kinase, a nonpeptidyl fungal metabolite (L-783,281) was identified that acted as an insulin mimetic in several biochemical and cellular assays. The compound was selective for insulin receptor versus insulin-like growth factor I (IGFI) receptor and other receptor tyrosine kinases. Oral administration of L-783,281 to two mouse models of diabetes resulted in significant Lowering in blood glucose Levels. These results demonstrate the feasibility of discovering novel insulin receptor activators that may Lead to new therapies for diabetes.	Merck Res Labs, Dept Mol Endocrinol, Rahway, NJ 07065 USA; Merck Res Labs, Dept Nat Prod Drug Discovery, Rahway, NJ 07065 USA; Merck Res Labs, Dept Mol Divers & Design, Rahway, NJ 07065 USA; Merck Sharp & Dohme Espana, Ctr Invest Basica, Madrid 28027, Spain; Merck Res Labs, Dept Canc Res, W Point, PA 19486 USA; Karolinska Inst, Karolinska Hosp, Dept Clin Physiol, S-17176 Stockholm, Sweden	Merck & Company; Merck & Company; Merck & Company; Merck & Company; Merck & Company; Karolinska Institutet; Karolinska University Hospital	Zhang, B (corresponding author), Merck Res Labs, Dept Mol Endocrinol, R80W250,POB 2000, Rahway, NJ 07065 USA.		Pelaez, Fernando/K-1790-2014	Pelaez, Fernando/0000-0002-4861-586X; Zierath, Juleen/0000-0001-6891-7497				CARO JF, 1987, J CLIN INVEST, V79, P1330, DOI 10.1172/JCI112958; Denu JM, 1996, P NATL ACAD SCI USA, V93, P2493, DOI 10.1073/pnas.93.6.2493; EBINA Y, 1985, CELL, V40, P747, DOI 10.1016/0092-8674(85)90334-4; EBINA Y, 1987, P NATL ACAD SCI USA, V84, P704, DOI 10.1073/pnas.84.3.704; EBINA Y, 1985, P NATL ACAD SCI USA, V82, P8014, DOI 10.1073/pnas.82.23.8014; ENDEMANN G, 1990, J BIOL CHEM, V265, P396; FRANKE TF, 1995, CELL, V81, P727, DOI 10.1016/0092-8674(95)90534-0; GOODYEAR LJ, 1995, J CLIN INVEST, V95, P2195, DOI 10.1172/JCI117909; HANSEN PA, 1994, J APPL PHYSIOL, V76, P979, DOI 10.1152/jappl.1994.76.2.979; Hubbard SR, 1997, EMBO J, V16, P5572, DOI 10.1093/emboj/16.18.5572; HUBBARD SR, 1994, NATURE, V372, P746, DOI 10.1038/372746a0; KAHN BB, 1988, J CLIN INVEST, V82, P691, DOI 10.1172/JCI113649; KENDALL RL, 1993, P NATL ACAD SCI USA, V90, P10705, DOI 10.1073/pnas.90.22.10705; LEVYTOLEDANO R, 1994, J BIOL CHEM, V269, P31178; MEYEROVITCH J, 1987, J BIOL CHEM, V262, P6658; ROSEN OM, 1989, DIABETES, V38, P1508, DOI 10.2337/diabetes.38.12.1508; Seely B.L., 1994, INSULIN RESISTANCE, P187; ULLRICH A, 1985, NATURE, V313, P756, DOI 10.1038/313756a0; WALLBERGHENRIKSSON H, 1987, J BIOL CHEM, V262, P7665; WHITE MF, 1994, INSULIN RESISTANCE, P9; ZHANG B, 1994, J BIOL CHEM, V269, P25735; ZHANG B, 1992, J BIOL CHEM, V267, P18320; Zhang B., UNPUB	23	372	409	0	31	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	MAY 7	1999	284	5416					974	977		10.1126/science.284.5416.974	http://dx.doi.org/10.1126/science.284.5416.974			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	194MU	10320380				2022-12-28	WOS:000080198800049
J	Radford, SE; Dobson, CM				Radford, SE; Dobson, CM			From computer simulations to human disease: Emerging themes in protein folding	CELL			English	Review							BETA-SHEET PROTEIN; ENERGY LANDSCAPE; TRANSITION-STATE; STABILITY; PATHWAYS; DOMAIN; KINETICS; DESIGN; CORE; CONFORMATIONS		Univ Leeds, Sch Biochem & Mol Biol, Leeds LS2 9JT, W Yorkshire, England; Univ Oxford, Oxford Ctr Mol Sci, New Chem Lab, Oxford OX1 3QT, England	University of Leeds; University of Oxford	Radford, SE (corresponding author), Univ Leeds, Sch Biochem & Mol Biol, Leeds LS2 9JT, W Yorkshire, England.			Radford, Sheena/0000-0002-3079-8039				ANFINSEN CB, 1973, SCIENCE, V181, P223, DOI 10.1126/science.181.4096.223; Blanco F, 1998, CURR OPIN STRUC BIOL, V8, P107, DOI 10.1016/S0959-440X(98)80017-1; BRYNGELSON JD, 1995, PROTEINS, V21, P167, DOI 10.1002/prot.340210302; Bukau B, 1998, CELL, V92, P351, DOI 10.1016/S0092-8674(00)80928-9; Bullock AN, 1997, P NATL ACAD SCI USA, V94, P14338, DOI 10.1073/pnas.94.26.14338; Burton RE, 1997, NAT STRUCT BIOL, V4, P305, DOI 10.1038/nsb0497-305; Capaldi AP, 1999, J MOL BIOL, V286, P1621, DOI 10.1006/jmbi.1998.2588; Capaldi AP, 1998, CURR OPIN STRUC BIOL, V8, P86, DOI 10.1016/S0959-440X(98)80014-6; Chan CK, 1997, P NATL ACAD SCI USA, V94, P1779, DOI 10.1073/pnas.94.5.1779; Chiti F, 1999, P NATL ACAD SCI USA, V96, P3590, DOI 10.1073/pnas.96.7.3590; Cohen FE, 1998, ANNU REV BIOCHEM, V67, P793, DOI 10.1146/annurev.biochem.67.1.793; Daura X, 1998, J MOL BIOL, V280, P925, DOI 10.1006/jmbi.1998.1885; Dill KA, 1997, NAT STRUCT BIOL, V4, P10, DOI 10.1038/nsb0197-10; DINNER A, 1999, IN PRESS J PHYS CH B; Dobson Christopher M., 1999, Current Opinion in Structural Biology, V9, P92, DOI 10.1016/S0959-440X(99)80012-8; Dobson CM, 1998, ANGEW CHEM INT EDIT, V37, P868, DOI 10.1002/(SICI)1521-3773(19980420)37:7<868::AID-ANIE868>3.0.CO;2-H; DOBSON CM, 1994, TRENDS BIOCHEM SCI, V19, P31, DOI 10.1016/0968-0004(94)90171-6; Duan Y, 1998, SCIENCE, V282, P740, DOI 10.1126/science.282.5389.740; Eaton WA, 1998, ACCOUNTS CHEM RES, V31, P745, DOI 10.1021/ar9700825; Ellis R. John, 1999, Current Opinion in Structural Biology, V9, P102, DOI 10.1016/S0959-440X(99)80013-X; Fersht AR, 1997, CURR OPIN STRUC BIOL, V7, P3, DOI 10.1016/S0959-440X(97)80002-4; Grantcharova VP, 1998, NAT STRUCT BIOL, V5, P714, DOI 10.1038/1412; Hagen SJ, 1996, P NATL ACAD SCI USA, V93, P11615, DOI 10.1073/pnas.93.21.11615; Harbury PB, 1998, SCIENCE, V282, P1462, DOI 10.1126/science.282.5393.1462; Jimenez JL, 1999, EMBO J, V18, P815, DOI 10.1093/emboj/18.4.815; Karplus M, 1997, FOLD DES, V2, pS69, DOI 10.1016/S1359-0278(97)00067-9; Kelly JW, 1998, CURR OPIN STRUC BIOL, V8, P101, DOI 10.1016/S0959-440X(98)80016-X; Kortemme T, 1998, SCIENCE, V281, P253, DOI 10.1126/science.281.5374.253; Ladurner AG, 1998, P NATL ACAD SCI USA, V95, P8473, DOI 10.1073/pnas.95.15.8473; Lazaridis T, 1997, SCIENCE, V278, P1928, DOI 10.1126/science.278.5345.1928; LEVINTHAL C, 1968, J CHIM PHYS PCB, V65, P44, DOI 10.1051/jcp/1968650044; Martinez JC, 1998, NAT STRUCT BIOL, V5, P721, DOI 10.1038/1418; Mateu MG, 1999, P NATL ACAD SCI USA, V96, P3595, DOI 10.1073/pnas.96.7.3595; Munoz V, 1997, BIOPOLYMERS, V41, P495, DOI 10.1002/(SICI)1097-0282(19970415)41:5<495::AID-BIP2>3.3.CO;2-6; Munson M, 1996, PROTEIN SCI, V5, P1584, DOI 10.1002/pro.5560050813; Nikolova PV, 1998, P NATL ACAD SCI USA, V95, P14675, DOI 10.1073/pnas.95.25.14675; Park SH, 1997, BIOCHEMISTRY-US, V36, P14277, DOI 10.1021/bi971914+; Plaxco KW, 1996, CURR OPIN STRUC BIOL, V6, P630, DOI 10.1016/S0959-440X(96)80029-7; Shakhnovich E, 1996, NATURE, V379, P96, DOI 10.1038/379096a0; Shakhnovich EI, 1997, CURR OPIN STRUC BIOL, V7, P29, DOI 10.1016/S0959-440X(97)80005-X; Viguera AR, 1996, NAT STRUCT BIOL, V3, P874, DOI 10.1038/nsb1096-874	41	104	104	1	20	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	APR 30	1999	97	3					291	298		10.1016/S0092-8674(00)80739-4	http://dx.doi.org/10.1016/S0092-8674(00)80739-4			8	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	192VP	10319810	Bronze			2022-12-28	WOS:000080100500003
J	Cesar, JA; Victora, CG; Barros, FC; Santos, IS; Flores, JA				Cesar, JA; Victora, CG; Barros, FC; Santos, IS; Flores, JA			Impact of breast feeding on admission for pneumonia during postneonatal period in Brazil: nested case-control study	BRITISH MEDICAL JOURNAL			English	Article							SOUTHERN BRAZIL; DISEASES; CHILDREN; DIARRHEAL	Objective To determine whether breast feeding protects infants against pneumonia and whether the protection varies with age. Design Nested case-control study. Setting Pelotas, southern Brazil. Subjects Cases were 152 infants aged 28-364 days who had been admitted to hospital for pneumonia. Controls were 2391 cases in a population based case-control study Main outcome measure Odds ratio of admission for pneumonia according to type of milk consumed (breast milk alone, breast and formula milk, or formula milk and other fluids only), use of fluid supplements apart from formula milk, and use of solid supplements. Results Infants who were not being breast fed were 17 times more likely than those being breast fed without formula milli to be admitted to hospital for pneumonia (95% confidence interval 7.7 to 36.0). This relative risk was 61 (19.0 to 195.5) for children under 3 months old, decreasing to 10 (2.8 to 36.2) thereafter. Supplementation with solids was associated with a relative risk of 13.4 (7.6 to 23.5) for all infants and 175 (21.8 to 1405.1) for those under 3 months old. Conclusion Breast feeding protects young children against pneumonia, especially in the first months of life. These results may be used for targeting intervention campaigns at the most vulnerable age groups.	Fdn Univ Rio Grande, Dept Materno Infantil, Rio Grande Sol, Brazil; Univ Fed Pelotas, Dept Social Med, Rio Grande Sol, Brazil; Hosp Pediat Santo Antonio, Rio Grande Sol, Brazil	Universidade Federal do Rio Grande; Universidade Federal de Pelotas	Cesar, JA (corresponding author), Univ London London Sch Hyg & Trop Med, Maternal & Child Epidemiol Unit, 49-51 Bedford Sq, London WC1B 3DP, England.		Santos, Ina S/C-2001-2009; Barros, Fernando C/D-4857-2013; Victora, Cesar Gomes/Y-2455-2019; Victora, Cesar G/D-4476-2013	Victora, Cesar Gomes/0000-0002-2465-2180; Victora, Cesar G/0000-0002-2465-2180				BARROS FC, 1986, ACTA PAEDIATR SCAND, V75, P558, DOI 10.1111/j.1651-2227.1986.tb10250.x; BROWN KH, 1989, PEDIATRICS, V83, P31; CERQUEIRO MC, 1990, REV INFECT DIS, V12, pS1021; Cesar JA, 1997, REV SAUDE PUBL, V31, P53, DOI 10.1590/S0034-89101997000100008; CHEN Y, 1988, PEDIATRICS, V81, P58; Dean A.G., 1994, EPI INFO VERSION 6 W; ELLESTADSAYED J, 1979, CAN MED ASSOC J, V120, P295; FEACHEM RG, 1984, B WORLD HEALTH ORGAN, V62, P271; Jelliffe D.B., 1978, HUMAN MILK MODERN WO, P84, DOI 10.1136/bmj.2.6151.1573; LABBOK M, 1990, STUD FAMILY PLANN, V21, P226, DOI 10.2307/1966617; LOMBARDI C, 1988, REV SAUDE PUBL, V22, P253, DOI 10.1590/S0034-89101988000400001; MORRIS SS, 1995, RISK FACTORS ACUTE L, P2; Norussis NJ, 1993, STAT PACKAGE SOCIAL; PIO A, 1985, ACUTE RESP INFECT CH, P100; RODRIGUES L, 1990, INT J EPIDEMIOL, V13, P87; ROSSNER B, 1995, FUNDAMENTALS BIOSTAT, P345; SCHLESSELMAN JJ, 1982, CASE CONTROL STUDIES, P27; SCHWARTZ B, 1994, AETIOLOGY ACUTE LOWE; SMITH PG, 1984, INT J EPIDEMIOL, V13, P356, DOI 10.1093/ije/13.3.356; *STAT RES CORP, 1988, EP GRAPH EST TEST PA; Victora CG, 1996, REV SAUDE PUBL, V30, P34, DOI 10.1590/S0034-89101996000100005; VICTORA CG, 1994, PEDIATRICS, V93, P977; Victora CG, 1997, INT J EPIDEMIOL, V26, P224, DOI 10.1093/ije/26.1.224; VICTORA CG, 1987, LANCET, V2, P319; VICTORA CG, 1990, BREASTFEEDING NUTR I, P405; VICTORA CG, 1992, MEASUREMENT MATERNAL, P85; VICTORA CG, IN PRESS AM J CLIN N	27	142	169	0	3	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	MAY 15	1999	318	7194					1316	1320		10.1136/bmj.318.7194.1316	http://dx.doi.org/10.1136/bmj.318.7194.1316			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	198HR	10323815	Green Submitted, Green Published, Bronze			2022-12-28	WOS:000080418400024
J	Gouet, P; Diprose, JM; Grimes, JM; Malby, R; Burroughs, JN; Zientara, S; Stuart, DI; Mertens, PPC				Gouet, P; Diprose, JM; Grimes, JM; Malby, R; Burroughs, JN; Zientara, S; Stuart, DI; Mertens, PPC			The highly ordered double-stranded RNA genome of bluetongue virus revealed by crystallography	CELL			English	Article							TOBACCO MOSAIC-VIRUS; MOLECULAR REPLACEMENT; ICOSAHEDRAL VIRUS; REOVIRUS GENOME; MESSENGER-RNA; VISUALIZATION; RESOLUTION; PARTICLES; PROTEIN; CORES	The concentration of double-stranded RNA within the bluetongue virus core renders the genome segments liquid crystalline. Powder diffraction rings confirm this local ordering with a 30 Angstrom separation between strands. Determination of the structure of the bluetongue virus core serotype 10 and comparison with that of serotype 1 reveals most of the gc nomic double-stranded RNA, packaged as well-ordered layers surrounding putative transcription complexes at the apices of the particle. The outer layer of RNA is sufficiently well ordered by interaction with the capsid that a model can be built and extended to the less-ordered inner layers, providing a structural framework for understanding the mechanism of this complex transcriptional machine. We show that the genome segments maintain local order during transcription.	Univ Oxford, Mol Biophys Lab, Oxford OX1 3QU, England; AFRC, Inst Anim Hlth, Pirbright Lab, Woking GU24 0NF, Surrey, England; Ctr Natl Etud Vet & Alimentaires Alfort, Lab Cent Rech Vet, F-94703 Maisons Alfort, France; Oxford Ctr Mol Sci, Oxford OX1 3QT, England	University of Oxford; UK Research & Innovation (UKRI); Biotechnology and Biological Sciences Research Council (BBSRC); Babraham Institute; Pirbright Institute; Ecole Nationale Veterinaire d'Alfort (ENVA); University of Oxford	Stuart, DI (corresponding author), Univ Oxford, Mol Biophys Lab, Rex Richards Bldg,S Parks Rd, Oxford OX1 3QU, England.	dave@biop.ox.ac.uk	Zientara, Stephan/A-5336-2016; Zientara, Stephan/AAA-7661-2021	Zientara, Stephan/0000-0003-0089-8175; Zientara, Stephan/0000-0002-6733-8503; Stuart, David/0000-0002-3426-4210; Mertens, Peter/0000-0002-3438-3738; Grimes, Jonathan Mark/0000-0001-9698-0389; gouet, patrice/0000-0001-9485-6157				BACON D, 1988, J MOL GRAPHICS, V6, P219, DOI 10.1016/S0263-7855(98)80030-1; BARTLETT NM, 1974, J VIROL, V14, P315, DOI 10.1128/JVI.14.2.315-326.1974; Bourgeois D, 1998, J APPL CRYSTALLOGR, V31, P22, DOI 10.1107/S0021889897006730; BRUNGER AT, 1992, XPLOR VERSION 3 1; BURROUGHS JN, 1995, VIROLOGY, V210, P217, DOI 10.1006/viro.1995.1335; CHEN ZG, 1989, SCIENCE, V245, P154, DOI 10.1126/science.2749253; DELANO WL, 1995, ACTA CRYSTALLOGR D, V51, P740, DOI 10.1107/S0907444995001284; Dryden KA, 1998, VIROLOGY, V245, P33, DOI 10.1006/viro.1998.9146; EATON BT, 1990, CURR TOP MICROBIOL, V162, P89; Esnouf RM, 1999, ACTA CRYSTALLOGR D, V55, P938, DOI 10.1107/S0907444998017363; Esnouf RM, 1997, J MOL GRAPH MODEL, V15, P132, DOI 10.1016/S1093-3263(97)00021-1; FISHER AJ, 1993, NATURE, V361, P176, DOI 10.1038/361176a0; Foulser D., 1995, Computer Graphics, V29, P13, DOI 10.1145/204362.204365; FRENCH S, 1978, ACTA CRYSTALLOGR A, V34, P517, DOI 10.1107/S0567739478001114; GILLIES S, 1971, SCIENCE, V174, P694, DOI 10.1126/science.174.4010.694; GRIME GW, 1991, NUCL INSTRUM METH B, V54, P52, DOI 10.1016/0168-583X(91)95490-5; Grimes JM, 1998, NATURE, V395, P470, DOI 10.1038/26694; Jacobs BL, 1996, VIROLOGY, V219, P339, DOI 10.1006/viro.1996.0259; Joklik WK, 1996, PROG NUCLEIC ACID RE, V53, P249, DOI 10.1016/S0079-6603(08)60147-6; JOKLIK WK, 1983, REOVIRIDAE, P9; LARSON SB, 1993, NATURE, V361, P179, DOI 10.1038/361179a0; Lawton JA, 1997, NAT STRUCT BIOL, V4, P118, DOI 10.1038/nsb0297-118; Livolant F, 1996, PROG POLYM SCI, V21, P1115, DOI 10.1016/S0079-6700(96)00016-0; MACFARLANE SA, 1991, VIROLOGY, V183, P405, DOI 10.1016/0042-6822(91)90155-5; MATTHEWS BW, 1968, J MOL BIOL, V33, P491, DOI 10.1016/0022-2836(68)90205-2; MERRITT EA, 1994, ACTA CRYSTALLOGR D, V50, P869, DOI 10.1107/S0907444994006396; Mertens P. P. C., 1992, Bluetongue, African horse sickness, and related orbiviruses: Proceedings of the Second International Symposium., P404; MERTENS PPC, 1987, VIROLOGY, V157, P375, DOI 10.1016/0042-6822(87)90280-7; Millward S, 1983, REOVIRIDAE, P107; NAMBA K, 1989, J MOL BIOL, V208, P307, DOI 10.1016/0022-2836(89)90391-4; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Payne C.C., 1983, P425; Prasad BVV, 1996, NATURE, V382, P471, DOI 10.1038/382471a0; Qiao XY, 1997, P NATL ACAD SCI USA, V94, P4074, DOI 10.1073/pnas.94.8.4074; Ramadevi N, 1998, P NATL ACAD SCI USA, V95, P13537, DOI 10.1073/pnas.95.23.13537; RAYMENT I, 1983, ACTA CRYSTALLOGR A, V39, P102, DOI 10.1107/S0108767383000197; REN JS, 1995, NAT STRUCT BIOL, V2, P293, DOI 10.1038/nsb0495-293; Roner MR, 1995, P NATL ACAD SCI USA, V92, P12362, DOI 10.1073/pnas.92.26.12362; RONER MR, 1990, VIROLOGY, V179, P845, DOI 10.1016/0042-6822(90)90153-I; ROUSSEL A, 1991, TURBO FRODO; ROY P, 1992, J GEN VIROL, V73, P3051, DOI 10.1099/0022-1317-73-12-3051; ROY P, 1989, VIRUS RES, V13, P179, DOI 10.1016/0168-1702(89)90015-4; Shaw AL, 1996, STRUCTURE, V4, P957, DOI 10.1016/S0969-2126(96)00102-5; SMITH RE, 1969, VIROLOGY, V39, P791, DOI 10.1016/0042-6822(69)90017-8; Stuart DI, 1998, ARCH VIROL, P235; TSAO J, 1991, SCIENCE, V251, P1456, DOI 10.1126/science.2006420; Tsuruta H, 1998, J MOL BIOL, V284, P1439, DOI 10.1006/jmbi.1998.2231; WANG BC, 1985, DIFFRACTION METHODS, P90; WHITE CK, 1976, VIROLOGY, V70, P171, DOI 10.1016/0042-6822(76)90247-6; YAZAKI K, 1980, VIROLOGY, V105, P467, DOI 10.1016/0042-6822(80)90047-1	50	147	156	0	6	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	MAY 14	1999	97	4					481	490		10.1016/S0092-8674(00)80758-8	http://dx.doi.org/10.1016/S0092-8674(00)80758-8			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	196FV	10338212	Bronze			2022-12-28	WOS:000080299100009
J	Griffith, JD; Comeau, L; Rosenfield, S; Stansel, RM; Bianchi, A; Moss, H; de Lange, T				Griffith, JD; Comeau, L; Rosenfield, S; Stansel, RM; Bianchi, A; Moss, H; de Lange, T			Mammalian telomeres end in a large duplex loop	CELL			English	Article							ESCHERICHIA-COLI; BINDING-PROTEIN; DNA; TRF1; MOUSE; YEAST; CELL; TETRAHYMENA; POLYMERASE; SEQUENCES	Mammalian telomeres contain a duplex array of telomeric repeats bound to the telomeric repeat-binding factors TRF1 and TRF2. Inhibition of TRF2 results in immediate deprotection of chromosome ends, manifested by loss of the telomeric 3' overhang, activation of p53, and end-to-end chromosome fusions. Electron microscopy reported here demonstrated that TRF2 can remodel linear telomeric DNA into large duplex loops (t loops) in vitro. Electron microscopy analysis of psoralen cross-linked telomeric DNA purified from human and mouse cells revealed abundant large t loops with a size distribution consistent with their telomeric origin. Binding of TRF1 and single strand binding protein suggested that t loops are formed by invasion of the 3' telomeric overhang into the duplex telomeric repeat array. T loops may provide a general mechanism for the protection and replication of telomeres.	Univ N Carolina, Lineberger Comprehens Canc Ctr, Chapel Hill, NC 27599 USA; Curriculum Genet & Mol Biol, Chapel Hill, NC 27599 USA; Rockefeller Univ, New York, NY 10021 USA	University of North Carolina; University of North Carolina Chapel Hill; Rockefeller University	Griffith, JD (corresponding author), Univ N Carolina, Lineberger Comprehens Canc Ctr, Chapel Hill, NC 27599 USA.		de Lange, Titia/B-8263-2011	de Lange, Titia/0000-0002-9267-367X; Bianchi, Alessandro/0000-0001-6583-1671	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM049046, R01GM049046, R01GM031819] Funding Source: NIH RePORTER; NCI NIH HHS [CA19043] Funding Source: Medline; NIGMS NIH HHS [GM49046, GM31819] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Bianchi A, 1997, EMBO J, V16, P1785, DOI 10.1093/emboj/16.7.1785; BIANCHI A, 1999, THESIS ROCKEFELLER U; Bilaud T, 1997, NAT GENET, V17, P236, DOI 10.1038/ng1097-236; Bodnar AG, 1998, SCIENCE, V279, P349, DOI 10.1126/science.279.5349.349; Broccoli D, 1996, MOL CELL BIOL, V16, P3765; Broccoli D, 1997, NAT GENET, V17, P231, DOI 10.1038/ng1097-231; Bryan TM, 1997, NAT MED, V3, P1271, DOI 10.1038/nm1197-1271; CECH TR, 1976, P NATL ACAD SCI USA, V73, P2644, DOI 10.1073/pnas.73.8.2644; CHASE JW, 1980, NUCLEIC ACIDS RES, V8, P3215, DOI 10.1093/nar/8.14.3215; CHONG L, 1995, SCIENCE, V270, P1663, DOI 10.1126/science.270.5242.1663; CHRYSOGELOS S, 1982, P NATL ACAD SCI-BIOL, V79, P5803, DOI 10.1073/pnas.79.19.5803; COUNTER CM, 1994, P NATL ACAD SCI USA, V91, P2900, DOI 10.1073/pnas.91.8.2900; de Lange T, 1999, SCIENCE, V283, P947, DOI 10.1126/science.283.5404.947; DELANGE T, 1990, MOL CELL BIOL, V10, P518, DOI 10.1128/MCB.10.2.518; deLange T, 1996, SEMIN CELL DEV BIOL, V7, P23, DOI 10.1006/scdb.1996.0005; DELANGE T, 1995, TELOMERES, P265; Gall J. G., 1995, TELOMERES, P1; GOLDBACH RW, 1979, BIOCHIM BIOPHYS ACTA, V562, P400, DOI 10.1016/0005-2787(79)90104-7; GOTTSCHLING DE, 1986, CELL, V47, P195, DOI 10.1016/0092-8674(86)90442-3; GREIDER CW, 1985, CELL, V43, P405, DOI 10.1016/0092-8674(85)90170-9; Griffith J, 1998, J MOL BIOL, V278, P79, DOI 10.1006/jmbi.1998.1686; GRIFFITH JD, 1978, ANNU REV BIOPHYS BIO, V7, P19, DOI 10.1146/annurev.bb.07.060178.000315; HANISH JP, 1994, P NATL ACAD SCI USA, V91, P8861, DOI 10.1073/pnas.91.19.8861; HANSON CV, 1976, SCIENCE, V193, P62, DOI 10.1126/science.935855; HARLEY CB, 1990, NATURE, V345, P458, DOI 10.1038/345458a0; HASTIE ND, 1990, NATURE, V346, P866, DOI 10.1038/346866a0; Horvath MP, 1998, CELL, V95, P963, DOI 10.1016/S0092-8674(00)81720-1; Karlseder J, 1999, SCIENCE, V283, P1321, DOI 10.1126/science.283.5406.1321; KIPLING D, 1990, NATURE, V347, P400, DOI 10.1038/347400a0; KLEINSCHMIDT A., 1959, ZEIT NATURFORSCH, V14b, P770; KLOBUTCHER LA, 1981, P NATL ACAD SCI-BIOL, V78, P3015, DOI 10.1073/pnas.78.5.3015; Kreuzer K. N., 1994, MOL BIOL BACTERIOP T, P28; Lee HW, 1998, NATURE, V392, P569, DOI 10.1038/33345; LUDER A, 1982, P NATL ACAD SCI-BIOL, V79, P1101, DOI 10.1073/pnas.79.4.1101; Luderus ME, 1996, J CELL BIOL, V135, P867, DOI 10.1083/jcb.135.4.867; LUNDBLAD V, 1989, CELL, V57, P633, DOI 10.1016/0092-8674(89)90132-3; McClintock B, 1941, GENETICS, V26, P234; MORIN GB, 1988, CELL, V52, P367, DOI 10.1016/S0092-8674(88)80029-1; Muller H.J., 1938, COLLECTING NET, V13, P181; Naito T, 1998, NAT GENET, V20, P203, DOI 10.1038/2517; Nugent CI, 1998, GENE DEV, V12, P1073, DOI 10.1101/gad.12.8.1073; Price C, 1999, NATURE, V397, P213, DOI 10.1038/16598; Rudolph KL, 1999, CELL, V96, P701, DOI 10.1016/S0092-8674(00)80580-2; SANDELL LL, 1993, CELL, V75, P729, DOI 10.1016/0092-8674(93)90493-A; SHORE D, 1981, P NATL ACAD SCI-BIOL, V78, P4833, DOI 10.1073/pnas.78.8.4833; Smith S, 1998, SCIENCE, V282, P1484, DOI 10.1126/science.282.5393.1484; van Steensel B, 1998, CELL, V92, P401, DOI 10.1016/S0092-8674(00)80932-0; vanSteensel B, 1997, NATURE, V385, P740, DOI 10.1038/385740a0; WEINERT TA, 1988, SCIENCE, V241, P317, DOI 10.1126/science.3291120; WILLIAMSON JR, 1989, CELL, V59, P871, DOI 10.1016/0092-8674(89)90610-7; ZHONG Z, 1992, MOL CELL BIOL, V12, P4834, DOI 10.1128/MCB.12.11.4834; Zijlmans JMJM, 1997, P NATL ACAD SCI USA, V94, P7423, DOI 10.1073/pnas.94.14.7423	52	1829	1908	9	139	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	MAY 14	1999	97	4					503	514		10.1016/S0092-8674(00)80760-6	http://dx.doi.org/10.1016/S0092-8674(00)80760-6			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	196FV	10338214	Bronze			2022-12-28	WOS:000080299100011
J	Pestano, GA; Zhou, YL; Trimble, LA; Daley, J; Weber, GF; Cantor, H				Pestano, GA; Zhou, YL; Trimble, LA; Daley, J; Weber, GF; Cantor, H			Inactivation of misselected CD8 T cells by CD8 gene methylation and cell death	SCIENCE			English	Article							MHC CLASS-I; IMMATURE THYMOCYTES; POSITIVE SELECTION; THYMIC SELECTION; DEFICIENT MICE; LPR MICE; RECEPTOR; LYMPHOCYTES; ANTIGEN; SPECIFICITY	Misselected CD8 cells that express T cell receptors (TCRs) that do not recognize class I major histocompatibility complex (MHC) protein can emerge from thymic selection. A postthymic quality control mechanism that purges these cells from the repertoire is defined here. The failure of mature CD8 cells to simultaneously engage their TCR and CD8 coreceptor triggers an activation process that begins with inhibition of CD8 gene expression through remethylation and concludes with up-regulation of surface Fas and pas Ligand and cellular apoptosis. Thus, inhibition of a death signal through continued TCR-CD8 coengagement of MHC molecules is a key checkpoint for the continued survival of correctly selected T cells. Molecular defects that prevent delivery of the death signal to mistakenly selected T cells underlie the expansion of double-negative T cells, which is the cellular signature of a subset of systemic autoimmune diseases.	Harvard Univ, Sch Med, Dana Farber Canc Inst, Dept Canc Immunol & AIDS, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dana Farber Canc Inst, Dept Adult Oncol, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Pathol, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Med, Boston, MA 02115 USA	Harvard University; Dana-Farber Cancer Institute; Harvard Medical School; Harvard University; Dana-Farber Cancer Institute; Harvard Medical School; Harvard University; Harvard Medical School; Harvard University; Harvard Medical School	Cantor, H (corresponding author), Harvard Univ, Sch Med, Dana Farber Canc Inst, Dept Canc Immunol & AIDS, 44 Binney St, Boston, MA 02115 USA.				NCI NIH HHS [CA76176] Funding Source: Medline; NIAID NIH HHS [AI 13600, AI 37833] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R29CA076176] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [P01AI037833, R01AI013600] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		APASOV SG, 1994, J IMMUNOL, V152, P2087; Basson MA, 1998, J EXP MED, V187, P1249; BENEDIKT K, 1998, J IMMUNOL, V161, P6939; CARBONE AM, 1988, SCIENCE, V242, P1174, DOI 10.1126/science.2460926; CARBONE AM, 1988, J IMMUNOL, V141, P1369; Cho BK, 1999, P NATL ACAD SCI USA, V96, P2976, DOI 10.1073/pnas.96.6.2976; Chung DH, 1996, HUM IMMUNOL, V45, P124, DOI 10.1016/0198-8859(95)00168-9; COHEN PL, 1991, ANNU REV IMMUNOL, V9, P243, DOI 10.1146/annurev.iy.09.040191.001331; CRUMP AL, 1993, P NATL ACAD SCI USA, V90, P10739, DOI 10.1073/pnas.90.22.10739; Devi BS, 1998, J AUTOIMMUN, V11, P471, DOI 10.1006/jaut.1998.0213; EBNET K, 1991, INT IMMUNOL, V3, P9, DOI 10.1093/intimm/3.1.9; Fehling HJ, 1997, CURR OPIN IMMUNOL, V9, P263, DOI 10.1016/S0952-7915(97)80146-X; FERRONE S, 1995, IMMUNOL TODAY, V16, P487, DOI 10.1016/0167-5699(95)80033-6; HASKINS K, 1983, J EXP MED, V157, P1149, DOI 10.1084/jem.157.4.1149; Hertz M, 1998, NATURE, V394, P292, DOI 10.1038/28419; IWABUCHI K, 1992, P NATL ACAD SCI USA, V89, P9000, DOI 10.1073/pnas.89.19.9000; Jameson SC, 1998, CURR OPIN IMMUNOL, V10, P214, DOI 10.1016/S0952-7915(98)80251-3; JEVNIKAR AM, 1994, J EXP MED, V179, P1137, DOI 10.1084/jem.179.4.1137; KEARNEY ER, 1994, IMMUNITY, V1, P327, DOI 10.1016/1074-7613(94)90084-1; KIRBERG J, 1994, J EXP MED, V180, P25, DOI 10.1084/jem.180.1.25; KISIELOW P, 1988, NATURE, V333, P742, DOI 10.1038/333742a0; KOH DR, 1995, EUR J IMMUNOL, V25, P2558, DOI 10.1002/eji.1830250923; KOLLER BH, 1990, SCIENCE, V248, P1227, DOI 10.1126/science.2112266; Kuo CT, 1997, SCIENCE, V277, P1986, DOI 10.1126/science.277.5334.1986; Laufer TM, 1996, NATURE, V383, P81, DOI 10.1038/383081a0; LeDeist F, 1996, LANCET, V348, P719, DOI 10.1016/S0140-6736(96)02293-3; Lim MS, 1998, AM J PATHOL, V153, P1541, DOI 10.1016/S0002-9440(10)65742-2; LJUNGGREN HG, 1985, J EXP MED, V162, P1745, DOI 10.1084/jem.162.6.1745; LYNCH DH, 1994, IMMUNITY, V1, P131, DOI 10.1016/1074-7613(94)90106-6; MALDONADO MA, 1995, J EXP MED, V181, P64; Maniatis T., 1982, MOL CLONING LAB MANU; Marrack P, 1997, CURR OPIN IMMUNOL, V9, P250, DOI 10.1016/S0952-7915(97)80144-6; Matechak EO, 1996, IMMUNITY, V4, P337, DOI 10.1016/S1074-7613(00)80247-2; MURPHY KM, 1990, SCIENCE, V250, P1720, DOI 10.1126/science.2125367; Nesic D, 1998, J IMMUNOL, V160, P3705; PATARCA R, 1990, J EXP MED, V172, P1177, DOI 10.1084/jem.172.4.1177; Perkins DL, 1996, J IMMUNOL, V156, P4961; PESTANO GA, UNPUB; Preckel T, 1998, EUR J IMMUNOL, V28, P3706, DOI 10.1002/(SICI)1521-4141(199811)28:11<3706::AID-IMMU3706>3.0.CO;2-7; RAO A, 1983, IMMUNOGENETICS, V17, P147, DOI 10.1007/BF00364755; Robey E, 1996, CELL, V87, P483, DOI 10.1016/S0092-8674(00)81368-9; Schulz RJ, 1996, J IMMUNOL, V157, P4379; SOBEL ES, 1995, CLIN IMMUNOL IMMUNOP, V74, P177, DOI 10.1006/clin.1995.1026; SUZUKI H, 1994, J IMMUNOL, V153, P4496; Tanchot C, 1997, SCIENCE, V276, P2057, DOI 10.1126/science.276.5321.2057; Volkmann A, 1998, J EXP MED, V188, P1083, DOI 10.1084/jem.188.6.1083; VONBOEHMER H, 1997, IMMUNOLOGIST, V5, P185; WATANABEFUKUNAGA R, 1992, NATURE, V356, P314, DOI 10.1038/356314a0; Yang XF, 1997, IMMUNITY, V7, P629, DOI 10.1016/S1074-7613(00)80384-2	49	72	78	0	0	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	MAY 14	1999	284	5417					1187	1191		10.1126/science.284.5417.1187	http://dx.doi.org/10.1126/science.284.5417.1187			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	197HJ	10325233				2022-12-28	WOS:000080359100043
J	Cummins, D				Cummins, D			My elective - The silent sentinels	BRITISH MEDICAL JOURNAL			English	Article									Harefield Hosp, Middlesex, England	Royal Brompton & Harefield NHS Foundation Trust; Harefield Hospital	Cummins, D (corresponding author), Harefield Hosp, Middlesex, England.								0	0	0	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	MAY 8	1999	318	7193					1245	1245						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	195XT	10231254				2022-12-28	WOS:000080278000025
J	Leiper, AD				Leiper, AD			What is in store after stem-cell transplantation?	LANCET			English	Editorial Material							BONE-MARROW TRANSPLANTATION; CHILDHOOD; LEUKEMIA; CANCER		Great Ormond St Hosp Children, Dept Haematol & Oncol, London WC1N 3JH, England	University of London; University College London; Great Ormond Street Hospital for Children NHS Foundation Trust	Leiper, AD (corresponding author), Great Ormond St Hosp Children, Dept Haematol & Oncol, Great Ormond St, London WC1N 3JH, England.							Cerveri I, 1999, THORAX, V54, P131, DOI 10.1136/thx.54.2.131; Curtis RE, 1997, NEW ENGL J MED, V336, P897, DOI 10.1056/NEJM199703273361301; Deeg HJ, 1996, BLOOD, V87, P386, DOI 10.1182/blood.V87.1.386.bloodjournal871386; Duell T, 1997, ANN INTERN MED, V126, P184, DOI 10.7326/0003-4819-126-3-199702010-00002; EARNES GM, 1997, BMJ-BRIT MED J, V19, P61; HAWKINS MM, 1992, BRIT MED J, V304, P951, DOI 10.1136/bmj.304.6832.951; Horowitz M., 1998, HEMATOPOIETIC CELL T, P12; LEIPER AD, 1995, ARCH DIS CHILD, V72, P382, DOI 10.1136/adc.72.5.382; OLSEN JH, 1993, BRIT MED J, V307, P1030, DOI 10.1136/bmj.307.6911.1030; Shalet SM, 1998, HORM RES, V50, P1, DOI 10.1159/000023193; Slavin S, 1998, BLOOD, V91, P756, DOI 10.1182/blood.V91.3.756.756_756_763; TUCKER MA, 1987, NEW ENGL J MED, V317, P588, DOI 10.1056/NEJM198709033171002	12	12	12	1	1	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	MAY 8	1999	353	9164					1544	1545		10.1016/S0140-6736(99)90033-8	http://dx.doi.org/10.1016/S0140-6736(99)90033-8			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	195XW	10334250				2022-12-28	WOS:000080278300006
J	Johnson, DW; Parnham, A; Herzig, K; Wittmann, J				Johnson, DW; Parnham, A; Herzig, K; Wittmann, J			Sunshine, sweating, and main d'accoucheur	LANCET			English	Article							PSEUDO-BARTTERS SYNDROME; CYSTIC-FIBROSIS; ABSENCE		Princess Alexandra Hosp, Dept Renal Med, Brisbane, Qld 4102, Australia; Gold Coast Hosp, Dept Renal Med, Southport, Qld, Australia	Gold Coast University Hospital	Johnson, DW (corresponding author), Princess Alexandra Hosp, Dept Renal Med, Brisbane, Qld 4102, Australia.	johnsond@health.qld.gov.au	Johnson, David/F-2897-2011	Johnson, David/0000-0001-5491-3460				ANGUIANO A, 1992, JAMA-J AM MED ASSOC, V267, P1794, DOI 10.1001/jama.267.13.1794; DEVLIN J, 1989, J ROY SOC MED, V82, P38; Durie RR, 1998, NEW ENGL J MED, V339, P687, DOI 10.1056/NEJM199809033391008; KENNEDY JD, 1990, ARCH DIS CHILD, V65, P786, DOI 10.1136/adc.65.7.786; RIGOT JM, 1991, NEW ENGL J MED, V325, P64	5	1	1	0	0	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	MAY 1	1999	353	9163					1492	1492		10.1016/S0140-6736(99)02271-0	http://dx.doi.org/10.1016/S0140-6736(99)02271-0			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	195XV	10232317				2022-12-28	WOS:000080278200014
J	San-Segundo, PA; Roeder, GS				San-Segundo, PA; Roeder, GS			Pch2 links chromatin silencing to meiotic checkpoint control	CELL			English	Article							SYNAPTONEMAL COMPLEX PROTEIN; SACCHAROMYCES-CEREVISIAE; CHROMOSOME SYNAPSIS; GENE-EXPRESSION; RIBOSOMAL DNA; YEAST; RECOMBINATION; MEIOSIS; NUCLEOLUS; MUTANTS	The PCH2 gene of Saccharomyces cerevisiae is required for the meiotic checkpoint that prevents chromosome segregation when recombination and chromosome synapsis are defective. Mutation of PCH2 relieves the checkpoint-induced pachytene arrest of the zip1, zip2, and dmc1 mutants, resulting in chromosome missegregation and low spore viability. Most of the Pch2 protein localizes to the nucleolus, where it represses meiotic interhomolog recombination in the ribosomal DNA, apparently by excluding the meiosis-specific Hop1 protein. Nucleolar localization of Pch2 depends on the silencing factor Sir2, and mutation of SIR2 also bypasses the zip1 pachytene arrest. Under certain circumstances, Sir3-dependent localization of Pch2 to telomeres also provides checkpoint function. These unexpected findings link the nucleolus, chromatin silencing, and the pachytene checkpoint.	Yale Univ, Howard Hughes Med Inst, New Haven, CT 06520 USA; Yale Univ, Dept Mol Cellular & Dev Biol, New Haven, CT 06520 USA; Yale Univ, Dept Genet, New Haven, CT 06520 USA	Howard Hughes Medical Institute; Yale University; Yale University; Yale University	Roeder, GS (corresponding author), Yale Univ, Howard Hughes Med Inst, New Haven, CT 06520 USA.		San-Segundo, Pedro A/L-4539-2014	San-Segundo, Pedro A/0000-0002-5616-574X	NIGMS NIH HHS [GM28904] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM028904] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Beyer A, 1997, PROTEIN SCI, V6, P2043; BISHOP DK, 1992, CELL, V69, P439, DOI 10.1016/0092-8674(92)90446-J; Bryk M, 1997, GENE DEV, V11, P255, DOI 10.1101/gad.11.2.255; BURNS N, 1994, GENE DEV, V8, P1087, DOI 10.1101/gad.8.9.1087; CAO L, 1990, CELL, V61, P1089, DOI 10.1016/0092-8674(90)90072-M; CHIEN CT, 1993, CELL, V75, P531, DOI 10.1016/0092-8674(93)90387-6; CHRISTIANSON TW, 1992, GENE, V110, P119, DOI 10.1016/0378-1119(92)90454-W; Chua PR, 1998, CELL, V93, P349, DOI 10.1016/S0092-8674(00)81164-2; COCKELL M, 1995, J CELL BIOL, V129, P909, DOI 10.1083/jcb.129.4.909; DRESSER ME, 1988, J CELL BIOL, V106, P567, DOI 10.1083/jcb.106.3.567; Edelmann W, 1996, CELL, V85, P1125, DOI 10.1016/S0092-8674(00)81312-4; ENGEBRECHT JA, 1989, GENETICS, V121, P237; Fritze CE, 1997, EMBO J, V16, P6495, DOI 10.1093/emboj/16.21.6495; Gotta M, 1997, EMBO J, V16, P3243, DOI 10.1093/emboj/16.11.3243; GOTTLIEB S, 1989, CELL, V56, P771, DOI 10.1016/0092-8674(89)90681-8; Guarente L, 1997, GENE DEV, V11, P2449, DOI 10.1101/gad.11.19.2449; HARTWELL LH, 1989, SCIENCE, V246, P629, DOI 10.1126/science.2683079; HOLLINGSWORTH NM, 1989, GENETICS, V121, P445; HOLLINGSWORTH NM, 1990, CELL, V61, P73, DOI 10.1016/0092-8674(90)90216-2; IVY JM, 1986, MOL CELL BIOL, V6, P688, DOI 10.1128/MCB.6.2.688; Leu JY, 1998, CELL, V94, P375, DOI 10.1016/S0092-8674(00)81480-4; LOIDL J, 1994, J CELL BIOL, V125, P1191, DOI 10.1083/jcb.125.6.1191; Loo S, 1995, ANNU REV CELL DEV BI, V11, P519, DOI 10.1146/annurev.cellbio.11.1.519; Lydall D, 1996, NATURE, V383, P840, DOI 10.1038/383840a0; McKee AHZ, 1997, GENETICS, V146, P817; MITCHELL AP, 1994, MICROBIOL REV, V58, P56, DOI 10.1128/MMBR.58.1.56-70.1994; Nierras CR, 1997, CHROMOSOMA, V105, P444; Pederson T, 1998, J CELL BIOL, V143, P279, DOI 10.1083/jcb.143.2.279; Pederson T, 1998, NUCLEIC ACIDS RES, V26, P3871, DOI 10.1093/nar/26.17.3871; PETES TD, 1977, P NATL ACAD SCI USA, V74, P5091, DOI 10.1073/pnas.74.11.5091; Pittman DL, 1998, MOL CELL, V1, P697, DOI 10.1016/S1097-2765(00)80069-6; ROCKMILL B, 1995, GENE DEV, V9, P2684, DOI 10.1101/gad.9.21.2684; Roeder GS, 1997, GENE DEV, V11, P2600, DOI 10.1101/gad.11.20.2600; Santos B, 1997, J CELL BIOL, V136, P95, DOI 10.1083/jcb.136.1.95; SCHNEIDER BL, 1995, YEAST, V11, P1265, DOI 10.1002/yea.320111306; Singer MS, 1998, GENETICS, V150, P613; Smith AV, 1997, J CELL BIOL, V136, P957, DOI 10.1083/jcb.136.5.957; Smith JS, 1997, GENE DEV, V11, P241, DOI 10.1101/gad.11.2.241; STONE EM, 1991, MOL CELL BIOL, V11, P2253, DOI 10.1128/MCB.11.4.2253; Storlazzi A, 1996, P NATL ACAD SCI USA, V93, P9043, DOI 10.1073/pnas.93.17.9043; StrahlBolsinger S, 1997, GENE DEV, V11, P83, DOI 10.1101/gad.11.1.83; SYM M, 1993, CELL, V72, P365, DOI 10.1016/0092-8674(93)90114-6; SYM M, 1995, J CELL BIOL, V128, P455, DOI 10.1083/jcb.128.4.455; SYM M, 1994, CELL, V79, P283, DOI 10.1016/0092-8674(94)90197-X; Tsukamoto Y, 1997, NATURE, V388, P900, DOI 10.1038/42288; Tung KS, 1998, GENETICS, V149, P817; Weinert T, 1998, CELL, V94, P555, DOI 10.1016/S0092-8674(00)81597-4; Yoshida K, 1998, MOL CELL, V1, P707, DOI 10.1016/S1097-2765(00)80070-2	48	207	210	3	18	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	APR 30	1999	97	3					313	324		10.1016/S0092-8674(00)80741-2	http://dx.doi.org/10.1016/S0092-8674(00)80741-2			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	192VP	10319812	hybrid			2022-12-28	WOS:000080100500005
J	Emerson, PM; Lindsay, SW; Walraven, GEL; Faal, H; Bogh, C; Lowe, K; Bailey, RL				Emerson, PM; Lindsay, SW; Walraven, GEL; Faal, H; Bogh, C; Lowe, K; Bailey, RL			Effect of fly control on trachoma and diarrhoea	LANCET			English	Article							GAMBIAN VILLAGE; MUSCA-DOMESTICA; TRANSMISSION; IMPACT	Background Domestic flies are accepted vectors of diarrhoea, but their role in trachoma transmission has never been quantified and no study has shown that fly control decreases the prevalence of trachoma. We assessed the effect of fly control on public health in a pilot study in Gambian villages. Methods We studied two pairs of villages-one pair in the 1997 wet season, and one pair in the 1998 dry season. For each pair, deltamethrin was sprayed for 3 months to control flies in one village whilst the other was used as a control. Fly populations were monitored with traps. We surveyed trachoma at baseline and at 3 months, and collected daily data on diarrhoea in children aged between 3 months and 5 years. Findings Fly control decreased numbers of muscid flies by around 75% in the intervention villages compared with controls. Trachoma prevalence was similar at baseline (wet season, prevalence in intervention village 8.8% vs control 12.2%; dry season, 18.0% vs 16.0%), but after 3 months of fly control there were 75% fewer new cases of trachoma in the intervention villages (wet season 3.7% vs 13.7%; dry season 10.0% vs 18.9%; rate ratio and relative risk of pooled data 0.25 [adjusted 95% CI 0.09-0.64], p=0.003). There was 22% less childhood diarrhoea in the wet season (14% vs 19%, period prevalence ratio 0.78 [0.64-0.95], p=0.01), and 26% less diarrhoea in the dry season (6% vs 8%; 0.74 [0.34-1.59], p=0.60) compared with controls. Interpretation Muscid flies are important vectors of trachoma and childhood diarrhoea in The Gambia. Deltamethrin spray is effective for fly control and may be useful for reducing trachoma and diarrhoea in some situations, but further research on sustainable fly-control methods is needed.	MRC, Banjul, Gambia; Univ Durham, Durham DH1 3HP, England; Danish Bilharziasis Lab, Charlottenlund, Denmark; Univ London London Sch Hyg & Trop Med, London WC1E 7HT, England	University of London; London School of Hygiene & Tropical Medicine; Durham University; University of London; London School of Hygiene & Tropical Medicine	Emerson, PM (corresponding author), MRC Labs, POB 273, Banjul, Gambia.			Emerson, Paul/0000-0002-6478-8816				BAILEY R, 1989, INT J EPIDEMIOL, V18, P944, DOI 10.1093/ije/18.4.944; BAILEY RL, 1994, J INFECT DIS, V170, P709, DOI 10.1093/infdis/170.3.709; BENN C, 1992, B WORLD HEALTH ORGAN, V70, P705; COHEN D, 1991, LANCET, V337, P993, DOI 10.1016/0140-6736(91)92657-N; DOLIN PJ, 1997, LANCET, V349, P151; FORSEY T, 1981, BRIT J OPHTHALMOL, V65, P147, DOI 10.1136/bjo.65.2.147; FOTEDAR R, 1992, J HOSP INFECT, V20, P209, DOI 10.1016/0195-6701(92)90089-5; GREENWOOD BM, 1993, T R SOC TROP MED S2, V87, pS2; MABEY DCW, 1991, ANN TROP PAEDIATR, V11, P295, DOI 10.1080/02724936.1991.11747518; Maccallan A F, 1931, Br J Ophthalmol, V15, P369, DOI 10.1136/bjo.15.7.369; MONZON R B, 1991, Southeast Asian Journal of Tropical Medicine and Public Health, V22, P222; REINHARD.J, 1968, B WORLD HEALTH ORGAN, V39, P497; ROTHMAN KJ, 1986, MODERN EPIDEMIOLOGY, P145; TAYLOR HR, 1988, AM J TROP MED HYG, V38, P623, DOI 10.4269/ajtmh.1988.38.623; THYLEFORS B, 1987, B WORLD HEALTH ORGAN, V65, P477; THYLEFORS B, 1995, B WORLD HEALTH ORGAN, V73, P115; WEST S, 1995, LANCET, V345, P155, DOI 10.1016/S0140-6736(95)90167-1; WEST SK, 1991, INT J EPIDEMIOL, V20, P1088, DOI 10.1093/ije/20.4.1088; WRIGHT EP, 1983, J HYG-CAMBRIDGE, V91, P223, DOI 10.1017/S0022172400060228	19	136	139	0	7	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	APR 24	1999	353	9162					1401	1403		10.1016/S0140-6736(98)09158-2	http://dx.doi.org/10.1016/S0140-6736(98)09158-2			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	191KD	10227221				2022-12-28	WOS:000080020800013
J	Goldhaber, SZ; Visani, L; De Rosa, M				Goldhaber, SZ; Visani, L; De Rosa, M		ICOPER	Acute pulmonary embolism: clinical outcomes in the International Cooperative Pulmonary Embolism Registry (ICOPER)	LANCET			English	Article							RANDOMIZED TRIAL; ALTEPLASE; HEPARIN; ECHOCARDIOGRAPHY; RECURRENCE; THERAPY	Background Pulmonary embolism (PE) remains poorly understood. Rates of clinical outcomes such as death and recurrence vary widely among trials. We therefore establish the International Cooperative Pulmonary Embolism Registry (ICOPER), with the aim of identifying factors associated with death. Methods 2454 consecutive eligible patients with acute PE were registered from 52 hospitals in seven countries in Europe and North America. The primary outcome measure was all-cause mortality at 3 months. The prognostic effect of baseline factors on survival was assessed with multivariate analyses, Findings 2110 (86.0%) patients had PE proven by necropsy, high-probability lung scan, pulmonary angiography, or venous ultrasonography plus high clinical suspicion; ICOPER accepted without independent review diagnoses and interpretation of imaging provided by participating centres; 3-month follow-up was completed in 98.0% of patients. The overall crude mortality rate at 3 months was 17.4% (426 of 2454 deaths, including 52 patients lost to follow-up): 179 of 397 (45.1%) deaths were ascribed to PE and 70 of 397 (17.6%) to cancer, and no information on the cause of death was available for 29 patients. After exclusion of 61 patients in whom PE was first discovered at necropsy, the mortality rate at 3 months was 15.3% (365 of 2393 deaths). On multiple-regression modelling, age over 70 years (hazard ratio 1.6 [95% CI 1.1-2.3]), cancer (2.3 [1.5-3.5]), congestive heart failure (2.4 [1.5-3.7]), chronic obstructive pulmonary disease (1.8 [1.2-2.7]), systolic arterial hypotension (2.9 [1.7-5.0]) tachypnoea (2.0 [1.2-3.2]), and right-ventricular hypokinesis on echocardiography (2.0 [1.3-2.9]) were identified as significant prognostic factors. Interpretation PE remains an important clinical problem with a high mortality rate. Data from ICOPER provide rates and highlight adverse prognostic categories that will help in planning of future trials of high-risk PE patients.	Brigham & Womens Hosp, Div Cardiovasc, Boston, MA 02115 USA; Harvard Univ, Sch Med, Boston, MA 02115 USA; Boehringer Ingelheim Italia, Milan, Italy; CINECA, Bologna, Italy	Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School; Boehringer Ingelheim; CINECA, Italy	Goldhaber, SZ (corresponding author), Brigham & Womens Hosp, Div Cardiovasc, 75 Francis St, Boston, MA 02115 USA.							Cannon CP, 1996, AM J CARDIOL, V78, P1149, DOI 10.1016/S0002-9149(96)90069-7; DALLAVOLTA S, 1992, J AM COLL CARDIOL, V20, P520, DOI 10.1016/0735-1097(92)90002-5; GIRARD P, 1987, THORAX, V42, P481, DOI 10.1136/thx.42.7.481; GOLDHABER SZ, 1993, LANCET, V341, P507, DOI 10.1016/0140-6736(93)90274-K; GOLDHABER SZ, 1994, CHEST, V106, P718, DOI 10.1378/chest.106.3.718; HIRSCH DR, 1995, JAMA-J AM MED ASSOC, V274, P335, DOI 10.1001/jama.274.4.335; Hull RD, 1997, ARCH INTERN MED, V157, P2317, DOI 10.1001/archinte.157.20.2317; Kanter DS, 1997, CHEST, V111, P1241, DOI 10.1378/chest.111.5.1241; Kasper W, 1997, J AM COLL CARDIOL, V30, P1165, DOI 10.1016/S0735-1097(97)00319-7; Kasper W, 1997, HEART, V77, P346, DOI 10.1136/hrt.77.4.346; *NAT COOP STUD, 1973, CIRCULATION S2, V47, P1; Ribeiro A, 1997, AM HEART J, V134, P479, DOI 10.1016/S0002-8703(97)70085-1	12	1969	2100	0	43	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	APR 24	1999	353	9162					1386	1389		10.1016/S0140-6736(98)07534-5	http://dx.doi.org/10.1016/S0140-6736(98)07534-5			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	191KD	10227218				2022-12-28	WOS:000080020800010
J	Baar, M				Baar, M			Frederick Baar - Obituary	BRITISH MEDICAL JOURNAL			English	Biographical-Item																			0	0	0	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	MAY 22	1999	318	7195					1423	1423		10.1136/bmj.318.7195.1423	http://dx.doi.org/10.1136/bmj.318.7195.1423			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	200DQ	10334776	Green Published			2022-12-28	WOS:000080524700065
J	Kisely, S				Kisely, S			Psychotherapy for severe personality disorder: exploring the limits of evidence based purchasing	BMJ-BRITISH MEDICAL JOURNAL			English	Article							PARASUICIDAL BORDERLINE PATIENTS; COGNITIVE-BEHAVIORAL TREATMENT		Univ Western Australia, Primary Care Mental Hlth Unit, Fremantle, WA 6160, Australia	University of Western Australia	Kisely, S (corresponding author), Univ Western Australia, Primary Care Mental Hlth Unit, 16 Terrace, Fremantle, WA 6160, Australia.	stephenk@cyllene.uwa.edu.au	Kisely, Steve/B-4680-2012	Kisely, Steve/0000-0003-4021-2924				American Psychiatric Association, 2000, DSM 4 DIAGN STAT MAN, V4th ed., DOI DOI 10.1001/JAMA.1994.03520100096; ANDREWS G, 1991, AUST NZ J PSYCHIAT, V25, P541; [Anonymous], 1991, AUST NZ J PSYCHIAT, V25, P392; BURVILL PW, 1991, AUST NZ J PSYCHIAT, V25, P311, DOI 10.3109/00048679109062630; CARNEY FL, 1974, CRIME DELINQUENCY, V20, P135, DOI 10.1177/001112877402000205; CARNEY FL, 1976, RAGE HATE ASSAULT OT; Coombe P, 1996, AUST NZ J PSYCHIAT, V30, P672, DOI 10.3109/00048679609062664; DAVIES S, 1997, P ANN M ROYAL COLL P, P23; Department of Health and Home Office, 1994, REP DEP HLTH HOM OFF; Dolan B, 1997, BRIT J PSYCHIAT, V171, P274, DOI 10.1192/bjp.171.3.274; DOLAN B, 1994, J FORENSIC PSYCHIATR, V5, P263, DOI 10.1080/09585189408412297; DOLAN B, 1996, PERSPECTIVES HENDERS; DRAKE RE, 1985, AM J PSYCHIAT, V142, P553; Gordon R A, 1977, Bull Am Acad Psychiatry Law, V5, P210; HODGES EF, 1971, AM J PSYCHIAT, V128, P291, DOI 10.1176/ajp.128.3.291; KERNBERG OF, 1989, TREATMENT PERSONALIT; LINEHAN MM, 1994, AM J PSYCHIAT, V151, P1771; LINEHAN MM, 1993, ARCH GEN PSYCHIAT, V50, P971; LINEHAN MM, 1991, ARCH GEN PSYCHIAT, V48, P1060; Marlowe MJ, 1996, BRIT J PSYCHIAT, V168, P72, DOI 10.1192/bjp.168.1.72; *NHS, 1996, NHS PSYCH SERV ENGL; Robins L. N., 1991, PSYCHIAT DISORDERS A, P258; Roth A., 1996, WHAT WORKS WHOM CRIT; Ryle A, 1990, COGNITIVE ANALYTIC T; STONE MH, 1993, BRIT J PSYCHIAT, V162, P299, DOI 10.1192/bjp.162.3.299	25	10	10	0	0	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	MAY 22	1999	318	7195					1410	1412		10.1136/bmj.318.7195.1410	http://dx.doi.org/10.1136/bmj.318.7195.1410			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	200DQ	10334757	Green Published			2022-12-28	WOS:000080524700036
J	Winters, JC; Jorritsma, W; Groenier, KH; Sobel, JS; Meyboom-de Jong, B; Arendzen, HJ				Winters, JC; Jorritsma, W; Groenier, KH; Sobel, JS; Meyboom-de Jong, B; Arendzen, HJ			Treatment of shoulder complaints in general practice: long term results of a randomised, single blind study comparing physiotherapy, manipulation, and corticosteroid injection	BRITISH MEDICAL JOURNAL			English	Article							CLINICAL-TRIALS; DISORDERS		Univ Groningen, Dept Family Practice, NL-9713 AW Groningen, Netherlands; Rehabil Ctr Beatrixoord, Haren, Netherlands	University of Groningen; University of Groningen	Winters, JC (corresponding author), Nieuwe Schoolweg 2A, NL-9756 BB Glimmen, Netherlands.							vanderHeijden GJMG, 1997, BRIT MED J, V315, P25, DOI 10.1136/bmj.315.7099.25; vanderHeijden GJMG, 1996, BRIT J GEN PRACT, V46, P309; vanderWindt DAWM, 1996, BRIT J GEN PRACT, V46, P519; VANDERWINDT DAWM, 1995, J CLIN EPIDEMIOL, V48, P691, DOI 10.1016/0895-4356(94)00170-U; Winters JC, 1997, BRIT MED J, V314, P1320, DOI 10.1136/bmj.314.7090.1320	5	42	42	0	2	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	MAY 22	1999	318	7195					1395	1396		10.1136/bmj.318.7195.1395	http://dx.doi.org/10.1136/bmj.318.7195.1395			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	200DQ	10334751	Green Published, Green Submitted			2022-12-28	WOS:000080524700030
J	[Anonymous]				[Anonymous]			Thorough cancer surgery may make radiation unnecessary	BMJ-BRITISH MEDICAL JOURNAL			English	News Item																		Page DL, 1999, NEW ENGL J MED, V340, P1499, DOI 10.1056/NEJM199905133401909; 1999, NEW ENGLAND J MED, V340, P1455	2	0	0	0	0	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	MAY 22	1999	318	7195					1369	1369						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	200DQ	10334728				2022-12-28	WOS:000080524700006
J	Korones, DN				Korones, DN			Saying good-bye	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material																			0	0	0	0	0	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAY 19	1999	281	19					1778	1778		10.1001/jama.281.19.1778	http://dx.doi.org/10.1001/jama.281.19.1778			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	196BH	10340343				2022-12-28	WOS:000080288800001
J	Nousari, HC; Deterding, R; Wojtczack, H; Aho, S; Uitto, J; Hashimoto, T; Anhalt, GJ				Nousari, HC; Deterding, R; Wojtczack, H; Aho, S; Uitto, J; Hashimoto, T; Anhalt, GJ			The mechanism of respiratory failure in paraneoplastic pemphigus	NEW ENGLAND JOURNAL OF MEDICINE			English	Article; Proceedings Paper	58th Annual Meeting of the Society-for-Investigative-Dermatology	APR 23-27, 1997	WASHINGTON, D.C.	Soc Invest Dermatol			VULGARIS ANTIGEN; BRONCHIOLITIS OBLITERANS; HUMAN AUTOANTIBODIES; NEONATAL MICE; DISEASE; ANTIBODIES; DESMOPLAKINS; INVOLVEMENT; FOLIACEUS		Johns Hopkins Univ, Div Dermatoimmunol, Dept Dermatol, Baltimore, MD 21205 USA; Childrens Hosp, Div Pulm Dis, Denver, CO 80218 USA; Thomas Jefferson Univ, Dept Dermatol & Cutaneous Biol, Philadelphia, PA 19107 USA; Kurume Univ, Dept Dermatol, Fukuoka, Japan	Johns Hopkins University; Children's Hospital Colorado; Jefferson University; Kurume University	Anhalt, GJ (corresponding author), Johns Hopkins Univ, Div Dermatoimmunol, Dept Dermatol, 720 Rutland Ave,Room 771, Baltimore, MD 21205 USA.				NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH [R01DE012354] Funding Source: NIH RePORTER; NIDCR NIH HHS [R01-DE12354] Funding Source: Medline	NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))		AMAGAI M, 1991, CELL, V67, P869, DOI 10.1016/0092-8674(91)90360-B; AMAGAI M, 1994, J CLIN INVEST, V94, P59, DOI 10.1172/JCI117349; Amagai M, 1998, J CLIN INVEST, V102, P775, DOI 10.1172/JCI3647; Amagai M, 1996, J INVEST DERMATOL, V106, P351, DOI 10.1111/1523-1747.ep12343081; Anhalt G J, 1997, Adv Dermatol, V12, P77; ANHALT GJ, 1990, NEW ENGL J MED, V323, P1729, DOI 10.1056/NEJM199012203232503; ANHALT GJ, 1982, NEW ENGL J MED, V306, P1189, DOI 10.1056/NEJM198205203062001; BERG WA, 1993, SOUTHERN MED J, V86, P215, DOI 10.1097/00007611-199302000-00014; BUXTON RS, 1993, J CELL BIOL, V121, P481, DOI 10.1083/jcb.121.3.481; FRANKE WW, 1982, DIFFERENTIATION, V23, P115, DOI 10.1111/j.1432-0436.1982.tb01274.x; FRIED R, 1993, J AM ACAD DERMATOL, V29, P815, DOI 10.1016/0190-9622(93)70244-N; FULLERTON SH, 1992, JAMA-J AM MED ASSOC, V267, P1500; GRANSTEIN RD, 1992, NEW ENGL J MED, V326, P1276; HELOU J, 1995, J AM ACAD DERMATOL, V32, P441, DOI 10.1016/0190-9622(95)90066-7; JORDON RE, 1971, ARCH DERMATOL, V103, P486, DOI 10.1001/archderm.103.5.486; Kim SC, 1998, BRIT J DERMATOL, V138, P667; Kim SC, 1997, J INVEST DERMATOL, V109, P365, DOI 10.1111/1523-1747.ep12336235; KING TE, 1989, LUNG, V167, P69, DOI 10.1007/BF02714935; KIRSNER RS, 1995, BRIT J DERMATOL, V132, P474, DOI 10.1111/j.1365-2133.1995.tb08688.x; KOULU L, 1984, J EXP MED, V160, P1509, DOI 10.1084/jem.160.5.1509; Lee M S, 1995, Australas J Dermatol, V36, P206, DOI 10.1111/j.1440-0960.1995.tb00976.x; Mahoney MG, 1998, J INVEST DERMATOL, V111, P308, DOI 10.1046/j.1523-1747.1998.00279.x; MEYERS SJ, 1992, AM J OPHTHALMOL, V114, P621, DOI 10.1016/S0002-9394(14)74494-0; Osmanski JP, 1997, CHEST, V112, P1704, DOI 10.1378/chest.112.6.1704; OSTEZAN LB, 1995, J AM ACAD DERMATOL, V33, P312, DOI 10.1016/0190-9622(95)90269-4; OURSLER JR, 1992, J CLIN INVEST, V89, P1775, DOI 10.1172/JCI115781; Pizarro A, 1998, HUM PATHOL, V29, P657, DOI 10.1016/S0046-8177(98)80024-5; STANLEY JR, 1984, J CLIN INVEST, V74, P313, DOI 10.1172/JCI111426; Yanase K, 1997, J CLIN INVEST, V100, P25, DOI 10.1172/JCI119517	29	158	173	0	6	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	MAY 6	1999	340	18					1406	1410		10.1056/NEJM199905063401805	http://dx.doi.org/10.1056/NEJM199905063401805			5	Medicine, General & Internal	Conference Proceedings Citation Index - Science (CPCI-S); Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	192QN	10228191	Bronze			2022-12-28	WOS:000080090600005
J	Bobrow, CS; Soothill, PW				Bobrow, CS; Soothill, PW			Fetal growth velocity: a cautionary tale	LANCET			English	Editorial Material							RETARDATION		Univ Bristol, Dept Obstet, St Michaels Hosp, Fetal Med Res Unit, Bristol BS2 8EG, Avon, England	University of Bristol	Bobrow, CS (corresponding author), Univ Bristol, Dept Obstet, St Michaels Hosp, Fetal Med Res Unit, Bristol BS2 8EG, Avon, England.		Soothill, Peter/D-2814-2009					Campbell S., 1993, ULTRASOUND OBSTET GY, P1432; CHARD T, 1993, BRIT J OBSTET GYNAEC, V100, P1076, DOI 10.1111/j.1471-0528.1993.tb15169.x; Gardosi J, 1997, CLIN OBSTET GYNECOL, V40, P715, DOI 10.1097/00003081-199712000-00005; GEIRSSON RT, 1991, BRIT J OBSTET GYNAEC, V98, P108, DOI 10.1111/j.1471-0528.1991.tb10323.x; HECHER K, 1995, CIRCULATION, V91, P129, DOI 10.1161/01.CIR.91.1.129; Jahn A, 1998, ACTA OBSTET GYN SCAN, V77, P643, DOI 10.1034/j.1600-0412.1998.770611.x; Mongelli M, 1998, OBSTET GYNECOL, V92, P908, DOI 10.1016/S0029-7844(98)00349-4; PEARCE JM, 1987, BRIT J OBSTET GYNAEC, V94, P100, DOI 10.1111/j.1471-0528.1987.tb02333.x; SOOTHILL PW, 1995, EUR J OBSTET GYN R B, V59, P21, DOI 10.1016/0028-2243(94)02013-5	9	20	22	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	MAY 1	1999	353	9163					1460	1460		10.1016/S0140-6736(98)00408-5	http://dx.doi.org/10.1016/S0140-6736(98)00408-5			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	195XV	10232308				2022-12-28	WOS:000080278200005
J	Filteau, SM; Tomkins, AM				Filteau, SM; Tomkins, AM			Promoting vitamin A status in low-income countries	LANCET			English	Editorial Material							LEAFY VEGETABLES; DARK-GREEN; A STATUS; CHILDREN; IMPROVEMENT; INDONESIA		Inst Child Hlth, Ctr Int Child Hlth, London WC1 1EH, England	University of London; University College London	Filteau, SM (corresponding author), Inst Child Hlth, Ctr Int Child Hlth, London WC1 1EH, England.							ARROYAVE G, 1981, AM J CLIN NUTR, V34, P41, DOI 10.1093/ajcn/34.1.41; de Pee S, 1998, AM J CLIN NUTR, V68, P1058, DOI 10.1093/ajcn/68.5.1058; de Pee S, 1998, AM J CLIN NUTR, V68, P1068, DOI 10.1093/ajcn/68.5.1068; DEPEE S, 1995, LANCET, V346, P75, DOI 10.1016/S0140-6736(95)92111-7; English RM, 1997, BRIT MED J, V315, P1122, DOI 10.1136/bmj.315.7116.1122; FAWZI WW, 1995, J NUTR, V125, P1211; Hume EM, 1949, 264 MED RES COUNC; Hussain A, 1996, ACTA PAEDIATR, V85, P971, DOI 10.1111/j.1651-2227.1996.tb14196.x; MUHILAL M A, 1988, American Journal of Clinical Nutrition, V48, P1265; SOMMER A, 1996, VITAMIN A DEFICIENCY; West KP, 1999, BMJ-BRIT MED J, V318, P570, DOI 10.1136/bmj.318.7183.570; *WHO UN CHILDR FUN, 1982, CONTR VIT A DEF XER	12	11	12	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	MAY 1	1999	353	9163					1458	1459		10.1016/S0140-6736(98)00391-2	http://dx.doi.org/10.1016/S0140-6736(98)00391-2			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	195XV	10232307				2022-12-28	WOS:000080278200004
J	Lye, M				Lye, M			Rhythm of life and vicissitudes of old age	LANCET			English	Editorial Material							CIRCADIAN-RHYTHMS; PEOPLE		Univ Liverpool, Dept Geriatr Med, Liverpool L69 3GA, Merseyside, England	University of Liverpool	Lye, M (corresponding author), Univ Liverpool, Dept Geriatr Med, Liverpool L69 3GA, Merseyside, England.							ASPLUND R, 1992, Scandinavian Journal of Primary Health Care, V10, P98, DOI 10.3109/02813439209014044; Asplund R, 1998, BRIT J UROL, V82, P642; Bodo G, 1998, SCAND J UROL NEPHROL, V32, P320; Carrier J, 1996, CHRONOBIOL INT, V13, P373, DOI 10.3109/07420529609012661; Friedler E, 1996, BUILD ENVIRON, V31, P385, DOI 10.1016/0360-1323(96)00008-X; JACK CIA, 1995, GERONTOLOGY, V41, P280; Moore RY, 1997, ANNU REV MED, V48, P253, DOI 10.1146/annurev.med.48.1.253; Nyberg L, 1996, J AM GERIATR SOC, V44, P156, DOI 10.1111/j.1532-5415.1996.tb02432.x; Ouslander JG, 1998, J AM GERIATR SOC, V46, P1274, DOI 10.1111/j.1532-5415.1998.tb04545.x; Price JL, 1998, CELL, V94, P83, DOI 10.1016/S0092-8674(00)81224-6; Ralph MR, 1996, SEMIN CELL DEV BIOL, V7, P821, DOI 10.1006/scdb.1996.0100; Reilly T, 1997, OCCUP ENVIRON MED, V54, P812, DOI 10.1136/oem.54.11.812; Rivkees SA, 1997, PEDIATR CLIN N AM, V44, P467, DOI 10.1016/S0031-3955(05)70486-7; ROBERTS W, 1859, EDINBURGH MED J, V5, P817; Rosato E, 1997, BIOESSAYS, V19, P1075, DOI 10.1002/bies.950191206; VISWANATHAN N, 1995, BRAIN RES, V686, P10, DOI 10.1016/0006-8993(95)00423-N; WATERHOUSE JM, 1996, REV CLIN GERONTOL, V6, P11	17	4	5	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	MAY 1	1999	353	9163					1461	1462		10.1016/S0140-6736(98)00367-5	http://dx.doi.org/10.1016/S0140-6736(98)00367-5			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	195XV	10232309				2022-12-28	WOS:000080278200006
J	Takeuchi, JK; Koshiba-Takeuchi, K; Matsumoto, K; Vogel-Hopker, A; Naitoh-Matsuo, M; Ogura, K; Takahashi, N; Yasuda, K; Ogura, T				Takeuchi, JK; Koshiba-Takeuchi, K; Matsumoto, K; Vogel-Hopker, A; Naitoh-Matsuo, M; Ogura, K; Takahashi, N; Yasuda, K; Ogura, T			Tbx5 and Tbx4 genes determine the wing/leg identity of limb buds	NATURE			English	Article							T-BOX GENES; VERTEBRATE LIMB; OPTOMOTOR-BLIND; EXPRESSION; SPECIFICATION; EVOLUTION; INVOLVEMENT; INITIATION; FAMILY; SYSTEM	Much progress has been made in understanding limb development(1-3). Most genes are expressed equally and in the same pattern in the fore- and hindlimbs, which nevertheless develop into distinct structures(3-8). The T-box genes Tbx5 and Tbx4 on the other hand, are expressed differently in chick wing (Tbx5) and leg (Tbx4) buds(9-12). Molecular analysis of the optomotor blind gene(13), which belongs to the same family of transcription factors, has revealed that this gene is involved in the transdetermination of Drosophila wing and leg imaginal discs(14). In addition, expression of Tbx5 and Tbx4 correlates well with the identity of ectopic limb buds induced by fibroblast growth factor(4,5,15-19). Thus, it is thought that Tbx5 and Tbx4 might be involved in determining limb identity. Another candidate is the Pitx1 gene, which encodes a bicoid-type homeodomain transcription factor that is expressed in leg buds(20,21). Here we determine the importance of these factors in establishing limb identity.	Nara Inst Sci & Technol, Grad Sch Biol Sci, Nara 6300101, Japan; Max Planck Inst Brain Res, D-60528 Frankfurt, Germany	Nara Institute of Science & Technology; Max Planck Society	Ogura, T (corresponding author), Nara Inst Sci & Technol, Grad Sch Biol Sci, 8916-5 Takayama, Nara 6300101, Japan.	ogura@bs.aist-nara.ac.jp						Carroll RL, 1997, PATTERNS PROCESSES V; Chapman DL, 1996, DEV DYNAM, V206, P379, DOI 10.1002/(SICI)1097-0177(199608)206:4<379::AID-AJA4>3.0.CO;2-F; Coates MI, 1998, BIOESSAYS, V20, P371, DOI 10.1002/(SICI)1521-1878(199805)20:5<371::AID-BIES4>3.0.CO;2-R; Cohn MJ, 1997, NATURE, V387, P97, DOI 10.1038/387097a0; COHN MJ, 1995, CELL, V80, P739, DOI 10.1016/0092-8674(95)90352-6; Crossley PH, 1996, CELL, V84, P127, DOI 10.1016/S0092-8674(00)80999-X; Gibson-Brown JJ, 1998, DEVELOPMENT, V125, P2499; GibsonBrown JJ, 1996, MECH DEVELOP, V56, P93, DOI 10.1016/0925-4773(96)00514-X; Grimm S, 1996, SCIENCE, V271, P1601, DOI 10.1126/science.271.5255.1601; Isaac A, 1998, DEVELOPMENT, V125, P1867; Johnson RL, 1997, CELL, V90, P979, DOI 10.1016/S0092-8674(00)80364-5; Logan M, 1998, DEVELOPMENT, V125, P2825; MOMOSE T, IN PRESS DEV GROWTH, V41; MOTGAN BA, 1996, METHOD CELL BIOL, V51, P185; Nelson CE, 1996, DEVELOPMENT, V122, P1449; OGURA T, 1995, P NATL ACAD SCI USA, V92, P392, DOI 10.1073/pnas.92.2.392; OGURA T, 1995, P NATL ACAD SCI USA, V92, P387, DOI 10.1073/pnas.92.2.387; Ohuchi H, 1998, DEVELOPMENT, V125, P51; Papaioannou VE, 1998, BIOESSAYS, V20, P9, DOI 10.1002/(SICI)1521-1878(199801)20:1<9::AID-BIES4>3.0.CO;2-Q; PETERSON RL, 1994, MECH DEVELOP, V47, P253, DOI 10.1016/0925-4773(94)90043-4; POECK B, 1993, DEVELOPMENT, V117, P1017; Shang J, 1997, GENOMICS, V40, P108, DOI 10.1006/geno.1996.4558; Shubin N, 1997, NATURE, V388, P639, DOI 10.1038/41710; Smith J, 1997, CURR OPIN GENET DEV, V7, P474, DOI 10.1016/S0959-437X(97)80073-1; STEPHENS TD, 1993, DEV DYNAM, V197, P157, DOI 10.1002/aja.1001970302; STEPHENS TD, 1989, DEV BIOL, V133, P1, DOI 10.1016/0012-1606(89)90290-X; Szeto DP, 1996, P NATL ACAD SCI USA, V93, P7706, DOI 10.1073/pnas.93.15.7706; Vogel A, 1996, DEVELOPMENT, V122, P1737; Wessells NK, 1977, TISSUE INTERACTION D; WILKINSON DG, 1993, IN SITU HYBRIDIZATIO, P75	30	198	207	0	26	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	APR 29	1999	398	6730					810	814		10.1038/19762	http://dx.doi.org/10.1038/19762			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	192BL	10235263				2022-12-28	WOS:000080058100059
J	Cobleigh, MA; Norlock, FE; Oleske, DM; Starr, A				Cobleigh, MA; Norlock, FE; Oleske, DM; Starr, A			Hormone replacement therapy and high S phase in breast cancer	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							DNA FLOW-CYTOMETRY; ESTROGEN-RECEPTOR STATUS; PROGNOSTIC FACTORS; RISK-FACTORS; WOMEN; CARCINOMA; PLOIDY; TUMOR; REGRESSION	Context Prolonged postmenopausal hormone replacement therapy (HRT) is associated with increased incidence of breast cancer and, paradoxically, reduced breast cancer mortality, The biological rationale for this discrepancy has not been explored. Objective To compare the prognostic characteristics of cancers arising in women who have used HRT with those in women who never have used HRT. Design Prospective cohort study from December 1989 to November 1996. Setting Teaching hospital in a large midwestern metropolitan area. Patients Cohort of 331 postmenopausal women who presented consecutively with 349 invasive breast cancers. Main outcome Measures Estrogen receptor (ER) status (ER positive vs ER negative) and S phase (low vs high) for current HRT users vs never users. Results The frequency of high S-phase fraction among cancers in women who were using HRT was markedly increased com pared with that in women who had never used HRT (adjusted odds ratio [OR], 2.82; 95% confidence interval [CI], 1.04-7.66). However, the greater frequency of high S-phase fraction was limited to women with ER-positive cancers (for HRT users vs never Users, OR, 5.25; 95% CI, 1.36-20.28; for ER-negative cancers in HRT users vs never users, OR, 1.08; 95% CI, 0.20-5.86). Conclusions Use of HRT appears to stimulate growth of ER-positive but not ER-negative breast cancer as measured by S-phase fraction. The prognostic significance of high S-phase fraction in current HRT users who have ER-positive tumors is unknown.	Rush Presbyterian St Lukes Med Ctr, Sect Med Oncol, Chicago, IL 60612 USA; Rush Presbyterian St Lukes Med Ctr, Dept Med, Chicago, IL 60612 USA; Rush Presbyterian St Lukes Med Ctr, Dept Prevent Med, Chicago, IL 60612 USA	Rush University; Rush University; Rush University	Cobleigh, MA (corresponding author), Rush Presbyterian St Lukes Med Ctr, Sect Med Oncol, 1725 W Harrison St,Suite 821, Chicago, IL 60612 USA.							BALSLEV I, 1994, INT J CANCER, V56, P16; Beral V, 1997, LANCET, V350, P1047, DOI 10.1016/S0140-6736(97)08233-0; BONNIER P, 1995, OBSTET GYNECOL, V85, P11, DOI 10.1016/0029-7844(94)00324-7; BOSARI S, 1992, CANCER-AM CANCER SOC, V70, P1943, DOI 10.1002/1097-0142(19921001)70:7<1943::AID-CNCR2820700722>3.0.CO;2-Y; CLARK GM, 1989, NEW ENGL J MED, V320, P627, DOI 10.1056/NEJM198903093201003; COBLEIGH MA, 1998, CANC TREAT RES, V94, P210; COLDITZ GA, 1990, JAMA-J AM MED ASSOC, V264, P2648, DOI 10.1001/jama.264.20.2648; COOPER JA, 1989, BRIT J CANCER, V59, P119, DOI 10.1038/bjc.1989.24; DHODAPKAR MV, 1995, CANCER-AM CANCER SOC, V75, P43, DOI 10.1002/1097-0142(19950101)75:1<43::AID-CNCR2820750109>3.0.CO;2-#; EWERS SB, 1992, BREAST CANCER RES TR, V24, P115, DOI 10.1007/BF01961244; FUQUA SAW, 1996, DIS BREAST, P262; Harding C, 1996, BRIT MED J, V312, P1646, DOI 10.1136/bmj.312.7047.1646; Harvey SC, 1996, AM J ROENTGENOL, V167, P394, DOI 10.2214/ajr.167.2.8686614; HILDRETH NG, 1983, J NATL CANCER I, V70, P1027; Holli K, 1998, J CLIN ONCOL, V16, P3115, DOI 10.1200/JCO.1998.16.9.3115; HOSMER DW, 1989, APPL LOGISTIC REGRES; HULKA BS, 1984, AM J EPIDEMIOL, V119, P692, DOI 10.1093/oxfordjournals.aje.a113790; JONES C, 1994, MED J AUSTRALIA, V161, P106, DOI 10.5694/j.1326-5377.1994.tb127340.x; LESSER ML, 1981, CANCER, V48, P299, DOI 10.1002/1097-0142(19810715)48:2<299::AID-CNCR2820480215>3.0.CO;2-2; LIPPMAN M, 1976, CANCER RES, V36, P4595; Magnusson C, 1996, BREAST CANCER RES TR, V38, P325, DOI 10.1007/BF01806152; MERKEL DE, 1993, CANCER, V72, P1926, DOI 10.1002/1097-0142(19930915)72:6<1926::AID-CNCR2820720622>3.0.CO;2-I; MUSS HB, 1989, CANCER, V64, P1894, DOI 10.1002/1097-0142(19891101)64:9<1894::AID-CNCR2820640923>3.0.CO;2-K; OREILLY SM, 1990, J CLIN ONCOL, V8, P2040, DOI 10.1200/JCO.1990.8.12.2040; SIGURDSSON H, 1990, NEW ENGL J MED, V322, P1045, DOI 10.1056/NEJM199004123221505; SQUITIERI R, 1994, J AM COLL SURGEONS, V178, P167; STAL O, 1993, J CLIN ONCOL, V11, P1717, DOI 10.1200/JCO.1993.11.9.1717; STANFORD JL, 1987, AM J EPIDEMIOL, V125, P184, DOI 10.1093/oxfordjournals.aje.a114519; TOIKKANEN S, 1989, BRIT J CANCER, V60, P693, DOI 10.1038/bjc.1989.342; WENGER CR, 1993, BREAST CANCER RES TR, V28, P9, DOI 10.1007/BF00666351; WINCHESTER DJ, 1990, ARCH SURG-CHICAGO, V125, P886; WITZIG TE, 1994, CANCER, V74, P1752, DOI 10.1002/1097-0142(19940915)74:6<1752::AID-CNCR2820740618>3.0.CO;2-5	32	34	35	0	0	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	APR 28	1999	281	16					1528	1530		10.1001/jama.281.16.1528	http://dx.doi.org/10.1001/jama.281.16.1528			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	188PP	10227323				2022-12-28	WOS:000079857400035
J	Van Heest, A; Swiontkowski, M				Van Heest, A; Swiontkowski, M			Bone-graft substitutes	LANCET			English	Article									Univ Minnesota Hosp, Dept Orthopaed Surg, Minneapolis, MN 55455 USA	University of Minnesota System; University of Minnesota Twin Cities; University of Minnesota Hospital	Swiontkowski, M (corresponding author), Univ Minnesota Hosp, Dept Orthopaed Surg, Minneapolis, MN 55455 USA.			Swiontkowski, Marc/0000-0001-7036-1782				Chapman MW, 1997, J BONE JOINT SURG AM, V79A, P495, DOI 10.2106/00004623-199704000-00004; CORNELL CN, 1992, TECH ORTHOP, V7, P55; Goodman SB, 1998, CLIN ORTHOP RELAT R, P42; HUSBAND J, 1997, AM ACAD ORTHOPEDIC S, P403; Karcher HL, 1997, BRIT MED J, V314, P1300; MCGEE P, 1998, ORTHOPAEDICS, V18, P1; URIST MR, 1994, BONE GRAFTS DERIVATI; Younger E M, 1989, J Orthop Trauma, V3, P192, DOI 10.1097/00005131-198909000-00002	8	54	54	1	3	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	APR	1999	353			1			SL28	SL29						2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	192NH	10319931				2022-12-28	WOS:000080084900012
J	Relman, DA				Relman, DA			The search for unrecognized pathogens	SCIENCE			English	Editorial Material							KAPOSIS-SARCOMA; MICROBIAL PATHOGENS; INFECTIOUS AGENTS; WHIPPLES-DISEASE; IDENTIFICATION; HERPESVIRUS; VIEW; BIODIVERSITY; SEQUENCES; ECOSYSTEM	The distribution and diversity of microorganisms in the world are far greater than have been previously appreciated. Molecular, cultivation-independent methods have played a key role in this insight. To what extent do humans remain ignorant of microbial diversity within the human body and the settings in which microorganisms cause human disease? In addition to implicating microbial agents in nontraditional infectious diseases, the use of methods such as broad-range polymerase chain reaction, representational difference analysis, expression Library screening, and host gene expression profiling may force a reassessment of the concepts of microbial disease causation.	Stanford Univ, Dept Microbiol & Immunol, Stanford, CA 94305 USA; VA Palo Alto Hlth Care Syst, Palo Alto, CA 94304 USA	Stanford University; US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Palo Alto Health Care System	Relman, DA (corresponding author), Stanford Univ, Dept Microbiol & Immunol, Stanford, CA 94305 USA.			Relman, David A./0000-0001-8331-1354				AMANN RI, 1995, MICROBIOL REV, V59, P143, DOI 10.1128/MMBR.59.1.143-169.1995; Bachmaier K, 1999, SCIENCE, V283, P1335, DOI 10.1126/science.283.5406.1335; Bais C, 1998, NATURE, V391, P86, DOI 10.1038/34193; Bonner RF, 1997, SCIENCE, V278, P1481, DOI 10.1126/science.278.5342.1481; Boshoff C, 1997, SCIENCE, V278, P290, DOI 10.1126/science.278.5336.290; Brown PO, 1998, NAT GENET, V18, P91, DOI 10.1038/ng0298-91; CHANG Y, 1994, SCIENCE, V266, P1865, DOI 10.1126/science.7997879; CHOO QL, 1989, SCIENCE, V244, P359, DOI 10.1126/science.2523562; Costerton JW, 1999, SCIENCE, V284, P1318, DOI 10.1126/science.284.5418.1318; Covacci A, 1999, SCIENCE, V284, P1328, DOI 10.1126/science.284.5418.1328; Eisen MB, 1998, P NATL ACAD SCI USA, V95, P14863, DOI 10.1073/pnas.95.25.14863; Falk PG, 1998, MICROBIOL MOL BIOL R, V62, P1157, DOI 10.1128/MMBR.62.4.1157-1170.1998; Fiocchi C, 1998, GASTROENTEROLOGY, V115, P182, DOI 10.1016/S0016-5085(98)70381-6; Fredricks DN, 1996, CLIN MICROBIOL REV, V9, P18, DOI 10.1128/CMR.9.1.18; Fredricks DN, 1998, CURR CLIN TOPICS INF, V18, P180; Gabay C, 1999, NEW ENGL J MED, V340, P448, DOI 10.1056/NEJM199902113400607; Gao SJ, 1996, EMERG INFECT DIS, V2, P159, DOI 10.3201/eid0203.960301; Hahn AF, 1998, LANCET, V352, P635, DOI 10.1016/S0140-6736(97)12308-X; Hoerauf A, 1999, J CLIN INVEST, V103, P11, DOI 10.1172/JCI4768; Hoffmann JA, 1999, SCIENCE, V284, P1313, DOI 10.1126/science.284.5418.1313; Hugenholtz P, 1998, J BACTERIOL, V180, P4765, DOI 10.1128/JB.180.18.4765-4774.1998; Iyer VR, 1999, SCIENCE, V283, P83, DOI 10.1126/science.283.5398.83; KOLENBRANDER PE, 1993, J BACTERIOL, V175, P3247, DOI 10.1128/jb.175.11.3247-3252.1993; LISITSYN N, 1993, SCIENCE, V259, P946, DOI 10.1126/science.8438152; Lower R, 1996, P NATL ACAD SCI USA, V93, P5177, DOI 10.1073/pnas.93.11.5177; MARSHALL BJ, 1995, JAMA-J AM MED ASSOC, V274, P1064, DOI 10.1001/jama.274.13.1064; MARSHALL BJ, 1984, LANCET, V1, P1311; Moore PS, 1998, AM J EPIDEMIOL, V147, P217, DOI 10.1093/oxfordjournals.aje.a009440; Moore PS, 1996, SCIENCE, V274, P1739, DOI 10.1126/science.274.5293.1739; Naeem S, 1997, NATURE, V390, P507, DOI 10.1038/37348; NICHOL ST, 1993, SCIENCE, V262, P914, DOI 10.1126/science.8235615; Pace NR, 1997, SCIENCE, V276, P734, DOI 10.1126/science.276.5313.734; Perkins BK, 1996, EMERG INFECT DIS, V2, P47, DOI 10.3201/eid0201.960106; Relman DA, 1998, EMERG INFECT DIS, V4, P382, DOI 10.3201/eid0403.980310; RELMAN DA, 1992, NEW ENGL J MED, V327, P293, DOI 10.1056/NEJM199207303270501; RELMAN DA, 1990, NEW ENGL J MED, V323, P1573, DOI 10.1056/NEJM199012063232301; Schena M, 1998, TRENDS BIOTECHNOL, V16, P301, DOI 10.1016/S0167-7799(98)01219-0; Ward DM, 1998, MICROBIOL MOL BIOL R, V62, P1353, DOI 10.1128/MMBR.62.4.1353-1370.1998; WILSON KH, 1991, LANCET, V338, P474, DOI 10.1016/0140-6736(91)90545-Z; Wilson M, 1998, INFECT IMMUN, V66, P2401, DOI 10.1128/IAI.66.6.2401-2409.1998; Woese C, 1998, P NATL ACAD SCI USA, V95, P6854, DOI 10.1073/pnas.95.12.6854; WOESE CR, 1990, P NATL ACAD SCI USA, V87, P4576, DOI 10.1073/pnas.87.12.4576	42	154	168	0	6	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	MAY 21	1999	284	5418					1308	1310		10.1126/science.284.5418.1308	http://dx.doi.org/10.1126/science.284.5418.1308			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	198NN	10334977	Green Submitted			2022-12-28	WOS:000080430600040
J	Greider, CW				Greider, CW			Telomeres do d-loop-t-loop	CELL			English	Review							DNA-BINDING PROTEIN; TETRAHYMENA; SEQUENCE; OXYTRICHA; TERMINUS; RNA		Johns Hopkins Univ, Sch Med, Dept Mol Biol & Genet, Baltimore, MD 21205 USA	Johns Hopkins University	Greider, CW (corresponding author), Johns Hopkins Univ, Sch Med, Dept Mol Biol & Genet, Baltimore, MD 21205 USA.			Greider, Carol/0000-0002-5494-8126				BLACKBURN EH, 1978, J MOL BIOL, V120, P33, DOI 10.1016/0022-2836(78)90294-2; CARDENAS ME, 1993, GENE DEV, V7, P883, DOI 10.1101/gad.7.5.883; DELANGE T, 1995, TELOMERES, P265; FANG G, 1995, TELOMERES, P69; Froelich-Ammon SJ, 1998, GENE DEV, V12, P1504, DOI 10.1101/gad.12.10.1504; Gall J. G., 1995, TELOMERES, P1; GARVIK B, 1995, MOL CELL BIOL, V15, P6128; GOTTSCHLING DE, 1986, CELL, V47, P195, DOI 10.1016/0092-8674(86)90442-3; Gravel S, 1998, SCIENCE, V280, P741, DOI 10.1126/science.280.5364.741; GREIDER CW, 1985, CELL, V43, P405, DOI 10.1016/0092-8674(85)90170-9; Griffith JD, 1999, CELL, V97, P503, DOI 10.1016/S0092-8674(00)80760-6; Horvath MP, 1998, CELL, V95, P963, DOI 10.1016/S0092-8674(00)81720-1; HOWARD MT, 1991, J MOL BIOL, V217, P53, DOI 10.1016/0022-2836(91)90610-I; Karlseder J, 1999, SCIENCE, V283, P1321, DOI 10.1126/science.283.5406.1321; KLOBUTCHER LA, 1981, P NATL ACAD SCI-BIOL, V78, P3015, DOI 10.1073/pnas.78.5.3015; KRUGER K, 1982, CELL, V31, P147, DOI 10.1016/0092-8674(82)90414-7; Lin JJ, 1996, P NATL ACAD SCI USA, V93, P13760, DOI 10.1073/pnas.93.24.13760; Nugent CI, 1996, SCIENCE, V274, P249, DOI 10.1126/science.274.5285.249; Shore D, 1997, TRENDS BIOCHEM SCI, V22, P233, DOI 10.1016/S0968-0004(97)01082-7; van Steensel B, 1998, CELL, V92, P401, DOI 10.1016/S0092-8674(00)80932-0	20	162	166	0	19	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	MAY 14	1999	97	4					419	422		10.1016/S0092-8674(00)80750-3	http://dx.doi.org/10.1016/S0092-8674(00)80750-3			4	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	196FV	10338204	hybrid			2022-12-28	WOS:000080299100001
J	Zuhlke, RD; Pitt, GS; Deisseroth, K; Tsien, RW; Reuter, H				Zuhlke, RD; Pitt, GS; Deisseroth, K; Tsien, RW; Reuter, H			Calmodulin supports both inactivation and facilitation of L-type calcium channels	NATURE			English	Article							CA2+ CHANNELS; CA2+-SENSITIVE INACTIVATION; ALPHA(1C) SUBUNIT; DEPENDENT INACTIVATION; INHIBITION; VOLTAGE; CELLS; MOTIF; MODULATION; MECHANISM	L-type Ca2+ channels support Ca2+ entry into cells, which triggers cardiac contraction(1), controls hormone secretion from endocrine cells(2) and initiates transcriptional events that support learning and memory(3). These channels are examples of molecular signal-transduction units that regulate themselves through their own activity. Among the many types of voltage-gated Ca2+ channel, L-type Ca2+ channels particularly display inactivation and facilitation, both of which are closely linked to the earlier entry of Ca2+ ions(4-10). Both forms of autoregulation have a significant impact on the amount of Ca2+ that enters the cell during repetitive activity, with major consequences downstream. Despite extensive biophysical analysis(9), the molecular basis of autoregulation remains unclear, although a putative Ca2+-binding EF-hand motif(11,12) and a nearby consensus calmodulin-binding isoleucine-glutamine ('IQ') motif(13,14) in the carboxy terminus of the alpha(1C) channel subunit have been implicated(12,14-16). Here we show that calmodulin is a critical Ca2+ sensor for both inactivation and facilitation, and that the nature of the modulatory effect depends on residues within the IQ motif important for calmodulin binding. Replacement of the native isoleucine by alanine removed Ca2+-dependent inactivation and unmasked a strong facilitation; conversion of the same residue to glutamate eliminated both forms of autoregulation. These results indicate that the same calmodulin molecule may act as a Ca2+ sensor for both positive and negative modulation.	Univ Bern, Dept Pharmacol, CH-3010 Bern, Switzerland; Stanford Univ, Sch Med, Div Cardiovasc Med, Stanford, CA 94305 USA; Stanford Univ, Sch Med, Dept Mol & Cellular Physiol, Stanford, CA 94305 USA	University of Bern; Stanford University; Stanford University	Reuter, H (corresponding author), Univ Bern, Dept Pharmacol, CH-3010 Bern, Switzerland.		Tuluc, Petronel/C-2527-2011; Pitt, Geoffrey/L-4927-2019					ARTALEJO CR, 1994, NATURE, V367, P72, DOI 10.1038/367072a0; BABITCH J, 1990, NATURE, V346, P321, DOI 10.1038/346321b0; Bernatchez G, 1998, BIOPHYS J, V75, P1727, DOI 10.1016/S0006-3495(98)77614-3; BERS DM, 1991, EXCITATION CONTRACTI; DELEON M, 1995, SCIENCE, V270, P1502, DOI 10.1126/science.270.5241.1502; ECKERT R, 1984, PROG BIOPHYS MOL BIO, V44, P215, DOI 10.1016/0079-6107(84)90009-9; GURNEY AM, 1989, NATURE, V341, P65, DOI 10.1038/341065a0; HAACK JA, 1994, BIOPHYS J, V66, P1051, DOI 10.1016/S0006-3495(94)80886-0; HESS P, 1986, J GEN PHYSIOL, V88, P293, DOI 10.1085/jgp.88.3.293; Hofer GF, 1997, BIOPHYS J, V73, P1857, DOI 10.1016/S0006-3495(97)78216-X; IMREDY JP, 1994, NEURON, V12, P1301, DOI 10.1016/0896-6273(94)90446-4; KINCAID RL, 1982, J BIOL CHEM, V257, P638; LIU MY, 1994, SCIENCE, V266, P1348, DOI 10.1126/science.266.5189.1348; MCDONALD TF, 1994, PHYSIOL REV, V74, P365, DOI 10.1152/physrev.1994.74.2.365; MURPHY TH, 1991, NEURON, V7, P625, DOI 10.1016/0896-6273(91)90375-A; NOBLE S, 1981, J PHYSIOL-LONDON, V310, P57, DOI 10.1113/jphysiol.1981.sp013537; Rhoads AR, 1997, FASEB J, V11, P331, DOI 10.1096/fasebj.11.5.9141499; RUTH P, 1989, SCIENCE, V245, P1115, DOI 10.1126/science.2549640; SINGER D, 1991, SCIENCE, V253, P1553, DOI 10.1126/science.1716787; SOLDATOV NM, 1992, P NATL ACAD SCI USA, V89, P4628, DOI 10.1073/pnas.89.10.4628; SOLDATOV NM, 1995, J BIOL CHEM, V270, P10540, DOI 10.1074/jbc.270.18.10540; Soldatov NM, 1997, J BIOL CHEM, V272, P3560, DOI 10.1074/jbc.272.6.3560; VORHERR T, 1990, BIOCHEMISTRY-US, V29, P355, DOI 10.1021/bi00454a008; Xia XM, 1998, NATURE, V395, P503, DOI 10.1038/26758; Zhang S, 1998, NEURON, V21, P443, DOI 10.1016/S0896-6273(00)80553-X; Zhou JM, 1997, P NATL ACAD SCI USA, V94, P2301, DOI 10.1073/pnas.94.6.2301; Zuhlke RD, 1998, P NATL ACAD SCI USA, V95, P3287, DOI 10.1073/pnas.95.6.3287; Zuhlke RD, 1998, FEBS LETT, V427, P220, DOI 10.1016/S0014-5793(98)00425-6; ZYGMUNT AC, 1990, J PHYSIOL-LONDON, V428, P653, DOI 10.1113/jphysiol.1990.sp018233	29	690	708	0	30	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	MAY 13	1999	399	6732					159	162		10.1038/20200	http://dx.doi.org/10.1038/20200			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	196XU	10335846				2022-12-28	WOS:000080335700052
J	Lu, QX; Gore, M; Zhang, Q; Camenisch, T; Boast, S; Casagranda, F; Lai, C; Skinner, MK; Klein, R; Matsushima, GK; Earp, HS; Goff, SP; Lemke, G				Lu, QX; Gore, M; Zhang, Q; Camenisch, T; Boast, S; Casagranda, F; Lai, C; Skinner, MK; Klein, R; Matsushima, GK; Earp, HS; Goff, SP; Lemke, G			Tyro-3 family receptors are essential regulators of mammalian spermatogenesis	NATURE			English	Article							TYROSINE KINASE RECEPTOR; PROTEIN-S; GENOMIC STRUCTURE; SERTOLI CELLS; GAS6; IDENTIFICATION; EXPRESSION; GROWTH; MER; AXL	We have generated and analysed null mutations in the mouse genes encoding three structurally related receptors with tyrosine kinase activity: Tyro 3, Axl, and Mer(1-4). Mice lacking any single receptor, or any combination of two receptors, are viable and fertile, but male animals that lack all three receptors produce no mature sperm, owing to the progressive death of differentiating germ cells. This degenerative phenotype appears to result from a failure of the tropic support that is normally provided by Sertoli cells of thc seminiferous tubules, whose function depends on testosterone and additional factors produced by Leydig cells(5-7). Tyro 3, Axl and Mer are all normally expressed by Sertoli cells during postnatal development, whereas their ligands, Gas6 and protein S, are produced by Leydig cells before sexual maturity, and by both Leydig and Sertoli cells thereafter. Here we show that the concerted activation of Tyro 3, Axl and Mer in Sertoli cells is critical to the role that these cells play as nurturers of developing germ cells. Additional observations indicate that these receptors may also be essential for the tropic maintenance of diverse cell types in the mature nervous, immune and reproductive systems.	Salk Inst Biol Studies, Mol Neurobiol Lab, La Jolla, CA 92037 USA; Columbia Univ, Coll Phys & Surg, Howard Hughes Med Inst, New York, NY 10032 USA; Columbia Univ, Coll Phys & Surg, Dept Biochem & Mol Biophys, New York, NY 10032 USA; Univ N Carolina, Ctr Neurosci, Chapel Hill, NC 27599 USA; Univ N Carolina, Dept Microbiol & Immunol, Chapel Hill, NC 27599 USA; Univ N Carolina, Lineberger Comprehens Canc Ctr, Chapel Hill, NC 27599 USA; European Mol Biol Lab, Dev Biol Programme, D-69117 Heidelberg, Germany; Scripps Res Inst, Dept Neuropharmacol, La Jolla, CA 92037 USA; Washington State Univ, Ctr Reprod Biol, Dept Genet & Cell Biol, Pullman, WA 99164 USA	Salk Institute; Columbia University; Howard Hughes Medical Institute; Columbia University; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill; European Molecular Biology Laboratory (EMBL); Scripps Research Institute; Washington State University	Lemke, G (corresponding author), Salk Inst Biol Studies, Mol Neurobiol Lab, La Jolla, CA 92037 USA.		Klein, Ruediger/C-6147-2008; Goff, Stephen P/K-6337-2014	Klein, Ruediger/0000-0002-3109-0163; Goff, Stephen P/0000-0003-0693-5547; Camenisch, Todd/0000-0002-7797-9822				Bellosta P, 1997, ONCOGENE, V15, P2387, DOI 10.1038/sj.onc.1201419; BIESECKER LG, 1995, ONCOGENE, V10, P2239; Camenisch TD, 1999, J IMMUNOL, V162, P3498; CAPECCHI MR, 1989, SCIENCE, V244, P1288, DOI 10.1126/science.2660260; Chen J, 1997, ONCOGENE, V14, P2033, DOI 10.1038/sj.onc.1201039; Crosier KE, 1997, PATHOLOGY, V29, P131, DOI 10.1080/00313029700169744; GODOWSKI PJ, 1995, CELL, V82, P355, DOI 10.1016/0092-8674(95)90424-7; GRAHAM DK, 1994, CELL GROWTH DIFFER, V5, P647; GRISWOLD MD, 1995, BIOL REPROD, V52, P211, DOI 10.1095/biolreprod52.2.211; HENRIKSEN K, 1995, ENDOCRINOLOGY, V136, P3285, DOI 10.1210/en.136.8.3285; JANSSEN JWG, 1991, ONCOGENE, V6, P2113; JIA R, 1994, J BIOL CHEM, V269, P1839; Joseph DR, 1997, STEROIDS, V62, P578, DOI 10.1016/S0039-128X(97)00045-7; LAI C, 1994, ONCOGENE, V9, P2567; LAI C, 1991, NEURON, V6, P691, DOI 10.1016/0896-6273(91)90167-X; LEBLOND CP, 1952, ANN NY ACAD SCI, V55, P548, DOI 10.1111/j.1749-6632.1952.tb26576.x; Lewis PM, 1996, GENOMICS, V31, P13, DOI 10.1006/geno.1996.0003; MARK MR, 1994, J BIOL CHEM, V269, P10720; Nagata K, 1996, J BIOL CHEM, V271, P30022, DOI 10.1074/jbc.271.47.30022; OBRYAN JP, 1991, MOL CELL BIOL, V11, P5016, DOI 10.1128/MCB.11.10.5016; RESCIGNO J, 1991, ONCOGENE, V6, P1909; SCHULZ AS, 1993, ONCOGENE, V8, P509; SKINNER MK, 1991, ENDOCR REV, V12, P45, DOI 10.1210/edrv-12-1-45; SKINNER MK, 1993, SERTOLI CELL, P237; Smiley ST, 1997, CELL IMMUNOL, V181, P120, DOI 10.1006/cimm.1997.1210; STITT TN, 1995, CELL, V80, P661, DOI 10.1016/0092-8674(95)90520-0; SUN YT, 1990, ENDOCRINOLOGY, V127, P1215, DOI 10.1210/endo-127-3-1215; TAYLOR ICA, 1995, J BIOL CHEM, V270, P6872, DOI 10.1074/jbc.270.12.6872; WONG V, 1983, AM J ANAT, V167, P143, DOI 10.1002/aja.1001670202; YOMOGIDA K, 1994, DEVELOPMENT, V120, P1759	30	368	390	1	12	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	APR 22	1999	398	6729					723	728		10.1038/19554	http://dx.doi.org/10.1038/19554			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	189RP	10227296				2022-12-28	WOS:000079920100054
J	Bowen, JR; Gibson, FL; Leslie, GI; Saunders, DM				Bowen, JR; Gibson, FL; Leslie, GI; Saunders, DM			Medical and developmental outcome at 1 year for children conceived by intracytoplasmic sperm injection	LANCET			English	Article							IN-VITRO FERTILIZATION; FOLLOW-UP; INVITRO FERTILIZATION; CHROMOSOME-ABNORMALITIES; PREGNANCIES; BORN; INSEMINATION; GROWTH	Background Intracytoplasmic sperm injection (ICSI) was introduced as a new form of in-vitro fertilisation (IVF) in 1993 and is now accepted as the treatment of choice for severe male infertility in many centres around the world. However, there is little information about the long-term outcome of children conceived by ICSI, We aimed to find out the medical and developmental outcome of children conceived by ICSI at age 1 year. Methods In this prospective study, we compared the medical and developmental outcome at 1 year of 89 children conceived by ICSI with 84 children conceived by routine IVF, and with 80 children conceived naturally. Formal developmental assessment was done with Bayley Scales of Infant Development (2nd edition) from which a mental development index (MDI) was derived. Findings There was no significant difference in the incidence of major congenital malformations or major health problems in the first year of life. However, the mean Bayley MDI was significantly lower for the children conceived by ICSI than for the children conceived by routine IVF or naturally (95.9 [SD 10.7], 101.8 [8.5], and 102.5 [7.6], respectively, p<0.0001). 15 (17%) of 89 children conceived by ICSI experienced mildly or significantly delayed development (MDI<85) at 1 year compared with two (2%) of the 84 children conceived by IVF and one (1%) of the 80 children conceived by natural conception (p<0.0001). Interpretation Although most children conceived by ICSI are healthy and develop normally, there is an increased risk of mild delays in development at 1 year when compared with children conceived by routine IVF or conceived naturally. These findings support the need for ongoing developmental follow-up of children conceived by ICSI to see whether they are at increased risk of intellectual impairment or learning difficulties at school age.	Royal N Shore Hosp, Dept Neonatol, St Leonards, NSW 2065, Australia; Royal N Shore Hosp, Dept Obstet & Gynaecol, St Leonards, NSW 2065, Australia; Univ Sydney, Dept Obstet & Gynaecol, Sydney, NSW 2006, Australia; Univ Sydney, Dept Paediat, Sydney, NSW 2006, Australia; Univ Sydney, Dept Med, Sydney, NSW 2006, Australia	Royal North Shore Hospital; Royal North Shore Hospital; University of Sydney; University of Sydney; University of Sydney	Bowen, JR (corresponding author), Royal N Shore Hosp, Dept Neonatol, St Leonards, NSW 2065, Australia.							Bayley N, 1993, BAYLEY SCALES INFANT; BONDUELLE M, 1994, HUM REPROD, V9, P1765, DOI 10.1093/oxfordjournals.humrep.a138791; Bonduelle M, 1995, HUM REPROD, V10, P3327, DOI 10.1093/oxfordjournals.humrep.a135914; Bonduelle M, 1996, HUM REPROD, V11, P1558; Bowen JR, 1996, J PAEDIATR CHILD H, V32, P25, DOI 10.1111/j.1440-1754.1996.tb01536.x; BRANDES JM, 1992, PEDIATRICS, V90, P424; CATT JW, 1995, REPROD FERT DEVELOP, V7, P255, DOI 10.1071/RD9950255; DEBRAEKELEER M, 1991, HUM REPROD, V6, P245, DOI 10.1093/oxfordjournals.humrep.a137315; deKretser DM, 1997, LANCET, V349, P787, DOI 10.1016/S0140-6736(96)08341-9; GIBSON F, 1996, P AM SOC REPR MED 52, P146; GIBSON F, 1998, IN PRESS HUMAN REPRO; JACOBS PA, 1992, J MED GENET, V29, P103, DOI 10.1136/jmg.29.2.103; KARLBERG P, 1968, ACTA PAEDIATR SCAND, VS, P48; Kurinczuk JJ, 1997, BRIT MED J, V315, P1260, DOI 10.1136/bmj.315.7118.1260; Lancaster P, 1997, ASSISTED CONCEPTION; LATHAM KE, 1995, INT REV CYTOL, V160, P53, DOI 10.1016/S0074-7696(08)61553-3; Liebaers I, 1995, FERTILITY AND STERILITY, P409; LIEBAERS I, 1995, LANCET, V346, P1095, DOI 10.1016/S0140-6736(95)91768-3; MCCALL RB, 1979, HDB INFANT DEV; McMahon CA, 1997, HUM REPROD, V12, P176, DOI 10.1093/humrep/12.1.176; Meschede D, 1995, HUM REPROD, V10, P2880, DOI 10.1093/oxfordjournals.humrep.a135812; MORIN NC, 1989, J PEDIATR-US, V115, P222, DOI 10.1016/S0022-3476(89)80069-1; Olivennes F, 1997, FERTIL STERIL, V67, P284, DOI 10.1016/S0015-0282(97)81912-7; PALERMO G, 1992, LANCET, V340, P17, DOI 10.1016/0140-6736(92)92425-F; Palermo GD, 1996, JAMA-J AM MED ASSOC, V276, P1893, DOI 10.1001/jama.276.23.1893; Pryor JL, 1997, NEW ENGL J MED, V336, P534, DOI 10.1056/NEJM199702203360802; SAUNDERS DM, 1989, AM J PERINAT, V6, P252, DOI 10.1055/s-2007-999587; Saunders K, 1996, PEDIATRICS, V97, P688; Slater A, 1997, ARCH DIS CHILD, V77, P474, DOI 10.1136/adc.77.6.474; SPENSLEY JC, 1986, AUST PAEDIATR J, V22, P285; *US PH HLTH RES AD, 1976, NCHS GROWTH CHARTS; VANSTEIRTEGHEM AC, 1993, HUM REPROD, V8, P1055, DOI 10.1093/oxfordjournals.humrep.a138191; Veld PAI, 1997, LANCET, V350, P490, DOI 10.1016/S0140-6736(05)63078-4; VELD PI, 1995, LANCET, V346, P773, DOI 10.1016/S0140-6736(95)91531-1; Wennerholm UB, 1996, HUM REPROD, V11, P1113	35	252	259	0	15	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	MAY 23	1998	351	9115					1529	1534		10.1016/S0140-6736(98)10168-X	http://dx.doi.org/10.1016/S0140-6736(98)10168-X			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZQ497	10326534				2022-12-28	WOS:000073868000007
J	Harding, R				Harding, R			Thirty one years on - A memorable patient	BRITISH MEDICAL JOURNAL			English	Article																			0	0	0	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	MAY 15	1999	318	7194					1327	1327		10.1136/bmj.318.7194.1327	http://dx.doi.org/10.1136/bmj.318.7194.1327			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	198HR	10323821	Green Published			2022-12-28	WOS:000080418400029
J	Holmes, R				Holmes, R			Obituaries - Henry Taylor Howatt	BRITISH MEDICAL JOURNAL			English	Biographical-Item																		HOWATT HT, PUBLICATION LIST	1	2	2	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	MAY 8	1999	318	7193					1292	1292						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	195XT	10231284				2022-12-28	WOS:000080278000060
J	Michaud, DS; Spiegelman, D; Clinton, SK; Rimm, EB; Curhan, GC; Willett, WC; Giovannucci, EL				Michaud, DS; Spiegelman, D; Clinton, SK; Rimm, EB; Curhan, GC; Willett, WC; Giovannucci, EL			Fluid intake and the risk of bladder cancer in men	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							FOOD FREQUENCY QUESTIONNAIRE; ALCOHOLIC BEVERAGE CONSUMPTION; CHLORINATION BY-PRODUCTS; DRINKING-WATER SOURCE; LOWER URINARY-TRACT; WASHINGTON COUNTY; COFFEE-DRINKING; DIETARY FACTORS; KIDNEY-STONES; LIFE-STYLE	Background Studies in animals have shown that the frequency of urination is inversely associated with the level of potential carcinogens in the urothelium. In humans, an increase in total fluid intake may reduce contact time between carcinogens and urothelium by diluting urinary metabolites and increasing the frequency of voiding. The data on fluid intake in relation to the risk of bladder cancer are inconclusive. Methods We examined the relation between total Fluid intake and the risk of bladder cancer over a period of 10 years among 47,909 participants in the prospective Health Professionals Follow-up Study. There were 252 newly diagnosed cases of bladder cancer during the follow-up period, information on total fluid intake was derived from the reported frequency of consumption of the 22 types of beverages on the food-frequency questionnaire, which was completed by each of the 47,909 participants who were free of cancer in 1986. Logistic-regression analyses were performed to adjust for known and suspected risk factors for bladder cancer. Results Total daily fluid intake was inversely associated with the risk of bladder cancer; the multivariate relative risk was 0.51 (95 percent confidence interval, 0.32 to 0.80) for the highest quintile of total daily fluid intake (>2531 mi per day) as compared with the lowest quintile (<1290 mi per day). The consumption of water contributed to a lower risk (relative risk, 0.49 [95 percent confidence interval, 0.28 to 0.86] for greater than or equal to 1440 mi [6 cups] per day vs. <240 mi [1 cup] per day), as did the consumption of other fluids (relative risk, 0.63 [95 percent confidence interval, 0.39 to 0.99] for >1831 mi per day vs. <735 mi per day). Conclusions A high fluid intake is associated with a decreased risk of bladder cancer in men. (N Engl J Med 1999;340:1390-7.) (C) 1999, Massachusetts Medical Society.	Harvard Univ, Sch Publ Hlth, Dept Nutr, Boston, MA 02115 USA; Harvard Univ, Sch Publ Hlth, Dept Epidemiol, Boston, MA 02115 USA; Harvard Univ, Sch Publ Hlth, Dept Biostat, Boston, MA 02115 USA; Harvard Univ, Sch Med, Channing Lab, Dept Med, Boston, MA 02115 USA; Brigham & Womens Hosp, Boston, MA 02115 USA; Ohio State Univ, Arthur G James Canc Hosp & Res Inst, Columbus, OH 43210 USA	Harvard University; Harvard T.H. Chan School of Public Health; Harvard University; Harvard T.H. Chan School of Public Health; Harvard University; Harvard T.H. Chan School of Public Health; Harvard University; Harvard Medical School; Harvard University; Brigham & Women's Hospital; James Cancer Hospital & Solove Research Institute; University System of Ohio; Ohio State University	Michaud, DS (corresponding author), Harvard Univ, Sch Publ Hlth, Dept Nutr, 665 Huntington Ave, Boston, MA 02115 USA.		Michaud, Dominique S/I-5231-2014		NCI NIH HHS [CA 55075] Funding Source: Medline; NHLBI NIH HHS [HL 35464] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA055075] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL035464] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		*AM I CANC RES, 1997, WORLD CANC RES FUND, P338; BRAVER DJ, 1987, J NATL CANCER I, V78, P437; BROWNSON RC, 1987, AM J PUBLIC HEALTH, V77, P1298, DOI 10.2105/AJPH.77.10.1298; CANTOR KP, 1987, J NATL CANCER I, V79, P1269; Cantor KP, 1998, EPIDEMIOLOGY, V9, P21, DOI 10.1097/00001648-199801000-00007; Chyou P H, 1993, Ann Epidemiol, V3, P211; CLAUDE J, 1986, AM J EPIDEMIOL, V124, P578, DOI 10.1093/oxfordjournals.aje.a114430; Curhan GC, 1996, AM J EPIDEMIOL, V143, P240, DOI 10.1093/oxfordjournals.aje.a008734; DAGOSTINO RB, 1990, STAT MED, V9, P1501, DOI 10.1002/sim.4780091214; *DEP AGR, 1995, USDA NUTR DAT STAND; DUNHAM LJ, 1968, J NATL CANCER I, V41, P683; DURRLEMAN S, 1989, STAT MED, V8, P551, DOI 10.1002/sim.4780080504; FESKANICH D, 1993, J AM DIET ASSOC, V93, P790, DOI 10.1016/0002-8223(93)91754-E; Freedman DM, 1997, CANCER CAUSE CONTROL, V8, P738, DOI 10.1023/A:1018431421567; GIOVANNUCCI E, 1991, AM J EPIDEMIOL, V133, P810; HOWE GR, 1980, JNCI-J NATL CANCER I, V64, P701; JENSEN OM, 1986, INT J CANCER, V37, P651, DOI 10.1002/ijc.2910370503; KADLUBAR FF, 1991, CANCER RES, V51, P4371; King WD, 1996, CANCER CAUSE CONTROL, V7, P596, DOI 10.1007/BF00051702; KUNZE E, 1992, CANCER-AM CANCER SOC, V69, P1776, DOI 10.1002/1097-0142(19920401)69:7<1776::AID-CNCR2820690721>3.0.CO;2-P; LAVECCHIA C, 1989, NUTR CANCER, V12, P93, DOI 10.1080/01635588909514006; LONGNECKER MP, 1994, CANCER CAUSE CONTROL, V5, P73, DOI 10.1007/BF01830729; MCGEEHIN MA, 1993, AM J EPIDEMIOL, V138, P492, DOI 10.1093/oxfordjournals.aje.a116883; MILLS PK, 1991, AM J EPIDEMIOL, V133, P230, DOI 10.1093/oxfordjournals.aje.a115867; MORRISON AS, 1982, JNCI-J NATL CANCER I, V68, P91; Pak CYC, 1998, LANCET, V351, P1797, DOI 10.1016/S0140-6736(98)01295-1; RIES LAG, 1997, NIH PUBLICATION; RIMM EB, 1992, AM J EPIDEMIOL, V135, P1114, DOI 10.1093/oxfordjournals.aje.a116211; RISCH HA, 1988, AM J EPIDEMIOL, V127, P1179, DOI 10.1093/oxfordjournals.aje.a114911; ROHERTSON GL, 1992, KIDNEY PHYSL PATHOPH, V2, P1595; Rothman N, 1997, CANCER EPIDEM BIOMAR, V6, P1039; Schilter B, 1996, CARCINOGENESIS, V17, P2377, DOI 10.1093/carcin/17.11.2377; SILVERMAN DT, 1992, HEMATOL ONCOL CLIN N, V6, P1; SLATTERY ML, 1988, INT J CANCER, V42, P17, DOI 10.1002/ijc.2910420105; STEINMETZ KA, 1993, CANCER RES, V53, P536; STENSVOLD I, 1994, CANCER CAUSE CONTROL, V5, P401, DOI 10.1007/BF01694753; THOMAS DB, 1983, AM J EPIDEMIOL, V118, P720, DOI 10.1093/oxfordjournals.aje.a113682; TUYNS AJ, 1979, CANCER RES, V39, P2840; VENA JE, 1993, ARCH ENVIRON HEALTH, V48, P191, DOI 10.1080/00039896.1993.9940820; VISCOLI CM, 1993, LANCET, V341, P1432, DOI 10.1016/0140-6736(93)90881-G; WILKINS JR, 1981, AM J EPIDEMIOL, V114, P178, DOI 10.1093/oxfordjournals.aje.a113181; Willett W, 1990, MONOGRAPHS EPIDEMIOL, V15; WILLETT WC, 1985, AM J EPIDEMIOL, V122, P51, DOI 10.1093/oxfordjournals.aje.a114086; World Health Organization, 1997, WORLD HLTH REP 1997; WYNDER EL, 1963, CANCER-AM CANCER SOC, V16, P1388, DOI 10.1002/1097-0142(196311)16:11<1388::AID-CNCR2820161104>3.0.CO;2-8	45	200	203	0	9	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	MAY 6	1999	340	18					1390	1397		10.1056/NEJM199905063401803	http://dx.doi.org/10.1056/NEJM199905063401803			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	192QN	10228189				2022-12-28	WOS:000080090600003
J	Chow, WH; Devesa, SS; Warren, JL; Fraumeni, JF				Chow, WH; Devesa, SS; Warren, JL; Fraumeni, JF			Rising incidence of renal cell cancer in the United States	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							HYPERTENSION; CARCINOMA; OBESITY; TRENDS	Context Clinical surveys have revealed that incidental detection of renal cell carcinoma is rising because of increased use of imaging procedures. Objective To examine incidence, mortality, and survival trends of renal cell and renal pelvis cancers by age, sex, race, and tumor stage at diagnosis, Design Calculation of age-adjusted incidence and mortality rates, along with 5-year relative survival rates, using data from the National Cancer Institute's Surveillance, Epidemiology, and End Results (SEER) program. Setting and Participants Patients diagnosed as having kidney cancer from 1975 through 1995 in the 9 geographic areas covered by tumor registries in the SEER program, which represent about 10% of the US population. Main Outcome Measures Incidence, mortality, and 5-year relative survival rates by time periods, Results The age-adjusted incidence rates for renal cell carcinoma between 1975 and 1995 for white men, white women, black men, and black women were 9.6, 4.4, 11.1, and 4.9 per 100 000 person-years, respectively. The corresponding rates for renal pelvis cancer were 1.5, 0.7, 0.8, and 0.5 per 100 000 person-years, Renal cell cancer incidence rates increased steadily between 1975 and 1995, by 2.3% annually among white men, 3.1% among white women, 3.9% among black men, and 4.3% among black women. Increases were greatest for localized tumors but were also seen for more advanced and unstaged tumors. In contrast, the incidence rates for renal pelvis cancer declined among white men and remained stable among white women and blacks. Although 5-year relative survival rates for patients with renal cell cancer improved among whites but not among blacks, kidney cancer mortality rates increased in all race and sex groups. Conclusions Increasing detection of presymptomatic tumors by imaging procedures, such as ultrasonography, computed tomography, and magnetic resonance imaging, does not fully explain the upward incidence trends of renal cell carcinoma. Other factors may be contributing to the rapidly increasing incidence of renal cell cancer in the United States, particularly among blacks.	NCI, Div Canc Epidemiol & Genet, Bethesda, MD 20892 USA; NCI, Div Canc Control & Populat Sci, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Chow, WH (corresponding author), NCI, Div Canc Epidemiol & Genet, 6120 Execut Blvd,EPS 8100, Bethesda, MD 20892 USA.	choww@exchange.nih.gov			DIVISION OF CANCER EPIDEMIOLOGY AND GENETICS [Z01CP010108] Funding Source: NIH RePORTER	DIVISION OF CANCER EPIDEMIOLOGY AND GENETICS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)NIH National Cancer Institute- Division of Cancer Epidemiology & Genetics)		Benichou J, 1998, AM J EPIDEMIOL, V148, P424; BRETHEAU D, 1995, EUR UROL, V27, P319; DEVESA SS, 1990, CANCER CAUSE CONTROL, V1, P133, DOI 10.1007/BF00053164; DEVESA SS, 1995, AM J EPIDEMIOL, V141, P300, DOI 10.1093/aje/141.4.300; EISNER GM, 1990, AM J KIDNEY DIS, V16, P35; Espeland MA, 1996, J AM GERIATR SOC, V44, P1183, DOI 10.1111/j.1532-5415.1996.tb01367.x; *FED AM SOC EXP BI, 1995, 3 REP NUTR MON US, V1, pES9; Flegal KM, 1998, INT J OBESITY, V22, P39, DOI 10.1038/sj.ijo.0800541; GROSS TP, 1989, HYPERTENSION S1, V13, P113; Homma Y, 1995, Int J Urol, V2, P77, DOI 10.1111/j.1442-2042.1995.tb00428.x; Jayson M, 1998, UROLOGY, V51, P203, DOI 10.1016/S0090-4295(97)00506-2; Landis SH, 1998, CA-CANCER J CLIN, V48, P6, DOI 10.3322/canjclin.48.1.6; MATERSON BJ, 1993, NEW ENGL J MED, V328, P914, DOI 10.1056/NEJM199304013281303; MCCREDIE M, 1994, CANCER SURV, V20, P343; McLaughlin J. K., 1996, CANC EPIDEMIOLOGY PR, P1142; *NAT CTR HLTH STAT, 1997, HLTH US 1996 97, P182; Percy C., 1990, INT CLASSIFICATION D; Ries L, 1998, SEER CANC STAT REV 1; VANZWIETEN PA, 1992, J HYPERTENS, V10, pS1; Weir MR, 1998, HYPERTENSION, V31, P1088, DOI 10.1161/01.HYP.31.5.1088; Yuan JM, 1998, BRIT J CANCER, V77, P1508, DOI 10.1038/bjc.1998.248	21	1182	1234	1	18	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAY 5	1999	281	17					1628	1631		10.1001/jama.281.17.1628	http://dx.doi.org/10.1001/jama.281.17.1628			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	191MJ	10235157	Bronze			2022-12-28	WOS:000080025900028
J	Schofer, JM				Schofer, JM			Violations of informed consent during War	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							INVESTIGATIONAL DRUGS		Hahnemann Sch Med, Philadelphia, PA 19102 USA	Drexel University	Schofer, JM (corresponding author), Hahnemann Sch Med, Philadelphia, PA 19102 USA.							ANNAS GJ, 1992, NEW ENGL J MED, V326, P770, DOI 10.1056/NEJM199203123261117; Annas GJ, 1998, AM J LAW MED, V24, P245; APPEL HL, 1992, NEW ENGL J MED, V327, P1096; GUNBY P, 1995, JAMA-J AM MED ASSOC, V273, P276; HOWE EG, 1986, SOC SCI MED, V23, P803, DOI 10.1016/0277-9536(86)90279-0; KEELER JR, 1991, JAMA-J AM MED ASSOC, V266, P693, DOI 10.1001/jama.266.5.693; POIKONEN J, 1991, AM J HOSP PHARM, V48, P1525, DOI 10.1093/ajhp/48.7.1525	7	5	5	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAY 5	1999	281	17					1657	1657		10.1001/jama.281.17.1657	http://dx.doi.org/10.1001/jama.281.17.1657			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	191MJ	10235163				2022-12-28	WOS:000080025900034
J	Olenyuk, B; Whiteford, JA; Fechtenkotter, A; Stang, PJ				Olenyuk, B; Whiteford, JA; Fechtenkotter, A; Stang, PJ			Self-assembly of nanoscale cuboctahedra by coordination chemistry	NATURE			English	Article								Self-assembled polyhedral structures are common in biology. The coats of many viruses, for example, have a structure based on icosahedral symmetry(1). The preparation of synthetic polyhedral molecular assemblies represents a challenging problem, but supramolecular chemistry(2-4) has now advanced to the Feint where the task may be addressed. Macromolecular and supramolecular entities of predefined geometric shape and with well-defined internal environments are potentially important for inclusion phenomena(5-8), molecular recognition(5,6) and catalysis(9). Here we report the use of self-assembly of molecular units driven by coordination to transition-metal ions(10) to prepare a cuboctahedron from 20 tridentate and bidentate subunits in a single step. The cuboctahedron is an archimedean semiregular polyhedron that combines square and triangular faces. Our self-assembled polyhedral capsules, characterized by NMR and electrospray mass spectrometry, are around 5 nanometres in diameter.	Univ Utah, Dept Chem, Salt Lake City, UT 84112 USA	Utah System of Higher Education; University of Utah	Stang, PJ (corresponding author), Univ Utah, Dept Chem, Salt Lake City, UT 84112 USA.		Stang, Peter J./Y-2744-2019					Cram D.J., 1994, CONTAINER MOL THEIR, DOI 10.1039/9781847550620-00107; CRAM DJ, 1991, ANGEW CHEM INT EDIT, V30, P1024, DOI 10.1002/anie.199110241; DINUR U, 1991, REV COMPUTATIONAL CH, V2, pCH4; FUJITA M, 1995, NATURE, V378, P469, DOI 10.1038/378469a0; Hansen J P, 1976, THEORY SIMPLE LIQUID; Horne R. W., 1974, VIRUS STRUCTURE; Kang JM, 1997, NATURE, V385, P50, DOI 10.1038/385050a0; Lehn J. M., 1996, COMPREHENSIVE SUPRAM, V1-11; Lehn J.-M., 1995, SUPRAMOLECULAR CHEM; MEISSNER RS, 1995, SCIENCE, V270, P1485, DOI 10.1126/science.270.5241.1485; *MOL SIM INC, 1998, INS 2 97 0; PERSKY NE, 1997, J AM CHEM SOC SOC, V119, P4777; Stang PJ, 1997, ACCOUNTS CHEM RES, V30, P502, DOI 10.1021/ar9602011; STEJSKAL EO, 1965, J CHEM PHYS, V42, P288, DOI 10.1063/1.1695690; STODDARD JF, 1989, MONOGRAPHS SUPRAMOLE, P1994	15	548	556	4	138	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	APR 29	1999	398	6730					796	799		10.1038/19740	http://dx.doi.org/10.1038/19740			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	192BL	10235260				2022-12-28	WOS:000080058100055
J	Sikorski, R; Peters, R				Sikorski, R; Peters, R			Some nerve!	SCIENCE			English	Article									Mednav Com, Byfield, MA 01922 USA		Sikorski, R (corresponding author), Mednav Com, Byfield, MA 01922 USA.							Morrison SJ, 1999, CELL, V96, P737, DOI 10.1016/S0092-8674(00)80583-8	1	1	1	0	1	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	APR 16	1999	284	5413					453	453						1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	187NE	10232993				2022-12-28	WOS:000079792200036
J	Shields, R				Shields, R			How experienced should a colorectal surgeon be? Commentary	BRITISH MEDICAL JOURNAL			English	Editorial Material									Royal Liverpool Univ Hosp, Dept Surg, Liverpool L69 3GA, Merseyside, England	Royal Liverpool & Broadgreen University Hospitals NHS Trust; Royal Liverpool University Hospital; University of Liverpool	Shields, R (corresponding author), Royal Liverpool Univ Hosp, Dept Surg, Liverpool L69 3GA, Merseyside, England.								0	2	2	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	MAY 22	1999	318	7195					1386	1386						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	200DQ	10334747				2022-12-28	WOS:000080524700024
J	[Anonymous]				[Anonymous]			Government condemned over juniors' hours	BMJ-BRITISH MEDICAL JOURNAL			English	Editorial Material																			0	0	0	0	0	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	MAY 22	1999	318	7195					1425	1425						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	200DQ	10334777				2022-12-28	WOS:000080524700077
J	Guyatt, GH; Sinclair, J; Cook, DJ; Glasziou, P				Guyatt, GH; Sinclair, J; Cook, DJ; Glasziou, P		Evidence-Based Med Working Grp; Cochrane Applicability Methods Working Grp	Users' guides to the medical literature - XVI. How to use a treatment recommendation	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							RESPIRATORY-TRACT INFECTIONS; CLINICAL-PRACTICE GUIDELINES; ATRIAL-FIBRILLATION; DIGESTIVE-TRACT; SELECTIVE DECONTAMINATION; MYOCARDIAL-INFARCTION; DECISION-ANALYSIS; HELP ME; WILL; PREFERENCES	Clinicians can often find treatment recommendations in traditional narrative reviews and the discussion sections of original articles and meta-analyses. Making a treatment recommendation involves framing a question, identifying management options and outcomes, collecting and summarizing evidence, and applying value judgments or preferences to arrive at an optimal course of action, Each step in this process can be conducted systematically (thus protecting against bias) or unsystematically (leaving the process open to bias). Clinicians faced with a plethora of recommendations may wish to attend to those that are less likely to be biased. Therefore, we propose a hierarchy of rigor of recommendations to guide clinicians when judging the usefulness of particular recommendations. Recommendations with the highest rigor consider all relevant options and outcomes, include a comprehensive collection of the methodologically highest quality data with an explicit strategy for summarizing the data (that is, a systematic review), and make an explicit statement of the values or preferences involved in moving from evidence to action, High rigor recommendations come from systematically developed, evidence-based practice guidelines or rigorously conducted decision analyses. Systematic reviews, which typically do not consider all relevant options and outcomes or make the preferences underlying recommendations explicit, offer intermediate rigor recommendations. Traditional approaches in which the collection and assessment of evidence remains unsystematic, all relevant options and outcomes may not be considered, and values remain implicit, provide recommendations of weak rigor. In an era in which clinicians are barraged by recommendations as to how to manage their patients, this hierarchy provides a potentially useful set of guides.	McMaster Univ, Hlth Sci Ctr, Dept Clin Epidemiol & Biostat, Hamilton, ON L8N 3Z5, Canada; McMaster Univ, Dept Med, Hamilton, ON L8N 3Z5, Canada; McMaster Univ, Dept Pediat, Hamilton, ON L8N 3Z5, Canada; Univ Queensland, Sch Med, Dept Social & Prevent Med, Herston, Qld, Australia	McMaster University; University of Manitoba; Children's Hospital Research Institute of Manitoba; McMaster University; McMaster University; University of Queensland	Guyatt, GH (corresponding author), McMaster Univ, Hlth Sci Ctr, Dept Clin Epidemiol & Biostat, 1200 Main St W,Room 2C12, Hamilton, ON L8N 3Z5, Canada.		Glasziou, Paul/A-7832-2008	Glasziou, Paul/0000-0001-7564-073X				AERDTS SJA, 1993, BRIT MED J, V307, P525; ANTMAN EM, 1992, JAMA-J AM MED ASSOC, V268, P240, DOI 10.1001/jama.268.2.240; CARO JJ, 1993, LANCET, V341, P1381, DOI 10.1016/0140-6736(93)90950-L; Drummond MF, 1997, JAMA-J AM MED ASSOC, V277, P1552, DOI 10.1001/jama.277.19.1552; GAGE BF, 1995, JAMA-J AM MED ASSOC, V274, P1839, DOI 10.1001/jama.274.23.1839; GLASZIOU PP, 1995, BMJ-BRIT MED J, V311, P1356, DOI 10.1136/bmj.311.7016.1356; GLASZIOU PP, 1994, MED J AUSTRALIA, V161, P532, DOI 10.5694/j.1326-5377.1994.tb127596.x; GROOTENDOORST P, IN PRESS MED CARE; GUYATT GH, 1995, JAMA-J AM MED ASSOC, V274, P1800, DOI 10.1001/jama.274.22.1800; HAYWARD RSA, 1995, JAMA-J AM MED ASSOC, V274, P570, DOI 10.1001/jama.274.7.570; HEYLAND DK, 1994, CHEST, V105, P1221, DOI 10.1378/chest.105.4.1221; KOLLEF MH, 1994, CHEST, V105, P1101, DOI 10.1378/chest.105.4.1101; Laupacis A, 1998, CHEST, V114, p579S, DOI 10.1378/chest.114.5_Supplement.579S; LAUPACIS A, 1988, NEW ENGL J MED, V318, P1728, DOI 10.1056/NEJM198806303182605; LAUPACIS A, 1994, ARCH INTERN MED, V154, P1449; LAUPACIS A, 1992, CAN MED ASSOC J, V146, P473; ManSonHing M, 1996, ARCH INTERN MED, V156, P1841, DOI 10.1001/archinte.156.16.1841; MCBRIDE R, 1994, LANCET, V343, P687; OBrien BJ, 1997, JAMA-J AM MED ASSOC, V277, P1802; OXMAN AD, 1992, ANN INTERN MED, V116, P78, DOI 10.7326/0003-4819-116-1-78; OXMAN AD, 1994, JAMA-J AM MED ASSOC, V272, P1367, DOI 10.1001/jama.272.17.1367; RICHARDSON WS, 1995, JAMA-J AM MED ASSOC, V273, P1610, DOI 10.1001/jama.273.20.1610; RICHARDSON WS, 1995, JAMA-J AM MED ASSOC, V273, P1292, DOI 10.1001/jama.273.16.1292; Robbins JM, 1998, ARCH PEDIAT ADOL MED, V152, P358; Silvestri G, 1998, BRIT MED J, V317, P771, DOI 10.1136/bmj.317.7161.771; SMITH GD, 1994, BMJ-BRIT MED J, V308, P72, DOI 10.1136/bmj.308.6921.72; SOLOMON NA, 1994, STROKE, V25, P1721, DOI 10.1161/01.STR.25.9.1721; VANDENBROUCKEGRAULS CMJE, 1991, LANCET, V338, P859, DOI 10.1016/0140-6736(91)91510-2; WILSON MC, 1995, JAMA-J AM MED ASSOC, V274, P1630, DOI 10.1001/jama.274.20.1630	29	118	124	0	11	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAY 19	1999	281	19					1836	1843		10.1001/jama.281.19.1836	http://dx.doi.org/10.1001/jama.281.19.1836			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	196BH	10340372				2022-12-28	WOS:000080288800038
J	James, O; Day, C				James, O; Day, C			Non-alcoholic steatohepatitis: another disease of affluence	LANCET			English	Editorial Material							NONALCOHOLIC STEATOHEPATITIS; FATTY LIVER; OBESITY		Newcastle Univ, Sch Med, Liver Res Ctr, Newcastle Upon Tyne NE2 4HH, Tyne & Wear, England	Newcastle University - UK	James, O (corresponding author), Newcastle Univ, Sch Med, Liver Res Ctr, Newcastle Upon Tyne NE2 4HH, Tyne & Wear, England.		Day, Christopher/Z-3305-2019					Arner P, 1998, LANCET, V351, P1301, DOI 10.1016/S0140-6736(05)79052-8; BACON BR, 1994, GASTROENTEROLOGY, V107, P1103, DOI 10.1016/0016-5085(94)90235-6; Bass NM, 1999, HEPATOLOGY, V29, P606, DOI 10.1002/hep.510290247; Byron D, 1996, HEPATOLOGY, V24, P813; Caldwell SH, 1999, HEPATOLOGY, V29, P664, DOI 10.1002/hep.510290347; Day CP, 1998, HEPATOLOGY, V27, P1463, DOI 10.1002/hep.510270601; Day CP, 1998, GASTROENTEROLOGY, V114, P842, DOI 10.1016/S0016-5085(98)70599-2; James OFW, 1998, J HEPATOL, V29, P495, DOI 10.1016/S0168-8278(98)80073-1; Kim WR, 1996, TRANSPLANTATION, V62, P1802, DOI 10.1097/00007890-199612270-00021; LUDWIG J, 1980, MAYO CLIN PROC, V55, P434; Teli MR, 1995, HEPATOLOGY, V22, P1714, DOI 10.1002/hep.1840220616; WANLESS IR, 1990, HEPATOLOGY, V12, P1106, DOI 10.1002/hep.1840120505; Weltman MD, 1998, HEPATOLOGY, V27, P128, DOI 10.1002/hep.510270121; Yang SQ, 1997, P NATL ACAD SCI USA, V94, P2557, DOI 10.1073/pnas.94.6.2557; Younossi ZM, 1998, HEPATOLOGY, V28, p303A	15	238	251	0	10	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	MAY 15	1999	353	9165					1634	1636		10.1016/S0140-6736(99)00163-4	http://dx.doi.org/10.1016/S0140-6736(99)00163-4			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	198DT	10335777				2022-12-28	WOS:000080408000002
J	Johnson, BJ; Miller, GH; Fogel, ML; Magee, JW; Gagan, MK; Chivas, AR				Johnson, BJ; Miller, GH; Fogel, ML; Magee, JW; Gagan, MK; Chivas, AR			65,000 years of vegetation change in central Australia and the Australian summer monsoon	SCIENCE			English	Article							SOUTH-AUSTRALIA; OSTRICH EGGSHELL; ATMOSPHERIC CO2; STABLE-CARBON; LAKE-EYRE; CLIMATE; HOLOCENE; PATTERNS; ISOTOPES; MIDDENS	Carbon isotopes in fossil emu (Dromaius novaehollandiae) eggshell from Lake Lyre, South Australia,demonstrate that the relative abundance of C-4 grasses varied substantially during the past 65,000 years. Currently, C-4 grasses are more abundant in regions that are increasingly affected by warm-season precipitation. Thus, an expansion of C-4 grasses Likely reflects an increase in the relative effectiveness of the Australian summer monsoon, which controls summer precipitation over Lake Lyre. The data imply that the Australian monsoon was most effective between 45,000 and 65,000 years ago, Least effective during the Last Glacial Maximum, and moderately effective during the Holocene.	Univ Washington, Sch Oceanog, Seattle, WA 98195 USA; Carnegie Inst Washington, Geophys Lab, Washington, DC 20015 USA; Univ Colorado, Inst Arctic & Alpine Res, Boulder, CO 80309 USA; Univ Colorado, Dept Geol Sci, Boulder, CO 80309 USA; Australian Natl Univ, Res Sch Earth Sci, Dept Geol, Canberra, ACT 0200, Australia; Univ Wollongong, Sch Geosci, Wollongong, NSW 2522, Australia	University of Washington; University of Washington Seattle; Carnegie Institution for Science; University of Colorado System; University of Colorado Boulder; University of Colorado System; University of Colorado Boulder; Australian National University; University of Wollongong	Johnson, BJ (corresponding author), Univ Washington, Sch Oceanog, Seattle, WA 98195 USA.		Chivas, Allan/B-4242-2013; Gagan, Michael/L-5014-2018	Gagan, Michael/0000-0002-8279-323X; Chivas, Allan/0000-0002-1459-6330				Adamson D. A., 1982, HIST AUSTRALASIAN VE, P109; AN ZH, 1991, QUATERNARY RES, V36, P29, DOI 10.1016/0033-5894(91)90015-W; AUCOUR AM, 1994, QUATERNARY RES, V41, P224; BARNOLA JM, 1987, NATURE, V329, P408, DOI 10.1038/329408a0; BOWLER JM, 1982, EVOLUTION FLORA FAUN, P35; Cerling TE, 1997, NATURE, V389, P153, DOI 10.1038/38229; CODDINGTON CL, 1992, THESIS AUSTR NATL U; Connin SL, 1998, QUATERNARY RES, V50, P179, DOI 10.1006/qres.1998.1986; Croke J, 1996, PALAEOGEOGR PALAEOCL, V124, P1, DOI 10.1016/0031-0182(96)00016-8; DAVIES SJJF, 1978, AUST J ECOL, V3, P411, DOI 10.1111/j.1442-9993.1978.tb01189.x; DAWSON TJ, 1984, EMU, V84, P93, DOI 10.1071/MU9840093; Flannery T. F., 1994, FUTURE EATERS; GENTILLI J, 1971, CLIMATES AUSTR NZ, P53; HATTERSLEY PW, 1983, OECOLOGIA, V57, P113, DOI 10.1007/BF00379569; HENDERSON-SELLERS A, 1993, J GEOPHYS RES-ATMOS, V98, P7289, DOI 10.1029/92JD02830; HOBSON KA, 1995, CONDOR, V97, P752, DOI 10.2307/1369183; Johnson BJ, 1998, GEOCHIM COSMOCHIM AC, V62, P2451, DOI 10.1016/S0016-7037(98)00175-6; KERSHAW AP, 1986, NATURE, V322, P47, DOI 10.1038/322047a0; Kutzbach J, 1996, NATURE, V384, P623, DOI 10.1038/384623a0; Latz Peter, 1995, BUSHFIRES BUSHTUCKER; Liu BL, 1996, PALAEOGEOGR PALAEOCL, V124, P233, DOI 10.1016/0031-0182(95)00093-3; LULY JG, 1993, J BIOGEOGR, V20, P587, DOI 10.2307/2845516; MAGEE JM, 1997, THESIS AUSTR NATL U; MAGEE JW, 1995, PALAEOGEOGR PALAEOCL, V113, P3, DOI 10.1016/0031-0182(95)00060-Y; Magee JW, 1998, PALAEOGEOGR PALAEOCL, V144, P307, DOI 10.1016/S0031-0182(98)00124-2; MARINO BD, 1991, NATURE, V349, P127, DOI 10.1038/349127a0; McCarthy L, 1996, PALAEOGEOGR PALAEOCL, V123, P205, DOI 10.1016/0031-0182(96)01113-3; Miller GH, 1999, SCIENCE, V283, P205, DOI 10.1126/science.283.5399.205; Miller GH, 1997, NATURE, V385, P241, DOI 10.1038/385241a0; MILLER GH, 1992, EOS T AM GEOPH UN S, V73, P104; NANSON GC, 1992, GEOLOGY, V20, P791, DOI 10.1130/0091-7613(1992)020<0791:WADOAO>2.3.CO;2; NICHOLLS N, 1991, VEGETATIO, V91, P23, DOI 10.1007/BF00036045; Noble J.C., 1997, DELICATE NOXIOUS SCR; PEARSON S, 1993, QUATERNARY RES, V39, P347, DOI 10.1006/qres.1993.1041; PRELL WL, 1987, J GEOPHYS RES-ATMOS, V92, P8411, DOI 10.1029/JD092iD07p08411; ROBERTS RG, 1994, QUATERNARY SCI REV, V13, P575, DOI 10.1016/0277-3791(94)90080-9; ROBERTS RG, 1990, NATURE, V345, P153, DOI 10.1038/345153a0; SINGH G, 1985, PHILOS T R SOC B, V311, P379, DOI 10.1098/rstb.1985.0156; SINGH G, 1991, PALAEOGEOGR PALAEOCL, V84, P75, DOI 10.1016/0031-0182(91)90036-Q; SMITH BN, 1971, PLANT PHYSIOL, V47, P380, DOI 10.1104/pp.47.3.380; StreetPerrott FA, 1997, SCIENCE, V278, P1422, DOI 10.1126/science.278.5342.1422; TAPPER NJ, 1993, AUSTR WEATHER PATTER; VONSCHIRNDING Y, 1982, ARCHAEOMETRY, V24, P3, DOI 10.1111/j.1475-4754.1982.tb00643.x; Wasson R.J., 1984, LATE CAINOZOIC PALAE, P183; WASSON RJ, 1986, GEOGRAPHICAL REV JAP, V59, P55; Xiao JL, 1999, QUATERNARY SCI REV, V18, P147, DOI 10.1016/S0277-3791(97)00097-8	46	147	153	6	55	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	MAY 14	1999	284	5417					1150	1152		10.1126/science.284.5417.1150	http://dx.doi.org/10.1126/science.284.5417.1150			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	197HJ	10325221				2022-12-28	WOS:000080359100031
J	Barsoum, MW; Farber, L				Barsoum, MW; Farber, L			Room-temperature deintercalation and self-extrusion of Ga from Cr2GaN	SCIENCE			English	Article							TI3SIC2	Bulk samples of the layered ternary nitride Cr2GaN were observed to extrude filaments of pure elemental gallium at room temperature. This self-extrusion phenomenon is best described as a room-temperature deintercalation of gallium from the basal planes of porous Cr2GaN samples. The extruded filaments are single crystals with 2- to 100-micrometer diameters and can be several centimeters long.	Drexel Univ, Dept Mat Engn, Philadelphia, PA 19104 USA	Drexel University	Barsoum, MW (corresponding author), Drexel Univ, Dept Mat Engn, Philadelphia, PA 19104 USA.		Gogotsi, Yury/B-2167-2008	Gogotsi, Yury/0000-0001-9423-4032				Barsoum MW, 1997, J MATER SYNTH PROCES, V5, P197; Barsoum MW, 1997, SCRIPTA MATER, V37, P1583, DOI 10.1016/S1359-6462(97)00288-1; Barsoum MW, 1997, SCRIPTA MATER, V36, P535, DOI 10.1016/S1359-6462(96)00418-6; Barsoum MW, 1999, J PHYS CHEM SOLIDS, V60, P429, DOI 10.1016/S0022-3697(98)00313-8; Barsoum MW, 1996, J AM CERAM SOC, V79, P1953, DOI 10.1111/j.1151-2916.1996.tb08018.x; BECKMANN O, 1969, MONATSH CHEM, V100, P1465, DOI 10.1007/BF00900159; CHAKRABORTY S, 1998, THESIS DREXEL U PHIL; LARSON AC, 1994, GSAS GEN STRUCTURE A	8	70	73	1	40	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	MAY 7	1999	284	5416					937	939		10.1126/science.284.5416.937	http://dx.doi.org/10.1126/science.284.5416.937			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	194MU	10320368				2022-12-28	WOS:000080198800037
J	Martinez-Cortizas, A; Pontevedra-Pombal, X; Garcia-Rodeja, E; Novoa-Munoz, JC; Shotyk, W				Martinez-Cortizas, A; Pontevedra-Pombal, X; Garcia-Rodeja, E; Novoa-Munoz, JC; Shotyk, W			Mercury in a Spanish peat bog: Archive of climate change and atmospheric metal deposition	SCIENCE			English	Article							CONTAMINATED SOILS; BINDING FORMS; REMOTE AREAS; RECORDS; FLUXES; SPAIN; AGE; PB	A. peat core from a bog in northwest Spain provides a record of the net accumulation of atmospheric mercury since 4000 radiocarbon years before the present. It was found that cold climates promoted an enhanced accumulation and the preservation of mercury with Low thermal stability, and warm climates were characterized by a lower accumulation and the predominance of mercury with moderate to high thermal stability. This record can be separated into natural and anthropogenic components. The substantial anthropogenic mercury component began similar to 2500 radiocarbon years before the present, which is near the time of the onset of mercury mining in Spain. Anthropogenic mercury has dominated the deposition-record since the Islamic period (8th to 11th centuries A.D.). The results shown here have implications for the global mercury cycle and also imply that the thermal lability of the accumulated mercury can be used not only to quantify the effects of human activity, but also as a new tool for quantitative paleotemperature reconstruction.	Univ Santiago Compostela, Fac Biol, Dept Edafol & Quim Agr, E-15706 Santiago De Compostela, Spain; Univ Bern, Inst Geol, CH-3012 Bern, Switzerland	Universidade de Santiago de Compostela; University of Bern	Martinez-Cortizas, A (corresponding author), Univ Santiago Compostela, Fac Biol, Dept Edafol & Quim Agr, Campus Sur S-N, E-15706 Santiago De Compostela, Spain.		Pontevedra-Pombal, Xabier/C-7831-2012; Nóvoa-Muñoz, J. C./A-9181-2009; Martínez-Cortizas, Antonio/M-6196-2015; Shotyk, William/E-7026-2010	Pontevedra-Pombal, Xabier/0000-0002-1095-6167; Nóvoa-Muñoz, J. C./0000-0003-3062-4191; Martínez-Cortizas, Antonio/0000-0003-0430-5760; Shotyk, William/0000-0002-2584-8388; Garcia-Rodeja Gayoso, Eduardo/0000-0002-9553-0711				ANDREU JM, 1993, REV ACAD GALICIA CIE, V12, P119; [Anonymous], [No title captured]; ANTELO AP, 1996, FERVEDES, V3, P151; Benoit J. M., 1994, P187; Benoit JM, 1998, ENVIRON RES, V78, P118, DOI 10.1006/enrs.1998.3850; Biester H, 1998, ENVIRON SCI TECHNOL, V32, P2755, DOI 10.1021/es9709379; Biester H, 1997, ENVIRON SCI TECHNOL, V31, P233, DOI 10.1021/es960369h; Bond G, 1997, SCIENCE, V278, P1257, DOI 10.1126/science.278.5341.1257; Brown DH., 1982, BRYOPHYTE ECOLOGY, P383, DOI [DOI 10.1007/978-94-009-5891-3_11, 10.1007/978-94-009-5891-3_11]; CODRON JCG, 1996, UN CLIMA PARA HIST U; DOMERGUE C, 1989, MINERIA METALURGIA A; Domergue C, 1990, MINES PENINSULE IBER, V127; Fitzgerald WF, 1998, ENVIRON SCI TECHNOL, V32, P1, DOI 10.1021/es970284w; Grove JM, 1988, LITTLE ICE AGE; Gstoettner EM, 1997, WATER AIR SOIL POLL, V93, P321, DOI 10.1023/A:1022117515040; JENSEN A, 1991, WATER AIR SOIL POLL, V56, P769, DOI 10.1007/BF00342315; MACKAY D, 1995, WATER AIR SOIL POLL, V80, P941, DOI 10.1007/BF01189748; MADSEN PP, 1981, NATURE, V293, P127, DOI 10.1038/293127a0; MARTINEZCORTIZA.A, 1996, GEOGRAPHICALIA, V33, P127; MartinezCortizas A, 1997, WATER AIR SOIL POLL, V100, P387, DOI 10.1023/A:1018312223189; MARTINVIDE J, 1995, CLIMATIC CHANGE, V30, P201, DOI 10.1007/BF01091842; MATILLA A, 1987, HIST MINAS ALMADEN, V2; MATURANA S, 1995, BOCAMINA, V1, P38; Norton SA, 1997, WATER AIR SOIL POLL, V100, P271, DOI 10.1023/A:1018380610893; NORTON SA, 1990, SOURCES DEPOSITION C, V3, P73; PORTER SC, 1967, AM J SCI, V265, P177, DOI 10.2475/ajs.265.3.177; RASMUSSEN PE, 1994, ENVIRON SCI TECHNOL, V28, P2233, DOI 10.1021/es00062a006; RASO JM, 1997, ADV HIST CLIMATOLOGY, P91; SOBRINO AH, 1993, GEOHISTORIA, V7, P67; SOBRINO AH, 1996, 1 JORN MIN TECN ED M, V1, P384; STEINNES E, 1991, WATER AIR SOIL POLL, V56, P391, DOI 10.1007/BF00342286; STUIVER M, 1993, RADIOCARBON, V35, P215, DOI 10.1017/S0033822200013904; THOMPSON LG, 1986, SCIENCE, V234, P361, DOI 10.1126/science.234.4774.361; VANDAL GM, 1993, NATURE, V362, P621, DOI 10.1038/362621a0; [No title captured]	35	331	344	4	113	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	MAY 7	1999	284	5416					939	942		10.1126/science.284.5416.939	http://dx.doi.org/10.1126/science.284.5416.939			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	194MU	10320369				2022-12-28	WOS:000080198800038
J	Yudkin, JS				Yudkin, JS			Tanzania: still optimistic after all these years?	LANCET			English	Article									UCL, Sch Med, Whittington Hosp, Dept Med,Ctr Diabet & Cardiovasc Risk, London N19 3UA, England	University of London; University College London; UCL Medical School	Yudkin, JS (corresponding author), UCL, Sch Med, Whittington Hosp, Dept Med,Ctr Diabet & Cardiovasc Risk, G Block,Archway Wing,Archway Rd, London N19 3UA, England.	j.yudkin@med.ucl.ac.uk	Yudkin, John S/C-1988-2008						0	12	12	0	0	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736			LANCET	Lancet	MAY 1	1999	353	9163					1519	1521		10.1016/S0140-6736(98)09440-9	http://dx.doi.org/10.1016/S0140-6736(98)09440-9			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	195XV	10232335				2022-12-28	WOS:000080278200047
J	Dessen, A; Tang, J; Schmidt, H; Stahl, M; Clark, JD; Seehra, J; Somers, WS				Dessen, A; Tang, J; Schmidt, H; Stahl, M; Clark, JD; Seehra, J; Somers, WS			Crystal structure of human cytosolic phospholipase A(2) reveals a novel topology and catalytic mechanism	CELL			English	Article							LIPID-BINDING DOMAIN; ARACHIDONIC-ACID; MACROMOLECULAR STRUCTURES; INTERFACIAL CATALYSIS; NUCLEAR-ENVELOPE; C2 DOMAIN; CALCIUM; PHOSPHORYLATION; IDENTIFICATION; TRANSLOCATION	Cytosolic phospholipase A, initiates the biosynthesis of prostaglandins, leukotrienes, and platelet-activating factor (PAF), mediators of the pathophysiology of asthma and arthritis. Here, we report the X-ray crystal structure of human cPLA(2) at 2.5 Angstrom. cPLA(2) consists of an N-terminal calcium-dependent lipid-binding/C2 domain and a catalytic unit whose topology is distinct from that of other lipases. An unusual Ser-Asp dyad located in a deep cleft at the center of a predominantly hydrophobic funnel selectively cleaves arachidonyl phospholipids. The structure reveals a flexible lid that must move to allow substrate access to the active site, thus explaining the interfacial activation of this important lipase.	Wyeth Ayerst Res, Biochem, Cambridge, MA 02140 USA	Pfizer	Dessen, A (corresponding author), Wyeth Ayerst Res, Biochem, 87 Cambridge Pk Dr, Cambridge, MA 02140 USA.	adessen@genetics.com; wsomers@genetics.com		Clark, James D./0000-0002-4801-0123; Dessen, Andrea/0000-0001-6487-4020				Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; BACON D, 1988, J MOL GRAPHICS, V6, P219, DOI 10.1016/S0263-7855(98)80030-1; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; Bonventre JV, 1997, NATURE, V390, P622, DOI 10.1038/37635; Borsch-Haubold AG, 1998, J BIOL CHEM, V273, P4449, DOI 10.1074/jbc.273.8.4449; BRICOGNE G, 1993, ACTA CRYSTALLOGR D, V49, P37, DOI 10.1107/S0907444992010400; BrUnger A. T., 1992, X PLOR VERSION 3 1 S; BRUNGER AT, 1992, NATURE, V355, P472, DOI 10.1038/355472a0; BRUNGER AT, 1990, ACTA CRYSTALLOGR A, V46, P585, DOI 10.1107/S0108767390002355; CLARK JD, 1991, CELL, V65, P1043, DOI 10.1016/0092-8674(91)90556-E; CLARK JD, 1995, J LIPID MEDIAT CELL, V12, P83, DOI 10.1016/0929-7855(95)00012-F; Cowtan KD, 1996, ACTA CRYSTALLOGR D, V52, P43, DOI 10.1107/S090744499500761X; Cygler M, 1997, METHOD ENZYMOL, V284, P3; deCarvalho MGS, 1996, J BIOL CHEM, V271, P6987, DOI 10.1074/jbc.271.12.6987; delaFortelle E, 1997, METHOD ENZYMOL, V276, P472, DOI 10.1016/S0076-6879(97)76073-7; Dennis EA, 1997, TRENDS BIOCHEM SCI, V22, P1, DOI 10.1016/S0968-0004(96)20031-3; DEREWENDA ZS, 1991, BIOCHEM CELL BIOL, V69, P842, DOI 10.1139/o91-125; DUGGLEBY HJ, 1995, NATURE, V373, P264, DOI 10.1038/373264a0; Essen LO, 1996, NATURE, V380, P595, DOI 10.1038/380595a0; GLOVER S, 1995, J BIOL CHEM, V270, P15359, DOI 10.1074/jbc.270.25.15359; Grobler JA, 1996, NAT STRUCT BIOL, V3, P788, DOI 10.1038/nsb0996-788; HANEL AM, 1993, BIOCHEMISTRY-US, V32, P5949, DOI 10.1021/bi00074a005; HANEL AM, 1995, BIOCHEMISTRY-US, V34, P7807, DOI 10.1021/bi00024a004; HENDRICKSON WA, 1991, SCIENCE, V254, P51, DOI 10.1126/science.1925561; Hixon MS, 1998, BIOCHEMISTRY-US, V37, P8516, DOI 10.1021/bi980416d; Huang Z, 1996, BIOCHEMISTRY-US, V35, P3712, DOI 10.1021/bi952541k; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; LESLIE CC, 1990, BIOCHIM BIOPHYS ACTA, V1045, P261, DOI 10.1016/0005-2760(90)90129-L; Leslie CC, 1997, J BIOL CHEM, V272, P16709, DOI 10.1074/jbc.272.27.16709; LIN LL, 1992, J BIOL CHEM, V267, P23451; LIN LL, 1992, P NATL ACAD SCI USA, V89, P6147, DOI 10.1073/pnas.89.13.6147; LIN LL, 1993, CELL, V72, P269, DOI 10.1016/0092-8674(93)90666-E; Matagne A, 1998, BIOCHEM J, V330, P581, DOI 10.1042/bj3300581; Mosior M, 1998, J BIOL CHEM, V273, P2184, DOI 10.1074/jbc.273.4.2184; Murshudov GN, 1997, ACTA CRYSTALLOGR D, V53, P240, DOI 10.1107/S0907444996012255; Nalefski EA, 1998, BIOCHEMISTRY-US, V37, P17642, DOI 10.1021/bi982372e; Nalefski EA, 1998, J BIOL CHEM, V273, P1365, DOI 10.1074/jbc.273.3.1365; Nalefski EA, 1996, PROTEIN SCI, V5, P2375, DOI 10.1002/pro.5560051201; NALEFSKI EA, 1994, J BIOL CHEM, V269, P18239; Nicholls A., 1992, GRASP GRAPHICAL REPR; OByrne PM, 1997, CHEST, V111, pS27, DOI 10.1378/chest.111.2_Supplement.27S; Otwinowski Z., 1993, DATA COLLECTION PROC, P56; Perisic O, 1998, J BIOL CHEM, V273, P1596, DOI 10.1074/jbc.273.3.1596; Pickard RT, 1996, J BIOL CHEM, V271, P19225, DOI 10.1074/jbc.271.32.19225; Qiu ZH, 1998, J BIOL CHEM, V273, P8203, DOI 10.1074/jbc.273.14.8203; Rao VD, 1998, CELL, V94, P829, DOI 10.1016/S0092-8674(00)81741-9; REYNOLDS LJ, 1993, BIOCHIM BIOPHYS ACTA, V1167, P272, DOI 10.1016/0005-2760(93)90229-3; Schievella AR, 1995, J BIOL CHEM, V270, P30749, DOI 10.1074/jbc.270.51.30749; Schrag JD, 1997, METHOD ENZYMOL, V284, P85; SCOTT DL, 1990, SCIENCE, V250, P1541, DOI 10.1126/science.2274785; SHARP JD, 1994, J BIOL CHEM, V269, P23250; Simon LS, 1998, ARTHRITIS RHEUM-US, V41, P1591, DOI 10.1002/1529-0131(199809)41:9<1591::AID-ART9>3.0.CO;2-J; TJOELKER LW, 1995, NATURE, V374, P549, DOI 10.1038/374549a0; TRIMBLE LA, 1993, BIOCHEMISTRY-US, V32, P12560, DOI 10.1021/bi00210a002; Underwood KW, 1998, J BIOL CHEM, V273, P21926, DOI 10.1074/jbc.273.34.21926; Uozumi N, 1997, NATURE, V390, P618, DOI 10.1038/37622; VENABLE ME, 1993, J BIOL CHEM, V268, P7965; Xu GY, 1998, J MOL BIOL, V280, P485, DOI 10.1006/jmbi.1998.1874	58	295	306	0	13	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	APR 30	1999	97	3					349	360		10.1016/S0092-8674(00)80744-8	http://dx.doi.org/10.1016/S0092-8674(00)80744-8			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	192VP	10319815	Bronze			2022-12-28	WOS:000080100500008
J	Gervais, FG; Xu, DG; Robertson, GS; Vaillancourt, JP; Zhu, YX; Huang, JQ; LeBlanc, A; Smith, D; Rigby, M; Shearman, MS; Clarke, FE; Zheng, H; Van Der Ploeg, LHT; Ruffolo, SC; Thornberry, NA; Xanthoudakis, S; Zamboni, RJ; Roy, S; Nicholson, DW				Gervais, FG; Xu, DG; Robertson, GS; Vaillancourt, JP; Zhu, YX; Huang, JQ; LeBlanc, A; Smith, D; Rigby, M; Shearman, MS; Clarke, FE; Zheng, H; Van Der Ploeg, LHT; Ruffolo, SC; Thornberry, NA; Xanthoudakis, S; Zamboni, RJ; Roy, S; Nicholson, DW			Involvement of caspases in proteolytic cleavage of Alzheimer's amyloid-beta precursor protein and amyloidogenic A beta peptide formation	CELL			English	Article							APOPTOTIC CELL-DEATH; COMBINATORIAL APPROACH; ICE/CED-3 PROTEASE; TRANSGENIC MICE; DISEASE; DAMAGE; BRAIN; MODEL; RAT; SPECIFICITIES	The amyloid-beta precursor protein (APP) is directly and efficiently cleaved by caspases during apoptosis, resulting in elevated amyloid-beta (A beta) peptide formation. The predominant site of caspase-mediated proteolysis is within the cytoplasmic tail of APP, and cleavage at this site occurs in hippocampal neurons in vivo following acute excitotoxic or ischemic brain injury. Caspase-3 is the predominant caspase involved in APP cleavage, consistent with its marked elevation in dying neurons of Alzheimer's disease brains and colocalization of its APP cleavage product with A beta in senile plaques. Caspases thus appear to play a dual role in proteolytic processing of APP and the resulting propensity for A beta peptide formation, as well as in the ultimate apoptotic death of neurons in Alzheimer's disease.	Merck Res Labs, Merck Frosst Ctr Therapeut Res, Dept Pharmacol Biochem & Mol Biol, Kirkland, PQ H9H 3L1, Canada; Merck Res Labs, Merck Frosst Ctr Therapeut Res, Dept Med Chem, Kirkland, PQ H9H 3L1, Canada; Merck Sharp & Dohme Res Labs, Neurosci Res Ctr, Dept Pharmacol Biochem & Mol Biol, Harlow CM20 2QR, Essex, England; Merck Res Labs, Dept Enzymol, Rahway, NJ 07065 USA; Merck Res Labs, Dept Metab Disorders, Rahway, NJ 07065 USA; McGill Univ, Dept Biochem, Montreal, PQ H3G 1Y6, Canada; Sir Mortimer B Davis Jewish Hosp, Lady Davis Inst Med Res, Montreal, PQ H3T 1E2, Canada	Merck & Company; Merck & Company; Merck & Company; Merck & Company; Merck & Company; McGill University; Lady Davis Institute; McGill University	Nicholson, DW (corresponding author), Merck Res Labs, Merck Frosst Ctr Therapeut Res, Dept Pharmacol Biochem & Mol Biol, Kirkland, PQ H9H 3L1, Canada.			Robertson, George/0000-0001-8411-7721				Alnemri ES, 1996, CELL, V87, P171, DOI 10.1016/S0092-8674(00)81334-3; Barnes NY, 1998, J NEUROSCI, V18, P5869; Black SC, 1998, J MOL CELL CARDIOL, V30, P733, DOI 10.1006/jmcc.1998.0660; Borg JP, 1998, J BIOL CHEM, V273, P14761, DOI 10.1074/jbc.273.24.14761; CAI XD, 1993, SCIENCE, V259, P514, DOI 10.1126/science.8424174; CITRON M, 1995, NEURON, V14, P661, DOI 10.1016/0896-6273(95)90323-2; CITRON M, 1992, NATURE, V360, P672, DOI 10.1038/360672a0; Cotman CW, 1996, BRAIN PATHOL, V6, P493, DOI 10.1111/j.1750-3639.1996.tb00878.x; FERNANDESALNEMRI T, 1994, J BIOL CHEM, V269, P30761; Forloni G, 1996, MOL CHEM NEUROPATHOL, V28, P163, DOI 10.1007/BF02815218; Garcia-Calvo M, 1998, J BIOL CHEM, V273, P32608, DOI 10.1074/jbc.273.49.32608; HAASS C, 1993, CELL, V75, P1039, DOI 10.1016/0092-8674(93)90312-E; HAASS C, 1995, NAT MED, V1, P1291, DOI 10.1038/nm1295-1291; Holcomb L, 1998, NAT MED, V4, P97, DOI 10.1038/nm0198-097; Kim TW, 1997, SCIENCE, V277, P373, DOI 10.1126/science.277.5324.373; Kuida K, 1996, NATURE, V384, P368, DOI 10.1038/384368a0; LAFERLA FM, 1995, NAT GENET, V9, P21, DOI 10.1038/ng0195-21; LeBlanc A, 1995, J NEUROSCI, V15, P7837; LeBlanc AC, 1996, J NEUROCHEM, V66, P2300; Li WP, 1997, J MOL NEUROSCI, V8, P75, DOI 10.1007/BF02736774; LOO DT, 1993, P NATL ACAD SCI USA, V90, P7951, DOI 10.1073/pnas.90.17.7951; Muzio M, 1998, J BIOL CHEM, V273, P2926, DOI 10.1074/jbc.273.5.2926; NICHOLSON DW, 1995, NATURE, V376, P37, DOI 10.1038/376037a0; Nicholson DW, 1997, TRENDS BIOCHEM SCI, V22, P299, DOI 10.1016/S0968-0004(97)01085-2; PULSINELLI WA, 1988, STROKE, V19, P913, DOI 10.1161/01.STR.19.7.913; PULSINELLI WA, 1982, ANN NEUROL, V11, P491, DOI 10.1002/ana.410110509; Rano TA, 1997, CHEM BIOL, V4, P149, DOI 10.1016/S1074-5521(97)90258-1; Rotonda J, 1996, NAT STRUCT BIOL, V3, P619, DOI 10.1038/nsb0796-619; Russo T, 1998, FEBS LETT, V434, P1, DOI 10.1016/S0014-5793(98)00941-7; Selkoe DJ, 1996, ANN NY ACAD SCI, V777, P57, DOI 10.1111/j.1749-6632.1996.tb34401.x; SISODIA SS, 1995, FASEB J, V9, P366, DOI 10.1096/fasebj.9.5.7896005; SMALE G, 1995, EXP NEUROL, V133, P225, DOI 10.1006/exnr.1995.1025; Srinivasula SM, 1998, MOL CELL, V1, P949, DOI 10.1016/S1097-2765(00)80095-7; Su JH, 1997, J NEUROPATH EXP NEUR, V56, P86, DOI 10.1097/00005072-199701000-00009; TEWARI M, 1995, CELL, V81, P801, DOI 10.1016/0092-8674(95)90541-3; Thornberry NA, 1997, J BIOL CHEM, V272, P17907, DOI 10.1074/jbc.272.29.17907; Vito P, 1997, J BIOL CHEM, V272, P28315, DOI 10.1074/jbc.272.45.28315; Wang R, 1996, J BIOL CHEM, V271, P31894, DOI 10.1074/jbc.271.50.31894; Xu DG, 1997, NAT MED, V3, P997, DOI 10.1038/nm0997-997; Yang XL, 1998, MOL CELL, V1, P319, DOI 10.1016/S1097-2765(00)80032-5; Zhang L, 1997, BIOCHEM BIOPH RES CO, V235, P845, DOI 10.1006/bbrc.1997.6698	41	673	719	0	22	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	APR 30	1999	97	3					395	406		10.1016/S0092-8674(00)80748-5	http://dx.doi.org/10.1016/S0092-8674(00)80748-5			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	192VP	10319819	Bronze			2022-12-28	WOS:000080100500012
J	West, RR				West, RR			Chlamydia pneumoniae infection and ischaemic heart disease - The story so far - Commentary	BMJ-BRITISH MEDICAL JOURNAL			English	Editorial Material							CORONARY; ASSOCIATION; TWAR		Cardiff Univ, Cardiff CF4 4XN, S Glam, Wales	Cardiff University	West, RR (corresponding author), Cardiff Univ, Heath Pk, Cardiff CF4 4XN, S Glam, Wales.							COOK PJ, 1995, CIRCULATION, V92, P3148; Danesh J, 1997, LANCET, V350, P430, DOI 10.1016/S0140-6736(97)03079-1; Davies MJ, 1995, EUR HEART J, V16, P3, DOI 10.1093/eurheartj/16.suppl_L.3; ELWOOD PC, 1984, J EPIDEMIOL COMMUN H, V38, P259, DOI 10.1136/jech.38.3.259; GRAYSTON JT, 1986, NEW ENGL J MED, V315, P161, DOI 10.1056/NEJM198607173150305; Gurfinkel E, 1997, LANCET, V350, P404, DOI 10.1016/S0140-6736(97)07201-2; Kol A, 1998, CIRCULATION, V98, P300, DOI 10.1161/01.CIR.98.4.300; Miettinen H, 1996, EUR HEART J, V17, P682; SAIKKU P, 1992, ANN INTERN MED, V116, P273, DOI 10.7326/0003-4819-116-4-273; SAIKKU P, 1988, LANCET, V2, P983, DOI 10.1016/S0140-6736(88)90741-6	10	1	1	0	0	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	APR 17	1999	318	7190					1039	1040						2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	193ML	10336284				2022-12-28	WOS:000080140000023
J	Stewart, AL; Rifkin, L; Amess, PN; Kirkbride, V; Townsend, JP; Miller, DH; Lewis, SW; Kingsley, DPE; Moseley, IF; Foster, O; Murray, RM				Stewart, AL; Rifkin, L; Amess, PN; Kirkbride, V; Townsend, JP; Miller, DH; Lewis, SW; Kingsley, DPE; Moseley, IF; Foster, O; Murray, RM			Brain structure and neurocognitive and behavioural function in adolescents who were born very preterm	LANCET			English	Article							ULTRASOUND APPEARANCE; NEURODEVELOPMENTAL IMPAIRMENT; INFANTS; PREDICTION	Background Infants born very preterm (<33 weeks) are at increased risk of neurocognitive deficits. Their neurodevelopmental outcome up to age 8 years can be predicted by neonatal ultrasonography, but little is known of their later function. We investigated the effect of very preterm birth on brain structure and neurocognitive and behavioural functioning in adolescence. Methods A cohort of 105 infants born before 33 weeks of gestation in 1979-80 had ultrasonographic scans at University College Hospital, London, and were prospectively examined at 1, 4, and 8 years. At age 14-15 years, 72 of those who remained in UK (cases) and 21 age-matched full-term controls underwent brain magnetic resonance imaging (MRI), as well as neurological, cognitive, and behavioural assessment. MRI images were assessed by two neuroradiologists unaware of ultrasonographic findings or case or control status. Findings Of the 72 cases, 40 had unequivocally abnormal MRI and 15 had equivocal scans. Of the 21 controls, one had abnormal and five equivocal MRI. Abnormalities of ventricles, corpus callosum, and white matter were especially common in cases. More brain lesions were identified by MRI than by neonatal ultrasonography. The cases had significantly more reading, adjustment, and neurological impairments than controls, but their behaviour was significantly related to MRI abnormality. Interpretation Individuals born very preterm show an excess of neurocognitive and behavioural problems in adolescence, and more than half have abnormal MRI brain scans.	UCL, Sch Med, Rayne Inst, Dept Pediat,Perinatal Brain Res Grp, London WC1E 6JJ, England; Kings Coll London, Inst Psychiat, London WC2R 2LS, England; UCL, Inst Neurol, London WC1E 6JJ, England; Univ Manchester, Sch Psychiat & Behav Sci, Manchester, Lancs, England	University of London; King's College London; University College London; UCL Medical School; University of London; King's College London; University of London; University College London; University of Manchester	Stewart, AL (corresponding author), UCL, Sch Med, Rayne Inst, Dept Pediat,Perinatal Brain Res Grp, London WC1E 6JJ, England.	ann@arlingtonave.demon.co.uk	Townsend, Jeffrey/H-2747-2019; Murray, Robin M/F-8658-2012	Townsend, Jeffrey/0000-0002-9890-3907; Murray, Robin M/0000-0003-0829-0519; Rifkin, Larry/0000-0003-2590-9010; Lewis, Shon/0000-0003-1861-4652	Multiple Sclerosis Society [491] Funding Source: Medline	Multiple Sclerosis Society(National Multiple Sclerosis Society)		Beery K. E, 1989, DEV TEST VISUAL MOTO, V3rd; CANNONSPOOR HE, 1982, SCHIZOPHRENIA BULL, V8, P470, DOI 10.1093/schbul/8.3.470; COSTELLO AMD, 1988, DEV MED CHILD NEUROL, V30, P711; FAIRWEATHER DVI, 1983, REIDS CONTROVERSY OB, V3, P154; FRANSELLA F, 1965, BRIT J EDUC PSYCHOL, V35, P86, DOI 10.1111/j.2044-8279.1965.tb01791.x; Giedd JN, 1996, DEV BRAIN RES, V91, P274; HOPE PL, 1988, DEV MED CHILD NEUROL, V30, P457; KIRKBRIDE V, 1994, PEDIATR RES, V36, pA20; LEVENE MI, 1981, ARCH DIS CHILD, V56, P900, DOI 10.1136/adc.56.12.900; PANETH N, 1994, BRAIN DAMAGE PRETERM, P99; PAPE KE, 1979, LANCET, V1, P1261; ROTH SC, 1994, DEV MED CHILD NEUROL, V36, P1049; ROTH SC, 1993, DEV MED CHILD NEUROL, V35, P755; Rutter M, 1981, ED HLTH BEHAV; SCHONNEL FJ, 1960, DIAGNOSTIC ATTAINMEN; STEWART AL, 1987, DEV MED CHILD NEUROL, V29, P3; STEWART AL, 1983, ARCH DIS CHILD, V58, P598, DOI 10.1136/adc.58.8.598; THORBURN RJ, 1981, LANCET, V1, P1119; THORBURN RJ, 1982, EARLY HUM DEV, V6, P31, DOI 10.1016/0378-3782(82)90055-X	19	297	305	0	17	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	MAY 15	1999	353	9165					1653	1657		10.1016/S0140-6736(98)07130-X	http://dx.doi.org/10.1016/S0140-6736(98)07130-X			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	198DT	10335784				2022-12-28	WOS:000080408000009
J	Prehoda, KE; Lee, DJ; Lim, WA				Prehoda, KE; Lee, DJ; Lim, WA			Structure of the enabled VASP homology 1 domain-peptide complex: A key component in the spatial control of actin assembly	CELL			English	Article							ALDRICH-SYNDROME PROTEIN; METABOTROPIC GLUTAMATE RECEPTORS; MULTIPLE ISOMORPHOUS REPLACEMENT; PROLINE-RICH MOTIF; LISTERIA-MONOCYTOGENES; PTB DOMAIN; PHOSPHOINOSITIDE BINDING; PHOSPHOTYROSINE-BINDING; SIGNAL-TRANSDUCTION; FOCAL ADHESION	The Enabled/VASP homology 1 (EVH1;also called WH1) domain is an interaction module found in several proteins implicated in actin-based cell motility. EVH1 domains bind the consensus proline-rich motif FPPPP and are required for targeting the actin assembly machinery to sites of cytoskeletal remodeling. The crystal structure of the mammalian Enabled (Mena) EVH1 domain complexed with a peptide ligand reveals a mechanism of recognition distinct from that used by other proline-binding modules. The EVH1 domain fold is unexpectedly similar to that of the pleckstrin homology domain, a membrane localization module. This finding demonstrates the functional plasticity of the pleckstrin homology fold as a binding scaffold and suggests that membrane association may play an auxiliary role in EVH1 targeting.	Univ Calif San Francisco, Dept Cellular & Mol Pharmacol, San Francisco, CA 94143 USA; Univ Calif San Francisco, Dept Biochem & Biophys, San Francisco, CA 94143 USA	University of California System; University of California San Francisco; University of California System; University of California San Francisco	Lim, WA (corresponding author), Univ Calif San Francisco, Dept Cellular & Mol Pharmacol, San Francisco, CA 94143 USA.	wlim@itsa.ucsf.edu		Prehoda, Ken/0000-0003-4214-6158				BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; Beckerle MC, 1998, CELL, V95, P741, DOI 10.1016/S0092-8674(00)81697-9; Bottomley MJ, 1998, BBA-MOL CELL BIOL L, V1436, P165, DOI 10.1016/S0005-2760(98)00141-6; Brakeman PR, 1997, NATURE, V386, P284, DOI 10.1038/386284a0; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; CHAKRABORTY T, 1995, EMBO J, V14, P1314, DOI 10.1002/j.1460-2075.1995.tb07117.x; COHEN GB, 1995, CELL, V80, P237, DOI 10.1016/0092-8674(95)90406-9; delaFortelle E, 1997, METHOD ENZYMOL, V276, P472, DOI 10.1016/S0076-6879(97)76073-7; FENG SB, 1994, SCIENCE, V266, P1241, DOI 10.1126/science.7526465; FERGUSON KM, 1995, CELL, V83, P1037, DOI 10.1016/0092-8674(95)90219-8; Finan PM, 1996, J BIOL CHEM, V271, P26291, DOI 10.1074/jbc.271.42.26291; Gertler FB, 1996, CELL, V87, P227, DOI 10.1016/S0092-8674(00)81341-0; Huttelmaier S, 1998, CURR BIOL, V8, P479, DOI 10.1016/S0960-9822(98)70199-X; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Kato A, 1997, FEBS LETT, V412, P183, DOI 10.1016/S0014-5793(97)00775-8; Kavran JM, 1998, J BIOL CHEM, V273, P30497, DOI 10.1074/jbc.273.46.30497; Kidd T, 1998, CELL, V92, P205, DOI 10.1016/S0092-8674(00)80915-0; Kuriyan J, 1997, ANNU REV BIOPH BIOM, V26, P259, DOI 10.1146/annurev.biophys.26.1.259; Lanier LM, 1999, NEURON, V22, P313, DOI 10.1016/S0896-6273(00)81092-2; Laurent V, 1999, J CELL BIOL, V144, P1245, DOI 10.1083/jcb.144.6.1245; Li R, 1997, J CELL BIOL, V136, P649, DOI 10.1083/jcb.136.3.649; Li SC, 1998, NAT STRUCT BIOL, V5, P1075, DOI 10.1038/4185; LIM WA, 1994, NATURE, V372, P375, DOI 10.1038/372375a0; Machesky LM, 1997, CURR BIOL, V7, pR164, DOI 10.1016/S0960-9822(97)70079-4; Machesky LM, 1998, CURR BIOL, V8, P1347, DOI 10.1016/S0960-9822(98)00015-3; MACIAS MJ, 1994, NATURE, V369, P675, DOI 10.1038/369675a0; Macias MJ, 1996, NATURE, V382, P646, DOI 10.1038/382646a0; Mahoney NM, 1997, NAT STRUCT BIOL, V4, P953, DOI 10.1038/nsb1197-953; MAYER BJ, 1993, CELL, V73, P629, DOI 10.1016/0092-8674(93)90244-K; Miki H, 1996, EMBO J, V15, P5326, DOI 10.1002/j.1460-2075.1996.tb00917.x; Mitchison TJ, 1996, CELL, V84, P371, DOI 10.1016/S0092-8674(00)81281-7; Nguyen JT, 1998, SCIENCE, V282, P2088, DOI 10.1126/science.282.5396.2088; Niebuhr K, 1997, EMBO J, V16, P5433, DOI 10.1093/emboj/16.17.5433; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; POLLARD TD, 1995, CURR BIOL, V5, P837, DOI 10.1016/S0960-9822(95)00167-9; Ponting CP, 1997, J MOL MED-JMM, V75, P769, DOI 10.1007/s001090050166; Rameh LE, 1997, J BIOL CHEM, V272, P22059, DOI 10.1074/jbc.272.35.22059; Ravichandran KS, 1997, MOL CELL BIOL, V17, P5540, DOI 10.1128/MCB.17.9.5540; REINHARD M, 1995, EMBO J, V14, P1583, DOI 10.1002/j.1460-2075.1995.tb07146.x; Smith GA, 1996, J CELL BIOL, V135, P647, DOI 10.1083/jcb.135.3.647; SOUTHWICK FS, 1994, P NATL ACAD SCI USA, V91, P5168, DOI 10.1073/pnas.91.11.5168; Symons M, 1996, CELL, V84, P723, DOI 10.1016/S0092-8674(00)81050-8; Terwilliger TC, 1996, ACTA CRYSTALLOGR D, V52, P749, DOI 10.1107/S0907444996000832; THERIOT JA, 1994, CELL, V76, P505, DOI 10.1016/0092-8674(94)90114-7; TILNEY LG, 1989, J CELL BIOL, V109, P1597, DOI 10.1083/jcb.109.4.1597; Tu JC, 1998, NEURON, V21, P717, DOI 10.1016/S0896-6273(00)80589-9; VANDUYNE GD, 1993, J MOL BIOL, V229, P105, DOI 10.1006/jmbi.1993.1012; YOON HS, 1994, NATURE, V369, P672, DOI 10.1038/369672a0; YU HT, 1994, CELL, V76, P933, DOI 10.1016/0092-8674(94)90367-0; Zallen JA, 1998, CELL, V92, P217, DOI 10.1016/S0092-8674(00)80916-2; Zhang ZT, 1997, EMBO J, V16, P6141, DOI 10.1093/emboj/16.20.6141; Zhou MM, 1996, NAT STRUCT BIOL, V3, P388, DOI 10.1038/nsb0496-388; Zhou MM, 1995, PROG BIOPHYS MOL BIO, V64, P221, DOI 10.1016/S0079-6107(96)00005-3; Zigmond SH, 1996, CURR OPIN CELL BIOL, V8, P66, DOI 10.1016/S0955-0674(96)80050-0	54	203	211	0	5	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	MAY 14	1999	97	4					471	480		10.1016/S0092-8674(00)80757-6	http://dx.doi.org/10.1016/S0092-8674(00)80757-6			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	196FV	10338211	Bronze			2022-12-28	WOS:000080299100008
J	Smith, KL; Kaufmann, RS				Smith, KL; Kaufmann, RS			Long-term discrepancy between food supply and demand in the deep eastern North Pacific	SCIENCE			English	Article							COMMUNITY OXYGEN-CONSUMPTION; ORGANIC-CARBON FLUX; TIME-SERIES MEASUREMENTS; CALIFORNIA CURRENT; ABYSSAL DEPTHS; OCEAN; CLIMATE; SEA; VARIABILITY; ABUNDANCE	A 7-year study of food supply [sinking particulate organic carbon (POC)] and food demand [sediment community: oxygen consumption (SCOC)] in the abyssal eastern North Pacific revealed a long-term deficit in food supply. The POC:SCOC ratio decreased by:52:to 59 percent between 1989 and 1996. A possible explanation for this. trend is the documented sea surface temperature increase and concomitant: plankton biomass decrease in the eastern North Pacific, resulting in an apparent reduction in POC export from,surface waters to the deep ocean. Continuation of this trend could profoundly impact geochemical cycling as:well as the structure and dynamics of deepsea communities.	Univ Calif San Diego, Scripps Inst Oceanog, Div Marine Biol Res, La Jolla, CA 92093 USA; Univ San Diego, Marine & Environm Studies Program, San Diego, CA 92110 USA	University of California System; University of California San Diego; Scripps Institution of Oceanography; University of San Diego	Smith, KL (corresponding author), Univ Calif San Diego, Scripps Inst Oceanog, Div Marine Biol Res, La Jolla, CA 92093 USA.							Baldwin RJ, 1998, DEEP-SEA RES PT II, V45, P643, DOI 10.1016/S0967-0645(97)00097-0; BARRY JP, 1995, SCIENCE, V267, P672, DOI 10.1126/science.267.5198.672; Beaulieu SE, 1998, DEEP-SEA RES PT II, V45, P781, DOI 10.1016/S0967-0645(98)00003-4; Bianchi TS, 1998, DEEP-SEA RES PT II, V45, P715, DOI 10.1016/S0967-0645(97)00099-4; Drazen JC, 1998, DEEP-SEA RES PT II, V45, P893, DOI 10.1016/S0967-0645(98)00007-1; Druffel ERM, 1998, DEEP-SEA RES PT II, V45, P667, DOI 10.1016/S0967-0645(98)00002-2; EPPLEY RW, 1979, NATURE, V282, P677, DOI 10.1038/282677a0; Kramer D., 1972, NOAA TECHNICAL REPOR; Lauerman LML, 1996, DEEP-SEA RES PT I, V43, P1075, DOI 10.1016/0967-0637(96)00045-3; Lauerman LML, 1998, DEEP-SEA RES PT II, V45, P817, DOI 10.1016/S0967-0645(98)00004-6; MARTIN WR, 1988, AM J SCI, V288, P561, DOI 10.2475/ajs.288.6.561; McGowan JA, 1998, SCIENCE, V281, P210, DOI 10.1126/science.281.5374.210; ROEMMICH D, 1992, SCIENCE, V257, P373, DOI 10.1126/science.257.5068.373; ROEMMICH D, 1995, SCIENCE, V267, P1324, DOI 10.1126/science.267.5202.1324; ROEMMICH D, 1995, SCIENCE, V268, P352, DOI 10.1126/science.268.5209.352-b; SAYLES FL, 1994, NATURE, V371, P686, DOI 10.1038/371686a0; Shaw TJ, 1998, DEEP-SEA RES PT II, V45, P763, DOI 10.1016/S0967-0645(97)00101-X; Sherrell RM, 1998, DEEP-SEA RES PT II, V45, P733, DOI 10.1016/S0967-0645(97)00100-8; SMITH KL, 1992, NATURE, V359, P313, DOI 10.1038/359313a0; Smith KL, 1997, LIMNOL OCEANOGR, V42, P1601, DOI 10.4319/lo.1997.42.7.1601; SMITH KL, 1994, LIMNOL OCEANOGR, V39, P1101, DOI 10.4319/lo.1994.39.5.1101; Smith KL, 1998, DEEP-SEA RES PT II, V45, P573, DOI 10.1016/S0967-0645(97)00094-5; SMITH KL, 1989, DEEP-SEA RES, V36, P1111, DOI 10.1016/0198-0149(89)90081-2; SMITH KL, 1987, LIMNOL OCEANOGR, V32, P201, DOI 10.4319/lo.1987.32.1.0201; Smith KL, 1998, DEEP-SEA RES PT II, V45, P843, DOI 10.1016/S0967-0645(98)00005-8; Tegner MJ, 1996, CAL COOP OCEAN FISH, V37, P111; Veit RR, 1996, MAR ECOL PROG SER, V139, P11, DOI 10.3354/meps139011; Veit RR, 1997, GLOB CHANGE BIOL, V3, P23, DOI 10.1046/j.1365-2486.1997.d01-130.x	28	108	109	2	23	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	MAY 14	1999	284	5417					1174	1177		10.1126/science.284.5417.1174	http://dx.doi.org/10.1126/science.284.5417.1174			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	197HJ	10325229				2022-12-28	WOS:000080359100039
J	Hickman, AB; Namboodiri, MAA; Klein, DC; Dyda, F				Hickman, AB; Namboodiri, MAA; Klein, DC; Dyda, F			The structural basis of ordered substrate binding by serotonin N-acetyltransferase: Enzyme complex at 1.8 angstrom resolution with a bisubstrate analog	CELL			English	Article							CATALYTIC MECHANISM; CRYSTAL-STRUCTURES; WATER-MOLECULES; PINEAL-GLAND; REFINEMENT; SUPERFAMILY; PARAMETERS; PROTEINS	Serotonin N-acetyltransferase, a member of the GNAT acetyltransferase superfamily, is the penultimate enzyme in the conversion of serotonin to melatonin, the circadian neurohormone. Comparison of the structures of the substrate-free enzyme and the complex with a bisubstrate analog, coenzyme A-S-acetyltryptamine, demonstrates that acetyl coenzyme A (AcCoA) binding is accompanied by a large conformational change that in turn leads to the formation of the serotonin-binding site. The structure of the complex also provides insight into how the enzyme may facilitate acetyl transfer. A water-filled channel leading from the active site to the surface provides a pathway for proton removal following amine deprotonation. Furthermore, structural and mutagenesis results indicate an important role for Tyr-168 in catalysis.	NIDDKD, Mol Biol Lab, NIH, Bethesda, MD 20892 USA; NIDDKD, Dev Neurobiol Lab, NICHHD, Bethesda, MD 20892 USA; Uniformed Serv Univ Hlth Sci, Dept Physiol, Bethesda, MD 20814 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK); National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD); NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK); Uniformed Services University of the Health Sciences - USA	Dyda, F (corresponding author), NIDDKD, Mol Biol Lab, NIH, Bethesda, MD 20892 USA.	dyda@ulti.niddk.nih.gov		Klein, David/0000-0002-1792-5806	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [ZIAHD000095, Z01HD000095] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [ZIHDK034002, Z01DK034002, ZIADK034002] Funding Source: NIH RePORTER	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Auerbach G, 1997, EMBO J, V16, P7219, DOI 10.1093/emboj/16.24.7219; Beaman TW, 1998, BIOCHEMISTRY-US, V37, P6689, DOI 10.1021/bi980106v; Bonhomme N, 1998, J CLIN PSYCHOPHARM, V18, P447, DOI 10.1097/00004714-199812000-00005; BrUnger A. T., 1992, X PLOR VERSION 3 1 S; BRUNGER AT, 1992, NATURE, V355, P472, DOI 10.1038/355472a0; CARSON M, 1991, J APPL CRYSTALLOGR, V24, P958, DOI 10.1107/S0021889891007240; COON SL, 1995, SCIENCE, V270, P1681, DOI 10.1126/science.270.5242.1681; De Angelis J, 1998, J BIOL CHEM, V273, P3045, DOI 10.1074/jbc.273.5.3045; Dunlap JC, 1999, CELL, V96, P271, DOI 10.1016/S0092-8674(00)80566-8; Dutnall RN, 1998, CELL, V94, P427, DOI 10.1016/S0092-8674(00)81584-6; ENGH RA, 1991, ACTA CRYSTALLOGR A, V47, P392, DOI 10.1107/S0108767391001071; Esposito D, 1997, NUCLEIC ACIDS RES, V25, P3605, DOI 10.1093/nar/25.18.3605; Gastel JA, 1998, SCIENCE, V279, P1358, DOI 10.1126/science.279.5355.1358; Hickman AB, 1999, MOL CELL, V3, P23, DOI 10.1016/S1097-2765(00)80171-9; JANCARIK J, 1991, J APPL CRYSTALLOGR, V24, P409, DOI 10.1107/S0021889891004430; Khalil EM, 1998, J BIOL CHEM, V273, P30321, DOI 10.1074/jbc.273.46.30321; Khalil EM, 1998, J AM CHEM SOC, V120, P6195, DOI 10.1021/ja981365a; Klein D.C., 1991, SUPRACHIASMATIC NUCL; Klein DC, 1997, RECENT PROG HORM RES, V52, P307; KLEIN DC, 1972, SCIENCE, V177, P532, DOI 10.1126/science.177.4048.532; Kohen A, 1998, ACCOUNTS CHEM RES, V31, P397, DOI 10.1021/ar9701225; Kordik CP, 1999, J MED CHEM, V42, P181, DOI 10.1021/jm980521l; LESLIE AGW, 1988, P NATL ACAD SCI USA, V85, P4133, DOI 10.1073/pnas.85.12.4133; Marx D, 1999, NATURE, V397, P601, DOI 10.1038/17579; *MERCK CO, 1976, MERCK IND, P1095; MEYER E, 1992, PROTEIN SCI, V1, P1543, DOI 10.1002/pro.5560011203; Modis Y, 1998, STRUCTURE, V6, P1345, DOI 10.1016/S0969-2126(98)00134-8; NAMBOODIRI MAA, 1987, METHOD ENZYMOL, V142, P583; NAVAZA J, 1994, ACTA CRYSTALLOGR A, V50, P157, DOI 10.1107/S0108767393007597; Neuwald AF, 1997, TRENDS BIOCHEM SCI, V22, P154, DOI 10.1016/S0968-0004(97)01034-7; Parkinson G, 1996, ACTA CRYSTALLOGR D, V52, P57, DOI 10.1107/S0907444995011115; POMES R, 1995, CHEM PHYS LETT, V234, P416, DOI 10.1016/0009-2614(95)00071-B; Reppert SM, 1998, NEURON, V21, P1, DOI 10.1016/S0896-6273(00)80234-2; RUSHMORE TH, 1993, J BIOL CHEM, V268, P11475; Tronrud DE, 1996, J APPL CRYSTALLOGR, V29, P100, DOI 10.1107/S002188989501421X; Wirz-Justice Anna, 1995, P999; Wolf E, 1998, CELL, V94, P439, DOI 10.1016/S0092-8674(00)81585-8	37	146	149	2	7	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	APR 30	1999	97	3					361	369		10.1016/S0092-8674(00)80745-X	http://dx.doi.org/10.1016/S0092-8674(00)80745-X			9	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	192VP	10319816	Bronze			2022-12-28	WOS:000080100500009
J	Lippard, SJ				Lippard, SJ			Biochemistry - Free copper ions in the cell?	SCIENCE			English	Editorial Material							SUPEROXIDE-DISMUTASE; CHAPERONE		MIT, Dept Chem, Cambridge, MA 02139 USA	Massachusetts Institute of Technology (MIT)	Lippard, SJ (corresponding author), MIT, Dept Chem, Cambridge, MA 02139 USA.							Casareno RLB, 1998, J BIOL CHEM, V273, P23625, DOI 10.1074/jbc.273.37.23625; Colpas GJ, 1999, BIOCHEMISTRY-US, V38, P4078, DOI 10.1021/bi982435t; Culotta VC, 1997, J BIOL CHEM, V272, P23469, DOI 10.1074/jbc.272.38.23469; HIROSE J, 1982, ARCH BIOCHEM BIOPHYS, V218, P179, DOI 10.1016/0003-9861(82)90334-4; Lippard S. J., 1994, PRINCIPLES BIOINORGA; Pufahl RA, 1997, SCIENCE, V278, P853, DOI 10.1126/science.278.5339.853; Radisky D, 1999, J BIOL CHEM, V274, P4481, DOI 10.1074/jbc.274.8.4481; Rae TD, 1999, SCIENCE, V284, P805, DOI 10.1126/science.284.5415.805; Rothstein JD, 1999, J NEUROCHEM, V72, P422, DOI 10.1046/j.1471-4159.1999.0720422.x; Tsien RY, 1998, SCIENCE, V280, P1954, DOI 10.1126/science.280.5371.1954; Valentine JS, 1997, SCIENCE, V278, P817, DOI 10.1126/science.278.5339.817; Wong PC, 1998, CURR OPIN NEUROBIOL, V8, P791, DOI 10.1016/S0959-4388(98)80123-2	12	69	70	1	19	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	APR 30	1999	284	5415					748	749		10.1126/science.284.5415.748	http://dx.doi.org/10.1126/science.284.5415.748			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	192AW	10336397				2022-12-28	WOS:000080056200027
J	Antman, K; Shea, S				Antman, K; Shea, S			Screening mammography under age 50	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material							BREAST-CANCER DETECTION; YOUNG-WOMEN; DEATH RATES; TRIALS; PERSPECTIVE; MORTALITY; RISK		Columbia Univ, Coll Phys & Surg, Herbert Irving Comprehens Canc Ctr, New York, NY USA; Columbia Univ, Coll Phys & Surg, Div Gen Med, New York, NY USA	Columbia University; Columbia University	Antman, K (corresponding author), MHB 6N 435,177 Ft Washington Ave, New York, NY 10032 USA.	kha@columbia.edu		/0000-0002-1093-8356	NCI NIH HHS [P01CA-40053, P20CA66244-01] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA040053, F32CA066244] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Andersson I, 1997, J Natl Cancer Inst Monogr, P63; Bjurstam N, 1997, J Natl Cancer Inst Monogr, P53; Dolan NC, 1997, CANCER, V80, P413; EDDY DM, 1989, ANN INTERN MED, V111, P389, DOI 10.7326/0003-4819-111-5-389; Elmore G, 1998, NEW ENGL J MED, V338, P1089, DOI 10.1056/NEJM199804163381601; Elwood JM, 1993, ONLINE J CURR CLIN T; FLETCHER SW, 1993, J NATL CANCER I, V85, P1644, DOI 10.1093/jnci/85.20.1644; Frisell J, 1997, BREAST CANCER RES TR, V45, P263, DOI 10.1023/A:1005872617944; KERLIKOWSKE K, 1995, JAMA-J AM MED ASSOC, V273, P149, DOI 10.1001/jama.273.2.149; Larsson L G, 1996, J Med Screen, V3, P129; Larsson L G, 1997, J Natl Cancer Inst Monogr, P57; Margolese R, 1996, LANCET, V347, P881, DOI 10.1016/S0140-6736(96)91352-5; Miller A B, 1997, J Natl Cancer Inst Monogr, P37; MILLER AB, 1992, CAN MED ASSOC J, V147, P1477; MILLER AB, 1992, CAN MED ASSOC J, V147, P1459; Narod SA, 1997, LANCET, V349, P1846, DOI 10.1016/S0140-6736(05)61736-9; NEUGUT AI, 1995, AM J PUBLIC HEALTH, V85, P832, DOI 10.2105/AJPH.85.6.832; NYSTROM L, 1993, LANCET, V341, P973, DOI 10.1016/0140-6736(93)91067-V; OSUCH JR, 1994, CANCER, V74, P271, DOI 10.1002/cncr.2820741311; ROBERTS MM, 1990, LANCET, V335, P241; Shapiro S, 1997, J Natl Cancer Inst Monogr, P27; SICKLES EA, 1995, ANN INTERN MED, V122, P534, DOI 10.7326/0003-4819-122-7-199504010-00010; SMART CR, 1995, CANCER, V75, P1619, DOI 10.1002/1097-0142(19950401)75:7<1619::AID-CNCR2820750711>3.0.CO;2-T; Tabar L, 1997, J Natl Cancer Inst Monogr, P43; TARONE RE, 1995, CANCER, V75, P997, DOI 10.1002/1097-0142(19950215)75:4<997::AID-CNCR2820750415>3.0.CO;2-M; Taubes G, 1997, SCIENCE, V275, P1056, DOI 10.1126/science.275.5303.1056; WRIGHT CJ, 1995, LANCET, V346, P29, DOI 10.1016/S0140-6736(95)92655-0	27	20	22	0	1	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	APR 28	1999	281	16					1470	1472		10.1001/jama.281.16.1470	http://dx.doi.org/10.1001/jama.281.16.1470			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	188PP	10227298				2022-12-28	WOS:000079857400001
J	Bender, R; Jockel, KH; Trautner, C; Spraul, M; Berger, M				Bender, R; Jockel, KH; Trautner, C; Spraul, M; Berger, M			Effect of age on excess mortality in obesity	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							BODY-MASS INDEX; 26-YEAR RISK; WEIGHT; WOMEN; POPULATION; MEN	Context The effect of age on excess mortality from all causes associated with obesity is controversial. Few studies have investigated the association between body mass index (BMI, calculated as weight in kilograms divided by the square of height in meters), age, and mortality, with sufficient numbers of subjects at all levels of obesity. Objective To assess the effect of age on the excess mortality associated with all degrees of obesity. Design Prospective cohort study. Setting and Participants A total of 6193 obese patients with mean (SD) BMI of 36.6 (6.1) kg/m(2) and mean (SD) age of 40.4 (12.9) years who had been referred to the obesity clinic of Heinrich-Heine University, Dusseldorf, Germany, between 1961 and 1994. Median follow-up time was 14.8 years. Main Outcome Measure All-cause mortality through 1994 among 6053 patients for whom follow-up data were available (1028 deaths) analyzed as standardized mortality ratios (SMRs) using the male-female population of the geographic region (North Rhine Westphalia) as reference. Results The cohort was grouped into approximate quartiles according to age (18-29, 30-39, 40-49, and 50-74 years) and BMI (25 to <32, 32 to <36, 36 to <40, and greater than or equal to 40 kg/m(2)) at baseline. The SMRs showed a significant excess mortality with an SMR for men of 1.67 (95% confidence interval, 1.51-1.85; P<.001) and an SMR for women of 1.45 (95% confidence interval, 1.34-1.57; P<.001), The excess mortality associated with obesity declined with age. For men, the SMRs of the 4 age groups were 2.46, 2.30, 1.99, and 1.31, respectively; for women, they were 1.81, 2.10, 1.70, and 1.26, respectively (Poisson trend test, P<.001). The SMRs increased with BMI but, within each BMI group, the SMRs decreased with age. The lowest SMRs (for men, 1.01; for women, 0.91) were obtained for patients older than 50 years with BMIs of 25 to less than 32 kg/m(2). Thus, older men and women at a BMI range of 25 to less than 32 kg/m(2) had no excess mortality. The highest SMRs (for men, 4.22; for women, 3.79) were calculated for the patients aged 18 to 29 years with a BMI of 40 kg/m(2) or higher. Conclusions In this large cohort of obese persons, risk of death increased with body weight, but obesity-related excess mortality declined with age at all levels of obesity.	Univ Dusseldorf, Dept Metab Dis & Nutr, WHO, Collaborating Ctr Diabet, D-40001 Dusseldorf, Germany; Biometry & Epidemiol Univ Clin, Inst Med Informat, Essen, Germany; Humboldt Univ, Inst Occupat & Social Med & Epidemiol, Berlin, Germany	Heinrich Heine University Dusseldorf; World Health Organization; University of Duisburg Essen; Humboldt University of Berlin	Bender, R (corresponding author), Univ Dusseldorf, Dept Metab Dis & Nutr, WHO, Collaborating Ctr Diabet, POB 101007, D-40001 Dusseldorf, Germany.	bender@uni-duesseldorf.de						Allison DB, 1997, INT J OBESITY, V21, P424, DOI 10.1038/sj.ijo.0800423; ANDRES R, 1985, ANN INTERN MED, V103, P1030, DOI 10.7326/0003-4819-103-6-1030; Bender R, 1998, AM J EPIDEMIOL, V147, P42; BERCHTOLD P, 1981, INT J OBESITY, V5, P1; BERGER M, 1976, INTERNIST, V17, P494; BERGER M, 1981, RECENT ADV OBESITY R, P1; Breslow NE., 1987, STAT METHODS CANC RE, P81; DRENICK EJ, 1980, JAMA-J AM MED ASSOC, V243, P443, DOI 10.1001/jama.243.5.443; Durazo-Arvizu RA, 1998, AM J EPIDEMIOL, V147, P739, DOI 10.1093/oxfordjournals.aje.a009518; Forschungsverbund DHP, 1998, DTSCH HERZ KREISL PR; Jones ME, 1998, AM J EPIDEMIOL, V148, P1012; KRONMAL RA, 1993, ARCH INTERN MED, V153, P1065, DOI 10.1001/archinte.153.9.1065; KUSHNER RF, 1993, NUTR REV, V51, P127, DOI 10.1111/j.1753-4887.1993.tb03089.x; LARSSON B, 1981, INT J OBESITY, V5, P97; Lindsted KD, 1997, AM J EPIDEMIOL, V146, P1, DOI 10.1093/oxfordjournals.aje.a009185; MANSON JE, 1987, JAMA-J AM MED ASSOC, V257, P353, DOI 10.1001/jama.257.3.353; MATTILA K, 1986, BRIT MED J, V292, P867, DOI 10.1136/bmj.292.6524.867-a; PANZRAM G, 1987, DIABETOLOGIA, V30, P123, DOI 10.1007/BF00274216; RISSANEN A, 1989, J CLIN EPIDEMIOL, V42, P781, DOI 10.1016/0895-4356(89)90076-0; RISSANEN A, 1991, J CLIN EPIDEMIOL, V44, P787, DOI 10.1016/0895-4356(91)90131-R; SAS, 1987, SAS STAT GUID PERS C; *SAS I INC, 1985, SAS PROC GUID PERS C; *SAS I INC, 1985, SAS IML US GUID VERS; Singh PN, 1998, EPIDEMIOLOGY, V9, P246, DOI 10.1097/00001648-199805000-00007; SJOSTROM L V, 1992, American Journal of Clinical Nutrition, V55, p516S, DOI 10.1093/ajcn/55.2.516s; Stevens J, 1998, NEW ENGL J MED, V338, P1, DOI 10.1056/NEJM199801013380101; STOLZENBERG H, 1995, NATL HLTH SURVEY GER; Troiano RP, 1996, INT J OBESITY, V20, P63	28	192	196	2	5	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	APR 28	1999	281	16					1498	1504		10.1001/jama.281.16.1498	http://dx.doi.org/10.1001/jama.281.16.1498			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	188PP	10227319	Bronze			2022-12-28	WOS:000079857400031
J	te Velde, ER; van Baar, AL; van Kooij, RJ				te Velde, ER; van Baar, AL; van Kooij, RJ			Concerns about assisted reproduction	LANCET			English	Editorial Material							INTRACYTOPLASMIC SPERM INJECTION		Univ Utrecht Hosp, Div Obstet & Gynaecol, Dept Fertil & Endocrinol, Utrecht, Netherlands; Univ Amsterdam, Acad Med Ctr, Dept Neonatol, NL-1105 AZ Amsterdam, Netherlands	Utrecht University; Utrecht University Medical Center; University of Amsterdam; Academic Medical Center Amsterdam	te Velde, ER (corresponding author), Univ Utrecht Hosp, Div Obstet & Gynaecol, Dept Fertil & Endocrinol, Utrecht, Netherlands.		van Baar, Anneloes/L-8236-2013	van Baar, Anneloes/0000-0002-3498-9019				Bonduelle M, 1996, HUM REPROD, V11, P1558; CUMMINS JM, 1995, HUM REPROD, V10, P138, DOI 10.1093/humrep/10.suppl_1.138; DULIOUST E, 1995, P NATL ACAD SCI USA, V92, P589, DOI 10.1073/pnas.92.2.589; Kurinczuk JJ, 1997, BRIT MED J, V315, P1260, DOI 10.1136/bmj.315.7118.1260; MOUZON D, 1997, J ASSIST REPROD GE S, V14, P251; PALERMO G, 1992, LANCET, V340, P17, DOI 10.1016/0140-6736(92)92425-F; Skuse DH, 1997, NATURE, V387, P705, DOI 10.1038/42706; Slater A, 1997, ARCH DIS CHILD, V77, P474, DOI 10.1136/adc.77.6.474; Sutcliffe AG, 1995, HUM REPROD, V10, P3332, DOI 10.1093/oxfordjournals.humrep.a135915; VanOpstal D, 1997, HUM REPROD, V12, P682, DOI 10.1093/humrep/12.4.682; Wennerholm UB, 1998, LANCET, V351, P1085, DOI 10.1016/S0140-6736(97)08247-0	11	51	51	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON WC1B 3SL, ENGLAND	0140-6736			LANCET	Lancet	MAY 23	1998	351	9115					1524	1525		10.1016/S0140-6736(98)22021-6	http://dx.doi.org/10.1016/S0140-6736(98)22021-6			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZQ497	10326529				2022-12-28	WOS:000073868000002
J	Dake, MD; Kato, N; Mitchell, RS; Semba, CP; Razavi, MK; Shimono, T; Hirano, T; Takeda, K; Yada, I; Miller, DC				Dake, MD; Kato, N; Mitchell, RS; Semba, CP; Razavi, MK; Shimono, T; Hirano, T; Takeda, K; Yada, I; Miller, DC			Endovascular stent-graft placement for the treatment of acute aortic dissection	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							VASCULAR COMPLICATIONS; ISCHEMIC COMPLICATIONS; A DISSECTION; ANEURYSMS; EXPERIENCE; SURGERY	Background The standard treatment for acute aortic dissection is either surgical or medical therapy, depending on the morphologic features of the lesion and any associated complications. Irrespective of the form of treatment, the associated mortality and morbidity are considerable. Methods We studied the placement of endovascular stent-grafts across the primary entry tear for the management of acute aortic dissection originating in the descending thoracic aorta. We evaluated the feasibility, safety, and effectiveness of transluminal stent-graft placement over the entry tear in 4 patients with acute type A aortic dissections (which involve the ascending aorta) and 15 patients with acute type B aortic dissections (which are confined to the descending aorta). Dissections involved aortic branches in 14 of the 19 patients (74 percent), and symptomatic compromise of multiple branch vessels was observed in 7 patients (37 percent). The stent-grafts were made of self-expanding stainless-steel covered with woven polyester or polytetrafluoroethylene material. Results Placement of endovascular stent-grafts across the primary entry tears was technically successful in all 19 patients. Complete thrombosis of the thoracic aortic false lumen was achieved in 15 patients (79 percent), and partial thrombosis was achieved in 4 (21 percent). Revascularization of ischemic branch vessels, with subsequent relief of corresponding symptoms, occurred in 76 percent of the obstructed branches. Three of the 19 patients died within 30 days, for an early mortality rate of 16 percent (95 percent confidence interval, 0 to 32 percent). There were no deaths and no instances of aneurysm or aortic rupture during the subsequent average follow-up period of 13 months. Conclusions These initial results suggest that stent-graft coverage of the primary entry tear may be a promising new treatment for selected patients with acute aortic dissection. This technique requires further evaluation, however, to assess its therapeutic potential fully. (N Engl J Med 1999;340:1546-52.) (C)1999, Massachusetts Medical Society.	Stanford Univ, Med Ctr, Sch Med, Div Cardiovasc & Intervent Radiol, Stanford, CA 94305 USA; Stanford Univ, Sch Med, Dept Cardiovasc & Thorac Surg, Stanford, CA 94305 USA; Mie Univ, Sch Med, Dept Radiol, Tsu, Mie 514, Japan; Mie Univ, Sch Med, Dept Thorac & Cardiovasc Surg, Tsu, Mie 514, Japan	Stanford University; Stanford University; Mie University; Mie University	Dake, MD (corresponding author), Stanford Univ, Med Ctr, Sch Med, Div Cardiovasc & Intervent Radiol, H-3647, Stanford, CA 94305 USA.	mddake@leland.stanford.edu		Miller, D. Craig/0000-0001-7619-0080				ANAGNOSTOPOULOS CE, 1972, AM J CARDIOL, V30, P263, DOI 10.1016/0002-9149(72)90070-7; Blum U, 1997, NEW ENGL J MED, V336, P13, DOI 10.1056/NEJM199701023360103; CAMBRIA RP, 1988, J VASC SURG, V7, P199, DOI 10.1067/mva.1988.avs0070199; CHARNSANGAVEJ C, 1985, RADIOLOGY, V157, P323, DOI 10.1148/radiology.157.2.4048439; CRAWFORD ES, 1988, ANN SURG, V208, P254, DOI 10.1097/00000658-198809000-00002; DAKE MD, 1994, NEW ENGL J MED, V331, P1729, DOI 10.1056/NEJM199412293312601; ELEFTERIADES JA, 1992, ANN THORAC SURG, V53, P11, DOI 10.1016/0003-4975(92)90752-P; ERBEL R, 1993, CIRCULATION, V87, P1604, DOI 10.1161/01.CIR.87.5.1604; ERGIN MA, 1994, ANN THORAC SURG, V57, P820, DOI 10.1016/0003-4975(94)90182-1; FANN JI, 1995, ANN VASC SURG, V9, P311, DOI 10.1007/BF02135293; FANN JI, 1990, ANN SURG, V212, P705, DOI 10.1097/00000658-199012000-00009; KATO N, 1994, J VASC INTERV RADIOL, V5, P417, DOI 10.1016/S1051-0443(94)71518-9; KATO N, 1994, J VASC INTERV RADIOL, V5, P805, DOI 10.1016/S1051-0443(94)71610-9; Kazui T, 1996, J THORAC CARDIOV SUR, V112, P973, DOI 10.1016/S0022-5223(96)70097-1; Kouchoukos NT, 1997, NEW ENGL J MED, V336, P1876, DOI 10.1056/NEJM199706263362606; MILLER DC, 1979, J THORAC CARDIOV SUR, V78, P365; MILLER DC, 1984, CIRCULATION, V70, P153; Miller DC., 1983, AORTIC DISSECTION, P193; Mitchell RS, 1996, J THORAC CARDIOV SUR, V111, P1054, DOI 10.1016/S0022-5223(96)70382-3; MOON MR, 1993, J SURG RES, V54, P381, DOI 10.1006/jsre.1993.1061; Parodi J C, 1991, Ann Vasc Surg, V5, P491, DOI 10.1007/BF02015271; PATE JW, 1976, AM SURGEON, V42, P395; RAZAVI MK, 1995, RADIOLOGY, V197, P801, DOI 10.1148/radiology.197.3.7480759; Slonim SM, 1996, J VASC SURG, V23, P241, DOI 10.1016/S0741-5214(96)70268-9; SORENSEN H R, 1964, Acta Chir Scand, V128, P644; TRENT MS, 1990, J VASC SURG, V11, P707, DOI 10.1067/mva.1990.18435; Wheat M W Jr, 1980, World J Surg, V4, P563; WHITE RD, 1988, AM J ROENTGENOL, V150, P87, DOI 10.2214/ajr.150.1.87; Williams DM, 1997, J VASC INTERV RADIOL, V8, P605, DOI 10.1016/S1051-0443(97)70619-5	29	917	1063	2	62	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	MAY 20	1999	340	20					1546	1552		10.1056/NEJM199905203402004	http://dx.doi.org/10.1056/NEJM199905203402004			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	197HG	10332016				2022-12-28	WOS:000080358900004
J	Agovino, T				Agovino, T			Caring for ethnic Albanians in Macedonia's refugee camps	LANCET			English	Article											Agovino, T (corresponding author), Flat 2,12 Benczur Utca, H-1068 Budapest, Hungary.								0	5	5	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	MAY 15	1999	353	9165					1701	1703		10.1016/S0140-6736(99)04433-5	http://dx.doi.org/10.1016/S0140-6736(99)04433-5			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	198DT	10335807				2022-12-28	WOS:000080408000048
J	Denley, I; Smith, SW				Denley, I; Smith, SW			Privacy in clinical information systems in secondary care	BRITISH MEDICAL JOURNAL			English	Article									Conquest Hosp, St Leonards On Sea TN37 7RD, England; Syst C, Maidstone ME14 1SR, Kent, England		Smith, SW (corresponding author), Conquest Hosp, St Leonards On Sea TN37 7RD, England.							Anderson R, 1996, SECURITY CLIN INFORM; BARBER B, 1997, PATIENT PRIVACY CONF; DENLEY I, 1999, HLTH INFORMATICS J, V4, P174	3	24	25	0	5	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	MAY 15	1999	318	7194					1328	1330		10.1136/bmj.318.7194.1328	http://dx.doi.org/10.1136/bmj.318.7194.1328			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	198HR	10323822	Green Submitted, Green Published, Bronze			2022-12-28	WOS:000080418400030
J	Josefson, D				Josefson, D			New formula predicts risk of prostate cancer relapse	BRITISH MEDICAL JOURNAL			English	News Item																		Pound CR, 1999, JAMA-J AM MED ASSOC, V281, P1591, DOI 10.1001/jama.281.17.1591	1	0	0	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	MAY 15	1999	318	7194					1309	1309		10.1136/bmj.318.7194.1309	http://dx.doi.org/10.1136/bmj.318.7194.1309			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	198HR	10323808	Green Published			2022-12-28	WOS:000080418400017
J	Silberberg, J				Silberberg, J			Better coronary risk assessment in women	LANCET			English	Editorial Material							HEART-DISEASE; FAMILY-HISTORY; HYPERTENSION; PREVENTION; MEN		John Hunter Hosp, Cardiovasc Unit, Newcastle, NSW 2320, Australia	John Hunter Hospital	Silberberg, J (corresponding author), John Hunter Hosp, Cardiovasc Unit, Newcastle, NSW 2320, Australia.							[Anonymous], 1996, J Am Coll Cardiol, V27, P957; BERWICK DM, 1980, CHOLESTEROL CHILDREN, P357; De Bacquer D, 1998, HEART, V80, P570, DOI 10.1136/hrt.80.6.570; Garber AM, 1996, ANN INTERN MED, V124, P518, DOI 10.7326/0003-4819-124-5-199603010-00013; HUNT SC, 1986, J CHRON DIS, V39, P809, DOI 10.1016/0021-9681(86)90083-4; KULLER LH, 1986, CIRCULATION, V73, P114, DOI 10.1161/01.CIR.73.1.114; Mosterd A, 1999, NEW ENGL J MED, V340, P1221, DOI 10.1056/NEJM199904223401601; Newnham HH, 1997, LANCET, V349, pS3, DOI 10.1016/S0140-6736(97)90002-7; PEDERSEN TR, 1994, LANCET, V344, P1383; PYORALA K, 1994, ATHEROSCLEROSIS, V110, P121, DOI 10.1016/0021-9150(94)90200-3; Ramsay LE, 1996, LANCET, V348, P387, DOI 10.1016/S0140-6736(96)05516-X; ROSE G, 1985, INT J EPIDEMIOL, V14, P32, DOI 10.1093/ije/14.1.32; Sacks FM, 1996, NEW ENGL J MED, V335, P1001, DOI 10.1056/NEJM199610033351401; Silberberg JS, 1998, AM J EPIDEMIOL, V147, P1133; Tonkin A, 1998, NEW ENGL J MED, V339, P1349	15	8	8	0	0	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	MAY 15	1999	353	9165					1637	1638		10.1016/S0140-6736(98)00382-1	http://dx.doi.org/10.1016/S0140-6736(98)00382-1			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	198DT	10335779				2022-12-28	WOS:000080408000004
J	Wimberly, BT; Guymon, R; McCutcheon, JP; White, SW; Ramakrishnan, V				Wimberly, BT; Guymon, R; McCutcheon, JP; White, SW; Ramakrishnan, V			A detailed view of a ribosomal active site: The structure of the L11-RNA complex	CELL			English	Article							RNA TERTIARY STRUCTURE; FACTOR EF-G; CRYSTAL-STRUCTURE; PROTEIN L11; ESCHERICHIA-COLI; GTPASE CENTER; ANOMALOUS DIFFRACTION; THIOSTREPTON INTERACT; SECONDARY STRUCTURE; BINDING	We report the crystal structure of a 58 nucleotide fragment of 23S ribosomal RNA bound to ribosomal protein L11. This highly conserved ribonucleoprotein domain is the target for the thiostrepton family of antibiotics that disrupt elongation factor function. The highly compact RNA has both familiar and novel structural motifs. While the C-terminal domain of L11 binds RNA tightly, the N-terminal domain makes only limited contacts with RNA and is proposed to function as a switch that reversibly associates with an adjacent region of RNA. The sites of mutations conferring resistance to thiostrepton and micrococcin line a narrow cleft between the RNA and the N-terminal domain. These antibiotics are proposed to bind in this cleft, locking the putative switch and interfering with the function of elongation factors.	Univ Utah, Sch Med, Dept Biochem, Salt Lake City, UT 84132 USA; Univ Tennessee, St Jude Childrens Hosp, Dept Biol Struct, Memphis, TN 38105 USA; Univ Tennessee, Dept Biochem, Memphis, TN 38105 USA	Utah System of Higher Education; University of Utah; St Jude Children's Research Hospital; University of Tennessee System; University of Tennessee Health Science Center; University of Tennessee System; University of Tennessee Health Science Center	Ramakrishnan, V (corresponding author), Univ Utah, Sch Med, Dept Biochem, Salt Lake City, UT 84132 USA.	stephen.white@stjude.org; v.ramakrishnan@m.cc.utah.edu	White, Stephen W/N-8164-2018	Ramakrishnan, V/0000-0002-4699-2194; McCutcheon, John/0000-0002-5489-6039	NIGMS NIH HHS [GM 44973] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Abrahams JP, 1996, ACTA CRYSTALLOGR D, V52, P30, DOI 10.1107/S0907444995008754; Briones E, 1998, J BIOL CHEM, V273, P31956, DOI 10.1074/jbc.273.48.31956; BRUNGER AT, 1988, J MOL BIOL, V203, P803, DOI 10.1016/0022-2836(88)90211-2; Bukhman YV, 1997, J MOL BIOL, V273, P1020, DOI 10.1006/jmbi.1997.1383; CARSON M, 1991, J APPL CRYSTALLOGR, V24, P958, DOI 10.1107/S0021889891007240; Cate JH, 1996, SCIENCE, V273, P1678, DOI 10.1126/science.273.5282.1678; Conn GL, 1998, BIOCHEMISTRY-US, V37, P11980, DOI 10.1021/bi980825+; CUNDLIFFE E, 1981, EUR J BIOCHEM, V118, P47, DOI 10.1111/j.1432-1033.1981.tb05484.x; CUNDLIFFE E, 1979, NATURE, V278, P859, DOI 10.1038/278859a0; Cundliffe E., 1986, STRUCTURE FUNCTION G, P586; delaFortelle E, 1997, METHOD ENZYMOL, V276, P472, DOI 10.1016/S0076-6879(97)76073-7; DONNER D, 1978, P NATL ACAD SCI USA, V75, P3192, DOI 10.1073/pnas.75.7.3192; DRAPER DE, 1995, NUCL ACIDS S SER, V33, P5; ENGH RA, 1991, ACTA CRYSTALLOGR A, V47, P392, DOI 10.1107/S0108767391001071; Ferre-D'Amare AR, 1998, NATURE, V395, P567, DOI 10.1038/26912; Fountain MA, 1996, BIOCHEMISTRY-US, V35, P6539, DOI 10.1021/bi952697k; GLOTZ C, 1981, NUCLEIC ACIDS RES, V9, P3287, DOI 10.1093/nar/9.14.3287; GRUENWEDEL DW, 1967, BIOPOLYMERS, V5, P847, DOI 10.1002/bip.1967.360050907; GRUENWEDEL DW, 1966, J MOL BIOL, V21, P129, DOI 10.1016/0022-2836(66)90084-2; HENDRICKSON WA, 1991, SCIENCE, V254, P51, DOI 10.1126/science.1925561; Hinck AP, 1997, J MOL BIOL, V274, P101, DOI 10.1006/jmbi.1997.1379; Jones TA, 1997, METHOD ENZYMOL, V277, P173, DOI 10.1016/S0076-6879(97)77012-5; KOSTURKO LD, 1974, BIOCHEMISTRY-US, V13, P3949, DOI 10.1021/bi00716a020; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; LU M, 1994, J MOL BIOL, V244, P572, DOI 10.1006/jmbi.1994.1753; LU M, 1995, NUCLEIC ACIDS RES, V23, P3426, DOI 10.1093/nar/23.17.3426; Markus MA, 1997, NAT STRUCT BIOL, V4, P70, DOI 10.1038/nsb0197-70; MOAZED D, 1988, NATURE, V334, P362, DOI 10.1038/334362a0; Munishkin A, 1997, P NATL ACAD SCI USA, V94, P12280, DOI 10.1073/pnas.94.23.12280; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; NISSEN P, 1995, SCIENCE, V270, P1464, DOI 10.1126/science.270.5241.1464; NOLLER HF, 1981, NUCLEIC ACIDS RES, V9, P6167, DOI 10.1093/nar/9.22.6167; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Parkinson G, 1996, ACTA CRYSTALLOGR D, V52, P57, DOI 10.1107/S0907444995011115; PESTKA S, 1970, BIOCHEM BIOPH RES CO, V40, P667, DOI 10.1016/0006-291X(70)90956-3; Porse BT, 1999, J MOL BIOL, V287, P33, DOI 10.1006/jmbi.1999.2600; Porse BT, 1998, J MOL BIOL, V276, P391, DOI 10.1006/jmbi.1997.1541; PRICE SR, 1995, J MOL BIOL, V249, P398, DOI 10.1006/jmbi.1995.0305; QUIGLEY GJ, 1976, SCIENCE, V194, P796, DOI 10.1126/science.790568; Ramakrishnan V, 1998, TRENDS BIOCHEM SCI, V23, P208, DOI 10.1016/S0968-0004(98)01214-6; RAMAKRISHNAN V, 1993, NATURE, V362, P219, DOI 10.1038/362219a0; Ramakrishnan V, 1997, METHOD ENZYMOL, V276, P538, DOI 10.1016/S0076-6879(97)76077-4; ROSENDAHL G, 1994, NUCLEIC ACIDS RES, V22, P357, DOI 10.1093/nar/22.3.357; ROSENDAHL G, 1993, J MOL BIOL, V234, P1013, DOI 10.1006/jmbi.1993.1655; SCHMIDT FJ, 1981, J BIOL CHEM, V256, P2301; SOPORI ML, 1972, BIOCHEM BIOPH RES CO, V46, P238, DOI 10.1016/0006-291X(72)90655-9; Spahn CMT, 1998, BIOL CHEM, V379, P753; STOFFLER G, 1980, J BIOL CHEM, V255, P517; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; SZEWCZAK AA, 1993, P NATL ACAD SCI USA, V90, P9581, DOI 10.1073/pnas.90.20.9581; Terwilliger TC, 1999, ACTA CRYSTALLOGR D, V55, P849, DOI 10.1107/S0907444999000839; THOMPSON J, 1979, EUR J BIOCHEM, V98, P261, DOI 10.1111/j.1432-1033.1979.tb13184.x; THOMPSON J, 1982, J BIOL CHEM, V257, P7915; WANG YX, 1993, BIOCHEMISTRY-US, V32, P12279, DOI 10.1021/bi00097a002; Wilson KS, 1998, CELL, V92, P337, DOI 10.1016/S0092-8674(00)80927-7; Wilson KS, 1998, CELL, V92, P131, DOI 10.1016/S0092-8674(00)80905-8; WIMBERLY B, 1994, NAT STRUCT BIOL, V1, P820, DOI 10.1038/nsb1194-820; WIMBERLY B, 1993, BIOCHEMISTRY-US, V32, P1078, DOI 10.1021/bi00055a013; Wimberly BT, 1997, STRUCTURE, V5, P1187, DOI 10.1016/S0969-2126(97)00269-4; XING YY, 1995, J MOL BIOL, V249, P319, DOI 10.1006/jmbi.1995.0299; Xing YY, 1997, NAT STRUCT BIOL, V4, P24, DOI 10.1038/nsb0197-24; Xing YY, 1996, BIOCHEMISTRY-US, V35, P1581, DOI 10.1021/bi952132o	62	297	307	0	14	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	MAY 14	1999	97	4					491	502		10.1016/S0092-8674(00)80759-X	http://dx.doi.org/10.1016/S0092-8674(00)80759-X			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	196FV	10338213	Bronze			2022-12-28	WOS:000080299100010
J	Bejjani, BP; Damier, P; Arnulf, I; Thivard, L; Bonnet, AM; Dormont, D; Cornu, P; Pidoux, B; Samson, Y; Agid, Y				Bejjani, BP; Damier, P; Arnulf, I; Thivard, L; Bonnet, AM; Dormont, D; Cornu, P; Pidoux, B; Samson, Y; Agid, Y			Transient acute depression induced by high-frequency deep-brain stimulation	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							SUBTHALAMIC NUCLEUS; PARKINSONS-DISEASE; MOOD DISORDERS; HUMAN AMYGDALA; STROKE		Grp Hosp Pitie Salpetriere, Ctr Invest Clin, Federat Neurol, F-75634 Paris, France; Grp Hosp Pitie Salpetriere, INSERM, U289, F-75634 Paris, France; Hop La Pitie Salpetriere, Serv Neurol, F-75651 Paris, France; Hop La Pitie Salpetriere, Serv Neurochirurg, F-75651 Paris 13, France; Hop La Pitie Salpetriere, Serv Explorat Fonct Neurol, F-75651 Paris 13, France; CEA, Serv Hosp Frederic Joliot, F-91406 Orsay, France	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Pitie-Salpetriere - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Sorbonne Universite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Pitie-Salpetriere - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Sorbonne Universite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Pitie-Salpetriere - APHP; UDICE-French Research Universities; Sorbonne Universite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Pitie-Salpetriere - APHP; UDICE-French Research Universities; Sorbonne Universite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Pitie-Salpetriere - APHP; UDICE-French Research Universities; Sorbonne Universite; CEA; UDICE-French Research Universities; Universite Paris Saclay	Bejjani, BP (corresponding author), Hop La Pitie Salpetriere, Ctr Invest Clin, 47 Blvd Hop, F-75651 Paris 13, France.		Damier, Philippe/T-7829-2019; dormont, didier/B-2175-2012; samson, yves/C-5647-2013; Dormont, Didier/F-5492-2012	Arnulf, Isabelle/0000-0002-2240-2516; Holy Spirit University of Kaslik (USEK), FACULTY OF MEDICINE AND MEDICAL SCIENCESHoly Spirit University of Kaslik (USEK)/0000-0001-6734-4105; samson, yves/0000-0002-8080-1427				ADOLPHS R, 1995, J NEUROSCI, V15, P5879; American Psychiatric Association, 2000, DSM 4 DIAGN STAT MAN, V4th ed., DOI DOI 10.1001/JAMA.1994.03520100096; Bejjani B, 1997, NEUROLOGY, V49, P1564, DOI 10.1212/WNL.49.6.1564; BENABID AL, 1991, LANCET, V337, P403, DOI 10.1016/0140-6736(91)91175-T; BERGMAN H, 1990, SCIENCE, V249, P1436, DOI 10.1126/science.2402638; Bevan MD, 1996, NEUROSCIENCE, V75, P5, DOI 10.1016/0306-4522(96)00377-6; DORMONT D, 1994, AM J NEURORADIOL, V15, P365; Drevets WC, 1997, NATURE, V386, P824, DOI 10.1038/386824a0; Fahn S., 1987, RECENT DEV PARKINSON, VVol. 2, P153; Fischer H, 1998, NEUROSCI LETT, V251, P137, DOI 10.1016/S0304-3940(98)00503-5; FOX PT, 1984, J CEREBR BLOOD F MET, V4, P329, DOI 10.1038/jcbfm.1984.49; Friston K., 1994, HUM BRAIN MAPP, V2, P189, DOI [DOI 10.1002/HBM.460020402, 10.1002/hbm.460020402]; GOLDMANRAKIC PS, 1985, J COMP NEUROL, V242, P535, DOI 10.1002/cne.902420406; HERRMANN M, 1995, STROKE, V26, P850, DOI 10.1161/01.STR.26.5.850; ILINSKY IA, 1985, J COMP NEUROL, V236, P315, DOI 10.1002/cne.902360304; Kumar R, 1998, NEUROLOGY, V51, P850, DOI 10.1212/WNL.51.3.850; LIMOUSIN P, 1995, LANCET, V345, P91, DOI 10.1016/S0140-6736(95)90062-4; Maguire EA, 1998, SCIENCE, V280, P921, DOI 10.1126/science.280.5365.921; Mayberg H S, 1995, Adv Neurol, V65, P49; PARDO JV, 1993, AM J PSYCHIAT, V150, P713; POTTER WZ, 1991, NEW ENGL J MED, V325, P633; ROBINSON RG, 1984, BRAIN, V107, P81, DOI 10.1093/brain/107.1.81; Schaltenbrand G., 1977, ATLAS STEREOTAXY HUM; Zald DH, 1997, P NATL ACAD SCI USA, V94, P4119, DOI 10.1073/pnas.94.8.4119	24	463	476	0	23	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	MAY 13	1999	340	19					1476	1480		10.1056/NEJM199905133401905	http://dx.doi.org/10.1056/NEJM199905133401905			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	194MT	10320386	Bronze			2022-12-28	WOS:000080198700005
J	Buckley, P; Marley, J; Robinson, J; Turnbull, D				Buckley, P; Marley, J; Robinson, J; Turnbull, D			Australia - Medical education	LANCET			English	Article									Univ Adelaide, Dept Obstet & Gynaecol, Adelaide, SA 5005, Australia	University of Adelaide	Buckley, P (corresponding author), Univ Adelaide, Dept Obstet & Gynaecol, Adelaide, SA 5005, Australia.		Marley, John/F-1239-2010	Buckley, Pat/0000-0003-1371-8882; Anderson, Warwick Peter/0000-0002-7130-3530					0	5	5	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON WC1B 3SL, ENGLAND	0140-6736			LANCET	Lancet	MAY 23	1998	351	9115					1569	1570		10.1016/S0140-6736(98)03136-5	http://dx.doi.org/10.1016/S0140-6736(98)03136-5			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZQ497	10326556				2022-12-28	WOS:000073868000041
J	Wyatt, KM; Dimmock, PW; Jones, PW; O'Brien, PMS				Wyatt, KM; Dimmock, PW; Jones, PW; O'Brien, PMS			Efficacy of vitamin B-6 in the treatment of premenstrual syndrome: systematic review	BMJ-BRITISH MEDICAL JOURNAL			English	Article							PRE-MENSTRUAL TENSION; NUTRITIONAL SUPPLEMENT; SENSORY NEUROPATHY; CLINICAL-TRIALS; PYRIDOXINE; NEUROTOXICITY; METAANALYSIS; SYMPTOMS; THERAPY; WOMEN	Objective To evaluate the efficacy of vitamin B-6 in the treatment of premenstrual syndrome. Design Systematic review of published and unpublished randomised placebo controlled trials of the effectiveness of vitamin B-6 in the management of premenstrual syndrome. Subjects Nine published trials representing 940 patients with premenstrual syndrome. Main outcome measures Proportion of women whose overall premenstrual symptoms showed an improvement over placebo. A secondary analysis was performed on the proportion of women whose premenstrual depressive symptoms showed an improvement over placebo. Results Odds ratio relative to placebo for an improvement in overall premenstrual symptoms was 2.32 (95% confidence interval 1.95 to 2.54). Odds ratio relative to placebo for an improvement in depressive symptoms was 1.69 (1.39 to 2.06) from four trials representing 541 patients. Conclusion Conclusions are limited by the low quality of most of the trials included. Results suggest that doses of vitamin B-6 up to 100 mg/day are likely to be of benefit in treating premenstrual symptoms and premenstrual depression.	N Staffordshire Hosp, Acad Dept Obstet & Gynaecol, Stoke On Trent ST4 6QG, Staffs, England; Univ Keele, Dept Math, Keele ST5 5BG, Staffs, England	Keele University; University Hospital of North Staffordshire NHS Trust; Keele University	Wyatt, KM (corresponding author), N Staffordshire Hosp, Acad Dept Obstet & Gynaecol, Stoke On Trent ST4 6QG, Staffs, England.	mea10@keele.ac.uk						ABRAHAM G E, 1980, Infertility, V3, P155; ABRAHAM GE, 1983, J REPROD MED, V28, P446; ADAMS PW, 1973, LANCET, V1, P897; Antopol W., 1942, J NEUROPATH EXP NEUR, V1, P330, DOI [10.1097/00005072-194207000-00006, DOI 10.1097/00005072-194207000-00006]; BARR W, 1984, PRACTITIONER, V228, P425; BERGER AR, 1992, NEUROLOGY, V42, P1367, DOI 10.1212/WNL.42.7.1367; BERMAN MK, 1990, J AM DIET ASSOC, V90, P859; BERNSTEIN AL, 1990, ANN NY ACAD SCI, V585, P250, DOI 10.1111/j.1749-6632.1990.tb28058.x; BLUE J, 1998, NZ MED J, V111, P34; BRUSH MG, 1988, BRIT J CLIN PRACT, V42, P448; BRUSH MG, 1988, CURRENT TOPICS NUTRI, V19, P363; CHAKMAKIJIAN Z H, 1985, Journal of Applied Nutrition, V37, P12; CHAKMAKJIAN ZH, 1983, J REPROD MED, V28, P532; Colin C, 1982, Rev Med Brux, V3, P605; DAY JB, 1979, CURR MED RES OPIN, V6, P40, DOI 10.1185/03007997909110097; DESOUZA MC, 1996, P NUTR SOC, V56, pA75; DOLL H, 1989, J ROY COLL GEN PRACT, V39, P364; DRISKELL JA, 1994, NUTR RES, V14, P293, DOI 10.1016/S0271-5317(05)80388-4; Egger M, 1997, BMJ-BRIT MED J, V315, P629, DOI 10.1136/bmj.315.7109.629; FOLKERS K, 1989, ANN NY ACAD SCI, P295; Frank RT, 1931, ARCH NEURO PSYCHIATR, V26, P1053, DOI 10.1001/archneurpsyc.1931.02230110151009; FUCHS N, 1985, Journal of Applied Nutrition, V37, P1; GAHLINGER PM, 1995, COMPUTER PROGRAMS EP; GOEI GS, 1983, J REPROD MED, V28, P527; HAGEN I, 1985, ACTA OBSTET GYN SCAN, V64, P667, DOI 10.3109/00016348509158211; HARRISON W, 1984, PSYCHOL BULL, P118; HASSELBLAD V, 1995, PSYCHOL BULL, V117, P167, DOI 10.1037/0033-2909.117.1.167; Jadad AR, 1996, CONTROL CLIN TRIALS, V17, P1, DOI 10.1016/0197-2456(95)00134-4; *JOINT FOOD SAF ST, 1997, SURV DIET SUPPL CONT; KENDALL KE, 1987, OBSTET GYNECOL, V70, P145; KERR GD, 1977, CURR MED RES OPIN, V4, P29, DOI 10.1185/03007997709115298; KRINKE G, 1985, J NEUROPATH EXP NEUR, V44, P117, DOI 10.1097/00005072-198503000-00001; LONDON RS, 1991, J AM COLL NUTR, V10, P494; MALMGREN R, 1987, NEUROPSYCHOBIOLOGY, V18, P83, DOI 10.1159/000118398; MATTES JA, 1982, HUM NUTR-APPL NUTR, V36, P131; OBRIEN PMS, 1993, BRIT MED J, V307, P1471, DOI 10.1136/bmj.307.6917.1471; OBRIEN PMS, 1982, DRUGS, V24, P140, DOI 10.2165/00003495-198224020-00004; OBRIEN PMS, 1987, PREMENSTRUAL SYNDROM; PARRY GJ, 1985, NEUROLOGY, V35, P1466, DOI 10.1212/WNL.35.10.1466; SCHAEPPI U, 1982, AGENTS ACTIONS, V12, P575, DOI 10.1007/BF01965944; SCHAUMBURG H, 1983, NEW ENGL J MED, V309, P445, DOI 10.1056/NEJM198308253090801; SMALLWOOD J, 1986, BRIT J CLIN PRACT, V40, P532; SMITH R, 1994, CLIN REV GYNAECOL, P939; STEWART A, 1987, J REPROD MED, V32, P435; STEWART JW, 1984, BIOL PSYCHIAT, V19, P613; STOKES J, 1972, LANCET, V1, P1177, DOI 10.1016/S0140-6736(72)91399-2; VANDENBERG H, 1989, VOEDING, V50, P58; VillegasSalas E, 1997, CONTRACEPTION, V55, P245, DOI 10.1016/S0010-7824(97)00005-X; WILLIAMS MJ, 1985, J INT MED RES, V13, P174, DOI 10.1177/030006058501300305; WINDEBANK AJ, 1985, NEUROCHEM PATHOL, V3, P159, DOI 10.1007/BF02834268; WINDEBANK AJ, 1985, NEUROLOGY, V35, P1617, DOI 10.1212/WNL.35.11.1617; WINSTON F, 1973, AM J PSYCHIAT, V130, P1217, DOI 10.1176/ajp.130.11.1217	52	162	173	1	13	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	MAY 22	1999	318	7195					1375	1381		10.1136/bmj.318.7195.1375	http://dx.doi.org/10.1136/bmj.318.7195.1375			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	200DQ	10334745	Green Published, Green Submitted, Bronze			2022-12-28	WOS:000080524700022
J	Makishima, M; Okamoto, AY; Repa, JJ; Tu, H; Learned, RM; Luk, A; Hull, MV; Lustig, KD; Mangelsdorf, DJ; Shan, B				Makishima, M; Okamoto, AY; Repa, JJ; Tu, H; Learned, RM; Luk, A; Hull, MV; Lustig, KD; Mangelsdorf, DJ; Shan, B			Identification of a nuclear receptor for bile acids	SCIENCE			English	Article							BINDING PROTEIN; RESPONSE PATHWAY; ORPHAN RECEPTORS; LXR-ALPHA; COACTIVATOR; ACTIVATION; SPECIFICITY; EXPRESSION; METABOLISM; TRANSPORT	Bile acids are essential for the solubilization and transport of dietary lipids and are the major products of cholesterol catabolism. Results presented here show that bile acids are physiological Ligands for the farnesoid X receptor (FXR), an orphan nuclear receptor. When bound to bile acids, FXR repressed transcription of the gene encoding cholesterol 7 alpha-hydroxylase, which is the rate-limiting enzyme in bile acid synthesis, and activated the gene encoding intestinal bile acid-binding protein, which is a candidate bile acid transporter. These results demonstrate a mechanism by which bile acids transcriptionally regulate their biosynthesis and enterohepatic transport.	Univ Texas, SW Med Ctr, Howard Hughes Med Inst, Dallas, TX 75235 USA; Univ Texas, SW Med Ctr, Dept Pharmacol, Dallas, TX 75235 USA; Tularik Inc, S San Francisco, CA 94080 USA	Howard Hughes Medical Institute; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	Mangelsdorf, DJ (corresponding author), Univ Texas, SW Med Ctr, Howard Hughes Med Inst, 5323 Harry Hines Blvd, Dallas, TX 75235 USA.			Hull, Mitchell/0000-0002-9364-1901; Mangelsdorf, David/0000-0002-4355-0796; Repa, Joyce/0000-0001-5740-1954				AKASHI Y, 1983, CLIN CHIM ACTA, V133, P125; CAREY MC, 1994, LIVER BIOL PATHOBIOL, pCH39; Craddock AL, 1998, AM J PHYSIOL-GASTR L, V274, pG157, DOI 10.1152/ajpgi.1998.274.1.G157; CROSSMAN MW, 1994, J CELL BIOL, V126, P1547, DOI 10.1083/jcb.126.6.1547; CROWTHER JR, 1995, METHODS MOL BIOL, V42; Darimont BD, 1998, GENE DEV, V12, P3343, DOI 10.1101/gad.12.21.3343; FORMAN BM, 1995, CELL, V81, P687, DOI 10.1016/0092-8674(95)90530-8; Glass CK, 1997, CURR OPIN CELL BIOL, V9, P222, DOI 10.1016/S0955-0674(97)80066-X; GONG YZ, 1994, P NATL ACAD SCI USA, V91, P4741, DOI 10.1073/pnas.91.11.4741; HOFMANN AF, 1994, LIVER BIOL PATHOBIOL, pCH38; Janowski BA, 1996, NATURE, V383, P728, DOI 10.1038/383728a0; Kanda T, 1998, BIOCHEM J, V330, P261, DOI 10.1042/bj3300261; LARUSSO NF, 1975, GASTROENTEROLOGY, V69, P1301; Lehmann JM, 1997, J BIOL CHEM, V272, P3137, DOI 10.1074/jbc.272.6.3137; LUSTIG KD, UNPUB; MANGELSDORF DJ, 1995, CELL, V83, P841, DOI 10.1016/0092-8674(95)90200-7; McInerney EM, 1998, GENE DEV, V12, P3357, DOI 10.1101/gad.12.21.3357; ONATE SA, 1995, SCIENCE, V270, P1354; Parks DJ, 1999, SCIENCE, V284, P1365, DOI 10.1126/science.284.5418.1365; Peet DJ, 1998, CURR OPIN GENET DEV, V8, P571, DOI 10.1016/S0959-437X(98)80013-0; Peet DJ, 1998, CELL, V93, P693, DOI 10.1016/S0092-8674(00)81432-4; REPA JJ, UNPUB; RUSSELL DW, 1992, BIOCHEMISTRY-US, V31, P4737, DOI 10.1021/bi00135a001; SEOL WG, 1995, MOL ENDOCRINOL, V9, P72, DOI 10.1210/me.9.1.72; Sippel CJ, 1997, J BIOL CHEM, V272, P18290, DOI 10.1074/jbc.272.29.18290; TURLEY SD, 1988, LIVER BIOL PATHOBIOL, pCH34; WILLY PJ, 1995, GENE DEV, V9, P1033, DOI 10.1101/gad.9.9.1033; WONG MH, 1995, J BIOL CHEM, V270, P27228, DOI 10.1074/jbc.270.45.27228; Zavacki AM, 1997, P NATL ACAD SCI USA, V94, P7909, DOI 10.1073/pnas.94.15.7909; Zhou GC, 1998, MOL ENDOCRINOL, V12, P1594, DOI 10.1210/me.12.10.1594	30	2070	2189	9	173	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	MAY 21	1999	284	5418					1362	1365		10.1126/science.284.5418.1362	http://dx.doi.org/10.1126/science.284.5418.1362			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	198NN	10334992				2022-12-28	WOS:000080430600055
J	Villar, RG; Macek, MD; Simons, S; Hayes, PS; Goldoft, MJ; Lewis, JH; Rowan, LL; Hursh, D; Patnode, M; Mead, PS				Villar, RG; Macek, MD; Simons, S; Hayes, PS; Goldoft, MJ; Lewis, JH; Rowan, LL; Hursh, D; Patnode, M; Mead, PS			Investigation of multidrug-resistant Salmonella serotype Typhimurium DT104 infections linked to raw-milk cheese in Washington State	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							ESCHERICHIA-COLI O157-H7; UNITED-STATES; MULTIRESISTANT STRAINS; SOFT CHEESE; OUTBREAK; CATTLE	Context Multidrug-resistant Salmonella Typhimurium DT104 has recently emerged as a cause of human and animal illness in Europe and North America. In early 1997, health officials in Yakima County, Washington, noted a 5-fold increase in salmonellosis among the county's Hispanic population. Objectives To characterize bacterial strains and identify risk factors for infection with Salmonella Typhimurium in Yakima County. Design Laboratory, case-control, and environmental investigations. Setting and Participants Patients with culture-confirmed Salmonella Typhimurium infection living in Yakima County and age- and neighborhood-matched control subjects. Main Outcome Measures Food vehicle implication based on case-control study and outbreak control. Results Between January 1 and May 5, 1997, 54 culture-confirmed cases of Salmonella Typhimurium were reported. The median age of patients was 4 years and 91% were Hispanic. Patients reported diarrhea (100%), abdominal cramps (93%), fever (93%), bloody stools (72%), and vomiting (53%); 5 patients (9%) were hospitalized. Twenty-two patients and 61 control subjects were enrolled in the case-control study. Seventeen case patients (77%) reported eating unpasteurized Mexican-style soft cheese in the 7 days before onset of illness compared with 17 control subjects (28%) (matched odds ratio, 32.3; 95% confidence interval, 3.0-874.6). All case-patient isolates were phage definitive type 104 (DT104) (n = 10) or DT104b (n = 12), and 20 (91%) were resistant to ampicillin, chloramphenicol, streptomycin, sulfamethoxazole, and tetracycline. The cheese produced and eaten by 2 unrelated patients was made with raw milk traced to the same local farm. Milk samples from nearby dairies yielded Salmonella Typhimurium DT104. The incidence of Salmonella Typhimurium infections in Yakima County returned to pre-1992 levels following interventions based on these findings. Conclusions Multidrug-resistant Salmonella Typhimurium DT104 emerged as a cause of salmonellosis in Yakima County, and Mexican-style soft cheese made with unpasteurized milk is an important vehicle for Salmonella Typhimurium DT104 transmission. We postulate that recent increases in human salmonellosis reflect the emergence of Salmonella Typhimurium DT104 among dairy cows in the region. Continued efforts are needed to discourage consumption of raw milk products, promote healthier alternatives, and study the ecology of multidrug-resistant Salmonella Typhimurium.	Ctr Dis Control & Prevent, Foodborne & Diarrheal Dis Branch, Natl Ctr Infect Dis, Atlanta, GA 30333 USA; Ctr Dis Control & Prevent, Epidem Intelligence Serv, Epidemiol Program Off, Atlanta, GA 30333 USA; Natl Ctr Hlth Stat, Illness & Disabil Stat Branch, Div Hlth Interview Stat, Hyattsville, MD 20782 USA; Washington State Dept Hlth, Seattle, WA USA; Washington State Univ, Cooperat Extens, Pullman, WA 99164 USA; Yakima Cty Hlth Dist, Yakima, WA USA	Centers for Disease Control & Prevention - USA; Centers for Disease Control & Prevention - USA; Centers for Disease Control & Prevention - USA; CDC National Center for Health Statistics (NCHS); Washington State University	Mead, PS (corresponding author), Ctr Dis Control & Prevent, Foodborne & Diarrheal Dis Branch, Natl Ctr Infect Dis, 1600 Clifton Rd,MS A-38, Atlanta, GA 30333 USA.			Macek, Mark/0000-0002-8677-2719				ANDERSON ES, 1977, J HYG-CAMBRIDGE, V78, P297, DOI 10.1017/S0022172400056187; Angulo FJ, 1997, AM J PUBLIC HEALTH, V87, P580, DOI 10.2105/AJPH.87.4.580; Ansay SE, 1997, LETT APPL MICROBIOL, V25, P131, DOI 10.1046/j.1472-765X.1997.00190.x; Barry AL., 1991, MANUAL CLIN MICROBIO, P117; Besser TE, 1997, VET REC, V140, P75; *CDCP, 1997, ANN TAB SALM SURV 19; *CDCP, 1997, MMWR-MORBID MORTAL W, V46, P308; CELUM CL, 1987, J INFECT DIS, V156, P998, DOI 10.1093/infdis/156.6.998; Cody SH, 1999, JAMA-J AM MED ASSOC, V281, P1805, DOI 10.1001/jama.281.19.1805; Deschenes G, 1996, PEDIATR NEPHROL, V10, P203; Desenclos JC, 1996, BRIT MED J, V312, P91, DOI 10.1136/bmj.312.7023.91; Djuretic T, 1997, Commun Dis Rep CDR Rev, V7, pR41; Evans S, 1996, VET REC, V139, P557; FRIEDMAN CR, 1998, INT C EM INF DIS MAR; Gautom RK, 1997, J CLIN MICROBIOL, V35, P2977, DOI 10.1128/JCM.35.11.2977-2980.1997; Glynn MK, 1998, NEW ENGL J MED, V338, P1333, DOI 10.1056/NEJM199805073381901; Headrick ML, 1998, AM J PUBLIC HEALTH, V88, P1219, DOI 10.2105/AJPH.88.8.1219; KASRAZADEH M, 1994, INT J FOOD MICROBIOL, V22, P127, DOI 10.1016/0168-1605(94)90137-6; MARTIN D, 1996, EPIDEMIOLOGY, V7, P2933; Quinto EJ, 1997, LETT APPL MICROBIOL, V24, P291, DOI 10.1046/j.1472-765X.1997.00072.x; RILEY LW, 1984, J INFECT DIS, V149, P878, DOI 10.1093/infdis/149.6.878; Slutsker L, 1997, ANN INTERN MED, V126, P505, DOI 10.7326/0003-4819-126-7-199704010-00002; TAUXE RV, 1991, J FOOD PROTECT, V54, P563, DOI 10.4315/0362-028X-54.7.563; Threlfall EJ, 1998, VET REC, V142, P255; Threlfall EJ, 1996, LANCET, V347, P1053, DOI 10.1016/S0140-6736(96)90199-3; WALL PG, 1995, VET REC, V136, P591, DOI 10.1136/vr.136.23.591; Wall PG, 1996, LANCET, V348, P471, DOI 10.1016/S0140-6736(96)24033-4; WALL PG, 1994, COMMUNICAB DIS REP, V4, P130; WRAY C, 1995, PUBLIC HLT LAB SERV, V13, P44	29	106	107	0	7	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAY 19	1999	281	19					1811	1816		10.1001/jama.281.19.1811	http://dx.doi.org/10.1001/jama.281.19.1811			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	196BH	10340368	Bronze			2022-12-28	WOS:000080288800034
J	Burns, JA; Showalter, MR; Hamilton, DP; Nicholson, PD; de Pater, I; Ockert-Bell, ME; Thomas, PC				Burns, JA; Showalter, MR; Hamilton, DP; Nicholson, PD; de Pater, I; Ockert-Bell, ME; Thomas, PC			The formation of Jupiter's faint rings	SCIENCE			English	Article							SATURNS E-RING; SOLAR-SYSTEM; DUST; RESONANCES; ORIGIN; EVOLUTION; LORENTZ	Observations by the Galileo spacecraft and the Keck telescope showed that Jupiter's outermost (gossamer) ring is actually two rings circumscribed by the orbits of the small satellites Amalthea and Thebe. The gossamer rings' unique morphology-especially the rectangular end profiles at the satellite's orbit and the enhanced intensities along the top and bottom edges of the rings-can be explained by collisional ejecta lost from the inclined satellites. The ejecta evolves inward under Poynting-Robertson drag. This mechanism may also explain the origin of Jupiter's main ring and suggests that faint rings may accompany all small inner satellites of the other jovian planets.	Cornell Univ, Ctr Radiophys & Space Res, Ithaca, NY 14853 USA; Stanford Univ, Space Telecommun & Radiosci Lab, Stanford, CA 94305 USA; Univ Maryland, Dept Astron, College Pk, MD 20742 USA; Univ Calif Berkeley, Dept Astron, Berkeley, CA 94720 USA	Cornell University; Stanford University; University System of Maryland; University of Maryland College Park; University of California System; University of California Berkeley	Burns, JA (corresponding author), Cornell Univ, Ctr Radiophys & Space Res, Ithaca, NY 14853 USA.	jab16@cornell.edu						Burns J.A., 1984, IAU COLLO Q 75 PLANE, P200; Burns J. A, 1983, B AM ASTRON SOC, V15, P1013; BURNS JA, 1989, NATURE, V337, P340, DOI 10.1038/337340a0; BURNS JA, 1980, ICARUS, V44, P339, DOI 10.1016/0019-1035(80)90029-9; BURNS JA, 1985, NATURE, V316, P115, DOI 10.1038/316115a0; CANUP RM, 1995, ICARUS, V113, P331, DOI 10.1006/icar.1995.1026; COLWELL JE, 1993, J GEOPHYS RES-PLANET, V98, P7387, DOI 10.1029/93JE00329; Cuzzi JN, 1998, ICARUS, V132, P1, DOI 10.1006/icar.1997.5863; de Pater I, 1999, ICARUS, V138, P214, DOI 10.1006/icar.1998.6068; DERMOTT SF, 1994, IAU SYMP, P127; DERMOTT SF, 1984, NATURE, V312, P505, DOI 10.1038/312505a0; Esposito L. W., 1991, URANUS, P410; FARINELLA P, 1993, ICARUS, V101, P174, DOI 10.1006/icar.1993.1016; GEHRELS T, 1984, SATURN, P546; GRUN E, 1985, ICARUS, V62, P244, DOI 10.1016/0019-1035(85)90121-6; HAMILTON DP, 1994, ICARUS, V109, P221, DOI 10.1006/icar.1994.1089; HAMILTON DP, 1993, ICARUS, V101, P244, DOI 10.1006/icar.1993.1022; HAMILTON DP, 1994, SCIENCE, V264, P550, DOI 10.1126/science.264.5158.550; Horanyi M, 1996, ANNU REV ASTRON ASTR, V34, P383, DOI 10.1146/annurev.astro.34.1.383; JACOBSON RA, COMMUNICATION; Murray CD, 1997, ICARUS, V129, P304, DOI 10.1006/icar.1997.5774; Ockert-Bell ME, 1999, ICARUS, V138, P188, DOI 10.1006/icar.1998.6072; Porco CC, 1995, SPACE SCI S, P703; Showalter M. R, 1998, B AM ASTRON SOC, V30, P1044; SHOWALTER MR, 1985, NATURE, V316, P526, DOI 10.1038/316526a0; SHOWALTER MR, 1987, ICARUS, V69, P458, DOI 10.1016/0019-1035(87)90018-2; Thomas PC, 1998, ICARUS, V135, P360, DOI 10.1006/icar.1998.5976; Weidenschilling S.J., 1984, PLANETARY RINGS, P367	28	103	104	0	6	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	MAY 14	1999	284	5417					1146	1150		10.1126/science.284.5417.1146	http://dx.doi.org/10.1126/science.284.5417.1146			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	197HJ	10325220				2022-12-28	WOS:000080359100030
J	Izaks, GJ; Westendorp, RGJ; Knook, DL				Izaks, GJ; Westendorp, RGJ; Knook, DL			The definition of anemia in older persons	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							MINI-MENTAL-STATE; RESIDENTS AGED 85; POPULATION; HEMOGLOBIN; PREVALENCE; MORTALITY	Context Whether hemoglobin concentrations defined as anemia by the World Health Organization (WHO) are associated with increased mortality in older persons is not known. Objective To investigate the association between hemoglobin concentration and cause-specific mortality in older persons. Design Community-based study conducted from 1986 to 1996 (follow-up period, 10 years). Setting Leiden, the Netherlands. Participants A total of 1016 community residents aged 85 years and older were eligible and 872 agreed to have a blood sample taken. Hemoglobin concentration was measured in 755 persons (74%), Main Outcome Measures Hemoglobin concentration, 10-year survival, and primary cause of death. According to the WHO criteria, anemia was defined as a hemoglobin concentration below 7.5 mmol/L (120 g/L) in women and below 8.1 mmol/L (130 g/L) in men. Results Compared with persons with a normal hemoglobin concentration, the mortality risk was 1.60 (95% confidence interval [CI], 1.24-2.06; P<.001) in women with anemia, and 2.29 (95% CI, 1.60-3.26; P<.001) in men with anemia. In both sexes, the mortality risk increased with lower hemoglobin concentrations. In persons without self-reported clinical disease at baseline, the mortality risk of anemia was 2.21 (95% CI, 1.37-3.57; P=.002). Mortality from malignant and infectious diseases was higher in persons with anemia. Conclusions Anemia defined by the WHO criteria was associated with an increased mortality risk in persons aged 85 years and older. The criteria are thus appropriate for older persons. A low hemoglobin concentration at old age signifies disease.	Leiden Univ, Med Ctr, Sect Gerontol & Geriat, Dept Gen Internal Med, NL-2300 RC Leiden, Netherlands; Leiden Univ, Med Ctr, Dept Clin Epidemiol, NL-2300 RC Leiden, Netherlands	Leiden University; Leiden University Medical Center (LUMC); Leiden University - Excl LUMC; Leiden University; Leiden University Medical Center (LUMC); Leiden University - Excl LUMC	Izaks, GJ (corresponding author), Leiden Univ, Med Ctr, Sect Gerontol & Geriat, Dept Gen Internal Med, LUMC P3-Q,POB 9600, NL-2300 RC Leiden, Netherlands.		Izaks, Gerbrand/F-5089-2014	Izaks, Gerbrand/0000-0003-3213-7637	NIA NIH HHS [AG 06354] Funding Source: Medline; NATIONAL INSTITUTE ON AGING [R01AG006354] Funding Source: NIH RePORTER	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Ania BJ, 1997, J AM GERIATR SOC, V45, P825, DOI 10.1111/j.1532-5415.1997.tb01509.x; FOLSTEIN MF, 1975, J PSYCHIAT RES, V12, P189, DOI 10.1016/0022-3956(75)90026-6; IZAKS GJ, 1995, PSYCHOL MED, V25, P841, DOI 10.1017/S0033291700035091; Izaks GJ, 1997, J AM GERIATR SOC, V45, P56, DOI 10.1111/j.1532-5415.1997.tb00978.x; JOOSTEN E, 1992, GERONTOLOGY, V38, P111, DOI 10.1159/000213315; LAGAAY AM, 1992, BRIT MED J, V304, P1091, DOI 10.1136/bmj.304.6834.1091; NILSSONEHLE H, 1989, BRIT J HAEMATOL, V71, P437; SALIVE ME, 1992, J AM GERIATR SOC, V40, P489, DOI 10.1111/j.1532-5415.1992.tb02017.x; TIMIRAS ML, 1987, J AM GERIATR SOC, V35, P639, DOI 10.1111/j.1532-5415.1987.tb04340.x; WeverlingRijnsburger AWE, 1997, LANCET, V350, P1119, DOI 10.1016/S0140-6736(97)04430-9; *WHO, 1968, NUTR AN REP WHO SCI; *WHO, 1977, INT STAT CLASS DIS	12	323	334	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAY 12	1999	281	18					1714	1717		10.1001/jama.281.18.1714	http://dx.doi.org/10.1001/jama.281.18.1714			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	193WR	10328071				2022-12-28	WOS:000080161200028
J	Siddiqui, RN				Siddiqui, RN			A valuable lesson - Always check the x ray film	BRITISH MEDICAL JOURNAL			English	Article																			0	0	0	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	MAY 8	1999	318	7193					1239	1239						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	195XT	10231251				2022-12-28	WOS:000080278000022
J	Shipley, WU; Thames, HD; Sandler, HM; Hanks, GE; Zietman, AL; Perez, CA; Kuban, DA; Hancock, SL; Smith, CD				Shipley, WU; Thames, HD; Sandler, HM; Hanks, GE; Zietman, AL; Perez, CA; Kuban, DA; Hancock, SL; Smith, CD			Radiation therapy for clinically localized prostate cancer - A multi-institutional pooled analysis	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							RADICAL RETROPUBIC PROSTATECTOMY; EXTERNAL-BEAM RADIATION; PSA ERA; ANTIGEN; RECURRENCE; PATTERNS; DISEASE; MEN	Context Prostate-specific antigen (PSA) evaluation leads to the early detection of both prostate cancer and recurrences following primary treatment. Prostate-specific antigen outcome information on patients 5 or more years following treatment is limited and available mainly as single-institution reports. Objectives To assess the likelihood and durability of tumor control using PSA evaluation 5 or more years after radical external beam radiation therapy and to identify pretreatment prognostic factors in men with early prostate cancer treated since 1988, the PSA era. Design and Setting Retrospective, nonrandomized, multi-institutional pooled analysis of patients treated with external beam radiation therapy alone between 1988 and 1995 at 6 US medical centers. Follow-up lasted up to a maximum of 9 years. Outcome data were analyzed using Cox regression and recursive partitioning techniques. Patients A total of 1765 men with stage T1b, T1c, and T2 tumors treated between 1988 and 1995 with external beam radiation. The majority (58%) of patients were older than 70 years and 24.2% had initial PSA values of 20 ng/mL or higher. A minimum of 2 years of subsequent follow-up was required for participation, Main Outcome Measure Actuarial estimates of freedom from biochemical failure. Results The 5-year estimates of overall survival, disease-specific survival, and the freedom from biochemical failure are 85.0% (95% confidence interval [CI], 82.5%-87.6%), 95.1% (95% CI, 94.0%-96.2%), and 65.8% (95% CI, 62.8%-68.0%), respectively, The PSA failure-free rates 5 and 7 years after treatment for patients presenting with a PSA of less than 10 ng/mL were 77.8% (95% CI, 74.5%-81.3%), and 72.9% (95% CI, 67.9%-78.2%). Recursive partitioning analysis of initial PSA level, palpation stage, and the Gleason score groupings yielded 4 separate prognostic groups: group 1, included patients with a PSA level of less than 9.2 ng/mL; group 2, PSA level of at least 9.2 but less than 19.7 ng/mL; group 3, PSA level at least 19.7 ng/mL and a Gleason score of 2 to 6; and group 4, PSA level of at least 19.7 ng/mL and a Gleason score of 7 to 10. The estimated rates of survival free of biochemical failure at 5 years are 81% for group 1, 69% for group 2, 47% for group 3, and 29% for group 4. Of the 302 patients followed up beyond 5 years who were free of biochemical disease, 5.0% relapsed from the fifth to the eighth year, Conclusions Estimated PSA control rates in this pooled analysis are similar to those of single institutions. These rates indicate the probability of success for subsets of patients with tumors of several prognostic category groupings. These results represent a multi-institutional benchmark for evidence-based counseling of prostate cancer patients about radiation treatment.	Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Radiat Oncol, Boston, MA 02114 USA; Univ Texas, MD Anderson Cancer Ctr, Dept Biomath, Houston, TX 77030 USA; Univ Michigan, Med Ctr, Dept Radiat Oncol, Ann Arbor, MI 48109 USA; Fox Chase Canc Ctr, Dept Radiat Oncol, Philadelphia, PA 19111 USA; Washington Univ, Mallinckrodt Inst Radiol, St Louis, MO USA; Eastern Virginia Med Sch, Dept Radiat Oncol, Norfolk, VA 23501 USA; Stanford Univ, Med Ctr, Dept Radiat Oncol, Palo Alto, CA 94304 USA	Harvard University; Harvard Medical School; Massachusetts General Hospital; University of Texas System; UTMD Anderson Cancer Center; University of Michigan System; University of Michigan; Fox Chase Cancer Center; Washington University (WUSTL); Eastern Virginia Medical School; Stanford University	Shipley, WU (corresponding author), Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Radiat Oncol, Boston, MA 02114 USA.							Breiman L., 1984, CLASSIFICATION REGRE; CARTER HB, 1992, JAMA-J AM MED ASSOC, V267, P2215, DOI 10.1001/jama.267.16.2215; CATALONA WJ, 1993, JAMA-J AM MED ASSOC, V270, P948, DOI 10.1001/jama.270.8.948; CATALONA WJ, 1994, J UROLOGY, V152, P1837, DOI 10.1016/S0022-5347(17)32397-2; COX DR, 1972, J R STAT SOC B, V34, P187; Cox JD, 1997, INT J RADIAT ONCOL, V37, P1035; D'Amico AV, 1998, JAMA-J AM MED ASSOC, V280, P969, DOI 10.1001/jama.280.11.969; FukunagaJohnson N, 1997, INT J RADIAT ONCOL, V38, P311, DOI 10.1016/S0360-3016(97)82499-6; Gerber GS, 1996, JAMA-J AM MED ASSOC, V276, P615; GRIGNON D, 1997, MODERN PATHOL, V10, P77; HANKS GE, 1995, J UROLOGY, V154, P456, DOI 10.1016/S0022-5347(01)67073-3; KAPLAN EL, 1958, J AM STAT ASSOC, V53, P457, DOI 10.2307/2281868; Kattan MW, 1998, JNCI-J NATL CANCER I, V90, P766, DOI 10.1093/jnci/90.10.766; Keyser D, 1997, INT J RADIAT ONCOL, V38, P723, DOI 10.1016/S0360-3016(97)00123-5; Klein EA, 1998, SEMIN RADIAT ONCOL, V8, P87, DOI 10.1016/S1053-4296(98)80004-0; Lessells AM, 1997, HUM PATHOL, V28, P646, DOI 10.1016/S0046-8177(97)90172-6; LuYao GL, 1996, J NATL CANCER I, V88, P166, DOI 10.1093/jnci/88.3-4.166; MANTEL N, 1959, J NATL CANCER I, V22, P719; MIDDLETON RG, 1995, J UROLOGY, V154, P2144, DOI 10.1016/S0022-5347(01)66718-1; MURPHY GP, 1994, J UROLOGY, V152, P1817, DOI 10.1016/S0022-5347(17)32392-3; Pound CR, 1997, UROL CLIN N AM, V24, P395, DOI 10.1016/S0094-0143(05)70386-4; Schellhammer P, 1997, UROLOGY, V49, P27, DOI 10.1016/S0090-4295(99)80321-5; *STAT SCI, 1993, S PLUS US MAN COMP P; TRAPASSO JG, 1994, J UROLOGY, V152, P1821, DOI 10.1016/S0022-5347(17)32394-7; Zagars GK, 1997, CANCER, V79, P1370, DOI 10.1002/(SICI)1097-0142(19970401)79:7<1370::AID-CNCR15>3.0.CO;2-X; Zietman AL, 1998, SEMIN RADIAT ONCOL, V8, P81, DOI 10.1016/S1053-4296(98)80003-9; ZINCKE H, 1994, J UROLOGY, V152, P1850, DOI 10.1016/S0022-5347(17)32399-6	27	355	368	0	4	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAY 5	1999	281	17					1598	1604		10.1001/jama.281.17.1598	http://dx.doi.org/10.1001/jama.281.17.1598			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	191MJ	10235152	Bronze			2022-12-28	WOS:000080025900023
J	Sankaranarayanan, R; Dock-Bregeon, AC; Romby, P; Caillet, J; Springer, M; Rees, B; Ehresmann, C; Ehresmann, B; Moras, D				Sankaranarayanan, R; Dock-Bregeon, AC; Romby, P; Caillet, J; Springer, M; Rees, B; Ehresmann, C; Ehresmann, B; Moras, D			The structure of threonyl-tRNA synthetase-tRNA(Thr) complex enlightens its repressor activity and reveals an essential zinc ion in the active site	CELL			English	Article							TRANSFER-RNA-SYNTHETASE; ESCHERICHIA-COLI; TRANSLATIONAL CONTROL; MOLECULAR MIMICRY; CRYSTAL-STRUCTURE; PROTEIN-SYNTHESIS; IDENTITY RULES; AMINO-ACIDS; RECOGNITION; GENE	E. coli threonyl-tRNA synthetase (ThrRS) is a class II enzyme that represses the translation of its own mRNA. We report the crystal structure at 2.9 Angstrom resolution of the complex between tRNA(Thr) and ThrRS, whose structural features reveal novel strategies for providing specificity in tRNA selection. These include an aminoterminal domain containing a novel protein fold that makes minor groove contacts with the tRNA acceptor stem. The enzyme induces a large deformation of the anticodon loop, resulting in an interaction between two adjacent anticodon bases, which accounts for their prominent role in tRNA identity and translational regulation. A zinc ion found in the active site is implicated in amino acid recognition/discrimination.	ULP, INSERM, CNRS,UPR 9004 Biol Struct, Inst Genet & Biol Mol & Cellulaire, F-67404 Illkirch Graffenstaden, France; CNRS, UPR 9002, Inst Biol Mol & Cellulaire, F-67084 Strasbourg, France; CNRS, UPR 9073, Inst Biol Phys Chim, F-75005 Paris, France	Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg; Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg; Centre National de la Recherche Scientifique (CNRS)	Moras, D (corresponding author), ULP, INSERM, CNRS,UPR 9004 Biol Struct, Inst Genet & Biol Mol & Cellulaire, BP163, F-67404 Illkirch Graffenstaden, France.	moras@igbmc.u-strasbg.fr	ROMBY, Pascale/AGP-3328-2022; Sankaranarayanan, Rajan/AAI-9295-2020	Rajan, Sankaranarayanan/0000-0003-4524-9953; Dock-Bregeon, Anne-Catherine/0000-0002-6913-4061				Arnez JG, 1997, TRENDS BIOCHEM SCI, V22, P211, DOI 10.1016/S0968-0004(97)01052-9; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; BARTON GJ, 1993, PROTEIN ENG, V6, P37, DOI 10.1093/protein/6.1.37; BIOU V, 1994, SCIENCE, V263, P1404, DOI 10.1126/science.8128220; BRUNEL C, 1993, BIOCHIMIE, V75, P1167, DOI 10.1016/0300-9084(93)90016-L; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; BRUNIE S, 1990, J MOL BIOL, V216, P411, DOI 10.1016/S0022-2836(05)80331-6; BUECHTER DD, 1993, BIOCHEMISTRY-US, V32, P5267, DOI 10.1021/bi00070a039; CAVARELLI J, 1993, NATURE, V362, P181, DOI 10.1038/362181a0; CHRISTIANSON DW, 1991, ADV PROTEIN CHEM, V42, P281; Cusack S, 1998, STRUCTURE, V6, P101, DOI 10.1016/S0969-2126(98)00011-2; CUSACK S, 1995, NAT STRUCT BIOL, V2, P824, DOI 10.1038/nsb1095-824; delaFortelle E, 1997, METHOD ENZYMOL, V276, P472, DOI 10.1016/S0076-6879(97)76073-7; DELARUE M, 1993, BIOESSAYS, V15, P675, DOI 10.1002/bies.950151007; ERIANI G, 1990, NATURE, V347, P203, DOI 10.1038/347203a0; EVANS SV, 1993, J MOL GRAPHICS, V11, P134, DOI 10.1016/0263-7855(93)87009-T; Fersht A., 1985, ENZYME STRUCTURE MEC; FERSHT AR, 1977, BIOCHEMISTRY-US, V16, P1025, DOI 10.1021/bi00624a034; FLORENTZ C, 1995, AMINOACYL TRNA SYNTH, P141; FREIST W, 1995, BIOL CHEM H-S, V376, P213; FREIST W, 1994, EUR J BIOCHEM, V220, P745, DOI 10.1111/j.1432-1033.1994.tb18675.x; Gabriel K, 1996, SCIENCE, V271, P195, DOI 10.1126/science.271.5246.195; GEISSLER S, 1993, GENE, V136, P253, DOI 10.1016/0378-1119(93)90474-H; GRAFFE M, 1992, SCIENCE, V255, P994, DOI 10.1126/science.1372129; HAMILTON CM, 1989, J BACTERIOL, V171, P4617, DOI 10.1128/jb.171.9.4617-4622.1989; HASEGAWA T, 1992, BIOCHEM BIOPH RES CO, V184, P478, DOI 10.1016/0006-291X(92)91219-G; JAKUBOWSKI H, 1992, MICROBIOL REV, V56, P412, DOI 10.1128/MMBR.56.3.412-429.1992; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Jovine L, 1996, STRUCTURE, V4, P621, DOI 10.1016/S0969-2126(96)00066-4; KOMINE Y, 1990, J MOL BIOL, V212, P579, DOI 10.1016/0022-2836(90)90224-A; MEINNEL T, 1995, AMINOACYL TRNA SYNTH, P251; MERRITT EA, 1994, ACTA CRYSTALLOGR D, V50, P869, DOI 10.1107/S0907444994006396; MOINE H, 1990, J MOL BIOL, V216, P299, DOI 10.1016/S0022-2836(05)80321-3; MUSIERFORSYTH K, 1992, NATURE, V357, P513, DOI 10.1038/357513a0; NICHOLLS A, 1991, J COMPUT CHEM, V12, P435, DOI 10.1002/jcc.540120405; NUREKI O, 1993, J BIOL CHEM, V268, P15368; Nureki O, 1998, SCIENCE, V280, P578, DOI 10.1126/science.280.5363.578; PARK SJ, 1988, J BIOL CHEM, V263, P16527; Romby P, 1996, EMBO J, V15, P5976, DOI 10.1002/j.1460-2075.1996.tb00984.x; ROMBY P, 1992, NUCLEIC ACIDS RES, V20, P5633, DOI 10.1093/nar/20.21.5633; ROULD MA, 1989, SCIENCE, V246, P1135, DOI 10.1126/science.2479982; RUFF M, 1991, SCIENCE, V252, P1682, DOI 10.1126/science.2047877; SCHULMAN LH, 1990, NUCLEIC ACIDS RES, V18, P285, DOI 10.1093/nar/18.2.285; Simos G, 1998, MOL CELL, V1, P235, DOI 10.1016/S1097-2765(00)80024-6; SPRINGER M, 1989, EMBO J, V8, P2417, DOI 10.1002/j.1460-2075.1989.tb08372.x; SPRINGER M, 1985, J MOL BIOL, V185, P93, DOI 10.1016/0022-2836(85)90185-8; THEOBALD A, 1988, EUR J BIOCHEM, V175, P511, DOI 10.1111/j.1432-1033.1988.tb14223.x; TSUI WC, 1981, NUCLEIC ACIDS RES, V9, P4627, DOI 10.1093/nar/9.18.4627	48	259	268	0	42	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	APR 30	1999	97	3					371	381		10.1016/S0092-8674(00)80746-1	http://dx.doi.org/10.1016/S0092-8674(00)80746-1			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	192VP	10319817	Bronze			2022-12-28	WOS:000080100500010
J	Hinrichs, KU; Hayes, JM; Sylva, SP; Brewer, PG; DeLong, EF				Hinrichs, KU; Hayes, JM; Sylva, SP; Brewer, PG; DeLong, EF			Methane-consuming archaebacteria in marine sediments	NATURE			English	Article							CARBON ISOTOPIC FRACTIONATION; METHANOGENIC BACTERIA; OXIDATION; DIVERSITY; ARCHAEA; SULFATE; SAMPLES; LIPIDS; FIELD	Large amounts of methane are produced in marine sediments but are then consumed before contacting aerobic waters or the atmosphere(1). Although no organism that can consume methane anaerobically has ever been isolated, biogeochemical evidence indicates that the overall process involves a transfer of electrons from methane to sulphate and is probably mediated by several organisms, including a methanogen (operating in reverse) and a sulphate-reducer (using an unknown intermediate substrate)(2). Here we describe studies of sediments related to a decomposing methane hydrate. These provide strong evidence that methane is being consumed by archaebacteria that are phylogenetically distinct from known methanogens, Specifically, lipid biomarkers that are commonly characteristic of archaea are so strongly depleted in carbon-13 that methane must be the carbon source, rather than the metabolic product, for the organisms that have produced them. Parallel gene surveys of small-subunit ribosomal RNA (16S rRNA) indicate the predominance of a new archael group which is peripherally related to the methanogenic orders Methanomicrobiales and Methanosarcinales.	Woods Hole Oceanog Inst, Woods Hole, MA 02543 USA; Monterey Bay Aquarium Res Inst, Moss Landing, CA 95039 USA	Woods Hole Oceanographic Institution; Monterey Bay Aquarium Research Institute	Hayes, JM (corresponding author), Woods Hole Oceanog Inst, Woods Hole, MA 02543 USA.	jhayes@whoi.edu	Hinrichs, Kai-Uwe/C-7675-2009; Sylva, Sean/D-4400-2014	Hinrichs, Kai-Uwe/0000-0002-0739-9291; Sylva, Sean/0000-0002-4727-440X				BELYAEV SS, 1983, APPL ENVIRON MICROB, V45, P691, DOI 10.1128/AEM.45.2.691-697.1983; BIAN L, 1994, ISOTOPIC BIOGEOCHEMI; Boone David R., 1993, P35; BROOKS JM, 1991, MAR GEOL, V96, P103, DOI 10.1016/0025-3227(91)90204-H; DELONG EF, 1992, P NATL ACAD SCI USA, V89, P5685, DOI 10.1073/pnas.89.12.5685; FREEMAN KH, 1990, NATURE, V343, P254, DOI 10.1038/343254a0; Grosskopf R, 1998, APPL ENVIRON MICROB, V64, P4983; Hansen LB, 1998, AQUAT MICROB ECOL, V14, P195, DOI 10.3354/ame014195; Harder J, 1997, MAR GEOL, V137, P13, DOI 10.1016/S0025-3227(96)00075-8; HAYES JM, 1990, ORG GEOCHEM, V16, P1115, DOI 10.1016/0146-6380(90)90147-R; Hershberger KL, 1996, NATURE, V384, P420, DOI 10.1038/384420a0; Hoehler TM, 1996, MICROBIAL GROWTH ON C(1) COMPOUNDS, P326; HOEHLER TM, 1994, GLOBAL BIOGEOCHEM CY, V8, P451, DOI 10.1029/94GB01800; HOLZER G, 1979, J CHROMATOGR, V186, P795, DOI 10.1016/S0021-9673(00)95296-8; IRWIN H, 1977, NATURE, V269, P209, DOI 10.1038/269209a0; Kato C, 1997, EXTREMOPHILES, V1, P117, DOI 10.1007/s007920050024; Koga Y, 1998, BIOSCI BIOTECH BIOCH, V62, P230, DOI 10.1271/bbb.62.230; Kvenvolden KA, 1998, GEOL SOC SPEC PUBL, V137, P9, DOI 10.1144/GSL.SP.1998.137.01.02; MacGregor BJ, 1997, APPL ENVIRON MICROB, V63, P1178, DOI 10.1128/AEM.63.3.1178-1181.1997; Massana R, 1997, APPL ENVIRON MICROB, V63, P50, DOI 10.1128/AEM.63.1.50-56.1997; Munson MA, 1997, APPL ENVIRON MICROB, V63, P4729, DOI 10.1128/AEM.63.12.4729-4733.1997; Pace NR, 1997, SCIENCE, V276, P734, DOI 10.1126/science.276.5313.734; Reeburgh WS, 1996, MICROBIAL GROWTH ON C(1) COMPOUNDS, P334; SPROTT GD, 1993, APPL ENVIRON MICROB, V59, P912, DOI 10.1128/AEM.59.3.912-914.1993; SUMMONS RE, 1994, GEOCHIM COSMOCHIM AC, V58, P2853, DOI 10.1016/0016-7037(94)90119-8; Summons RE, 1998, ORG GEOCHEM, V28, P465, DOI 10.1016/S0146-6380(98)00011-4; TEIXIDOR P, 1992, J CHROMATOGR, V607, P253, DOI 10.1016/0021-9673(92)87083-K; TORNABENE TG, 1979, SCIENCE, V203, P51, DOI 10.1126/science.758677; Vetriani C, 1998, FEMS MICROBIOL LETT, V161, P83, DOI 10.1111/j.1574-6968.1998.tb12932.x; ZEHNDER AJB, 1979, J BACTERIOL, V137, P420, DOI 10.1128/JB.137.1.420-432.1979	30	903	991	15	321	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	APR 29	1999	398	6730					802	805		10.1038/19751	http://dx.doi.org/10.1038/19751			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	192BL	10235261				2022-12-28	WOS:000080058100057
J	Ozonoff, D; Clapp, R				Ozonoff, D; Clapp, R			Cancer survival is no lottery	LANCET			English	Editorial Material									Boston Univ, Sch Publ Hlth, Dept Environm Hlth, Boston, MA 02118 USA	Boston University	Ozonoff, D (corresponding author), Boston Univ, Sch Publ Hlth, Dept Environm Hlth, Boston, MA 02118 USA.			Ozonoff, David/0000-0002-4281-4171; Clapp, Richard/0000-0001-8174-0825				Black JA, 1998, LANCET, V352, P50, DOI 10.1016/S0140-6736(98)02466-0; COLEMAN M, 1999, STUD MED POPUL SUBJ, V61; Geller AC, 1996, AM J PUBLIC HEALTH, V86, P538, DOI 10.2105/AJPH.86.4.538; Hert JT, 1998, LANCET, V352, P51; SAVAGE D, 1984, CANCER, V54, P3085, DOI 10.1002/1097-0142(19841215)54:12<3085::AID-CNCR2820541246>3.0.CO;2-Z	5	1	1	0	1	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	APR 24	1999	353	9162					1379	1380		10.1016/S0140-6736(99)00109-9	http://dx.doi.org/10.1016/S0140-6736(99)00109-9			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	191KD	10227215	hybrid			2022-12-28	WOS:000080020800006
J	Horton, R				Horton, R			Doctors, the General Medical Council, and Bristol	LANCET			English	Editorial Material									Lancet, London WC1B 3SL, England		Horton, R (corresponding author), Lancet, London WC1B 3SL, England.							Irvine D, 1997, BRIT MED J, V314, P1540, DOI 10.1136/bmj.314.7093.1540; Irvine D, 1997, BRIT MED J, V314, P1613, DOI 10.1136/bmj.314.7094.1613; Morris K, 1998, LANCET, V351, P885, DOI 10.1016/S0140-6736(98)23012-1; MURRAY I, 1998, TIMES           0413, P5; Ramsay S, 1998, LANCET, V351, P1499, DOI 10.1016/S0140-6736(05)78890-5; SMITH R, 1998, BRIT MED J, V316, P946	6	11	11	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON WC1B 3SL, ENGLAND	0140-6736			LANCET	Lancet	MAY 23	1998	351	9115					1525	1526		10.1016/S0140-6736(05)61115-4	http://dx.doi.org/10.1016/S0140-6736(05)61115-4			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZQ497	10326530				2022-12-28	WOS:000073868000003
J	Mackay, J				Mackay, J			International aspects of US government tobacco bills	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article									Asian Consultancy Tobacco Control, Hong Kong, Peoples R China		Mackay, J (corresponding author), Asian Consultancy Tobacco Control, DD 229,Lot 147,Clearwater Bay Rd, Hong Kong, Peoples R China.							Blendon RJ, 1998, JAMA-J AM MED ASSOC, V280, P1279, DOI 10.1001/jama.280.14.1279; Chaloupka Frank J., 1996, 5543 NAT BUR EC RES; FISH D, 1999, BLILEY  ORDERS RELEA; FOX M, 1997, REUTERS         0617; Koop CE, 1998, JAMA-J AM MED ASSOC, V279, P550, DOI 10.1001/jama.279.7.550; LOBE J, 1998, INT PRESS 3 WORLD NE; MACKAY J, 1998, GROWING EPIDEMIC; MEIER B, 1998, NY TIMES        0710, pA8; NADER R, 1998, LOS ANGELES TIM 1124; *P MORR CO INC, 1996, ANN REP; PETO R, 1994, MORTALITY SMOKING DE, P103; *US STAT DEP, 1999, TOB GUID US DIPL POS; 1998, ECONOMIST       0711, P66	13	4	4	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAY 19	1999	281	19					1849	1850		10.1001/jama.281.19.1849	http://dx.doi.org/10.1001/jama.281.19.1849			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	196BH	10340375				2022-12-28	WOS:000080288800041
J	Dudley, NE				Dudley, NE			A hands on or hands off approach to patients?	BRITISH MEDICAL JOURNAL			English	Editorial Material																			0	1	1	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	MAY 15	1999	318	7194					1361	1361		10.1136/bmj.318.7194.1361	http://dx.doi.org/10.1136/bmj.318.7194.1361			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	198HR	10323847	Green Published			2022-12-28	WOS:000080418400070
J	Feek, CM; McKean, W; Henneveld, L; Barrow, G; Edgar, T; Paterson, RJ				Feek, CM; McKean, W; Henneveld, L; Barrow, G; Edgar, T; Paterson, RJ			Experience with rationing health care in New Zealand	BRITISH MEDICAL JOURNAL			English	Article; Proceedings Paper	2nd International Conference on Priorities in Health Care	OCT 08-10, 1998	LONDON, ENGLAND						Minist Hlth, Natl Hlth Comm Secretariat, Wellington, New Zealand; Clin Training Agcy, Christchurch, New Zealand; Whangarei Area Hosp, Northland Hlth, Whangarei, New Zealand; No Advocate New Zealand, Whangarei, New Zealand; Univ Auckland, Sch Law, Auckland 1, New Zealand	University of Auckland	Feek, CM (corresponding author), Minist Hlth, Natl Hlth Comm Secretariat, POB 503, Wellington, New Zealand.							Collins JF, 1998, NEW ETHICALS J   AUG, P13; *NAT ADV COMM COR, 1992, CONS DEV C REP NAT A; *NAT ADV COMM COR, 1994, COR DEB; *NO REG HLTH AUTH, 1996, GUID ENTR NO REG STA	4	12	12	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	MAY 15	1999	318	7194					1346	1348		10.1136/bmj.318.7194.1346	http://dx.doi.org/10.1136/bmj.318.7194.1346			3	Medicine, General & Internal	Conference Proceedings Citation Index - Science (CPCI-S); Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	198HR	10323826	Green Published			2022-12-28	WOS:000080418400042
J	Horton, B				Horton, B			Out of the lab and into the marketplace	NATURE			English	Article																			0	1	1	0	0	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	MAY 13	1999	399	6732					175	176		10.1038/20221	http://dx.doi.org/10.1038/20221			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	196XU	10335849				2022-12-28	WOS:000080335700055
J	Kandela, P				Kandela, P			Pollution	LANCET			English	Editorial Material											Kandela, P (corresponding author), 29 Greenlands Rd, Staines TW18 4LR, Middx, England.							1930, LANCET          0712, P107; 1929, LANCET          0316, P563; 1905, LANCET          0805, P390; 1906, LANCET          0721, P172	4	0	0	0	1	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	MAY 8	1999	353	9164					1631	1631		10.1016/S0140-6736(05)75761-5	http://dx.doi.org/10.1016/S0140-6736(05)75761-5			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	195XW	10334296				2022-12-28	WOS:000080278300068
J	Spencer, JA; Jordan, RK				Spencer, JA; Jordan, RK			Learner centred approaches in medical education	BRITISH MEDICAL JOURNAL			English	Article							CURRICULUM; RATIONALE; EFFICACY; ISSUES; NEED		Univ Newcastle Upon Tyne, Fac Med, Newcastle Upon Tyne NE2 4HH, Tyne & Wear, England	Newcastle University - UK	Spencer, JA (corresponding author), Univ Newcastle Upon Tyne, Fac Med, Newcastle Upon Tyne NE2 4HH, Tyne & Wear, England.							ALBANESE MA, 1993, ACAD MED, V68, P52, DOI 10.1097/00001888-199301000-00012; BARROWS HS, 1983, JAMA-J AM MED ASSOC, V250, P3077, DOI 10.1001/jama.250.22.3077; BERKSON L, 1993, ACAD MED, V68, pS79, DOI 10.1097/00001888-199310000-00053; Boud D., 1991, CHALLENGE PROBLEM BA; Brown G., 1988, EFFECTIVE TEACHING H; CHAMBERLIN TC, 1965, SCIENCE, V148, P745; Chastonay P, 1996, MED EDUC, V30, P235; COLES C, 1998, MED ED MILLENNIUM, P63; *COUNC NAT AC AW I, 1992, IMPR STUD LEARN; DESMARCHAIS JE, 1993, CAN MED ASSOC J, V148, P1567; Dolmans D, 1996, POSTGRAD MED J, V72, P535, DOI 10.1136/pgmj.72.851.535; Finucane PM, 1998, MED J AUSTRALIA, V168, P445, DOI 10.5694/j.1326-5377.1998.tb139025.x; *GEN MED COUNC, 1993, TOM DOCT REC UND MED; Harden RM, 1997, MED EDUC, V31, P264, DOI 10.1111/j.1365-2923.1997.tb02923.x; Harden RM, 1984, SOME ED STRATEGIES C; HARDEN RM, 1996, TASK BASED LEARNING; Holsgrove GJ, 1998, MED TEACH, V20, P99; IRBY DM, 1994, ACAD MED, V69, P333, DOI 10.1097/00001888-199405000-00003; JORDAN RK, 1997, P CTICM COMP MED C C, P19; Knowles M., 1990, ADULT LEARNER NEGLEC; Kolb D.A, 1984, EXPERIENTIAL LEARNIN; Lloyd-Jones G, 1998, MED EDUC, V32, P492; Maudsley G, 1999, ACAD MED, V74, P178, DOI 10.1097/00001888-199902000-00016; National Committee of Enquiry into Higher Education, 1997, HIGH ED LEARN SOC; NORMAN GR, 1988, MED EDUC, V22, P279, DOI 10.1111/j.1365-2923.1988.tb00754.x; NORMAN GR, 1992, ACAD MED, V67, P657; OSullivan I, 1995, P C UCG; Regehr G, 1996, ACAD MED, V71, P988, DOI 10.1097/00001888-199609000-00015; SALIH MA, 1985, TUTORIALS PROBLEM BA, V2; Scally G, 1998, BRIT MED J, V317, P61, DOI 10.1136/bmj.317.7150.61; SCHMIDT HG, 1983, MED EDUC, V17, P11, DOI 10.1111/j.1365-2923.1983.tb01086.x; SCHMIDT HG, 1990, ACAD MED, V65, P611, DOI 10.1097/00001888-199010000-00001; SKELLY G, 1997, P CTICM COMP MED C C, P65; Towle A, 1996, ARCH DIS CHILD, V74, P357, DOI 10.1136/adc.74.4.357; VERNON DTA, 1993, ACAD MED, V68, P550, DOI 10.1097/00001888-199307000-00015; Woodward CA, 1996, ADV HEALTH SCI EDUC, V1, P83, DOI 10.1007/BF00596231	36	273	284	1	14	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	MAY 8	1999	318	7193					1280	1283						4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	195XT	10231266				2022-12-28	WOS:000080278000035
J	Townsend, D				Townsend, D			I don't believe in excellence	BRITISH MEDICAL JOURNAL			English	Editorial Material																			0	0	0	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	MAY 8	1999	318	7193					1297	1297						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	195XT	10231292				2022-12-28	WOS:000080278000071
J	Couser, WG				Couser, WG			Glomerulonephritis	LANCET			English	Article							C VIRUS-INFECTION; RAPIDLY PROGRESSIVE GLOMERULONEPHRITIS; ANTINEUTROPHIL-CYTOPLASMIC ANTIBODIES; SMALL-VESSEL VASCULITIS; DENSE-DEPOSIT DISEASE; LONG-TERM PROGNOSIS; IGA NEPHROPATHY; MEMBRANOPROLIFERATIVE GLOMERULONEPHRITIS; POSTSTREPTOCOCCAL GLOMERULONEPHRITIS; GOODPASTURES-SYNDROME	The differential diagnosis of glomerulonephritis without systemic disease includes poststreptococcal glomerulonephritis, IgA nephropathy, rapidly progressive glomerulonephritis (RPGN), and membanoproliferative glomerulonephritis (MPGN). Glomerular inflammation is probably induced directly by a nephritogenic streptococcal protein in poststreptococcal glomerulonephritis, and by mesangial deposition of abnormally glycosylated IgA1-containing immune aggregates in IgA nephropathy. In crescentic RPGN the role of cellular rather than humoral immune mechanisms is now becoming clear. Many patients with MPGN have chronic hepatitis C infection. There is no effective disease-specific therapy for poststreptococcal glomerulonephritis or IgA nephropathy. RPGN benefits from high-dose steroids and cytotoxic drug therapy with the addition of plasma exchange in disease induced by antibody to glomerular basement membrane. Antiviral therapies reduce the severity of MPGN due to hepatitis C virus. However, various new therapies directed at specific cytokines, growth factors, fibrin deposition, and other mediators of injury are being developed, as well as more specific and less toxic forms of immunotherapy.	Univ Washington, Dept Med, Div Nephrol, UWMC, Seattle, WA 98195 USA	University of Washington; University of Washington Seattle	Couser, WG (corresponding author), Univ Washington, Dept Med, Div Nephrol, UWMC, BB1265 Hlth Sci Bldg,1959 NE Pacific St,Box 35652, Seattle, WA 98195 USA.	wge@u.washington.edu						Allen A, 1998, ADV EXP MED BIOL, V435, P175; ANDRASSY K, 1991, CLIN NEPHROL, V35, P139; Andresdottir MB, 1997, TRANSPLANTATION, V63, P1628, DOI 10.1097/00007890-199706150-00016; ARSIAN S, 1997, INT UROL NEPHROL S6, V29, P711; Atkins RC, 1996, J AM SOC NEPHROL, V7, P2271; BALDWIN DS, 1974, ANN INTERN MED, V80, P342, DOI 10.7326/0003-4819-80-3-342; BENNETT WM, 1989, AM J KIDNEY DIS, V13, P469, DOI 10.1016/S0272-6386(89)80004-6; Bolton WK, 1996, KIDNEY INT, V50, P1753, DOI 10.1038/ki.1996.495; CAMERON JS, 1983, AM J MED, V74, P175, DOI 10.1016/0002-9343(83)90606-X; CAMERON JS, 1982, TRANSPLANTATION, V34, P237; CATTRAN DC, 1994, AM J KIDNEY DIS, V23, P247, DOI 10.1016/S0272-6386(12)80980-2; CEDERHOLM B, 1988, P NATL ACAD SCI USA, V85, P4865, DOI 10.1073/pnas.85.13.4865; Chan TM, 1996, NEPHROLOGY, V2, pS31, DOI 10.1111/j.1440-1797.1996.tb00136.x; Couser WG, 1998, NEPHROL DIAL TRANSPL, V13, P10, DOI 10.1093/ndt/13.suppl_1.10; COUSER WG, 1994, AM J KIDNEY DIS, V23, P193, DOI 10.1016/S0272-6386(12)80971-1; COUSER WG, 1988, AM J KIDNEY DIS, V11, P449, DOI 10.1016/S0272-6386(88)80079-9; COUSER WG, 1985, KIDNEY INT, V28, P569, DOI 10.1038/ki.1985.167; COUSER WG, 1993, KIDNEY INT       S42, V44, P19; Couser William G., 1997, P915; D'Amico G, 1998, KIDNEY INT, V54, P650, DOI 10.1046/j.1523-1755.1998.00028.x; DAMICO G, 1992, J AM SOC NEPHROL, V2, pS159; DAMICO G, 1987, Q J MED, V64, P709; DONADIO JV, 1994, NEW ENGL J MED, V331, P1194, DOI 10.1056/NEJM199411033311804; Donadio JV, 1997, J AM SOC NEPHROL, V8, P1324; Falk RJ, 1997, J AM SOC NEPHROL, V8, P314; GALLA JH, 1995, KIDNEY INT, V47, P377, DOI 10.1038/ki.1995.50; GLASSOCK RJ, 1992, KIDNEY INT, V42, pS121; GLASSOCK RJ, 1996, KIDNEY, P1392; Haas M, 1997, AM J KIDNEY DIS, V29, P829, DOI 10.1016/S0272-6386(97)90456-X; Hagen EC, 1998, KIDNEY INT, V53, P743, DOI 10.1046/j.1523-1755.1998.00807.x; Harris AA, 1998, AM J KIDNEY DIS, V32, P179; HERODY M, 1993, CLIN NEPHROL, V40, P249; Hogg RJ, 1996, SEMIN NEPHROL, V16, P511; Hricik DE, 1998, NEW ENGL J MED, V339, P888, DOI 10.1056/NEJM199809243391306; IBELS LS, 1994, MEDICINE, V73, P79, DOI 10.1097/00005792-199403000-00002; JANSEN JH, 1993, AM J PATHOL, V143, P1356; Jennette JC, 1997, NEW ENGL J MED, V337, P1512, DOI 10.1056/NEJM199711203372106; Jennette JC, 1998, NEPHROL DIAL TRANSPL, V13, P16, DOI 10.1093/ndt/13.suppl_1.16; Jennette JC, 1997, MED CLIN N AM, V81, P653, DOI 10.1016/S0025-7125(05)70538-1; Jennette JC, 1998, KIDNEY INT, V53, P796, DOI 10.1038/ki.1998.36; JENNETTE JC, 1991, AM J KIDNEY DIS, V18, P466, DOI 10.1016/S0272-6386(12)80115-6; JOHNSON RJ, 1994, KIDNEY INT, V45, P352, DOI 10.1038/ki.1994.45; JOHNSON RJ, 1994, KIDNEY INT, V46, P1255, DOI 10.1038/ki.1994.393; JOHNSON RJ, 1994, KIDNEY INT, V46, P1700, DOI 10.1038/ki.1994.471; JOHNSON RJ, 1994, KIDNEY INT, V45, P1769, DOI 10.1038/ki.1994.230; JOHNSON RJ, 1993, NEW ENGL J MED, V328, P465, DOI 10.1056/NEJM199302183280703; JOHNSTON PA, 1992, Q J MED, V84, P619; KALLURI R, 1995, J AM SOC NEPHROL, V6, P1178; KELLY PT, 1994, MEDICINE, V73, P171, DOI 10.1097/00005792-199407000-00001; Kotanko P, 1997, TRANSPLANTATION, V63, P1045, DOI 10.1097/00007890-199704270-00001; Levy JB, 1997, J NEPHROL, V10, P7; LEWY JE, 1971, MEDICINE, V50, P453, DOI 10.1097/00005792-197111000-00001; LIEN JWK, 1979, Q J MED, V48, P99; LIN W, 1997, CHUNG HUA NEI KO TSA, V36, P83; Madore F, 1996, J AM SOC NEPHROL, V7, P367; MASON PD, 1994, BRIT MED J, V309, P1557, DOI 10.1136/bmj.309.6968.1557; MATHEW TH, 1988, AM J KIDNEY DIS, V12, P85, DOI 10.1016/S0272-6386(88)80001-5; Merkel F, 1996, KIDNEY INT, V49, P1127, DOI 10.1038/ki.1996.163; MERKEL F, 1998, KIDNEY INT S64, V53, pS31; METSTECKY J, 1993, CONTRIB NEPHROL, V104, P172; MISIANI R, 1992, ANN INTERN MED, V117, P573, DOI 10.7326/0003-4819-117-7-573; NIELSEN EG, 1997, IMMUNOLOGIC RENAL DI; NISSENSON AR, 1979, ANN INTERN MED, V91, P76, DOI 10.7326/0003-4819-91-1-76; PEAKE PW, 1991, APMIS, V99, P460, DOI 10.1111/j.1699-0463.1991.tb05176.x; PONTICELLI C, 1994, KIDNEY INT, V46, P595, DOI 10.1038/ki.1994.311; POPOVICROLOVIC M, 1991, NEPHRON, V58, P393, DOI 10.1159/000186469; Radford MG, 1997, J AM SOC NEPHROL, V8, P199; Rasmussen N., 1998, Clinical and Experimental Immunology, V112, P13; RENNKE HG, 1994, KIDNEY INT, V45, P1044, DOI 10.1038/ki.1994.141; RODRIGUEZITURBE B, 1980, ANN INTERN MED, V92, P478, DOI 10.7326/0003-4819-92-4-478; RONDEAU E, 1993, J NEPHROL, V6, P14; ROSE BD, 1989, SCI AM MED, P1; Scheinman JI, 1997, NEPHRON, V75, P251, DOI 10.1159/000189545; SCHLONDORFF D, 1995, KIDNEY INT, V48, pS19; Schmitt WH, 1998, KIDNEY INT, pS39; SIMPSON IJ, 1982, AM J NEPHROL, V2, P301, DOI 10.1159/000166666; TEJANI A, 1990, NEPHRON, V55, P1, DOI 10.1159/000185909; Tisher CC, 1994, RENAL PATHOLOGY CLIN, V2nd; TOPHAM PS, 1994, Q J MED, V87, P329; Turner AN, 1996, ANNU REV MED, V47, P377; US Renal Data System, 1997, USRDS 1997 ANN DAT R; WEBER MFA, 1992, J AM SOC NEPHROL, V2, P1227; WEST CD, 1986, KIDNEY INT, V29, P1077, DOI 10.1038/ki.1986.110; WILSON CB, 1996, KIDNEY, P1253; YAMABE H, 1995, J AM SOC NEPHROL, V6, P220	85	100	107	0	5	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	MAY 1	1999	353	9163					1509	1515		10.1016/S0140-6736(98)06195-9	http://dx.doi.org/10.1016/S0140-6736(98)06195-9			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	195XV	10232333				2022-12-28	WOS:000080278200045
J	Renard, JP; Chastant, S; Chesne, P; Richard, C; Marchal, J; Cordonnier, N; Chavatte, P; Vignon, X				Renard, JP; Chastant, S; Chesne, P; Richard, C; Marchal, J; Cordonnier, N; Chavatte, P; Vignon, X			Lymphoid hypoplasia and somatic cloning	LANCET			English	Article							NUCLEAR TRANSPLANTATION; CELL LINE; EMBRYOS; CALVES; ADULT; FETAL	Background Adult somatic cloning by nuclear transfer is associated with high rate of perinatal mortality but there is still no evidence that nuclear transfer itself is responsible for these failures. We report on a longlasting defect linked to somatic cloning. Methods Skin cells grown from an ear biopsy specimen from a 15-day-old calf were used as a source of nuclei. The donor animal was a clone of three females obtained from embryonic cells. Clinical examination, haematological, and biochemical profiles, and echocardiography of the somatic clone were done from birth to death. Findings After 6 weeks of normal development, the somatic cloned calf had a sudden and rapid fall in lymphocyte count and a decrease in haemoglobin. The calf died on day 51 from severe anaemia. Necropsy revealed no abnormality except thymic atrophy and lymphoid hypoplasia. Interpretation Somatic cloning may be the cause of longlasting deleterious effects. Our observation should be taken into account in debates on reproductive cloning in human beings.	INRA, Unite Biol Dev, F-78352 Jouy En Josas, France; INRA, Unite Biol Cellulaire, F-78352 Jouy En Josas, France; INRA, F-91630 Leudeville, France; ENVA, F-94704 Maisons Alfort, France	INRAE; UDICE-French Research Universities; Universite Paris Saclay; INRAE; UDICE-French Research Universities; Universite Paris Saclay; INRAE; Ecole Nationale Veterinaire d'Alfort (ENVA)	Renard, JP (corresponding author), INRA, Unite Biol Dev, F-78352 Jouy En Josas, France.		richard, christophe/E-9529-2015; CHASTANT, Sylvie/ABG-2003-2020; Chavatte-Palmer, Pascale/K-7349-2012	CHASTANT, Sylvie/0000-0003-0790-6377; Chavatte-Palmer, Pascale/0000-0002-4581-6092				Campbell KHS, 1996, NATURE, V380, P64, DOI 10.1038/380064a0; CHESNE P, 1993, CR ACAD SCI III-VIE, V316, P487; Cibelli JB, 1998, SCIENCE, V280, P1256, DOI 10.1126/science.280.5367.1256; GARY FB, 1996, THERIOGENOLOGY, V45, P141; Heyman Y, 1996, ANIM REPROD SCI, V42, P427, DOI 10.1016/0378-4320(96)01528-X; HILL JR, 1998, P ANN M SOC THER DEC; Kato Y, 1998, SCIENCE, V282, P2095, DOI 10.1126/science.282.5396.2095; Kruip TAM, 1997, THERIOGENOLOGY, V47, P43, DOI 10.1016/S0093-691X(96)00338-X; PRATHER RS, 1987, BIOL REPROD, V37, P859, DOI 10.1095/biolreprod37.4.859; REIK W, 1993, DEVELOPMENT, V119, P933; ROMER I, 1997, CURR BIOL, V7, P277; SIMS M, 1993, P NATL ACAD SCI USA, V90, P6143; Vignon X, 1998, CR ACAD SCI III-VIE, V321, P735, DOI 10.1016/S0764-4469(98)80014-0; Wakayama T, 1998, NATURE, V394, P369, DOI 10.1038/28615; Wells DN, 1997, BIOL REPROD, V57, P385, DOI 10.1095/biolreprod57.2.385; WILLADSEN SM, 1986, NATURE, V320, P63, DOI 10.1038/320063a0; Wilmut I, 1997, NATURE, V385, P810, DOI 10.1038/385810a0; Young LE, 1998, REV REPROD, V3, P155, DOI 10.1530/revreprod/3.3.155	18	177	187	0	3	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	MAY 1	1999	353	9163					1489	1491		10.1016/S0140-6736(98)12173-6	http://dx.doi.org/10.1016/S0140-6736(98)12173-6			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	195XV	10232316				2022-12-28	WOS:000080278200013
J	Wiktor, SZ; Sassan-Morokro, M; Grant, AD; Abouya, L; Karon, JM; Maurice, C; Djomand, G; Ackah, A; Domoua, K; Kadio, A; Yapi, A; Combe, P; Tossou, O; Roels, TH; Lackritz, EM; Coulibaly, D; De Cock, KM; Coulibaly, IM; Greenberg, AE				Wiktor, SZ; Sassan-Morokro, M; Grant, AD; Abouya, L; Karon, JM; Maurice, C; Djomand, G; Ackah, A; Domoua, K; Kadio, A; Yapi, A; Combe, P; Tossou, O; Roels, TH; Lackritz, EM; Coulibaly, D; De Cock, KM; Coulibaly, IM; Greenberg, AE			Efficacy of trimethoprim-sulphamethoxazole prophylaxis to decrease morbidity and mortality in HIV-1-infected patients with tuberculosis in Abidjan, Cote d'Ivoire: a randomised controlled trial	LANCET			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; HIV-INFECTED PATIENTS; PULMONARY TUBERCULOSIS; IVORY-COAST; ANTIBIOTIC-RESISTANCE; AFRICAN PATIENTS; WEST-AFRICA; ADULTS; KENYA; CHEMOTHERAPY	Background There is a high incidence of opportunistic infection among HIV-1-infected patients with tuberculosis in Africa and, consequently, high mortality. We assessed the safety and efficacy of trimethoprim-sulphamethoxazole 800 mg/160 mg (co-trimoxazole) prophylaxis in prevention of such infections and in decrease of morbidity and mortality. Methods Between October, 1995, and April, 1998, we enrolled 771 HIV-1 seropositive and HIV-1 and HIV-2 dually seroreactive patients who had sputum-smear-positive pulmonary tuberculosis (median age 32 years [range 18-64], median CD4-cell count 317 cells/mu L) attending Abidjan's four largest outpatient tuberculosis treatment centres. Patients were randomly assigned one daily tablet of co-trimoxazole (n=386) or placebo (n=385) 1 month after the start of a standard 6-month tuberculosis regimen. We assessed adherence to study drug and tolerance monthly for 5 months and every 3 months thereafter, as well as rates of admission to hospital. Findings Rates of laboratory and clinical adverse events were similar in the two groups. 51 patients in the co-trimoxazole group (13.8/100 person-years) and 86 in the placebo group (25.4/100 person-years) died (decrease In risk 46% [95% CI 23-62], p<0.001). 29 patients on co-trimoxazole (8.2/100 person-years) and 47 on placebo (15.0/100 person-years) were admitted to hospital at least once after randomisation (decrease 43% [10-64]), p=0.02). There were significantly fewer admissions for septicaemia and enteritis in the co-trimoxazole group than in the placebo group. Interpretation In HIV-1-infected patients with tuberculosis, daily co-trimoxazole prophylaxis was well tolerated and significantly decreased mortality and hospital admission rates. Our findings may have important implications for improvement of clinical care for such patients in Africa.	Projet RETRO CI, Abidjan 01, Cote Ivoire; Ctr Dis Control & Prevent, Div HIV AIDS Prevent, Atlanta, GA USA; London Sch Hyg & Trop Med, London WC1, England; Ctr Diagnost & Rech SIDA, Abidjan, Cote Ivoire; CHU Treichville, Abidjan, Cote Ivoire; Minist Sante Publ, Programme Natl Lutte Contre SIDA, Malad Sexuellement Transmissibles & TB, Abidjan, Cote Ivoire	Centers for Disease Control & Prevention - USA; University of London; London School of Hygiene & Tropical Medicine	Wiktor, SZ (corresponding author), Projet RETRO CI, 01 BP 1712, Abidjan 01, Cote Ivoire.	szw0@cdc.gov		Roels, Thierry/0000-0002-0886-5645; Lackritz, Eve/0000-0002-5397-7291				Abouya L, 1998, AIDS, V12, P505, DOI 10.1097/00002030-199805000-00012; ABOUYA YL, 1992, AM REV RESPIR DIS, V145, P617, DOI 10.1164/ajrccm/145.3.617; Anglaret X, 1999, LANCET, V353, P1463, DOI 10.1016/S0140-6736(98)07399-1; Anglaret X, 1997, J CLIN MICROBIOL, V35, P1915, DOI 10.1128/JCM.35.7.1915-1915.1997; Aseffa A, 1997, E AFR MED J, V74, P708; COLEBUNDERS RL, 1989, AM REV RESPIR DIS, V139, P535; DECOCK KM, 1990, AIDS, V4, P875, DOI 10.1097/00002030-199009000-00007; DECOCK KM, 1992, JAMA-J AM MED ASSOC, V268, P1581, DOI 10.1001/jama.1992.03490120095035; GILKS CF, 1990, LANCET, V336, P545, DOI 10.1016/0140-6736(90)92096-Z; GRAHAM NMH, 1992, NEW ENGL J MED, V326, P1037, DOI 10.1056/NEJM199204163261601; Grant AD, 1998, INT J TUBERC LUNG D, V2, P926; Grant AD, 1997, AIDS, V11, P1357, DOI 10.1097/00002030-199711000-00010; GREENBERG AE, 1995, AIDS, V9, P1251, DOI 10.1097/00002030-199511000-00006; Hawken MP, 1997, AIDS, V11, P875, DOI 10.1097/00002030-199707000-00006; Kariuki S, 1996, J ANTIMICROB CHEMOTH, V38, P425, DOI 10.1093/jac/38.3.425; KASSIM S, 1995, AIDS, V9, P1185, DOI 10.1097/00002030-199510000-00011; LUCAS SB, 1993, AIDS, V7, P1569, DOI 10.1097/00002030-199312000-00005; Mache A, 1997, E AFR MED J, V74, P183; MARTIN DJ, 1995, J ACQ IMMUN DEF SYND, V8, P386; Mwinga A, 1998, AIDS, V12, P2447, DOI 10.1097/00002030-199818000-00014; *NAT I ALL INF DIS, 1998, SER ADV EXP REP MAN; Nkengasong JN, 1999, AIDS, V13, P109, DOI 10.1097/00002030-199901140-00015; Nkengasong JN, 1998, J CLIN MICROBIOL, V36, P123, DOI 10.1128/JCM.36.1.123-127.1998; NUNN P, 1992, AM REV RESPIR DIS, V146, P849, DOI 10.1164/ajrccm/146.4.849; OKWERA A, 1994, LANCET, V344, P1323, DOI 10.1016/S0140-6736(94)90693-9; PAPE JW, 1993, LANCET, V342, P268, DOI 10.1016/0140-6736(93)91817-6; PERRIENS JH, 1995, NEW ENGL J MED, V332, P779, DOI 10.1056/NEJM199503233321204; PERRIENS JH, 1991, AM REV RESPIR DIS, V144, P750, DOI 10.1164/ajrccm/144.4.750; Satten GA, 1998, J AM STAT ASSOC, V93, P318, DOI 10.2307/2669628; VUGIA DJ, 1993, J INFECT DIS, V168, P564, DOI 10.1093/infdis/168.3.564; Whalen CC, 1997, NEW ENGL J MED, V337, P801, DOI 10.1056/NEJM199709183371201; Wilkinson D, 1998, BRIT MED J, V317, P625, DOI 10.1136/bmj.317.7159.625	32	355	359	1	6	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	MAY 1	1999	353	9163					1469	1475		10.1016/S0140-6736(99)03465-0	http://dx.doi.org/10.1016/S0140-6736(99)03465-0			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	195XV	10232312				2022-12-28	WOS:000080278200009
J	Cosma, MP; Tanaka, TU; Nasmyth, K				Cosma, MP; Tanaka, TU; Nasmyth, K			Ordered recruitment of transcription and chromatin remodeling factors to a cell cycle- and developmentally regulated promoter	CELL			English	Article							YEAST MATING-TYPE; LINKING HISTONE ACETYLATION; ASH1 MESSENGER-RNA; HO GENE; SACCHAROMYCES-CEREVISIAE; SWI/SNF COMPLEX; NUCLEOSOMAL DNA; BINDING PROTEIN; BUDDING YEAST; GCN5 PROTEIN	Gene activation in eukaryotes requires chromatin remodeling complexes like Swi/Snf and histone acetylases like SAGA. How these factors are recruited to promoters is not yet understood. Using CHIP, we measured recruitment of Swi/Snf, SAGA, the repressor Ash1p, and transcription factors Swi5p and SBF to the HO endonuclease promoter as cells progress through the yeast cell cycle. Swi5p's entry into nuclei at the end of anaphase recruits Swi/Snf, which then recruits SAGA. These two factors then facilitate SBF's binding. Ash1p, which only accumulates in daughter cell nuclei, binds to HO soon after Swi5p and aborts recruitment of Swi/Snf, SAGA, and SBF. Swi5p remains at HO for only 5 min. Swi/Snf's and SAGA's subsequent persistence at HO is self sustaining and constitutes an "epigenetic memory" of HO's transient interaction with Swi5p.	Res Inst Mol Pathol, A-1030 Vienna, Austria; Univ Naples Federico II, Dipartimento Biochim & Biotecnol Med, I-80131 Naples, Italy	Vienna Biocenter (VBC); Research Institute of Molecular Pathology (IMP); University of Naples Federico II	Nasmyth, K (corresponding author), Res Inst Mol Pathol, Dr Bohr Gasse 7, A-1030 Vienna, Austria.	nasmyth@nt.imp.univie.ac.at	Tanaka, Tomoyuki U/A-4775-2008; Cosma, Maria Pia/E-8731-2015	Cosma, Maria Pia/0000-0003-4207-5097; Nasmyth, Kim/0000-0001-7030-4403; Tanaka, Tomoyuki/0000-0002-9886-5947				ANDREWS BJ, 1989, NATURE, V342, P830, DOI 10.1038/342830a0; BERGER SL, 1992, CELL, V70, P251, DOI 10.1016/0092-8674(92)90100-Q; Bertrand E, 1998, MOL CELL, V2, P437, DOI 10.1016/S1097-2765(00)80143-4; Bobola N, 1996, CELL, V84, P699, DOI 10.1016/S0092-8674(00)81048-X; BREEDEN L, 1987, CELL, V48, P389, DOI 10.1016/0092-8674(87)90190-5; BREEDEN L, 1991, GENE DEV, V5, P1183, DOI 10.1101/gad.5.7.1183; Brownell JE, 1996, CELL, V84, P843, DOI 10.1016/S0092-8674(00)81063-6; Brownell JE, 1996, CURR OPIN GENET DEV, V6, P176, DOI 10.1016/S0959-437X(96)80048-7; Burns LG, 1997, MOL CELL BIOL, V17, P4811, DOI 10.1128/MCB.17.8.4811; Ciosk R, 1998, CELL, V93, P1067, DOI 10.1016/S0092-8674(00)81211-8; CohenFix O, 1996, GENE DEV, V10, P3081, DOI 10.1101/gad.10.24.3081; COTE J, 1994, SCIENCE, V265, P53, DOI 10.1126/science.8016655; DIRICK L, 1992, NATURE, V357, P508, DOI 10.1038/357508a0; GEORGAKOPOULOS T, 1992, EMBO J, V11, P4145, DOI 10.1002/j.1460-2075.1992.tb05507.x; GONZALEZ I, 1999, IN PRESS CURR BIOL; Grant PA, 1997, GENE DEV, V11, P1640, DOI 10.1101/gad.11.13.1640; GRANT PA, 1998, NATURE, V383, P92; HIRSCHHORN JN, 1992, GENE DEV, V6, P2288, DOI 10.1101/gad.6.12a.2288; Holstege FCP, 1998, CELL, V95, P717, DOI 10.1016/S0092-8674(00)81641-4; IMBALZANO AN, 1994, NATURE, V370, P481, DOI 10.1038/370481a0; Jansen RP, 1996, CELL, V84, P687, DOI 10.1016/S0092-8674(00)81047-8; Kadonaga JT, 1998, CELL, V92, P307, DOI 10.1016/S0092-8674(00)80924-1; Kadosh D, 1998, MOL CELL BIOL, V18, P5121, DOI 10.1128/MCB.18.9.5121; Kadosh D, 1997, CELL, V89, P365, DOI 10.1016/S0092-8674(00)80217-2; Kingston RE, 1996, GENE DEV, V10, P905, DOI 10.1101/gad.10.8.905; KOCH C, 1994, CURR OPIN CELL BIOL, V6, P451, DOI 10.1016/0955-0674(94)90039-6; KRUGER W, 1995, GENE DEV, V9, P2770, DOI 10.1101/gad.9.22.2770; KRUGER W, 1991, MOL CELL BIOL, V11, P4135, DOI 10.1128/MCB.11.8.4135; KWON H, 1994, NATURE, V370, P477, DOI 10.1038/370477a0; Lim HH, 1998, CURR BIOL, V8, P231, DOI 10.1016/S0960-9822(98)70088-0; Long RM, 1997, SCIENCE, V277, P383, DOI 10.1126/science.277.5324.383; MARCUS GA, 1994, EMBO J, V13, P4807, DOI 10.1002/j.1460-2075.1994.tb06806.x; Mizzen CA, 1998, CELL MOL LIFE SCI, V54, P6, DOI 10.1007/s000180050121; MOLL T, 1991, CELL, V66, P743, DOI 10.1016/0092-8674(91)90118-I; MUNCHOW S, 1989, IN PRESS J CELL SCI, V112; NASMYTH K, 1993, CURR OPIN GENET DEV, V3, P286, DOI 10.1016/0959-437X(93)90036-O; NASMYTH K, 1985, CELL, V42, P225, DOI 10.1016/S0092-8674(85)80118-5; NASMYTH K, 1987, EMBO J, V6, P243, DOI 10.1002/j.1460-2075.1987.tb04745.x; NASMYTH K, 1983, NATURE, V302, P670, DOI 10.1038/302670a0; NASMYTH KA, 1982, ANNU REV GENET, V16, P439, DOI 10.1146/annurev.ge.16.120182.002255; OSHIMA Y, 1971, GENETICS, V67, P327; OwenHughes T, 1996, SCIENCE, V273, P513, DOI 10.1126/science.273.5274.513; Pazin MJ, 1997, CELL, V88, P737, DOI 10.1016/S0092-8674(00)81918-2; Perez-Martin J, 1998, MOL CELL BIOL, V18, P1049, DOI 10.1128/MCB.18.2.1049; Peterson CL, 1996, CURR OPIN GENET DEV, V6, P171, DOI 10.1016/S0959-437X(96)80047-5; Pollard KJ, 1997, MOL CELL BIOL, V17, P6212, DOI 10.1128/MCB.17.11.6212; Pollard KJ, 1998, BIOESSAYS, V20, P771, DOI 10.1002/(SICI)1521-1878(199809)20:9<771::AID-BIES10>3.0.CO;2-V; PRIMIG M, 1992, NATURE, V358, P593, DOI 10.1038/358593a0; Pugh BF, 1996, CURR OPIN CELL BIOL, V8, P303, DOI 10.1016/S0955-0674(96)80002-0; RuizGarcia AB, 1997, FEBS LETT, V403, P186, DOI 10.1016/S0014-5793(97)00049-5; Rundlett SE, 1998, NATURE, V392, P831, DOI 10.1038/33952; Schnitzler G, 1998, CELL, V94, P17, DOI 10.1016/S0092-8674(00)81217-9; Shirayama M, 1998, EMBO J, V17, P1336, DOI 10.1093/emboj/17.5.1336; Sil A, 1996, CELL, V84, P711, DOI 10.1016/S0092-8674(00)81049-1; STERN M, 1984, J MOL BIOL, V178, P853, DOI 10.1016/0022-2836(84)90315-2; Sterner DE, 1999, MOL CELL BIOL, V19, P86; STILLMAN DJ, 1994, GENETICS, V136, P781; STILLMAN DJ, 1988, EMBO J, V7, P485, DOI 10.1002/j.1460-2075.1988.tb02836.x; STRATHERN JN, 1982, CELL, V31, P183, DOI 10.1016/0092-8674(82)90418-4; Struhl K, 1998, GENE DEV, V12, P599, DOI 10.1101/gad.12.5.599; TABA MRM, 1991, GENE DEV, V5, P2000, DOI 10.1101/gad.5.11.2000; Takizawa PA, 1997, NATURE, V389, P90, DOI 10.1038/38015; Tanaka TU, 1997, CELL, V90, P649, DOI 10.1016/S0092-8674(00)80526-7; TEBB G, 1993, GENE DEV, V7, P517, DOI 10.1101/gad.7.3.517; Visintin R, 1998, MOL CELL, V2, P709, DOI 10.1016/S1097-2765(00)80286-5; Visintin R, 1997, SCIENCE, V278, P460, DOI 10.1126/science.278.5337.460; WINSTON F, 1992, TRENDS GENET, V8, P387, DOI 10.1016/0168-9525(92)90167-3	67	586	595	3	32	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	APR 30	1999	97	3					299	311		10.1016/S0092-8674(00)80740-0	http://dx.doi.org/10.1016/S0092-8674(00)80740-0			13	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	192VP	10319811	Bronze			2022-12-28	WOS:000080100500004
J	Alperovitch, A				Alperovitch, A			Uncertainty over length of incubation tempers optimism - Commentary	BMJ-BRITISH MEDICAL JOURNAL			English	Editorial Material							CREUTZFELDT-JAKOB-DISEASE; VARIANT		Hop La Pitie Salpetriere, INSERM, U360, F-75651 Paris 13, France	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Pitie-Salpetriere - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Sorbonne Universite	Alperovitch, A (corresponding author), Hop La Pitie Salpetriere, INSERM, U360, F-75651 Paris 13, France.							Cousens SN, 1997, NATURE, V385, P197, DOI 10.1038/385197a0; DESILVA R, 1994, CNS DRUGS, V2, P96, DOI 10.2165/00023210-199402020-00002; Hill AF, 1997, LANCET, V349, P99, DOI 10.1016/S0140-6736(97)24002-X; Hilton DA, 1998, LANCET, V352, P703, DOI 10.1016/S0140-6736(98)24035-9; PRUSINER SB, 1982, ANN NEUROL, V12, P1, DOI 10.1002/ana.410120102; Will RG, 1996, LANCET, V347, P921, DOI 10.1016/S0140-6736(96)91412-9; Will RG, 1998, ANN NEUROL, V43, P763, DOI 10.1002/ana.410430611	7	0	0	0	0	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	APR 17	1999	318	7190					1045	1045						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	193ML	10336285				2022-12-28	WOS:000080140000029
J	Oliveira, DBG				Oliveira, DBG			Prophylaxis against contrast-induced nephropathy	LANCET			English	Editorial Material							ACUTE-RENAL-FAILURE; AGENTS; RISK		Univ London St Georges Hosp, Sch Med, Dept Renal Med, London SW17 0RE, England	St Georges University London	Oliveira, DBG (corresponding author), Univ London St Georges Hosp, Sch Med, Dept Renal Med, London SW17 0RE, England.			Oliveira, David/0000-0002-7507-5651				Abizaid AS, 1999, AM J CARDIOL, V83, P260, DOI 10.1016/S0002-9149(98)00833-9; BARRETT BJ, 1993, RADIOLOGY, V188, P171, DOI 10.1148/radiology.188.1.8511292; Hans SS, 1998, AM SURGEON, V64, P432; Kolonko A, 1998, J NEPHROL, V11, P151; McCullough PA, 1997, AM J MED, V103, P368, DOI 10.1016/S0002-9343(97)00150-2; Perneger T. V., 1993, Journal of the American Society of Nephrology, V4, P256; Solomon R, 1998, KIDNEY INT, V53, P230, DOI 10.1038/sj.ki.4495510; SOLOMON R, 1994, NEW ENGL J MED, V331, P1416, DOI 10.1056/NEJM199411243312104; Stevens NA, 1999, J AM COLL CARDIOL, V33, P403; Taylor AJ, 1998, CHEST, V114, P1570, DOI 10.1378/chest.114.6.1570; WEISBERG LS, 1994, KIDNEY INT, V45, P259, DOI 10.1038/ki.1994.32	11	14	14	0	0	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	MAY 15	1999	353	9165					1638	1639		10.1016/S0140-6736(98)90076-9	http://dx.doi.org/10.1016/S0140-6736(98)90076-9			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	198DT	10335780				2022-12-28	WOS:000080408000005
J	Porse, BT; Garrett, RA				Porse, BT; Garrett, RA			Ribosomal mechanics, antibiotics, and GTP hydrolysis	CELL			English	Review							FACTOR EF-G; RNA; BINDING; L11; SITE		Univ Copenhagen, Inst Mol Biol, RNA Regulat Ctr, DK-1307 Copenhagen K, Denmark	University of Copenhagen	Garrett, RA (corresponding author), Univ Copenhagen, Inst Mol Biol, RNA Regulat Ctr, Solvgade 83, DK-1307 Copenhagen K, Denmark.		Garrett, Roger A/M-2450-2014; Porse, Bo/B-1332-2012	Garrett, Roger A/0000-0001-8452-9099; Porse, Bo/0000-0001-6043-0844				Bukhman YV, 1997, J MOL BIOL, V273, P1020, DOI 10.1006/jmbi.1997.1383; GALE EF, 1981, ANTIBIOTIC INHIBITOR, P402; HORNIG H, 1987, BIOCHIMIE, V69, P803, DOI 10.1016/0300-9084(87)90207-0; MESTERS JR, 1994, J MOL BIOL, V242, P644, DOI 10.1006/jmbi.1994.1614; Munishkin A, 1997, P NATL ACAD SCI USA, V94, P12280, DOI 10.1073/pnas.94.23.12280; Nyborg J, 1998, FEBS LETT, V430, P95, DOI 10.1016/S0014-5793(98)00624-3; Porse BT, 1999, J MOL BIOL, V287, P33, DOI 10.1006/jmbi.1999.2600; Porse BT, 1998, J MOL BIOL, V276, P391, DOI 10.1006/jmbi.1997.1541; ROSENDAHL G, 1993, J MOL BIOL, V234, P1013, DOI 10.1006/jmbi.1993.1655; THOMPSON J, 1993, EMBO J, V12, P1499, DOI 10.1002/j.1460-2075.1993.tb05793.x; Traut RR, 1995, BIOCHEM CELL BIOL, V73, P949, DOI 10.1139/o95-102; Wilson KS, 1998, CELL, V92, P131, DOI 10.1016/S0092-8674(00)80905-8; Wimberly BT, 1999, CELL, V97, P491, DOI 10.1016/S0092-8674(00)80759-X; Xing YY, 1997, NAT STRUCT BIOL, V4, P24, DOI 10.1038/nsb0197-24	14	29	31	0	3	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	MAY 14	1999	97	4					423	426		10.1016/S0092-8674(00)80751-5	http://dx.doi.org/10.1016/S0092-8674(00)80751-5			4	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	196FV	10338205	Bronze			2022-12-28	WOS:000080299100002
J	Mainen, ZF; Malinow, R; Svoboda, K				Mainen, ZF; Malinow, R; Svoboda, K			Synaptic calcium transients in single spines indicate that NMDA receptors are not saturated	NATURE			English	Article							LONG-TERM POTENTIATION; DENDRITIC SPINES; MULTIVESICULAR RELEASE; GLUTAMATE DIFFUSION; EXCITATORY SYNAPSES; PYRAMIDAL NEURONS; TIME COURSE; HIPPOCAMPUS; TRANSMITTER; PROBABILITY	At excitatory synapses in the central nervous system, the number of glutamate molecules released from a vesicle is much larger than the number of postsynaptic receptors. But does release of a single vesicle normally saturate these receptors? Answering this question is critical to understanding how the amplitude and variability of synaptic transmission are set and regulated. Here we describe the use of two-photon microscopy(1) to image transient increases in Ca2+ concentration mediated by NMDA (N-methyl-D-aspartate) receptors in single dendritic spines of CAI pyramidal neurons in hippocampal slices. To test for NMDA-receptor saturation, we compared responses to stimulation with single and double pulses. We find that a single release event does not saturate spine NMDA receptors; a second release occurring 10 ms later produces similar to 80% more NMDA-receptor activation. The amplitude of spine NMDA-receptor-mediated [Ca2+] transients (and the synaptic plasticity which depends on this) may thus be sensitive to the number of quanta released by a burst of action potentials and to changes in the concentration profile of glutamate in the synaptic cleft.	Cold Spring Harbor Lab, Cold Spring Harbor, NY 11724 USA	Cold Spring Harbor Laboratory	Svoboda, K (corresponding author), Cold Spring Harbor Lab, 1 Bungtown Rd, Cold Spring Harbor, NY 11724 USA.			Mainen, Zachary/0000-0001-7913-9109				Auger C, 1998, J NEUROSCI, V18, P4532; Barbour B, 1997, TRENDS NEUROSCI, V20, P377; BLISS TVP, 1993, NATURE, V361, P31, DOI 10.1038/361031a0; Clements JD, 1996, TRENDS NEUROSCI, V19, P163, DOI 10.1016/S0166-2236(96)10024-2; CLEMENTS JD, 1992, SCIENCE, V258, P1498, DOI 10.1126/science.1359647; Cummings JA, 1996, NEURON, V16, P825, DOI 10.1016/S0896-6273(00)80102-6; Denk W, 1997, NEURON, V18, P351, DOI 10.1016/S0896-6273(00)81237-4; Dobrunz LE, 1997, P NATL ACAD SCI USA, V94, P14843, DOI 10.1073/pnas.94.26.14843; FABER DS, 1992, SCIENCE, V258, P1494, DOI 10.1126/science.1279813; Frerking M, 1996, CURR OPIN NEUROBIOL, V6, P395, DOI 10.1016/S0959-4388(96)80125-5; HARRIS KM, 1989, J NEUROSCI, V9, P2982; Helmchen F, 1996, BIOPHYS J, V70, P1069, DOI 10.1016/S0006-3495(96)79653-4; Holmes WR, 1995, BIOPHYS J, V69, P1734, DOI 10.1016/S0006-3495(95)80043-3; KORN H, 1982, J NEUROPHYSIOL, V48, P679, DOI 10.1152/jn.1982.48.3.679; LESTER RAJ, 1990, NATURE, V346, P565, DOI 10.1038/346565a0; Mainen ZF, 1998, NAT NEUROSCI, V1, P579, DOI 10.1038/2812; MAINEN ZF, IN RPESS METHODS COM, V18; MANABE T, 1994, SCIENCE, V265, P1888, DOI 10.1126/science.7916483; MARKRAM H, 1995, J PHYSIOL-LONDON, V485, P1; NOWAK L, 1984, NATURE, V307, P462, DOI 10.1038/307462a0; REGEHR WG, 1995, BIOPHYS J, V68, P2156, DOI 10.1016/S0006-3495(95)80398-X; Rusakov DA, 1998, J NEUROSCI, V18, P3158; Schikorski T, 1997, J NEUROSCI, V17, P5858; Silver RA, 1996, J PHYSIOL-LONDON, V494, P231, DOI 10.1113/jphysiol.1996.sp021487; STEVENS CF, 1995, NEURON, V14, P795, DOI 10.1016/0896-6273(95)90223-6; Svoboda K, 1996, SCIENCE, V272, P716, DOI 10.1126/science.272.5262.716; TANG CM, 1994, NEURON, V13, P1385, DOI 10.1016/0896-6273(94)90423-5; TONG G, 1994, NEURON, V13, P1195, DOI 10.1016/0896-6273(94)90057-4; TONG G, 1994, NEURON, V12, P51, DOI 10.1016/0896-6273(94)90151-1; YUSTE R, 1995, NATURE, V375, P682, DOI 10.1038/375682a0	30	238	244	0	14	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	MAY 13	1999	399	6732					151	155		10.1038/20187	http://dx.doi.org/10.1038/20187			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	196XU	10335844				2022-12-28	WOS:000080335700050
J	Silverstein, MJ; Lagios, MD; Groshen, S; Waisman, JR; Lewinsky, BS; Martino, S; Gamagami, P; Colburn, WJ				Silverstein, MJ; Lagios, MD; Groshen, S; Waisman, JR; Lewinsky, BS; Martino, S; Gamagami, P; Colburn, WJ			The influence of margin width on local control of ductal carcinoma in situ of the breast	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							SURGICAL ADJUVANT BREAST; IN-SITU; INTRADUCTAL CARCINOMA; RADIATION-THERAPY; DEFINITIVE IRRADIATION; CONSERVING SURGERY; PROGNOSTIC INDEX; INSITU; CLASSIFICATION; REPRODUCIBILITY	Background Ductal carcinoma in situ is a noninvasive carcinoma that is unlikely to recur if completely excised. Margin width, the distance between the boundary of the lesion and the edge of the excised specimen, may be an important determinant of local recurrence, Methods Margin widths, determined by direct measurement or ocular micrometry, and standardized evaluation of the tumor for nuclear grade, comedonecrosis, and size were performed on 469 specimens of ductal carcinoma in situ from patients who had been treated with breast-conserving surgery with or without postoperative radiation therapy, according to the choice of the patient or her physician. We analyzed the results in relation to margin width and whether the patient received postoperative radiation therapy. Results The mean (+/-SE) estimated probability of recurrence at eight years was 0.04+/-0.02 among 133 patients whose excised lesions had margin widths of 10 mm or more in every direction. Among these patients there was no benefit from postoperative radiation therapy. There was also no statistically significant benefit from postoperative radiation therapy among patients with margin widths of 1 to <10 mm. In contrast, there was a statistically significant benefit from radiation among patients in whom margin widths were less than 1 mm. Conclusions Postoperative radiation therapy did not lower the recurrence rate among patients with ductal carcinoma in situ that was excised with margins of 10 mm or more. Patients in whom the margin width is less than 1 mm can benefit from postoperative radiation therapy. (N Engl J Med 1999;340:1455-61.) (C) 1999, Massachusetts Medical Society.	Univ So Calif, Kenneth Norris Jr Comprehens Canc Ctr, Harold E & Henrietta C Lee Breast Ctr, Los Angeles, CA 90033 USA; Univ So Calif, Sch Med, Dept Surg, Los Angeles, CA 90033 USA; Univ So Calif, Sch Med, Dept Prevent Med, Los Angeles, CA 90033 USA; Univ So Calif, Sch Med, Dept Med, Los Angeles, CA 90033 USA; St Marys Hosp, San Francisco, CA USA; Breast Ctr, Van Nuys, CA 91405 USA	University of Southern California; University of Southern California; University of Southern California; University of Southern California	Silverstein, MJ (corresponding author), Univ So Calif, Kenneth Norris Jr Comprehens Canc Ctr, Harold E & Henrietta C Lee Breast Ctr, 1441 Eastlake Ave,Rm 7415, Los Angeles, CA 90033 USA.							ASHIKARI R, 1971, CANCER, V28, P1182, DOI 10.1002/1097-0142(1971)28:5<1182::AID-CNCR2820280515>3.0.CO;2-H; BELLAMY COC, 1993, HUM PATHOL, V24, P16, DOI 10.1016/0046-8177(93)90057-N; Bethwaite P, 1998, J CLIN PATHOL, V51, P450, DOI 10.1136/jcp.51.6.450; BORNSTEIN BA, 1991, CANCER-AM CANCER SOC, V67, P7, DOI 10.1002/1097-0142(19910101)67:1<7::AID-CNCR2820670103>3.0.CO;2-B; BRADLEY SJ, 1990, AM SURGEON, V56, P428; DouglasJones AG, 1996, HISTOPATHOLOGY, V29, P397, DOI 10.1046/j.1365-2559.1996.d01-513.x; FAVERLY DRG, 1994, SEMIN DIAGN PATHOL, V11, P193; FENTIMAN IS, 1986, EUR J SURG ONCOL, V12, P261; FISHER B, 1993, NEW ENGL J MED, V328, P1581, DOI 10.1056/NEJM199306033282201; Fisher B, 1998, J CLIN ONCOL, V16, P441, DOI 10.1200/JCO.1998.16.2.441; FISHER ER, 1995, CANCER-AM CANCER SOC, V75, P1310, DOI 10.1002/1097-0142(19950315)75:6<1310::AID-CNCR2820750613>3.0.CO;2-G; HOLLAND R, 1990, LANCET, V335, P519, DOI 10.1016/0140-6736(90)90747-S; HOLLAND R, 1997, DUCTAL CARCINOMA IN, P233; KAPLAN EL, 1958, J AM STAT ASSOC, V53, P457, DOI 10.2307/2281868; KUSKE RR, 1993, INT J RADIAT ONCOL, V26, P391, DOI 10.1016/0360-3016(93)90955-U; LAGIOS MD, 1982, CANCER-AM CANCER SOC, V50, P1309, DOI 10.1002/1097-0142(19821001)50:7<1309::AID-CNCR2820500716>3.0.CO;2-#; LAGIOS MD, 1989, CANCER, V63, P618, DOI 10.1002/1097-0142(19890215)63:4<618::AID-CNCR2820630403>3.0.CO;2-J; LAGIOS MD, 1990, SURG CLIN N AM, V70, P853; LAGIOS MD, 1993, NEW ENGL J MED, V329, P1577; LAGIOS MD, 1995, BREAST J, V1, P68; MCCORMICK B, 1991, INT J RADIAT ONCOL, V21, P289, DOI 10.1016/0360-3016(91)90773-W; Miller R. G., 1981, SURVIVAL ANAL; OTTESEN GL, 1992, AM J SURG PATHOL, V16, P1183, DOI 10.1097/00000478-199212000-00005; PAGE DL, 1995, CANCER, V75, P1219, DOI 10.1002/1097-0142(19950315)75:6<1219::AID-CNCR2820750602>3.0.CO;2-X; POLLER DN, 1994, MODERN PATHOL, V7, P257; ROSAI J, 1991, AM J SURG PATHOL, V15, P209, DOI 10.1097/00000478-199103000-00001; ROSNER D, 1980, ANN SURG, V192, P139, DOI 10.1097/00000658-198008000-00001; Schnitt SJ, 1996, CANCER, V77, P2189, DOI 10.1002/(SICI)1097-0142(19960601)77:11<2189::AID-CNCR1>3.0.CO;2-L; SCHNITT SJ, 1992, AM J SURG PATHOL, V16, P1133, DOI 10.1097/00000478-199212000-00001; SCHWARTZ GF, 1992, CANCER, V70, P2468, DOI 10.1002/1097-0142(19921115)70:10<2468::AID-CNCR2820701013>3.0.CO;2-K; Scott MA, 1997, HUM PATHOL, V28, P967, DOI 10.1016/S0046-8177(97)90013-7; SILVERSTEIN MJ, 1995, LANCET, V345, P1154; Silverstein MJ, 1998, J CLIN ONCOL, V16, P1367, DOI 10.1200/JCO.1998.16.4.1367; SILVERSTEIN MJ, 1995, EUR J CANCER, V31A, P1425, DOI 10.1016/0959-8049(95)00283-O; Silverstein MJ, 1996, CANCER-AM CANCER SOC, V77, P2267, DOI 10.1002/(SICI)1097-0142(19960601)77:11<2267::AID-CNCR13>3.0.CO;2-V; SOLIN LJ, 1991, CANCER-AM CANCER SOC, V68, P2337, DOI 10.1002/1097-0142(19911201)68:11<2337::AID-CNCR2820681102>3.0.CO;2-R; SOLIN LJ, 1993, CANCER-AM CANCER SOC, V71, P2532, DOI 10.1002/1097-0142(19930415)71:8<2532::AID-CNCR2820710817>3.0.CO;2-0; Wolmark N, 1998, BREAST CANC RES TREA, V50, P227; ZAFRANI B, 1994, SEMIN DIAGN PATHOL, V11, P208	39	496	517	0	2	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	MAY 13	1999	340	19					1455	1461		10.1056/NEJM199905133401902	http://dx.doi.org/10.1056/NEJM199905133401902			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	194MT	10320383	Bronze			2022-12-28	WOS:000080198700002
J	Taub, J; Lau, JF; Ma, C; Hahn, JH; Hoque, R; Rothblatt, J; Chalfie, M				Taub, J; Lau, JF; Ma, C; Hahn, JH; Hoque, R; Rothblatt, J; Chalfie, M			RETRACTED: A cytosolic catalase is needed to extend adult lifespan in C-elegans daf-C and clk-1 mutants (Retracted Article. See, vol 421, pg 764, 2003)	NATURE			English	Article; Retracted Publication							CAENORHABDITIS-ELEGANS; GUINEA-PIG; CYTOCHEMICAL DEMONSTRATION; OXIDATIVE STRESS; FAMILY-MEMBER; LONGEVITY; LIVER; GENE; OVEREXPRESSION; PEROXISOMES	The dauer larva is an alternative larval stage in Caenorhabditis elegans which allows animals to survive through periods of low food availability. Well-fed worms live for about three weeks, but dauer larvae can live for at least two months without affecting post-dauer lifespan(1). Mutations in daf-2 and age-1, which produce a dauer constitutive (Daf-C) phenotype, and in clk-1, which are believed to slow metabolism, markedly increase adult lifespan(2). Here we show that a ctl-1 mutation reduces adult lifespan in otherwise wild-type animals and eliminates the daf-c and clk-1-mediated extension of adult lifespan. ctl-1 encodes an unusual cytosolic catalase; a second gene, ctl-2, encodes a peroxisomal catalase. ctl-1 messenger RNA is increased in dauer larvae and adults with the daf-c mutations. We suggest that the ctl-1 catalase is needed during periods of starvation, as in the dauer larva, and that its misexpression in daf-c and clk-1 adults extends lifespan. Cytosolic catalase may have evolved to protect nematodes from oxidative damage produced during prolonged dormancy before reproductive maturity, or it may represent a general mechanism for permitting organisms to cope with the metabolic changes that accompany starvation.	Columbia Univ, Dept Biol Sci, New York, NY 10027 USA; Dartmouth Coll, Dept Biol Sci, Gilman Lab 6044, Hanover, NH 03755 USA	Columbia University; Dartmouth College	Chalfie, M (corresponding author), Columbia Univ, Dept Biol Sci, 1212 Amsterdam Ave, New York, NY 10027 USA.	mc21@columbia.edu						AMSTAD P, 1991, BIOCHEMISTRY-US, V30, P9305, DOI 10.1021/bi00102a024; Beckman KB, 1998, PHYSIOL REV, V78, P547, DOI 10.1152/physrev.1998.78.2.547; BISSINGER PH, 1989, MOL CELL BIOL, V9, P1309, DOI 10.1128/MCB.9.3.1309; Bulitta C, 1996, BBA-PROTEIN STRUCT M, V1293, P55, DOI 10.1016/0167-4838(95)00241-3; Ewbank JJ, 1997, SCIENCE, V275, P980, DOI 10.1126/science.275.5302.980; GOULD SJ, 1989, J CELL BIOL, V108, P1657, DOI 10.1083/jcb.108.5.1657; HOSOKAWA H, 1994, MECH AGEING DEV, V74, P161, DOI 10.1016/0047-6374(94)90087-6; KENYON C, 1997, C ELEGANS, V2, P791; Kimura KD, 1997, SCIENCE, V277, P942, DOI 10.1126/science.277.5328.942; KIRKWOOD TBL, 1991, PHILOS T R SOC B, V332, P15, DOI 10.1098/rstb.1991.0028; LARSEN PL, 1995, GENETICS, V139, P1567; Lin K, 1997, SCIENCE, V278, P1319, DOI 10.1126/science.278.5341.1319; LOEWEN PC, 1997, OXIDATIVE STRESS MOL, P273; MASORO EJ, 1991, ANN NY ACAD SCI, V621, P337; Mello C, 1995, METHOD CELL BIOL, V48, P451; Morris JZ, 1996, NATURE, V382, P536, DOI 10.1038/382536a0; Ogg S, 1997, NATURE, V389, P994, DOI 10.1038/40194; ORR WC, 1994, SCIENCE, V263, P1128, DOI 10.1126/science.8108730; Parkes TL, 1998, NAT GENET, V19, P171, DOI 10.1038/534; PETERS TJ, 1972, J EXP MED, V136, P1117, DOI 10.1084/jem.136.5.1117; Riddle DL, 1997, C ELEGANS, P739; ROELS F, 1976, J HISTOCHEM CYTOCHEM, V24, P713, DOI 10.1177/24.6.950458; ROELS F, 1977, J HISTOCHEM CYTOCHEM, V25, P157, DOI 10.1177/25.2.65420; RUIS H, 1997, OXIDATIVE STRESS MOL, P309; Sambrook J., 2002, MOL CLONING LAB MANU; Scandalios J.G., 1997, OXIDATIVE STRESS MOL, V34, P343, DOI [DOI 10.1101/087969502.34.343, 10.1101/0.343-406, DOI 10.1101/0.343-406]; Sulston J., 1988, NEMATODE CAENORHABDI, P587; VANFLETEREN JR, 1993, BIOCHEM J, V292, P605, DOI 10.1042/bj2920605; WATERSTON R, 1992, NAT GENET, V1, P114, DOI 10.1038/ng0592-114; YAMAMOTO K, 1988, EUR J CELL BIOL, V46, P129	30	191	204	0	20	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	MAY 13	1999	399	6732					162	166		10.1038/20208	http://dx.doi.org/10.1038/20208			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	196XU	10335847				2022-12-28	WOS:000080335700053
J	Mottonen, T; Hannonen, P; Leirisalo-Repo, M; Nissila, M; Kautiainen, H; Korpela, M; Laasonen, L; Julkunen, H; Luukkainen, R; Vuori, K; Paimela, L; Blafield, H; Hakala, M; Ilva, K; Yli-Kerttula, U; Puolakka, K; Jarvinen, P; Hakola, M; Piirainen, H; Ahonen, J; Palvimaki, I; Forsberg, S; Koota, K; Friman, C				Mottonen, T; Hannonen, P; Leirisalo-Repo, M; Nissila, M; Kautiainen, H; Korpela, M; Laasonen, L; Julkunen, H; Luukkainen, R; Vuori, K; Paimela, L; Blafield, H; Hakala, M; Ilva, K; Yli-Kerttula, U; Puolakka, K; Jarvinen, P; Hakola, M; Piirainen, H; Ahonen, J; Palvimaki, I; Forsberg, S; Koota, K; Friman, C		FIN RACo Trial Grp	Comparison of combination therapy with single-drug therapy in early rheumatoid arthritis: a randomised trial	LANCET			English	Article							DOUBLE-BLIND; SULFASALAZINE; METHOTREXATE; REMISSION; HYDROXYCHLOROQUINE; CRITERIA	Background The treatment of rheumatoid arthritis should aim at clinical remission. This multicentre, randomised trial with 2-year follow-up sought evidence on the efficacy and tolerability of combination therapy (sulphasalazine, methotrexate, hydroxychloroquine, and prednisolone) compared with treatment with a single disease-modifying antirheumatic drug, with or without prednisolone, in the treatment of early rheumatoid arthritis. Methods 199 patients were randomly assigned to two treatment groups. 195 started the treatment (97 received combination and 98 single drug therapy). Single-drug therapy in all patients started with sulphasalazine; in 51 patients methotrexate was later substituted. Oral prednisolone was required by 63 patients. The primary outcome measure was induction of remission. Analyses were intention to treat. Findings 87 patients in the combination group and 91 in the single-therapy group completed the trial. After a year, remission was achieved in 24 of 97 patients with combination therapy, and 11 of 98 with single-drug therapy (p=0.011). The remission frequencies at 2 years were 36 of 97 and 18 of 98 (p=0.003). Clinical improvement (American College of Rheumatology criteria of 50% clinical response) was achieved after 1 year in 68 (75%) patients with combination therapy, and in 56 (60%) using single-drug therapy (p=0.028), while at the 2-year visit 69 and 57 respectively (71% vs 58%, p=0.058) had clinically improved. The frequencies of adverse events were similar in both treatment groups. Interpretation Combination therapy was better and not more hazardous than single treatment in induction of remission in early rheumatoid arthritis. The combination strategy as an initial therapy seems to increase the efficacy of the treatment in at least a proportion of patients with early rheumatoid arthritis.	Turku Univ, Cent Hosp, Div Rheumatol, Turku, Finland; Jyvaskyla Cent Hosp, Dept Med, Jyvaskyla, Finland; Univ Helsinki, Cent Hosp, Rheumatism Fdn Hosp, Div Rheumatol, Heinola, Finland; Univ Helsinki, Cent Hosp, Rheumatism Fdn Hosp, Dept Radiol, Heinola, Finland; MedCare Ltd, Aanekoski, Finland; Tampere Univ Hosp, Div Rheumatol, Tampere, Finland; Peijas Hosp, Dept Med, Vantaa, Finland; Satalinna Hosp, Div Rheumatol, Harjavalta, Finland; Helsinki City Hosp, Div Rheumatol, Helsinki, Finland; Seinajoki Cent Hosp, Dept Med, Seinajoki, Finland; Oulu Univ, Cent Hosp, Div Rheumatol, Oulu, Finland; Hameenlinna Cent Hosp, Hameenlinna, Finland; Lappeenranta Cent Hosp, Lappeenranta, Finland; Kiljava Hosp, Kiljava, Finland; Joensuu Cent Hosp, Joensuu, Finland	University of Turku; Central Finland Central Hospital; Rheumatism Foundation Hospital; University of Helsinki; Helsinki University Central Hospital; Rheumatism Foundation Hospital; University of Helsinki; Helsinki University Central Hospital; Tampere University; Tampere University Hospital; Seinajoki Central Hospital; University of Oulu	Mottonen, T (corresponding author), Turku Univ, Cent Hosp, Paimio Hosp, Div Rheumatol, FIN-21540 Paimio, Finland.			Mottonen, Timo/0000-0003-1273-4805				ARNETT FC, 1987, ARTHRITIS RHEUM, V31, P315; Boers M, 1997, LANCET, V350, P309, DOI 10.1016/S0140-6736(97)01300-7; BOERS M, 1991, J RHEUMATOL, V18, P316; BORG G, 1991, J RHEUMATOL, V18, P1015; CASH JM, 1994, NEW ENGL J MED, V330, P1368; EBERHARDT KB, 1990, RHEUMATOL INT, V10, P135, DOI 10.1007/BF02274837; FELSON DT, 1995, ARTHRITIS RHEUM, V38, P727, DOI 10.1002/art.1780380602; FELSON DT, 1994, ARTHRITIS RHEUM, V37, P487; FRIES JF, 1980, ARTHRITIS RHEUM, V23, P137, DOI 10.1002/art.1780230202; FURST DE, 1990, DRUGS, V39, P19, DOI 10.2165/00003495-199039010-00003; Gordon DA, 1994, RHEUMATOLOGY, P1; Haagsma CJ, 1997, BRIT J RHEUMATOL, V36, P1082; HANNONEN P, 1993, ARTHRITIS RHEUM-US, V36, P1501, DOI 10.1002/art.1780361104; IANNUZZI L, 1983, NEW ENGL J MED, V309, P1023, DOI 10.1056/NEJM198310273091704; KIRWAN JR, 1995, NEW ENGL J MED, V333, P142, DOI 10.1056/NEJM199507203330302; KIRWAN JR, 1983, CLIN RHEUM DIS, V9, P581; Kwoh CK, 1996, ARTHRITIS RHEUM-US, V39, P713; LARSEN A, 1977, ACTA RADIOL DIAGN, V18, P481, DOI 10.1177/028418517701800415; Mottonen T, 1996, ARTHRITIS RHEUM, V39, P996, DOI 10.1002/art.1780390617; Mulherin D, 1996, BRIT J RHEUMATOL, V35, P1263; ODell JR, 1996, NEW ENGL J MED, V334, P1287, DOI 10.1056/NEJM199605163342002; PINALS RS, 1981, ARTHRITIS RHEUM, V24, P1308, DOI 10.1002/art.1780241012; PINCUS T, 1988, J CLIN EPIDEMIOL, V41, P1037, DOI 10.1016/0895-4356(88)90072-8; Prevoo MLL, 1996, BRIT J RHEUMATOL, V35, P1101; SCOTT DL, 1987, LANCET, V1, P1108; TUGWELL P, 1995, NEW ENGL J MED, V333, P137, DOI 10.1056/NEJM199507203330301; VANDERHEIJDE DMFM, 1990, LANCET, V335, P539, DOI 10.1016/0140-6736(90)90771-V; WILSKE KR, 1989, J RHEUMATOL, V16, P565; WOLDE ST, 1996, LANCET, V347, P347; WOLFE F, 1985, J RHEUMATOL, V12, P245; WOLFE F, 1990, J RHEUMATOL, V17, P24	31	696	714	0	18	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	MAY 8	1999	353	9164					1568	1573		10.1016/S0140-6736(98)08513-4	http://dx.doi.org/10.1016/S0140-6736(98)08513-4			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	195XW	10334255				2022-12-28	WOS:000080278300012
J	Fellers, RS; Leforestier, C; Braly, LB; Brown, MG; Saykally, RJ				Fellers, RS; Leforestier, C; Braly, LB; Brown, MG; Saykally, RJ			Spectroscopic determination the water pair potential	SCIENCE			English	Article							AB-INITIO; DIMER; VIBRATION; SPECTRA; DYNAMICS; CLUSTERS; ENERGY; (D2O)2; VAPOR	A polarizable water pair potential was determined by fitting a potential form to microwave, terahertz, and mid-infrared (D2O)(2) spectra through a rigorous calculation of the water dimer eigenstates. It accurately reproduces most ground state vibration-rotation-tunneling spectra and yields excellent second viral coefficients. The calculated dimer structure and dipole moment are very close to those determined from microwave spectroscopy and high-level ab initio calculations. The dimer binding energy and acceptor switching and donor-acceptor interchange tunneling barriers are in excellent agreement with recent ab initio theory, as are cyclic water trimer and tetramer structures and binding energies.	Univ Calif Berkeley, Dept Chem, Berkeley, CA 94720 USA; Univ Montpellier 2, Lab Struct & Dynam Syst Mol & Solides, UMR 5636, F-34095 Montpellier 05, France	University of California System; University of California Berkeley; Universite de Montpellier	Saykally, RJ (corresponding author), Univ Calif Berkeley, Dept Chem, Berkeley, CA 94720 USA.			SAYKALLY, RICHARD/0000-0001-8942-3656				Burnham CJ, 1999, J CHEM PHYS, V110, P4566, DOI 10.1063/1.478797; CURTISS LA, 1979, J CHEM PHYS, V71, P2703, DOI 10.1063/1.438628; ELROD MJ, 1994, CHEM REV, V94, P1975, DOI 10.1021/cr00031a010; ELROD MJ, 1995, J CHEM PHYS, V103, P933, DOI 10.1063/1.469794; Fellers RS, 1999, J CHEM PHYS, V110, P6306, DOI 10.1063/1.478535; Feyereisen MW, 1996, J PHYS CHEM-US, V100, P2993, DOI 10.1021/jp952860l; FRASER GT, 1991, INT REV PHYS CHEM, V10, P189, DOI 10.1080/01442359109353257; Gregory JK, 1996, J PHYS CHEM-US, V100, P18014, DOI 10.1021/jp9616019; GREGORY JK, 1995, J CHEM PHYS, V102, P7817, DOI 10.1063/1.468982; Halkier A, 1997, THEOR CHEM ACC, V97, P150, DOI 10.1007/s002140050248; JORGENSEN WL, 1983, J CHEM PHYS, V79, P926, DOI 10.1063/1.445869; KARYAKIN EN, 1993, MOL PHYS, V78, P1179, DOI 10.1080/00268979300100771; KELL GS, 1989, P ROY SOC LOND A MAT, V425, P49, DOI 10.1098/rspa.1989.0098; Leforestier C, 1997, J CHEM PHYS, V106, P8527, DOI 10.1063/1.473908; Liu K, 1997, J PHYS CHEM A, V101, P8995, DOI 10.1021/jp9707807; Liu K, 1996, SCIENCE, V271, P929, DOI 10.1126/science.271.5251.929; Mas EM, 1996, J CHEM PHYS, V104, P7606, DOI 10.1063/1.471469; McQuarrie D. A, 2000, STAT MECH; Millot C, 1998, J PHYS CHEM A, V102, P754, DOI 10.1021/jp972578+; MILLOT C, 1992, MOL PHYS, V77, P439, DOI 10.1080/00268979200102541; ODUTOLA JA, 1980, J CHEM PHYS, V72, P5062, DOI 10.1063/1.439795; Paul JB, 1998, J PHYS CHEM A, V102, P3279, DOI 10.1021/jp980763x; PUGLIANO N, 1992, J CHEM PHYS, V96, P1832, DOI 10.1063/1.462084; REIMERS JR, 1982, CHEM PHYS, V64, P95, DOI 10.1016/0301-0104(82)85006-4; SAYKALLY RJ, 1993, SCIENCE, V259, P1570, DOI 10.1126/science.259.5101.1570; SMITH BJ, 1990, J CHEM PHYS, V92, P1240, DOI 10.1063/1.458133; Solomon S, 1998, J GEOPHYS RES-ATMOS, V103, P3847, DOI 10.1029/97JD03285; Stone A.J., 1995, ORIENT PROGRAM STUDY; WALES DJ, IN PRESS THEORY ATOM, V2; XANTHEAS SS, 1993, J CHEM PHYS, V99, P8774, DOI 10.1063/1.465599	30	213	214	1	47	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	MAY 7	1999	284	5416					945	948		10.1126/science.284.5416.945	http://dx.doi.org/10.1126/science.284.5416.945			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	194MU	10320371				2022-12-28	WOS:000080198800040
J	Raju, TNK				Raju, TNK			The Nobel chronicles	LANCET			English	Article									Univ Illinois, Chicago, IL 60680 USA	University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital	Raju, TNK (corresponding author), Univ Illinois, Chicago, IL 60680 USA.								0	2	2	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	APR 24	1999	353	9162					1450	1450		10.1016/S0140-6736(05)75980-8	http://dx.doi.org/10.1016/S0140-6736(05)75980-8			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	191KD	10227260				2022-12-28	WOS:000080020800067
J	[Anonymous]				[Anonymous]			The Soho bomb	BMJ-BRITISH MEDICAL JOURNAL			English	Editorial Material																			0	0	0	0	0	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	MAY 22	1999	318	7195					1429	1429						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	200DQ	10334784				2022-12-28	WOS:000080524700082
J	Costerton, JW; Stewart, PS; Greenberg, EP				Costerton, JW; Stewart, PS; Greenberg, EP			Bacterial biofilms: A common cause of persistent infections	SCIENCE			English	Review							PSEUDOMONAS-AERUGINOSA BIOFILMS; AIRWAY SURFACE FLUID; LUXR-LUXI FAMILY; CYSTIC-FIBROSIS; MICROBIAL BIOFILMS; ANTIMICROBIAL AGENTS; IN-VITRO; STAPHYLOCOCCUS-EPIDERMIDIS; TRANSCRIPTIONAL REGULATORS; CHLORINE PENETRATION	Bacteria that attach to surfaces aggregate in a hydrated polymeric matrix of their own synthesis to form biofilms. Formation of these sessile communities and their inherent resistance to antimicrobial agents are at the root of many persistent and chronic bacterial infections. Studies of biofilms have revealed differentiated, structured groups of cells with community properties. Recent advances in our understanding of the genetic and molecular basis of bacterial community behavior point to therapeutic targets that may provide a means for the control of biofilm infections.	Univ Iowa, Dept Microbiol, Iowa City, IA 52242 USA; Montana State Univ, Ctr Biofilm Engn, Bozeman, MT 59717 USA	University of Iowa; Montana State University System; Montana State University Bozeman	Greenberg, EP (corresponding author), Univ Iowa, Dept Microbiol, Iowa City, IA 52242 USA.			Stewart, Philip/0000-0001-7773-8570; Greenberg, Everett/0000-0001-9474-8041	NIGMS NIH HHS [GM59026] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM059026] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BOLISTER N, 1991, J ANTIMICROB CHEMOTH, V27, P285, DOI 10.1093/jac/27.3.285; BOYD A, 1994, APPL ENVIRON MICROB, V60, P2355, DOI 10.1128/AEM.60.7.2355-2359.1994; BROWN MRW, 1993, J APPL BACTERIOL, V74, pS87, DOI 10.1111/j.1365-2672.1993.tb04345.x; BROWN MRW, 1988, J ANTIMICROB CHEMOTH, V22, P777, DOI 10.1093/jac/22.6.777; CHEEMA M S, 1986, Journal of Pharmacy and Pharmacology, V38, p53P; Chen X, 1996, ENVIRON SCI TECHNOL, V30, P2078, DOI 10.1021/es9509184; COCHRANE DMG, 1988, J MED MICROBIOL, V27, P255, DOI 10.1099/00222615-27-4-255; COSTERTON JW, 1995, ANNU REV MICROBIOL, V49, P711, DOI 10.1146/annurev.mi.49.100195.003431; COSTERTON JW, 1978, SCI AM, V238, P86, DOI 10.1038/scientificamerican0178-86; COSTERTON JW, 1987, ANNU REV MICROBIOL, V41, P435, DOI 10.1146/annurev.mi.41.100187.002251; DAROUICHE RO, 1994, J INFECT DIS, V170, P720, DOI 10.1093/infdis/170.3.720; DASGUPTA MK, 1989, CLIN INVEST MED, V12; Davies DG, 1998, SCIENCE, V280, P295, DOI 10.1126/science.280.5361.295; DAVIES DG, 1995, APPL ENVIRON MICROB, V61, P860, DOI 10.1128/AEM.61.3.860-867.1995; DAVIES DG, 1993, APPL ENVIRON MICROB, V59, P1181, DOI 10.1128/AEM.59.4.1181-1186.1993; DEBEER D, 1994, APPL ENVIRON MICROB, V60, P4339, DOI 10.1128/AEM.60.12.4339-4344.1994; DEBEER D, 1994, BIOTECHNOL BIOENG, V44, P636, DOI 10.1002/bit.260440510; Dibdin GH, 1996, J ANTIMICROB CHEMOTH, V38, P757, DOI 10.1093/jac/38.5.757; DUNNE WM, 1993, ANTIMICROB AGENTS CH, V37, P2522, DOI 10.1128/AAC.37.12.2522; Fuqua C, 1996, ANNU REV MICROBIOL, V50, P727, DOI 10.1146/annurev.micro.50.1.727; FUQUA WC, 1994, J BACTERIOL, V176, P269, DOI 10.1128/JB.176.2.269-275.1994; Goldman MJ, 1997, CELL, V88, P553, DOI 10.1016/S0092-8674(00)81895-4; GORDON CA, 1988, J ANTIMICROB CHEMOTH, V22, P667, DOI 10.1093/jac/22.5.667; HOYLE BD, 1992, ANTIMICROB AGENTS CH, V36, P2054, DOI 10.1128/AAC.36.9.2054; Ishida H, 1998, ANTIMICROB AGENTS CH, V42, P1641, DOI 10.1128/AAC.42.7.1641; Johansen Helle Krogh, 1996, APMIS, V104, P1; JORIS L, 1993, AM REV RESPIR DIS, V148, P1633, DOI 10.1164/ajrccm/148.6_Pt_1.1633; KHOURY AE, 1992, AM SOC ARTIF INTERN, V38, P174; KINNIMENT SL, 1992, APPL ENVIRON MICROB, V58, P1629, DOI 10.1128/AEM.58.5.1629-1635.1992; KUMON H, 1994, MICROBIOL IMMUNOL, V38, P615, DOI 10.1111/j.1348-0421.1994.tb01831.x; LAM J, 1980, INFECT IMMUN, V28, P546; LAMBE DW, 1991, CLIN ORTHOP RELAT R, P285; LAWRENCE JR, 1991, J BACTERIOL, V173, P6558, DOI 10.1128/jb.173.20.6558-6567.1991; Liu XF, 1998, BIOTECHNOL BIOENG, V59, P156; MARRIE TJ, 1982, CIRCULATION, V66, P1339, DOI 10.1161/01.CIR.66.6.1339; MCCARTER L, 1990, MOL MICROBIOL, V4, P1057, DOI 10.1111/j.1365-2958.1990.tb00678.x; Neu TR, 1997, FEMS MICROBIOL ECOL, V24, P11, DOI 10.1016/S0168-6496(97)00027-5; NICHOLS WW, 1988, ANTIMICROB AGENTS CH, V32, P518, DOI 10.1128/AAC.32.4.518; NICKEL JC, 1985, ANTIMICROB AGENTS CH, V27, P619, DOI 10.1128/AAC.27.4.619; O'Toole GA, 1998, MOL MICROBIOL, V30, P295, DOI 10.1046/j.1365-2958.1998.01062.x; Pier GB, 1997, P NATL ACAD SCI USA, V94, P12088, DOI 10.1073/pnas.94.22.12088; Puskas A, 1997, J BACTERIOL, V179, P7530, DOI 10.1128/jb.179.23.7530-7537.1997; Shigeta M, 1997, CHEMOTHERAPY, V43, P340, DOI 10.1159/000239587; Smith JJ, 1996, CELL, V85, P229, DOI 10.1016/S0092-8674(00)81099-5; STEWART PS, 1995, CHEM ENG SCI, V50, P3099, DOI 10.1016/0009-2509(95)00143-S; Stewart PS, 1998, BIOTECHNOL BIOENG, V59, P261, DOI 10.1002/(SICI)1097-0290(19980805)59:3<261::AID-BIT1>3.0.CO;2-9; Stewart PS, 1996, ANTIMICROB AGENTS CH, V40, P2517, DOI 10.1128/AAC.40.11.2517; Stickler DJ, 1998, APPL ENVIRON MICROB, V64, P3486; SUCI PA, 1994, ANTIMICROB AGENTS CH, V38, P2125, DOI 10.1128/AAC.38.9.2125; Vrany JD, 1997, ANTIMICROB AGENTS CH, V41, P1352, DOI 10.1128/AAC.41.6.1352; WARD KH, 1992, J MED MICROBIOL, V36, P406, DOI 10.1099/00222615-36-6-406; WELSH MJ, 1993, CELL, V73, P1251, DOI 10.1016/0092-8674(93)90353-R; WELSH MJ, 1995, METABOLIC MOL BASES, V3, P3799; Wentland EJ, 1996, BIOTECHNOL PROGR, V12, P316, DOI 10.1021/bp9600243; Whittaker CJ, 1996, ANNU REV MICROBIOL, V50, P513, DOI 10.1146/annurev.micro.50.1.513; Xu KD, 1998, APPL ENVIRON MICROB, V64, P4035; Xu XM, 1996, BIOTECHNOL BIOENG, V49, P93, DOI 10.1002/(SICI)1097-0290(19960105)49:1<93::AID-BIT12>3.3.CO;2-P; YASUDA H, 1994, ANTIMICROB AGENTS CH, V38, P138, DOI 10.1128/AAC.38.1.138; YASUDA H, 1993, ANTIMICROB AGENTS CH, V37, P1749, DOI 10.1128/AAC.37.9.1749; Zabner J, 1998, MOL CELL, V2, P397, DOI 10.1016/S1097-2765(00)80284-1	60	8106	8755	97	2750	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	MAY 21	1999	284	5418					1318	1322		10.1126/science.284.5418.1318	http://dx.doi.org/10.1126/science.284.5418.1318			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	198NN	10334980				2022-12-28	WOS:000080430600043
J	Ohba, T; Nakamura, M; Nishitani, H; Nishimoto, T				Ohba, T; Nakamura, M; Nishitani, H; Nishimoto, T			Self-organization of microtubule asters induced in Xenopus egg extracts by GTP-bound Ran	SCIENCE			English	Article							GAMMA-TUBULIN; NUCLEOTIDE EXCHANGE; CYTOPLASMIC DYNEIN; RING COMPLEX; RCC1; CENTROSOME; PROTEIN; NUCLEATION; REGULATOR; TRANSPORT	The nucleotide exchange activity of RCC1,the only known nucleotide exchange factor for Ran, a Ras-like small guanosine triphosphatase, was required for microtubule aster formation with or without demembranated sperm in Xenopus egg extracts arrested in meiosis II. Consistently, in the RCC1-depleted egg extracts, Ran guanosine triphosphate (RanGTP), but not Ran guanosine diphosphate (RanGDP), induced self-organization of microtubule asters, and the process required the activity of dynein. Thus, Ran was shown to regulate formation of the microtubule network.	Kyushu Univ, Grad Sch Med Sci, Dept Mol Biol, Maidashi Higashi Ku, Fukuoka 8128582, Japan	Kyushu University	Nishimoto, T (corresponding author), Kyushu Univ, Grad Sch Med Sci, Dept Mol Biol, Maidashi Higashi Ku, Fukuoka 8128582, Japan.		Oba, Tomoyuki/ABT-2152-2022	Oba, Tomoyuki/0000-0002-6715-7892; Nishitani, Hideo/0000-0001-5907-9380				Azuma Y, 1996, J BIOCHEM-TOKYO, V120, P82; BOGUSKI MS, 1993, NATURE, V366, P643, DOI 10.1038/366643a0; DASSO M, 1994, EMBO J, V13, P5732, DOI 10.1002/j.1460-2075.1994.tb06911.x; DASSO M, 1992, MOL CELL BIOL, V12, P3337, DOI 10.1128/MCB.12.8.3337; GAGLIO T, 1995, J CELL BIOL, V131, P693, DOI 10.1083/jcb.131.3.693; Gorlich D, 1998, EMBO J, V17, P2721, DOI 10.1093/emboj/17.10.2721; Heald R, 1997, J CELL BIOL, V138, P615, DOI 10.1083/jcb.138.3.615; Heald R, 1996, NATURE, V382, P420, DOI 10.1038/382420a0; Kalt Astrid, 1993, Trends in Cell Biology, V3, P118, DOI 10.1016/0962-8924(93)90174-Y; KELLOGG DR, 1994, ANNU REV BIOCHEM, V63, P639, DOI 10.1146/annurev.bi.63.070194.003231; KLEBE C, 1995, BIOCHEMISTRY-US, V34, P12543, DOI 10.1021/bi00039a008; Martin OC, 1998, J CELL BIOL, V141, P675, DOI 10.1083/jcb.141.3.675; Matunis MJ, 1996, J CELL BIOL, V135, P1457, DOI 10.1083/jcb.135.6.1457; Merdes A, 1996, CELL, V87, P447, DOI 10.1016/S0092-8674(00)81365-3; Mitchell P, 1997, CELL, V91, P457, DOI 10.1016/S0092-8674(00)80432-8; MORITZ M, 1995, NATURE, V378, P638, DOI 10.1038/378638a0; Nakamura M, 1998, J CELL BIOL, V143, P1041, DOI 10.1083/jcb.143.4.1041; Nigg EA, 1997, NATURE, V386, P779, DOI 10.1038/386779a0; NISHITANI H, 1990, J BIOCHEM-TOKYO, V107, P228, DOI 10.1093/oxfordjournals.jbchem.a123031; Noguchi E, 1996, EMBO J, V15, P5595, DOI 10.1002/j.1460-2075.1996.tb00944.x; Oki M, 1998, MOL GEN GENET, V257, P624; Pereira G, 1997, J CELL SCI, V110, P295; SAGATA N, 1989, NATURE, V342, P512, DOI 10.1038/342512a0; Sazer S, 1996, TRENDS CELL BIOL, V6, P81, DOI 10.1016/0962-8924(96)80992-5; Seki T, 1996, J BIOCHEM, V120, P207; STEARNS T, 1994, CELL, V76, P623, DOI 10.1016/0092-8674(94)90503-7; VERDE F, 1991, J CELL BIOL, V112, P1177, DOI 10.1083/jcb.112.6.1177; ZHENG YX, 1995, NATURE, V378, P578, DOI 10.1038/378578a0	28	247	250	0	6	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	MAY 21	1999	284	5418					1356	1358		10.1126/science.284.5418.1356	http://dx.doi.org/10.1126/science.284.5418.1356			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	198NN	10334990				2022-12-28	WOS:000080430600053
J	Greenberg, RA; Chin, L; Femino, A; Lee, KH; Gottlieb, GJ; Singer, RH; Greider, CW; DePinho, RA				Greenberg, RA; Chin, L; Femino, A; Lee, KH; Gottlieb, GJ; Singer, RH; Greider, CW; DePinho, RA			Short dysfunctional telomeres impair tumorigenesis in the INK4a(Delta 2/3) cancer-prone mouse	CELL			English	Article							ARF TUMOR-SUPPRESSOR; IMMORTAL HUMAN-CELLS; LIFE-SPAN; P53-DEPENDENT APOPTOSIS; CELLULAR SENESCENCE; LACKING TELOMERASE; HUMAN FIBROBLASTS; FISSION YEAST; INK4A LOCUS; P53	Maintenance of telomere length is predicted to be essential for bypass of senescence and crisis checkpoints in cancer cells. The impact of telomere dysfunction on tumorigenesis was assessed in successive generations of mice doubly null for the telomerase RNA (mTR) and the INK4a tumor suppressor genes. Significant reductions in tumor formation in vivo and oncogenic potential in vitro were observed in late generations of telomerase deficiency, coincident with severe telomere shortening and associated dysfunction. Reintroduction of mTR into cells significantly restored the oncogenic potential, indicating telomerase activation is a cooperating event in the malignant transformation of cells containing critically short telomeres. The results described here demonstrate that loss of telomere function in a cancer-prone mouse model possessing intact DNA damage responses impairs, but does not prevent, tumor formation.	Dana Farber Canc Inst, Dept Adult Oncol, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Med & Genet, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Dermatol, Boston, MA 02115 USA; Yeshiva Univ Albert Einstein Coll Med, Dept Microbiol & Immunol, Bronx, NY 10461 USA; Yeshiva Univ Albert Einstein Coll Med, Dept Struct Biol & Anat, Bronx, NY 10461 USA; Quest Diagnost Inc, Anat Pathol, Teterboro, NJ USA; Johns Hopkins Univ, Sch Med, Dept Mol Biol & Genet, Baltimore, MD 21205 USA	Harvard University; Dana-Farber Cancer Institute; Harvard University; Harvard Medical School; Harvard University; Harvard Medical School; Yeshiva University; Albert Einstein College of Medicine; Yeshiva University; Albert Einstein College of Medicine; Johns Hopkins University	DePinho, RA (corresponding author), Dana Farber Canc Inst, Dept Adult Oncol, 44 Binney St, Boston, MA 02115 USA.			DePinho, Ronald/0000-0002-5625-577X	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD028317] Funding Source: NIH RePORTER; NATIONAL CANCER INSTITUTE [P01CA016519] Funding Source: NIH RePORTER; NCI NIH HHS [CA16519] Funding Source: Medline; NICHD NIH HHS [HD28317, HD348880] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		Bacchetti S, 1996, CANCER SURV, V28, P197; Bates S, 1998, NATURE, V395, P124, DOI 10.1038/25867; Bednarek AK, 1997, MOL CARCINOGEN, V20, P329, DOI 10.1002/(SICI)1098-2744(199712)20:4<329::AID-MC1>3.0.CO;2-E; Bertrand E, 1998, MOL CELL, V2, P437, DOI 10.1016/S1097-2765(00)80143-4; Blasco MA, 1996, NAT GENET, V12, P200, DOI 10.1038/ng0296-200; Blasco MA, 1997, CELL, V91, P25, DOI 10.1016/S0092-8674(01)80006-4; Bodnar AG, 1998, SCIENCE, V279, P349, DOI 10.1126/science.279.5349.349; Broccoli D, 1996, MOL CELL BIOL, V16, P3765; Bryan TM, 1997, HUM MOL GENET, V6, P921, DOI 10.1093/hmg/6.6.921; BRYAN TM, 1995, EMBO J, V14, P4240, DOI 10.1002/j.1460-2075.1995.tb00098.x; CHADENEAU C, 1995, ONCOGENE, V11, P893; Chin L, 1999, CELL, V97, P527, DOI 10.1016/S0092-8674(00)80762-X; Conzen SD, 1995, ONCOGENE, V11, P2295; Counter CM, 1998, P NATL ACAD SCI USA, V95, P14723, DOI 10.1073/pnas.95.25.14723; COUNTER CM, 1992, EMBO J, V11, P1921, DOI 10.1002/j.1460-2075.1992.tb05245.x; de Stanchina E, 1998, GENE DEV, V12, P2434, DOI 10.1101/gad.12.15.2434; DYKHUIZEN D, 1974, NATURE, V251, P616, DOI 10.1038/251616a0; Femino A, 1998, SCIENCE, V280, P585, DOI 10.1126/science.280.5363.585; Greenberg RA, 1998, ONCOGENE, V16, P1723, DOI 10.1038/sj.onc.1201933; Greenberg RA, 1999, ONCOGENE, V18, P1219, DOI 10.1038/sj.onc.1202669; HARA E, 1991, BIOCHEM BIOPH RES CO, V179, P528, DOI 10.1016/0006-291X(91)91403-Y; HARLEY CB, 1990, NATURE, V345, P458, DOI 10.1038/345458a0; Kamijo T, 1998, P NATL ACAD SCI USA, V95, P8292, DOI 10.1073/pnas.95.14.8292; Kamijo T, 1997, CELL, V91, P649, DOI 10.1016/S0092-8674(00)80452-3; Karlseder J, 1999, SCIENCE, V283, P1321, DOI 10.1126/science.283.5406.1321; KIM NW, 1994, SCIENCE, V266, P2011, DOI 10.1126/science.7605428; KIPLING D, 1991, GENOMICS, V11, P235, DOI 10.1016/0888-7543(91)90128-2; Kiyono T, 1998, NATURE, V396, P84, DOI 10.1038/23962; KRAEMER PM, 1986, J NATL CANCER I, V76, P703, DOI 10.1093/jnci/76.4.703; Lee HW, 1998, NATURE, V392, P569, DOI 10.1038/33345; Lin AW, 1998, GENE DEV, V12, P3008, DOI 10.1101/gad.12.19.3008; Lloyd AC, 1997, GENE DEV, V11, P663, DOI 10.1101/gad.11.5.663; LUNDBLAD V, 1993, CELL, V73, P347, DOI 10.1016/0092-8674(93)90234-H; Martin-Rivera L, 1998, P NATL ACAD SCI USA, V95, P10471, DOI 10.1073/pnas.95.18.10471; McEachern MJ, 1996, GENE DEV, V10, P1822, DOI 10.1101/gad.10.14.1822; Naito T, 1998, NAT GENET, V20, P203, DOI 10.1038/2517; Nakamura TM, 1998, SCIENCE, V282, P493, DOI 10.1126/science.282.5388.493; Niida H, 1998, NAT GENET, V19, P203, DOI 10.1038/580; PALERMO I, 1998, NATURE, V395, P125; Pomerantz J, 1998, CELL, V92, P713, DOI 10.1016/S0092-8674(00)81400-2; PROWSE KR, 1995, P NATL ACAD SCI USA, V92, P4818, DOI 10.1073/pnas.92.11.4818; Radfar A, 1998, P NATL ACAD SCI USA, V95, P13194, DOI 10.1073/pnas.95.22.13194; Rudolph KL, 1999, CELL, V96, P701, DOI 10.1016/S0092-8674(00)80580-2; SAGER R, 1991, ENVIRON HEALTH PERSP, V93, P59, DOI 10.2307/3431170; Serrano M, 1996, CELL, V85, P27, DOI 10.1016/S0092-8674(00)81079-X; SERRANO M, 1993, NATURE, V366, P704, DOI 10.1038/366704a0; SHAY JW, 1991, EXP CELL RES, V196, P33, DOI 10.1016/0014-4827(91)90453-2; Sherr CJ, 1998, GENE DEV, V12, P2984, DOI 10.1101/gad.12.19.2984; Stott FJ, 1998, EMBO J, V17, P5001, DOI 10.1093/emboj/17.17.5001; Vaziri H, 1998, CURR BIOL, V8, P279, DOI 10.1016/S0960-9822(98)70109-5; Wang J, 1998, GENE DEV, V12, P1769, DOI 10.1101/gad.12.12.1769; WRIGHT WE, 1995, TRENDS CELL BIOL, V5, P293, DOI 10.1016/S0962-8924(00)89044-3; Wu KJ, 1999, NAT GENET, V21, P220, DOI 10.1038/6010; Zhang YP, 1998, CELL, V92, P725, DOI 10.1016/S0092-8674(00)81401-4; Zhu JY, 1998, GENE DEV, V12, P2997, DOI 10.1101/gad.12.19.2997; Zijlmans JMJM, 1997, P NATL ACAD SCI USA, V94, P7423, DOI 10.1073/pnas.94.14.7423; Zindy F, 1998, GENE DEV, V12, P2424, DOI 10.1101/gad.12.15.2424	57	316	329	1	8	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	MAY 14	1999	97	4					515	525		10.1016/S0092-8674(00)80761-8	http://dx.doi.org/10.1016/S0092-8674(00)80761-8			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	196FV	10338215	Bronze			2022-12-28	WOS:000080299100012
J	Yoon, JW; Yoon, CS; Lim, HW; Huang, QQ; Kang, Y; Pyun, KH; Hirasawa, K; Sherwin, RS; Jun, HS				Yoon, JW; Yoon, CS; Lim, HW; Huang, QQ; Kang, Y; Pyun, KH; Hirasawa, K; Sherwin, RS; Jun, HS			Control of autoimmune diabetes in NOD mice by CAD expression or suppression in beta cells	SCIENCE			English	Article							GLUTAMIC-ACID DECARBOXYLASE; T-CELLS; TRANSGENIC MICE; LYMPHOCYTES; DESTRUCTION; MELLITUS; MOUSE; CD4+; IDENTIFICATION; PREVENTION	Glutamic acid decarboxylase (GAD) is a pancreatic beta cell autoantigen in humans and nonobese diabetic (NOD) mice. beta Cell-specific suppression of GAD expression in two Lines of antisense CAD transgenic NOD mice prevented autoimmune diabetes, whereas persistent GAD expression in the beta cells in the other four Lines of antisense CAD transgenic NOD mice resulted in diabetes, similar to that seen in transgene-negative NOD mice. Complete suppression of beta cell GAD expression blocked the generation of diabetogenic T cells and protected islet grafts from autoimmune injury. Thus, beta cell-specific CAD expression is required for the development of autoimmune diabetes in NOD mice, and modulation of GAD might, therefore, have therapeutic value in type 1 diabetes.	Univ Calgary, Fac Med, Julia McFarlane Diabet Res Ctr, Lab Viral & Immunopathogenesis Diabet, Calgary, AB T2N 4N1, Canada; Univ Calgary, Fac Med, Dept Microbiol & Infect Dis, Calgary, AB T2N 4N1, Canada; Ajou Univ, Sch Med, Dept Endocrinol & Metab, Lab Endocrinol,Inst Med Sci, Suwon 442749, South Korea; Yale Univ, Sch Med, Diabet Endocrinol Res Ctr, New Haven, CT 06520 USA; Korea Res Inst Biosci & Biotechnol, Taejon 305333, South Korea	University of Calgary; University of Calgary; Ajou University; Yale University; Korea Research Institute of Bioscience & Biotechnology (KRIBB)	Yoon, JW (corresponding author), Univ Calgary, Fac Med, Julia McFarlane Diabet Res Ctr, Lab Viral & Immunopathogenesis Diabet, Calgary, AB T2N 4N1, Canada.			Jun, Hee-Sook/0000-0002-1166-4932	NIDDK NIH HHS [DK 53015-01, DK 45735] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P01DK053015, P30DK045735] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ATKINSON MA, 1990, LANCET, V335, P1357, DOI 10.1016/0140-6736(90)91241-2; ATKINSON MA, 1992, LANCET, V339, P458, DOI 10.1016/0140-6736(92)91061-C; BAEKKESKOV S, 1987, J CLIN INVEST, V79, P926, DOI 10.1172/JCI112903; BAEKKESKOV S, 1990, NATURE, V347, P151, DOI 10.1038/347151a0; ELLIOTT JF, 1994, DIABETES, V43, P1494, DOI 10.2337/diabetes.43.12.1494; Endl J, 1997, J CLIN INVEST, V99, P2405, DOI 10.1172/JCI119423; GILON P, 1991, HISTOCHEMISTRY, V96, P355, DOI 10.1007/BF00271357; GORDON JW, 1993, METHOD ENZYMOL, V225, P747; HANAHAN D, 1985, NATURE, V315, P115, DOI 10.1038/315115a0; KANG YK, UNPUB; KAUFMAN DL, 1993, NATURE, V366, P69, DOI 10.1038/366069a0; KAWAMURA T, 1993, J IMMUNOL, V151, P4362; NAGATA M, 1992, DIABETES, V41, P998, DOI 10.2337/diabetes.41.8.998; NAGATA M, 1994, J IMMUNOL, V152, P2042; Rossini A.A., 1993, DIABETES REV ALEX, V1, P43; Tisch R, 1996, CELL, V85, P291, DOI 10.1016/S0092-8674(00)81106-X; TISCH R, 1993, NATURE, V366, P72, DOI 10.1038/366072a0; UTSUGI T, 1994, TRANSPLANTATION, V57, P1799, DOI 10.1097/00007890-199406270-00020; Wong FS, 1997, RES IMMUNOL, V148, P327, DOI 10.1016/S0923-2494(97)87242-2; YOON JW, 1982, NATURE, V296, P566, DOI 10.1038/296566a0; YOON JW, 1976, NATURE, V264, P178, DOI 10.1038/264178a0; Yoon JW, 1998, AUTOIMMUNITY, V27, P109, DOI 10.3109/08916939809008041; Zekzer D, 1998, J CLIN INVEST, V101, P68, DOI 10.1172/JCI119878	23	211	225	0	3	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	MAY 14	1999	284	5417					1183	1187		10.1126/science.284.5417.1183	http://dx.doi.org/10.1126/science.284.5417.1183			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	197HJ	10325232				2022-12-28	WOS:000080359100042
J	Lee, A; Wong, ST; Gallagher, D; Li, B; Storm, DR; Scheuer, T; Catterall, WA				Lee, A; Wong, ST; Gallagher, D; Li, B; Storm, DR; Scheuer, T; Catterall, WA			Ca2+/calmodulin binds to and modulates P/Q-type calcium channels	NATURE			English	Article							BETA-GAMMA-SUBUNITS; RAT BRAIN-STEM; CA2+ CHANNELS; CALMODULIN-BINDING; SUBCELLULAR-DISTRIBUTION; ALPHA(1A) SUBUNITS; PROTEIN; INACTIVATION; MECHANISM; SYNAPSE	Neurotransmitter release at many central synapses is initiated by an influx of calcium ions through P/Q-type calcium channels(1,2), which are densely localized in nerve terminals(3). Because neurotransmitter release is proportional to the fourth power of calcium concentration(4,5), regulation of its entry can profoundly influence neurotransmission. N- and P/Q-type calcium channels are inhibited by G proteins(6,7), and recent evidence indicates feedback regulation of P/Q-type channels by calcium(8). Although calcium-dependent inactivation of L-type channels is well documented(9-11), little is known about how calcium modulates P/Q-type channels. Here we report a calcium-dependent interaction between calmodulin and a novel site in the carboxy-terminal domain of the cu,A subunit of P/Q-type channels. In the presence of low concentrations of intracellular calcium chelators, calcium influx through P/Q-type channels enhances channel inactivation, increases recovery from inactivation and produces a long-lasting facilitation of the calcium current. These effects are prevented by overexpression of a calmodulin-binding inhibitor peptide and by deletion of the calmodulin-binding domain. Our results reveal an unexpected association of Ca2+/calmodulin with P/Q-type calcium channels that may contribute to calcium-dependent synaptic plasticity.	Univ Washington, Dept Pharmacol, Seattle, WA 98195 USA	University of Washington; University of Washington Seattle	Catterall, WA (corresponding author), Univ Washington, Dept Pharmacol, Seattle, WA 98195 USA.	wcatt@u.washington.edu		Lee, Amy/0000-0001-8021-0443				Borst JGG, 1998, J PHYSIOL-LONDON, V513, P149, DOI 10.1111/j.1469-7793.1998.149by.x; Cuttle MF, 1998, J PHYSIOL-LONDON, V512, P723, DOI 10.1111/j.1469-7793.1998.723bd.x; DODGE FA, 1967, J PHYSIOL-LONDON, V193, P419, DOI 10.1113/jphysiol.1967.sp008367; DUNLAP K, 1995, TRENDS NEUROSCI, V18, P89, DOI 10.1016/0166-2236(95)93882-X; ERICKSONVIITANEN S, 1987, METHOD ENZYMOL, V139, P455; Fletcher CF, 1996, CELL, V87, P607, DOI 10.1016/S0092-8674(00)81381-1; Forsythe ID, 1998, NEURON, V20, P797, DOI 10.1016/S0896-6273(00)81017-X; HARPER JW, 1993, CELL, V75, P805; Herlitze S, 1996, NATURE, V380, P258, DOI 10.1038/380258a0; Hofer GF, 1997, BIOPHYS J, V73, P1857, DOI 10.1016/S0006-3495(97)78216-X; Ikeda SR, 1996, NATURE, V380, P255, DOI 10.1038/380255a0; IMREDY JP, 1994, NEURON, V12, P1301, DOI 10.1016/0896-6273(94)90446-4; JAMES P, 1995, TRENDS BIOCHEM SCI, V20, P38, DOI 10.1016/S0968-0004(00)88949-5; KAMIYA H, 1994, NATURE, V371, P603, DOI 10.1038/371603a0; LIU MY, 1994, SCIENCE, V266, P1348, DOI 10.1126/science.266.5189.1348; MINTZ IM, 1995, NEURON, V15, P675, DOI 10.1016/0896-6273(95)90155-8; NEELY A, 1994, BIOPHYS J, V66, P1895, DOI 10.1016/S0006-3495(94)80983-X; Peterson BZ, 1999, BIOPHYS J, V76, pA340; SAIMI Y, 1994, FEBS LETT, V350, P155, DOI 10.1016/0014-5793(94)00782-9; Sakurai T, 1996, J CELL BIOL, V134, P511, DOI 10.1083/jcb.134.2.511; STARR TVB, 1991, P NATL ACAD SCI USA, V88, P5621, DOI 10.1073/pnas.88.13.5621; TEO TS, 1973, J BIOL CHEM, V248, P5950; TSIEN RW, 1991, TRENDS PHARMACOL SCI, V12, P349, DOI 10.1016/0165-6147(91)90595-J; vonGersdorff H, 1996, J NEUROSCI, V16, P115; Wang LY, 1998, NATURE, V394, P384, DOI 10.1038/28645; WESTENBROEK RE, 1995, J NEUROSCI, V15, P6403; WU ZL, 1993, J BIOL CHEM, V268, P23766; Xia XM, 1998, NATURE, V395, P503, DOI 10.1038/26758; Yokoyama CT, 1997, J NEUROSCI, V17, P6929; Zuhlke RD, 1999, BIOPHYS J, V76, pA343	30	395	403	1	17	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	MAY 13	1999	399	6732					155	159		10.1038/20194	http://dx.doi.org/10.1038/20194			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	196XU	10335845				2022-12-28	WOS:000080335700051
J	Alpert, JS				Alpert, JS			Coronary heart disease: where have we been and where are we going?	LANCET			English	Editorial Material							MYOCARDIAL-INFARCTION; MORTALITY; TRENDS		Univ Arizona, Dept Med, Tucson, AZ 85724 USA	University of Arizona	Alpert, JS (corresponding author), Univ Arizona, Dept Med, Tucson, AZ 85724 USA.							*CLASS MED LIB, 1982, HIPP APHOR, V44, P38; Gillum RF, 1996, NEW ENGL J MED, V335, P1597, DOI 10.1056/NEJM199611213352110; GORDON T, 1971, J AMER MED ASSOC, V215, P1617, DOI 10.1001/jama.215.10.1617; HAVLIK RJ, 1979, NIH PUBLICATION; Hunink MGM, 1997, JAMA-J AM MED ASSOC, V277, P535, DOI 10.1001/jama.277.7.535; McGovern PG, 1997, AM J CARDIOL, V80, P557, DOI 10.1016/S0002-9149(97)00421-9; Rosamond W, 1999, AM J CARDIOL, V83, P1180, DOI 10.1016/S0002-9149(99)00056-9; Rosamond WD, 1998, NEW ENGL J MED, V339, P861, DOI 10.1056/NEJM199809243391301	8	5	5	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	MAY 8	1999	353	9164					1540	1541		10.1016/S0140-6736(99)00154-3	http://dx.doi.org/10.1016/S0140-6736(99)00154-3			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	195XW	10334246				2022-12-28	WOS:000080278300002
J	Appleby, L; Shaw, J; Amos, T; McDonnell, R; Harris, C; McCann, K; Kiernan, K; Davies, S; Bickley, H; Parsons, R				Appleby, L; Shaw, J; Amos, T; McDonnell, R; Harris, C; McCann, K; Kiernan, K; Davies, S; Bickley, H; Parsons, R			Suicide within 12 months of contact with mental health services: national clinical survey	BRITISH MEDICAL JOURNAL			English	Article							ASSERTIVE COMMUNITY TREATMENT; PSYCHIATRIC-PATIENTS; AFTER-DISCHARGE; DISORDERS; TRENDS	Objective To describe the clinical circumstances in which psychiatric patients commit suicide. Design National clinical survey: Setting England and Wales. Subjects A two year sample of people who had committed suicide, in particular those who had.been in contact with mental health services in the 12 months before death. Main outcome measures Proportion of suicides in people who had had recent contact with mental health services; proportion of suicides in inpatients; proportion of people committing suicide and timing of suicide within three months of hospital discharge; proportion receiving high priority under the care programme approach; proportion who were recently non-compliant and not attending. Results 10 040 suicides were notified to the study between April 1996 and March 1998, of whom 2370 (24%; 95% confidence interval 23% to 24%) had had contact with mental health services in the year before death. Data were obtained on 2177, a response rate of 92%. In general these subjects had broad social and clinical needs. Alcohol and drug misuse were common. 358 (16%; 15% to 18%) were psychiatric inpatients at the time of death, 21% (17% to 25%) of whom were under special observation. Difficulties in observing patients because of ward design and nursing shortages were both reported in around a quarter of inpatient suicides. 519 (24%; 22% to 26%) suicides occurred within three months of hospital discharge, the highest number occurring in the first week after discharge. 914 (43%; 40% to 44%) were in the highest priority category for community care. 488 (26% excluding people whose compliance was unknown; 24% to 28%) were non-compliant with drug treatment while 486 (28%; 26% to 30%) community patients had lost contact with services. Most people who committed suicide were thought to have been at no or low immediate risk at the final service contact Mental health teams believed suicide could have been prevented in 423 (22%; 20% to 24%) cases. Conclusions Several suicide prevention measures in mental health services are implied by these findings, including measures to improve compliance and prevent loss of contact with services. Inpatient facilities should remove structural difficulties in observing patients and fixtures that can be used in hanging. Prevention of suicide after discharge may require earlier follow up in the community. Better suicide prevention in psychiatric patients is likely to need measures to improve the safety of mental health services as a whole, rather than specific measures for people known to be at high risk.	Univ Manchester, Withington Hosp, Sch Psychiat & Behav Sci, Manchester M20 8LR, Lancs, England	University of Manchester	Appleby, L (corresponding author), Univ Manchester, Withington Hosp, Sch Psychiat & Behav Sci, Manchester M20 8LR, Lancs, England.			shaw, jennifer/0000-0003-2569-7687; Bickley, Harriet/0000-0002-3756-7137				APPLEBY L, 1997, NATL CONFIDENTIAL IN; Appleby L., 1999, SAFER SERVICES REPOR; BURNS BJ, 1995, PSYCHIAT SERV, V46, P669; COPAS JB, 1971, PSYCHOL MED, V1, P400, DOI 10.1017/S0033291700044780; *DEP HLTH, 1990, HC9023LASSL901 DOH; Department of Health, 1992, HLTH NAT STRAT HLTH; Dixon L, 1997, AM J PSYCHIAT, V154, P1302; GEDDES JR, 1995, BRIT MED J, V311, P357, DOI 10.1136/bmj.311.7001.357; GOLDACRE M, 1993, LANCET, V342, P283, DOI 10.1016/0140-6736(93)91822-4; Harris EC, 1997, BRIT J PSYCHIAT, V170, P205, DOI 10.1192/bjp.170.3.205; Hawton K, 1998, J AFFECT DISORDERS, V50, P269; HENRIKSSON MM, 1993, AM J PSYCHIAT, V150, P935; *HOM OFF, 1998, PRIS STAT ENGL WAL 1; Kemp R, 1996, BRIT MED J, V312, P345; MYERS DH, 1978, BRIT J PSYCHIAT, V133, P38, DOI 10.1192/bjp.133.1.38; Neeleman J, 1997, PSYCHOL MED, V27, P467, DOI 10.1017/S0033291796004631; ODONNELL I, 1995, BRIT J PSYCHIAT, V166, P458, DOI 10.1192/bjp.166.4.458; ROY A, 1982, ARCH GEN PSYCHIAT, V39, P1089; Shaw J, 1999, BRIT MED J, V318, P1240	19	341	350	0	12	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	MAY 8	1999	318	7193					1235	1239						5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	195XT	10231250				2022-12-28	WOS:000080278000021
J	Hillbom, M; Pyhtinen, J; Pylvanen, V; Sotaniemi, K				Hillbom, M; Pyhtinen, J; Pylvanen, V; Sotaniemi, K			Pregnant, vomiting, and coma	LANCET			English	Article									Univ Hosp Oulu, Dept Neurol, FIN-90220 Oulu, Finland; Univ Hosp Oulu, Dept Radiol, FIN-90220 Oulu, Finland		Hillbom, M (corresponding author), Univ Hosp Oulu, Dept Neurol, FIN-90220 Oulu, Finland.							IRONSIDE R, 1961, BRAIN, V84, P212, DOI 10.1093/brain/84.2.212; KOEPPEN AH, 1978, NEUROLOGY, V28, P290, DOI 10.1212/WNL.28.3.290; LANGLAIS P, 1998, ALCOHOL CLIN EXP R S, V22, P137; LEONG ASY, 1979, PATHOLOGY, V11, P241, DOI 10.3109/00313027909061950; NICOLI F, 1994, REV NEUROL, V150, P157	5	19	21	0	1	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	MAY 8	1999	353	9164					1584	1584		10.1016/S0140-6736(99)01410-5	http://dx.doi.org/10.1016/S0140-6736(99)01410-5			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	195XW	10334258				2022-12-28	WOS:000080278300015
J	Brewer, PG; Friederich, C; Peltzer, ET; Orr, FM				Brewer, PG; Friederich, C; Peltzer, ET; Orr, FM			Direct experiments on the ocean disposal of fossil fuel CO2	SCIENCE			English	Article							HYDRATE FORMATION; CARBON-DIOXIDE; SYSTEM; SEA	Field experiments were conducted to test ideas for fossil fuel carbon dioxide ocean disposal as a solid hydrate at depths ranging from 349 to 3627 meters and from 8 degrees to 1.6 degrees C. Hydrate formed instantly from the gas phase at 349 meters but then decomposed rapidly in ambient seawater. At 3627 meters, the seawater-carbon dioxide interface rose rapidly because of massive hydrate formation, forcing spillover of the Liquid carbon dioxide from the container. A strong barrier between the liquid carbon dioxide and interaction with the sediments was observed. A pool of Liquid carbon dioxide on the sea floor would expand in volume more than four times, forming hydrate, which will dissolve.	Monterey Bay Aquarium Res Inst, Moss Landing, CA 95039 USA; Stanford Univ, Sch Earth Sci, Stanford, CA 94305 USA	Monterey Bay Aquarium Research Institute; Stanford University	Brewer, PG (corresponding author), Monterey Bay Aquarium Res Inst, POB 628, Moss Landing, CA 95039 USA.			Brewer, Peter/0000-0002-5448-0199; Orr, Franklin/0000-0001-9708-7621; Peltzer, Edward/0000-0003-2821-3553				Archer D, 1997, GEOPHYS RES LETT, V24, P405, DOI 10.1029/97GL00168; Aya I, 1997, ENERGY, V22, P263, DOI 10.1016/S0360-5442(96)00093-X; Bakker RJ, 1996, GEOCHIM COSMOCHIM AC, V60, P1657, DOI 10.1016/0016-7037(96)00032-4; Brewer PG, 1998, ENERG FUEL, V12, P183, DOI 10.1021/ef970172q; Brewer PG, 1997, GEOPHYS RES LETT, V24, P1367, DOI 10.1029/97GL01179; Broecker WS, 1997, SCIENCE, V278, P1582, DOI 10.1126/science.278.5343.1582; COLE KH, 1993, ENERG CONVERS MANAGE, V34, P991, DOI 10.1016/0196-8904(93)90046-D; FUJIOKA Y, 1995, INT J ENERG RES, V19, P659, DOI 10.1002/er.4440190803; Harris J G, 1995, J Int Neuropsychol Soc, V1, P10; HOLDER GD, 1975, ENVIRON SCI TECHNOL, V28, P276; Houghton J.T., 1990, CLIMATE CHANGE IPCC; North WJ, 1998, ENVIRON SCI TECHNOL, V32, P676, DOI 10.1021/es970483f; OHGAKI K, 1993, J CHEM ENG JPN, V26, P558, DOI 10.1252/jcej.26.558; Ohmura R, 1998, ENVIRON SCI TECHNOL, V32, P1120, DOI 10.1021/es9700764; SAKAI H, 1990, SCIENCE, V248, P1093, DOI 10.1126/science.248.4959.1093; Sloan E. D., 1990, CLATHRATE HYDRATES N; SOCOLOW R, 1997, FUELS DECARBONIZATIO; 1997, ENERGY CONVERSION S, V38	18	310	321	4	59	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	MAY 7	1999	284	5416					943	945		10.1126/science.284.5416.943	http://dx.doi.org/10.1126/science.284.5416.943			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	194MU	10320370				2022-12-28	WOS:000080198800039
J	Capron, AM				Capron, AM			Ethical and human-rights issues in research on mental disorders that may affect decision-making capacity	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material									Univ So Calif, Los Angeles, CA 90089 USA	University of Southern California	Capron, AM (corresponding author), Univ So Calif, Los Angeles, CA 90089 USA.							ALEXANDER L, 1949, NEW ENGL J MED, V241, P39, DOI 10.1056/NEJM194907142410201; Annas George J., 1992, NAZI DOCTORS NUREMBU; *BRIT MED RES COUN, 1963, CMND2382, P23; CAPRON AM, 1972, NEW GENETICS FUTURE, P133; *DEP HHS, 1998, I REV BOARDS TIM REF; Hornblum Allen, 1998, ACRES SKIN HUMAN EXP; Jonas H., 1970, EXPT HUMAN SUBJECTS, P1; Jones JH., 1981, BAD BLOOD TUSKEGEE S; Katz Jay, 1993, St Louis Univ Law J, V38, P7; Kong D, 1998, BOSTON GLOBE    1115, pA1; LEVINE RJ, 1986, ETHICS REGULATION CL, P8; Marshall E, 1999, SCIENCE, V283, P464, DOI 10.1126/science.283.5401.464; MCCORMICK RA, 1974, PERSPECT BIOL MED, V18, P2; *NAT BIOETH ADV CO, 1998, RES INV PERS MENT DI; *NAT COMM PROT HUM, 1978, REP REC RES INV THOS; National Commission for the Protection of Human Subjects of Biomedical and Behavioral Research, 1977, REP REC RES INV CHIL; *NY STAT ADV WORK, 1998, REC OV HUM SUBJ RES, pD56; *US ADV COMM HUM R, 1996, FIN REP HUM RAD EXPT; *WORLD MED ASS, 1964, NEW ENGL J MED, V271, P473; 1983, FED REG         0308, V48, P9818	20	54	55	0	1	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	MAY 6	1999	340	18					1430	1434		10.1056/NEJM199905063401812	http://dx.doi.org/10.1056/NEJM199905063401812			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	192QN	10228198				2022-12-28	WOS:000080090600012
J	Manos, MM; Kinney, WK; Hurley, LB; Sherman, ME; Shieh-Ngai, J; Kurman, RJ; Ransley, JE; Fetterman, BJ; Hartinger, JS; McIntosh, KM; Pawlick, GF; Hiatt, RA				Manos, MM; Kinney, WK; Hurley, LB; Sherman, ME; Shieh-Ngai, J; Kurman, RJ; Ransley, JE; Fetterman, BJ; Hartinger, JS; McIntosh, KM; Pawlick, GF; Hiatt, RA			Identifying women with cervical neoplasia - Using human papillomavirus DNA testing for equivocal Papanicolaou results	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							THINPREP PAP TEST; ATYPICAL SQUAMOUS CELLS; UNDETERMINED SIGNIFICANCE; QUALITY ASSURANCE; SMEAR REPORTS; MANAGEMENT; EXPERIENCE; DIAGNOSES; CYTOLOGY; RISK	Context A Papanicolaou (Pap) test result of atypical squamous cells of undetermined significance (ASCUS) presents a clinical challenge. Only 5% to 10% of women with ASCUS harbor serious cervical disease, but more than one third of the high-grade squamous intraepithelial lesions (HSILs) in screening populations are identified from ASCUS Pap test results. Objective To determine whether human papillomavirus (HPV) DNA testing of residual material from liquid-based Pap tests and referral of cases found to be HPV-positive directly to colposcopy could provide sensitive detection of underlying HSILs in women with ASCUS Pap results, compared with repeat Pap testing. Design and Setting Natural history of women with ASCUS Pap smear results, all of whom had liquid-based cytology, HPV testing, and subsequent repeat Pap tests and colposcopy with histologic evaluation, conducted at 12 gynecology clinics in a targe managed care organization between October 1995 and June 1996. Participants From a cohort of 46 009 women who had routine cervical examinations, 995 women with Pap test results of ASCUS who consented to participate were identified. Main Outcome Measures Cervical histology, HPV test results, and repeat Pap smear results, and sensitivity of HPV testing to identify patients found to have HSIL+ histology. Results Of 995 participants with ASCUS Pap test results, 973 had both a definitive histologic diagnosis and HPV result. Sixty-five (6.7%) had histologic HSIL or cancer. For women with histologic HSIL+, the HPV test was positive in 89.2% (95% confidence interval [CI], 78.4%-95.2%), and the specificity was 64.1% (95% CI, 60.9%-67.2%). The repeat Pap smear result was abnormal in 76.2% (95% CI, 63.5%-85.7%). Triage based on HPV testing only or on repeat Pap testing only would refer similar proportions (approximately 39%) to colposcopy. The sensitivity of HPV DNA testing for HSIL was equivalent to, if not greater than, that of the repeat Pap test. We further estimated that an HPV-based algorithm including the immediate colposcopy of HPV-positive women, and then repeat Pap testing of all others, would provide an overall sensitivity of 96.9% (95% CI, 88.3%-99.5%). Conclusions For women with ASCUS Pap tests, HPV DNA testing of residual specimens collected for routine cervical cytology can help identify those who have underlying HSIL. By testing the specimen collected at initial screening, the majority of highrisk cases can be identified and referred for colposcopy based on a single screening.	No Calif Kaiser Permanente Med Grp, Div Res, Oakland, CA USA; No Calif Kaiser Permanente Med Grp, Div Gynecol Oncol, Oakland, CA USA; No Calif Kaiser Permanente Med Grp, Dept Pathol, Oakland, CA USA; No Calif Kaiser Permanente Med Grp, Reg Lab, Oakland, CA USA; Johns Hopkins Med Inst, Dept Pathol, Baltimore, MD 21205 USA; Johns Hopkins Med Inst, Dept Obstet & Gynecol, Baltimore, MD 21205 USA	Kaiser Permanente; Permanente Medical Groups; Kaiser Permanente; Permanente Medical Groups; Kaiser Permanente; Permanente Medical Groups; Kaiser Permanente; Permanente Medical Groups; Johns Hopkins University; Johns Hopkins Medicine; Johns Hopkins University; Johns Hopkins Medicine	Manos, MM (corresponding author), Kaiser Permanente Med Care Program, Div Res, 3505 Broadway, Oakland, CA 94611 USA.		Hiatt, Robert/AAQ-1537-2021					Bishop JW, 1997, ACTA CYTOL, V41, P269, DOI 10.1159/000332511; BOSCH FX, 1995, JNCI-J NATL CANCER I, V87, P796, DOI 10.1093/jnci/87.11.796; Corkill M, 1998, J Low Genit Tract Dis, V2, P12, DOI 10.1097/00128360-199801000-00003; COX JT, 1995, AM J OBSTET GYNECOL, V172, P946, DOI 10.1016/0002-9378(95)90026-8; COX JT, 1996, HUMAN PAPILLOMAVIRUS, V2, P811; *CYT SOFTW CORP, 1996, STATX 3 WIND US MAN; DAVEY DD, 1994, DIAGN CYTOPATHOL, V11, P390, DOI 10.1002/dc.2840110416; Dupree WB, 1998, CANCER CYTOPATHOL, V84, P202, DOI 10.1002/(SICI)1097-0142(19980825)84:4<202::AID-CNCR4>3.0.CO;2-O; Ferenczy A, 1996, AM J OBSTET GYNECOL, V175, P651; FERENCZY A, 1995, INT J GYNECOL CANCER, V5, P321, DOI 10.1046/j.1525-1438.1995.05050321.x; Ferris DG, 1998, J FAM PRACTICE, V46, P125; Ferris DG, 1998, J FAM PRACTICE, V46, P136; Fleiss J. L., 1981, STAT METHODS RATES P, V2; Kinney WK, 1998, OBSTET GYNECOL, V91, P973, DOI 10.1016/S0029-7844(98)00080-5; KRIEGER N, 1992, AM J PUBLIC HEALTH, V82, P703, DOI 10.2105/AJPH.82.5.703; KURMAN RJ, 1994, JAMA-J AM MED ASSOC, V271, P1866, DOI 10.1001/jama.271.23.1866; Lee KR, 1997, OBSTET GYNECOL, V90, P278, DOI 10.1016/S0029-7844(97)00228-7; Linder J, 1997, ACTA CYTOL, V41, P30, DOI 10.1159/000332302; LORINCZ A, 1996, PAPILLOMAVIRUS REPOR, V7, P1; Papillo JL, 1998, ACTA CYTOL, V42, P203, DOI 10.1159/000331547; Roberts JM, 1997, MED J AUSTRALIA, V167, P466, DOI 10.5694/j.1326-5377.1997.tb126672.x; RONNETT BM, IN PRESS HUM PATHOL; *SAS I INC, 1977, SAS STAT SOFTW CHANG; SCHIFFMAN MH, 1993, JNCI-J NATL CANCER I, V85, P958, DOI 10.1093/jnci/85.12.958; SHERMAN ME, 1994, AM J CLIN PATHOL, V102, P182, DOI 10.1093/ajcp/102.2.182; Sherman ME, 1997, CANCER CYTOPATHOL, V81, P89; SOLOMON D, 1989, JAMA-J AM MED ASSOC, V262, P931; Wright TC, 1998, AM J OBSTET GYNECOL, V178, P962, DOI 10.1016/S0002-9378(98)70531-9; WRIGHT TC, 1995, OBSTET GYNECOL, V85, P202, DOI 10.1016/0029-7844(94)00373-L	29	435	460	0	20	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAY 5	1999	281	17					1605	1610		10.1001/jama.281.17.1605	http://dx.doi.org/10.1001/jama.281.17.1605			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	191MJ	10235153	Bronze			2022-12-28	WOS:000080025900024
J	Rosenthal, E; Pradier, C; Keita-Perse, O; Altare, J; Dellamonica, P; Cassuto, JP				Rosenthal, E; Pradier, C; Keita-Perse, O; Altare, J; Dellamonica, P; Cassuto, JP			Needlestick injuries among French medical students	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							EXPOSURE		Nice Sophia Antipolis Univ, Archet Hop 1, Dept Internal Med & Hematol, Serv Med Interne 2, F-06202 Nice 3, France; Nice Sophia Antipolis Univ, Archet Hop 1, Ctr Informat & Soins Immunodeficience Humaine, F-06202 Nice, France	CHU Nice; UDICE-French Research Universities; Universite Cote d'Azur; CHU Nice; UDICE-French Research Universities; Universite Cote d'Azur	Rosenthal, E (corresponding author), Nice Sophia Antipolis Univ, Archet Hop 1, Dept Internal Med & Hematol, Serv Med Interne 2, 151 Route St Antoine Ginestiere,BP 3079, F-06202 Nice 3, France.		Pradier, Christian/AAE-9669-2022; Pradier, Christian/AFE-8255-2022					Cardo DM, 1997, NEW ENGL J MED, V337, P1485, DOI 10.1056/NEJM199711203372101; *CDCP, 1995, MMWR-MORBID MORTAL W, V44, P929; DEVRIES B, 1994, MED J AUSTRALIA, V160, P398; KOENIG S, 1995, AM J INFECT CONTROL, V23, P40, DOI 10.1016/0196-6553(95)90007-1; ONEILL TM, 1992, ARCH INTERN MED, V152, P1451, DOI 10.1001/archinte.152.7.1451; RESNIC FS, 1995, ARCH INTERN MED, V155, P75, DOI 10.1001/archinte.155.1.75; TERESKERZ P, 1995, ADV EXPOSURE PREV, V1, P10; WATERMAN J, 1994, J HOSP INFECT, V26, P149, DOI 10.1016/0195-6701(94)90058-2; 1996, MMWR MORB MORTAL WKL, V45, P468	9	22	24	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAY 5	1999	281	17					1660	1660		10.1001/jama.281.17.1660	http://dx.doi.org/10.1001/jama.281.17.1660			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	191MJ	10336348				2022-12-28	WOS:000080025900036
J	Zhang, SM; Hunter, DJ; Hankinson, SE; Giovannucci, EL; Rosner, BA; Colditz, GA; Speizer, FE; Willett, WC				Zhang, SM; Hunter, DJ; Hankinson, SE; Giovannucci, EL; Rosner, BA; Colditz, GA; Speizer, FE; Willett, WC			A prospective study of folate intake and the risk of breast cancer	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							PLASMA HOMOCYSTEINE; ALCOHOL-CONSUMPTION; WOMEN; QUESTIONNAIRE; METHIONINE; DISEASE; COLON; DIET	Context Folate is involved in DNA synthesis and methylation and may reduce breast cancer risk, particularly among women with greater alcohol consumption. Objectives To assess the association between folate intake and risk of breast cancer and whether higher folate intake may reduce excess risk among women who consume alcohol. Design Prospective cohort study performed in 1980, with 16 years of follow-up, Setting and Participants A total of 88 818 women who completed the dietary questionnaire section of the Nurses' Health Study in 1980. Main Outcome Measure Incidence of invasive breast cancer by levels of folate and alcohol intake, Results A total of 3483 cases of breast cancer were documented. Total folate intake was not associated with overall risk of breast cancer. However, among women who consumed at least 15 g/d of alcohol, the risk of breast cancer was highest among those with low folate intake. For total folate intake of at least 600 mu g/d compared with 150 to 299 mu g/d, the multivariate relative risk (RR) was 0.55 (95% confidence interval [CI], 0.39-0.76; P for trend = .001). This association was only slightly attenuated after additional adjustment for intake of beta carotene, lutein/zeaxanthin, preformed vitamin A, and total vitamins C and E. The risk of breast cancer associated with alcohol intake was strongest among women with total folate intake of less than 300 mu g/d (for alcohol intake greater than or equal to 15 g/d vs <15 g/d, multivariate RR, 1.32; 95% CI, 1.15-1.50). For women who consumed at least 300 mu g/d of total folate, the multivariate RR for intake of at least 15 g/d of alcohol vs less than 15 g/d was 1.05 (95% CI, 0.92-1.20), Current use of multivitamin supplements, the major source of folate, was associated with lower breast cancer risk among women who consumed at least 15 g/d of alcohol (for current users of supplements vs never users, RR, 0.74; 95% CI, 0.59-0.93). Conclusions Our findings suggest that the excess risk of breast cancer associated with alcohol consumption may be reduced by adequate folate intake.	Channing Lab, Boston, MA 02115 USA; Harvard Univ, Ctr Canc Prevent, Dept Epidemiol, Cambridge, MA 02138 USA; Harvard Univ, Ctr Canc Prevent, Dept Nutr, Cambridge, MA 02138 USA; Harvard Univ, Sch Publ Hlth, Cambridge, MA 02138 USA; Harvard Univ, Sch Med, Dept Med, Cambridge, MA 02138 USA; Brigham & Womens Hosp, Boston, MA 02115 USA	Harvard University; Harvard University; Harvard University; Harvard T.H. Chan School of Public Health; Harvard University; Harvard University; Brigham & Women's Hospital	Zhang, SM (corresponding author), Channing Lab, 181 Longwood Ave, Boston, MA 02115 USA.		Colditz, Graham/A-3963-2009	Colditz, Graham/0000-0002-7307-0291	NATIONAL CANCER INSTITUTE [R37CA040356, R01CA040356] Funding Source: NIH RePORTER; NCI NIH HHS [CA 40356] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Blount BC, 1997, P NATL ACAD SCI USA, V94, P3290, DOI 10.1073/pnas.94.7.3290; BOUSHEY CJ, 1995, JAMA-J AM MED ASSOC, V274, P1049, DOI 10.1001/jama.274.13.1049; COOPER AJL, 1983, ANNU REV BIOCHEM, V52, P187, DOI 10.1146/annurev.bi.52.070183.001155; CUPPLES LA, 1988, STAT MED, V7, P205, DOI 10.1002/sim.4780070122; DAGOSTINO RB, 1990, STAT MED, V9, P1501, DOI 10.1002/sim.4780091214; Freudenheim JL, 1996, JNCI-J NATL CANCER I, V88, P340, DOI 10.1093/jnci/88.6.340; FREUDENHEIM JL, 1991, INT J EPIDEMIOL, V20, P368, DOI 10.1093/ije/20.2.368; GIOVANNUCCI E, 1995, JNCI-J NATL CANCER I, V87, P265, DOI 10.1093/jnci/87.4.265; GIOVANNUCCI E, 1993, J NATL CANCER I, V85, P875, DOI 10.1093/jnci/85.11.875; GRAHAM S, 1991, AM J EPIDEMIOL, V134, P552, DOI 10.1093/oxfordjournals.aje.a116129; Hankinson SE, 1997, CANCER CAUSE CONTROL, V8, P65, DOI 10.1023/A:1018435205695; HILLMAN RS, 1982, ANNU REV MED, V33, P345, DOI 10.1146/annurev.me.33.020182.002021; Hu FB, 1999, AM J EPIDEMIOL, V149, P531, DOI 10.1093/oxfordjournals.aje.a009849; Mason J B, 1996, Oncology (Williston Park), V10, P1727; Mason JB, 1996, ONCOLOGY, V10, P1742; Michels KB, 1996, LANCET, V347, P431, DOI 10.1016/S0140-6736(96)90010-0; *NAT RES COUNC, 1989, REC DIET ALL, P150; Oakley GP, 1998, NEW ENGL J MED, V338, P1060, DOI 10.1056/NEJM199804093381509; Rayburn WF, 1996, J AM COLL NUTR, V15, P121; Rimm EB, 1998, JAMA-J AM MED ASSOC, V279, P359, DOI 10.1001/jama.279.5.359; Rothman K, 1986, MODERN EPIDEMIOLOGY; SALVINI S, 1989, INT J EPIDEMIOL, V18, P858, DOI 10.1093/ije/18.4.858; SCHATZKIN A, 1994, CANCER, V74, P1101, DOI 10.1002/1097-0142(19940801)74:3+<1101::AID-CNCR2820741519>3.0.CO;2-X; SELHUB J, 1995, NEW ENGL J MED, V332, P286, DOI 10.1056/NEJM199502023320502; Smith-Warner SA, 1998, JAMA-J AM MED ASSOC, V279, P535, DOI 10.1001/jama.279.7.535; STAMPFER MJ, 1984, AM J EPIDEMIOL, V119, P837, DOI 10.1093/oxfordjournals.aje.a113804; Swanson CA, 1997, EPIDEMIOLOGY, V8, P231, DOI 10.1097/00001648-199705000-00001; WILLETT W, 1986, AM J EPIDEMIOL, V124, P17, DOI 10.1093/oxfordjournals.aje.a114366; WILLETT WC, 1988, AM J EPIDEMIOL, V127, P188, DOI 10.1093/oxfordjournals.aje.a114780; WILLETT WC, 1987, NEW ENGL J MED, V316, P1174, DOI 10.1056/NEJM198705073161902; WILLETT WC, 1985, AM J EPIDEMIOL, V122, P51, DOI 10.1093/oxfordjournals.aje.a114086; 1973, FED REG         0802, V38, P20725	32	314	328	0	11	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAY 5	1999	281	17					1632	1637		10.1001/jama.281.17.1632	http://dx.doi.org/10.1001/jama.281.17.1632			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	191MJ	10235158				2022-12-28	WOS:000080025900029
J	Holmdahl, L				Holmdahl, L			Making and covering of surgical footprints	LANCET			English	Editorial Material							ADHESIONS; PERITONEUM; FIBRINOLYSIS; MULTICENTER; OBSTRUCTION; MECHANISM; OPERATION; MEMBRANE		Gothenburg Univ, Sahlgrenska Univ Hosp Ostra, Colorectal Unit, Dept Surg, S-41685 Gothenburg, Sweden	Sahlgrenska University Hospital; University of Gothenburg	Holmdahl, L (corresponding author), Gothenburg Univ, Sahlgrenska Univ Hosp Ostra, Colorectal Unit, Dept Surg, S-41685 Gothenburg, Sweden.							Becker JM, 1996, J AM COLL SURGEONS, V183, P297; BUCKMAN RF, 1976, J SURG RES, V20, P1, DOI 10.1016/0022-4804(76)90075-5; Diamond MP, 1996, FERTIL STERIL, V66, P904, DOI 10.1016/S0015-0282(16)58716-0; Edna TH, 1998, EUR J SURG, V164, P587; FAZIO VW, 1995, ANN SURG, V222, P120, DOI 10.1097/00000658-199508000-00003; Holmdahl L, 1998, SURGERY, V123, P539, DOI 10.1067/msy.1998.86984; Holmdahl L, 1996, SURGERY, V119, P701, DOI 10.1016/S0039-6060(96)80196-6; HOLMDAHL L, 1994, WOUND REPAIR REGEN, V7, P171; Ivarsson ML, 1998, BRIT J SURG, V85, P1549; Ivarsson ML, 1998, FIBRINOLYSIS PROTEOL, V12, P61, DOI 10.1016/S0268-9499(98)80009-X; MENZIES D, 1990, ANN ROY COLL SURG, V72, P60; RAF LE, 1969, ACTA CHIR SCAND, V135, P67; RAFTERY AT, 1979, J ANAT, V129, P659; THOMPSON JN, 1989, BRIT J SURG, V76, P382, DOI 10.1002/bjs.1800760422; VIPOND MN, 1990, LANCET, V335, P1120, DOI 10.1016/0140-6736(90)91125-T	15	101	105	0	5	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	MAY 1	1999	353	9163					1456	1457		10.1016/S0140-6736(99)90061-2	http://dx.doi.org/10.1016/S0140-6736(99)90061-2			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	195XV	10232305				2022-12-28	WOS:000080278200002
J	Ridgway, WM; Fasso, M; Fathman, CG				Ridgway, WM; Fasso, M; Fathman, CG			Immunology - A new look at MHC and autoimmune disease	SCIENCE			English	Editorial Material							NONOBESE DIABETIC MICE; GLUTAMIC-ACID DECARBOXYLASE; ANTIGEN PRESENTATION; POSITIVE SELECTION; NOD MOUSE; T-CELLS; TOLERANCE; INSULITIS; PEPTIDE; AUTOREACTIVITY		Stanford Univ, Sch Med, Dept Med, Div Rheumatol & Immunol, Stanford, CA 94305 USA	Stanford University	Ridgway, WM (corresponding author), Stanford Univ, Sch Med, Dept Med, Div Rheumatol & Immunol, Stanford, CA 94305 USA.							ACHAORBEA H, 1987, P NATL ACAD SCI USA, V84, P2435, DOI 10.1073/pnas.84.8.2435; ASHTONRICKARDT PG, 1994, CELL, V76, P651, DOI 10.1016/0092-8674(94)90505-3; CARRASCOMARIN E, 1996, J IMMUNOL, V156, P50; Costagliola S, 1996, ENDOCRINOLOGY, V137, P4637, DOI 10.1210/en.137.11.4637; FungLeung WP, 1996, SCIENCE, V271, P1278, DOI 10.1126/science.271.5253.1278; HUMPHREYSBEHER MG, 1994, ADV EXP MED BIOL, V350, P631; JAMESON SC, 1995, ANNU REV IMMUNOL, V13, P93, DOI 10.1146/annurev.iy.13.040195.000521; Kanagawa O, 1998, P NATL ACAD SCI USA, V95, P1721, DOI 10.1073/pnas.95.4.1721; KAUFMAN DL, 1993, NATURE, V366, P69, DOI 10.1038/366069a0; Kim DT, 1996, J IMMUNOL, V156, P2737; Laufer TM, 1996, NATURE, V383, P81, DOI 10.1038/383081a0; LIU GY, 1995, IMMUNITY, V3, P407, DOI 10.1016/1074-7613(95)90170-1; MAKINO S, 1985, EXP ANIM TOKYO, V34, P425, DOI 10.1538/expanim1978.34.4_425; Martin WD, 1996, CELL, V84, P543, DOI 10.1016/S0092-8674(00)81030-2; Miyazaki T, 1996, CELL, V84, P531, DOI 10.1016/S0092-8674(00)81029-6; PROCHAZKA M, 1987, SCIENCE, V237, P286, DOI 10.1126/science.2885918; Ridgway WM, 1998, CLIN IMMUNOL IMMUNOP, V86, P3, DOI 10.1006/clin.1997.4449; Ridgway WM, 1996, J EXP MED, V183, P1657, DOI 10.1084/jem.183.4.1657; Ridgway WM, 1998, J EXP MED, V188, P2267, DOI 10.1084/jem.188.12.2267; RIDGWAY WM, 1998, CAN J DIAB CARE S, V3, P6; SEBZDA E, 1994, SCIENCE, V263, P1615, DOI 10.1126/science.8128249; SVEJGAARD A, 1983, IMMUNOL REV, V70, P193, DOI 10.1111/j.1600-065X.1983.tb00715.x; TISCH R, 1993, NATURE, V366, P72, DOI 10.1038/366072a0; WICKER LS, 1987, J EXP MED, V165, P1639, DOI 10.1084/jem.165.6.1639	24	74	78	0	3	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	APR 30	1999	284	5415					749	+		10.1126/science.284.5415.749	http://dx.doi.org/10.1126/science.284.5415.749			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	192AW	10336398				2022-12-28	WOS:000080056200028
J	Imai, Y; Kimura, T; Murakami, A; Yajima, N; Sakamaki, K; Yonehara, S				Imai, Y; Kimura, T; Murakami, A; Yajima, N; Sakamaki, K; Yonehara, S			The CED-4-homologous protein FLASH is involved in Fas-mediated activation of caspase-8 during apoptosis	NATURE			English	Article							DOMAIN-CONTAINING PROTEIN; SIGNALING COMPLEX DISC; DEATH-EFFECTOR DOMAIN; CYTOCHROME-C; MOLECULAR-CLONING; ANTIGEN FAS; CELL-DEATH; CED-4; MITOCHONDRIA; RELEASE	Fas is a cell-surface receptor molecule that relays apoptotic (cell death) signals into cells. When Fas is activated by binding of its ligand, the proteolytic: protein caspase-8 is recruited to a signalling complex known as DISC by binding to a Fas-associated adapter protein. A large new protein, FLASH, has now been identified by cloning of its complementary DNA. This protein contains a motif with oligomerizing activity whose sequence is similar to that of the Caenorhabditis elegans protein CED-4, and another domain (DRD domain) that interacts with a death-effector domain in caspase-8 or in the adapter protein. Stimulated Fas binds FLASH, so FLASH is probably a component of the DISC signalling complex. Transient expression of FLASH activates caspase-8, whereas overexpression of a truncated form of FLASH containing only one of its DRD or CED-4-like domains does not allow activation of caspase-8 and Fas-mediated apoptosis to occur, Overexpression of full-length FLASH blocks the anti-apoptotic effect of the adenovirus protein E1B19K. FLASH is therefore necessary for the activation of caspase-8 in Fas-mediated apoptosis.	Kyoto Univ, Inst Virus Res, Sakyo Ku, Kyoto 6068507, Japan	Kyoto University	Yonehara, S (corresponding author), Kyoto Univ, Inst Virus Res, Sakyo Ku, Kyoto 6068507, Japan.	syonehar@virus.kyoto-u.ac.jp	Imai, Yuzuru/AAA-6472-2019	Imai, Yuzuru/0000-0003-2924-5231; Sakamaki, Kazuhiro/0000-0002-7072-9628				BOLDIN MP, 1995, J BIOL CHEM, V270, P7795, DOI 10.1074/jbc.270.14.7795; Boldin MP, 1996, CELL, V85, P803, DOI 10.1016/S0092-8674(00)81265-9; CHINNAIYAN AM, 1995, CELL, V81, P505, DOI 10.1016/0092-8674(95)90071-3; Chinnaiyan AM, 1997, NATURE, V388, P728, DOI 10.1038/41913; Chinnaiyan AM, 1997, SCIENCE, V275, P1122, DOI 10.1126/science.275.5303.1122; Eberstadt M, 1998, NATURE, V392, P941, DOI 10.1038/31972; Enari M, 1998, NATURE, V391, P43, DOI 10.1038/34112; Enari M, 1996, NATURE, V380, P723, DOI 10.1038/380723a0; FERNANDESALNEMRI T, 1995, CANCER RES, V55, P2737; Hengartner MO, 1997, NATURE, V388, P714, DOI 10.1038/41873; Hu YM, 1998, P NATL ACAD SCI USA, V95, P4386, DOI 10.1073/pnas.95.8.4386; ITOH N, 1991, CELL, V66, P233, DOI 10.1016/0092-8674(91)90614-5; KISCHKEL FC, 1995, EMBO J, V14, P5579, DOI 10.1002/j.1460-2075.1995.tb00245.x; Kluck RM, 1997, SCIENCE, V275, P1132, DOI 10.1126/science.275.5303.1132; KOZAK M, 1989, J CELL BIOL, V108, P229, DOI 10.1083/jcb.108.2.229; Li HL, 1998, CELL, V94, P491, DOI 10.1016/S0092-8674(00)81590-1; Li P, 1997, CELL, V91, P479, DOI 10.1016/S0092-8674(00)80434-1; Liu XS, 1997, CELL, V89, P175, DOI 10.1016/S0092-8674(00)80197-X; Luo X, 1998, CELL, V94, P481, DOI 10.1016/S0092-8674(00)81589-5; Medema JP, 1998, J BIOL CHEM, V273, P3388, DOI 10.1074/jbc.273.6.3388; Medema JP, 1997, EMBO J, V16, P2794, DOI 10.1093/emboj/16.10.2794; Muzio M, 1998, J BIOL CHEM, V273, P2926, DOI 10.1074/jbc.273.5.2926; Nagata S, 1997, CELL, V88, P355, DOI 10.1016/S0092-8674(00)81874-7; Nigg EA, 1997, NATURE, V386, P779, DOI 10.1038/386779a0; NISHIMURA Y, 1995, J IMMUNOL, V154, P4395; Pan GH, 1998, J BIOL CHEM, V273, P5841, DOI 10.1074/jbc.273.10.5841; Perez D, 1998, J CELL BIOL, V141, P1255, DOI 10.1083/jcb.141.5.1255; Rudel T, 1997, SCIENCE, V276, P1571, DOI 10.1126/science.276.5318.1571; Sakamaki K, 1998, EUR J BIOCHEM, V253, P399, DOI 10.1046/j.1432-1327.1998.2530399.x; SAKAMAKI K, 1992, EMBO J, V11, P3541, DOI 10.1002/j.1460-2075.1992.tb05437.x; Scaffidi C, 1998, EMBO J, V17, P1675, DOI 10.1093/emboj/17.6.1675; Srinivasula SM, 1998, MOL CELL, V1, P949, DOI 10.1016/S1097-2765(00)80095-7; Stegh AH, 1998, EMBO J, V17, P5974, DOI 10.1093/emboj/17.20.5974; SUDA T, 1993, CELL, V75, P1169, DOI 10.1016/0092-8674(93)90326-L; Takahashi A, 1997, ONCOGENE, V14, P2741, DOI 10.1038/sj.onc.1201131; TRAUTH BC, 1989, SCIENCE, V245, P301, DOI 10.1126/science.2787530; van der Biezen EA, 1998, CURR BIOL, V8, pR226, DOI 10.1016/S0960-9822(98)70145-9; Villa P, 1997, TRENDS BIOCHEM SCI, V22, P388, DOI 10.1016/S0968-0004(97)01107-9; Wada A, 1998, EMBO J, V17, P1635, DOI 10.1093/emboj/17.6.1635; WALKER JE, 1982, EMBO J, V1, P945, DOI 10.1002/j.1460-2075.1982.tb01276.x; Yang J, 1997, SCIENCE, V275, P1129, DOI 10.1126/science.275.5303.1129; Yang XL, 1998, MOL CELL, V1, P319, DOI 10.1016/S1097-2765(00)80032-5; Yang XL, 1998, SCIENCE, V281, P1355, DOI 10.1126/science.281.5381.1355; Yeh WC, 1998, SCIENCE, V279, P1954, DOI 10.1126/science.279.5358.1954; YONCHARA S, 1989, J EXP MED, V169, P1747; YONEHARA S, 1994, INT IMMUNOL, V6, P1849, DOI 10.1093/intimm/6.12.1849; Zhang JK, 1998, NATURE, V392, P296, DOI 10.1038/32681	47	210	226	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	APR 29	1999	398	6730					777	785		10.1038/19709	http://dx.doi.org/10.1038/19709			9	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	192BL	10235259				2022-12-28	WOS:000080058100050
J	Ferrari, G; Langen, H; Naito, M; Pieters, J				Ferrari, G; Langen, H; Naito, M; Pieters, J			A coat protein on phagosomes involved in the intracellular survival of mycobacteria	CELL			English	Article							ACTIN-BINDING-PROTEIN; GREEN FLUORESCENT PROTEIN; CLASS-II MOLECULES; WD-REPEAT; ENDOPLASMIC-RETICULUM; BACTERIAL PATHOGENS; VESICLE FORMATION; INVARIANT CHAIN; LYSOSOME FUSION; SEC13P COMPLEX	Mycobacteria are intracellular pathogens that can survive within macrophage phagosomes, thereby evading host defense strategies by largely unknown mechanisms. We have identified a WD repeat host protein that was recruited to and actively retained on phagosomes by living, but not dead, mycobacteria. This protein, termed TACO, represents a component of the phagosome coat that is normally released prior to phagosome fusion with or maturation into lysosomes. In macrophages lacking TACO, mycobacteria were readily transported to lysosomes followed by their degradation. Expression of TACO in nonmacrophages prevented lysosomal delivery of mycobacteria and prolonged their intracellular survival. Active retention of TACO on phagosomes by living mycobacteria thus represents a mechanism preventing cargo delivery to lysosomes, allowing mycobacteria to survive within macrophages.	Basel Inst Immunol, CH-4005 Basel, Switzerland; Hoffmann La Roche Ag, CH-4002 Basel, Switzerland; Niigata Univ, Sch Med, Dept Pathol, Niigata 9518510, Japan	Roche Holding; Niigata University	Pieters, J (corresponding author), Basel Inst Immunol, Grenzacherstr 487, CH-4005 Basel, Switzerland.			Pieters, Jean/0000-0002-5284-9757				ARMSTRONG JA, 1971, J EXP MED, V134, P713, DOI 10.1084/jem.134.3.713; Bednarek SY, 1995, CELL, V83, P1183, DOI 10.1016/0092-8674(95)90144-2; BERGER B, 1995, P NATL ACAD SCI USA, V92, P8259, DOI 10.1073/pnas.92.18.8259; BERLIN RD, 1978, CELL, V15, P327, DOI 10.1016/0092-8674(78)90002-8; Beverley SM, 1996, CELL, V87, P787, DOI 10.1016/S0092-8674(00)81984-4; BLISKA JB, 1993, CELL, V73, P903, DOI 10.1016/0092-8674(93)90270-Z; Blocker A, 1998, J CELL SCI, V111, P303; BRANDBORG LL, 1990, HEPATOLOGY TXB LIVER, P1086; BURKHARDT JK, 1993, J EXP MED, V178, P1845, DOI 10.1084/jem.178.6.1845; CLEMENS DL, 1995, J EXP MED, V181, P257, DOI 10.1084/jem.181.1.257; Cosson P, 1997, CURR OPIN CELL BIOL, V9, P484, DOI 10.1016/S0955-0674(97)80023-3; CROWLE AJ, 1991, INFECT IMMUN, V59, P1823, DOI 10.1128/IAI.59.5.1823-1831.1991; DEHOSTOS EL, 1991, EMBO J, V10, P4097, DOI 10.1002/j.1460-2075.1991.tb04986.x; DEHOSTOS EL, 1993, J CELL BIOL, V120, P163, DOI 10.1083/jcb.120.1.163; DESJARDINS M, 1994, J CELL BIOL, V124, P677, DOI 10.1083/jcb.124.5.677; DHANDAYUTHAPANI S, 1995, MOL MICROBIOL, V17, P901, DOI 10.1111/j.1365-2958.1995.mmi_17050901.x; Faigle W, 1998, J CELL BIOL, V141, P1121, DOI 10.1083/jcb.141.5.1121; FALKOW S, 1991, CELL, V65, P1099, DOI 10.1016/0092-8674(91)90003-H; Ferrari G, 1997, J CELL BIOL, V139, P1433, DOI 10.1083/jcb.139.6.1433; Finlay BB, 1997, SCIENCE, V276, P718, DOI 10.1126/science.276.5313.718; Fountoulakis M, 1997, ANAL BIOCHEM, V250, P153, DOI 10.1006/abio.1997.2213; Galan JE, 1996, ANNU REV CELL DEV BI, V12, P221, DOI 10.1146/annurev.cellbio.12.1.221; GORDON AH, 1980, NATURE, V286, P79, DOI 10.1038/286079a0; GREENBERG S, 1990, J EXP MED, V172, P1853, DOI 10.1084/jem.172.6.1853; Grogan A, 1997, J CELL SCI, V110, P3071; HART PD, 1991, J EXP MED, V174, P881, DOI 10.1084/jem.174.4.881; Hasan Z, 1997, MOL MICROBIOL, V24, P545, DOI 10.1046/j.1365-2958.1997.3591731.x; HEUSER J, 1989, J CELL BIOL, V108, P855, DOI 10.1083/jcb.108.3.855; ISOBE Y, 1977, ACTA HISTOCHEM CYTOC, V10, P161, DOI 10.1267/ahc.10.161; JOHNSON JP, 1981, EUR J IMMUNOL, V11, P825, DOI 10.1002/eji.1830111015; KIELIAN MC, 1982, J CELL BIOL, V93, P875, DOI 10.1083/jcb.93.3.875; KING SM, 1995, J CELL BIOL, V131, P399, DOI 10.1083/jcb.131.2.399; Kirchhausen T, 1997, CURR OPIN CELL BIOL, V9, P488, DOI 10.1016/S0955-0674(97)80024-5; KNOLL AH, 1992, SCIENCE, V256, P622, DOI 10.1126/science.1585174; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEE SH, 1986, J EXP MED, V163, P54, DOI 10.1084/jem.163.1.54; Lefkovits I, 1985, IMMUNOLOGICAL METHOD, V3, P163; LI QW, 1994, J BIOL CHEM, V269, P31777; MANIAK M, 1995, CELL, V83, P915, DOI 10.1016/0092-8674(95)90207-4; MELLMAN I, 1986, ANNU REV BIOCHEM, V55, P663, DOI 10.1146/annurev.biochem.55.1.663; NEER EJ, 1994, NATURE, V371, P297, DOI 10.1038/371297a0; NIBBERING PH, 1989, CLIN EXP IMMUNOL, V75, P147; NIIWA H, 1991, GENE, V108, P193; NORTH RJ, 1974, INFECT IMMUN, V10, P66, DOI 10.1128/IAI.10.1.66-71.1974; Perou CM, 1996, NAT GENET, V13, P303, DOI 10.1038/ng0796-303; PIETERS J, 1991, J CELL BIOL, V115, P1213, DOI 10.1083/jcb.115.5.1213; PRYER NK, 1993, J CELL BIOL, V120, P865, DOI 10.1083/jcb.120.4.865; Rathman M, 1997, INFECT IMMUN, V65, P1475, DOI 10.1128/IAI.65.4.1475-1485.1997; Rauchenberger R, 1997, CURR BIOL, V7, P215, DOI 10.1016/S0960-9822(97)70093-9; Rothman JE, 1996, SCIENCE, V272, P227, DOI 10.1126/science.272.5259.227; RUSSELL DG, 1995, TRENDS CELL BIOL, V5, P125, DOI 10.1016/S0962-8924(00)88963-1; SALAMA NR, 1993, EMBO J, V12, P4073, DOI 10.1002/j.1460-2075.1993.tb06091.x; Sathyamoorthy M, 1997, J BIOL CHEM, V272, P9141; Schekman R, 1996, SCIENCE, V271, P1526, DOI 10.1126/science.271.5255.1526; Shirayama M, 1998, EMBO J, V17, P1336, DOI 10.1093/emboj/17.5.1336; SMALL PLC, 1994, SCIENCE, V263, P637, DOI 10.1126/science.8303269; STURGILLKOSZYCKI S, 1994, SCIENCE, V263, P678, DOI 10.1126/science.8303277; SUZUKI K, 1995, FEBS LETT, V364, P283, DOI 10.1016/0014-5793(95)00393-N; Tsunawaki S, 1996, J EXP MED, V184, P893, DOI 10.1084/jem.184.3.893; TULP A, 1994, NATURE, V369, P120, DOI 10.1038/369120a0; VALERIUS NH, 1981, CELL, V24, P195, DOI 10.1016/0092-8674(81)90515-8; WARDLE EN, 1987, LIVER, V7, P63; WOODMAN RC, 1991, J CLIN INVEST, V87, P1345, DOI 10.1172/JCI115138	63	432	455	0	10	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	MAY 14	1999	97	4					435	447		10.1016/S0092-8674(00)80754-0	http://dx.doi.org/10.1016/S0092-8674(00)80754-0			13	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	196FV	10338208	Bronze			2022-12-28	WOS:000080299100005
J	Friedman, MA; Woodcock, J; Lumpkin, MM; Shuren, JE; Hass, AE; Thompson, LJ				Friedman, MA; Woodcock, J; Lumpkin, MM; Shuren, JE; Hass, AE; Thompson, LJ			The safety of newly approved medicines - Do recent market removals mean there is a problem?	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							APPETITE-SUPPRESSANT DRUGS; VALVULAR HEART-DISEASE; FEXOFENADINE; MIBEFRADIL; FENFLURAMINE; PHENTERMINE; TERFENADINE	The removal of 5 pharmaceuticals from the market in a 12-month period because of unexpected adverse events raised concerns about the adequacy of the drug review process at the US Food and Drug Administration (FDA), Specifically, concerns were raised about improvements in drug review efficiency that significantly reduced FDA review times. We have reviewed the circumstances of the 5 removals to determine whether there was any relationship to the increased efficiencies in the drug review process. When the removed drugs were analyzed by date of approval, no increase in the number of drugs taken off the market was seen, demonstrating that reduced review processing time was not the reason for the cluster of removals, We conclude that the agency's drug review procedures and postmarketing surveillance system after a drug has been marketed are currently adequate but must continually adjust to future challenges.	US FDA, Off Commissioner, Rockville, MD 20857 USA; US FDA, Ctr Drug Res & Evaluat, Rockville, MD 20857 USA; US FDA, Off Policy, Rockville, MD 20857 USA; US FDA, Off Performance Evaluat, Rockville, MD 20857 USA; US FDA, Off Publ Affairs, Off Commissioner, Rockville, MD 20857 USA	US Food & Drug Administration (FDA); US Food & Drug Administration (FDA); US Food & Drug Administration (FDA); US Food & Drug Administration (FDA); US Food & Drug Administration (FDA)	Friedman, MA (corresponding author), US FDA, Off Commissioner, 5600 Fishers Ln,Hf-28, Rockville, MD 20857 USA.							[Anonymous], 1998, Mayo Clin Health Lett, V16, P4; Bernstein DI, 1997, ANN ALLERG ASTHMA IM, V79, P443, DOI 10.1016/S1081-1206(10)63041-4; Bronsky EA, 1998, ALLERGY ASTHMA PROC, V19, P135, DOI 10.2500/108854198778604112; Connolly HM, 1997, NEW ENGL J MED, V337, P581, DOI 10.1056/NEJM199708283370901; CRUZAN SM, 1997, WARNING LABELING CHA; DEVANE PJ, 1998, COMMUNICATION   0622; DEVANE PJ, 1998, COMMUNICATION   0210; Devereux RB, 1998, NEW ENGL J MED, V339, P765, DOI 10.1056/NEJM199809103391109; ELLISON RH, 1997, COMMUNICATION    DEC; HONIG PK, 1992, CLIN PHARMACOL THER, V52, P231, DOI 10.1038/clpt.1992.135; HONIG PK, 1993, JAMA-J AM MED ASSOC, V269, P1513, DOI 10.1001/jama.269.12.1513; Jick H, 1998, NEW ENGL J MED, V339, P719, DOI 10.1056/NEJM199809103391102; JOHNSON JA, 1995, ARCH INTERN MED, V155, P1949, DOI 10.1001/archinte.155.18.1949; Khan MA, 1998, NEW ENGL J MED, V339, P713, DOI 10.1056/NEJM199809103391101; Kleinke JD, 1998, BRIT MED J, V317, P899; Krahenbuhl S, 1998, TRANSPLANTATION, V66, P1113; Kupec I., 1998, SELDANE GENERIC TERF; Lazarou J, 1998, JAMA-J AM MED ASSOC, V279, P1200, DOI 10.1001/jama.279.15.1200; Mark EJ, 1997, NEW ENGL J MED, V337, P602, DOI 10.1056/NEJM199708283370904; Markham A, 1998, DRUGS, V55, P269, DOI 10.2165/00003495-199855020-00012; Mullins ME, 1998, JAMA-J AM MED ASSOC, V280, P157, DOI 10.1001/jama.280.2.157; *ROCH LAB, 1998, ROCH LAB ANN WITHDR; ROCHE, 1998, AM J HLTH SYST PHARM, V55, P1445; ROCK A, 1998, MONEY            DEC, P123; RUBIN R, 1998, US TODAY        0710, P1; Schmassmann-Suhijar D, 1998, LANCET, V351, P1929, DOI 10.1016/S0140-6736(05)78613-X; SHIMMINGS A, 1999, SCRIP MAGAZINE, V75, P62; *US FDA, 1999, GUID IND EXT POP EXP; *US FDA, 1998, WARN LAB CHANG PAIN; *US FDA, 1997, AN CARD VALV DYSF PA; US Food and Drug administration, 1995, FED REGISTER, V60, P11270; WEINTRAUB M, 1992, CLIN PHARMACOL THER, V51, P581, DOI 10.1038/clpt.1992.68; *WYETH LAB, 1998, WYETHAYERST LAB ANN; 1998, DEL MED J, V70, P405; 1998, WASHINGTON TIME 0831, pA8	35	172	182	0	3	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAY 12	1999	281	18					1728	1734		10.1001/jama.281.18.1728	http://dx.doi.org/10.1001/jama.281.18.1728			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	193WR	10328074				2022-12-28	WOS:000080161200031
J	Montaner, JSG				Montaner, JSG			Induction/maintenance treatment regimens for HIV - New England Journal of Medicine maintenance antiretroviral therapies in HIV-infected subjects with undetectable plasma HIV RNA after triple-drug therapy - Abstract and commentary	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material							IMMUNODEFICIENCY-VIRUS INFECTION; PROLONGED SUPPRESSION; INDUCTION THERAPY; VIRAL LOAD; ZIDOVUDINE; INDINAVIR; LAMIVUDINE; TRIAL; INDIVIDUALS; INITIATION		Univ British Columbia, St Pauls Hosp, Vancouver, BC V5Z 1M9, Canada; Canadian HIV Trials Network, Vancouver, BC, Canada	St. Paul's Hospital; University of British Columbia; University of Saskatchewan	Montaner, JSG (corresponding author), Univ British Columbia, St Pauls Hosp, Vancouver, BC V5Z 1M9, Canada.							Carpenter CCJ, 1998, JAMA-J AM MED ASSOC, V280, P78, DOI 10.1001/jama.280.1.78; Carr A, 1998, AIDS, V12, pF51, DOI 10.1097/00002030-199807000-00003; Carr A, 1998, LANCET, V351, P1881, DOI 10.1016/S0140-6736(98)03391-1; Chun TW, 1997, P NATL ACAD SCI USA, V94, P13193, DOI 10.1073/pnas.94.24.13193; Cooper DA, 1998, NEW ENGL J MED, V339, P1319, DOI 10.1056/NEJM199810293391810; Finzi D, 1997, SCIENCE, V278, P1295, DOI 10.1126/science.278.5341.1295; FISCHL M, 1998, 12 WORLD AIDS C JUN; Gulick RM, 1997, NEW ENGL J MED, V337, P734, DOI 10.1056/NEJM199709113371102; Gulick RM, 1998, JAMA-J AM MED ASSOC, V280, P35, DOI 10.1001/jama.280.1.35; Hall DB, 1998, AIDS, V12, pF41, DOI 10.1097/00002030-199807000-00001; Hammer SM, 1997, NEW ENGL J MED, V337, P725, DOI 10.1056/NEJM199709113371101; Havlir DV, 1998, NEW ENGL J MED, V339, P1261, DOI 10.1056/NEJM199810293391801; Hogg RS, 1998, JAMA-J AM MED ASSOC, V279, P450, DOI 10.1001/jama.279.6.450; Montaner JSG, 1998, AIDS, V12, P1398, DOI 10.1097/00002030-199811000-00028; Montaner JSG, 1998, LANCET, V352, P1919, DOI 10.1016/S0140-6736(98)07532-1; Montaner JSG, 1998, JAMA-J AM MED ASSOC, V279, P930, DOI 10.1001/jama.279.12.930; MONTANER JSG, 1998, 38 INT C ANT AG CHEM; Palella FJ, 1998, NEW ENGL J MED, V338, P853, DOI 10.1056/NEJM199803263381301; Pialoux G, 1998, NEW ENGL J MED, V339, P1269, DOI 10.1056/NEJM199810293391802; Raboud JM, 1998, AIDS, V12, P1619, DOI 10.1097/00002030-199813000-00008; Reijers MHE, 1998, LANCET, V352, P185, DOI 10.1016/S0140-6736(98)06193-5; RENAUD M, 1998, 12 WORLD AIDS C JUN; STASZEWSKI S, 1998, 12 WORLD AIDS C JUN; Wong JK, 1997, SCIENCE, V278, P1291, DOI 10.1126/science.278.5341.1291	24	6	6	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAY 12	1999	281	18					1680	1682		10.1001/jama.281.18.1680	http://dx.doi.org/10.1001/jama.281.18.1680			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	193WR	10328054				2022-12-28	WOS:000080161200002
J	Xu, KP; Shi, ZM; Veeck, LL; Hughes, MR; Rosenwaks, Z				Xu, KP; Shi, ZM; Veeck, LL; Hughes, MR; Rosenwaks, Z			First unaffected pregnancy using preimplantation genetic diagnosis for sickle cell anemia	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							POLYMERASE CHAIN-REACTION; CYSTIC-FIBROSIS DELTA-F508; PRENATAL-DIAGNOSIS; DNA ANALYSIS; ENZYMATIC AMPLIFICATION; PREEMBRYO DEVELOPMENT; DISEASE; EMBRYO; BIOPSY; BLASTOMERES	Context Sickle cell anemia is a common autosomal recessive disorder. However, pre implantation genetic diagnosis (PCD) for this severe genetic disorder previously has not been successful. Objective To achieve pregnancy with an unaffected embryo using in vitro fertilization (IVF) and PCD, Design Laboratory analysis of DNA from single cells obtained by biopsy from embryos in 2 IVF attempts, 1 in 1996 and 1 in 1997, to determine the genetic status of each embryo before intrauterine transfer. Setting University hospital in a large metropolitan area. Patients A couple, both carriers of the recessive mutation for sickle cell disease. Interventions Standard IVF treatment, intracytoplasmic sperm injection, embryo biopsy, single-cell polymerase chain reaction and DNA analyses, embryo transfer to uterus, pregnancy confirmation, and prenatal diagnosis by amniocentesis at 16.5 weeks' gestation, Main Outcome Measure DNA analysis of single blastomeres indicating whether embryos carried the sickle cell mutation, allowing only unaffected or carrier embryos to be transferred. Results The first IVF attempt failed to produce a pregnancy. Of the 7 embryos analyzed in the second attempt, PCD indicated that 4 were normal and 2 were carriers; diagnosis was not possible in 1. Three embryos were transferred to the uterus on the fourth day after oocyte retrieval. A twin pregnancy was confirmed by ultrasonography, and subsequent amniocentesis revealed that both fetuses were unaffected and were not carriers of the sickle cell mutation. The patient delivered healthy twins at 39 weeks' gestation. Conclusion This first unaffected pregnancy resulting from PGD for sickle cell anemia demonstrates that the technique can be a powerful diagnostic tool for carrier couples who desire a healthy child but wish to avoid the difficult decision of whether to abort an affected fetus.	Cornell Univ, Weill Med Coll, Ctr Reprod Med & Infertil, New York, NY 10021 USA; Cornell Univ, Weill Med Coll, Dept Obstet & Gynecol, New York, NY 10021 USA; Wayne State Univ, Detroit Med Ctr, Dept Reprod Genet, Detroit, MI USA	Cornell University; Cornell University; Detroit Medical Center; Wayne State University	Rosenwaks, Z (corresponding author), Cornell Univ, Weill Med Coll, Ctr Reprod Med & Infertil, 505 E 70th St,Room HT326a, New York, NY 10021 USA.	zrosenw@mail.med.cornell.edu						Adams RJ, 1998, NEW ENGL J MED, V339, P5, DOI 10.1056/NEJM199807023390102; Ao A, 1996, PRENATAL DIAG, V16, P137, DOI 10.1002/(SICI)1097-0223(199602)16:2<137::AID-PD824>3.0.CO;2-H; Barmat LI, 1998, FERTIL STERIL, V70, P1109, DOI 10.1016/S0015-0282(98)00335-5; Barnes FL, 1995, HUM REPROD, V10, P3243, DOI 10.1093/oxfordjournals.humrep.a135896; CHANG JC, 1982, NEW ENGL J MED, V307, P30, DOI 10.1056/NEJM198207013070105; CHEHAB FF, 1987, NATURE, V329, P293, DOI 10.1038/329293b0; Cohen AR, 1998, NEW ENGL J MED, V339, P42, DOI 10.1056/NEJM199807023390109; Davis H, 1997, PUBLIC HEALTH REP, V112, P52; DAVIS OK, 1996, REPROD ENDOCRINOLOGY, P2319; EMBURY SH, 1987, NEW ENGL J MED, V316, P656, DOI 10.1056/NEJM198703123161103; Gardner DK, 1998, FERTIL STERIL, V69, P84, DOI 10.1016/S0015-0282(97)00438-X; GAY JC, 1996, EMERY RIMONS PRINCIP, P1599; GIBBONS WE, 1995, FERTIL STERIL, V63, P723, DOI 10.1016/S0015-0282(16)57472-X; HANDYSIDE AH, 1990, NATURE, V344, P768, DOI 10.1038/344768a0; HANDYSIDE AH, 1992, NEW ENGL J MED, V327, P905, DOI 10.1056/NEJM199209243271301; HARDY K, 1990, HUM REPROD, V5, P708, DOI 10.1093/oxfordjournals.humrep.a137173; HARPER JC, 1995, PRENATAL DIAG, V15, P41, DOI 10.1002/pd.1970150109; KAN YW, 1978, LANCET, V2, P910; KULOZIK AE, 1988, BRIT J HAEMATOL, V70, P455, DOI 10.1111/j.1365-2141.1988.tb02516.x; LI H, 1991, Methods (Orlando), V2, P49, DOI 10.1016/S1046-2023(05)80125-2; LIU J, 1993, PRENATAL DIAG, V13, P873, DOI 10.1002/pd.1970130911; Menezo YJR, 1997, HUM REPROD, V12, P2802, DOI 10.1093/humrep/12.12.2802; MOTULSKY AG, 1973, NEW ENGL J MED, V288, P31, DOI 10.1056/NEJM197301042880108; ORKIN SH, 1982, NEW ENGL J MED, V307, P32, DOI 10.1056/NEJM198207013070106; PLATT OS, 1994, NEW ENGL J MED, V330, P1639, DOI 10.1056/NEJM199406093302303; PLATT OS, 1995, HEMATOLOGY INFANCY C, P732; POWARS DR, 1994, JAMA-J AM MED ASSOC, V271, P1885, DOI 10.1001/jama.271.23.1885; ROGERS ZR, 1989, JAMA-J AM MED ASSOC, V261, P2991, DOI 10.1001/jama.261.20.2991; SAIKI RK, 1985, SCIENCE, V230, P1350, DOI 10.1126/science.2999980; SHEARDOWN SA, 1992, HUM REPROD, V7, P1297, DOI 10.1093/oxfordjournals.humrep.a137845; TAKEUCHI K, 1992, FERTIL STERIL, V57, P425; VEECK LL, 1999, ATLAS HUMAN GAMETES, P48; WU DY, 1989, P NATL ACAD SCI USA, V86, P2757, DOI 10.1073/pnas.86.8.2757	33	66	72	0	7	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAY 12	1999	281	18					1701	1706		10.1001/jama.281.18.1701	http://dx.doi.org/10.1001/jama.281.18.1701			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	193WR	10328069	Bronze			2022-12-28	WOS:000080161200026
J	Besson, JM				Besson, JM			The neurobiology of pain	LANCET			English	Article							SUBSTANCE-P RECEPTOR; CAPSAICIN RECEPTOR; SPINAL MECHANISMS; SENSORY NEURONS; AFFERENT; HYPERALGESIA; CHANNEL; PHARMACOLOGY; NOCICEPTION; INHIBITION	Understanding the plasticity of pain and analgesia exhibited in different pain states may improve therapies for the two major types of pain, neuropathic and inflammatory pain, in which nerve and tissue damage leads to alterations at both peripheral and central levels. At the level of the peripheral nerve, drugs that act on particular sodium channels may target only pain-related activity. Agents that act on some of the peripheral mediators of pain may control peripheral nerve activity. A new generation of non-steroidal anti-inflammatory drugs, cyclo-oxygenase 2 Inhibitors, that lack gastric actions are becoming available. In the spinal cord, the release of peptides and glutamate causes activation of multiple receptors, particularly, the N-methyl-D-aspartate receptor for glutamate, which, in concert with other spinal systems, generates spinal hypersensitivity. Blocking the generation of excitability is one approach, but increasing inhibitions may also provide analgesia. Opioid actions are via presynaptic and post-synaptic inhibitory effects on central and peripheral C fibre terminals, spinal neurones, and supraspinal mechanisms. Our knowledge of brain mechanisms of pain is still, however, limited. Other new targets have been revealed by molecular biology and animal models of clinical pain, but the possibility of a "magic bullet" is doubtful. Thus, another approach could be single molecules with dual drug actions, that encompass targets where additive or synergistic effects of different mechanisms may enable pain relief without major adverse effects.	INSERM, U161, F-75014 Paris, France; EPHE, F-75014 Paris, France	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; PSL Research University Paris; Ecole Pratique des Hautes Etudes (EPHE)	Besson, JM (corresponding author), INSERM, U161, 2 Rue Aleslia, F-75014 Paris, France.							Akopian AN, 1996, NATURE, V379, P257, DOI 10.1038/379257a0; BASBAUM AI, 1991, NEW PHARM PAIN; Belmonte C., 1997, BIOMED PHARMACOTHER, V51, P187; Bernard JF, 1995, FRONTIER PAIN RES, P27; BESSON JM, 1987, PHYSIOL REV, V67, P67, DOI 10.1152/physrev.1987.67.1.67; Burnstock G, 1996, CURR OPIN NEUROBIOL, V6, P526, DOI 10.1016/S0959-4388(96)80060-2; Cao YQ, 1998, NATURE, V392, P390, DOI 10.1038/32897; Carlton SM, 1998, PAIN FORUM, V7, P71; Caterina MJ, 1997, NATURE, V389, P816, DOI 10.1038/39807; CERVERO F, IN PRESS LANCET; Cesare P, 1997, CURR OPIN NEUROBIOL, V7, P493, DOI 10.1016/S0959-4388(97)80028-1; De Felipe C, 1998, NATURE, V392, P394, DOI 10.1038/32904; Derbyshire SWG, 1997, PAIN, V73, P431, DOI 10.1016/S0304-3959(97)00138-3; DICKENSON AH, 1995, BRIT J ANAESTH, V75, P193, DOI 10.1093/bja/75.2.193; DICKENSON AH, 1997, HDB EXPT PHARM, V130; Dray A, 1997, CAN J PHYSIOL PHARM, V75, P704, DOI 10.1139/cjpp-75-6-704; Dray Andy, 1998, Trends in Neurosciences, V21, P315, DOI 10.1016/S0166-2236(98)01291-0; HOKFELT T, 1994, TRENDS NEUROSCI, V17, P22, DOI 10.1016/0166-2236(94)90031-0; Janig W, 1996, PROG BRAIN RES, V113, P161, DOI 10.1016/S0079-6123(08)61087-0; JESSELL TM, 1977, NATURE, V268, P549, DOI 10.1038/268549a0; KIEFFER BL, 1997, HDB EXPT PHARM PHARM, P281; LEBARS D, 1981, TRENDS PHARMACOL SCI, V2, P323, DOI 10.1016/0165-6147(81)90354-0; LEVINE JD, 1993, J NEUROSCI, V13, P2273, DOI 10.1523/JNEUROSCI.13-06-02273.1993; MALMBERG AB, 1992, SCIENCE, V257, P1276, DOI 10.1126/science.1381521; MANSOUR A, 1995, TRENDS NEUROSCI, V18, P22, DOI 10.1016/0166-2236(95)93946-U; Mantyh PW, 1997, SCIENCE, V278, P275, DOI 10.1126/science.278.5336.275; MANTYH PW, 1997, SCIENCE, V268, P1269; MELLER ST, 1993, PAIN, V52, P127, DOI 10.1016/0304-3959(93)90124-8; MELZACK R, 1965, SCIENCE, V150, P971, DOI 10.1126/science.150.3699.971; MEYER RA, 1994, PERIPHERAL NEURAL ME, P13; Perl ER, 1998, NAT NEUROSCI, V1, P177, DOI 10.1038/624; PICOT D, 1994, NATURE, V367, P243, DOI 10.1038/367243a0; RANG HP, 1995, BRIT J ANAESTH, V75, P145, DOI 10.1093/bja/75.2.145; ROQUES BP, 1993, PHARMACOL REV, V45, P87; SCHAIBLE HG, 1993, PAIN, V55, P5, DOI 10.1016/0304-3959(93)90183-P; Stein C, 1997, PROG PAIN RES MANAG, V9, P25; Tominaga M, 1998, NEURON, V21, P531, DOI 10.1016/S0896-6273(00)80564-4; URBAN L, 1994, TRENDS NEUROSCI, V17, P432, DOI 10.1016/0166-2236(94)90018-3; VANE JR, 1995, INFLAMM RES, V44, P1, DOI 10.1007/BF01630479; VILLANUEVA L, 1999, HDB BEHAV STATE CONT, P569; Waldmann R, 1997, NATURE, V386, P173, DOI 10.1038/386173a0; Willis WD, 1997, J CLIN NEUROPHYSIOL, V14, P2, DOI 10.1097/00004691-199701000-00002; Woolf CJ, 1998, NEURON, V20, P1063, DOI 10.1016/S0896-6273(00)80487-0; WOOLF CJ, IN PRESS LANCET; XIE WL, 1991, P NATL ACAD SCI USA, V88, P2692, DOI 10.1073/pnas.88.7.2692; YAKSH TL, 1981, PAIN, V11, P293, DOI 10.1016/0304-3959(81)90633-3; Zimmer A, 1998, P NATL ACAD SCI USA, V95, P2630, DOI 10.1073/pnas.95.5.2630	47	256	272	1	29	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	MAY 8	1999	353	9164					1610	1615		10.1016/S0140-6736(99)01313-6	http://dx.doi.org/10.1016/S0140-6736(99)01313-6			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	195XW	10334274				2022-12-28	WOS:000080278300045
J	Stevens, RJ; Publicover, NG; Smith, TK				Stevens, RJ; Publicover, NG; Smith, TK			Induction and organization of Ca2+ waves by enteric neural reflexes	NATURE			English	Article							PIG SMALL-INTESTINE; INTERSTITIAL-CELLS; ELECTRICAL RHYTHMICITY; CIRCULAR MUSCLE; NERVE PATHWAYS; DISTENSION; CAJAL; MUSCULARIS; MUCOSA; ILEUM	The motility of the gastrointestinal tract consists of local, nonpropulsive mixing (pendular or segmental) and propulsive (peristaltic) movements(1-5). It is generally considered that mixing movements are produced by intrinsic pacemakers which generate rhythmic contractions(4-6), and peristalsis by intrinsic excitatory and inhibitory neural reflex pathways(1-5,7,8), but the relationship between mixing and peristalsis is poorly understood4-6. Peristalsis is compromised in mice lacking interstitial cells of Cajal(9), suggesting that these pacemaker cells(10-14) may also be involved in neural reflexes. Here we show that mixing movements within longitudinal muscle result from spontaneously generated waves of elevated internal calcium concentration which originate from discrete locations (pacing sites), spread with anisotropic conduction velocities in all directions, and terminate by colliding with each other or with adjacent neurally suppressed regions. Excitatory neural reflexes control the spread of excitability by inducing new pacing sites and enhancing the overall frequency of pacing, whereas inhibitory reflexes suppress the ability of calcium waves to propagate. We provide evidence that the enteric nervous system organizes mixing movements to generate peristalsis, linking the neural regulation of pacemakers to both types of gut motility.	Univ Nevada, Sch Med, Biomed Engn Program, Reno, NV 89557 USA; Univ Nevada, Sch Med, Dept Physiol & Cell Biol, Reno, NV 89557 USA	Nevada System of Higher Education (NSHE); University of Nevada Reno; Nevada System of Higher Education (NSHE); University of Nevada Reno	Smith, TK (corresponding author), Univ Nevada, Sch Med, Biomed Engn Program, Reno, NV 89557 USA.			Smith, Terence/0000-0002-2120-2766				Bayliss W M, 1899, J Physiol, V24, P99; Bayliss WM, 1900, J PHYSIOL-LONDON, V26, P107; BURNSTOCK G, 1960, AM J PHYSIOL, V199, P553, DOI 10.1152/ajplegacy.1960.199.3.553; CHRISTENSEN J, 1994, PHYSL GASTROINTESTIN, V1, P991; COSTA M, 1976, N-S ARCH PHARMACOL, V294, P47, DOI 10.1007/BF00692784; COSTA M, 1982, MEDIATORS DRUGS GAST, P279; COUSINS HM, 1993, J PHYSIOL-LONDON, V471, P61, DOI 10.1113/jphysiol.1993.sp019891; GILLESPIE JS, 1962, J PHYSIOL-LONDON, V162, P54, DOI 10.1113/jphysiol.1962.sp006914; HIRST GDS, 1975, J PHYSIOL-LONDON, V244, P113, DOI 10.1113/jphysiol.1975.sp010786; HOLMAN ME, 1958, J PHYSIOL-LONDON, V141, P464, DOI 10.1113/jphysiol.1958.sp005989; HOLMAN ME, 1981, SMOOTH MUSCLE ASSESS, P311; Horowitz B, 1999, ANNU REV PHYSIOL, V61, P19, DOI 10.1146/annurev.physiol.61.1.19; HUIZINGA JD, 1995, NATURE, V373, P347, DOI 10.1038/373347a0; Huizinga JD, 1998, J PHYSIOL-LONDON, V506, P843, DOI 10.1111/j.1469-7793.1998.843bv.x; Koh SD, 1998, J PHYSIOL-LONDON, V513, P203, DOI 10.1111/j.1469-7793.1998.203by.x; KOSTERLITZ HW, 1959, J PHYSIOL-LONDON, V146, P369, DOI 10.1113/jphysiol.1959.sp006198; MACKENNA B R, 1972, Journal of Physiology (Cambridge), V220, P33; OZAKI H, 1991, AM J PHYSIOL, V260, pC917, DOI 10.1152/ajpcell.1991.260.5.C917; Publicover NG, 1995, PACEMAKER ACTIVITY I, P175; SMIH TK, 1998, J PHYSIOL-LONDON, V506, P563; SMITH T, 1995, TXB GASTROENTEROLOGY, P234; SMITH TK, 1987, AM J PHYSIOL, V252, pC290, DOI 10.1152/ajpcell.1987.252.3.C290; Smith TK, 1998, J PHYSIOL-LONDON, V512, P893, DOI 10.1111/j.1469-7793.1998.893bd.x; SMITH TK, 1988, J AUTONOM NERV SYST, V25, P205, DOI 10.1016/0165-1838(88)90025-2; SMITH TK, 1992, J NEUROSCI, V12, P1502; Thomsen L, 1998, NAT MED, V4, P848, DOI 10.1038/nm0798-848; TOMITA T, 1966, J PHYSIOL-LONDON, V183, P450, DOI 10.1113/jphysiol.1966.sp007876; Ward SM, 1997, J PHYSIOL-LONDON, V505, P241, DOI 10.1111/j.1469-7793.1997.241bc.x	28	55	55	0	2	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	MAY 6	1999	399	6731					62	66		10.1038/19973	http://dx.doi.org/10.1038/19973			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	194BK	10331390				2022-12-28	WOS:000080172100055
J	Tsukaguchi, H; Tokui, T; Mackenzie, B; Berger, UV; Chen, XZ; Wang, YX; Brubaker, RF; Hediger, MA				Tsukaguchi, H; Tokui, T; Mackenzie, B; Berger, UV; Chen, XZ; Wang, YX; Brubaker, RF; Hediger, MA			A family of mammalian Na+-dependent L-ascorbic acid transporters	NATURE			English	Article							NA+/GLUCOSE COTRANSPORTER SGLT1; DEHYDROASCORBIC ACID; BIOCHEMICAL FUNCTIONS; AQUEOUS-HUMOR; VITAMIN-C; CELLS; SPECIFICITY; MECHANISM; CURRENTS	Vitamin C (L-ascorbic acid) is essential for many enzymatic reactions, in which it serves to maintain prosthetic metal ions in their reduced forms (for example, Fe2+, Cu+)(1,2), and for scavenging free radicals in order to protect tissues from oxidative damage(3). The facilitative sugar transporters of the GLUT type can transport the oxidized form of the vitamin, dehydroascorbic acid(4-6), but these transporters are unlikely to allow significant physiological amounts of vitamin C to be taken up in the presence of normal glucose concentrations, because the vitamin is present in plasma essentially only in its reduced form(7). Here we describe the isolation of two L-ascorbic acid transporters, SVCT1 and SVCT2, from rat complementary DNA libraries, as the first step in investigating the importance of L-ascorbic acid transport in regulating the supply and metabolism of vitamin C. We find that SVCT1 and SVCT2 each mediate concentrative, high-affinity L-ascorbic acid transport that is stereospecific and is driven by the Na+ electrochemical gradient. Despite their close sequence homology and similar functions, the two isoforms of the transporter are discretely distributed: SVCT1 is mainly confined to epithelial systems (intestine, kidney, liver), whereas SVCT2 serves a host of metabolically active cells and specialized tissues in the brain, ey and other organs.	Brigham & Womens Hosp, Dept Med, Membrane Biol Program, Boston, MA 02115 USA; Brigham & Womens Hosp, Dept Med, Div Renal, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Biol Chem & Mol Pharmacol, Boston, MA 02115 USA; Mayo Clin & Mayo Fdn, Dept Ophthalmol, Rochester, MN 55905 USA	Harvard University; Brigham & Women's Hospital; Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School; Mayo Clinic	Hediger, MA (corresponding author), Brigham & Womens Hosp, Dept Med, Membrane Biol Program, 75 Francis St, Boston, MA 02115 USA.			Mackenzie, Bryan/0000-0002-9661-8838; Hediger, Matthias/0000-0003-1946-027X				Agus DB, 1997, J CLIN INVEST, V100, P2842, DOI 10.1172/JCI119832; BOWERSKOMRO DM, 1991, J NUTR, V121, P57, DOI 10.1093/jn/121.1.57; DHARIWAL KR, 1991, AM J CLIN NUTR, V54, P712, DOI 10.1093/ajcn/54.4.712; DIALLINAS G, 1995, J BIOL CHEM, V270, P8610; ENGLARD S, 1986, ANNU REV NUTR, V6, P365, DOI 10.1146/annurev.nu.06.070186.002053; Eskandari S, 1997, J BIOL CHEM, V272, P27230, DOI 10.1074/jbc.272.43.27230; FRANCESCHI RT, 1995, AM J PHYSIOL-CELL PH, V268, pC1430, DOI 10.1152/ajpcell.1995.268.6.C1430; GUIMARAES MJ, 1995, DEVELOPMENT, V121, P3335; Gunshin H, 1997, NATURE, V388, P482, DOI 10.1038/41343; HAMMARSTROM LARS, 1966, ACTA PHYSIOL SCAND, V70, P1, DOI 10.1111/j.1748-1716.1966.tb03661.x; Hazama A, 1997, J MEMBRANE BIOL, V155, P175, DOI 10.1007/s002329900169; HELBIG H, 1989, AM J PHYSIOL, V256, pC44, DOI 10.1152/ajpcell.1989.256.1.C44; KODAMA T, 1985, OPHTHALMIC RES, V17, P331, DOI 10.1159/000265396; Mackenzie B, 1996, J BIOL CHEM, V271, P32678, DOI 10.1074/jbc.271.51.32678; Mackenzie B, 1998, J MEMBRANE BIOL, V162, P101, DOI 10.1007/s002329900347; Mackenzie B., 1999, BIOMEMBRANE TRANSPOR, P327; Nagase T, 1996, DNA Res, V3, P321, DOI 10.1093/dnares/3.5.321; PADH H, 1991, NUTR REV, V49, P65, DOI 10.1111/j.1753-4887.1991.tb07407.x; REISS GR, 1986, ARCH OPHTHALMOL-CHIC, V104, P753; Romero MF, 1998, METHOD ENZYMOL, V296, P17; ROSE RC, 1991, COMP BIOCHEM PHYS A, V100, P273, DOI 10.1016/0300-9629(91)90470-W; ROSE RC, 1993, FASEB J, V7, P1135, DOI 10.1096/fasebj.7.12.8375611; ROSE RC, 1997, VITAMIN C HLTH DIS, P143; Rumsey SC, 1997, J BIOL CHEM, V272, P18982, DOI 10.1074/jbc.272.30.18982; SCHAERENWIEMERS N, 1993, HISTOCHEMISTRY, V100, P431, DOI 10.1007/BF00267823; Segel IH, 1976, BIOCH CALCULATIONS; TOGGENBURGER G, 1981, BIOCHIM BIOPHYS ACTA, V646, P433, DOI 10.1016/0005-2736(81)90312-6; VERA JC, 1993, NATURE, V364, P79, DOI 10.1038/364079a0; Wright EM, 1996, CURR OPIN CELL BIOL, V8, P468, DOI 10.1016/S0955-0674(96)80022-6	29	687	715	1	39	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	MAY 6	1999	399	6731					70	75		10.1038/19986	http://dx.doi.org/10.1038/19986			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	194BK	10331392				2022-12-28	WOS:000080172100057
J	Merritt, EF				Merritt, EF			Human health and the environment: Are physician educators lagging behind?	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							EXPOSURE		Lahey Hitchcock Med Ctr, Dept Internal Med, Burlington, MA 01803 USA	Lahey Hospital & Medical Center	Merritt, EF (corresponding author), Lahey Hitchcock Med Ctr, Dept Internal Med, Burlington, MA 01803 USA.							AGOCS MM, 1990, NEW ENGL J MED, V323, P1096, DOI 10.1056/NEJM199010183231603; Hoyer AP, 1998, LANCET, V352, P1816, DOI 10.1016/S0140-6736(98)04504-8; HU H, 1994, CRITICAL CONDITION H, P31; Jacobson JL, 1996, NEW ENGL J MED, V335, P783, DOI 10.1056/NEJM199609123351104; Pope AM, 1995, ENV MED INTEGRATING	5	8	8	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAY 5	1999	281	17					1661	1661		10.1001/jama.281.17.1661	http://dx.doi.org/10.1001/jama.281.17.1661			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	191MJ	10235165				2022-12-28	WOS:000080025900037
J	Southgate, MT				Southgate, MT			Messages	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material																			0	0	0	0	0	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAY 5	1999	281	17					1571	1571		10.1001/jama.281.17.1571	http://dx.doi.org/10.1001/jama.281.17.1571			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	191MJ	10235136				2022-12-28	WOS:000080025900001
J	Wolf, G				Wolf, G			Endure!: how Paul Klee's illness influenced his art	LANCET			English	Article							MEDICINE		Univ Hamburg, Hosp Eppendorf, Dept Med, Div Nephrol & Osteol, D-20246 Hamburg, Germany	University of Hamburg	Wolf, G (corresponding author), Univ Hamburg, Hosp Eppendorf, Dept Med, Div Nephrol & Osteol, Pavil 61,Martinistr 52, D-20246 Hamburg, Germany.							BARRON S, 1991, DEGENERATIVE ART FAT, P280; Espinel CH, 1995, LANCET, V346, P1684, DOI 10.1016/S0140-6736(95)92846-4; GIELDIONWELCKER C, 1961, P KLEE; GOEDL M, 1996, P KLEE ZEIT REIFE, P13; GROHMANN W, 1966, MP KLEE; HELFENSTEIN J, 1996, P KLEE LEBEN WERK; Horton R, 1997, LANCET, V349, P872, DOI 10.1016/S0140-6736(97)02336-2; KANDINSKY W, 1912, BLAUE REITER; Klee Paul, 1957, TAGEBUCHER; LeRoy EC, 1996, B RHEUM DIS, V45, P4; MORSCHER C, 1994, PSYCHOTHER PSYCH MED, V44, P200; SANDBLOM P, 1989, CREATIVITY DIS, P149; STIRLING G, 1997, PERSPECT BIOL MED, V37, P67; WANKMULLER R, 1965, CONFIN PSYCHIAT, V8, P69; WERCKMEISTER OK, 1988, MAKING P KLEES CANC; Zhao ZS, 1998, SCIENCE, V279, P1344, DOI 10.1126/science.279.5355.1344	16	7	7	0	1	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	MAY 1	1999	353	9163					1516	1518		10.1016/S0140-6736(98)09455-0	http://dx.doi.org/10.1016/S0140-6736(98)09455-0			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	195XV	10232334				2022-12-28	WOS:000080278200046
J	Hirayama, T; Kieber, JJ; Hirayama, N; Kogan, M; Guzman, P; Nourizadeh, S; Alonso, JM; Dailey, WP; Dancis, A; Ecker, JR				Hirayama, T; Kieber, JJ; Hirayama, N; Kogan, M; Guzman, P; Nourizadeh, S; Alonso, JM; Dailey, WP; Dancis, A; Ecker, JR			Responsive-to-antagonist1, a Menkes/Wilson disease-related copper transporter, is required for ethylene signaling in Arabidopsis	CELL			English	Article							RECEPTOR GENE FAMILY; MENKES-DISEASE; SACCHAROMYCES-CEREVISIAE; RESPONSE PATHWAY; CANDIDATE GENE; BIOCHEMICAL-CHARACTERIZATION; FUNCTIONAL EXPRESSION; TRANSDUCTION PATHWAY; IRON UPTAKE; PROTEIN	Ethylene is an important regulator of plant growth. We identified an Arabidopsis mutant, responsive-to-antagonist1 (ran1), that shows ethylene phenotypes in response to treatment with trans-cyclooctene, a potent receptor antagonist. Genetic epistasis studies revealed an early requirement for RAN1 in the ethylene pathway. RAN1 was cloned and found to encode a protein with similarity to copper-transporting P-type ATPases, including the human Menkes/Wilson proteins and yeast Ccc2p. Expression of RAN1 complemented the defects of a ccc2 Delta mutant, demonstrating its function as a copper transporter. Transgenic CaMV 35S::RAN1 plants showed constitutive expression of ethylene responses, due to cosuppression of RAN1. These results provide an in planta demonstration that ethylene signaling requires copper and reveal that RAN1 acts by delivering copper to create functional hormone receptors.	Univ Penn, Div Hematol Oncol, Inst Plant Sci, Dept Biol, Philadelphia, PA 19104 USA; Univ Penn, Div Hematol Oncol, Dept Chem, Philadelphia, PA 19104 USA; Univ Penn, Div Hematol Oncol, Dept Med, Philadelphia, PA 19104 USA	University of Pennsylvania; University of Pennsylvania; University of Pennsylvania	Ecker, JR (corresponding author), Univ Penn, Div Hematol Oncol, Inst Plant Sci, Dept Biol, Philadelphia, PA 19104 USA.		Ecker, Joseph R/B-9144-2008; Alonso, Jose M/K-6826-2014; Guzman, Plinio/A-3073-2012; Kieber, Joseph/GLN-6328-2022; HIRAYAMA, Takashi/B-2496-2011	Ecker, Joseph R/0000-0001-5799-5895; Alonso, Jose M/0000-0001-7087-1571; Kieber, Joseph/0000-0002-5766-812X; HIRAYAMA, Takashi/0000-0002-3868-2380				Abeles F, 1992, ETHYLENE PLANT BIOL; BAULCOMBE DC, 1986, NATURE, V321, P446, DOI 10.1038/321446a0; BECHTOLD N, 1993, CR ACAD SCI III-VIE, V316, P1194; BEYER EM, 1976, PLANT PHYSIOL, V58, P268, DOI 10.1104/pp.58.3.268; BLEECKER AB, 1988, SCIENCE, V241, P1086, DOI 10.1126/science.241.4869.1086; BULL PC, 1993, NAT GENET, V5, P327, DOI 10.1038/ng1293-327; BURG SP, 1967, PLANT PHYSIOL, V42, P144, DOI 10.1104/pp.42.1.144; CHANG C, 1993, SCIENCE, V262, P539, DOI 10.1126/science.8211181; Chao QM, 1997, CELL, V89, P1133, DOI 10.1016/S0092-8674(00)80300-1; CHELLY J, 1993, NAT GENET, V5, P317, DOI 10.1038/ng1293-317; CHELLY J, 1993, NAT GENET, V3, P14, DOI 10.1038/ng0193-14; CHEN QHG, 1995, PLANT PHYSIOL, V108, P597, DOI 10.1104/pp.108.2.597; DANCIS A, 1994, J BIOL CHEM, V269, P25660; ECKER JR, 1995, SCIENCE, V268, P667, DOI 10.1126/science.7732375; FU DD, 1995, YEAST, V11, P283, DOI 10.1002/yea.320110310; Gamble RL, 1998, P NATL ACAD SCI USA, V95, P7825, DOI 10.1073/pnas.95.13.7825; Gitschier J, 1998, NAT STRUCT BIOL, V5, P47, DOI 10.1038/nsb0198-47; GUZMAN P, 1990, PLANT CELL, V2, P513, DOI 10.1105/tpc.2.6.513; Hua J, 1998, PLANT CELL, V10, P1321, DOI 10.1105/tpc.10.8.1321; Hua J, 1998, CELL, V94, P261, DOI 10.1016/S0092-8674(00)81425-7; HUA J, 1995, SCIENCE, V269, P1712, DOI 10.1126/science.7569898; Hung IH, 1997, J BIOL CHEM, V272, P21461, DOI 10.1074/jbc.272.34.21461; Iida M, 1998, FEBS LETT, V428, P281, DOI 10.1016/S0014-5793(98)00546-8; ITO H, 1983, J BACTERIOL, V153, P163, DOI 10.1128/JB.153.1.163-168.1983; ITZHAKI H, 1993, PLANT MOL BIOL, V22, P43, DOI 10.1007/BF00038994; Johnson PR, 1998, ANNU REV GENET, V32, P227, DOI 10.1146/annurev.genet.32.1.227; KIEBER JJ, 1993, CELL, V72, P427, DOI 10.1016/0092-8674(93)90119-B; MERCER JFB, 1993, NAT GENET, V3, P20, DOI 10.1038/ng0193-20; Payne AS, 1998, J BIOL CHEM, V273, P3765, DOI 10.1074/jbc.273.6.3765; Petris MJ, 1996, EMBO J, V15, P6084, DOI 10.1002/j.1460-2075.1996.tb00997.x; PETRUKHIN K, 1993, NAT GENET, V5, P338, DOI 10.1038/ng1293-338; Rodriguez FI, 1999, SCIENCE, V283, P996, DOI 10.1126/science.283.5404.996; ROMAN G, 1995, GENETICS, V139, P1393; Sakai H, 1998, P NATL ACAD SCI USA, V95, P5812, DOI 10.1073/pnas.95.10.5812; Sambongi Y, 1997, J BIOCHEM-TOKYO, V121, P1169, DOI 10.1093/oxfordjournals.jbchem.a021711; SCHALLER GE, 1995, SCIENCE, V270, P1809, DOI 10.1126/science.270.5243.1809; Sisler EC, 1996, PLANT GROWTH REGUL, V18, P79, DOI 10.1007/BF00028491; SISLER EC, 1990, PLANT HORMONE ETHYLE, P81; Solano R, 1998, GENE DEV, V12, P3703, DOI 10.1101/gad.12.23.3703; Stearman R, 1996, SCIENCE, V271, P1552, DOI 10.1126/science.271.5255.1552; THOMPSON JS, 1983, J AM CHEM SOC, V105, P3522, DOI 10.1021/ja00349a026; VAN DER STRAETEN D, 1993, PLANT PHYSIOL, V102, P401, DOI 10.1104/pp.102.2.401; VULPE C, 1993, NAT GENET, V3, P7, DOI 10.1038/ng0193-7; Yamaguchi Y, 1996, P NATL ACAD SCI USA, V93, P14030, DOI 10.1073/pnas.93.24.14030; Yuan DS, 1997, J BIOL CHEM, V272, P25787, DOI 10.1074/jbc.272.41.25787; YUAN DS, 1995, P NATL ACAD SCI USA, V92, P2632, DOI 10.1073/pnas.92.7.2632	46	286	315	1	37	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	APR 30	1999	97	3					383	393		10.1016/S0092-8674(00)80747-3	http://dx.doi.org/10.1016/S0092-8674(00)80747-3			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	192VP	10319818	hybrid			2022-12-28	WOS:000080100500011
J	Foyer, CH; Noctor, G				Foyer, CH; Noctor, G			Plant biology - Leaves in the dark see the light	SCIENCE			English	Editorial Material							REDOX		Inst Food Res, Inst Arable Crops Res, Dept Biochem & Physiol, Rothamsted, Harpenden AL5 2JQ, Herts, England	UK Research & Innovation (UKRI); Biotechnology and Biological Sciences Research Council (BBSRC); Quadram Institute; Rothamsted Research	Foyer, CH (corresponding author), Inst Food Res, Inst Arable Crops Res, Dept Biochem & Physiol, Rothamsted, Harpenden AL5 2JQ, Herts, England.	christine.foyer@bbsrc.ac.uk	Foyer, Christine/K-2143-2012	Foyer, Christine/0000-0001-5989-6989				Baker NR, 1994, PHOTOINHIBITION PHOT; FOYER C, 1990, PHOTOSYNTH RES, V25, P83, DOI 10.1007/BF00035457; FOYER OH, IN PRESS PHOTOCHEMIS; HALLIWELL B., 1984, CHLOROPLAST METABOLI; HORTON P, 1990, PLANT BIOL, V10, P145; Karpinski S, 1999, SCIENCE, V284, P654, DOI 10.1126/science.284.5414.654; KRAUSE GH, 1991, ANNU REV PLANT PHYS, V42, P313, DOI 10.1146/annurev.pp.42.060191.001525; Noctor G, 1998, ANNU REV PLANT PHYS, V49, P249, DOI 10.1146/annurev.arplant.49.1.249; Pfannschmidt T, 1999, NATURE, V397, P625, DOI 10.1038/17624; Van Camp W, 1998, TRENDS PLANT SCI, V3, P330, DOI 10.1016/S1360-1385(98)01297-7; Vener AV, 1998, CURR OPIN PLANT BIOL, V1, P217, DOI 10.1016/S1369-5266(98)80107-6	11	65	75	2	10	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	APR 23	1999	284	5414					599	601		10.1126/science.284.5414.599	http://dx.doi.org/10.1126/science.284.5414.599			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	190FH	10328743				2022-12-28	WOS:000079951100032
J	Tyers, M; Willems, AR				Tyers, M; Willems, AR			Biochemistry - One ring to rule a superfamily of E3 ubiquitin ligases	SCIENCE			English	Editorial Material							F-BOX; PROTEOLYSIS; COMPLEX; SCF		Mt Sinai Hosp, Samuel Lunenfeld Res Inst, Toronto, ON M5G 1X5, Canada; Univ Toronto, Grad Dept Mol & Med Genet, Toronto, ON M5S 1A8, Canada	University of Toronto; University Toronto Affiliates; Sinai Health System Toronto; Lunenfeld Tanenbaum Research Institute; University of Toronto	Tyers, M (corresponding author), Mt Sinai Hosp, Samuel Lunenfeld Res Inst, 600 Univ Ave, Toronto, ON M5G 1X5, Canada.		Tyers, Michael/ABE-3194-2021					Bai C, 1996, CELL, V86, P263, DOI 10.1016/S0092-8674(00)80098-7; Borden KLB, 1996, CURR OPIN STRUC BIOL, V6, P395, DOI 10.1016/S0959-440X(96)80060-1; Hershko A, 1998, ANNU REV BIOCHEM, V67, P425, DOI 10.1146/annurev.biochem.67.1.425; Hochstrasser M, 1998, GENE DEV, V12, P901, DOI 10.1101/gad.12.7.901; Kaelin WG, 1998, TRENDS GENET, V14, P423, DOI 10.1016/S0168-9525(98)01558-3; Kamura T, 1999, SCIENCE, V284, P657, DOI 10.1126/science.284.5414.657; Kamura T, 1998, GENE DEV, V12, P3872, DOI 10.1101/gad.12.24.3872; Maniatis T, 1999, GENE DEV, V13, P505, DOI 10.1101/gad.13.5.505; Patton EE, 1998, TRENDS GENET, V14, P236, DOI 10.1016/S0168-9525(98)01473-5; Peters JM, 1998, CURR OPIN CELL BIOL, V10, P759, DOI 10.1016/S0955-0674(98)80119-1; Skowyra D, 1997, CELL, V91, P209, DOI 10.1016/S0092-8674(00)80403-1; Skowyra D, 1999, SCIENCE, V284, P662, DOI 10.1126/science.284.5414.662; Starr R, 1999, BIOESSAYS, V21, P47, DOI 10.1002/(SICI)1521-1878(199901)21:1<47::AID-BIES6>3.0.CO;2-N; Stebbins CE, 1999, SCIENCE, V284, P455, DOI 10.1126/science.284.5413.455; Yu HT, 1998, SCIENCE, V279, P1219, DOI 10.1126/science.279.5354.1219; Zachariae W, 1998, SCIENCE, V279, P1216, DOI 10.1126/science.279.5354.1216	16	137	142	2	10	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	APR 23	1999	284	5414					601	+		10.1126/science.284.5414.601	http://dx.doi.org/10.1126/science.284.5414.601			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	190FH	10328744				2022-12-28	WOS:000079951100033
J	Howitt, A; Armstrong, D				Howitt, A; Armstrong, D			Implementing evidence based medicine in general practice: audit and qualitative study of antithrombotic treatment for atrial fibrillation	BMJ-BRITISH MEDICAL JOURNAL			English	Article							COMMUNITY	Objective To determine the extent to which implementation of an evidence based treatment, antithrombotic treatment in atrial fibrillation, is possible in general practice. Design Audit and qualitative study of patients with atrial fibrillation and an educational intervention for patients judged eligible for antithrombotic treatment Setting South east England. Subjects 56 patients with a history of atrial fibrillation. Interventions Assessment and interview to ascertain patients' views on antithrombotic treatment Main outcome measures Number of patients receiving antithrombotic treatment Results Out of 13 239 patients, 132 had a history of atrial fibrillation of which 100 were at risk of thromboembolism. After the study, 52 patients were taking warfarin. Of the remaining 48 patients (of whom 41 were taking aspirin), eight were too ill to participate, 16 were unable to consent, four refused the interview and 20 declined warfarin. Patients declining warfarin were inclined to seek a higher level of benefit than those taking it, as measured by the minimal clinically important difference. Qualitative data obtained during the interviews suggested that patients' health beliefs were important factors in determining their choice of treatment Conclusion Patients' unwillingness to take warfarin seemed to be a major factor in limiting the number who would eventually take it.	Warders Med Ctr, Tonbridge TN9 1LA, Kent, England; Guys Kings & St Thomas Sch Med, Dept Gen Practice, London SE11 6SP, England	University of London; King's College London	Howitt, A (corresponding author), Warders Med Ctr, Tonbridge TN9 1LA, Kent, England.	ajhowitt@warders.co.uk	Armstrong, David/AAI-4476-2021	Armstrong, David/0000-0003-3652-9662				ANDERSON DC, 1992, ANN INTERN MED, V116, P1, DOI 10.7326/0003-4819-116-1-1; LAUPACIS A, 1994, ARCH INTERN MED, V154, P1449; Lip GYH, 1997, BRIT J GEN PRACT, V47, P285; Lip GYH, 1996, BRIT MED J, V312, P45, DOI 10.1136/bmj.312.7022.45; ManSonHing M, 1996, ARCH INTERN MED, V156, P1841, DOI 10.1001/archinte.156.16.1841; OConnell JE, 1996, AGE AGEING, V25, P307, DOI 10.1093/ageing/25.4.307; Roderick E, 1997, BRIT J GEN PRACT, V47, P660; Sudlow M, 1998, LANCET, V352, P1167, DOI 10.1016/S0140-6736(98)01401-9; TAYLOR F, 1993, BRIT MED J, V307, P1493, DOI 10.1136/bmj.307.6917.1493; Thomson R, 1998, BRIT MED J, V316, P509, DOI 10.1136/bmj.316.7130.509; Wheeldon NM, 1998, HEART, V79, P50, DOI 10.1136/hrt.79.1.50	11	129	134	0	6	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	MAY 15	1999	318	7194					1324	1327		10.1136/bmj.318.7194.1324	http://dx.doi.org/10.1136/bmj.318.7194.1324			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	198HR	10323820	Green Submitted, Green Published, Bronze			2022-12-28	WOS:000080418400028
J	Nam, HJ; Poy, F; Krueger, NX; Saito, H; Frederick, CA				Nam, HJ; Poy, F; Krueger, NX; Saito, H; Frederick, CA			Crystal structure of the tandem phosphatase domains of RPTP LAR	CELL			English	Article							PROTEIN-TYROSINE-PHOSPHATASE; LEUKOCYTE COMMON ANTIGEN; CATALYTIC DOMAINS; MOLECULAR REPLACEMENT; ALPHA; EXPRESSION; MUTANTS; COMPLEX; ROLES; LCA	Most receptor-like protein tyrosine phosphatases (RPTPs) contain two conserved phosphatase domains (D1 and D2) in their intracellular region. The carboxyterminal D2 domain has little or no catalytic activity. The crystal structure of the tandem D1 and D2 domains of the human RPTP LAR revealed that the tertiary structures of the LAR D1 and D2 domains are very similar to each other, with the exception of conformational differences at two amino acid positions in the D2 domain. Site-directed mutational changes at these positions (Leu-1644-to-Tyr and Glu-1779-to-Asp) conferred a robust PTPase activity to the D2 domain. The catalytic sites of both domains are accessible, in contrast to the dimeric blocked orientation model previously suggested. The relative orientation of the LAR D1 and D2 domains, constrained by a short linker, is stabilized by extensive interdomain interactions, suggesting that this orientation might be favored in solution.	Harvard Univ, Sch Med, Dana Farber Canc Inst, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Biol Chem & Mol Pharmacol, Boston, MA 02115 USA	Harvard University; Dana-Farber Cancer Institute; Harvard Medical School; Harvard University; Harvard Medical School	Frederick, CA (corresponding author), Harvard Univ, Sch Med, Dana Farber Canc Inst, 44 Binney St, Boston, MA 02115 USA.	caf@red.dfci.harvard.edu	Saito, Haruo/AAF-6113-2019	Saito, Haruo/0000-0001-7891-1689	NIGMS NIH HHS [GM 53415] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; BARFORD D, 1994, SCIENCE, V263, P1397, DOI 10.1126/science.8128219; Bilwes AM, 1996, NATURE, V382, P555, DOI 10.1038/382555a0; BRUNGER AT, 1990, ACTA CRYSTALLOGR A, V46, P46, DOI 10.1107/S0108767389009633; Buist P, 1999, BIOCHEMISTRY-US, V38, P914, DOI 10.1021/bi981936b; CHARBONNEAU H, 1992, ANNU REV CELL BIOL, V8, P463, DOI 10.1146/annurev.cellbio.8.1.463; EVANS R, 1990, VIA, V11, P134; Flint AJ, 1997, P NATL ACAD SCI USA, V94, P1680, DOI 10.1073/pnas.94.5.1680; FURUKAWA T, 1994, P NATL ACAD SCI USA, V91, P10928, DOI 10.1073/pnas.91.23.10928; Hof P, 1998, CELL, V92, P441, DOI 10.1016/S0092-8674(00)80938-1; Hoffmann KMV, 1997, J BIOL CHEM, V272, P27505, DOI 10.1074/jbc.272.44.27505; ITOH M, 1992, J BIOL CHEM, V267, P12356; JIA ZC, 1995, SCIENCE, V268, P1754, DOI 10.1126/science.7540771; KRUEGER NX, 1990, EMBO J, V9, P3241, DOI 10.1002/j.1460-2075.1990.tb07523.x; LESLIE AG, 1988, DARESBURY LAB INFORM, P33; Lim KL, 1998, J BIOL CHEM, V273, P28986, DOI 10.1074/jbc.273.44.28986; Lohse DL, 1997, BIOCHEMISTRY-US, V36, P4568, DOI 10.1021/bi963094r; MAIGNAN S, 1995, SCIENCE, V268, P291, DOI 10.1126/science.7716522; Majeti R, 1998, SCIENCE, V279, P88, DOI 10.1126/science.279.5347.88; NAVAZA J, 1994, ACTA CRYSTALLOGR A, V50, P157, DOI 10.1107/S0108767393007597; O'Grady P, 1998, J CELL BIOL, V141, P1675, DOI 10.1083/jcb.141.7.1675; OSTMAN A, 1994, P NATL ACAD SCI USA, V91, P9680, DOI 10.1073/pnas.91.21.9680; PAWSON T, 1995, NATURE, V373, P573, DOI 10.1038/373573a0; Saito H, 1993, Semin Cell Biol, V4, P379, DOI 10.1006/scel.1993.1045; SEIMIYA H, 1995, ONCOGENE, V10, P1731; STREULI M, 1988, J EXP MED, V168, P1523, DOI 10.1084/jem.168.5.1523; STREULI M, 1990, EMBO J, V9, P2399, DOI 10.1002/j.1460-2075.1990.tb07415.x; STUCKEY JA, 1994, NATURE, V370, P571, DOI 10.1038/370571a0; TSAI AYM, 1991, J BIOL CHEM, V266, P10534; Wallace MJ, 1998, MOL CELL BIOL, V18, P2608, DOI 10.1128/MCB.18.5.2608; WANG Y, 1991, EMBO J, V10, P3231, DOI 10.1002/j.1460-2075.1991.tb04886.x; Wu L, 1997, J BIOL CHEM, V272, P6994, DOI 10.1074/jbc.272.11.6994; ZHANG ZY, 1994, P NATL ACAD SCI USA, V91, P1624, DOI 10.1073/pnas.91.5.1624	33	146	151	0	3	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	MAY 14	1999	97	4					449	457		10.1016/S0092-8674(00)80755-2	http://dx.doi.org/10.1016/S0092-8674(00)80755-2			9	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	196FV	10338209	Bronze			2022-12-28	WOS:000080299100006
J	Smith, JK; Dykes, R; Douglas, JE; Krishnaswamy, G; Berk, S				Smith, JK; Dykes, R; Douglas, JE; Krishnaswamy, G; Berk, S			Long-term exercise and atherogenic activity of blood mononuclear cells in persons at risk of developing ischemic heart disease	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							ALL-CAUSE MORTALITY; PHYSICAL-ACTIVITY; CARDIOVASCULAR-DISEASE; ENDOTHELIAL-CELLS; CORONARY-ARTERIES; INTERFERON-GAMMA; HEALTHY-MEN; ATHEROSCLEROSIS; IL-10; EXPRESSION	Context Increasing evidence demonstrates that atherosclerosis is an immunologically mediated disease in which the secretion of atherogenic and atheroprotective cytokines, by infiltrating blood mononuclear cells, plays an important role. It is not known whether long-term exercise alters this atherogenic and atheroprotedive activity directly. Objective To determine the effect of long-term exercise on the atherogenic activity of blood mononuclear cells in persons at risk of developing ischemic heart disease. Design Before-after trial using a 6-month individualized, supervised exercise program, with an enrollment period from December 1996 to October 1997. Setting Hospital-based community wellness center. Participants Of 110 persons who responded to a public request for volunteers, 52 met the inclusion criteria (risk ratio for myocardial infarction greater than or equal to 1.7 based on serum complement and/or C-reactive protein levels, and normal exercise treadmill test results). Forty-three of the 52 enrollees (25 women [mean age, 49.7 years] and 18 men [mean age, 48.1 years]) completed the study; 9 withdrew for personal reasons. Additional risk factors for ischemic heart disease included hypercholesterolemia (65.1%), a family history of coronary heart disease (62.8%), inactivity (60.5%), hypertension (32.6%), obesity (25.6%), smoking (11.6%), and diabetes mellitus (4.7%). Main Outcome Measures Blood levels were compared at baseline and after the exercise program had been completed for the following: spontaneous and phytohemagglutinin-induced production of interleukin 1 alpha, tumor necrosis factor alpha, and interferon gamma (atherogenic cytokines), and interleukin 4, interleukin 10, and transforming growth factor beta 1 (atheroprotective cytokines) by blood mononuclear cells; lymphocyte phenotypes and mitogenic responses to phytohemagglutinin; and serum C-reactive protein levels. Results Subjects exercised for a mean of 2.5 (range, 0.3-7.4) hours per week. Mononuclear cell production of atherogenic cytokines fell by 58.3% (P < .001) following the exercise program, whereas the production of atheroprotective cytokines rose by 35.9% (P < .001). Changes in transforming growth factor beta 1 and in phytohemagglutinin-induced atherogenic cytokine production after the exercise program were proportionate to the time subjects spent performing repetitive lower-body motion exercises (P < .02), indicating a dose-response relationship. After the exercise program, changes in cellular function were reflected systemically by a 35% decrease in serum levels of C-reactive protein (P = .12). Conclusions Our data suggest that long-term exercise decreases the atherogenic activity of blood mononuclear cells in persons at risk of developing ischemic heart disease. This may be a mechanism whereby physical activity protects against ischemic heart disease.	E Tennessee State Univ, James H Quillen Coll Med, Dept Internal Med, Div Immunol, Johnson City, TN 37614 USA; E Tennessee State Univ, James H Quillen Coll Med, Dept Internal Med, Div Cardiol, Johnson City, TN 37614 USA	East Tennessee State University; East Tennessee State University	Smith, JK (corresponding author), E Tennessee State Univ, James H Quillen Coll Med, Dept Internal Med, Div Immunol, Johnson City, TN 37614 USA.	smithj@access.etsu.edu	Krishnaswamy, Guha/R-9076-2019; KRISHNASWAMY, GUHA/AAR-8844-2021	KRISHNASWAMY, GUHA/0000-0002-9848-6197				ADAM E, 1987, LANCET, V2, P291; AnglesCano E, 1997, BRAZ J MED BIOL RES, V30, P1271, DOI 10.1590/S0100-879X1997001100002; [Anonymous], 1996, JAMA, V276, P241; BLAIR SN, 1995, JAMA-J AM MED ASSOC, V273, P1093, DOI 10.1001/jama.273.14.1093; Blair SN, 1996, JAMA-J AM MED ASSOC, V276, P205, DOI 10.1001/jama.276.3.205; BLAIR SN, 1993, ANN INTERN MED, V119, P702, DOI 10.7326/0003-4819-119-7_Part_2-199310011-00015; BLAIR SN, 1989, JAMA-J AM MED ASSOC, V262, P2395, DOI 10.1001/jama.262.17.2395; BOGDAN C, 1991, J EXP MED, V174, P1549, DOI 10.1084/jem.174.6.1549; Borish L, 1996, J ALLERGY CLIN IMMUN, V97, P719, DOI 10.1016/S0091-6749(96)80146-1; Campbell JH, 1997, AUST NZ J MED, V27, P497, DOI 10.1111/j.1445-5994.1997.tb02225.x; Centre for Disease Control Prevention, 1997, MMWR-MORBID MORTAL W, V46, P941; DANDREA A, 1993, J EXP MED, V178, P1041, DOI 10.1084/jem.178.3.1041; Danesh J, 1998, JAMA-J AM MED ASSOC, V279, P1477, DOI 10.1001/jama.279.18.1477; Di Febbo C, 1998, ATHEROSCLEROSIS, V136, P377, DOI 10.1016/S0021-9150(97)00240-2; ELLIOTT MJ, 1991, BLOOD, V77, P2739; FARRAR MA, 1993, ANNU REV IMMUNOL, V11, P571, DOI 10.1146/annurev.iy.11.040193.003035; FENTON MJ, 1992, J IMMUNOL, V149, P1283; FIORENTINO DF, 1991, J IMMUNOL, V147, P3815; Grainger DJ, 1997, J LIPID RES, V38, P2344; GRAZINELLI TT, 1992, J IMMUNOL, V148, P1792; Gupta S, 1997, J CLIN INVEST, V99, P2752, DOI 10.1172/JCI119465; Hakim AA, 1998, NEW ENGL J MED, V338, P94, DOI 10.1056/NEJM199801083380204; HOLLOSZY JO, 1993, MED SCI SPORT EXER, V25, P1; KRAKAUER T, 1995, IMMUNOL LETT, V45, P61, DOI 10.1016/0165-2478(94)00226-H; Kujala UM, 1998, JAMA-J AM MED ASSOC, V279, P440, DOI 10.1001/jama.279.6.440; KUO CC, 1995, P NATL ACAD SCI USA, V92, P6911, DOI 10.1073/pnas.92.15.6911; Kushi LH, 1997, JAMA-J AM MED ASSOC, V277, P1287, DOI 10.1001/jama.277.16.1287; Labarrere CA, 1997, JAMA-J AM MED ASSOC, V278, P1169, DOI 10.1001/jama.278.14.1169; LEE IM, 1995, JAMA-J AM MED ASSOC, V273, P1179, DOI 10.1001/jama.273.15.1179; LIBBY P, 1991, LAB INVEST, V64, P5; Maluish A, 1986, MANUAL CLIN LAB IMMU, P274; Mayer-Davis EJ, 1998, JAMA-J AM MED ASSOC, V279, P669, DOI 10.1001/jama.279.9.669; MUNRO JM, 1988, LAB INVEST, V58, P249; MUSCARI A, 1995, AM J MED, V98, P357, DOI 10.1016/S0002-9343(99)80314-3; PAFFENBARGER RS, 1978, AM J EPIDEMIOL, V108, P161, DOI 10.1093/oxfordjournals.aje.a112608; Reckless J, 1997, CIRCULATION, V95, P1542; Ridker PM, 1997, NEW ENGL J MED, V336, P973, DOI 10.1056/NEJM199704033361401; ROSS R, 1993, NATURE, V362, P801, DOI 10.1038/362801a0; Selwyn AP, 1997, AM J CARDIOL, V80, pH3, DOI 10.1016/S0002-9149(97)00813-8; Stefanovic-Racic M., 1994, P417; Takami S, 1998, CIRCULATION, V97, P721, DOI 10.1161/01.CIR.97.8.721; Tashiro H, 1997, CORONARY ARTERY DIS, V8, P143, DOI 10.1097/00019501-199703000-00004; Uyemura K, 1996, J CLIN INVEST, V97, P2130, DOI 10.1172/JCI118650; Vadas MA, 1997, CLIN EXP PHARMACOL P, V24, pA33, DOI 10.1111/j.1440-1681.1997.tb03052.x; VANDERWAL AC, 1989, LAB INVEST, V61, P166; Vasse M, 1996, BRIT J HAEMATOL, V93, P955, DOI 10.1046/j.1365-2141.1996.d01-1731.x; Velde AA, 1990, BLOOD, V76, P1392; Watanabe T, 1996, INT J CARDIOL, V54, pS51, DOI 10.1016/S0167-5273(96)88773-0; WICK G, 1995, IMMUNOL TODAY, V16, P27, DOI 10.1016/0167-5699(95)80067-0; Wick G, 1997, FASEB J, V11, P1199, DOI 10.1096/fasebj.11.13.9367355; Witztum JL, 1997, ATHEROSCLEROSIS, V131, pS9, DOI 10.1016/S0021-9150(97)06116-9; YAMASHIROYA HM, 1988, AM J PATHOL, V130, P71; Yokota T, 1995, J INTERN MED, V238, P479, DOI 10.1111/j.1365-2796.1995.tb01229.x	53	305	319	0	9	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAY 12	1999	281	18					1722	1727		10.1001/jama.281.18.1722	http://dx.doi.org/10.1001/jama.281.18.1722			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	193WR	10328073	Bronze			2022-12-28	WOS:000080161200030
J	Shaw, J; Appleby, L; Amos, T; McDonnell, R; Harris, C; McCann, K; Kiernan, K; Davies, S; Bickley, H; Parsons, R				Shaw, J; Appleby, L; Amos, T; McDonnell, R; Harris, C; McCann, K; Kiernan, K; Davies, S; Bickley, H; Parsons, R			Mental disorder and clinical care in people convicted of homicide: national clinical survey	BRITISH MEDICAL JOURNAL			English	Article								Objectives To estimate the rate of mental disorder in those convicted of homicide and to examine the social and clinical characteristics of those with a history bf contact with psychiatric services. Design National clinical survey. Setting England and Wales. Subjects Eighteen month sample of people convicted of homicide. Main outcome measures Offence related and clinical information collected from psychiatric court reports on people convicted of homicide. Detailed clinical data collected on those with a history of contact with psychiatric services. Results 718 homicides were reported to the inquiry between April 1996 and November 1997. Of die 500 cases for whom psychiatric reports were retrieved, 220 (44%; 95% confidence interval 40% to 48%) had a lifetime history of mental disorder, while 71 (14%; 11% to 17%) had symptoms of mental illness at the time of the homicide. Of the total sample, 102 (14%; 12% to 17%)were confirmed to have been in contact with mental health services at some time, 58 (8%; 6% to 10%) in the year before the homicide. The commonest diagnosis was personality disorder (20 cases, 22%; 13% to 30%). Alcohol and drug misuse were also common. Only 15 subjects (18%; 10% to 26%) were receiving intensive community care, and 60 (63%; 53% to 73%) were out of contact at the time of the homicide. Conclusions There are substantial rates of mental disorder in people convicted of homicide. Most do not have severe mental illness or a history of contact with mental health services. Inquiry findings suggest that preventing loss of contact with services and improving the clinical management of patients with both mental illness and substance misuse may reduce risk, but clinical trials are needed to examine the effectiveness of such interventions.	Univ Manchester, Withington Hosp, Sch Psychiat & Behav Sci, Manchester M20 8LR, Lancs, England	University of Manchester	Appleby, L (corresponding author), Univ Manchester, Withington Hosp, Sch Psychiat & Behav Sci, Manchester M20 8LR, Lancs, England.			Bickley, Harriet/0000-0002-3756-7137				Appleby L, 1999, BRIT MED J, V318, P1235; Appleby L., 1999, SAFER SERVICES REPOR; BURNS BJ, 1995, PSYCHIAT SERV, V46, P669; COID J, 1983, PSYCHOL MED, V13, P855, DOI 10.1017/S0033291700051576; COPE R, 1993, J FORENSIC PSYCHIATR, V4, P215; DAVIES N, 1998, GUARDIAN         JUL, V14, P2; *DEP HLTH, 1994, HSG955 DOH; *DEP HLTH, 1990, HC9023LASSL901 DOH; Department of Health, 1994, GUID DISCH MENT DIS; Eastman N, 1999, BRIT MED J, V318, P206; Fallon P., 1999, REPORT COMMITTEE INQ; GILLA A, 1998, GUARDIAN         OCT, V24, P1; HINSLIFF G, 1998, DAILY MAIL, V27; KENDELL R, 1998, TIMES           1029, P25; Meltzer H., 1995, 1 OPCS; Peay J, 1997, INT REV PSYCHIATR, V9, P171, DOI 10.1080/09540269775367; Peay J, 1996, INQUIRIES HOMICIDE; PETURSSON H, 1981, ACTA PSYCHIAT SCAND, V64, P363, DOI 10.1111/j.1600-0447.1981.tb00795.x; Stafford D.M., 1995, WHAKAREWAREWA BRIEF; STRAW J, 1998, TIMES           1031, P27; Taylor PJ, 1999, BRIT J PSYCHIAT, V174, P9, DOI 10.1192/bjp.174.1.9; Weaver T, 1999, BMJ-BRIT MED J, V318, P137, DOI 10.1136/bmj.318.7177.137	22	66	67	0	5	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	MAY 8	1999	318	7193					1240	+						5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	195XT	10231252	Bronze, Green Published, Green Submitted			2022-12-28	WOS:000080278000023
J	Alm, JS; Swartz, J; Lilja, G; Scheynius, A; Pershagen, G				Alm, JS; Swartz, J; Lilja, G; Scheynius, A; Pershagen, G			Atopy in children of families with an anthroposophic lifestyle	LANCET			English	Article							BCG VACCINATION; ALLERGY; VIRUS; PREVALENCE; ANTIBODIES; RESPONSES; INFECTION; MEASLES; ASTHMA	Background Increased prevalence of atopic disorders in children may be associated with changes in types of childhood infections, vaccination programmes, and intestinal microflora. People who follow an anthroposophic way of life use antibiotics restrictively, have few vaccinations, and their diet usually contains live lactobacilli, which may affect the intestinal microflora. We aimed to study the prevalence of atopy in children from anthroposophic families and the influence of an anthroposophic lifestyle on atopy prevalence. have few live Methods In a cross-sectional study, 295 children aged 5-13 years at two anthroposophic (Steiner) schools near Stockholm, Sweden, were compared with 380 children of the same age at two neighbouring schools in terms of history;of atopic and infectious diseases, use of antibiotics and vaccinations, and social and environmental variables. Skin-prick tests were done for 13 common allergens, and we took blood samples from children and their parents for analysis of allergen-specific serum IgE-antibodies. Findings At the Steiner schools, 52% of the children had had antibiotics in the past, compared with 90% in the control schools. 18% and 93% of children, respectively, had had combined immunisation against measles, mumps, and rubella, and 61% of the children at the Steiner schools had had measles. Fermented vegetables, containing live lactobacilli, were consumed by 63% of the children at Steiner schools, compared with 4.5% at the control schools. Skin-prick tests and blood tests showed that-the children from Steiner schools had lower prevalence of atopy than controls (odds ratio 0.62 [95% CI 0.43-0.91]). There was an inverse relation between the number of characteristic features of an anthroposophic lifestyle and risk of atopy (p for trend=0.01). Interpretation Prevalence of atopy is lower in children from anthroposophic families than in children from other families. Lifestyle factors associated with anthroposophy may lessen the risk of atopy in childhood.	Karolinska Inst, Sachs Childrens Hosp, S-11895 Stockholm, Sweden; Karolinska Hosp & Inst, Dept Lab Med, Div Clin Immunol, Stockholm, Sweden; Karolinska Inst, Inst Environm Med, Div Environm Epidemiol, S-10401 Stockholm, Sweden; Vidar Clin, Jarna, Sweden	Karolinska Institutet; Karolinska Institutet; Karolinska University Hospital; Karolinska Institutet	Alm, JS (corresponding author), Karolinska Inst, Sachs Childrens Hosp, Box 179 12, S-11895 Stockholm, Sweden.	Johan.Alm@sos.ki.se		Pershagen, Goran/0000-0002-9701-1130; Alm, Johan/0000-0002-9062-4479				ABERG N, 1995, CLIN EXP ALLERGY, V25, P815, DOI 10.1111/j.1365-2222.1995.tb00023.x; Alm JS, 1997, LANCET, V350, P400, DOI 10.1016/S0140-6736(97)02207-1; Beasley R, 1998, LANCET, V351, P1225, DOI 10.1016/S0140-6736(97)07302-9; BRABACK L, 1994, CLIN EXP ALLERGY, V24, P826, DOI 10.1111/j.1365-2222.1994.tb01805.x; BURR M L, 1989, Archives of Disease in Childhood, V64, P1452, DOI 10.1136/adc.64.10.1452; CHILDS G., 1995, R STEINER HIS LIFE W; GOEBEL W, 1990, GUIDE CHILD HLTH; HANIFIN JM, 1980, ACTA DERM-VENEREOL S, V92, P44, DOI [10.2340/00015555924447, DOI 10.2340/00015555924447]; HATTEVIG G, 1993, PEDIAT ALLERGY IMMUN, V4, P181; JOHANSSON ML, 1993, APPL ENVIRON MICROB, V59, P15, DOI 10.1128/AEM.59.1.15-20.1993; JORMALAINEN V, 1997, SMITTSKYDD, V6, P61; KONDO N, 1993, CLIN EXP ALLERGY, V23, P44, DOI 10.1111/j.1365-2222.1993.tb02483.x; LARSEN FS, 1993, J AM ACAD DERMATOL, V28, P719, DOI 10.1016/0190-9622(93)70099-F; LINDFORS A, 1995, ARCH DIS CHILD, V73, P408, DOI 10.1136/adc.73.5.408; Majamaa H, 1997, J ALLERGY CLIN IMMUN, V99, P179, DOI 10.1016/S0091-6749(97)70093-9; Matricardi PM, 1997, BRIT MED J, V314, P999, DOI 10.1136/bmj.314.7086.999; Murosaki S, 1998, J ALLERGY CLIN IMMUN, V102, P57, DOI 10.1016/S0091-6749(98)70055-7; Pepys J., 1975, , Clinical aspects of immunology., P877; Pershagen G, 1997, ALLERGY, V52, P1045, DOI 10.1111/j.1398-9995.1997.tb00174.x; Rogers WH, 1993, STATA TECHN B, V13, P19; Schilthuis Willy, 1994, BIODYNAMIC AGR; SCHONECK A, 1998, CULTURED CABBAGE; Sepp E, 1997, ACTA PAEDIATR, V86, P956, DOI 10.1111/j.1651-2227.1997.tb15178.x; Shaheen SO, 1996, LANCET, V347, P1792, DOI 10.1016/S0140-6736(96)91617-7; Shida K, 1998, INT ARCH ALLERGY IMM, V115, P278, DOI 10.1159/000069458; Shirakawa T, 1997, SCIENCE, V275, P77, DOI 10.1126/science.275.5296.77; SIGURS N, 1995, PEDIATRICS, V95, P500; STADLER JF, 1993, DERMATOLOGY, V186, P23; Strannegard IL, 1998, ALLERGY, V53, P249, DOI 10.1111/j.1398-9995.1998.tb03884.x; Vandenplas Y, 1997, ACTA PAEDIATR, V86, P1283, DOI 10.1111/j.1651-2227.1997.tb14898.x	30	385	390	0	32	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	MAY 1	1999	353	9163					1485	1488		10.1016/S0140-6736(98)09344-1	http://dx.doi.org/10.1016/S0140-6736(98)09344-1			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	195XV	10232315	Green Submitted			2022-12-28	WOS:000080278200012
J	Marubio, LM; Arroyo-Jimenez, MD; Cordero-Erausquin, M; Lena, C; Le Novere, N; d'Exaerde, AD; Huchet, M; Damaj, MI; Changeux, JP				Marubio, LM; Arroyo-Jimenez, MD; Cordero-Erausquin, M; Lena, C; Le Novere, N; d'Exaerde, AD; Huchet, M; Damaj, MI; Changeux, JP			Reduced antinociception in mice lacking neuronal nicotinic receptor subunits	NATURE			English	Article							NUCLEUS RAPHE MAGNUS; CENTRAL NERVOUS-SYSTEM; ACETYLCHOLINE-RECEPTORS; ANALGESIC ACTIVITY; RAT-BRAIN; MODULATION; THALAMUS; GENE; PAIN	Nicotine exerts antinociceptive effects by interacting with one or more of the subtypes of nicotinic acetylcholine receptors (nAChRs) that are present throughout the neuronal pathways that respond to pain(1-5). To identify the particular subunits involved in this process, we generated mice lacking the alpha 4 subunit of the neuronal nAChR by homologous recombination techniques and studied these together with previously generated mutant mice lacking the beta 2 nAChR subunit(6). Here we show that the homozygous alpha 4(-/-) mice no longer express high-affinity [H-3]nicotine and [H-3]epibatidine binding sites throughout the brain. In addition, both types of mutant mice display a reduced antinociceptive effect of nicotine on the hot-plate test and diminished sensitivity to nicotine in the tail-flick test. Patch-clamp recordings further reveal that raphe magnus and thalamic neurons no longer respond to nicotine. The alpha 4 nAChR subunit, possibly associated with the beta 2 nAChR subunit, is therefore crucial for nicotine-elicited antinociception.	Inst Pasteur, CNRS, UA D1284, F-75724 Paris 15, France; Virginia Commonwealth Univ, Med Coll Virginia, Dept Pharmacol, Richmond, VA 23298 USA	Centre National de la Recherche Scientifique (CNRS); Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; Virginia Commonwealth University	Changeux, JP (corresponding author), Inst Pasteur, CNRS, UA D1284, 28 Rue Dr Roux, F-75724 Paris 15, France.		de Kerchove d'Exaerde, Alban/R-6984-2019; Beldar, Sagar V/C-8542-2011; Le Novère, Nicolas/F-9973-2010; , clement/ADN-8076-2022; Léna, Clément/T-8458-2018; Léna, Clément/P-6929-2019; Léna, Clément/ABE-4862-2021; Arroyo-Jimenez, Maria del Mar/R-6124-2017	Le Novère, Nicolas/0000-0002-6309-7327; Léna, Clément/0000-0002-1431-7717; Léna, Clément/0000-0002-1431-7717; Léna, Clément/0000-0002-1431-7717; Arroyo-Jimenez, Maria del Mar/0000-0002-8390-5352; de Kerchove d'Exaerde, Alban/0000-0002-0682-5877				ASGHAR K, 1971, BIOCHEM PHARMACOL, V20, P2787, DOI 10.1016/0006-2952(71)90189-4; Bannon AW, 1998, SCIENCE, V279, P77, DOI 10.1126/science.279.5347.77; Bitner RS, 1998, J NEUROSCI, V18, P5426, DOI 10.1523/JNEUROSCI.18-14-05426.1998; CAGGIULA AR, 1995, PSYCHOPHARMACOLOGY, V122, P301, DOI 10.1007/BF02246552; CLARKE PBS, 1985, J NEUROSCI, V5, P1307; D'amour FE, 1941, J PHARMACOL EXP THER, V72, P74; Damaj MI, 1997, J PHARMACOL EXP THER, V282, P410; Flores CM, 1996, J NEUROSCI, V16, P7892; Franklin K. B. J., 2008, PAXINOS FRANKLINS MO; IWAMOTO ET, 1991, J PHARMACOL EXP THER, V257, P120; JURNA I, 1993, CLIN INVESTIGATOR, V72, P65; Lena C, 1997, J NEUROSCI, V17, P576; LeNovere N, 1996, EUR J NEUROSCI, V8, P2428; LENOVERE N, 1995, J MOL EVOL, V40, P155, DOI 10.1007/BF00167110; PAN ZZ, 1993, NEUROSCIENCE, V54, P421, DOI 10.1016/0306-4522(93)90263-F; Picciotto MR, 1998, NATURE, V391, P173, DOI 10.1038/34413; PICCIOTTO MR, 1995, NATURE, V374, P65, DOI 10.1038/374065a0; RamirezLatorre J, 1996, NATURE, V380, P347, DOI 10.1038/380347a0; Rao TS, 1996, NEUROPHARMACOLOGY, V35, P393, DOI 10.1016/0028-3908(96)00013-5; SAHLEY TL, 1979, PSYCHOPHARMACOLOGY, V65, P279, DOI 10.1007/BF00492216; SPANDE TF, 1992, J AM CHEM SOC, V114, P3475, DOI 10.1021/ja00035a048; TALLARIDA RJ, 1987, MANUAL PHARM CALCULA; TRIPATHI HL, 1982, J PHARMACOL EXP THER, V221, P91; WADA E, 1989, J COMP NEUROL, V284, P314, DOI 10.1002/cne.902840212; YAGI T, 1993, ANAL BIOCHEM, V214, P77, DOI 10.1006/abio.1993.1459; ZIMMERMANN M, 1983, PAIN, V16, P109, DOI 10.1016/0304-3959(83)90201-4; Zoli M, 1998, J NEUROSCI, V18, P4461	27	473	492	0	21	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	APR 29	1999	398	6730					805	810		10.1038/19756	http://dx.doi.org/10.1038/19756			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	192BL	10235262				2022-12-28	WOS:000080058100058
J	Tappero, JW; Lagos, R; Ballesteros, AM; Plikaytis, B; Williams, D; Dykes, J; Gheesling, LL; Carlone, GM; Hoiby, EA; Holst, J; Nokleby, H; Rosenqvist, E; Sierra, G; Campa, C; Sotolongo, F; Vega, J; Garcia, J; Herrera, P; Poolman, JT; Perkins, BA				Tappero, JW; Lagos, R; Ballesteros, AM; Plikaytis, B; Williams, D; Dykes, J; Gheesling, LL; Carlone, GM; Hoiby, EA; Holst, J; Nokleby, H; Rosenqvist, E; Sierra, G; Campa, C; Sotolongo, F; Vega, J; Garcia, J; Herrera, P; Poolman, JT; Perkins, BA			Immunogenicity of 2 serogroup B outer-membrane protein meningococcal vaccines - A randomized controlled trial in Chile	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							NEISSERIA-MENINGITIDIS; VESICLE VACCINE; IMMUNE-RESPONSE; BACTERICIDAL ANTIBODIES; SAO-PAULO; DISEASE; EFFICACY; EPIDEMIC; PORA; POLYSACCHARIDE	Context Meningococcal disease occurs worldwide, and serogroup B disease accounts for a large proportion of cases. Although persons younger than 4 years are at greatest risk for serogroup B meningococcal disease, vaccine efficacy has not been demonstrated in this age group. Objective To evaluate serum bactericidal activity (SBA) against homologous vaccine type strains and a heterologous Chilean epidemic strain of Neisseria meningitidis as a potential correlate for vaccine efficacy. Design Double-blind, randomized controlled trial conducted between March 14 and July 20, 1994, All blood samples were taken by December 1994. Setting Santiago, Chile, where a clonal serogroup B meningococcal disease epidemic began in 1993. Participants Infants younger than 1 year (n = 187), children aged 2 to 4 years (n = 183), and adults aged 17 to 30 years (n = 173). Intervention Participants received 3 doses of outer-membrane protein (OMP) meningococcal vaccine developed in either Cuba or Norway or a control vaccine, with each dose given 2 months apart. Blood samples were obtained at baseline, prior to dose 3, and at 4 to 6 weeks after dose 3, Main Outcome Measure Immune response, defined as a 4-fold or greater rise in SEA titer 4 to 6 weeks after dose 3 compared with prevaccination titer. Results Children and adult recipients of either meningococcal vaccine were more likely than controls to develop an immune response to the heterologous epidemic strain. After 3 doses of vaccine, 31% to 35% of children responded to the vaccine vs 5% to placebo; 37% to 60% of adults responded to vaccine vs 4% to placebo (P<.05 vs control for all). Infants, however, did not respond. In contrast, against homologous vaccine type strains, the response rate was 67% or higher among children and adults and 90% or higher among infants (P<.001 vs control for all). Subsequent SBA against 7 isogenic homologous target strains identified class 1 OMP as the immunodominant antigen. Conclusions These data suggest that neither serogroup B OMP meningococcal vaccine would confer protection during a heterologous epidemic. However, epidemic strain-specific vaccines homologous for class 1 OMP are promising candidates for the control of epidemic serogroup B meningococcal disease.	Ctr Dis Control & Prevent, Meningitis & Special Pathogens Branch, Atlanta, GA 30333 USA; Hosp Roberto del Rio, Santiago, Chile; Ctr Vacunas Desarrollo, Santiago, Chile; Inst Salud Publ, Santiago, Chile; Univ Chile, Santiago, Chile; Natl Inst Publ Hlth, Oslo, Norway; Finlay Inst, Havana, Cuba; Natl Inst Publ Hlth & Environm Protect, Lab Vaccine Dev & Immune Mech, NL-3720 BA Bilthoven, Netherlands	Centers for Disease Control & Prevention - USA; Universidad de Chile; Universidad de Chile; Netherlands National Institute for Public Health & the Environment	Tappero, JW (corresponding author), Ctr Dis Control & Prevent, Meningitis & Special Pathogens Branch, Mail Stop C-09,1600 Clifton Rd NE, Atlanta, GA 30333 USA.		CAMPA, Claudine/C-9241-2015					AASE A, 1995, INFECT IMMUN, V63, P3531, DOI 10.1128/IAI.63.9.3531-3536.1995; [Anonymous], 1990, SAS STAT US GUID VER; BJUNE G, 1991, LANCET, V338, P1093, DOI 10.1016/0140-6736(91)91961-S; BORROW R, 1998, 11 INT PATH NEISS C, P178; BOSLEGO J, 1995, VACCINE, V13, P821, DOI 10.1016/0264-410X(94)00037-N; BROOKS JL, 1995, FEMS MICROBIOL LETT, V128, P145, DOI 10.1016/0378-1097(95)00098-P; CARTWRIGHT K, IN PRESS VACCINE; CAUGANT DA, 1986, P NATL ACAD SCI USA, V83, P4927, DOI 10.1073/pnas.83.13.4927; *CDCP, 1993, MMWR-MORBID MORTAL W, V42, P21; *CDCP, 1998, MMWR-MORBID MORTAL W, V47, P833; Centers for Disease Control and Prevention, 1997, MMWR-MORBID MORTAL W, V46, P1; Centers for Disease Control and Prevention (CDC), 1995, MMWR Morb Mortal Wkly Rep, V44, P121; CRUZ C, 1990, EPIDEMIOL INFECT, V105, P119, DOI 10.1017/S0950268800047713; Dean A.G., 1994, EPI INFO VERSION 6 W; DEMORAES JC, 1992, LANCET, V340, P1074; ESTABROOK MM, 1993, J INFECT DIS, V167, P966, DOI 10.1093/infdis/167.4.966; FINNE J, 1983, LANCET, V2, P355; Fischer M, 1997, SEMIN PEDIAT INFECT, V8, P50; FRASCH CE, 1985, REV INFECT DIS, V7, P504; Frasch CE, 1995, MENINGOCOCCAL DIS, P245; FREDRIKSEN J H, 1991, NIPH (National Institute of Public Health) Annals (Oslo), V14, P67; GOLDSCHNEIDER I, 1969, J EXP MED, V129, P1307, DOI 10.1084/jem.129.6.1307; GOLDSCHNEIDER I, 1969, J EXP MED, V129, P1327, DOI 10.1084/jem.129.6.1327; GOTSCHLICH EC, 1969, J EXP MED, V129, P1367, DOI 10.1084/jem.129.6.1367; HITCHCOCK PJ, 1989, CLIN MICROBIOL REV, V2, pS64, DOI 10.1128/CMR.2.Suppl.S64-S65.1989; HOIBY E A, 1991, NIPH (National Institute of Public Health) Annals (Oslo), V14, P147; IDANPAANHEIKKILA I, 1995, J MED MICROBIOL, V43, P335, DOI 10.1099/00222615-43-5-335; Jones GR, 1998, J INFECT DIS, V178, P451, DOI 10.1086/515622; Kaczmarski E B, 1997, Commun Dis Rep CDR Rev, V7, pR55; MANDRELL RE, 1982, J IMMUNOL, V129, P2172; Martin DR, 1998, J INFECT DIS, V177, P497, DOI 10.1086/517385; MCGUINNESS BT, 1991, LANCET, V337, P514, DOI 10.1016/0140-6736(91)91297-8; MCGUINNESS BT, 1993, MOL MICROBIOL, V7, P505, DOI 10.1111/j.1365-2958.1993.tb01141.x; MILAGRES LG, 1994, INFECT IMMUN, V62, P4419, DOI 10.1128/IAI.62.10.4419-4424.1994; MURRAY JCL, 1996, GLOBAL BURDEN DIS IN, V2, P292; Peeters CCAM, 1996, VACCINE, V14, P1009, DOI 10.1016/0264-410X(96)00001-1; Perkins BA, 1998, J INFECT DIS, V177, P683, DOI 10.1086/514232; REEVES MW, 1995, EMERG INFECT DIS, V1, P53, DOI 10.3201/eid0102.950203; REINGOLD AL, 1985, LANCET, V2, P114; ROMERO JD, 1994, CLIN MICROBIOL REV, V7, P559, DOI 10.1128/CMR.7.4.559-575.1994; ROSENQVIST E, 1995, INFECT IMMUN, V63, P4642, DOI 10.1128/IAI.63.12.4642-4652.1995; ROSENQVIST E, 1993, J INFECT DIS, V167, P1065, DOI 10.1093/infdis/167.5.1065; Rosenstein N, 1998, JAMA-J AM MED ASSOC, V279, P435, DOI 10.1001/jama.279.6.435; Sacchi CT, 1998, CLIN DIAGN LAB IMMUN, V5, P845, DOI 10.1128/CDLI.5.6.845-855.1998; SACCHI CT, 1992, J CLIN MICROBIOL, V30, P1734, DOI 10.1128/JCM.30.7.1734-1738.1992; Schuchat A, 1997, NEW ENGL J MED, V337, P970, DOI 10.1056/NEJM199710023371404; SIERRA G V G, 1991, NIPH (National Institute of Public Health) Annals (Oslo), V14, P195; SUKER J, 1994, MOL MICROBIOL, V12, P253, DOI 10.1111/j.1365-2958.1994.tb01014.x; TAPPERO J, 1994, 34 INT C ANT AG CHEM; VanDerVoort ER, 1996, INFECT IMMUN, V64, P2745, DOI 10.1128/IAI.64.7.2745-2751.1996; WEDEGE E, 1993, J MED MICROBIOL, V38, P23, DOI 10.1099/00222615-38-1-23; WEDEGE E, 1990, J MED MICROBIOL, V31, P195, DOI 10.1099/00222615-31-3-195; WENGER JD, 1998, EMERG INFECT DIS, V1, P125; WYLE FA, 1972, J INFECT DIS, V126, P514, DOI 10.1093/infdis/126.5.514; Zollinger W.D., 1997, NEW GENERATION VACCI, V2nd ed., P469	55	302	326	0	6	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	APR 28	1999	281	16					1520	1527		10.1001/jama.281.16.1520	http://dx.doi.org/10.1001/jama.281.16.1520			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	188PP	10227322				2022-12-28	WOS:000079857400034
J	Tremblay, L; Schultz, W				Tremblay, L; Schultz, W			Relative reward preference in primate orbitofrontal cortex	NATURE			English	Article							PREFRONTAL CORTEX; NEURONAL-ACTIVITY; WORKING-MEMORY; RHESUS-MONKEY; DISSOCIATION; EXPECTATION; CONNECTIONS; RESPONSES; STRIATUM; MACAQUE	The orbital part of prefrontal cortex appears to be crucially involved in the motivational control of goal-directed behaviour(1,2). Patients with lesions of orbitofrontal cortex show impairments in making decisions about the expected outcome of actions(3). Monkeys with orbitofrontal lesions respond abnormally to changes in reward expectations(4,5) and show altered reward preferences(6). As rewards constitute basic goals of behaviour(7) we investigated here how neurons in the orbitofrontal cortex of monkeys process information about liquid and food rewards in a typical frontal task, spatial delayed responding(8). The activity of orbitofrontal neurons increases in response to reward-predicting signals, during: the expectation of rewards, and after the receipt of rewards. Neurons discriminate between different rewards, mainly irrespective of the spatial and visual features of reward-predicting stimuli and behavioural reactions. Most reward discriminations reflect the animals' relative preference among the available rewards, as expressed by their choice behaviour, rather than physical reward properties. Thus, neurons in the orbitofrontal cortex appear to process the motivational value of rewarding outcomes of voluntary action.	Univ Fribourg, Inst Physiol, CH-1700 Fribourg, Switzerland; Univ Fribourg, Program Neurosci, CH-1700 Fribourg, Switzerland; Univ Freiburg, Inst Physiol, CH-1700 Fribourg, Switzerland; Hop La Pitie Salpetriere, F-75651 Paris, France	University of Fribourg; University of Fribourg; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Pitie-Salpetriere - APHP; UDICE-French Research Universities; Sorbonne Universite	Schultz, W (corresponding author), Hop La Pitie Salpetriere, INSERM, Unit 289, 47 Blvd Hop, F-75651 Paris, France.		Tremblay, Leon/H-1559-2017	Tremblay, Leon/0000-0001-8370-6903				BARBAS H, 1988, J COMP NEUROL, V276, P313, DOI 10.1002/cne.902760302; BAYLIS LL, 1991, EXP BRAIN RES, V86, P617; Bechara A, 1998, J NEUROSCI, V18, P428; Carmichael ST, 1995, J COMP NEUROL, V363, P615, DOI 10.1002/cne.903630408; Critchley HD, 1996, J NEUROPHYSIOL, V75, P1659, DOI 10.1152/jn.1996.75.4.1659; Critchley HD, 1996, J NEUROPHYSIOL, V75, P1673, DOI 10.1152/jn.1996.75.4.1673; DAMASIO AR, 1994, DESCARTES ERROR; Dias R, 1996, NATURE, V380, P69, DOI 10.1038/380069a0; DICKINSON A, 1994, ANIM LEARN BEHAV, V22, P1, DOI 10.3758/BF03199951; FUNAHASHI S, 1993, NATURE, V365, P753, DOI 10.1038/365753a0; FUSTER JM, 1971, SCIENCE, V173, P652, DOI 10.1126/science.173.3997.652; HIKOSAKA O, 1989, J NEUROPHYSIOL, V61, P814, DOI 10.1152/jn.1989.61.4.814; Hollerman JR, 1998, J NEUROPHYSIOL, V80, P947, DOI 10.1152/jn.1998.80.2.947; IVERSEN SD, 1970, EXP BRAIN RES, V11, P376; Jacobsen CF, 1937, J COMP PSYCHOL, V23, P101, DOI 10.1037/h0056632; KUBOTA K, 1971, J NEUROPHYSIOL, V34, P337, DOI 10.1152/jn.1971.34.3.337; Miller EK, 1996, J NEUROSCI, V16, P5154; Pandya DN, 1996, PHILOS T ROY SOC B, V351, P1423, DOI 10.1098/rstb.1996.0127; PETRIDES M, 1988, J COMP NEUROL, V273, P52, DOI 10.1002/cne.902730106; Rao SC, 1997, SCIENCE, V276, P821, DOI 10.1126/science.276.5313.821; Rolls ET, 1996, PHILOS T ROY SOC B, V351, P1433, DOI 10.1098/rstb.1996.0128; Rolls ET, 1996, J NEUROPHYSIOL, V75, P1970, DOI 10.1152/jn.1996.75.5.1970; ROSENKILDE CE, 1981, BRAIN RES, V209, P375, DOI 10.1016/0006-8993(81)90160-8; SCHOENBAUM G, 1995, J NEUROPHYSIOL, V74, P733, DOI 10.1152/jn.1995.74.2.733; Schoenbaum G, 1998, NAT NEUROSCI, V1, P155, DOI 10.1038/407; SCHULTZ W, 1992, J NEUROSCI, V12, P4595, DOI 10.1523/jneurosci.12-12-04595.1992; THORPE SJ, 1983, EXP BRAIN RES, V49, P93; Tinklepaugh OL, 1928, J COMP PSYCHOL, V8, P197, DOI 10.1037/h0075798; Watanabe M, 1996, NATURE, V382, P629, DOI 10.1038/382629a0; WILSON FAW, 1993, SCIENCE, V260, P1955, DOI 10.1126/science.8316836	30	936	948	2	49	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	APR 22	1999	398	6729					704	708		10.1038/19525	http://dx.doi.org/10.1038/19525			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	189RP	10227292				2022-12-28	WOS:000079920100050
J	Hamilton, W; Round, A; Sharp, D				Hamilton, W; Round, A; Sharp, D			Effect on hospital attendance rates of giving patients a copy of their referral letter: randomised controlled trial	BMJ-BRITISH MEDICAL JOURNAL			English	Article							OUTPATIENT CLINICS; APPOINTMENTS; AUDIT	Objectives To investigate whether sending patients a copy of their referral letter can reduce non-attendance at outpatient departments. Design Blinded randomised controlled trial. Setting 13 general practices in Exeter, Devon. Subjects 2078 new consultant referrals from 26 doctors. Main outcome measures Non-attendance at outpatient departments. Results The doctors excluded 117 (5.6%) referrals, and 100 (4.8%) received no appointment Attendance data were available for 1857 of the 1861 patients sent an appointment (99.8%). The receipt of a copy letter had no effect on the non-attendance rate: copy 50/912 (5.5%) versus control 50/945 (5.34%). Conclusion Copy letters are ineffective in reducing non-attendance at outpatient departments.	N&E Devon Hlth Author, Exeter EX1 1PQ, Devon, England; Univ Bristol, Div Primary HlthCare, Bristol BS8 2PR, Avon, England	University of Bristol	Hamilton, W (corresponding author), 12 Barnfield Hill, Exeter EX1 1SR, Devon, England.	barnfield.hill.research@which.net	Hamilton, Willie/G-8612-2014	Hamilton, William/0000-0003-1611-1373				ANDREWS R, 1990, ARCH DIS CHILD, V65, P192, DOI 10.1136/adc.65.2.192; BOTTOMLEY WW, 1994, CLIN EXP DERMATOL, V19, P399, DOI 10.1111/j.1365-2230.1994.tb02691.x; CAMPBELL JR, 1994, CLIN PEDIATR, V33, P268, DOI 10.1177/000992289403300503; *COMM PUBL ACC, 1995, 42 COMM PUBL ACC NAT; COTTRELL D, 1988, BRIT J PSYCHIAT, V152, P201, DOI 10.1192/bjp.152.2.201; DIETCH R, 1984, LANCET, V1, P1419; FRANKEL S, 1989, BRIT MED J, V298, P1343, DOI 10.1136/bmj.298.6684.1343; Hamilton W, 1997, BRIT MED J, V314, P1416; HERRICK J, 1994, J DENT, V22, P307, DOI 10.1016/0300-5712(94)90068-X; HILLMAN JG, 1994, BRIT MED J, V308, P953, DOI 10.1136/bmj.308.6934.953; Humfress H, 1997, BRIT MED J, V314, P1416; JENKINS RM, 1993, BRIT J GEN PRACT, V43, P111; KING A, 1995, J ROY SOC MED, V88, P88; KOCH A, 1991, S AFR MED J, V80, P289; LLOYD M, 1993, FAM PRACT, V10, P111, DOI 10.1093/fampra/10.2.111; Pal B, 1998, INT J CLIN PRACT, V52, P436; PARTRIDGE JW, 1992, ARCH DIS CHILD, V67, P206, DOI 10.1136/adc.67.2.206; POTAMITIS T, 1994, J ROY SOC MED, V87, P591; Read M, 1997, BR J HEALTHCARE MANA, V3, P307; SIMS J, 1995, HEALTHCARE MANAG JUN, P16; Stone CA, 1999, J ROY SOC MED, V92, P114, DOI 10.1177/014107689909200304; TURNER AG, 1991, BRIT J CLIN PRACT, V45, P97; Ward R, 1998, BRIT MED J, V316, P1541, DOI 10.1136/bmj.316.7143.1541a; Waterston T, 1994, Qual Health Care, V3, P142, DOI 10.1136/qshc.3.3.142; 1997, NHS MAGAZINE, P34	25	47	47	0	3	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	MAY 22	1999	318	7195					1392	1395		10.1136/bmj.318.7195.1392	http://dx.doi.org/10.1136/bmj.318.7195.1392			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	200DQ	10334750	Green Published, Green Submitted, Bronze			2022-12-28	WOS:000080524700029
J	Parks, DJ; Blanchard, SG; Bledsoe, RK; Chandra, G; Consler, TG; Kliewer, SA; Stimmel, JB; Willson, TM; Zavacki, AM; Moore, DD; Lehmann, JM				Parks, DJ; Blanchard, SG; Bledsoe, RK; Chandra, G; Consler, TG; Kliewer, SA; Stimmel, JB; Willson, TM; Zavacki, AM; Moore, DD; Lehmann, JM			Bile acids: Natural ligands for an orphan nuclear receptor	SCIENCE			English	Article							BINDING-PROTEIN; CHOLESTEROL 7-ALPHA-HYDROXYLASE; MOLECULAR-CLONING; EXPRESSION; COACTIVATORS; IDENTIFICATION; FLUORESCENCE; TRANSPORT; ASSAYS; TISSUE	Bile acids regulate the transcription of genes that control cholesterol homeostasis through molecular mechanisms that are poorly understood. Physiological concentrations of free and conjugated chenodeoxycholic acid, Lithocholic acid, and deoxycholic acid activated the farnesoid X receptor (FXR; NR1H4), an orphan nuclear receptor. As Ligands, these bile acids and their conjugates modulated interaction of FXR with a peptide derived from steroid receptor coactivator 1. These results provide evidence for a nuclear bile acid signaling pathway that may regulate cholesterol homeostasis.	Glaxo Wellcome Inc, Res & Dev, Dept Med Chem, Res Triangle Pk, NC 27709 USA; Glaxo Wellcome Inc, Res & Dev, Dept Mol Sci, Res Triangle Pk, NC 27709 USA; Glaxo Wellcome Inc, Res & Dev, Dept Mol Biochem, Res Triangle Pk, NC 27709 USA; Baylor Coll Med, Dept Cell Biol, Houston, TX 77030 USA	GlaxoSmithKline; GlaxoSmithKline; GlaxoSmithKline; Baylor College of Medicine	Willson, TM (corresponding author), Glaxo Wellcome Inc, Res & Dev, Dept Med Chem, Res Triangle Pk, NC 27709 USA.		feinstein, doug/M-9414-2019		NIDDK NIH HHS [R01 DK53366, F32 DK09793] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK053366, F32DK009793] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Craddock AL, 1998, AM J PHYSIOL-GASTR L, V274, pG157, DOI 10.1152/ajpgi.1998.274.1.G157; CRESTANI M, 1994, BIOCHEM BIOPH RES CO, V198, P546, DOI 10.1006/bbrc.1994.1080; DICKSON EFG, 1995, J PHOTOCH PHOTOBIO B, V27, P3; FORMAN BM, 1995, CELL, V81, P687, DOI 10.1016/0092-8674(95)90530-8; FUJITA M, 1995, EUR J BIOCHEM, V233, P406, DOI 10.1111/j.1432-1033.1995.406_2.x; Glass CK, 1997, CURR OPIN CELL BIOL, V9, P222, DOI 10.1016/S0955-0674(97)80066-X; GONG YZ, 1994, P NATL ACAD SCI USA, V91, P4741, DOI 10.1073/pnas.91.11.4741; Heery DM, 1997, NATURE, V387, P733, DOI 10.1038/42750; Kanda T, 1996, FEBS LETT, V384, P131, DOI 10.1016/0014-5793(96)00291-8; Kanda T, 1998, BIOCHEM J, V330, P261, DOI 10.1042/bj3300261; Kliewer SA, 1999, SCIENCE, V284, P757, DOI 10.1126/science.284.5415.757; Krey G, 1997, MOL ENDOCRINOL, V11, P779, DOI 10.1210/me.11.6.779; LeDouarin B, 1996, EMBO J, V15, P6701, DOI 10.1002/j.1460-2075.1996.tb01060.x; LEHMANN JM, 1995, J BIOL CHEM, V270, P12953, DOI 10.1074/jbc.270.22.12953; Makishima M, 1999, SCIENCE, V284, P1362, DOI 10.1126/science.284.5418.1362; MALLORY A, 1973, GASTROENTEROLOGY, V64, P26; MANGELSDORF DJ, 1995, CELL, V83, P835, DOI 10.1016/0092-8674(95)90199-X; Moras D, 1998, CURR OPIN CELL BIOL, V10, P384, DOI 10.1016/S0955-0674(98)80015-X; Paige LA, 1999, P NATL ACAD SCI USA, V96, P3999, DOI 10.1073/pnas.96.7.3999; PARKS DE, UNPUB; RIDDIHOUGH G, 1987, EMBO J, V6, P3729, DOI 10.1002/j.1460-2075.1987.tb02707.x; RUSSELL DW, 1992, BIOCHEMISTRY-US, V31, P4737, DOI 10.1021/bi00135a001; SEOL WG, 1995, MOL ENDOCRINOL, V9, P72, DOI 10.1210/me.9.1.72; Setchell KDR, 1997, GASTROENTEROLOGY, V112, P226, DOI 10.1016/S0016-5085(97)70239-7; Sippel CJ, 1997, J BIOL CHEM, V272, P18290, DOI 10.1074/jbc.272.29.18290; SOINI E, 1990, ANN BIOL CLIN-PARIS, V48, P567; TWISK J, 1995, EUR J BIOCHEM, V228, P596, DOI 10.1111/j.1432-1033.1995.tb20299.x; WONG MH, 1995, J BIOL CHEM, V270, P27228, DOI 10.1074/jbc.270.45.27228; Zavacki AM, 1997, P NATL ACAD SCI USA, V94, P7909, DOI 10.1073/pnas.94.15.7909; ZAVACKI AM, UNPUB; Zhou GC, 1998, MOL ENDOCRINOL, V12, P1594, DOI 10.1210/me.12.10.1594	31	1772	1876	10	118	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	MAY 21	1999	284	5418					1365	1368		10.1126/science.284.5418.1365	http://dx.doi.org/10.1126/science.284.5418.1365			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	198NN	10334993				2022-12-28	WOS:000080430600056
J	Rosakis, AJ; Samudrala, O; Coker, D				Rosakis, AJ; Samudrala, O; Coker, D			Cracks faster than the shear wave speed	SCIENCE			English	Article							RUPTURE PROPAGATION; EARTHQUAKE; VELOCITIES	Classical dynamic fracture theories predict the surface wave speed to be the limiting speed for propagation of in-plane cracks in homogeneous, Linear elastic materials subjected to remote Loading. This report presents experimental evidence to the contrary. Intersonic shear-dominated crack growth featuring shear shock waves was observed along weak planes in a brittle polyester resin under far-field asymmetric loading. When steady-state conditions were attained, the shear cracks propagated at speeds close to root 2 times the material shear wave speed. These observations have similarities to shallow earthquake events where intersonic shear rupture speeds have been surmised.	CALTECH, Grad Aeronaut Labs, Pasadena, CA 91125 USA	California Institute of Technology	Rosakis, AJ (corresponding author), CALTECH, Grad Aeronaut Labs, Pasadena, CA 91125 USA.		Coker, Demirkan/B-3386-2011; Coker, Demirkan/R-6729-2019	Coker, Demirkan/0000-0001-7385-7089; Coker, Demirkan/0000-0001-7385-7089; Rosakis, Ares/0000-0003-0559-0794				ANDREWS DJ, 1976, J GEOPHYS RES, V81, P3575, DOI 10.1029/JB081i020p03575; ARCHULETA RJ, 1980, B SEISMOL SOC AM, V70, P671; Broberg K. B., 1995, ARCH MECH, V47, P859; BROBERG KB, 1989, INT J FRACTURE, V39, P1, DOI 10.1007/BF00047435; BROBERG KB, 1994, GEOPHYS J INT, V119, P706, DOI 10.1111/j.1365-246X.1994.tb04010.x; BROBERG KB, 1964, J APPL MECH, V31, P546; BURRIDGE R, 1979, J GEOPHYS RES, V84, P2210, DOI 10.1029/JB084iB05p02210; COKER D, 1998, 9816 CALTECH SM; Cotterell B, 1965, APPL MATER RES, V4, P227; DAS S, 1985, INT J FRACTURE, V27, P263, DOI 10.1007/BF00017972; DAS S, 1977, GEOPHYS J ROY ASTR S, V50, P643, DOI 10.1111/j.1365-246X.1977.tb01339.x; DMOWSKA R, 1986, CONTINUUM THEORIES S, P187; ESHELBY JD, 1949, P PHYS SOC LOND A, V62, P307, DOI 10.1088/0370-1298/62/5/307; FREUND LB, 1979, J GEOPHYS RES, V84, P2199, DOI 10.1029/JB084iB05p02199; Freund LB, 1990, DYNAMIC FRACTURE MEC, DOI [10.1017/oretCBO9780511546761-en, DOI 10.1017/ORETCBO9780511546761-EN]; GAO H, 1993, J MECH PHYS SOLIDS, V1, P457; GAO H, IN PRESS J MECH PHYS; Gumbsch P, 1999, SCIENCE, V283, P965, DOI 10.1126/science.283.5404.965; Kanamori H, 1998, SCIENCE, V279, P839, DOI 10.1126/science.279.5352.839; Olsen KB, 1997, SCIENCE, V278, P834, DOI 10.1126/science.278.5339.834; RAVICHANDAR K, 1984, INT J FRACTURE, V26, P141, DOI 10.1007/BF01157550; Rice J. R., 1980, PHYS EARTHS INTERIOR, P555; Rosakis AJ, 1998, J MECH PHYS SOLIDS, V46, P1789, DOI 10.1016/S0022-5096(98)00036-2; ROSAKIS P, 1995, INT J SOLIDS STRUCT, V32, P2711, DOI 10.1016/0020-7683(94)00293-6; WASHABAUGH PD, 1994, INT J FRACTURE, V65, P97; Weertman J.., 1969, MATH THEORY DISLOCAT, P178; WINKLER S, 1970, INT J FRACT MECH, V6, P151, DOI 10.1007/BF00189822	27	367	376	1	74	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	MAY 21	1999	284	5418					1337	1340		10.1126/science.284.5418.1337	http://dx.doi.org/10.1126/science.284.5418.1337			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	198NN	10334984	Green Accepted			2022-12-28	WOS:000080430600047
J	Levine, C				Levine, C			The loneliness of the long-term care giver	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material									United Hosp Fund, New York, NY 10118 USA		Levine, C (corresponding author), United Hosp Fund, New York, NY 10118 USA.							Angell M, 1999, NEW ENGL J MED, V340, P48, DOI 10.1056/NEJM199901073400108; Arno PS, 1999, HEALTH AFFAIR, V18, P182, DOI 10.1377/hlthaff.18.2.182; BARUSCH AS, 1995, SOC WORK, V40, P315; Cassel CK, 1999, HEALTH AFFAIR, V18, P118, DOI 10.1377/hlthaff.18.1.118; GRAHAM J, 1999, CHICAGO TRIBUNE 0117; Levine C, 1999, ANN INTERN MED, V130, P148, DOI 10.7326/0003-4819-130-2-199901190-00010; LEVINE C, IN PRESS J HLTH AGIN; Levine C., 1998, ROUGH CROSSINGS FAMI; MINTZ S, 1999, COMMUNICATION   0106; SCHOFIELD H, 1998, FAMILY CAREGIVERS DI	10	69	72	0	10	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	MAY 20	1999	340	20					1587	1590		10.1056/NEJM199905203402013	http://dx.doi.org/10.1056/NEJM199905203402013			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	197HG	10332025				2022-12-28	WOS:000080358900013
J	Chin, L; Artandi, SE; Shen, Q; Tam, A; Lee, SL; Gottlieb, GJ; Greider, CW; DePinho, RA				Chin, L; Artandi, SE; Shen, Q; Tam, A; Lee, SL; Gottlieb, GJ; Greider, CW; DePinho, RA			p53 deficiency rescues the adverse effects of telomere loss and cooperates with telomere dysfunction to accelerate carcinogenesis	CELL			English	Article							MOUSE CELLS LACKING; DNA-DAMAGE; LIFE-SPAN; IMMORTAL CELLS; YEAST TELOMERE; SENESCENCE; FIBROBLASTS; ARREST; GROWTH; RNA	Maintenance of telomere length and function is critical for the efficient proliferation of eukaryotic cells. Here, we examine the interactions between telomere dysfunction and p53 in cells and organs of telomerase-deficient mice. Coincident with severe telomere shortening and associated genomic instability, p53 is activated, leading to growth arrest and/or apoptosis. Deletion of p53 significantly attenuated the adverse cellular and organismal effects of telomere dysfunction, but only during the earliest stages of genetic crisis. Correspondingly, the loss of telomere function and p53 deficiency cooperated to initiate the transformation process. Together, these studies establish a key role for p53 in the cellular response to telomere dysfunction in both normal and neoplastic cells, question the significance of crisis as a tumor suppressor mechanism, and identify a biologically relevant stage of advanced crisis, termed genetic catastrophe.	Dana Farber Canc Inst, Dept Adult Oncol, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Med & Genet, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Dermatol, Boston, MA 02115 USA; Quest Diagnost Inc, Anat Pathol, Teterboro, NJ 07608 USA; Johns Hopkins Univ, Sch Med, Dept Mol Biol & Genet, Baltimore, MD 21205 USA	Harvard University; Dana-Farber Cancer Institute; Harvard University; Harvard Medical School; Harvard University; Harvard Medical School; Johns Hopkins University	DePinho, RA (corresponding author), Dana Farber Canc Inst, Dept Adult Oncol, 44 Binney St, Boston, MA 02115 USA.	depinho@dfci.harvard.edu		Greider, Carol/0000-0002-5494-8126; DePinho, Ronald/0000-0002-5625-577X	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD028317, R01HD034880] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [K08AR002104] Funding Source: NIH RePORTER; NIAMS NIH HHS [K08AR02104-01] Funding Source: Medline; NICHD NIH HHS [R01HD28317, R01HD34880] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		Blasco MA, 1997, CELL, V91, P25, DOI 10.1016/S0092-8674(01)80006-4; Bodnar AG, 1998, SCIENCE, V279, P349, DOI 10.1126/science.279.5349.349; BRUGAROLAS J, 1995, NATURE, V377, P552, DOI 10.1038/377552a0; BRYAN TM, 1995, EMBO J, V14, P4240, DOI 10.1002/j.1460-2075.1995.tb00098.x; Bunz F, 1998, SCIENCE, V282, P1497, DOI 10.1126/science.282.5393.1497; Counter CM, 1998, P NATL ACAD SCI USA, V95, P14723, DOI 10.1073/pnas.95.25.14723; COUNTER CM, 1992, EMBO J, V11, P1921, DOI 10.1002/j.1460-2075.1992.tb05245.x; DENG CX, 1995, CELL, V82, P675, DOI 10.1016/0092-8674(95)90039-X; Gottlieb E, 1997, EMBO J, V16, P1381, DOI 10.1093/emboj/16.6.1381; Greenberg RA, 1999, CELL, V97, P515, DOI 10.1016/S0092-8674(00)80761-8; GREIDER CW, 1989, NATURE, V337, P331, DOI 10.1038/337331a0; Greider CW, 1998, CURR BIOL, V8, pR178, DOI 10.1016/S0960-9822(98)70105-8; HARA E, 1991, BIOCHEM BIOPH RES CO, V179, P528, DOI 10.1016/0006-291X(91)91403-Y; HARVEY M, 1993, ONCOGENE, V8, P2457; HAYFLICK L, 1961, EXP CELL RES, V25, P585, DOI 10.1016/0014-4827(61)90192-6; Herrera E, 1999, EMBO J, V18, P1172, DOI 10.1093/emboj/18.5.1172; Kamijo T, 1997, CELL, V91, P649, DOI 10.1016/S0092-8674(00)80452-3; Karlseder J, 1999, SCIENCE, V283, P1321, DOI 10.1126/science.283.5406.1321; KERN SE, 1992, SCIENCE, V256, P827, DOI 10.1126/science.1589764; KIM NW, 1994, SCIENCE, V266, P2011, DOI 10.1126/science.7605428; Kiyono T, 1998, NATURE, V396, P84, DOI 10.1038/23962; LAND H, 1983, NATURE, V304, P596, DOI 10.1038/304596a0; Lee HW, 1998, NATURE, V392, P569, DOI 10.1038/33345; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; LOWE SW, 1993, CELL, V74, P957, DOI 10.1016/0092-8674(93)90719-7; LUNDBLAD V, 1993, CELL, V73, P347, DOI 10.1016/0092-8674(93)90234-H; McEachern MJ, 1996, GENE DEV, V10, P1822, DOI 10.1101/gad.10.14.1822; MUKHERJEE B, 1992, GENE DEV, V6, P1480, DOI 10.1101/gad.6.8.1480; Niida H, 1998, NAT GENET, V19, P203, DOI 10.1038/580; Pomerantz J, 1998, CELL, V92, P713, DOI 10.1016/S0092-8674(00)81400-2; Prives C, 1998, CELL, V95, P5, DOI 10.1016/S0092-8674(00)81774-2; Rudolph KL, 1999, CELL, V96, P701, DOI 10.1016/S0092-8674(00)80580-2; Rufer N, 1998, NAT BIOTECHNOL, V16, P743, DOI 10.1038/nbt0898-743; SAH VP, 1995, NAT GENET, V10, P175, DOI 10.1038/ng0695-175; SANDELL LL, 1993, CELL, V75, P729, DOI 10.1016/0092-8674(93)90493-A; Serrano M, 1997, CELL, V88, P593, DOI 10.1016/S0092-8674(00)81902-9; SHAY JW, 1991, EXP CELL RES, V196, P33, DOI 10.1016/0014-4827(91)90453-2; Shieh SY, 1997, CELL, V91, P325, DOI 10.1016/S0092-8674(00)80416-X; Siliciano JD, 1997, GENE DEV, V11, P3471, DOI 10.1101/gad.11.24.3471; van Steensel B, 1998, CELL, V92, P401, DOI 10.1016/S0092-8674(00)80932-0; vanSteensel B, 1997, NATURE, V385, P740, DOI 10.1038/385740a0; Vaziri H, 1998, CURR BIOL, V8, P279, DOI 10.1016/S0960-9822(98)70109-5; VENKATACHALAM S, 1996, EMBO, V17, P4657; YU GL, 1990, NATURE, V344, P126, DOI 10.1038/344126a0	44	760	794	1	28	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	MAY 14	1999	97	4					527	538		10.1016/S0092-8674(00)80762-X	http://dx.doi.org/10.1016/S0092-8674(00)80762-X			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	196FV	10338216	Bronze			2022-12-28	WOS:000080299100013
J	Koechlin, E; Basso, G; Pietrini, P; Panzer, S; Grafman, J				Koechlin, E; Basso, G; Pietrini, P; Panzer, S; Grafman, J			The role of the anterior prefrontal cortex in human cognition	NATURE			English	Article							WORKING-MEMORY; EPISODIC MEMORY; RETRIEVAL; RECOGNITION; ACTIVATION; SYSTEM; BRAIN; TASK	Complex problem-solving and planning involve the most anterior part of the frontal lobes including the fronto-polar prefrontal cortex (FPPC)(1-6), which is especially well developed in humans compared with other primates(7,8). The specific role of this region in human cognition, however, is poorly understood. Here we show using functional magnetic resonance imaging, that bilateral regions in the FPPC alone are selectively activated when subjects have to keep in mind a main goal while performing concurrent (sub)goals. Neither keeping in mind a goal over time (working memory) nor successively allocating attentional resources between alternative goals (dual-task performance) could by themselves activate these regions. Our results indicate that the FPPC selectively mediates the human ability to hold in mind goals while exploring and processing secondary goals, a process generally required in planning and reasoning.	NINDS, Cognit Neurosci Sect, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Neurological Disorders & Stroke (NINDS)	Grafman, J (corresponding author), NINDS, Cognit Neurosci Sect, NIH, Bethesda, MD 20892 USA.	jgr@box-j.nih.gov	Basso, Gianpaolo/A-9208-2012; Pietrini, Pietro/Z-4202-2019; Koechlin, Etienne/AAF-5717-2021; Koechlin, Etienne/E-5061-2016	Basso, Gianpaolo/0000-0002-6245-9402; Koechlin, Etienne/0000-0002-6514-9311; Koechlin, Etienne/0000-0002-6514-9311; Grafman, Jordan H./0000-0001-8645-4457; Pietrini, Pietro/0000-0002-6768-5556				[Anonymous], 1983, CANADIAN PSYCHOL; Baker SC, 1996, NEUROPSYCHOLOGIA, V34, P515, DOI 10.1016/0028-3932(95)00133-6; BUCKNER RL, 1995, J NEUROSCI, V15, P12; Corbetta M, 1998, P NATL ACAD SCI USA, V95, P831, DOI 10.1073/pnas.95.3.831; Courtney SM, 1997, NATURE, V386, P608, DOI 10.1038/386608a0; DESPOSITO M, 1995, NATURE, V378, P279, DOI 10.1038/378279a0; Duvernoy H. M., 1991, HUMAN BRAIN SURFACE; FRISTON KJ, 1991, J CEREBR BLOOD F MET, V11, P690, DOI 10.1038/jcbfm.1991.122; Furey ML, 1997, P NATL ACAD SCI USA, V94, P6512, DOI 10.1073/pnas.94.12.6512; Fuster J., 1989, DISSERT ABSTRACTS IN, V60, P255; GALABURDA AM, 1978, SCIENCE, V199, P852, DOI 10.1126/science.341314; Goldman-Rakic P.S., 2011, HDB PHYSL, P373, DOI DOI 10.1002/CPHY.CP010509; GRADY CL, 1995, SCIENCE, V269, P218, DOI 10.1126/science.7618082; Grafman J, 1995, ANN NY ACAD SCI, V769, P337, DOI 10.1111/j.1749-6632.1995.tb38149.x; GRAFTON ST, 1995, J COGNITIVE NEUROSCI, V7, P497, DOI 10.1162/jocn.1995.7.4.497; MacLeod AK, 1998, NEUROIMAGE, V7, P41, DOI 10.1006/nimg.1997.0308; Owen AM, 1996, EUR J NEUROSCI, V8, P353, DOI 10.1111/j.1460-9568.1996.tb01219.x; Pallier C, 1997, BEHAV RES METH INS C, V29, P322, DOI 10.3758/BF03200583; PETRIDES M, 1994, HDB NEUROPSYCHOLOGY, P59; SHALLICE T, 1994, NATURE, V368, P633, DOI 10.1038/368633a0; Sirigu A, 1995, ANN NY ACAD SCI, V769, P277, DOI 10.1111/j.1749-6632.1995.tb38145.x; SPECTOR L, 1994, HDB NEUROPSYCHOLOGY, P377; SQUIRE LR, 1992, P NATL ACAD SCI USA, V89, P1837, DOI 10.1073/pnas.89.5.1837; Stuss D.T., 1986, FRONTAL LOBES; Talairach J, 1988, CO PLANAR STEREOTAXI; TULVING E, 1994, P NATL ACAD SCI USA, V91, P2012, DOI 10.1073/pnas.91.6.2012; Wharton CM, 1998, TRENDS COGN SCI, V2, P54, DOI 10.1016/S1364-6613(98)01122-X	27	718	727	0	47	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	MAY 13	1999	399	6732					148	151		10.1038/20178	http://dx.doi.org/10.1038/20178			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	196XU	10335843				2022-12-28	WOS:000080335700049
J	Fananapazir, L				Fananapazir, L			Advances in molecular genetics and management of hypertrophic cardiomyopathy	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							HEAVY-CHAIN GENE; BETA-CARDIAC MYOSIN; OBSTRUCTIVE CARDIOMYOPATHY; SKELETAL-MUSCLE; SUDDEN-DEATH; MUTATIONS; EXPRESSION; REDUCTION; DISTINCT; DISEASE		NHLBI, Sect Clin electrophysiol & Inherited Cardiac Dis, Cardiol Branch, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI)	Fananapazir, L (corresponding author), NHLBI, Sect Clin electrophysiol & Inherited Cardiac Dis, Cardiol Branch, NIH, Bldg 10,Room 7B14,10 Ctr Dr,MSC 1650, Bethesda, MD 20892 USA.	fananapa@nih.gov						Bonne G, 1998, CIRC RES, V83, P580, DOI 10.1161/01.RES.83.6.580; BONNE G, 1995, NAT GENET, V11, P438, DOI 10.1038/ng1295-438; Cuda G, 1997, J MUSCLE RES CELL M, V18, P275, DOI 10.1023/A:1018613907574; CUDA G, 1993, J CLIN INVEST, V91, P2861, DOI 10.1172/JCI116530; DILSIZIAN V, 1993, J AM COLL CARDIOL, V22, P796, DOI 10.1016/0735-1097(93)90193-5; EPSTEIN ND, 1992, CIRCULATION, V86, P345, DOI 10.1161/01.CIR.86.2.345; Faber L, 1998, CIRCULATION, V98, P2415, DOI 10.1161/01.CIR.98.22.2415; FANANAPAZIR I, 1998, ADV CARDIAC PACING G, V4, P35; Fananapazir L, 1997, PACE, V20, P478, DOI 10.1111/j.1540-8159.1997.tb06206.x; Fananapazir L, 1998, J AM COLL CARDIOL, V31, P259; FANANAPAZIR L, 1994, CIRCULATION, V89, P22, DOI 10.1161/01.CIR.89.1.22; FANANAPAZIR L, 1992, CIRCULATION, V86, P730, DOI 10.1161/01.CIR.86.3.730; FANANAPAZIR L, 1993, P NATL ACAD SCI USA, V90, P3993, DOI 10.1073/pnas.90.9.3993; FANANAPAZIR L, 1995, CIRCULATION, V92, P700, DOI 10.1161/01.CIR.92.4.700; FANANAPAZIR L, 1991, AM J CARDIOL, V67, P169, DOI 10.1016/0002-9149(91)90440-V; FANANAPAZIR L, 1995, CARDIAC ELECTROPHYSI, P769; FANANAPAZIR L, 1996, CIRCULATION, V94, P1; GEISTERFERLOWRANCE AAT, 1990, CELL, V62, P999, DOI 10.1016/0092-8674(90)90274-I; GEITZEN F, 1996, CIRCULATION S1, V94, P84; Kimura A, 1997, NAT GENET, V16, P379, DOI 10.1038/ng0897-379; KRAMER CM, 1994, CIRCULATION, V90, P186, DOI 10.1161/01.CIR.90.1.186; Lakkis NM, 1998, CIRCULATION, V98, P1750, DOI 10.1161/01.CIR.98.17.1750; LANKFORD EB, 1995, J CLIN INVEST, V95, P1409, DOI 10.1172/JCI117795; LECHIN M, 1994, CIRCULATION, V90, P174; MACRAE CA, 1995, J CLIN INVEST, V96, P1216, DOI 10.1172/JCI118154; Molkentin JD, 1998, CELL, V93, P215, DOI 10.1016/S0092-8674(00)81573-1; ODONOGHUE S, 1994, J AM COLL CARDIOL, V23, P11; Palmiter KA, 1997, BASIC RES CARDIOL, V92, P63, DOI 10.1007/BF00794070; Poetter K, 1996, NAT GENET, V13, P63, DOI 10.1038/ng0596-63; RAYMENT I, 1995, P NATL ACAD SCI USA, V92, P3864, DOI 10.1073/pnas.92.9.3864; RIGAT B, 1990, J CLIN INVEST, V86, P1343, DOI 10.1172/JCI114844; Seggewiss H, 1998, J AM COLL CARDIOL, V31, P252, DOI 10.1016/S0735-1097(97)00508-1; SIGWART U, 1995, LANCET, V346, P211, DOI 10.1016/S0140-6736(95)91267-3; Sussman MA, 1998, SCIENCE, V281, P1690, DOI 10.1126/science.281.5383.1690; THIERFELDER L, 1994, CELL, V77, P701, DOI 10.1016/0092-8674(94)90054-X; WIGLE ED, 1995, CIRCULATION, V92, P1680, DOI 10.1161/01.CIR.92.7.1680; Zhu DWX, 1998, PACE, V21, P299, DOI 10.1111/j.1540-8159.1998.tb01109.x	37	31	45	0	1	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAY 12	1999	281	18					1746	1752		10.1001/jama.281.18.1746	http://dx.doi.org/10.1001/jama.281.18.1746			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	193WR	10328076				2022-12-28	WOS:000080161200033
J	Inglesby, TV; Henderson, DA; Bartlett, JG; Ascher, MS; Eitzen, E; Friedlander, AM; Hauer, J; McDade, J; Osterholm, MT; O'Toole, T; Parker, G; Perl, TM; Russell, PK; Tonat, K				Inglesby, TV; Henderson, DA; Bartlett, JG; Ascher, MS; Eitzen, E; Friedlander, AM; Hauer, J; McDade, J; Osterholm, MT; O'Toole, T; Parker, G; Perl, TM; Russell, PK; Tonat, K		Working Grp Civilian Biodefense	Anthrax as a biological weapon - Medical and public health management	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							ORAL-OROPHARYNGEAL ANTHRAX; BACILLUS-ANTHRACIS; INHALATION ANTHRAX; WARFARE; TERRORISM; INFECTION; OUTBREAK; VACCINES; FUTURE	Objective To develop consensus-based recommendations for measures to be taken by medical and public health professionals following the use of anthrax as a biological weapon against a civilian population. Participants The working group included 21 representatives from staff of major academic medical centers and research, government, military, public health, and emergency management institutions and agencies. Evidence MEDLINE databases were searched from January 1966 to April 1998, using the Medical Subject Headings anthrax, Bacillus anthracis, biological weapon, biological terrorism, biological warfare, and biowarfare. Review of references identified by this search led to identification of relevant references published prior to 1966, In addition, participants identified other unpublished references and sources. Consensus Process The first draft of the consensus statement was a synthesis of information obtained in the formal evidence-gathering process. Members of the working group provided formal written comments which were incorporated into the second draft of the statement. The working group reviewed the second draft on June 12, 1998. No significant disagreements existed and comments were incorporated into a third draft. The fourth and final statement incorporates all relevant evidence obtained by the literature search in conjunction with final consensus recommendations supported by all working group members. Conclusions Specific consensus recommendations are made regarding the diagnosis of anthrax, indications for vaccination, therapy for those exposed, postexposure prophylaxis, decontamination of the environment, and additional research needs.	Johns Hopkins Univ, Johns Hopkins Ctr Civilian Biodef Studies, Baltimore, MD 21202 USA; Johns Hopkins Univ, Sch Med, Baltimore, MD USA; Johns Hopkins Univ, Sch Publ Hlth, Baltimore, MD USA; Calif State Dept Hlth, Berkeley, CA USA; USA, Med Res Inst Infect Dis, Frederick, MD USA; Office Emergency Management, New York, NY USA; Ctr Dis Control & Prevent, Atlanta, GA USA; Minnesota Dept Hlth, Minneapolis, MN USA; US Dept HHS, Office Emergency Preparedness, Rockville, MD USA	Johns Hopkins University; Johns Hopkins University; Johns Hopkins University; Centers for Disease Control & Prevention - USA; Minnesota Department of Health (MHD)	Inglesby, TV (corresponding author), Johns Hopkins Univ, Johns Hopkins Ctr Civilian Biodef Studies, Candler Bldg,Suite 850,111 Market Pl, Baltimore, MD 21202 USA.							ALBRINK WS, 1960, AM J PATHOL, V36, P457; *AM HOSP FORM SERV, 1996, AHFS DRUG INF; *AM PUBL HLTH ASS, 1995, CONTR COMM DIS MAN, P18; AMRAMOVA FA, 1993, P NATL ACAD SCI USA, V90, P2291; BARNES JM, 1947, J PATHOL BACTERIOL, V194, P113; Brachman P S, 1980, Ann N Y Acad Sci, V353, P83, DOI 10.1111/j.1749-6632.1980.tb18910.x; Brachman P. S., 1999, VACCINES, P629; Brachman P.S., 1994, INFECT DIS, P1003; BRACHMAN PS, 1962, AM J PUBLIC HEALTH N, V52, P632, DOI 10.2105/AJPH.52.4.632; Carter A, 1998, FOREIGN AFF, V77, P80, DOI 10.2307/20049132; *CDCP, 1994, MMWR-MORBID MORTAL W, V43, P70; Centers for Disease Control and Prevention, 1998, MMWR MORB MORTAL WKL, V48, P69; CHINN KS, 1996, PUBLICATION US DEP A, P1; Christopher GW, 1997, JAMA-J AM MED ASSOC, V278, P412, DOI 10.1001/jama.278.5.412; Cole LA, 1996, SCI AM, V275, P60, DOI 10.1038/scientificamerican1296-60; CRISTY GA, 1981, PUBLICATION ORNL; DAHLGREN CM, 1960, AM J HYG, V72, P24, DOI 10.1093/oxfordjournals.aje.a120131; DALLDORF FG, 1971, ARCH PATHOL, V92, P418; *DEF INT AG, 1986, PUBL US DEP DEF; DOGANAY M, 1991, SCAND J INFECT DIS, V23, P333, DOI 10.3109/00365549109024319; DRAGON DC, 1995, CAN VET J, V36, P295; DRUETT HA, 1953, J HYG-CAMBRIDGE, V51, P359, DOI 10.1017/S0022172400015795; DUTZ W, 1970, GUT, V11, P352, DOI 10.1136/gut.11.4.352; Franz DR, 1997, JAMA-J AM MED ASSOC, V278, P399, DOI 10.1001/jama.278.5.399; FRIEDLANDER A, 1997, TXB MILITARY MED MED, P467; FRIEDLANDER AM, 1993, J INFECT DIS, V167, P1239, DOI 10.1093/infdis/167.5.1239; GLASSMAN HN, 1966, BACTERIOL REV, V30, P657, DOI 10.1128/MMBR.30.3.657-659.1966; GLEISER CA, 1963, BRIT J EXP PATHOL, V44, P416; GUILLERMIN J, ANTHRAX INVESTIGATIO; HATCH TF, 1961, BACTERIOL REV, V25, P237, DOI 10.1128/MMBR.25.3.237-240.1961; HENDERSON D. W., 1956, JOUR HYG, V54, P28; *I MED NAT RES COU, 1998, IMPR CIV MED RESP CH, P1; Ivins B.E., 1996, SALISBURY MED B, V87, P125; Kaufmann AF, 1997, EMERG INFECT DIS, V3, P83, DOI 10.3201/eid0302.970201; KELLY DJ, 1992, J INFECT DIS, V166, P1184, DOI 10.1093/infdis/166.5.1184; KOHOUT E, 1964, AM J MED SCI, V247, P565, DOI 10.1097/00000441-196405000-00006; KUNANUSONT C, 1990, ANN TROP MED PARASIT, V84, P507, DOI 10.1080/00034983.1990.11812502; LEW D, 1995, PRINCIPLES PRACTICE, P1885; Lightfoot NF., 1990, SALISBURY MEDICAL B, V68, P95; LINCOLN R. E., 1965, P759; LINCOLN RE, 1965, J INFECT DIS, V115, P481, DOI 10.1093/infdis/115.5.481; MANCHEE RJ, 1988, CHEM BR          JUL, P690; MESELSON M, 1994, SCIENCE, V266, P1202, DOI 10.1126/science.7973702; *MI DEP PUBL HLTH, 1978, ANTHR VACC ABS; MORSE SA, 1994, METHOD ENZYMOL, V235, P1; MYENYE KS, 1996, CENT AFR J MED, V42, P312; ODENDAAL MW, 1991, ONDERSTEPOORT J VET, V58, P17; *OFF TECHN ASS, 1993, PUBL OFF TECHN ASS, P53; PENN CC, 1998, INFECT DIS, P1575; PERKINS WA, 1961, BACTERIOL REV, V25, P347, DOI 10.1128/MMBR.25.3.347-355.1961; PIENAAR UDV, 1967, FED PROC, V26, P1496; Pile JC, 1998, ARCH INTERN MED, V158, P429, DOI 10.1001/archinte.158.5.429; Pomerantsev AP, 1997, VACCINE, V15, P1846, DOI 10.1016/S0264-410X(97)00132-1; *PUBL HLTH SERV OF, 1995, P SEM RESP CONS CHEM; RESNICK JG, 1990, PUBLICATION US DEP A, P1; ROSS JM, 1957, J PATHOL BACTERIOL, V73, P485, DOI 10.1002/path.1700730219; SCHAAD UB, 1995, PEDIATR INFECT DIS J, V14, P1, DOI 10.1097/00006454-199501000-00001; Simon JD, 1997, JAMA-J AM MED ASSOC, V278, P428, DOI 10.1001/jama.278.5.428; SIRISANTHANA T, 1984, AM J TROP MED HYG, V33, P144, DOI 10.4269/ajtmh.1984.33.144; SIRISANTHANA T, 1988, AM J TROP MED HYG, V39, P575, DOI 10.4269/ajtmh.1988.39.575; SMITH H, 1954, NATURE, V173, P869, DOI 10.1038/173869a0; Stepanov AV, 1996, J BIOTECHNOL, V44, P155, DOI 10.1016/0168-1656(95)00092-5; Tekin A, 1997, BRIT J SURG, V84, P813, DOI 10.1046/j.1365-2168.1997.02539.x; TITBALL RW, 1991, J APPL BACTERIOL, V70, pS9; TURNBULL PCB, 1991, VACCINE, V9, P533, DOI 10.1016/0264-410X(91)90237-Z; *USA MED RES I INF, 1998, MED RESP BIOL WARF T; VESSAL K, 1975, CLIN RADIOL, V26, P471, DOI 10.1016/S0009-9260(75)80100-0; WALKER JS, 1967, FED PROC, V26, P1539; WHO Group of Consultants, 1970, HLTH ASP CHEM BIOL W, P98; WILLIAMS RP, 1986, INFECT DIS MED MICRO, P270; WUDUNN S, 1998, NY TIMES        0526, P1; Zilinskas RA, 1997, JAMA-J AM MED ASSOC, V278, P418, DOI 10.1001/jama.278.5.418	72	556	578	1	57	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAY 12	1999	281	18					1735	1745		10.1001/jama.281.18.1735	http://dx.doi.org/10.1001/jama.281.18.1735			11	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	193WR	10328075				2022-12-28	WOS:000080161200032
J	Threlfall, EJ; Ward, LR; Skinner, JA; Smith, HR; Lacey, S				Threlfall, EJ; Ward, LR; Skinner, JA; Smith, HR; Lacey, S			Ciprofloxacin-resistant Salmonella typhi and treatment failure	LANCET			English	Article									Cent Publ Hlth Lab, Lab Enter Pathogens, London NW9 5HT, England; King George Hosp, Goodmayes, Essex, England	Public Health England; King George Hospital	Threlfall, EJ (corresponding author), Cent Publ Hlth Lab, Lab Enter Pathogens, 61 Colindale Ave, London NW9 5HT, England.							Murdoch DA, 1998, LANCET, V351, P339, DOI 10.1016/S0140-6736(05)78338-0; ROWE B, 1992, LANCET, V339, P740, DOI 10.1016/0140-6736(92)90635-G; ROWE B, 1990, LANCET, V336, P1065, DOI 10.1016/0140-6736(90)92532-M; UMSANKAR S, 1992, CDR REV, V2, pR139; Wain J, 1997, CLIN INFECT DIS, V25, P1404, DOI 10.1086/516128	5	117	124	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	MAY 8	1999	353	9164					1590	1591		10.1016/S0140-6736(99)01001-6	http://dx.doi.org/10.1016/S0140-6736(99)01001-6			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	195XW	10334265				2022-12-28	WOS:000080278300022
J	Houtsmuller, AB; Rademakers, S; Nigg, AL; Hoogstraten, D; Hoeijmakers, JHJ; Vermeulen, W				Houtsmuller, AB; Rademakers, S; Nigg, AL; Hoogstraten, D; Hoeijmakers, JHJ; Vermeulen, W			Action of DNA repair endonuclease ERCC1/XPF in living cells	SCIENCE			English	Article							NUCLEOTIDE EXCISION-REPAIR; PIGMENTOSUM GROUP-F; GREEN-FLUORESCENT PROTEIN; XERODERMA-PIGMENTOSUM; PHOTOBLEACHING RECOVERY; ULTRAVIOLET-LIGHT; COMPLEX; DIFFUSION; TRANSCRIPTION; ERCC4	To study the nuclear organization and dynamics of nucleotide excision repair (NER), the endonuclease ERCC1/XPF (for excision repair cross complementation group 1/xeroderma pigmentosum group F) was tagged with green fluorescent protein and its mobility was monitored in Living Chinese hamster ovary cells. In the absence of DNA damage, the complex moved freely through the nucleus, with a diffusion coefficient (15 +/- 5 square micrometers per second) consistent with its molecular size. Ultraviolet Light-induced DNA damage caused a transient dose-dependent immobilization of ERCC1/XPF, likely due to engagement of the complex in a single repair event. After 4 minutes, the complex regained mobility. These results suggest (i) that NER operates by assembly of individual NER factors at sites of DNA damage rather than by preassembly of holocomplexes and (ii) that ERCC1/XPF participates in repair of DNA damage in a distributive fashion rather than by processive scanning of large genome segments.	Erasmus Univ, Dept Cell Biol & Genet, Ctr Med Genet, CBG, NL-3000 DR Rotterdam, Netherlands; Erasmus Univ, Dept Pathol, Josephine Nefkens Inst, NL-3000 DR Rotterdam, Netherlands	Erasmus University Rotterdam; Erasmus University Rotterdam; Erasmus MC	Hoeijmakers, JHJ (corresponding author), Erasmus Univ, Dept Cell Biol & Genet, Ctr Med Genet, CBG, POB 1738, NL-3000 DR Rotterdam, Netherlands.		Hoeijmakers, Jan/AAX-6972-2021; Vermeulen, Wim/W-8708-2019	Vermeulen, Wim/0000-0003-3616-734X				ABOUSSEKHRA A, 1995, CELL, V80, P859, DOI 10.1016/0092-8674(95)90289-9; AXELROD D, 1976, BIOPHYS J, V16, P1055, DOI 10.1016/S0006-3495(76)85755-4; BIGGERSTAFF M, 1993, EMBO J, V12, P3685, DOI 10.1002/j.1460-2075.1993.tb06043.x; Bootsma D., 1998, GENETIC BASIS HUMAN, P245; CHALFIE M, 1994, SCIENCE, V263, P802, DOI 10.1126/science.8303295; COVERLEY D, 1991, NATURE, V349, P538, DOI 10.1038/349538a0; de Laat WL, 1998, GENE DEV, V12, P2598, DOI 10.1101/gad.12.16.2598; de Laat WL, 1999, GENE DEV, V13, P768, DOI 10.1101/gad.13.7.768; Ellenberg J, 1997, J CELL BIOL, V138, P1193, DOI 10.1083/jcb.138.6.1193; FRIEDBERG EC, 1995, DNA REPAIR MUTAGENES; Guzder SN, 1996, J BIOL CHEM, V271, P8903, DOI 10.1074/jbc.271.15.8903; Guzder SN, 1998, J BIOL CHEM, V273, P6292, DOI 10.1074/jbc.273.11.6292; HANAWALT PC, 1994, CURR BIOL, V4, P518, DOI 10.1016/S0960-9822(00)00112-3; Hoeijmakers JHJ, 1996, CURR OPIN GENET DEV, V6, P26, DOI 10.1016/S0959-437X(96)90006-4; JACKSON DA, 1994, J CELL SCI, V107, P1745; Koehler DR, 1996, NUCLEIC ACIDS RES, V24, P2877, DOI 10.1093/nar/24.15.2877; MCCREADY SJ, 1984, J CELL SCI, V70, P189; MITCHELL DL, 1985, MUTAT RES, V143, P109, DOI 10.1016/S0165-7992(85)80018-X; MITCHELL DL, 1989, PHOTOCHEM PHOTOBIOL, V49, P805, DOI 10.1111/j.1751-1097.1989.tb05578.x; ODONOVAN A, 1994, NATURE, V371, P432, DOI 10.1038/371432a0; OH EY, 1989, J BIOL CHEM, V264, P1336; PARK CH, 1995, J BIOL CHEM, V270, P22657, DOI 10.1074/jbc.270.39.22657; PRASHER DC, 1992, GENE, V111, P229, DOI 10.1016/0378-1119(92)90691-H; RADEMAKERS S, UNPUB; Rijkers T, 1998, MOL CELL BIOL, V18, P6423, DOI 10.1128/MCB.18.11.6423; SANCAR A, 1996, ANNU REV BIOCHEM, V43, P135; Seksek O, 1997, J CELL BIOL, V138, P131, DOI 10.1083/jcb.138.1.131; Sijbers AM, 1996, NUCLEIC ACIDS RES, V24, P3370, DOI 10.1093/nar/24.17.3370; Sijbers AM, 1996, CELL, V86, P811, DOI 10.1016/S0092-8674(00)80155-5; Sugasawa K, 1998, MOL CELL, V2, P223, DOI 10.1016/S1097-2765(00)80132-X; SVEJSTRUP JQ, 1995, CELL, V80, P21, DOI 10.1016/0092-8674(95)90447-6; Swaminathan R, 1997, BIOPHYS J, V72, P1900, DOI 10.1016/S0006-3495(97)78835-0; TANAKA K, 1990, NATURE, V348, P73, DOI 10.1038/348073a0; VANVUUREN AJ, 1993, EMBO J, V12, P3693, DOI 10.1002/j.1460-2075.1993.tb06044.x; WEY CL, 1981, BIOPHYS J, V33, P225, DOI 10.1016/S0006-3495(81)84883-7; Wood RD, 1996, ANNU REV BIOCHEM, V65, P135, DOI 10.1146/annurev.bi.65.070196.001031; Yagi T, 1997, MUTAGENESIS, V12, P41, DOI 10.1093/mutage/12.1.41	37	285	291	0	18	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	MAY 7	1999	284	5416					958	961		10.1126/science.284.5416.958	http://dx.doi.org/10.1126/science.284.5416.958			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	194MU	10320375				2022-12-28	WOS:000080198800044
J	Komeili, A; O'Shea, EK				Komeili, A; O'Shea, EK			Roles of phosphorylation sites in regulating activity of the transcription factor Pho4	SCIENCE			English	Article							CYCLIN-CDK COMPLEX; SACCHAROMYCES-CEREVISIAE; PROTEIN; PHO80-PHO85; PROMOTER; YEAST; IDENTIFICATION; SEQUENCES; NUCLEUS; REGULON	Transcription factors are often phosphorylated at multiple sites. Here it is shown that multiple phosphorylation sites on the budding yeast transcription factor Pho4 play distinct and separable roles in regulating the factor's activity. Phosphorylation of Pho4 at two sites promotes the factor's nuclear export and phosphorylation at a third site inhibits its nuclear import. Phosphorylation of a fourth site blocks the interaction of Pho4 with the transcription factor Pho2. Multiple phosphorylation sites provide overlapping and partially redundant Layers of regulation that function to efficiently control the activity of Pho4.	Univ Calif San Francisco, Dept Biochem & Biophys, San Francisco, CA 94143 USA	University of California System; University of California San Francisco	O'Shea, EK (corresponding author), Univ Calif San Francisco, Dept Biochem & Biophys, 513 Parnassus Ave, San Francisco, CA 94143 USA.	oshea@biochem.ucsf.edu						Barbaric S, 1996, NUCLEIC ACIDS RES, V24, P4479, DOI 10.1093/nar/24.22.4479; BRAZAS RM, 1993, MOL CELL BIOL, V13, P5524, DOI 10.1128/MCB.13.9.5524; Calkhoven CF, 1996, BIOCHEM J, V317, P329, DOI 10.1042/bj3170329; HIRST K, 1994, EMBO J, V13, P5410, DOI 10.1002/j.1460-2075.1994.tb06876.x; JOHNSTON M, 1984, MOL CELL BIOL, V4, P1440, DOI 10.1128/MCB.4.8.1440; Kaffman A, 1998, GENE DEV, V12, P2673, DOI 10.1101/gad.12.17.2673; Kaffman A, 1998, NATURE, V396, P482, DOI 10.1038/24898; KAFFMAN A, 1994, SCIENCE, V263, P1153, DOI 10.1126/science.8108735; KARIN M, 1995, CURR BIOL, V5, P747, DOI 10.1016/S0960-9822(95)00151-5; KOMEILI A, UNPUB; Magbanua JPV, 1997, J BIOCHEM, V121, P1182; McAndrew PC, 1998, MOL CELL BIOL, V18, P5818, DOI 10.1128/MCB.18.10.5818; NASMYTH K, 1990, CELL, V62, P631, DOI 10.1016/0092-8674(90)90110-Z; OGAWA N, 1990, MOL CELL BIOL, V10, P2224, DOI 10.1128/MCB.10.5.2224; ONeill EM, 1996, SCIENCE, V271, P209, DOI 10.1126/science.271.5246.209; Oshima Y, 1997, GENES GENET SYST, V72, P323, DOI 10.1266/ggs.72.323; PEARSON RB, 1991, METHOD ENZYMOL, V200, P62; SCHNEIDER KR, 1994, SCIENCE, V266, P122, DOI 10.1126/science.7939631; STRAWN J, 1980, COMPUT MUSIC J, V4, P3, DOI 10.2307/3679635; TOHE A, 1973, J BACTERIOL, V113, P727, DOI 10.1128/JB.113.2.727-738.1973	20	234	237	4	25	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAY 7	1999	284	5416					977	980		10.1126/science.284.5416.977	http://dx.doi.org/10.1126/science.284.5416.977			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	194MU	10320381				2022-12-28	WOS:000080198800050
J	Bergmark, K; Avall-Lundqvist, E; Dickman, PW; Henningsohn, L; Steineck, G				Bergmark, K; Avall-Lundqvist, E; Dickman, PW; Henningsohn, L; Steineck, G			Vaginal changes and sexuality in women with a history of cervical cancer	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							DYSFUNCTION; CARCINOMA; RADIATION; THERAPY; SURGERY	Background In women with cervical cancer, treatment causes changes in vaginal anatomy and function. The effect of these changes on sexual function and the extent, if any, to which they distress women are not known. Methods In 1996 and 1997, we attempted to contact 332 women with a history of early-stage cervical cancer (age range, 26 to 80 years) who had been treated in 1991 and 1992 at the seven departments of gynecological oncology in Sweden and 489 women without a history of cancer (controls) to ask them to answer an anonymous questionnaire about vaginal changes and sexual function. Results We received completed questionnaires from 256 of the women with a history of cervical cancer and 350 of the controls. A total of 167 of 247 women with a history of cancer (68 percent) and 236 of 330 controls (72 percent) reported that they had regular vaginal intercourse. Twenty-six percent of the women who had cancer and 11 percent of the controls reported insufficient vaginal lubrication for sexual intercourse, 26 percent of the women who had cancer and 3 percent of the controls reported a short vagina, and 23 percent of the women who had cancer and 4 percent of the controls reported an insufficiently elastic vagina. Twenty-six percent of the women who had cancer reported moderate or much distress due to vaginal changes, as compared with 8 percent of the women in the control group. Dyspareunia was also more common among the women who had cervical cancer. The frequency of orgasms and orgasmic pleasure was similar in the two groups. Among the women who had cervical cancer, the type of treatment received had little if any effect on the prevalence of specific vaginal changes. Conclusions Women who have been treated for cervical cancer have persistent vaginal changes that compromise sexual activity and result in considerable distress. (N Engl J Med 1999;340:1383-9.) (C) 1999, Massachusetts Medical Society.	Karolinska Hosp, Div Epidemiol, S-17176 Stockholm, Sweden; Karolinska Inst, Radiumhemmet, Dept Oncol, Div Gynecol Oncol, Stockholm, Sweden; Karolinska Inst, Radiumhemmet, Dept Oncol, Div Clin Epidemiol, Stockholm, Sweden; Huddinge Hosp, Dept Urol, Stockholm, Sweden	Karolinska Institutet; Karolinska University Hospital; Karolinska Institutet; Karolinska Institutet	Steineck, G (corresponding author), Karolinska Hosp, Div Epidemiol, Norrbacka S-2 06, S-17176 Stockholm, Sweden.		Dickman, Paul W/B-4572-2013; Steineck, Gunnar/W-1515-2019; Avall-Lundqvist, Elisabeth/C-9292-2009	Dickman, Paul W/0000-0002-5788-3380; Steineck, Gunnar/0000-0002-0787-3969; Henningsohn, Lars/0000-0002-5521-8934				ABITBOL MM, 1974, AM J OBSTET GYNECOL, V119, P181, DOI 10.1016/0002-9378(74)90031-3; ANDERSEN BL, 1989, J CONSULT CLIN PSYCH, V57, P683, DOI 10.1037/0022-006X.57.6.683; Benedet J, 1998, J EPIDEMIOL BIOSTAT, V3, P5; BERTELSEN K, 1983, DAN MED BULL, V30, P31; Borjeson S, 1997, CANCER NURS, V20, P260; BOS G, 1986, INT C SERIES, V707, P575; BRUNER DW, 1993, INT J RADIAT ONCOL, V27, P825, DOI 10.1016/0360-3016(93)90455-5; CORNEY RH, 1993, BRIT J OBSTET GYNAEC, V100, P73, DOI 10.1111/j.1471-0528.1993.tb12955.x; FLAY LD, 1995, INT J RADIAT ONCOL, V31, P399, DOI 10.1016/0360-3016(94)E0139-B; Helgason A, 1996, BRIT J CANCER, V73, P1417, DOI 10.1038/bjc.1996.268; HELGASON AR, 1997, J EPIDEMIOL BIOSTAT, V2, P213; KRUMM S, 1993, J PSYCHOSOM OBST GYN, V14, P51, DOI 10.3109/01674829309084430; PISANI P, 1985, INT J CANCER, V55, P891; PITKIN RM, 1971, RADIOLOGY, V99, P417, DOI 10.1148/99.2.417; ROTHMAN KJ, 1998, MODERN EPIDEMIOLOGY, P271; *SAS I, 1990, SAS PROC GUID VERS 6, P350; SCHOVER LR, 1989, CANCER, V63, P204, DOI 10.1002/1097-0142(19890101)63:1<204::AID-CNCR2820630133>3.0.CO;2-U; SEIBEL MM, 1980, OBSTET GYNECOL, V55, P484; Steineck G, 1998, ACTA ONCOL, V37, P15, DOI 10.1080/028418698423131; STEINECK G, 1992, EPIDEMIOLOGY, V3, P477, DOI 10.1097/00001648-199211000-00003; VASICKA A, 1958, OBSTET GYNECOL, V11, P403	21	493	503	0	22	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	MAY 6	1999	340	18					1383	1389		10.1056/NEJM199905063401802	http://dx.doi.org/10.1056/NEJM199905063401802			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	192QN	10228188				2022-12-28	WOS:000080090600002
J	Michels, R				Michels, R			Are research ethics bad for our mental health?	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material							MEDICAL PROGRESS; PSYCHIATRY		Cornell Univ Med Coll, New York, NY 10021 USA	Cornell University	Michels, R (corresponding author), Cornell Univ Med Coll, New York, NY 10021 USA.							Appelbaum PS, 1997, ARCH GEN PSYCHIAT, V54, P117; BEECHER HK, 1966, NEW ENGL J MED, V274, P1354, DOI 10.1056/NEJM196606162742405; BEECHER HK, 1959, AM LECT SERIES PUBLI, V52; GRISSO T, 1995, LAW HUMAN BEHAV, V19, P149, DOI 10.1007/BF01499323; Kong D, 1998, BOSTON GLOBE    1115, pA1; Marshall E, 1998, SCIENCE, V282, P1617; MICHELS R, 1993, NEW ENGL J MED, V329, P628, DOI 10.1056/NEJM199308263290908; MICHELS R, 1993, NEW ENGL J MED, V329, P552, DOI 10.1056/NEJM199308193290808; *NAT COMM PROT HUM, 1978, REP REC RES INV THOS, P58; National Bioethics Advisory Commission, 1998, RES INV PERS MENT DI; *NIH I HIGH ED DEP, 1995, PSYCHIAT REP, V10, P19; *NUR MIL TRIB, 1949, 10 NUR MIL TRIB, V2, P181; *NY STAT DEP HLTH, 1998, REC OV HUM SUBJ RES; *OFF MD ATT GEN, 1998, FIN REP ATT GEN WORK; *OFF PROT RES RISK, 1994, EV HUM SUBJ PROT SCH; PINCUS HA, 1999, ETHICS PSYCHIAT RES, P282; Sugarman Jeremy, 1998, IRB, V20, P1, DOI 10.2307/3564262; *WHO, 1997, GLOB BURD DIS; WOLPE PR, 1999, ETHICS PSYCHIAT RES, P11; *WORLD MED ASS DEC, 1997, JAMA-J AM MED ASSOC, V277, P925, DOI DOI 10.1001/JAMA.1997.03540350075038	20	69	70	0	3	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	MAY 6	1999	340	18					1427	1430		10.1056/NEJM199905063401811	http://dx.doi.org/10.1056/NEJM199905063401811			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	192QN	10228197				2022-12-28	WOS:000080090600011
J	Saitta, AM; Soper, PD; Wasserman, E; Klein, ML				Saitta, AM; Soper, PD; Wasserman, E; Klein, ML			Influence of a knot on the strength of a polymer strand	NATURE			English	Article							MECHANICAL-PROPERTIES; MOLECULAR-DYNAMICS; TOPOLOGY; DNA; POLYETHYLENE; BEHAVIOR	Many experiments have been done to determine the relative strengths of different knots, and these show that the break in a knotted rope almost invariably occurs at the point just outside the 'entrance' to the knot(1). The influence of knots on the properties of polymers has become of great interest,in part because of their effect on mechanical properties(2). Knot theory(3,4) applied to the topology of macromolecules(5-8) indicates that the simple trefoil or 'overhand' knot is likely to be present in any long polymer strand(9-12). Fragments of DNA have been observed to contain such knots in experiments(13,14) and computer simulations(15). Here we use ab initio computational methods(16) to investigate the effect of a trefoil knot on the breaking strength of a polymer strand. We find that the knot weakens the strand significantly, and that, like a knotted rope, it breaks under tension at the entrance to the knot.	Univ Penn, Dept Chem, Ctr Mol Modeling, Philadelphia, PA 19104 USA; Dupont Co, Cent Res & Dev, Expt Stn, Wilmington, DE 19880 USA	University of Pennsylvania; DuPont	Klein, ML (corresponding author), Univ Penn, Dept Chem, Ctr Mol Modeling, Philadelphia, PA 19104 USA.		Saitta, Antonino Marco/D-9605-2015	Saitta, Antonino Marco/0000-0002-3298-2040				Ancilotto F, 1997, SCIENCE, V275, P1288, DOI 10.1126/science.275.5304.1288; ARAI Y, IN PRESS NATURE; Ashley CW., 1993, ASHLEY BOOK KNOTS; ATIYHA MF, 1990, GEOMETRY PHYSICS KNO; BAYER RK, 1994, COLLOID POLYM SCI, V272, P910, DOI 10.1007/BF00658889; BECKE AD, 1988, PHYS REV A, V38, P3098, DOI 10.1103/PhysRevA.38.3098; DEGENNES PG, 1984, MACROMOLECULES, V17, P703, DOI 10.1021/ma00134a030; FRANKKAMENETSKII MD, 1975, NATURE, V258, P398, DOI 10.1038/258398a0; FRISCH HL, 1993, NEW J CHEM, V17, P697; FRISCH HL, 1961, J AM CHEM SOC, V83, P3789, DOI 10.1021/ja01479a015; KARASAWA N, 1991, J PHYS CHEM-US, V95, P2260, DOI 10.1021/j100159a031; Katritch V, 1997, NATURE, V388, P148, DOI 10.1038/40582; LEE CT, 1988, PHYS REV B, V37, P785, DOI 10.1103/PhysRevB.37.785; MANSFIELD ML, 1994, MACROMOLECULES, V27, P5924, DOI 10.1021/ma00098a057; MARTYNA GJ, IN PRESS COMP PHYS C; Mislow K., 1965, INTRO STEREOCHEMISTR; Montanari B, 1997, CHEM PHYS LETT, V272, P347, DOI 10.1016/S0009-2614(97)00455-7; Mundy CJ, 1996, FARADAY DISCUSS, V104, P17, DOI 10.1039/fd9960400017; Schill G., 1971, CATENANES ROTAXANES; SCHLICK T, 1992, SCIENCE, V257, P1110, DOI 10.1126/science.257.5073.1110; SHAW SY, 1993, SCIENCE, V260, P533, DOI 10.1126/science.8475384; SIEPMANN JI, 1993, NATURE, V365, P330, DOI 10.1038/365330a0; VANRENSBURG EJJ, 1992, J PHYS A-MATH GEN, V25, P6557, DOI 10.1088/0305-4470/25/24/010; WALBA DM, 1985, TETRAHEDRON, V41, P3161, DOI 10.1016/S0040-4020(01)96671-2; WASSERMAN SA, 1986, SCIENCE, V232, P951, DOI 10.1126/science.3010458	26	179	181	4	81	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	MAY 6	1999	399	6731					46	48		10.1038/19935	http://dx.doi.org/10.1038/19935			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	194BK	10331387	Green Submitted			2022-12-28	WOS:000080172100049
J	Pound, CR; Partin, AW; Eisenberger, MA; Chan, DW; Pearson, JD; Walsh, PC				Pound, CR; Partin, AW; Eisenberger, MA; Chan, DW; Pearson, JD; Walsh, PC			Natural history of progression after PSA elevation following radical prostatectomy	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							RETROPUBIC PROSTATECTOMY; PROGNOSTIC FACTORS; CANCER; RECURRENCE; CARCINOMA; ANTIGEN; MEN; SURVIVAL; LEUPROLIDE; VARIABLES	Context In men who develop an elevated serum prostate-specific antigen level (PSA) after having undergone a radical prostatectomy, the natural history of progression to distant metastases and death due to prostate cancer is unknown. Objective To characterize the time course of disease progression in men with biochemical recurrence after radical prostatectomy. Design A retrospective review of a large surgical series with median (SD) follow-up of 5.3 (3.7) years (range, 0.5-15 years) between April 1982 and April 1997, Setting An urban academic tertiary referral institution. Patients A total of 1997 men undergoing radical prostatectomy, by a single surgeon, for clinically localized prostate cancer. None received neoadjuvant therapy, and none had received adjuvant hormonal therapy prior to documented distant metastases. Main Outcome Measures After surgery, men were followed up with PSA assays and digital rectal examinations every 3 months for the first year, semiannually for the second year, and annually thereafter. A detectable serum PSA level of at least 0.2 ng/mL was evidence of biochemical recurrence. Distant metastases were diagnosed by radionuclide bone scan, chest radiograph, or other body imaging, which was performed at the time of biochemical recurrence and annually thereafter. Results The actuarial metastasis-free survival for all 1997 men was 82% (95% confidence interval, 76%-88%) at 15 years after surgery, Of the 1997 men, 315 (15%) developed biochemical PSA level elevation. Eleven of these underwent early hormone therapy after the recurrence and are not included in the study. Of the remaining 304 men, 103 (34%) developed metastatic disease within the study period. The median actuarial time to metastases was 8 years from the time of PSA level elevation. in survival analysis, time to biochemical progression (P<.001), Gleason score (P<.001), and PSA doubling time (P<.001) were predictive of the probability and time to the development of metastatic disease. An algorithm combining these parameters was constructed to stratify men into risk groups. Once men developed metastatic disease, the median actuarial time to death was 5 years. The time interval from surgery to the appearance of metastatic disease was predictive of time until death (P<.02). Conclusions Several clinical parameters help predict the outcomes of men with PSA elevation after radical prostatectomy. These data may be useful in the design of clinical trials, the identification of men for enrollment into experimental protocols, and counseling men regarding the timing of administration of adjuvant therapies.	Johns Hopkins Med Inst, James Buchanan Brady Urol Inst, Dept Urol, Baltimore, MD 21205 USA; Johns Hopkins Med Inst, Dept Oncol, Baltimore, MD 21205 USA; Johns Hopkins Med Inst, Dept Pathol, Baltimore, MD 21205 USA; Merck Res Labs, Dept Epidemiol, Blue Bell, PA USA	Johns Hopkins University; Johns Hopkins Medicine; Johns Hopkins University; Johns Hopkins Medicine; Johns Hopkins University; Johns Hopkins Medicine; Merck & Company	Partin, AW (corresponding author), Johns Hopkins Hosp, James Buchanan Brady Urol Inst, 600 N Wolfe St, Baltimore, MD 21287 USA.		Chan, Doris/O-1227-2014	Chan, Doris/0000-0002-4990-986X	NCI NIH HHS [CA58326] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R29CA058326] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ADOLFSSON J, 1993, CANCER-AM CANCER SOC, V72, P310, DOI 10.1002/1097-0142(19930715)72:2<310::AID-CNCR2820720203>3.0.CO;2-T; Bauer JJ, 1997, CANCER, V79, P952, DOI 10.1002/(SICI)1097-0142(19970301)79:5<952::AID-CNCR12>3.0.CO;2-1; Byar D P, 1988, NCI Monogr, P165; BYAR DP, 1973, CANCER, V32, P1126, DOI 10.1002/1097-0142(197311)32:5<1126::AID-CNCR2820320518>3.0.CO;2-C; CATALONA WJ, 1994, J UROLOGY, V152, P1837, DOI 10.1016/S0022-5347(17)32397-2; CRAWFORD ED, 1989, NEW ENGL J MED, V321, P419, DOI 10.1056/NEJM198908173210702; Dillioglugil O, 1997, UROLOGY, V50, P93, DOI 10.1016/S0090-4295(97)00106-4; Eisenberger MA, 1998, NEW ENGL J MED, V339, P1036, DOI 10.1056/NEJM199810083391504; Gerber GS, 1996, JAMA-J AM MED ASSOC, V276, P615; GIBBONS RP, 1989, J UROLOGY, V141, P564, DOI 10.1016/S0022-5347(17)40895-0; GOLIMBU M, 1987, UROLOGY, V30, P427, DOI 10.1016/0090-4295(87)90373-6; KAPLAN EL, 1958, J AM STAT ASSOC, V53, P457, DOI 10.2307/2281868; KRAMOLOWSKY EV, 1988, J UROLOGY, V139, P1242, DOI 10.1016/S0022-5347(17)42879-5; Krongrad A, 1997, JAMA-J AM MED ASSOC, V278, P44; LEPOR H, 1989, J UROLOGY, V141, P82, DOI 10.1016/S0022-5347(17)40596-9; OHORI M, 1994, J UROLOGY, V152, P1843, DOI 10.1016/S0022-5347(17)32398-4; PARTIN AW, 1994, UROLOGY, V43, P649, DOI 10.1016/0090-4295(94)90180-5; PARTIN AW, 1995, UROLOGY, V45, P831, DOI 10.1016/S0090-4295(99)80091-0; PARTIN AW, 1993, UROL CLIN N AM, V20, P713; Patel A, 1997, J UROLOGY, V158, P1441, DOI 10.1016/S0022-5347(01)64238-1; Pound CR, 1997, UROL CLIN N AM, V24, P395, DOI 10.1016/S0094-0143(05)70386-4; Scher H I, 1992, Semin Urol, V10, P55; Schroder FH, 1998, CAMPBELLS UROLOGY, V3, P2627; SGRIGNOLI AR, 1994, J UROLOGY, V152, P1077, DOI 10.1016/S0022-5347(17)32507-7; SHARIFI R, 1990, J UROLOGY, V143, P68, DOI 10.1016/S0022-5347(17)39868-3; SOLOWAY MS, 1990, CANCER, V66, P1017; STECKEL J, 1994, AUA UPDATE SERIES, V13, P166; TRAPASSO JG, 1994, J UROLOGY, V152, P1821, DOI 10.1016/S0022-5347(17)32394-7; Veltri R W, 1998, Semin Urol Oncol, V16, P106; WALSH PC, 1989, J UROLOGY, V141, P1032; ZINCKE H, 1994, J UROLOGY, V152, P1850, DOI 10.1016/S0022-5347(17)32399-6; ZINCKE H, 1992, CANCER, V70, P312	32	2390	2446	0	67	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAY 5	1999	281	17					1591	1597		10.1001/jama.281.17.1591	http://dx.doi.org/10.1001/jama.281.17.1591			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	191MJ	10235151	Bronze			2022-12-28	WOS:000080025900022
J	LeBoff, MS; Kohlmeier, L; Hurwitz, S; Franklin, J; Wright, J; Glowacki, J				LeBoff, MS; Kohlmeier, L; Hurwitz, S; Franklin, J; Wright, J; Glowacki, J			Occult vitamin D deficiency in postmenopausal US women with acute hip fracture	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							PARATHYROID-HORMONE LEVELS; FEMORAL-NECK FRACTURE; BONE TURNOVER; ELDERLY WOMEN; PROXIMAL FEMUR; OLDER WOMEN; OSTEOPOROSIS; OSTEOMALACIA; POPULATION; CALCIUM	Context Low vitamin D levels may contribute to hip fractures in women, although limited data are available on vitamin D levels in US women admitted with acute hip fractures. Objective To determine whether postmenopausal women with hip fractures have low vitamin D and high parathyroid hormone levels compared with nonosteoporotic and osteoporotic women admitted for elective joint replacement. Design Comparative case series conducted between January 1995 and June 1998, Setting and Patients Ninety-eight postmenopausal community-dwelling women with no secondary causes of bone loss admitted for hip replacement, of whom 30 women had acute hip fractures and 68 women were admitted for elective joint replacement. Of the women admitted for elective joint replacement, 17 had osteoporosis and 51 did not. Women with comorbid conditions or who were taking medications that affect bone density and turnover were excluded. Main Outcome Measures Primary measures were levels of vitamin D and parathyroid hormone; secondary measures were body composition and markers of bone turnover. Results Women with hip fractures had lower levels of 25-hydroxyvitamin D than women without osteoporosis admitted for elective joint replacement (P=.02) and than women with osteoporosis admitted for elective joint replacement (P=.01) (medians, 32.4, 49.9, and 55.0 nmol/L, respectively; comparisons adjusted for age and estrogen intake). Parathyroid hormone levels were higher in women with fractures than women in the nonosteoporotic control group (P<.001) or than elective osteoporotic women (P=.001) (medians, 5.58, 3.26, and 3.79 pmol/L, respectively; comparisons adjusted for age and estrogen intake). Fifteen patients (50.0%) with hip fractures had deficient vitamin D levels (less than or equal to 30.0 nmol/L) and 11 (36.7%) had a parathyroid hormone level greater than 6.84 pmol/L, Levels of N-telopeptide, a marker of bone resorption, were greater in the women with hip fractures than in the elective nonosteoporotic controls (P=.004). Conclusions Postmenopausal community-living women who presented with hip fracture showed occult vitamin D deficiency. Repletion of vitamin D and suppression of parathyroid hormone at the time of fracture may reduce future fracture risk and facilitate hip fracture repair. Because vitamin D deficiency is preventable, heightened awareness is necessary to ensure adequate vitamin D nutrition, particularly in northern latitudes.	Brigham & Womens Hosp, Div Endocrine Hypertens, Skeletal Hlth & Osteoporosis Program, Dept Internal Med, Boston, MA 02115 USA; Brigham & Womens Hosp, Div Endocrine Hypertens, Skeletal Hlth & Osteoporosis Program, Dept Orthoped Surg, Boston, MA 02115 USA	Harvard University; Brigham & Women's Hospital; Harvard University; Brigham & Women's Hospital	LeBoff, MS (corresponding author), Brigham & Womens Hosp, Div Endocrine Hypertens, Skeletal Hlth & Osteoporosis Program, Dept Internal Med, 221 Longwood Ave, Boston, MA 02115 USA.	msleboff@bics.bwh.harvard.edu			NIA NIH HHS [R01 AG 13519, R01 AG 12271] Funding Source: Medline; NATIONAL INSTITUTE ON AGING [R01AG013519, R01AG012271] Funding Source: NIH RePORTER	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		AARON JE, 1974, LANCET, V1, P229; AKESSON K, 1993, CALCIFIED TISSUE INT, V53, P162, DOI 10.1007/BF01321832; BAKER MR, 1979, BRIT MED J, V1, P589, DOI 10.1136/bmj.1.6163.589; Boonen S, 1996, J ENDOCRINOL, V149, P13, DOI 10.1677/joe.0.1490013; BOUILLON RA, 1987, AM J CLIN NUTR, V45, P755, DOI 10.1093/ajcn/45.4.755; Carey VJ, 1997, AM J EPIDEMIOL, V145, P614, DOI 10.1093/oxfordjournals.aje.a009158; Chalmers J, 1969, Clin Orthop Relat Res, V63, P196; Chapuy MC, 1997, OSTEOPOROSIS INT, V7, P439, DOI 10.1007/s001980050030; CHAPUY MC, 1992, NEW ENGL J MED, V327, P1637, DOI 10.1056/NEJM199212033272305; COMPSTON JE, 1989, CLIN ENDOCRINOL, V31, P667, DOI 10.1111/j.1365-2265.1989.tb01291.x; Cummings SR, 1998, NEW ENGL J MED, V339, P733, DOI 10.1056/NEJM199809103391104; DawsonHughes B, 1997, NEW ENGL J MED, V337, P670, DOI 10.1056/NEJM199709043371003; EL-HAJJ FULEIHAN G, 1995, J BONE MINER RES, V10, P1004; Garnero P, 1996, J BONE MINER RES, V11, P337, DOI 10.1002/jbmr.5650110307; GUNDBERG CM, 1991, J CLIN ENDOCR METAB, V72, P438, DOI 10.1210/jcem-72-2-438; Haden ST, 1999, CALCIFIED TISSUE INT, V64, P275, DOI 10.1007/s002239900618; HARMA M, 1987, ANN CLIN RES, V19, P378; HORDON LD, 1990, BONE MINER, V11, P247, DOI 10.1016/0169-6009(90)90063-L; JOHNSTON CC, 1985, J CLIN ENDOCR METAB, V61, P551, DOI 10.1210/jcem-61-3-551; JONGEN MJM, 1984, CLIN CHEM, V30, P399; KAMEL S, 1994, BONE MINER, V26, P197, DOI 10.1016/S0169-6009(08)80169-9; KANIS JA, 1994, OSTEOPOROSIS INT, V4, P368, DOI 10.1007/BF01622200; Khosla S, 1997, J CLIN ENDOCR METAB, V82, P1522, DOI 10.1210/jc.82.5.1522; KRISKA AM, 1992, DIABETES METAB REV, V8, P355, DOI 10.1002/dmr.5610080404; LIPS P, 1982, METAB BONE DIS RELAT, V4, P85, DOI 10.1016/0221-8747(82)90021-2; LIPS P, 1983, J CLIN ENDOCR METAB, V57, P204, DOI 10.1210/jcem-57-1-204; LIPS P, 1995, J BONE MINER RES, V10, pS496; Looker AC, 1997, J BONE MINER RES, V12, P1761, DOI 10.1359/jbmr.1997.12.11.1761; MCKENNA MJ, 1992, AM J MED, V93, P69, DOI 10.1016/0002-9343(92)90682-2; OOMS ME, 1995, J BONE MINER RES, V10, P1177; PARFITT AM, 1982, AM J CLIN NUTR, V36, P1014, DOI 10.1093/ajcn/36.5.1014; PEACOCK M, 1985, 6 WORKSH VIT D, P569; Prestwood KM, 1996, OSTEOPOROSIS INT, V6, P314, DOI 10.1007/BF01623391; Ray NF, 1997, J BONE MINER RES, V12, P24, DOI 10.1359/jbmr.1997.12.1.24; SOKOLOFF L, 1978, AM J SURG PATHOL, V2, P21, DOI 10.1097/00000478-197803000-00003; SOLOMON L, 1973, S AFR J SURG, V11, P269; WEBB AR, 1990, AM J CLIN NUTR, V51, P1075, DOI 10.1093/ajcn/51.6.1075	38	357	374	0	3	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	APR 28	1999	281	16					1505	1511		10.1001/jama.281.16.1505	http://dx.doi.org/10.1001/jama.281.16.1505			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	188PP	10227320	Bronze			2022-12-28	WOS:000079857400032
J	Fears, R; Poste, G				Fears, R; Poste, G			Health care delivery - Building population genetics resources using the UK NHS	SCIENCE			English	Editorial Material							EPIDEMIOLOGY; DISEASE; GENOME		SmithKline Beecham, Harlow CM19 5AW, Essex, England	GlaxoSmithKline	Fears, R (corresponding author), SmithKline Beecham, New Frontiers Sci Pk, Harlow CM19 5AW, Essex, England.	robin_b_fears@sbphrd.com						*ASS MED COLL, 1998, MAX INV; Bell J, 1998, BMJ-BRIT MED J, V316, P618, DOI 10.1136/bmj.316.7131.618; Blair Tony, 1998, 3 WAY NEW POLITICS N, V588; COUCH FJ, 1998, NAT GENET, V279, P955; Department of Health, 1997, NEW NHS; Enserink M, 1998, SCIENCE, V281, P890, DOI 10.1126/science.281.5379.890; Enserink M, 1998, SCIENCE, V282, P859, DOI 10.1126/science.282.5390.859; Enserink M, 1999, SCIENCE, V283, P13; FEARS R, IN PRESS BR MED B; Firn D, 1998, NAT MED, V4, P1096, DOI 10.1038/2583; Godlee F, 1998, BRIT MED J, V317, P6, DOI 10.1136/bmj.317.7150.6; Grimshaw JM, 1998, J ROY SOC MED, V91, P20, DOI 10.1177/014107689809135S06; Hodgson J, 1998, NAT BIOTECHNOL, V16, P1017, DOI 10.1038/3463; Khoury MJ, 1997, EPIDEMIOL REV, V19, P175, DOI 10.1093/oxfordjournals.epirev.a017940; Khoury MJ, 1998, AM J EPIDEMIOL, V148, P1; KORN D, 1996, ISSUES SCI TECH, V55; KUKULL WA, 1998, NAT GENET, V279, P788; LENAGHAN J, 1998, BRAVE NEW NHS; McGleenan T, 1997, RIGHT KNOW RIGHT NOT, P43; MITCHELL P, 1998, HLTH SERVICES J  OCT, P1; Murray CJL, 1996, SCIENCE, V274, P740, DOI 10.1126/science.274.5288.740; Poste G, 1998, Nat Biotechnol, V16 Suppl, P19, DOI 10.1038/5403; Reilly PR, 1998, NAT GENET, V20, P15, DOI 10.1038/1668; *ROYAL COLL PHYS, 1995, SETT PRIOR NHS; *SMITHKL BEECH SCI, 1995, HUM GENET, P81; Stephenson J, 1998, JAMA-J AM MED ASSOC, V279, P735, DOI 10.1001/jama.279.10.735; WALSHE K, 1997, ACTING EVIDENCE PROG; Welch HG, 1998, JAMA-J AM MED ASSOC, V280, P1525, DOI 10.1001/jama.280.17.1525; Wyatt J, 1998, BRIT MED J, V317, P900; 1998, NATURE GENET, V20, P99; 1998, NATURE GENET, V20, P217	31	22	22	0	3	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	APR 9	1999	284	5412					267	268		10.1126/science.284.5412.267	http://dx.doi.org/10.1126/science.284.5412.267			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	184WH	10232974				2022-12-28	WOS:000079636400026
J	De Socio, GVL; Marroni, M; Menichetti, F				De Socio, GVL; Marroni, M; Menichetti, F			Sepsis with multiple organ dysfunction	LANCET			English	Article									Univ Perugia, Inst Infect Dis, I-06122 Perugia, Italy	University of Perugia	De Socio, GVL (corresponding author), Univ Perugia, Inst Infect Dis, I-06122 Perugia, Italy.		De Socio, Giuseppe Vittorio/H-6237-2012	De Socio, Giuseppe Vittorio/0000-0001-8774-4843				BONE RC, 1992, CHEST, V101, P1644, DOI 10.1378/chest.101.6.1644; Quinn TC, 1997, JAMA-J AM MED ASSOC, V278, P58, DOI 10.1001/jama.278.1.58; RANGELFRAUSTO MS, 1995, JAMA-J AM MED ASSOC, V273, P117, DOI 10.1001/jama.273.2.117; WANG YJ, 1995, ALCOHOL, V12, P105, DOI 10.1016/0741-8329(94)00090-5; Wenzel RP, 1996, CLIN INFECT DIS, V22, P407, DOI 10.1093/clinids/22.3.407	5	0	0	0	2	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON WC1B 3SL, ENGLAND	0140-6736			LANCET	Lancet	MAY 23	1998	351	9115					1552	1552						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZQ497	10326539				2022-12-28	WOS:000073868000012
J	Sharifi, I; FeKri, AR; Aflatonian, MR; Khamesipour, A; Nadim, A; Mousavi, MRA; Momeni, AZ; Dowlati, Y; Godal, T; Zicker, F; Smith, PG; Modabber, F				Sharifi, I; FeKri, AR; Aflatonian, MR; Khamesipour, A; Nadim, A; Mousavi, MRA; Momeni, AZ; Dowlati, Y; Godal, T; Zicker, F; Smith, PG; Modabber, F			Randomised vaccine trial of single dose of killed Leishmania major plus BCG against anthroponotic cutaneous leishmaniasis in Bam, Iran	LANCET			English	Article							AMERICAN DERMAL LEISHMANIASIS; IMMUNOTHERAPY; MICE	Background A vaccine consisting of a single dose of whole-cell autoclave-killed Leishmania major (ALM) mixed with BCG was assessed in comparison with BCG alone against anthroponotic (human to human transmission) cutaneous leishmaniasis in a randomised double-blind trial in Bam, Iran. Methods 3637 schoolchildren, aged 6-15 years, with no history of cutaneous leishmaniasis and no response to a leishmanin skin test, were randomly assigned to receive 1 mg ALM mixed with BCG (n=1839), or BCG alone (n=1798). Safety of the vaccine and the incidence of confirmed-cases of cutaneous leishmaniasis were followed up for 2 years. Findings Side-effects were those usually associated with BCG vaccination, but-tended to persist longer in the ALM+BCG group. After exclusion of four cases occurring within 80 days of vaccination tone in the ALM+BCG group and three in the BCG group), the 2-year incidence of cutaneous leishmaniasis did not differ significantly between vaccine and BCG groups: 2-8% vs 3-3%, respectively (total cases 112). A sex-stratified analysis showed that in boys the vaccine conferred a protective efficacy of 18% and 78% for the first and second years, respectively-a crude 2-year overall protection of 55% (95% CI 19-75%, p<0.01). In the first 9 months after vaccination, there was a non-significant excess of cases in the ALM+BCG group (25 vs 16), whereas the incidence of cutaneous leishmaniasis-thereafter was significantly reduced in the ALM+BCG group (27 vs 44, p<0.05). Interpretation A single dose of ALM+BCG was safe and more immunogenic than BCG alone, as measured by leishmanin shin test. The exact reason-for the apparent protective effect of the vaccine in boys is unknown, and maybe a chance finding. However, since boys are more exposed to the infection, which is indicated-by higher disease prevalence in boys in this study population, the preferential protective effect in boys may have resulted from a greater booster effect produced by repeated exposure to infected sandflies. Booster injections or alternative adjuvants should be tried to improve the potential efficacy of this vaccine.	WHO, UNDP, World Bank, Special Programme Res & Training Trop Dis, CH-1211 Geneva 27, Switzerland; Kerman Univ Med Sch, Sch Med, Kerman, Iran; Prov Hlth Ctr, Bam Kerman, Iran; Univ Tehran Med Sci, Ctr Res & Training Skin Dis & Leprosy, Tehran, Iran; Univ Tehran Med Sci, Sch Publ Hlth, Tehran, Iran; Isfahan Univ Med Sci, Esfahan, Iran; London Sch Hyg & Trop Med, London WC1, England	The World Bank; World Health Organization; Kerman University of Medical Sciences; Tehran University of Medical Sciences; Tehran University of Medical Sciences; Isfahan University Medical Science; University of London; London School of Hygiene & Tropical Medicine	Modabber, F (corresponding author), WHO, UNDP, World Bank, Special Programme Res & Training Trop Dis, CH-1211 Geneva 27, Switzerland.		Zicker, Fabio/I-4138-2012; Fekri, Alireza/ABH-1440-2020; Sharifi, Iraj/AAY-8267-2020; Reza, Aflatoonian Mohammad/Y-2246-2018; smith, peter/ABH-9627-2020	Zicker, Fabio/0000-0002-9751-7430; Fekri, Alireza/0000-0001-7009-2164; Reza, Aflatoonian Mohammad/0000-0002-2148-6690; smith, peter/0000-0003-0080-7560; Aflatounian, Mohammadreza/0000-0003-4834-5086; Sharifi, Iraj/0000-0002-6894-6834				Abbas AK, 1996, NATURE, V383, P787, DOI 10.1038/383787a0; Alimohammadian MH, 1993, MED J ISLAM REPUB IR, V7, P23; ANTUNES CM, 1986, INT J EPIDEMIOL, V15, P572, DOI 10.1093/ije/15.4.572; Bahar K, 1996, CLIN DERMATOL, V14, P489, DOI 10.1016/0738-081X(96)00071-5; CONVIT J, 1989, J INFECT DIS, V160, P104, DOI 10.1093/infdis/160.1.104; CONVIT J, 1987, LANCET, V1, P401; Desjeux P, 1996, CLIN DERMATOL, V14, P417, DOI 10.1016/0738-081X(96)00057-0; Evans D.A., 1987, P52; HASHEMIFESHARKI R, 1992, ARCH I RAZI, V43, P39; MAYRINK W, 1979, T ROY SOC TROP MED H, V73, P385, DOI 10.1016/0035-9203(79)90159-7; MAYRINK W, 1985, ANN TROP MED PARASIT, V79, P259, DOI 10.1080/00034983.1985.11811917; MODABBER F, 1996, MOL IMMUNE MECHANISM, P23; Mohebali M, 1995, MED J ISLAMIC REP IR, V8, P211; Nadim A., 1988, RES CONTROL STRATEGI, P162; NADIM A, 1988, RES CONTROL STRATEGI, P336; SMRKOVSKI LL, 1977, INFECT IMMUN, V18, P561, DOI 10.1128/IAI.18.2.561-562.1977; SOKAL JE, 1975, NEW ENGL J MED, V293, P501, DOI 10.1056/NEJM197509042931013; STEFANI MMA, 1993, RES IMMUNOL, V144, P233, DOI 10.1016/0923-2494(93)80100-D; WEINTRAUB J, 1977, J IMMUNOL, V118, P2288	19	185	189	0	6	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736			LANCET	Lancet	MAY 23	1998	351	9115					1540	1543		10.1016/S0140-6736(98)09552-X	http://dx.doi.org/10.1016/S0140-6736(98)09552-X			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZQ497	10326536				2022-12-28	WOS:000073868000009
J	Baughman, RH; Cui, CX; Zakhidov, AA; Iqbal, Z; Barisci, JN; Spinks, GM; Wallace, GG; Mazzoldi, A; De Rossi, D; Rinzler, AG; Jaschinski, O; Roth, S; Kertesz, M				Baughman, RH; Cui, CX; Zakhidov, AA; Iqbal, Z; Barisci, JN; Spinks, GM; Wallace, GG; Mazzoldi, A; De Rossi, D; Rinzler, AG; Jaschinski, O; Roth, S; Kertesz, M			Carbon nanotube actuators	SCIENCE			English	Article							GRAPHITE-INTERCALATION COMPOUNDS; CHARGE-TRANSFER; ARTIFICIAL MUSCLES; DIFFRACTION	Electromechanical actuators based on sheets of single-walled carbon nanotubes were shown to generate higher stresses than natural muscle and higher strains than high-modulus ferroelectrics. Like natural muscles, the macroscopic actuators are assemblies of billions of individual nanoscale actuators. The actuation mechanism (quantum chemical-based expansion due to electrochemical double-layer charging) does not require ion intercalation, which Limits the Life and rate of faradaic conducting polymer actuators. Unlike conventional ferroelectric actuators, low operating voltages of a few volts generate large actuator strains. Predictions based on measurements suggest that actuators using optimized nanotube sheets may eventually provide substantially higher work densities per cycle than any previously known technology.	Allied Signal Inc, Res & Technol, Morristown, NJ 07962 USA; Univ Wollongong, Intelligent Polymer Res Inst, Wollongong, NSW 2522, Australia; Univ Pisa, Ctr E Piaggio, Sch Engn, I-56100 Pisa, Italy; Univ Florida, Dept Phys, Gainesville, FL 32611 USA; Max Planck Inst Festkorperforsch, D-70569 Stuttgart, Germany; Georgetown Univ, Dept Chem, Washington, DC 20057 USA	University of Wollongong; University of Pisa; State University System of Florida; University of Florida; Max Planck Society; Georgetown University	Baughman, RH (corresponding author), Allied Signal Inc, Res & Technol, 101 Columbia Rd, Morristown, NJ 07962 USA.		Spinks, Geoffrey/T-6363-2019; Spinks, Geoffrey/E-5612-2011; Kertesz, Miklos/E-7122-2010; Wallace, Gordon G/H-1123-2011; Han, Jinhua/F-9464-2010; Baughman, Ray Henry/A-8628-2018	Spinks, Geoffrey/0000-0003-4656-9473; Spinks, Geoffrey/0000-0003-4656-9473; Kertesz, Miklos/0000-0002-7930-3260; Wallace, Gordon G/0000-0002-0381-7273; Baughman, Ray Henry/0000-0001-5845-5137; Zakhidov, Anvar/0000-0003-3983-2229				BARON F, 1982, SOLID STATE COMMUN, V42, P759, DOI 10.1016/0038-1098(82)90001-1; BAUGHMAN RH, 1992, PHYS REV B, V46, P10515, DOI 10.1103/PhysRevB.46.10515; Baughman RH, 1996, SYNTHETIC MET, V78, P339, DOI 10.1016/0379-6779(96)80158-5; BAUGHMAN RH, 1990, NATO ADV SCI I E-APP, V182, P559; BAUGHMAN RH, UNPUB; CHAN CT, 1987, PHYS REV LETT, V58, P1528, DOI 10.1103/PhysRevLett.58.1528; DellaSanta A, 1997, SMART MATER STRUCT, V6, P23, DOI 10.1088/0964-1726/6/1/003; Falvo MR, 1997, NATURE, V389, P582, DOI 10.1038/39282; FISHER JE, 1987, PHYS REV B, V36, P4449; FLANDROIS S, 1990, SYNTHETIC MET, V34, P399, DOI 10.1016/0379-6779(89)90415-3; FORSTER RJ, 1994, CHEM SOC REV, V23, P289, DOI 10.1039/cs9942300289; GANDHI MR, 1995, SYNTHETIC MET, V73, P247, DOI 10.1016/0379-6779(95)80022-0; Gao GH, 1998, NANOTECHNOLOGY, V9, P184, DOI 10.1088/0957-4484/9/3/007; GERISCHER H, 1987, J PHYS CHEM-US, V91, P1930, DOI 10.1021/j100291a049; KAMITAKAHARA WA, 1985, SYNTHETIC MET, V12, P301, DOI 10.1016/0379-6779(85)90126-2; KANETO K, 1995, SYNTHETIC MET, V71, P2211, DOI 10.1016/0379-6779(94)03226-V; KERTESZ M, 1985, MOL CRYST LIQ CRYST, V126, P103, DOI 10.1080/15421408508084159; Liu J, 1998, SCIENCE, V280, P1253, DOI 10.1126/science.280.5367.1253; MADDEN JD, 1996, P WORKSH WORK MICR I, P9; MURAKAMI Y, 1990, J PHYS SOC JPN, V59, P571, DOI 10.1143/JPSJ.59.571; NIXON DE, 1969, J PHYS PART C SOLID, V2, P1732, DOI 10.1088/0022-3719/2/10/305; OREN Y, 1985, J ELECTROANAL CHEM, V187, P59, DOI 10.1016/0368-1874(85)85575-1; Otero TF, 1998, ADV MATER, V10, P491, DOI 10.1002/(SICI)1521-4095(199804)10:6<491::AID-ADMA491>3.0.CO;2-Q; PIETRONERO L, 1981, PHYS REV LETT, V47, P593, DOI 10.1103/PhysRevLett.47.593; RADIN JP, 1972, ELECTROANAL CHEM INT, V36, P257; Rao AM, 1997, NATURE, V388, P257, DOI 10.1038/40827; Rinzler AG, 1998, APPL PHYS A-MATER, V67, P29, DOI 10.1007/s003390050734; SMELA E, 1995, SCIENCE, V268, P1735, DOI 10.1126/science.268.5218.1735; SPUDICH JA, 1994, NATURE, V372, P515, DOI 10.1038/372515a0; Thess A, 1996, SCIENCE, V273, P483, DOI 10.1126/science.273.5274.483; Treacy MMJ, 1996, NATURE, V381, P678, DOI 10.1038/381678a0; Uchino K., 1997, PIEZOELECTRIC ACTUAT; Wong EW, 1997, SCIENCE, V277, P1971, DOI 10.1126/science.277.5334.1971; Ye Y, 1999, APPL PHYS LETT, V74, P2307, DOI 10.1063/1.123833; Zhang QM, 1998, SCIENCE, V280, P2101, DOI 10.1126/science.280.5372.2101	35	2139	2240	22	771	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	MAY 21	1999	284	5418					1340	1344		10.1126/science.284.5418.1340	http://dx.doi.org/10.1126/science.284.5418.1340			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	198NN	10334985	Green Submitted			2022-12-28	WOS:000080430600048
J	Galan, JE; Collmer, A				Galan, JE; Collmer, A			Type III secretion machines: Bacterial devices for protein delivery into host cells	SCIENCE			English	Review							ENTEROPATHOGENIC ESCHERICHIA-COLI; PLANT-PATHOGENIC BACTERIA; SALMONELLA-TYPHIMURIUM; EPITHELIAL-CELLS; YERSINIA-ENTEROCOLITICA; PSEUDOMONAS-SYRINGAE; SHIGELLA-FLEXNERI; TARGET-CELL; TYROSINE-PHOSPHATASE; ERWINIA-AMYLOVORA	Several Cram-negative pathogenic bacteria have evolved a complex protein secretion system termed type III to deliver bacterial effector proteins into host cells that then modulate host cellular functions. These bacterial devices are present in both plant and animal pathogenic bacteria and are evolutionarily related to the flagellar apparatus. Although type III secretion systems are substantially conserved, the effector molecules they deliver are unique for each bacterial species. Understanding the biology of these devices may allow the development of novel prevention and therapeutic approaches for several infectious diseases.	Yale Univ, Sch Med, Boyer Ctr Mol Med, Sect Microbial Pathogenesis, New Haven, CT 06536 USA; Cornell Univ, Dept Plant Pathol, Ithaca, NY 14853 USA	Yale University; Cornell University	Galan, JE (corresponding author), Yale Univ, Sch Med, Boyer Ctr Mol Med, Sect Microbial Pathogenesis, 333 Cedar St, New Haven, CT 06536 USA.	jorge.galan@yale.edu			NIAID NIH HHS [AI30491] Funding Source: Medline; NIGMS NIH HHS [GM52543] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM052543] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Aizawa SI, 1996, MOL MICROBIOL, V19, P1, DOI 10.1046/j.1365-2958.1996.344874.x; Alfano JR, 1996, PLANT CELL, V8, P1683, DOI 10.1105/tpc.8.10.1683; Alfano JR, 1997, J BACTERIOL, V179, P5655, DOI 10.1128/jb.179.18.5655-5662.1997; Anderson DM, 1999, MOL MICROBIOL, V31, P1139, DOI 10.1046/j.1365-2958.1999.01254.x; Anderson DM, 1997, SCIENCE, V278, P1140, DOI 10.1126/science.278.5340.1140; ANDERSON DM, UNPUB; Baker B, 1997, SCIENCE, V276, P726, DOI 10.1126/science.276.5313.726; Black DS, 1997, EMBO J, V16, P2730, DOI 10.1093/emboj/16.10.2730; BLISKA JB, 1995, INFECT IMMUN, V63, P681, DOI 10.1128/IAI.63.2.681-685.1995; Bogdanove AJ, 1998, P NATL ACAD SCI USA, V95, P1325, DOI 10.1073/pnas.95.3.1325; Bonas U, 1997, PLANT J, V12, P1, DOI 10.1046/j.1365-313X.1997.12010001.x; Boyd AP, 1998, MOL MICROBIOL, V27, P425, DOI 10.1046/j.1365-2958.1998.00691.x; Chen YJ, 1996, EMBO J, V15, P3853, DOI 10.1002/j.1460-2075.1996.tb00759.x; Cheng LW, 1997, MOL MICROBIOL, V24, P757, DOI 10.1046/j.1365-2958.1997.3831750.x; Collazo CM, 1997, MOL MICROBIOL, V24, P747, DOI 10.1046/j.1365-2958.1997.3781740.x; Collmer A, 1998, CURR OPIN PLANT BIOL, V1, P329, DOI 10.1016/1369-5266(88)80055-4; Cornelis GR, 1998, MICROBIOL MOL BIOL R, V62, P1315, DOI 10.1128/MMBR.62.4.1315-1352.1998; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; Donnenberg MS, 1997, TRENDS MICROBIOL, V5, P109, DOI 10.1016/S0966-842X(97)01000-7; EICHELBERG K, 1994, J BACTERIOL, V176, P4501, DOI 10.1128/JB.176.15.4501-4510.1994; Fan F, 1996, J BIOL CHEM, V271, P31981, DOI 10.1074/jbc.271.50.31981; Fu YX, 1998, MOL MICROBIOL, V27, P359, DOI 10.1046/j.1365-2958.1998.00684.x; Galan JE, 1999, CURR OPIN MICROBIOL, V2, P46, DOI 10.1016/S1369-5274(99)80008-3; GALAN JE, 1992, J BACTERIOL, V174, P4338; Galan JE, 1998, P NATL ACAD SCI USA, V95, P14006, DOI 10.1073/pnas.95.24.14006; Galan JE, 1998, TRENDS MICROBIOL, V6, P3, DOI 10.1016/S0966-842X(97)01183-9; Gaudriault S, 1997, MOL MICROBIOL, V26, P1057, DOI 10.1046/j.1365-2958.1997.6442015.x; GINOCCHIO CC, 1995, INFECT IMMUN, V63, P729, DOI 10.1128/IAI.63.2.729-732.1995; GINOCCHIO CC, 1994, CELL, V76, P717, DOI 10.1016/0092-8674(94)90510-X; GOGUEN JD, 1986, INFECT IMMUN, V51, P788, DOI 10.1128/IAI.51.3.788-794.1986; GROISMAN EA, 1993, EMBO J, V12, P3779, DOI 10.1002/j.1460-2075.1993.tb06056.x; Groisman EA, 1996, CELL, V87, P791, DOI 10.1016/S0092-8674(00)81985-6; Hakansson S, 1996, EMBO J, V15, P5812, DOI 10.1002/j.1460-2075.1996.tb00968.x; Ham JH, 1998, P NATL ACAD SCI USA, V95, P10206, DOI 10.1073/pnas.95.17.10206; Hardt WD, 1997, P NATL ACAD SCI USA, V94, P9887, DOI 10.1073/pnas.94.18.9887; Hardt WD, 1998, CELL, V93, P815, DOI 10.1016/S0092-8674(00)81442-7; Hueck CJ, 1998, MICROBIOL MOL BIOL R, V62, P379, DOI 10.1128/MMBR.62.2.379-433.1998; HUGHES KT, 1993, SCIENCE, V262, P1277, DOI 10.1126/science.8235660; Iriarte M, 1998, EMBO J, V17, P1907, DOI 10.1093/emboj/17.7.1907; KANIGA K, 1995, J BACTERIOL, V177, P7078, DOI 10.1128/jb.177.24.7078-7085.1995; Kenny B, 1997, CELL, V91, P511, DOI 10.1016/S0092-8674(00)80437-7; Kim JF, 1998, MOL PLANT MICROBE IN, V11, P1247, DOI 10.1094/MPMI.1998.11.12.1247; Knutton S, 1998, EMBO J, V17, P2166, DOI 10.1093/emboj/17.8.2166; Kubori T, 1998, SCIENCE, V280, P602, DOI 10.1126/science.280.5363.602; Leach JE, 1996, ANNU REV PHYTOPATHOL, V34, P153, DOI 10.1146/annurev.phyto.34.1.153; Lee CA, 1997, TRENDS MICROBIOL, V5, P148, DOI 10.1016/S0966-842X(97)01029-9; Lee VT, 1999, MOL MICROBIOL, V31, P1619, DOI 10.1046/j.1365-2958.1999.01270.x; MACBETH KJ, 1993, INFECT IMMUN, V61, P1544, DOI 10.1128/IAI.61.4.1544-1546.1993; Macnab R., 1996, ESCHERICHIA COLI SAL, V2nd ed, P119; MENARD R, 1994, CELL, V79, P515, DOI 10.1016/0092-8674(94)90260-7; MENARD R, 1994, EMBO J, V13, P5293, DOI 10.1002/j.1460-2075.1994.tb06863.x; MICHIELS T, 1991, J BACTERIOL, V173, P4994, DOI 10.1128/jb.173.16.4994-5009.1991; Mills SD, 1997, P NATL ACAD SCI USA, V94, P12638, DOI 10.1073/pnas.94.23.12638; Monack DM, 1997, P NATL ACAD SCI USA, V94, P10385, DOI 10.1073/pnas.94.19.10385; Neyt C, 1999, MOL MICROBIOL, V31, P143, DOI 10.1046/j.1365-2958.1999.01154.x; Norris FA, 1998, P NATL ACAD SCI USA, V95, P14057, DOI 10.1073/pnas.95.24.14057; PARSOT C, 1995, MOL MICROBIOL, V16, P291, DOI 10.1111/j.1365-2958.1995.tb02301.x; Persson C, 1997, EMBO J, V16, P2307, DOI 10.1093/emboj/16.9.2307; PERSSON C, 1995, MOL MICROBIOL, V18, P135, DOI 10.1111/j.1365-2958.1995.mmi_18010135.x; Pettersson J, 1996, SCIENCE, V273, P1231, DOI 10.1126/science.273.5279.1231; PUGSLEY AP, 1993, MICROBIOL REV, V57, P50, DOI 10.1128/MMBR.57.1.50-108.1993; Roine E, 1997, P NATL ACAD SCI USA, V94, P3459, DOI 10.1073/pnas.94.7.3459; ROSQVIST R, 1995, EMBO J, V14, P4187, DOI 10.1002/j.1460-2075.1995.tb00092.x; ROSQVIST R, 1994, EMBO J, V13, P964, DOI 10.1002/j.1460-2075.1994.tb06341.x; SNEATH J, 1973, NUMERICAL TAXONOMY; Sory MP, 1995, P NATL ACAD SCI USA, V92, P11998, DOI 10.1073/pnas.92.26.11998; SORY MP, 1994, MOL MICROBIOL, V14, P583, DOI 10.1111/j.1365-2958.1994.tb02191.x; TUCKER S, UNPUB; Van Gijsegem F, 1993, Trends Microbiol, V1, P175, DOI 10.1016/0966-842X(93)90087-8; Van Nhieu GT, 1999, CURR OPIN MICROBIOL, V2, P51; VanNhieu GT, 1997, EMBO J, V16, P2717, DOI 10.1093/emboj/16.10.2717; WATTIAU P, 1993, MOL MICROBIOL, V8, P123, DOI 10.1111/j.1365-2958.1993.tb01209.x; WATTIAU P, 1994, P NATL ACAD SCI USA, V91, P10493, DOI 10.1073/pnas.91.22.10493; WEI ZM, 1992, SCIENCE, V257, P85, DOI 10.1126/science.1621099; Yahr TL, 1996, MOL MICROBIOL, V22, P991, DOI 10.1046/j.1365-2958.1996.01554.x; Zhou D, 1999, SCIENCE, V283, P2092, DOI 10.1126/science.283.5410.2092; ZIERLER MK, 1995, INFECT IMMUN, V63, P4024, DOI 10.1128/IAI.63.10.4024-4028.1995; ZYCHLINSKY A, 1992, NATURE, V358, P167, DOI 10.1038/358167a0; Zychlinsky A, 1997, J CLIN INVEST, V100, P493, DOI 10.1172/JCI119557	79	974	1033	2	12	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAY 21	1999	284	5418					1322	1328		10.1126/science.284.5418.1322	http://dx.doi.org/10.1126/science.284.5418.1322			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	198NN	10334981				2022-12-28	WOS:000080430600044
J	Chamberlain, G; Steer, PL				Chamberlain, G; Steer, PL			ABC of labour care - Obstetric emergencies	BRITISH MEDICAL JOURNAL			English	Review									Singleton Hosp, Swansea SA2 8QA, W Glam, Wales; Chelsea & Westminster Hosp, Imperial Coll, Sch Med, London, England	Singleton Hospital; Imperial College London	Chamberlain, G (corresponding author), Singleton Hosp, Swansea SA2 8QA, W Glam, Wales.							*DEP HLTH, 1994, CONF ENQ MAT DEATH 1, P43; DOUGLAS KA, 1994, BMJ-BRIT MED J, V309, P1395, DOI 10.1136/bmj.309.6966.1395; JAMES D, 1999, HIGH RISK OBSTET; Love CDB, 1996, BRIT J OBSTET GYNAEC, V103, P864, DOI 10.1111/j.1471-0528.1996.tb09903.x; *SANDS, 1991, GUID PROF	5	11	14	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	MAY 15	1999	318	7194					1342	1345		10.1136/bmj.318.7194.1342	http://dx.doi.org/10.1136/bmj.318.7194.1342			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	198HR	10323825	Green Published			2022-12-28	WOS:000080418400041
J	Harper, R; Reeves, B				Harper, R; Reeves, B			Reporting of precision of estimates for diagnostic accuracy: a review	BRITISH MEDICAL JOURNAL			English	Review							MEDICAL LITERATURE; USERS GUIDES; ARTICLE		Manchester Royal Eye Hosp, Dept Ophthalmol, Manchester M13 9WH, Lancs, England; Univ London London Sch Hyg & Trop Med, Hlth Serv Res Unit, London WC1E 7HT, England	Manchester Royal Eye Hospital; University of London; London School of Hygiene & Tropical Medicine	Harper, R (corresponding author), Manchester Royal Eye Hosp, Dept Ophthalmol, Manchester M13 9WH, Lancs, England.			Harper, Robert/0000-0001-5437-2553				HARPER R, 1998, OPTOM VIS SCI, V75, P78; JAESCHKE R, 1994, JAMA-J AM MED ASSOC, V271, P389, DOI 10.1001/jama.271.5.389; JAESCHKE R, 1994, JAMA-J AM MED ASSOC, V271, P703, DOI 10.1001/jama.271.9.703; Mikelberg F S, 1995, J Glaucoma, V4, P242; REID MC, 1995, JAMA-J AM MED ASSOC, V274, P645, DOI 10.1001/jama.274.8.645	5	134	136	0	3	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	MAY 15	1999	318	7194					1322	1323		10.1136/bmj.318.7194.1322	http://dx.doi.org/10.1136/bmj.318.7194.1322			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	198HR	10323817	Green Published			2022-12-28	WOS:000080418400026
J	Nicolson, RI; Fawcett, AJ; Berry, EL; Jenkins, IH; Dean, P; Brooks, DJ				Nicolson, RI; Fawcett, AJ; Berry, EL; Jenkins, IH; Dean, P; Brooks, DJ			Association of abnormal cerebellar activation with motor learning difficulties in dyslexic adults	LANCET			English	Article							DEVELOPMENTAL DYSLEXIA; INVOLVEMENT; CHILDREN; DEFICITS	Background In addition to their impairments in literacy-related skills, dyslexic children show characteristic difficulties in phonological skill, motor skill, and balance. There is behavioural and biochemical evidence that these difficulties may be attributable to mild cerebellar dysfunction. We wanted to find out whether there was abnormal brain activation when dyslexic adults undertook tasks known normally to involve cerebellar activation. Methods Brain activation was monitored by positron emission tomography in matched groups of six dyslexic adults and six control adults as they carried out either a prelearned sequence or learned a navel sequence of finger movements. Findings Brain activation was significantly lower (p<0.01) far the dyslexic adults than for the controls in the right cerebellar cortex and the left cingulate gyrus when executing the prelearned sequence,and in the right cerebellar cortex when learning the new sequence. Interpretation The results provided direct evidence that, for this group of dyslexic adults, the behavioural signs of cerebellar abnormality reflect underlying abnormalities in cerebellar activation.	Univ Sheffield, Dept Psychol, Sheffield S10 2TP, S Yorkshire, England; Hammersmith Hosp, MRC, Cyclotron Unit, London W12 0HS, England; Inst Neurol, London WC1N 3BG, England	University of Sheffield; Imperial College London; University of London; University College London	Nicolson, RI (corresponding author), Univ Sheffield, Dept Psychol, Western Bank, Sheffield S10 2TP, S Yorkshire, England.	r.nicolson@shef.ac.uk	Nicolson, Rod Ian/GQZ-4137-2022; Fawcett, Angela/AAA-6600-2021	Brooks, David/0000-0003-2602-2518				AKSHOOMOFF NA, 1992, BEHAV NEUROSCI, V106, P731, DOI 10.1037/0735-7044.106.5.731; Allen G, 1997, SCIENCE, V275, P1940, DOI 10.1126/science.275.5308.1940; American Psychiatric Association, 1987, DIAGN STAT MAN MENT; BRADLEY L, 1983, NATURE, V301, P419, DOI 10.1038/301419a0; Dow R. S., 1958, PHYSL PATHOLOGY CERE; Eccles J.C., 1967, CEREBELLUM NEURONAL, DOI [10.1016/0013-4694(69)90099-6, DOI 10.1016/0013-4694(69)90099-6]; Eden GF, 1996, NATURE, V382, P66, DOI 10.1038/382066a0; Fawcett A., 1994, DYSLEXIA CHILDREN MU; Fawcett AJ, 1996, ANN DYSLEXIA, V46, P259, DOI 10.1007/BF02648179; Fawcett AJ, 1999, J MOTOR BEHAV, V31, P68, DOI 10.1080/00222899909601892; FRANK J, 1973, J AM ACAD CHILD PSY, V12, P690, DOI 10.1016/S0002-7138(09)61276-0; Friston K., 1994, HUM BRAIN MAPP, V2, P189, DOI [DOI 10.1002/HBM.460020402, 10.1002/hbm.460020402]; Holmes G, 1917, BRAIN, V40, P461, DOI 10.1093/brain/40.4.461; ITO M, 1990, REV NEUROL, V146, P564; Ivry R B, 1989, J Cogn Neurosci, V1, P136, DOI 10.1162/jocn.1989.1.2.136; JENKINS IH, 1994, J NEUROSCI, V14, P3775; JORM AF, 1986, J CHILD PSYCHOL PSYC, V27, P45, DOI 10.1111/j.1469-7610.1986.tb00620.x; LEINER HC, 1993, TRENDS NEUROSCI, V16, P444, DOI 10.1016/0166-2236(93)90072-T; NICOLSON RI, 1994, ANN DYSLEXIA, V44, P147, DOI 10.1007/BF02648159; NICOLSON RI, 1995, P ROY SOC B-BIOL SCI, V259, P43, DOI 10.1098/rspb.1995.0007; NICOLSON RI, 1994, Q J EXP PSYCHOL-A, V47, P29, DOI 10.1080/14640749408401142; NICOLSON RI, 1990, COGNITION, V35, P159, DOI 10.1016/0010-0277(90)90013-A; PAULESU E, 1993, NATURE, V362, P342, DOI 10.1038/362342a0; Paulesu E, 1996, BRAIN, V119, P143, DOI 10.1093/brain/119.1.143; Rae C, 1998, LANCET, V351, P1849, DOI 10.1016/S0140-6736(97)99001-2; Rudel R. G., 1985, DYSLEXIA NEUROSCIENT, P33; SILVERI MC, 1994, NEUROLOGY, V44, P2047, DOI 10.1212/WNL.44.11.2047; STANOVICH KE, 1988, ANN DYSLEXIA, V38, P154, DOI 10.1007/BF02648254; Talairach J, 1988, COPLANAR STEROTAXIC; *WELLC DEP COGN NE, 1996, SPM96 WELLC I WELL D; WOLF M, 1991, READ RES QUART, V26, P123, DOI 10.2307/747978; WOLFF PH, 1990, DEV PSYCHOL, V26, P349, DOI 10.1037/0012-1649.26.3.349; World Federation of Neurology, 1968, REP RES GROUP DYSL W; YAP RL, 1994, J LEARN DISABIL, V27, P660, DOI 10.1177/002221949402701006; [No title captured]	35	241	249	0	28	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	MAY 15	1999	353	9165					1662	1667		10.1016/S0140-6736(98)09165-X	http://dx.doi.org/10.1016/S0140-6736(98)09165-X			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	198DT	10335786				2022-12-28	WOS:000080408000011
J	Discher, BM; Won, YY; Ege, DS; Lee, JCM; Bates, FS; Discher, DE; Hammer, DA				Discher, BM; Won, YY; Ege, DS; Lee, JCM; Bates, FS; Discher, DE; Hammer, DA			Polymersomes: Tough vesicles made from diblock copolymers	SCIENCE			English	Article							COMPLEX PHASE-BEHAVIOR; FLUID MEMBRANES; CURVATURE ELASTICITY; PHYSICAL-PROPERTIES; BILAYER-MEMBRANES; BLOCK-COPOLYMERS; SURFACTANT; COHESION	Vesicles were made from amphiphilic diblock copolymers and characterized by micromanipulation. The average molecular weight of the specific polymer studied, polyethyleneoxide-polyethylethylene (EO40-EE37), is several times greater than that of typical phospholipids in natural membranes. Both the membrane bending and area expansion moduli of electroformed polymersomes (polymer-based Liposomes) fell within the range of Lipid membrane measurements, but the giant polymersomes proved to be almost an order of magnitude tougher and sustained far greater areal strain before rupture. The polymersome membrane was also at Least 10 times Less permeable to water than common phospholipid bilayers. The results suggest a new class of synthetic thin-shelled capsules based on block copolymer chemistry.	Univ Penn, Sch Engn & Appl Sci, Philadelphia, PA 19104 USA; Univ Penn, Inst Med & Engn, Philadelphia, PA 19104 USA; Univ Minnesota, Dept Chem Engn & Mat Sci, Minneapolis, MN 55455 USA	University of Pennsylvania; University of Pennsylvania; Pennsylvania Medicine; University of Minnesota System; University of Minnesota Twin Cities	Discher, DE (corresponding author), Univ Penn, Sch Engn & Appl Sci, Philadelphia, PA 19104 USA.			discher, dennis/0000-0001-6163-2229; Lee, James/0000-0002-7173-4875	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL018208, R01HL062352] Funding Source: NIH RePORTER; NHLBI NIH HHS [R01-HL62352-01, P01-HL18208] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ANGELOVA MI, 1992, PROG COLL POL SCI S, V89, P127; BENSHAUL A, 1995, HDB PHYSICS BIOL SYS, V1, pCH7; BLOOM M, 1991, Q REV BIOPHYS, V24, P293, DOI 10.1017/S0033583500003735; Cevc G., 1995, HDB BIOL PHYSICS, V1; Chaieb S, 1998, PHYS REV E, V58, P7733, DOI 10.1103/PhysRevE.58.7733; Cornelissen JJLM, 1998, SCIENCE, V280, P1427, DOI 10.1126/science.280.5368.1427; DEULING HJ, 1976, J PHYS-PARIS, V37, P1335, DOI 10.1051/jphys:0197600370110133500; Dobereiner HG, 1997, PHYS REV E, V55, P4458, DOI 10.1103/PhysRevE.55.4458; EVANS E, 1990, PHYS REV LETT, V64, P2094, DOI 10.1103/PhysRevLett.64.2094; EVANS E, 1987, J PHYS CHEM-US, V91, P4219, DOI 10.1021/j100300a003; Hajduk DA, 1998, J PHYS CHEM B, V102, P4269, DOI 10.1021/jp973323z; Harasym TO, 1997, CANCER CHEMOTH PHARM, V40, P309, DOI 10.1007/s002800050662; Harris J. M., 1997, POLYETHYLENE GLYCOL; HELFRICH W, 1984, NUOVO CIMENTO D, V3, P137, DOI 10.1007/BF02452208; Hillmyer MA, 1996, SCIENCE, V271, P976, DOI 10.1126/science.271.5251.976; Israelachvili J.N., 1991, INTERMOLECULAR SURFA; Koltover I, 1998, SCIENCE, V281, P78, DOI 10.1126/science.281.5373.78; Lasic D., 1995, HDB BIOL PHYS, V1; LIN Z, 1993, J PHYS CHEM-US, V97, P3571, DOI 10.1021/j100116a022; LONGO MI, 1994, SCIENCE, V266, P1032; Longo ML, 1997, BIOPHYS J, V73, P1430, DOI 10.1016/S0006-3495(97)78175-X; NEEDHAM D, 1990, BIOPHYS J, V58, P997, DOI 10.1016/S0006-3495(90)82444-9; Needham D., 1996, VESICLES; Netz RR, 1996, PHYS REV E, V53, P3875, DOI 10.1103/PhysRevE.53.3875; PETROV AG, 1984, PROG SURF SCI, V16, P389, DOI 10.1016/0079-6816(84)90016-9; SACKMANN E, 1995, HDB BIOL PHYSICS A, V1; Seifert U., 1995, P403; SEIFERT U, 1991, PHYS REV A, V44, P1182, DOI 10.1103/PhysRevA.44.1182; SVETINA S, 1989, EUR BIOPHYS J BIOPHY, V17, P101, DOI 10.1007/BF00257107; SZLEIFER I, 1988, PHYS REV LETT, V60, P1966, DOI 10.1103/PhysRevLett.60.1966; WALTER A, 1991, BIOPHYS J, V60, P1315, DOI 10.1016/S0006-3495(91)82169-5; Warriner HE, 1996, SCIENCE, V271, P969, DOI 10.1126/science.271.5251.969; Won YY, 1999, SCIENCE, V283, P960, DOI 10.1126/science.283.5404.960; Yu K, 1998, MACROMOLECULES, V31, P3509, DOI 10.1021/ma971419l	34	2103	2183	18	963	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAY 14	1999	284	5417					1143	1146		10.1126/science.284.5417.1143	http://dx.doi.org/10.1126/science.284.5417.1143			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	197HJ	10325219				2022-12-28	WOS:000080359100029
J	Chamberlain, G; Steer, P				Chamberlain, G; Steer, P			ABC of labour care - Operative delivery	BRITISH MEDICAL JOURNAL			English	Review							CESAREAN-SECTION		Univ London Imperial Coll Sci Technol & Med, Chelsea & Westminster Hosp, Sch Med, London, England	Imperial College London	Chamberlain, G (corresponding author), Univ London Imperial Coll Sci Technol & Med, Chelsea & Westminster Hosp, Sch Med, London, England.							CHAMBERLAIN G, 1999, PRACTICE OBSTET GYNA; CHAMBERLAIN G, 1997, HOME BIRTHS, P67; *DEP HLTH, 1997, NHS MAT STAT 1980 19; Drife JO, 1996, BRIT J OBSTET GYNAEC, V103, P608, DOI 10.1111/j.1471-0528.1996.tb09825.x; ENKIN M, 1995, EFFECTIVE CARE PREGN, P284; Grant A, 1996, BRIT J OBSTET GYNAEC, V103, P1197, DOI 10.1111/j.1471-0528.1996.tb09628.x; KUIT JA, 1993, OBSTET GYNECOL, V82, P280; ODRISCOL K, 1995, ACTIVE MANAGEMENT LA; SAVAGE W, 1993, BRIT J OBSTET GYNAEC, V100, P493, DOI 10.1111/j.1471-0528.1993.tb15280.x; Steer P, 1998, BRIT J OBSTET GYNAEC, V105, P1052, DOI 10.1111/j.1471-0528.1998.tb09935.x	10	10	13	0	2	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	MAY 8	1999	318	7193					1260	1264						5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	195XT	10231260				2022-12-28	WOS:000080278000029
J	Dehaene, S; Spelke, E; Pinel, P; Stanescu, R; Tsivkin, S				Dehaene, S; Spelke, E; Pinel, P; Stanescu, R; Tsivkin, S			Sources of mathematical thinking: Behavioral and brain-imaging evidence	SCIENCE			English	Article							POSITRON-EMISSION-TOMOGRAPHY; VISUOSPATIAL ATTENTION; MENTAL CALCULATION; PARIETAL CORTEX; NUMBER; REPRESENTATION; ACTIVATION; MULTIPLICATION; LOCALIZATION; BILINGUALS	Does the human capacity for mathematical intuition depend on linguistic competence or on visuo-spatial representations? A series of behavioral and brain-imaging experiments provides evidence for both sources, Exact arithmetic is acquired in a Language-specific format, transfers poorly to a different Language or to novel facts, and recruits networks involved in word-association processes. In contrast, approximate arithmetic shows language independence, relies on a sense of numerical magnitudes, and recruits bilateral areas of the parietal Lobes involved in visuo-spatial processing. Mathematical intuition may emerge from the interplay of these brain systems.	Serv Hosp Frederic Joliot, CEA, DSV, INSERM,U334, F-91401 Orsay, France; MIT, Dept Brain & Cognit Sci, Cambridge, MA 02139 USA	CEA; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Saclay; Massachusetts Institute of Technology (MIT)	Dehaene, S (corresponding author), Serv Hosp Frederic Joliot, CEA, DSV, INSERM,U334, F-91401 Orsay, France.	dehaene@shfj.cea.fr	pinel, philippe/AAJ-3768-2020	pinel, philippe/0000-0001-6945-1369	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [R01HD023103] Funding Source: NIH RePORTER; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R37HD023103] Funding Source: NIH RePORTER; NICHD NIH HHS [HD23103] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		ABDULLAEV YG, 1993, INT J PSYCHOPHYSIOL, V14, P167, DOI 10.1016/0167-8760(93)90031-J; Andersen RA, 1997, PHILOS T ROY SOC B, V352, P1421, DOI 10.1098/rstb.1997.0128; BENTON AL, 1992, ARCH NEUROL-CHICAGO, V49, P445, DOI 10.1001/archneur.1992.00530290027007; BOURBAKI N, 1948, J SYMBOLIC LOGIC, V14, P1; Boysen S. T., 1993, DEV NUMERICAL COMPET; Brannon EM, 1998, SCIENCE, V282, P746, DOI 10.1126/science.282.5389.746; Brouwer L.E.J., 1981, CAMBRIDGE LECT INTUI; CAMPBELL JID, 1988, J EXP PSYCHOL GEN, V117, P204, DOI 10.1037/0096-3445.117.2.204; CORBETTA M, 1995, SCIENCE, V270, P802, DOI 10.1126/science.270.5237.802; CORBETTA M, 1993, J NEUROSCI, V13, P1202; Damasio AR, 1984, ANNU REV NEUROSCI, V7, P127, DOI 10.1146/annurev.ne.07.030184.001015; Dantzig T., 1967, NUMBER LANGUAGE SCI; Dehaene S, 1996, NEUROPSYCHOLOGIA, V34, P1097, DOI 10.1016/0028-3932(96)00027-9; Dehaene S, 1997, CORTEX, V33, P219, DOI 10.1016/S0010-9452(08)70002-9; DEHAENE S, 1991, NEUROPSYCHOLOGIA, V29, P1045, DOI 10.1016/0028-3932(91)90076-K; Dehaene S, 1996, J COGNITIVE NEUROSCI, V8, P47, DOI 10.1162/jocn.1996.8.1.47; Dehaene S, 1998, TRENDS NEUROSCI, V21, P355, DOI 10.1016/S0166-2236(98)01263-6; Dehaene S., 1997, NUMBER SENSE; Dehaene S., 1995, MATH COGNITION, P83, DOI DOI 10.1155/2014/461647; Delazer M, 1997, CORTEX, V33, P697, DOI 10.1016/S0010-9452(08)70727-5; EINSTEIN A, 1975, ESSAY PSYCHOL INVENT, P142; FRENCKMESTRE C, 1993, MEM COGNITION, V21, P809, DOI 10.3758/BF03202748; GALLISTEL CR, 1989, ANNU REV PSYCHOL, V40, P155, DOI 10.1146/annurev.ps.40.020189.001103; Hadamard J., 1945, ESSAY PSYCHOL INVENT; HECAEN H., 1961, REV NEUROL [PARIS], V105, P85; Hilbert D., 1950, PRINCIPLES MATH LOGI; Ifrah G., 1994, HIST UNIVERSELLE CHI; Kawamichi H, 1998, NEUROREPORT, V9, P1127, DOI 10.1097/00001756-199804200-00031; Kawashima R, 1996, NEUROREPORT, V7, P1253, DOI 10.1097/00001756-199605170-00006; Kline M., 1972, MATH THOUGHT ANCIENT; KOLERS PA, 1968, SCI AM, V218, P78, DOI 10.1038/scientificamerican0368-78; Kosslyn SM, 1998, PSYCHOPHYSIOLOGY, V35, P151, DOI 10.1017/S0048577298001516; KRUEGER LE, 1984, MEM COGNITION, V12, P171, DOI 10.3758/BF03198431; LeFevre J, 1996, J EXP PSYCHOL LEARN, V22, P216, DOI 10.1037/0278-7393.22.1.216; LeFevre JA, 1996, J EXP PSYCHOL GEN, V125, P284, DOI 10.1037/0096-3445.125.3.284; MARSH LG, 1976, MEM COGNITION, V4, P216; MCCLAIN L, 1982, MEM COGNITION, V10, P591, DOI 10.3758/BF03202441; McCloskey M., 1992, NATURE ORIGINS MATH, P493, DOI DOI 10.1016/S0166-4115(08)60895-X; Nobre AC, 1997, BRAIN, V120, P515, DOI 10.1093/brain/120.3.515; PERRIN F, 1989, ELECTROEN CLIN NEURO, V72, P184, DOI 10.1016/0013-4694(89)90180-6; PETERSEN SE, 1988, NATURE, V331, P585, DOI 10.1038/331585a0; POINCARE H, 1907, SCI HYPOTHESIS; POSNER MI, 1994, TRENDS NEUROSCI, V17, P75, DOI 10.1016/0166-2236(94)90078-7; Richter W, 1997, NEUROREPORT, V8, P3697, DOI 10.1097/00001756-199712010-00008; ROLAND PE, 1985, J NEUROPHYSIOL, V53, P1219, DOI 10.1152/jn.1985.53.5.1219; Rueckert L, 1996, NEUROIMAGE, V3, P97, DOI 10.1006/nimg.1996.0011; Scherg M., 1990, BESA BRAIN ELECT SOU; SHANON B, 1984, NEW IDEAS PSYCHOL, V2, P75, DOI 10.1016/0732-118X(84)90035-7; TAKAYAMA Y, 1994, ARCH NEUROL-CHICAGO, V51, P286, DOI 10.1001/archneur.1994.00540150084021; TUCKER DM, 1993, ELECTROEN CLIN NEURO, V87, P154, DOI 10.1016/0013-4694(93)90121-B; Whitehead A., 1910, PRINCIPIA MATH; Wynn K, 1998, TRENDS COGN SCI, V2, P296, DOI 10.1016/S1364-6613(98)01203-0	52	1113	1148	10	181	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAY 7	1999	284	5416					970	974		10.1126/science.284.5416.970	http://dx.doi.org/10.1126/science.284.5416.970			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	194MU	10320379				2022-12-28	WOS:000080198800048
J	Belay, ED; Bresee, JS; Holman, RC; Khan, AS; Shahriari, A; Schonberger, LB				Belay, ED; Bresee, JS; Holman, RC; Khan, AS; Shahriari, A; Schonberger, LB			Reye's syndrome in the United States from 1981 through 1997	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							PUBLIC-HEALTH-SERVICE; ASPIRIN USE; CHILDREN; MEDICATIONS; PATTERN; RISK	Background Reye's syndrome is characterized by encephalopathy and fatty degeneration of the liver, usually after influenza or varicella. Beginning in 1980, warnings were issued about the use of salicylates in children with those viral infections because of the risk of Reye's syndrome. Methods To describe the pattern of Reye's syndrome in the United States, characteristics of the patients, and risk factors for poor outcomes, we analyzed national surveillance data collected from December 1980 through November 1997. The surveillance system is based on voluntary reporting with the use of a standard case-report form. Results From December 1980 through November 1997 (surveillance years 1981 through 1997), 1207 cases of Reye's syndrome were reported in patients less than 18 years of age. Among those for whom data on race and sex were available, 93 percent were white and 52 percent were girls. The number of reported cases of Reye's syndrome declined sharply after the association of Reye's syndrome with aspirin was reported. After a peak of 555 cases in children reported in 1980, there have been no more than 36 cases per year since 1987. Antecedent illnesses were reported in 93 percent of the children, and detectable blood salicylate levels in 82 percent. The overall case fatality rate was 31 percent. The case fatality rate was highest in children under five years of age (relative risk, 1.8; 95 percent confidence interval, 1.5 to 2.1) and in those with a serum ammonia level above 45 mu g per deciliter (26 mu mol per liter) (relative risk, 3.4; 95 percent confidence interval, 1.9 to 6.2). Conclusions Since 1980, when the association between Reye's syndrome and the use of aspirin during varicella or influenza-like illness was first reported, there has been a sharp decline in the number of infants and children reported to have Reye's syndrome. Because Reye's syndrome is now very rare, any infant or child suspected of having this disorder should undergo extensive investigation to rule out the treatable inborn metabolic disorders that can mimic Reye's syndrome. (N Engl J Med 1999;340:1377-82.) (C) 1999, Massachusetts Medical Society.	Ctr Dis Control & Prevent, Div Viral & Rickettsial Dis, Natl Ctr Infect Dis, Atlanta, GA 30333 USA	Centers for Disease Control & Prevention - USA	Belay, ED (corresponding author), Ctr Dis Control & Prevent, Div Viral & Rickettsial Dis, Natl Ctr Infect Dis, Mailstop A-39,1600 Clifton Rd NE, Atlanta, GA 30333 USA.	ebb8@cdc.gov	Belay, Ermias/A-8829-2013	Belay, Ermias/0000-0002-9837-0960				[Anonymous], 1998, MMWR Recomm Rep, V47, P1; ARROWSMITH JB, 1987, PEDIATRICS, V79, P858; Brain WR, 1929, LANCET, V1, P221; Centers for Disease Control and Prevention, 1980, MMWR-MORBID MORTAL W, V29, P537; Centers for Disease Control and Prevention, 1980, MMWR-MORBID MORTAL W, V29, P532; COREY L, 1976, AM J MED, V61, P615, DOI 10.1016/0002-9343(76)90139-X; DAVIS DL, 1992, LANCET, V340, P1042; FORSYTH BW, 1991, AM J DIS CHILD, V145, P964, DOI 10.1001/archpedi.1991.02160090014005; GREEN A, 1992, ARCH DIS CHILD, V67, P1313, DOI 10.1136/adc.67.10.1313; HALPIN TJ, 1982, JAMA-J AM MED ASSOC, V248, P687, DOI 10.1001/jama.248.6.687; Hardie RM, 1996, ARCH DIS CHILD, V74, P400, DOI 10.1136/adc.74.5.400; HURWITZ ES, 1987, JAMA-J AM MED ASSOC, V257, P3366; HURWITZ ES, 1985, NEW ENGL J MED, V313, P849, DOI 10.1056/NEJM198510033131403; HURWITZ ES, 1987, JAMA-J AM MED ASSOC, V257, P1905, DOI 10.1001/jama.257.14.1905; JOHNSON G M, 1963, N C Med J, V24, P464; Kleinbaum D. G., 1998, APPL REGRESSION ANAL; *NAT SURV REY SYND, 1982, MMWR-MORBID MORTAL W, V31, P53; NELSON DB, 1979, REYES SYNDROME, V2, P33; PARTIN JS, 1984, HEPATOLOGY, V4, P687, DOI 10.1002/hep.1840040421; PINSKY PF, 1988, JAMA-J AM MED ASSOC, V260, P657, DOI 10.1001/jama.260.5.657; REMINGTON PL, 1986, PEDIATRICS, V77, P93; REMINGTON PL, 1985, AM J DIS CHILD, V139, P870, DOI 10.1001/archpedi.1985.02140110024021; RENNEBOHM RM, 1985, J PEDIATR-US, V107, P877, DOI 10.1016/S0022-3476(85)80179-7; REYE RDK, 1963, LANCET, V2, P749; ROE CR, 1986, J PEDIATR-US, V108, P13, DOI 10.1016/S0022-3476(86)80762-4; ROWE PC, 1988, JAMA-J AM MED ASSOC, V260, P3167, DOI 10.1001/jama.260.21.3167; STARKO KM, 1980, PEDIATRICS, V66, P859; *SURG GEN, 1982, MMWR-MORBID MORTAL W, V31, P289; TAYLOR JP, 1985, AM J DIS CHILD, V139, P486, DOI 10.1001/archpedi.1985.02140070060034; WALDMAN RJ, 1982, JAMA-J AM MED ASSOC, V247, P3089, DOI 10.1001/jama.247.22.3089; 1997, MMWR MORB MORTAL WKL, V46, P750; 1980, MMWR MORB MORTAL WKL, V29, P321	32	186	202	0	13	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	MAY 6	1999	340	18					1377	1382		10.1056/NEJM199905063401801	http://dx.doi.org/10.1056/NEJM199905063401801			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	192QN	10228187				2022-12-28	WOS:000080090600001
J	Clark, WW; Bohne, BA				Clark, WW; Bohne, BA			Effects of noise on hearing	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							EXPOSURE		Cent Inst Deaf, St Louis, MO 63110 USA		Clark, WW (corresponding author), Cent Inst Deaf, St Louis, MO 63110 USA.		Bohne, Barbara/A-9113-2008	Bohne, Barbara/0000-0003-3874-7620				AXELSSON A, 1995, OCCUPATIONAL MED STA, P657; CLARK WW, 1987, J ACOUST SOC AM, V82, P1253, DOI 10.1121/1.395261; CLARK WW, 1991, J ACOUST SOC AM, V90, P175, DOI 10.1121/1.401285; *NAT RIFL ASS, 1999, 1999 FACT CARD; Toynbee J., 1860, DIS EAR THEIR NATURE; WATKINS D, 1998, SPECTRUM-J STATE GOV, V15, P1	6	74	77	0	7	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAY 5	1999	281	17					1658	1659		10.1001/jama.281.17.1658	http://dx.doi.org/10.1001/jama.281.17.1658			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	191MJ	10235164				2022-12-28	WOS:000080025900035
J	Nightingale, SL				Nightingale, SL			Regularly updated drug product safety information on the Internet	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	News Item									US FDA, Off Hlth Affairs, Rockville, MD 20857 USA	US Food & Drug Administration (FDA)	Nightingale, SL (corresponding author), US FDA, Off Hlth Affairs, Parklawn Bldg,5600 Fishers Ln, Rockville, MD 20857 USA.								0	0	0	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAY 5	1999	281	17					1580	1580		10.1001/jama.281.17.1580	http://dx.doi.org/10.1001/jama.281.17.1580			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	191MJ	10235141				2022-12-28	WOS:000080025900007
J	Anglaret, X; Chene, G; Attia, A; Toure, S; Lafont, S; Combe, P; Manlan, K; N'Dri-Yoman, T; Salamon, R				Anglaret, X; Chene, G; Attia, A; Toure, S; Lafont, S; Combe, P; Manlan, K; N'Dri-Yoman, T; Salamon, R		Cotrimo Cl Study Grp	Early chemoprophylaxis with trimethoprim-sulphamethoxazole for HIV-1-infected adults in Abidjan, Cote d'Ivoire: a randomised trial	LANCET			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; WEST-AFRICAN CITY; DEVELOPING-WORLD; IVORY-COAST; HIV; INFECTION; KENYA; SULFAMETHOXAZOLE; COTRIMOXAZOLE; PROPHYLAXIS	Background In sub-Saharan Africa, various bacterial diseases occur before pneumocystosis or toxoplasmosis in the course of HIV-1 infection, and are major causes of morbidity and mortality. We did a randomised, double blind, placebo-controlled clinical trial at community-health centres in Abidjan, Cote d'Ivoire, to assess the efficacy of trimethoprim-sulphamethoxazole (co-trimoxazole) chemoprophylaxis at early stages of HIV-1 infection. Method 843 HIV-infected patients were screened and 545 enrolled in the study. Eligible adults (with HIV-1 or HIV-1 and HIV-2 dual seropositivity at stages 2 or 3 of the WHO staging system) received co-trimoxazole chemoprophylaxis (trimethoprim 160 mg, sulphamethoxazole 800 mg) daily or a matching placebo. The primary outcome was the occurrence of severe clinical events, defined as death or hospital admission irrespective of the cause. Analyses were by intention to treat. Findings Four of the randomised patients were excluded (positive for HIV-2 only). 120 severe events occurred among 271 patients in the co-trimoxazole group and 198 among 270 in the placebo group. Significantly fewer patients in the co-trimoxazole group than in the placebo group had at least one severe event (84 vs 124); the probability of remaining free of severe events was 63.7% versus 45.8% (hazard ratio 0.57 [95% CI 0.43-0.75], p=0.0001) and the benefit was apparent in all subgroups of initial CD4-cell count. Survival did not differ between the groups (41 vs 46 deaths, p=0.51). Cotrimoxazole was generally well tolerated though moderate neutropenia occurred in 62 patients ( vs 26 in the placebo group). Interpretation Patients who might benefit from cotrimoxazole trimoxazole could be recruited on clinical criteria in community clinics without knowing the patients CD4-cell count. This affordable measure will enable quick public-health intervention, while monitoring bacterial susceptibility and haematological tolerance.	CHU Treichville, Ctr Diagnost & Rech SIDA, Abidjan 01, Cote Ivoire; Univ Bordeaux 2, INSERM, U330, F-33076 Bordeaux, France; CHU Yopougon, Med Serv, Abidjan, Cote Ivoire	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite de Bordeaux	Anglaret, X (corresponding author), CHU Treichville, Ctr Diagnost & Rech SIDA, 01 BP 1839, Abidjan 01, Cote Ivoire.		Anglaret, Xavier/T-2757-2019; Anglaret, Xavier/F-7333-2013; chene, genevieve/H-8665-2014; Lafont, Sylviane/AAD-4464-2019	chene, genevieve/0000-0002-8368-6460; Lafont, Sylviane/0000-0003-0483-6238; Anglaret, Xavier/0000-0003-3319-8423; Ouassa, Timothee Dieudonne/0000-0002-5456-3103				Anglaret X, 1997, J CLIN MICROBIOL, V35, P1915, DOI 10.1128/JCM.35.7.1915-1915.1997; Anglaret X, 1998, INT J STD AIDS, V9, P432; BATUNGWANAYO J, 1994, AM J RESP CRIT CARE, V149, P1591, DOI 10.1164/ajrccm.149.6.8004318; BLOLAND PB, 1991, LANCET, V337, P518, DOI 10.1016/0140-6736(91)91299-A; BRINDLE RJ, 1993, AIDS, V7, P1469, DOI 10.1097/00002030-199311000-00010; CAHN P, 1993, AIDS, V7, P711; CARR A, 1992, ANN INTERN MED, V117, P106, DOI 10.7326/0003-4819-117-2-106; CLERINX J, 1995, CLIN INFECT DIS, V21, P1282, DOI 10.1093/clinids/21.5.1282; COLEBUNDERS R, 1987, ANN INTERN MED, V107, P599, DOI 10.7326/0003-4819-107-4-599_2; DECOCK KM, 1990, SCIENCE, V249, P793, DOI 10.1126/science.2167515; DEHOVITZ JA, 1986, NEW ENGL J MED, V315, P87, DOI 10.1056/NEJM198607103150203; DJOMAND G, 1995, J ACQ IMMUN DEF SYND, V10, P358; Edge MD, 1996, AIDS, V10, P1635, DOI 10.1097/00002030-199612000-00007; GILKS CF, 1990, LANCET, V336, P545, DOI 10.1016/0140-6736(90)92096-Z; Gilks CF, 1996, LANCET, V347, P718, DOI 10.1016/S0140-6736(96)90076-8; GILKS CF, 1993, J ANTIMICROB CHEMOTH, V31, P119, DOI 10.1093/jac/31.suppl_B.119; HIRSCHTICK RE, 1995, NEW ENGL J MED, V333, P845, DOI 10.1056/NEJM199509283331305; Kaplan JE, 1996, AM J TROP MED HYG, V55, P1; Kariuki S, 1996, J ANTIMICROB CHEMOTH, V38, P425, DOI 10.1093/jac/38.3.425; KOORNHOF HJ, 1992, CLIN INFECT DIS, V15, P84, DOI 10.1093/clinids/15.1.84; LANGE JMA, 1993, AIDS, V7, P1675, DOI 10.1097/00002030-199312000-00021; LUCAS SB, 1993, AIDS, V7, P1569, DOI 10.1097/00002030-199312000-00005; MAYER HB, 1993, AIDS, V7, P1687, DOI 10.1097/00002030-199312000-00029; Tumbarello M, 1997, AIDS, V11, P1070; Wiktor SZ, 1999, LANCET, V353, P1469, DOI 10.1016/S0140-6736(99)03465-0; World Health Organization, 1997, Weekly Epidemiological Record, V72, P357	26	317	325	0	11	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	MAY 1	1999	353	9163					1463	1468		10.1016/S0140-6736(98)07399-1	http://dx.doi.org/10.1016/S0140-6736(98)07399-1			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	195XV	10232311				2022-12-28	WOS:000080278200008
J	Kondo, T; Duboule, D				Kondo, T; Duboule, D			Breaking colinearity in the mouse HoxD complex	CELL			English	Article							IN-VIVO; GENE-EXPRESSION; POLYCOMB GROUP; MURINE; MICE; CHROMATIN; DROSOPHILA; SPECIFICATION; ORGANIZATION; HIERARCHY	Vertebrate Hox genes are activated in a spatiotemporal sequence that reflects their clustered organization. While this colinear relationship is a property of most metazoans with an anterior to posterior polarity, the underlying molecular mechanisms are unknown. Previous work suggested that Hox genes were made progressively available for transcription in the course of gastrulation, implying the existence of an element capable of initiating a repressive conformation, subsequently relieved from the clusters sequentially. We searched for this element by combining a genomic walk with successive transgene insertions upstream of the HoxD complex followed by a series of deletions. The largest deficiency induced posterior homeotic transformations coincidentally with an earlier activation of Herd genes. These data suggest that a regulatory element located upstream of the complex is necessary for setting up the early pattern of Hox gene colinear activation.	Univ Geneva, Dept Zool & Anim Biol, CH-1211 Geneva 4, Switzerland	University of Geneva	Duboule, D (corresponding author), Univ Geneva, Dept Zool & Anim Biol, Quai Ernest Ansermet 30, CH-1211 Geneva 4, Switzerland.			jin teng, long/0000-0002-1948-9331; duboule, denis/0000-0001-9961-2960				AKAM M, 1989, CELL, V57, P347, DOI 10.1016/0092-8674(89)90909-4; Akasaka T, 1996, DEVELOPMENT, V122, P1513; Beckers J, 1998, DEV DYNAM, V213, P1; CHURCH GM, 1984, P NATL ACAD SCI-BIOL, V81, P1991, DOI 10.1073/pnas.81.7.1991; Core N, 1997, DEVELOPMENT, V124, P721; DOETSCHMAN TC, 1985, J EMBRYOL EXP MORPH, V87, P27; DOLLE P, 1994, DEVELOPMENT, P143; DOLLE P, 1989, NATURE, V342, P767, DOI 10.1038/342767a0; DUBOULE D, 1994, TRENDS GENET, V10, P358, DOI 10.1016/0168-9525(94)90132-5; DUBOULE D, 1989, EMBO J, V8, P1497, DOI 10.1002/j.1460-2075.1989.tb03534.x; Duboule D, 1998, CURR OPIN GENET DEV, V8, P514, DOI 10.1016/S0959-437X(98)80004-X; Dupe V, 1997, DEVELOPMENT, V124, P399; DUSH MK, 1992, DEV BIOL, V151, P273, DOI 10.1016/0012-1606(92)90232-6; FAIELLA A, 1991, NUCLEIC ACIDS RES, V19, P6541, DOI 10.1093/nar/19.23.6541; FEATHERSTONE MS, 1988, P NATL ACAD SCI USA, V85, P4760, DOI 10.1073/pnas.85.13.4760; Felsenfeld G, 1996, CELL, V86, P13, DOI 10.1016/S0092-8674(00)80073-2; FROHMAN MA, 1992, MECH DEVELOP, V38, P55, DOI 10.1016/0925-4773(92)90038-L; GAUNT SJ, 1988, DEVELOPMENT S, P71; Gerard M, 1996, GENE DEV, V10, P2326, DOI 10.1101/gad.10.18.2326; Gould A, 1997, CURR OPIN GENET DEV, V7, P488, DOI 10.1016/S0959-437X(97)80075-5; GRAHAM A, 1989, CELL, V57, P367, DOI 10.1016/0092-8674(89)90912-4; Herault Y, 1998, NAT GENET, V20, P381, DOI 10.1038/3861; Herault Y, 1999, DEV BIOL, V208, P157, DOI 10.1006/dbio.1998.9179; Herault Y, 1996, EMBO J, V15, P6727, DOI 10.1002/j.1460-2075.1996.tb01062.x; Higgs DR, 1998, CELL, V95, P299, DOI 10.1016/S0092-8674(00)81761-4; INOUYE M, 1976, Congenital Anomalies, V16, P171; IZPISUABELMONTE.JC, 1990, DEVELOPMENT, V119, P733; JEANNOTTE L, 1993, GENE DEV, V7, P2085, DOI 10.1101/gad.7.11.2085; KESSEL M, 1991, CELL, V67, P89, DOI 10.1016/0092-8674(91)90574-I; Kondo T, 1998, MOL CELL, V1, P289, DOI 10.1016/S1097-2765(00)80029-5; Kondo T, 1997, NATURE, V390, P29, DOI 10.1038/36234; KRUMLAUF R, 1994, CELL, V78, P191, DOI 10.1016/0092-8674(94)90290-9; LEWIN B, 1994, CELL, V79, P397, DOI 10.1016/0092-8674(94)90249-6; LEWIS EB, 1978, NATURE, V276, P565, DOI 10.1038/276565a0; Mann RS, 1997, BIOESSAYS, V19, P661, DOI 10.1002/bies.950190804; MULLER J, 1995, DEVELOPMENT, V121, P2847; Nelson CE, 1996, DEVELOPMENT, V122, P1449; Pirrotta V, 1997, CURR OPIN GENET DEV, V7, P249, DOI 10.1016/S0959-437X(97)80135-9; RENUCCI A, 1992, EMBO J, V11, P1459, DOI 10.1002/j.1460-2075.1992.tb05190.x; Rijli FM, 1997, CURR OPIN GENET DEV, V7, P481, DOI 10.1016/S0959-437X(97)80074-3; Sordino P, 1996, MECH DEVELOP, V59, P165, DOI 10.1016/0925-4773(96)00587-4; SPYROPOULOS DD, 1994, GENE DEV, V8, P1949, DOI 10.1101/gad.8.16.1949; vanderHoeven F, 1996, CELL, V85, P1025, DOI 10.1016/S0092-8674(00)81303-3; VANDERLUGT NMT, 1994, GENE DEV, V8, P757, DOI 10.1101/gad.8.7.757; WIJGERDE M, 1995, NATURE, V377, P209, DOI 10.1038/377209a0; Zakany J, 1997, EMBO J, V16, P4393, DOI 10.1093/emboj/16.14.4393; Zakany J, 1996, NATURE, V384, P69, DOI 10.1038/384069a0	47	121	123	0	3	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	APR 30	1999	97	3					407	417		10.1016/S0092-8674(00)80749-7	http://dx.doi.org/10.1016/S0092-8674(00)80749-7			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	192VP	10319820	Bronze			2022-12-28	WOS:000080100500013
J	Metzger, H				Metzger, H			It's spring, and thoughts turn to ... allergies	CELL			English	Review							FC; MECHANISM; CELL		NIA, Arthrit & Rheumatism Branch, Bethesda, MD 20892 USA; NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Institute on Aging (NIA); National Institutes of Health (NIH) - USA	Metzger, H (corresponding author), NIA, Arthrit & Rheumatism Branch, Bethesda, MD 20892 USA.				NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [Z01AR041025] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		Alberts B, 1998, CELL, V92, P291, DOI 10.1016/S0092-8674(00)80922-8; Barnes KC, 1998, IMMUNOL TODAY, V19, P325, DOI 10.1016/S0167-5699(97)01241-3; Bhalla US, 1999, SCIENCE, V283, P381, DOI 10.1126/science.283.5400.381; Daeron M, 1997, ANNU REV IMMUNOL, V15, P203, DOI 10.1146/annurev.immunol.15.1.203; Garman SC, 1998, CELL, V95, P951, DOI 10.1016/S0092-8674(00)81719-5; Heusser C, 1997, CURR OPIN IMMUNOL, V9, P805, DOI 10.1016/S0952-7915(97)80182-3; HOPFIELD JJ, 1974, P NATL ACAD SCI USA, V71, P4135, DOI 10.1073/pnas.71.10.4135; Klemm JD, 1998, ANNU REV IMMUNOL, V16, P569, DOI 10.1146/annurev.immunol.16.1.569; Lantz CS, 1997, J IMMUNOL, V158, P2517; Miller KL, 1996, J EXP MED, V183, P2227, DOI 10.1084/jem.183.5.2227; POWELL MS, 1999, IN PRESS NAT STRUCT; RIGBY L, 1997, IGE RECEPTOR FC EPSI, P7; Sayers I, 1998, BIOCHEMISTRY-US, V37, P16152, DOI 10.1021/bi981456k; SHEETS ED, 1999, IN PRESS CURR OPIN C; Shirakawa T, 1997, SCIENCE, V275, P77, DOI 10.1126/science.275.5296.77; Sondermann P, 1999, EMBO J, V18, P1095, DOI 10.1093/emboj/18.5.1095; Suzuki K, 1998, MOL IMMUNOL, V35, P259, DOI 10.1016/S0161-5890(98)00047-9; VERCELLI D, 1997, ALLERGY, P82	18	20	21	0	1	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	APR 30	1999	97	3					287	290		10.1016/S0092-8674(00)80738-2	http://dx.doi.org/10.1016/S0092-8674(00)80738-2			4	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	192VP	10319809	Bronze			2022-12-28	WOS:000080100500002
J	Visintin, R; Hwang, ES; Amon, A				Visintin, R; Hwang, ES; Amon, A			Cfi1 prevents premature exit from mitosis by anchoring Cdc14 phosphatase in the nucleolus	NATURE			English	Article							ANAPHASE PROMOTING COMPLEX; SISTER-CHROMATID COHESION; SACCHAROMYCES-CEREVISIAE; CELL-CYCLE; BUDDING YEAST; MULTICOPY SUPPRESSOR; PROTEIN PHOSPHATASE; PROTEOLYSIS; TRANSITION; METAPHASE	In eukaryotes, the activation of mitotic cyclin-dependent kinases (CDKs) induces mitosis, and their inactivation causes cells to leave mitosis(1). In budding yeast, two redundant mechanisms induce the inactivation of mitotic CDKs. In one mechanism, a specialized ubiquitin-dependent proteolytic system (called the APC-dependent proteolysis machinery) degrades the mitotic (Clb) cyclin subunit. In the other, the kinase-inhibitor Sic1 binds to mitotic CDKs and inhibits their kinase activity(1,2). The highly conserved protein phosphatase Cdc14 promotes both Clb degradation and Sic1 accumulation. Cdc14 promotes SIC1 transcription and the stabilization of Sic1 protein by dephosphorylating Sic1 and its transcription factor Swi5. Cdc14 activates the degradation of Clb cyclins by dephosphorylating the APC-specificity factor Cdh1 (refs 3, 4). So how is Cdc14 regulated? Here we show that Cdc14 is sequestered in the nucleolus for most of the cell cycle. During nuclear division, Cdc14 is released from the nucleolus, allowing it to reach its targets. A highly conserved signalling cascade, critical for the exit from mitosis, is required for this movement of Cdc14 during anaphase. Furthermore, we have identified a negative regulator of Cdc14 Cfi1, that anchors Cdc14 in the nucleolus.	MIT, Ctr Canc Res, Cambridge, MA 02139 USA	Massachusetts Institute of Technology (MIT)	Amon, A (corresponding author), MIT, Ctr Canc Res, Bldg E17,40 Ames St, Cambridge, MA 02139 USA.		Visintin, Rosella/J-9690-2012	Visintin, Rosella/0000-0001-6758-9946; Amon, Angelika/0000-0001-9837-0314				AMON A, 1994, CELL, V77, P1037, DOI 10.1016/0092-8674(94)90443-X; BELL SP, 1992, NATURE, V357, P128, DOI 10.1038/357128a0; Ciosk R, 1998, CELL, V93, P1067, DOI 10.1016/S0092-8674(00)81211-8; CohenFix O, 1996, GENE DEV, V10, P3081, DOI 10.1101/gad.10.24.3081; Guacci V, 1997, CELL, V91, P47, DOI 10.1016/S0092-8674(01)80008-8; Higgins DG, 1996, METHOD ENZYMOL, V266, P383; James P, 1996, GENETICS, V144, P1425; KILMARTIN JV, 1984, J CELL BIOL, V98, P922, DOI 10.1083/jcb.98.3.922; King RW, 1996, SCIENCE, V274, P1652, DOI 10.1126/science.274.5293.1652; KITADA K, 1993, MOL CELL BIOL, V13, P4445, DOI 10.1128/MCB.13.7.4445; Maillet L, 1996, GENE DEV, V10, P1796, DOI 10.1101/gad.10.14.1796; MCGREW JT, 1992, MOL BIOL CELL, V3, P1443, DOI 10.1091/mbc.3.12.1443; Michaelis C, 1997, CELL, V91, P35, DOI 10.1016/S0092-8674(01)80007-6; Morgan DO, 1997, ANNU REV CELL DEV BI, V13, P261, DOI 10.1146/annurev.cellbio.13.1.261; SCHNEIDER BL, 1995, YEAST, V11, P1265, DOI 10.1002/yea.320111306; Shirayama M, 1998, EMBO J, V17, P1336, DOI 10.1093/emboj/17.5.1336; SHIRAYAMA M, 1994, MOL CELL BIOL, V14, P7476, DOI 10.1128/MCB.14.11.7476; SHIRAYAMA M, 1994, YEAST, V10, P451, DOI 10.1002/yea.320100404; Smith JS, 1998, GENETICS, V149, P1205; SURANA U, 1993, EMBO J, V12, P1969, DOI 10.1002/j.1460-2075.1993.tb05846.x; Taylor GS, 1997, J BIOL CHEM, V272, P24054, DOI 10.1074/jbc.272.38.24054; TOLLERVEY D, 1991, EMBO J, V10, P573, DOI 10.1002/j.1460-2075.1991.tb07984.x; TOYN JH, 1994, EMBO J, V13, P1103, DOI 10.1002/j.1460-2075.1994.tb06359.x; TU JL, 1995, EMBO J, V14, P5939, DOI 10.1002/j.1460-2075.1995.tb00282.x; Visintin R, 1998, MOL CELL, V2, P709, DOI 10.1016/S1097-2765(00)80286-5; Visintin R, 1997, SCIENCE, V278, P460, DOI 10.1126/science.278.5337.460; Yamamoto A, 1996, J CELL BIOL, V133, P99, DOI 10.1083/jcb.133.1.99; Zachariae W, 1998, SCIENCE, V282, P1721, DOI 10.1126/science.282.5394.1721	28	488	491	1	11	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	APR 29	1999	398	6730					818	823		10.1038/19775	http://dx.doi.org/10.1038/19775			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	192BL	10235265				2022-12-28	WOS:000080058100061
J	Daley, J; Hartman, EE				Daley, J; Hartman, EE			A 45-year-old man with low back pain and a numb left foot, 1 year later	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material																		WEISNTEIN JN, 1998, JAMA-J AM MED ASSOC, V280, P730	1	1	1	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	APR 28	1999	281	16					1540	1540		10.1001/jama.281.16.1540	http://dx.doi.org/10.1001/jama.281.16.1540			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	188PP	10227325				2022-12-28	WOS:000079857400037
J	Elstein, D; Klutstein, MW; Lahad, A; Abrahamov, A; Hadas-Halpern, I; Zimran, A				Elstein, D; Klutstein, MW; Lahad, A; Abrahamov, A; Hadas-Halpern, I; Zimran, A			Echocardiographic assessment of pulmonary hypertension in Gaucher's disease	LANCET			English	Article							REPLACEMENT THERAPY	Background Enzyme therapy has been shown to decrease the signs and symptoms of Gaucher's disease. A few patients, however, develop pulmonary hypertension on such treatment. We investigated the frequency of pulmonary hypertension in Gaucher's disease. Methods We studied 134 adults with type 1 Gaucher's disease, including 73 patients on enzyme replacement, with echocardiography. We measured tricuspid incompetence (TI) with continuous-wave doppler. Pulmonary hypertension was indicated by a TI gradient of more than 30 mm Hg. Findings Nine (7%) patients had pulmonary hypertension: all were treated and six had undergone splenectomy. Chest radiographs confirmed the presence of pulmonary hypertension in these patients as well as in most patients with TI gradients of 25-29 mm Hg. Interpretation The confounding effects of disease severity and splenectomy in many treated patients precluded definitive conclusion of cause and effect. Nonetheless, we found an unexpectedly high rate of pulmonary hypertension and recommended routine echocardiographic monitoring of all treated and untreated patients with type 1 Gaucher's disease. We also suggest consideration of treatment withdrawal if the TI gradient progresses to more than 30 mm Hg.	Shaare Zedek Med Ctr, Gaucher Clin, IL-91031 Jerusalem, Israel; Shaare Zedek Med Ctr, Dept Med, IL-91031 Jerusalem, Israel; Shaare Zedek Med Ctr, Dept Cardiol, IL-91031 Jerusalem, Israel; Shaare Zedek Med Ctr, Dept Pediat, IL-91031 Jerusalem, Israel; Shaare Zedek Med Ctr, Dept Diagnost Radiol, IL-91031 Jerusalem, Israel	Hebrew University of Jerusalem; Shaare Zedek Medical Center; Hebrew University of Jerusalem; Shaare Zedek Medical Center; Hebrew University of Jerusalem; Shaare Zedek Medical Center; Hebrew University of Jerusalem; Shaare Zedek Medical Center; Hebrew University of Jerusalem; Shaare Zedek Medical Center	Elstein, D (corresponding author), Shaare Zedek Med Ctr, Gaucher Clin, POB 3235, IL-91031 Jerusalem, Israel.							Abenhaim L, 1996, NEW ENGL J MED, V335, P609, DOI 10.1056/NEJM199608293350901; BARTON NW, 1991, NEW ENGL J MED, V324, P1464, DOI 10.1056/NEJM199105233242104; DAWSON A, 1995, CLIN RES, V43, P277; GOLDSMITH GH, 1988, ANN INTERN MED, V108, P797, DOI 10.7326/0003-4819-108-6-797; Harats D, 1997, ACTA HAEMATOL-BASEL, V98, P47; Kerem E, 1996, EUR RESPIR J, V9, P340, DOI 10.1183/09031936.96.09020340; LEE RE, 1988, LAB INVEST, V58, pA54; Rich S, 1997, HEART DIS TXB CARDIO, P780; ROBERTS WC, 1967, CIRCULATION, V35, P783, DOI 10.1161/01.CIR.35.4.783; Ross DJ, 1997, NEW ENGL J MED, V336, P379, DOI 10.1056/NEJM199701303360516; Rubin LJ, 1997, NEW ENGL J MED, V336, P111, DOI 10.1056/NEJM199701093360207; THEISE ND, 1990, AM J PEDIAT HEMATOL, V12, P74; ZIMRAN A, 1994, AM J MED, V97, P3, DOI 10.1016/0002-9343(94)90042-6	13	75	80	0	2	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON WC1B 3SL, ENGLAND	0140-6736			LANCET	Lancet	MAY 23	1998	351	9115					1544	1546		10.1016/S0140-6736(98)10194-0	http://dx.doi.org/10.1016/S0140-6736(98)10194-0			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZQ497	10326537				2022-12-28	WOS:000073868000010
J	Dai, PC; Mook, HA; Hayden, SM; Aeppli, G; Perring, TG; Hunt, RD; Dogan, F				Dai, PC; Mook, HA; Hayden, SM; Aeppli, G; Perring, TG; Hunt, RD; Dogan, F			The magnetic excitation spectrum and thermodynamics of high-T-c superconductors	SCIENCE			English	Article							ELECTRONIC SPECIFIC-HEAT; NEUTRON-SCATTERING; YBA2CU3O6+X; FLUCTUATIONS; RESISTIVITY; ENERGY; 300-K	Inelastic neutron scattering was used to study the wave vector- and frequency-dependent magnetic fluctuations in single crystals of superconducting YBa2Cu3O6+x. The spectra contain several important features, including a gap in the superconducting state, a pseudogap in the normal state, and the much-discussed resonance peak. The appearance of the pseudogap determined from transport and nuclear resonance coincides with formation of the resonance in the magnetic excitations. The exchange energy associated with the resonance has the temperature and doping dependences as well as the magnitude to describe approximately the electronic specific heat near the superconducting transition temperature (T-c).	Oak Ridge Natl Lab, Div Solid State, Oak Ridge, TN 37831 USA; Univ Bristol, HH Wills Phys Lab, Bristol BS8 1TL, Avon, England; NEC Res Inst, Princeton, NJ 08540 USA; Rutherford Appleton Lab, Didcot OX11 0QX, Oxon, England; Oak Ridge Natl Lab, Div Chem Technol, Oak Ridge, TN 37831 USA; Univ Washington, Dept Mat Sci & Engn, Seattle, WA 98195 USA	United States Department of Energy (DOE); Oak Ridge National Laboratory; University of Bristol; NEC Corporation; UK Research & Innovation (UKRI); Science & Technology Facilities Council (STFC); STFC Rutherford Appleton Laboratory; United States Department of Energy (DOE); Oak Ridge National Laboratory; University of Washington; University of Washington Seattle	Dai, PC (corresponding author), Oak Ridge Natl Lab, Div Solid State, POB 2008, Oak Ridge, TN 37831 USA.	piq@ornl.gov	Dai, Pengcheng/C-9171-2012; Instrument, MARI/AAB-2270-2020; Hayden, Stephen M/F-4162-2011	Dai, Pengcheng/0000-0002-6088-3170; Hayden, Stephen M/0000-0002-3209-027X				Aeppli G, 1997, PHYS WORLD, V10, P33; BATLOGG B, 1996, P 10 ANN HIGH TEMP S; Bourges P, 1997, PHYS REV B, V56, P11439, DOI 10.1103/PhysRevB.56.R11439; Dai P, 1996, PHYS REV LETT, V77, P5425, DOI 10.1103/PhysRevLett.77.5425; Dai PC, 1998, PHYS REV LETT, V80, P1738, DOI 10.1103/PhysRevLett.80.1738; Demler E, 1998, NATURE, V396, P733, DOI 10.1038/25482; FONG HF, 1995, PHYS REV LETT, V75, P316, DOI 10.1103/PhysRevLett.75.316; Fong HF, 1997, PHYS REV LETT, V78, P713, DOI 10.1103/PhysRevLett.78.713; Haworth C, 1998, PHYSICA B, V246, P73, DOI 10.1016/S0921-4526(98)00028-3; Hayden SM, 1996, PHYS REV B, V54, pR6905, DOI 10.1103/PhysRevB.54.R6905; Hayden SM, 1996, PHYS REV LETT, V76, P1344, DOI 10.1103/PhysRevLett.76.1344; ITO T, 1993, PHYS REV LETT, V70, P3995, DOI 10.1103/PhysRevLett.70.3995; LORAM JW, 1990, PHYSICA C, V171, P243, DOI 10.1016/0921-4534(90)90137-4; LORAM JW, 1994, J SUPERCOND, V7, P243, DOI 10.1007/BF00730405; MOOK HA, 1993, PHYS REV LETT, V70, P3490, DOI 10.1103/PhysRevLett.70.3490; Mook HA, 1998, NATURE, V395, P580, DOI 10.1038/26931; ROSSATMIGNOD J, 1991, PHYSICA C, V185, P86, DOI 10.1016/0921-4534(91)91955-4; Scalapino DJ, 1998, PHYS REV B, V58, P8222, DOI 10.1103/PhysRevB.58.8222; SHAMOTO S, 1993, PHYS REV B, V48, P13817, DOI 10.1103/PhysRevB.48.13817; Shrieffer J., 1964, THEORY SUPERCONDUCTI; TAKIGAWA M, 1991, PHYS REV B, V43, P247, DOI 10.1103/PhysRevB.43.247; Wuyts B, 1996, PHYS REV B, V53, P9418, DOI 10.1103/PhysRevB.53.9418; ZHANG FC, 1988, PHYS REV B, V37, P3759, DOI 10.1103/PhysRevB.37.3759	23	237	239	0	22	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAY 21	1999	284	5418					1344	1347		10.1126/science.284.5418.1344	http://dx.doi.org/10.1126/science.284.5418.1344			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	198NN	10334986	Green Submitted			2022-12-28	WOS:000080430600049
J	Hoffmann, JA; Kafatos, FC; Janeway, CA; Ezekowitz, RAB				Hoffmann, JA; Kafatos, FC; Janeway, CA; Ezekowitz, RAB			Phylogenetic perspectives in innate immunity	SCIENCE			English	Review							DROSOPHILA HOST-DEFENSE; MANNOSE-BINDING PROTEIN; MALARIA PARASITE DEVELOPMENT; RA-REACTIVE FACTOR; ANTIMICROBIAL PEPTIDES; ANOPHELES-GAMBIAE; SERINE-PROTEASE; HUMAN BETA-DEFENSIN-1; RECEPTOR FAMILY; CYSTIC-FIBROSIS	The concept of innate immunity refers to the first-line host defense that serves to Limit infection in the early hours after exposure to microorganisms, Recent data have highlighted similarities between pathogen recognition, signaling pathways, and effector mechanisms of innate immunity in Drosophila and mammals, pointing to a common ancestry of these defenses. In addition to its role in the early phase of defense, innate immunity;in mammals appears to play a key role in stimulating the subsequent, clonal response of adaptive immunity.	CNRS, Inst Mol & Cellular Biol, F-67084 Strasbourg, France; European Mol Biol Lab, D-69012 Heidelberg, Germany; Yale Univ, Immunobiol Sect, New Haven, CT 06520 USA; Massachusetts Gen Hosp, Dept Pediat, Boston, MA 02114 USA	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg; European Molecular Biology Laboratory (EMBL); Yale University; Harvard University; Massachusetts General Hospital	Hoffmann, JA (corresponding author), CNRS, Inst Mol & Cellular Biol, F-67084 Strasbourg, France.	jhoff@ibmc.u-strasbg.fr						Aderem A, 1999, ANNU REV IMMUNOL, V17, P593, DOI 10.1146/annurev.immunol.17.1.593; Agrawal A, 1998, NATURE, V394, P744, DOI 10.1038/29457; ALPER CA, 1970, NEW ENGL J MED, V282, P349, DOI 10.1056/NEJM197002122820701; ANDERS EM, 1990, P NATL ACAD SCI USA, V87, P4485, DOI 10.1073/pnas.87.12.4485; ANDERSON KV, 1984, NATURE, V311, P223, DOI 10.1038/311223a0; ANDERSON KV, 1986, GAMETOGENESIS EARLY, P177; Baker B, 1997, SCIENCE, V276, P726, DOI 10.1126/science.276.5313.726; Beamer LJ, 1997, SCIENCE, V276, P1861, DOI 10.1126/science.276.5320.1861; Beier JC, 1998, ANNU REV ENTOMOL, V43, P519, DOI 10.1146/annurev.ento.43.1.519; Belvin MP, 1996, ANNU REV CELL DEV BI, V12, P393, DOI 10.1146/annurev.cellbio.12.1.393; Bevins CL, 1996, GENOMICS, V31, P95, DOI 10.1006/geno.1996.0014; BOMAN HG, 1995, ANNU REV IMMUNOL, V13, P61, DOI 10.1146/annurev.immunol.13.1.61; Botas C, 1998, P NATL ACAD SCI USA, V95, P11869, DOI 10.1073/pnas.95.20.11869; BOTTO M, 1990, J EXP MED, V172, P1011, DOI 10.1084/jem.172.4.1011; Braun A, 1998, P NATL ACAD SCI USA, V95, P14337, DOI 10.1073/pnas.95.24.14337; BREY PT, 1997, MOL MECHANISMS IMMUN; BROEKAERT WF, 1995, PLANT PHYSIOL, V108, P1353, DOI 10.1016/j.chiabu.2021.105188; Chaudhary PM, 1998, BLOOD, V91, P4020, DOI 10.1182/blood.V91.11.4020.411a44_4020_4027; COLLINS FH, 1986, SCIENCE, V234, P607, DOI 10.1126/science.3532325; Crouch EC, 1998, AM J RESP CELL MOL, V19, P177, DOI 10.1165/ajrcmb.19.2.140; Dimopoulos G, 1998, EMBO J, V17, P6115, DOI 10.1093/emboj/17.21.6115; Dushay MS, 1996, P NATL ACAD SCI USA, V93, P10343, DOI 10.1073/pnas.93.19.10343; EDEN CS, 1988, J IMMUNOL, V140, P3180; Eggleton P, 1999, CURR OPIN IMMUNOL, V11, P28, DOI 10.1016/S0952-7915(99)80006-5; ELDON E, 1994, DEVELOPMENT, V120, P885; Elsbach P, 1998, CURR OPIN IMMUNOL, V10, P45, DOI 10.1016/S0952-7915(98)80030-7; Epstein J, 1996, CURR OPIN IMMUNOL, V8, P29, DOI 10.1016/S0952-7915(96)80101-4; EZEKOWITZ R A B, 1991, Current Biology, V1, P60; Fearon DT, 1996, SCIENCE, V272, P50, DOI 10.1126/science.272.5258.50; FEIZI T, 1990, Glycobiology, V1, P17, DOI 10.1093/glycob/1.1.17; Fenton MJ, 1998, J LEUKOCYTE BIOL, V64, P25, DOI 10.1002/jlb.64.1.25; Ferrandon D, 1998, EMBO J, V17, P1217, DOI 10.1093/emboj/17.5.1217; Gallo RL, 1998, J INVEST DERMATOL, V111, P739, DOI 10.1046/j.1523-1747.1998.00361.x; GANZ T, 1985, J CLIN INVEST, V76, P1427, DOI 10.1172/JCI112120; Ganz T, 1998, CURR OPIN IMMUNOL, V10, P41, DOI 10.1016/S0952-7915(98)80029-0; GARRED P, 1995, LANCET, V346, P941, DOI 10.1016/S0140-6736(95)91559-1; Gazit E, 1996, J MOL BIOL, V258, P860, DOI 10.1006/jmbi.1996.0293; Goldman MJ, 1997, CELL, V88, P553, DOI 10.1016/S0092-8674(00)81895-4; GOVIND S, 1991, TRENDS GENET, V7, P119, DOI 10.1016/0168-9525(91)90456-Z; GutierrezRamos JC, 1997, IMMUNOL TODAY, V18, P329, DOI 10.1016/S0167-5699(97)01085-2; HammondKosack KE, 1997, ANNU REV PLANT PHYS, V48, P575, DOI 10.1146/annurev.arplant.48.1.575; Haziot A, 1996, IMMUNITY, V4, P407, DOI 10.1016/S1074-7613(00)80254-X; HETRU C, 1977, MOL MECHANISMS IMMUN, P40; Hoffmann JA, 1997, TRENDS CELL BIOL, V7, P309, DOI 10.1016/S0962-8924(97)01087-8; HULTMARK D, 1993, TRENDS GENET, V9, P178, DOI 10.1016/0168-9525(93)90165-E; Iovine NM, 1997, P NATL ACAD SCI USA, V94, P10973, DOI 10.1073/pnas.94.20.10973; IP YT, 1993, CELL, V75, P753, DOI 10.1016/0092-8674(93)90495-C; Iwanaga S, 1998, J BIOCHEM, V123, P1; Jack RS, 1997, NATURE, V389, P742, DOI 10.1038/39622; JANEWAY CA, 1989, COLD SPRING HARB SYM, V54, P1; JI YH, 1993, J IMMUNOL, V150, P571; Kopp EB, 1999, CURR OPIN IMMUNOL, V11, P13, DOI 10.1016/S0952-7915(99)80003-X; Lehane MJ, 1997, P NATL ACAD SCI USA, V94, P11502, DOI 10.1073/pnas.94.21.11502; Lehrer RI, 1997, CLIN INFECT DIS, V25, P1141, DOI 10.1086/516082; Lemaitre B, 1996, CELL, V86, P973, DOI 10.1016/S0092-8674(00)80172-5; Lemaitre B, 1997, P NATL ACAD SCI USA, V94, P14614, DOI 10.1073/pnas.94.26.14614; LEMAITRE B, 1995, P NATL ACAD SCI USA, V92, P9465, DOI 10.1073/pnas.92.21.9465; LeVine AM, 1997, J IMMUNOL, V158, P4336; Luckhart S, 1998, P NATL ACAD SCI USA, V95, P5700, DOI 10.1073/pnas.95.10.5700; MALHOTRA R, 1995, TRENDS MICROBIOL, V3, P240, DOI 10.1016/S0966-842X(00)88932-5; MATSUSHITA M, 1992, J EXP MED, V176, P1497, DOI 10.1084/jem.176.6.1497; Matsushita M, 1998, CURR OPIN IMMUNOL, V10, P29, DOI 10.1016/S0952-7915(98)80027-7; Matsuzaki K, 1998, BBA-REV BIOMEMBRANES, V1376, P391, DOI 10.1016/S0304-4157(98)00014-8; Medzhitov R, 1997, NATURE, V388, P394, DOI 10.1038/41131; Medzhitov R, 1998, MOL CELL, V2, P253, DOI 10.1016/S1097-2765(00)80136-7; Medzhitov R, 1997, CELL, V91, P295, DOI 10.1016/S0092-8674(00)80412-2; MORRISON DC, 1987, ANNU REV MED, V38, P417, DOI 10.1146/annurev.me.38.020187.002221; MULLEREBERHARD HJ, 1988, ANNU REV BIOCHEM, V57, P321, DOI 10.1146/annurev.biochem.57.1.321; NONAKA M, 1992, J IMMUNOL, V148, P3290; OUELLETTE AJ, 1994, INFECT IMMUN, V62, P5040, DOI 10.1128/IAI.62.11.5040-5047.1994; Paskewitz Susan M., 1996, P371; Poltorak A, 1998, SCIENCE, V282, P2085, DOI 10.1126/science.282.5396.2085; Porter EM, 1998, FEBS LETT, V434, P272, DOI 10.1016/S0014-5793(98)00994-6; Qureshi ST, 1999, J EXP MED, V189, P615, DOI 10.1084/jem.189.4.615; REID KBM, 1981, ANNU REV BIOCHEM, V50, P433, DOI 10.1146/annurev.bi.50.070181.002245; REID KBM, 1994, SPRINGER SEMIN IMMUN, V15, P307, DOI 10.1007/BF01837363; Richman AM, 1997, EMBO J, V16, P6114, DOI 10.1093/emboj/16.20.6114; Rock FL, 1998, P NATL ACAD SCI USA, V95, P588, DOI 10.1073/pnas.95.2.588; SASTRY K, 1993, CURR OPIN IMMUNOL, V5, P59, DOI 10.1016/0952-7915(93)90082-4; SELSTED ME, 1995, TRENDS CELL BIOL, V5, P114, DOI 10.1016/S0962-8924(00)88961-8; Selsted ME, 1996, J BIOL CHEM, V271, P16430, DOI 10.1074/jbc.271.27.16430; Smith JJ, 1996, CELL, V85, P229, DOI 10.1016/S0092-8674(00)81099-5; Smith LC, 1996, J IMMUNOL, V156, P593; Soderhall K, 1998, CURR OPIN IMMUNOL, V10, P23, DOI 10.1016/S0952-7915(98)80026-5; STEINER H, 1981, NATURE, V292, P246, DOI 10.1038/292246a0; STEWARD R, 1987, SCIENCE, V238, P692, DOI 10.1126/science.3118464; Stolzenberg ED, 1997, P NATL ACAD SCI USA, V94, P8686, DOI 10.1073/pnas.94.16.8686; Summerfield JA, 1997, BRIT MED J, V314, P1229, DOI 10.1136/bmj.314.7089.1229; SUPER M, 1989, LANCET, V2, P1236; TAKAYAMA Y, 1994, J IMMUNOL, V152, P2308; Thiel S, 1997, NATURE, V386, P506, DOI 10.1038/386506a0; TOBIAS PS, 1986, J EXP MED, V164, P777, DOI 10.1084/jem.164.3.777; Turner MW, 1996, IMMUNOL TODAY, V17, P532, DOI 10.1016/0167-5699(96)10062-1; Ulevitch RJ, 1999, CURR OPIN IMMUNOL, V11, P19, DOI 10.1016/S0952-7915(99)80004-1; Valore EV, 1998, J CLIN INVEST, V101, P1633, DOI 10.1172/JCI1861; VERNICK KD, 1995, EXP PARASITOL, V80, P583, DOI 10.1006/expr.1995.1074; Warren HS, 1997, NEW ENGL J MED, V336, P952, DOI 10.1056/NEJM199703273361311; WEIS WI, 1992, NATURE, V360, P127, DOI 10.1038/360127a0; Weis WI, 1996, ANNU REV BIOCHEM, V65, P441, DOI 10.1146/annurev.bi.65.070196.002301; Weis WI, 1998, IMMUNOL REV, V163, P19, DOI 10.1111/j.1600-065X.1998.tb01185.x; Weiss J, 1994, Curr Opin Hematol, V1, P78; Williams MJ, 1997, EMBO J, V16, P6120, DOI 10.1093/emboj/16.20.6120; Wright JR, 1997, PHYSIOL REV, V77, P931, DOI 10.1152/physrev.1997.77.4.931; WRIGHT SD, 1990, SCIENCE, V249, P1431, DOI 10.1126/science.1698311; Wu LP, 1998, NATURE, V392, P93, DOI 10.1038/32195; Wurfel MM, 1997, J EXP MED, V186, P2051, DOI 10.1084/jem.186.12.2051; Wurzner R, 1992, Immunodefic Rev, V3, P123; Yang YO, 1997, GENE DEV, V11, P1621, DOI 10.1101/gad.11.13.1621; Zanetti M, 1997, ANN NY ACAD SCI, V832, P147, DOI 10.1111/j.1749-6632.1997.tb46244.x	109	2004	2131	10	260	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAY 21	1999	284	5418					1313	1318		10.1126/science.284.5418.1313	http://dx.doi.org/10.1126/science.284.5418.1313			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	198NN	10334979				2022-12-28	WOS:000080430600042
J	Ebenbichler, GR; Erdogmus, CB; Resch, KL; Funovics, MA; Kainberger, F; Barisani, G; Aringer, M; Nicolakis, P; Wiesinger, GF; Baghestanian, M; Preisinger, E; Fialka-Moser, V				Ebenbichler, GR; Erdogmus, CB; Resch, KL; Funovics, MA; Kainberger, F; Barisani, G; Aringer, M; Nicolakis, P; Wiesinger, GF; Baghestanian, M; Preisinger, E; Fialka-Moser, V			Ultrasound therapy for calcific tendinitis of the shoulder	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							INFLAMMATION	Background and Methods Although ultrasound therapy is used to treat calcific tendinitis of the shoulder, its efficacy has not been rigorously evaluated. We conducted a randomized, double-blind comparison of ultrasonography and sham insonation in patients with symptomatic calcific tendinitis verified by radiography. Patients were assigned to receive 24 15-minute sessions of either pulsed ultrasound (frequency, 0.89 MHz; intensity, 2.5 W per square centimeter; pulsed mode, 1:4) or an indistinguishable sham treatment to the area over the calcification. The first 15 treatments were given daily (five times per week), and the remainder were given three times a week for three weeks. Randomization was conducted according to shoulders rather than patients, so a patient with bilateral tendinitis might receive either or both therapies. Results We enrolled 63 consecutive patients (70 shoulders). Fifty-four patients (61 shoulders) completed the study. There were 32 shoulders in the ultrasound-treatment group and 29 in the sham-treatment group. After six weeks of treatment, calcium deposits had resolved in six shoulders (19 percent) in the ultrasound-treatment group and decreased by at least 50 percent in nine shoulders (28 percent), as compared with respective values of zero and three (10 percent) in the sham-treatment group (P=0.003). At the nine-month follow-up visit, calcium deposits had resolved in 13 shoulders (42 percent) in the ultrasound-treatment group and improved in 7 shoulders (23 percent), as compared with respective values of 2 (8 percent) and 3 (12 percent) in the sham-treatment group (P=0.002). At the end of treatment, patients who had received ultrasound treatment had greater decreases in pain and greater improvements in the quality of life than those who had received sham treatment; at nine months, the differences between the groups were no longer significant. Conclusions In patients with symptomatic calcific tendinitis of the shoulder, ultrasound treatment helps resolve calcifications and is associated with shortterm clinical improvement. (N Engl J Med 1999;340:1533-8.) (C)1999, Massachusetts Medical Society.	Univ Hosp Vienna, Dept Phys Med & Rehabil, A-1090 Vienna, Austria; Univ Hosp Vienna, Dept Osteoradiol, A-1090 Vienna, Austria; Univ Hosp Vienna, Dept Traumat Surg, A-1090 Vienna, Austria; Univ Hosp Vienna, Dept Rheumatol, A-1090 Vienna, Austria; Univ Hosp Vienna, Dept Angiol, A-1090 Vienna, Austria; Forschungsinst Balneol & Kurortwissensch, Bad Elster, Germany	University Hospital Vienna; University Hospital Vienna; University Hospital Vienna; University Hospital Vienna; University Hospital Vienna	Ebenbichler, GR (corresponding author), Univ Hosp Vienna, Dept Phys Med & Rehabil, Wahringer Gurtel 18-20, A-1090 Vienna, Austria.		Aringer, Martin/AAJ-7641-2020	Aringer, Martin/0000-0003-4471-8375				ALDES J H, 1954, West J Surg Obstet Gynecol, V62, P369; ARK JW, 1992, ARTHROSCOPY, V8, P183, DOI 10.1016/0749-8063(92)90034-9; BINDER A, 1984, LANCET, V1, P695; BOOTH RE, 1975, ORTHOP CLIN N AM, V6, P353; Bosworth BM, 1941, J AMER MED ASSOC, V116, P2477, DOI 10.1001/jama.1941.02820220019004; CHARD MD, 1994, ANN RHEUM DIS, V53, P30, DOI 10.1136/ard.53.1.30; CONSTANT CR, 1987, CLIN ORTHOP RELAT R, P160; DYSON M, 1968, CLIN SCI, V35, P273; Dyson M, 1978, Physiotherapy, V64, P105; Ebenbichler GR, 1997, J RHEUMATOL, V24, P235; FLAX H J, 1964, Am J Phys Med, V43, P117; GAM AN, 1995, PAIN, V63, P85, DOI 10.1016/0304-3959(95)00018-N; GARTNER J, 1995, ORTHOPADE, V24, P284; GARTNER J, 1993, Z ORTHOP GRENZGEB, V131, P461, DOI 10.1055/s-2008-1040055; Green S, 1998, BRIT MED J, V316, P354, DOI 10.1136/bmj.316.7128.354; HARMON PH, 1958, AM J SURG, V95, P527, DOI 10.1016/0002-9610(58)90436-7; KENDALL M, 1979, ADV THEORY STAT, V2, P580; KLEIN W, 1992, ARTHOSKOPIE, V5, P247; Ley K, 1996, CARDIOVASC RES, V32, P733, DOI 10.1016/0008-6363(96)00066-1; Loew M, 1995, J Shoulder Elbow Surg, V4, P101, DOI 10.1016/S1058-2746(05)80062-X; MANTEL N, 1959, J NATL CANCER I, V22, P719; MCKENDRY RJR, 1982, J RHEUMATOL, V9, P75; MORTIMER AJ, 1988, ULTRASOUND MED BIOL, V14, P499, DOI 10.1016/0301-5629(88)90111-1; NACCACHE PH, 1991, ARTHRITIS RHEUM, V34, P333, DOI 10.1002/art.1780340311; Perron M, 1997, ARCH PHYS MED REHAB, V78, P379, DOI 10.1016/S0003-9993(97)90229-X; Proost P, 1996, INT J CLIN LAB RES, V26, P211, DOI 10.1007/BF02602952; Rathbun J B, 1970, J Bone Joint Surg Br, V52, P540; ROMPE JD, 1995, CLIN ORTHOP RELAT R, P196; SAS Institute, 1990, SAS STAT US GUID VER; Smith RE, 1997, J LEUKOCYTE BIOL, V62, P612, DOI 10.1002/jlb.62.5.612; TERHAAR G, 1987, ULTRASOUND MED BIOL, V13, P659, DOI 10.1016/0301-5629(87)90064-0; TERKELTAUB R, 1991, ARTHRITIS RHEUM, V34, P894, DOI 10.1002/art.1780340716; UHTHOFF HK, 1976, CLIN ORTHOP RELAT R, P164; Uhthoff HK, 1996, ANN CHIR GYNAECOL FE, V85, P111	34	174	179	0	11	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	MAY 20	1999	340	20					1533	1538		10.1056/NEJM199905203402002	http://dx.doi.org/10.1056/NEJM199905203402002			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	197HG	10332014				2022-12-28	WOS:000080358900002
J	Rosenberg, RD; Aird, WC				Rosenberg, RD; Aird, WC			Vascular-bed - Specific hemostasis and hypercoagulable states	NEW ENGLAND JOURNAL OF MEDICINE			English	Review							THROMBOTIC THROMBOCYTOPENIC PURPURA; MICROVASCULAR ENDOTHELIAL-CELLS; NECROSIS-FACTOR-ALPHA; SMOOTH-MUSCLE CELLS; PAROXYSMAL-NOCTURNAL HEMOGLOBINURIA; PLASMINOGEN-ACTIVATOR INHIBITOR-1; DEEP VENOUS THROMBOSIS; FLUID SHEAR-STRESS; GROWTH-FACTOR-BETA; MYOCARDIAL-INFARCTION		Beth Israel Deaconess Med Ctr, Dept Med, Div Mol Med, Boston, MA 02215 USA; Beth Israel Deaconess Med Ctr, Dept Med, Div Hematol Oncol, Boston, MA 02215 USA; MIT, Dept Biol, Cambridge, MA USA	Harvard University; Beth Israel Deaconess Medical Center; Harvard University; Beth Israel Deaconess Medical Center; Massachusetts Institute of Technology (MIT)	Aird, WC (corresponding author), Beth Israel Deaconess Med Ctr, Dept Med, Div Mol Med, RW-663, Boston, MA 02215 USA.							Aird WC, 1997, J CELL BIOL, V138, P1117, DOI 10.1083/jcb.138.5.1117; AIRD WC, 1995, P NATL ACAD SCI USA, V92, P4567, DOI 10.1073/pnas.92.10.4567; Armstead VE, 1997, FASEB J, V11, P1271, DOI 10.1096/fasebj.11.14.9409546; Arruda VR, 1998, CARDIOVASC RES, V37, P42, DOI 10.1016/S0008-6363(97)00211-3; ASADA Y, 1985, THROMB RES, V38, P469, DOI 10.1016/0049-3848(85)90180-X; ASHERSON RA, 1989, MEDICINE, V68, P366, DOI 10.1097/00005792-198911000-00004; BAHNAK BR, 1989, J CELL PHYSIOL, V138, P305, DOI 10.1002/jcp.1041380212; Bombeli T, 1997, THROMB HAEMOSTASIS, V77, P408; BOYER C, 1986, THROMB HAEMOSTASIS, V56, P18; Calnek DS, 1998, EXP CELL RES, V238, P294, DOI 10.1006/excr.1997.3812; CHOWDHURY V, 1994, THROMB HAEMOSTASIS, V72, P198; CHRIST G, 1993, BLOOD, V81, P1277; Cines DB, 1998, BLOOD, V91, P3527; COFFIN JD, 1991, DEV BIOL, V148, P51, DOI 10.1016/0012-1606(91)90316-U; COMP PC, 1990, SEMIN THROMB HEMOST, V16, P293, DOI 10.1055/s-2007-1002682; CONWAY EM, 1989, THROMB RES, V53, P231, DOI 10.1016/0049-3848(89)90098-4; CONWAY EM, 1988, MOL CELL BIOL, V8, P5588, DOI 10.1128/MCB.8.12.5588; DAVIES PF, 1995, PHYSIOL REV, V75, P519, DOI 10.1152/physrev.1995.75.3.519; De Stefano V, 1998, BLOOD, V91, P3562, DOI 10.1182/blood.V91.10.3562.3562_3562_3565; DeStefano V, 1996, BLOOD, V87, P3531, DOI 10.1182/blood.V87.9.3531.bloodjournal8793531; DILAWARI JB, 1994, MEDICINE, V73, P21, DOI 10.1097/00005792-199401000-00003; DRAKE TA, 1993, AM J PATHOL, V142, P1458; DRAKE TA, 1993, AM J PATHOL, V143, P649; Edelberg JM, 1998, J CLIN INVEST, V102, P837, DOI 10.1172/JCI3058; Everett AD, 1998, AM J PHYSIOL-LUNG C, V274, pL1058, DOI 10.1152/ajplung.1998.274.6.L1058; Finazzi G, 1996, AM J MED, V100, P530, DOI 10.1016/S0002-9343(96)00060-5; FINAZZI G, 1987, THROMB HAEMOSTASIS, V58, P1094; GALLICCHIO M, 1994, ARTERIOSCLER THROMB, V14, P815, DOI 10.1161/01.ATV.14.5.815; Gille J, 1996, BLOOD, V87, P211, DOI 10.1182/blood.V87.1.211.bloodjournal871211; GREAVES M, 1991, BRIT J HAEMATOL, V79, P148, DOI 10.1111/j.1365-2141.1991.tb04514.x; HILLMEN P, 1995, NEW ENGL J MED, V333, P1253, DOI 10.1056/NEJM199511093331904; HIROKAWA K, 1991, J CELL PHYSIOL, V147, P157, DOI 10.1002/jcp.1041470120; ISHII H, 1986, BLOOD, V67, P362; Kawai Y, 1996, BLOOD, V87, P2314, DOI 10.1182/blood.V87.6.2314.bloodjournal8762314; KHAMASHTA MA, 1995, NEW ENGL J MED, V332, P993, DOI 10.1056/NEJM199504133321504; Lin MC, 1997, J CLIN INVEST, V99, P737, DOI 10.1172/JCI119219; MACIK BG, 1995, CLIN CHEST MED, V16, P375; MALEK AM, 1994, CIRC RES, V74, P852, DOI 10.1161/01.RES.74.5.852; Margaglione M, 1998, ANN INTERN MED, V129, P89, DOI 10.7326/0003-4819-129-2-199807150-00003; Martinelli I, 1998, NEW ENGL J MED, V338, P1793, DOI 10.1056/NEJM199806183382502; Martinelli I, 1997, ANN INTERN MED, V126, P707, DOI 10.7326/0003-4819-126-9-199705010-00006; MEADE TW, 1986, LANCET, V2, P533, DOI 10.1016/S0140-6736(86)90111-X; Miller GJ, 1996, THROMB HAEMOSTASIS, V75, P767; Mitra D, 1997, BLOOD, V89, P1224, DOI 10.1182/blood.V89.4.1224; NACHMAN RL, 1993, ANN INTERN MED, V119, P819, DOI 10.7326/0003-4819-119-8-199310150-00008; Niebauer J, 1996, J AM COLL CARDIOL, V28, P1652, DOI 10.1016/S0735-1097(96)00393-2; OHJI T, 1995, THROMB HAEMOSTASIS, V73, P812; OKAJIMA K, 1989, THROMB HAEMOSTASIS, V61, P20; Pabinger I, 1996, ARTERIOSCL THROM VAS, V16, P742, DOI 10.1161/01.ATV.16.6.742; PAGE C, 1992, AM J PATHOL, V141, P673; PEPPER MS, 1991, BIOCHEM BIOPH RES CO, V181, P902, DOI 10.1016/0006-291X(91)91276-I; Pinsky DJ, 1998, J CLIN INVEST, V102, P919, DOI 10.1172/JCI307; Poppa V, 1998, ARTERIOSCL THROM VAS, V18, P1312, DOI 10.1161/01.ATV.18.8.1312; Price DT, 1997, ANN INTERN MED, V127, P895, DOI 10.7326/0003-4819-127-10-199711150-00007; RAND JH, 1987, ARTERIOSCLEROSIS, V7, P287, DOI 10.1161/01.ATV.7.3.287; Reuner KH, 1998, STROKE, V29, P1765, DOI 10.1161/01.STR.29.9.1765; RIDOLFI RL, 1981, MEDICINE, V60, P413, DOI 10.1097/00005792-198111000-00003; ROSENBERG RD, 1995, MOL CARDIOVASCULAR M, P115; Rosendaal FR, 1997, BLOOD, V89, P2817, DOI 10.1182/blood.V89.8.2817; Rosendaal FR, 1997, BLOOD, V90, P1747, DOI 10.1182/blood.V90.5.1747; Ruggenenti P, 1996, EUR J HAEMATOL, V56, P191; Ryan DH, 1998, ANN INTERN MED, V128, P270, DOI 10.7326/0003-4819-128-4-199802150-00003; SATO TN, 1995, NATURE, V376, P70, DOI 10.1038/376070a0; SAWDEY M, 1989, J BIOL CHEM, V264, P10396; SAWDEY MS, 1991, J CLIN INVEST, V88, P1346, DOI 10.1172/JCI115440; SCHLAEGER TM, 1995, DEVELOPMENT, V121, P1089; Schlaeger TM, 1997, P NATL ACAD SCI USA, V94, P3058, DOI 10.1073/pnas.94.7.3058; Shreeve SM, 1996, STROKE, V27, P2211, DOI 10.1161/01.STR.27.12.2211; Silverman MD, 1996, BLOOD COAGUL FIBRIN, V7, P281, DOI 10.1097/00001721-199604000-00001; Socie G, 1996, LANCET, V348, P573, DOI 10.1016/S0140-6736(95)12360-1; TAKADA Y, 1994, BIOCHEM BIOPH RES CO, V205, P1345, DOI 10.1006/bbrc.1994.2813; Thomas DP, 1997, ANN INTERN MED, V126, P638, DOI 10.7326/0003-4819-126-8-199704150-00009; THOMPSON SG, 1995, NEW ENGL J MED, V332, P635, DOI 10.1056/NEJM199503093321003; Uematsu M, 1995, AM J PHYSIOL-CELL PH, V269, pC1371, DOI 10.1152/ajpcell.1995.269.6.C1371; Weiler-Guettler H, 1998, J CLIN INVEST, V101, P1983, DOI 10.1172/JCI2006; WILHELMSEN L, 1984, NEW ENGL J MED, V311, P501, DOI 10.1056/NEJM198408233110804; WU QY, 1987, ARTERIOSCLEROSIS, V7, P47, DOI 10.1161/01.ATV.7.1.47; Yamamoto K, 1996, J CLIN INVEST, V97, P2440, DOI 10.1172/JCI118691; Yang ZH, 1997, CIRCULATION, V95, P1870; Ziegler T, 1998, HYPERTENSION, V32, P351, DOI 10.1161/01.HYP.32.2.351	80	446	468	2	33	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	MAY 20	1999	340	20					1555	1564		10.1056/NEJM199905203402007	http://dx.doi.org/10.1056/NEJM199905203402007			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	197HG	10332019				2022-12-28	WOS:000080358900007
J	Goldie, SJ; Kuntz, KM; Weinstein, MC; Freedberg, KA; Welton, ML; Palefsky, JM				Goldie, SJ; Kuntz, KM; Weinstein, MC; Freedberg, KA; Welton, ML; Palefsky, JM			The clinical effectiveness and cost-effectiveness of screening for anal squamous intraepithelial lesions in homosexual and bisexual HIV-positive men	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article; Proceedings Paper	12th World AIDS Conference	JUN 28-JUL 03, 1998	GENEVA, SWITZERLAND				HUMAN-IMMUNODEFICIENCY-VIRUS; HUMAN-PAPILLOMAVIRUS INFECTION; CELL CARCINOMA; RISK-FACTORS; CYTOLOGIC ABNORMALITIES; ANTIRETROVIRAL THERAPY; CANCER INCIDENCE; NEOPLASIA; ASSOCIATION; DYSPLASIA	Context Homosexual and bisexual men infected with human immunodeficiency virus (HIV) are at increased risk for human papillomavirus-related anal neoplasia and anal squamous cell carcinoma (SCC). Objective To estimate the clinical benefits and cost-effectiveness of screening HIV-positive homosexual and bisexual men for anal squamous intraepithelial lesions (ASIL) and anal SCC. Design Cost-effectiveness analysis performed from a societal perspective that used reference case recommendations from the Panel on Cost-Effectiveness in Health and Medicine. A state-transition Markov model was developed to calculate lifetime costs, life expectancy, and quality-adjusted life expectancy for no screening vs several screening strategies for ASIL and anal SCC using anal Papanicolaou (Pap) testing at different intervals. Values for incidence, progression, and regression of anal neoplasia; efficacy of screening and treatment; natural history of HIV; health-related quality of life; and costs were obtained from the literature, Setting and Participants Hypothetical cohort of homosexual and bisexual HIV-positive men living in the United States. Main Outcome Measures Life expectancy, quality-adjusted life expectancy, quality-adjusted years of life saved, lifetime costs, and incremental cost-effectiveness ratio. Results Screening for ASIL increased quality-adjusted life expectancy at all stages of HIV disease. Screening with anal Pap tests every 2 years, beginning in early HIV disease (CD4 cell count >0.50 x 10(9)/L), resulted in a 2.7-month gain in quality-adjusted life expectancy for an incremental cost-effectiveness ratio of $13 000 per quality-adjusted life year saved. Screening with anal Pap tests yearly provided additional benefit at an incremental cost of $16 600 per quality-adjusted life year saved. If screening was not initiated until later in the course of HIV disease (CD4 cell count <0.50 x 10(9)/L), then yearly Pap test screening was preferred due to the greater amount of prevalent anal disease (cost-effectiveness ratio of less than $25 000 per quality-adjusted life year saved compared with no screening). Screening every 6 months provided little additional benefit over that of yearly screening. Results were most sensitive to the rate of progression of ASIL to anal SCC and the effectiveness of treatment of precancerous lesions. Conclusions Screening HIV-positive homosexual and bisexual men for ASIL and anal SCC with anal Pap tests offers quality-adjusted life expectancy benefits at a cost comparable with other accepted clinical preventive interventions.	Harvard Univ, Sch Publ Hlth, Dept Hlth Policy & Management, Ctr Risk Anal, Boston, MA 02115 USA; Boston Univ, Sch Med, Gen Internal Med Sect, Clin Econ Res Unit, Boston, MA 02118 USA; Boston Univ, Sch Med, Dept Med, Clin AIDS Program, Boston, MA 02118 USA; Boston Univ, Sch Med, Dept Epidemiol & Biostat, Boston Med Ctr,Evans Med Fdn, Boston, MA 02118 USA; Boston Univ, Sch Publ Hlth, Boston, MA USA; Univ Calif San Francisco, Dept Surg, San Francisco, CA 94143 USA; Univ Calif San Francisco, Dept Lab Med & Med, San Francisco, CA 94143 USA	Harvard University; Harvard T.H. Chan School of Public Health; Boston University; Boston University; Boston Medical Center; Boston University; Boston University; University of California System; University of California San Francisco; University of California System; University of California San Francisco	Goldie, SJ (corresponding author), Harvard Univ, Sch Publ Hlth, Dept Hlth Policy & Management, Ctr Risk Anal, 718 Huntington Ave,Suite 2, Boston, MA 02115 USA.	sgoldie@hsph.harvard.edu			NCI NIH HHS [R01 CA054053, R01-CA 54053] Funding Source: Medline; NCRR NIH HHS [5 M01-RR-00079] Funding Source: Medline; PHS HHS [U64/CCU114927-01] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA054053] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR000079] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))		*AIDS, 1994, NAT TECHN INF SERV P; [Anonymous], 1997, STAT ABSTR US; Aynaud O, 1998, SEX TRANSM INFECT, V74, P32, DOI 10.1136/sti.74.1.32; BERK M, 1993, AHCPR PUBLICATION; Bottomley D M, 1996, Clin Oncol (R Coll Radiol), V8, P319, DOI 10.1016/S0936-6555(05)80720-4; CARDINALE V, 1997, DRUG TOPICS RED BOOK; CAUSSY D, 1990, INT J CANCER, V46, P214, DOI 10.1002/ijc.2910460212; CELENTANO D P, 1989, Public Health Reviews, V17, P173; CHADHA M, 1994, DIS COLON RECTUM, V37, P861, DOI 10.1007/BF02052589; Condra JH, 1998, ANN INTERN MED, V128, P951, DOI 10.7326/0003-4819-128-11-199806010-00017; Cornelius L, 1991, AHCPR PUBLICATION; CRITCHLOW CW, 1995, AIDS, V9, P1255, DOI 10.1097/00002030-199511000-00007; DALING JR, 1987, NEW ENGL J MED, V317, P973, DOI 10.1056/NEJM198710153171601; DANIEL GL, 1994, DIS COLON RECTUM, V37, P670, DOI 10.1007/BF02054410; DERUITER A, 1994, GENITOURIN MED, V70, P22; Enger C, 1996, JAMA-J AM MED ASSOC, V275, P1329, DOI 10.1001/jama.275.17.1329; Flexner C, 1998, NEW ENGL J MED, V338, P1281, DOI 10.1056/NEJM199804303381808; FORTI RL, 1995, CLIN INFECT DIS, V21, P603, DOI 10.1093/clinids/21.3.603; FRAZER IH, 1986, LANCET, V2, P657; Freedberg KA, 1998, JAMA-J AM MED ASSOC, V279, P130, DOI 10.1001/jama.279.2.130; Goedert JJ, 1998, LANCET, V351, P1833, DOI 10.1016/S0140-6736(97)09028-4; Gold MR, 1996, COST EFFECTIVENESS H; Gulick RM, 1997, NEW ENGL J MED, V337, P734, DOI 10.1056/NEJM199709113371102; Gulick RM, 1998, JAMA-J AM MED ASSOC, V280, P35, DOI 10.1001/jama.280.1.35; Hammer SM, 1997, NEW ENGL J MED, V337, P725, DOI 10.1056/NEJM199709113371101; HAYE KR, 1988, GENITOURIN MED, V64, P378; HELLINGER FJ, 1993, JAMA-J AM MED ASSOC, V270, P474, DOI 10.1001/jama.270.4.474; HOLLAND JM, 1994, RADIOLOGY, V193, P251, DOI 10.1148/radiology.193.1.8090901; HOLLY EA, 1989, JNCI-J NATL CANCER I, V81, P1726, DOI 10.1093/jnci/81.22.1726; HSIAO WC, 1988, JAMA-J AM MED ASSOC, V260, P2347, DOI 10.1001/jama.260.16.2347; Jay N, 1997, DIS COLON RECTUM, V40, P919, DOI 10.1007/BF02051199; KIVIAT NB, 1993, AIDS, V7, P43, DOI 10.1097/00002030-199301000-00007; Koblin BA, 1996, AM J EPIDEMIOL, V144, P916, DOI 10.1093/oxfordjournals.aje.a008861; KURMAN RJ, 1994, JAMA-J AM MED ASSOC, V271, P1866, DOI 10.1001/jama.271.23.1866; LAW CLH, 1991, GENITOURIN MED, V67, P92; LONGINI IM, 1991, J ACQ IMMUN DEF SYND, V4, P1141; LONGINI IM, 1989, STAT MED, V8, P831, DOI 10.1002/sim.4780080708; LONGO WE, 1994, ANN SURG, V220, P40, DOI 10.1097/00000658-199407000-00007; MELBYE M, 1994, AM J EPIDEMIOL, V139, P772, DOI 10.1093/oxfordjournals.aje.a117073; MELBYE M, 1994, LANCET, V343, P636, DOI 10.1016/S0140-6736(94)92636-0; MELBYE M, 1990, INT J CANCER, V46, P203, DOI 10.1002/ijc.2910460210; MENDENHALL WM, 1994, SURG ONCOL, V3, P135, DOI 10.1016/0960-7404(94)90042-6; *NAT CANC I, 1998, SEER CANC STAT REV; *NAT TECHN INF SER, 1995, MULT AIDS COH STUD M; Northfelt DW, 1996, HEMATOL ONCOL CLIN N, V10, P1177, DOI 10.1016/S0889-8588(05)70392-0; Palefsky JM, 1997, J ACQ IMMUN DEF SYND, V14, P415, DOI 10.1097/00042560-199704150-00004; PALEFSKY JM, 1994, J ACQ IMMUN DEF SYND, V7, P599; PALEFSKY JM, 1994, AIDS, V8, P283, DOI 10.1097/00002030-199403000-00001; Palefsky JM, 1998, J ACQ IMMUN DEF SYND, V17, P314, DOI 10.1097/00042560-199804010-00004; PALEFSKY JM, 1995, CANCER EPIDEM BIOMAR, V4, P415; Palefsky JM, 1998, AIDS, V12, P495, DOI 10.1097/00002030-199805000-00011; PALEFSKY JM, 1990, JAMA-J AM MED ASSOC, V263, P2911, DOI 10.1001/jama.263.21.2911; Palefsky JM, 1998, J INFECT DIS, V177, P361, DOI 10.1086/514194; Palefsky JM, 1998, J ACQ IMMUN DEF SYND, V17, P320, DOI 10.1097/00042560-199804010-00005; PALEFSKY JM, 1992, J ACQ IMMUN DEF SYND, V5, P1258; Palefsky Joel, 1995, Current Opinion in Oncology, V7, P437, DOI 10.1097/00001622-199509000-00009; Peddada AV, 1997, INT J RADIAT ONCOL, V37, P1101, DOI 10.1016/S0360-3016(96)00596-2; Qualters J R, 1992, MMWR CDC Surveill Summ, V41, P1; Sayers SJ, 1998, INT J STD AIDS, V9, P37, DOI 10.1258/0956462981921017; SEGAL MJ, 1997, MED RBRVS PHYSICIANS; SHERMAN ME, 1995, MODERN PATHOL, V8, P270; SONNEX C, 1991, GENITOURIN MED, V67, P21; SURAWICZ CM, 1995, AM J GASTROENTEROL, V90, P1776; SURAWICZ CM, 1993, GASTROENTEROLOGY, V105, P658, DOI 10.1016/0016-5085(93)90880-L; TAPLIN SH, 1995, J NATL CANCER I, V87, P417, DOI 10.1093/jnci/87.6.417; Tsevat J, 1996, MED CARE, V34, P44, DOI 10.1097/00005650-199601000-00004; Unger ER, 1997, ARCH PATHOL LAB MED, V121, P820; WEXNER SD, 1987, DIS COLON RECTUM, V30, P942, DOI 10.1007/BF02554281	68	282	293	0	8	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAY 19	1999	281	19					1822	1829		10.1001/jama.281.19.1822	http://dx.doi.org/10.1001/jama.281.19.1822			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Conference Proceedings Citation Index - Science (CPCI-S)	General & Internal Medicine	196BH	10340370	Bronze			2022-12-28	WOS:000080288800036
J	Ahn, CH; Gariglio, S; Paruch, P; Tybell, T; Antognazza, L; Triscone, JM				Ahn, CH; Gariglio, S; Paruch, P; Tybell, T; Antognazza, L; Triscone, JM			Electrostatic modulation of superconductivity in ultrathin GdBa2Cu3O7-x films	SCIENCE			English	Article							QUANTUM PHASE-TRANSITIONS; FIELD-EFFECT TRANSISTOR; INSULATOR TRANSITION; NORMAL-STATE; YBA2CU3O7-DELTA FILMS; METAL CROSSOVER; VORTEX DYNAMICS; THIN-FILM; TEMPERATURE; TRANSPORT	The polarization field of the ferroelectric oxide Lead zirconate titanate [Pb(ZrxTi1-x)O-3] was used to tune the critical temperature of the high-temperature superconducting cuprate gadolinium barium copper oxide (GdBa2Cu3O7-x) in a reversible, nonvolatile fashion. For slightly underdoped samples, a uniform shift of several Kelvin in the critical temperature was observed, whereas for more underdoped samples, an insulating state was induced. This transition from superconducting to insulating behavior does not involve chemical or crystalline, modification of the material.	Univ Geneva, Dept Phys Mat Condensee, CH-1211 Geneva 4, Switzerland	University of Geneva	Ahn, CH (corresponding author), Univ Geneva, Dept Phys Mat Condensee, 24 Quai E Ansermet, CH-1211 Geneva 4, Switzerland.		Tybell, Thomas/B-8297-2013	Tybell, Thomas/0000-0003-0787-8476; Paruch, Patrycja/0000-0001-7799-6721				AHN CH, 1995, SCIENCE, V269, P373, DOI 10.1126/science.269.5222.373; Ahn CH, 1997, APPL PHYS LETT, V70, P206, DOI 10.1063/1.118203; Ahn CH, 1997, SCIENCE, V276, P1100, DOI 10.1126/science.276.5315.1100; Akazaki T, 1996, APPL PHYS LETT, V68, P418, DOI 10.1063/1.116704; ANDO Y, 1995, PHYS REV LETT, V75, P4662, DOI 10.1103/PhysRevLett.75.4662; ARIOSA D, 1991, PHYS REV B, V43, P344, DOI 10.1103/PhysRevB.43.344; Boebinger GS, 1996, PHYS REV LETT, V77, P5417, DOI 10.1103/PhysRevLett.77.5417; CAO LX, 1998, PHYSICA C, V47, P303; CARRINGTON A, 1992, PHYS REV LETT, V69, P2855, DOI 10.1103/PhysRevLett.69.2855; Chow E, 1998, PHYS REV LETT, V81, P204, DOI 10.1103/PhysRevLett.81.204; DONIACH S, 1990, PHYS REV B, V41, P6668, DOI 10.1103/PhysRevB.41.6668; EMERY VJ, 1995, PHYS REV LETT, V74, P3253, DOI 10.1103/PhysRevLett.74.3253; Eremets MI, 1998, SCIENCE, V281, P1333, DOI 10.1126/science.281.5381.1333; FISHER MPA, 1990, PHYS REV LETT, V65, P923, DOI 10.1103/PhysRevLett.65.923; FISHER MPA, 1990, PHYS REV LETT, V64, P587, DOI 10.1103/PhysRevLett.64.587; Fournier P, 1998, PHYS REV LETT, V81, P4720, DOI 10.1103/PhysRevLett.81.4720; Fukuzumi Y, 1996, PHYS REV LETT, V76, P684, DOI 10.1103/PhysRevLett.76.684; GLOVER RE, 1960, PHYS REV LETT, V5, P248, DOI 10.1103/PhysRevLett.5.248; Goldman AM, 1998, PHYS TODAY, V51, P39, DOI 10.1063/1.882069; HEBARD AF, 1990, PHYS REV LETT, V65, P927, DOI 10.1103/PhysRevLett.65.927; HONTSU S, 1995, APPL PHYS LETT, V67, P554, DOI 10.1063/1.115167; Hontsu S, 1997, IEICE T ELECTRON, VE80C, P1304; Hussey NE, 1998, PHYS REV LETT, V80, P2909, DOI 10.1103/PhysRevLett.80.2909; ITO T, 1993, PHYS REV LETT, V70, P3995, DOI 10.1103/PhysRevLett.70.3995; Kabasawa U, 1997, J APPL PHYS, V81, P2302, DOI 10.1063/1.364234; Karpinska K, 1996, PHYS REV LETT, V77, P3033, DOI 10.1103/PhysRevLett.77.3033; Kastner MA, 1998, REV MOD PHYS, V70, P897, DOI 10.1103/RevModPhys.70.897; KLEINSASSER AW, 1989, APPL PHYS LETT, V55, P1909, DOI 10.1063/1.102166; LIU Y, 1991, PHYS REV LETT, V67, P2068, DOI 10.1103/PhysRevLett.67.2068; Mannhart J, 1996, SUPERCOND SCI TECH, V9, P49, DOI 10.1088/0953-2048/9/2/001; MANNHART J, 1991, PHYS REV LETT, V67, P2099, DOI 10.1103/PhysRevLett.67.2099; Mayer B, 1996, APPL PHYS LETT, V68, P3031, DOI 10.1063/1.115567; PREYER NW, 1989, PHYS REV B, V39, P11563, DOI 10.1103/PhysRevB.39.11563; Rimberg AJ, 1997, PHYS REV LETT, V78, P2632, DOI 10.1103/PhysRevLett.78.2632; SCHNEIDER T, 1992, PHYS REV LETT, V69, P3374, DOI 10.1103/PhysRevLett.69.3374; SEIDLER GT, 1992, PHYS REV B, V45, P10162, DOI 10.1103/PhysRevB.45.10162; Sondhi SL, 1997, REV MOD PHYS, V69, P315, DOI 10.1103/RevModPhys.69.315; SUN AG, 1994, PHYS REV B, V50, P3266, DOI 10.1103/PhysRevB.50.3266; TERASHIMA T, 1991, PHYS REV LETT, V67, P1362, DOI 10.1103/PhysRevLett.67.1362; Triscone JM, 1996, J APPL PHYS, V79, P4298, DOI 10.1063/1.361798; Triscone JM, 1997, REP PROG PHYS, V60, P1673, DOI 10.1088/0034-4885/60/12/004; WALKENHORST A, 1992, PHYS REV LETT, V69, P2709, DOI 10.1103/PhysRevLett.69.2709; WATANABE Y, 1995, APPL PHYS LETT, V66, P1770, DOI 10.1063/1.113362; XI XX, 1992, PHYS REV LETT, V68, P1240, DOI 10.1103/PhysRevLett.68.1240; YAZDANI A, 1995, PHYS REV LETT, V74, P3037, DOI 10.1103/PhysRevLett.74.3037; Zhang SC, 1997, SCIENCE, V275, P1089, DOI 10.1126/science.275.5303.1089	47	238	241	2	95	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	MAY 14	1999	284	5417					1152	1155		10.1126/science.284.5417.1152	http://dx.doi.org/10.1126/science.284.5417.1152			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	197HJ	10325222				2022-12-28	WOS:000080359100032
J	Vladeck, BC				Vladeck, BC			Plenty of nothing - A report from the Medicare Commission	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material									CUNY Mt Sinai Sch Med, New York, NY 10029 USA	City University of New York (CUNY) System; Icahn School of Medicine at Mount Sinai	Vladeck, BC (corresponding author), CUNY Mt Sinai Sch Med, New York, NY 10029 USA.							Aaron HJ, 1995, HEALTH AFFAIR, V14, P8, DOI 10.1377/hlthaff.14.4.8	1	13	13	0	1	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	MAY 13	1999	340	19					1503	1506		10.1056/NEJM199905133401911	http://dx.doi.org/10.1056/NEJM199905133401911			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	194MT	10320392				2022-12-28	WOS:000080198700011
J	Campbell, JK; Johnson, C				Campbell, JK; Johnson, C			Trend spotting: fashions in medical education	BRITISH MEDICAL JOURNAL			English	Article							REVIEWS		Univ Wales, Coll Med, Acad Dept Med & Dent Educ, Cardiff CF14 4XN, S Glam, Wales	Cardiff University	Campbell, JK (corresponding author), Univ Wales, Coll Med, Acad Dept Med & Dent Educ, Cardiff CF14 4XN, S Glam, Wales.							Anderson MB, 1999, ACAD MED, V74, P13; Atkins JM, 1997, NURS EDUC TODAY, V17, P319, DOI 10.1016/S0260-6917(97)80063-9; Buckley G, 1998, MED EDUC, V32, P1, DOI 10.1046/j.1365-2923.1998.00187.x; CLARK RE, 1983, REV EDUC RES, V53, P238; CLARK RE, 1988, HDB ED RES, P464; *GEN MED COUNC, 1995, TOM DOCT; Harris DL, 1998, ACAD MED, V73, pS13, DOI 10.1097/00001888-199810000-00031; HENRY RC, 1993, J AM PODIAT MED ASSN, V83, P328, DOI 10.7547/87507315-83-6-328; Hofer BK, 1997, REV EDUC RES, V67, P88, DOI 10.2307/1170620; KOZMA RB, 1994, ETR&D-EDUC TECH RES, V42, P7, DOI 10.1007/BF02299087; KOZMA RB, 1991, REV EDUC RES, V61, P179, DOI 10.2307/1170534; Lave J., 2021, SITUATED COGNITION, P17; Mason R, 1994, USING COMMUNICATIONS; Maudsley G, 1999, ACAD MED, V74, P178, DOI 10.1097/00001888-199902000-00016; MOORE DM, 1996, HDB RES ED COMMUNICA, P851; Murray FB, 1996, REV EDUC RES, V66, P417, DOI 10.3102/00346543066004417; OGAWA RT, 1995, REV EDUC RES, V66, P265; PATTON MQ, 1991, REV EDUC RES, V61, P287, DOI 10.2307/1170631; Tonelli MR, 1998, ACAD MED, V73, P1234, DOI 10.1097/00001888-199812000-00011	19	41	43	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	MAY 8	1999	318	7193					1272	+						4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	195XT	10231264	Green Published			2022-12-28	WOS:000080278000033
J	Cantillon, P; Jones, R				Cantillon, P; Jones, R			Does continuing medical education in general practice make a difference?	BMJ-BRITISH MEDICAL JOURNAL			English	Article							PHYSICIAN PERFORMANCE; CLINICAL-PRACTICE; HEALTH-CARE; PRACTITIONERS; GUIDELINES; BEHAVIOR; PROGRAM; INTERVENTIONS; TRIALS; CME		Kings Coll London, Guys Kings & St Thomass Sch Med, Dept Gen Practice & Primary Care, London SE11 6SP, England	University of London; King's College London	Cantillon, P (corresponding author), Kings Coll London, Guys Kings & St Thomass Sch Med, Dept Gen Practice & Primary Care, London SE11 6SP, England.	peter.cantillon@kcl.ac.uk						Allery LA, 1997, BMJ-BRIT MED J, V314, P870; Armstrong D, 1996, BRIT MED J, V312, P949; Boud D., 2005, REFLECTION TURNING E; Brookfield S., 1986, UNDERSTANDING FACILI; CALMAN K, 1998, REV CONTINUING PROFE; CARTER AO, 1995, CAN MED ASSOC J, V153, P901; Davis D, 1998, INT J PSYCHIAT MED, V28, P21, DOI 10.2190/UA3R-JX9W-MHR5-RC81; Davis D, 1998, BMJ-BRIT MED J, V316, P385, DOI 10.1136/bmj.316.7128.385; DAVIS DA, 1995, JAMA-J AM MED ASSOC, V274, P700; DAVIS DA, 1992, JAMA-J AM MED ASSOC, V268, P1111, DOI 10.1001/jama.268.9.1111; Fox RD, 1998, BRIT MED J, V316, P466, DOI 10.1136/bmj.316.7129.466; GRANT J, 1998, GOOD CME GUIDE; Grant Joanne, 1998, EFFECTIVENESS CONTIN, P1; GRIMSHAW JM, 1993, LANCET, V342, P1317, DOI 10.1016/0140-6736(93)92244-N; GROL R, 1997, EUR J GEN PRACT, V3, P123; HORDER J, 1986, J ROY COLL GEN PRACT, V36, P517; JOHNSTON ME, 1994, ANN INTERN MED, V120, P135, DOI 10.7326/0003-4819-120-2-199401150-00007; JOLLY B, 1997, GOOD ASSESSMENT GUID; KERWICK SW, 1996, PRIMARY CARE PSYCHIA, V2, P107; Levine H., 1984, EVALUATING CONTINUIN; Lobach D F, 1996, Proc AMIA Annu Fall Symp, P493; LOMAS J, 1994, DISSEMINATING RES CH; Mittman B S, 1992, QRB Qual Rev Bull, V18, P413; Moran JA, 1996, CAN FAM PHYSICIAN, V42, P272; OCONNELL DL, 1999, BMJ-BRIT MED J, V318, P508; OXMAN AD, 1995, CAN MED ASSOC J, V153, P1423; Pill R, 1998, FAM PRACT, V15, P229, DOI 10.1093/fampra/15.3.229; Pringle M, 1998, BMJ-BRIT MED J, V317, P1120; Pringle M, 1995, OCCAS PAP R COLL GEN, P1; Richards T, 1998, BRIT MED J, V316, P246, DOI 10.1136/bmj.316.7127.246; Rogers C. R., 1969, FREEDOM LEARN 80S; ROLFE I, 1997, IMPERATIVES MED ED N; RUTZ W, 1992, ACTA PSYCHIAT SCAND, V85, P83, DOI 10.1111/j.1600-0447.1992.tb01448.x; RUTZ W, 1989, ACTA PSYCHIAT SCAND, V79, P19, DOI 10.1111/j.1600-0447.1989.tb09229.x; Salisbury C, 1997, BRIT J GEN PRACT, V47, P319; Schon D.A., 1987, ED REFLECTIVE PRACTI; SIBLEY JC, 1982, NEW ENGL J MED, V306, P511, DOI 10.1056/NEJM198203043060904; Singleton D, 1996, BRIT J GEN PRACT, V46, P339; STANLEY I, 1993, BRIT J GEN PRACT, V43, P210; Towle A, 1998, BRIT MED J, V316, P301, DOI 10.1136/bmj.316.7127.301; Tracey JM, 1997, BRIT MED J, V315, P1426, DOI 10.1136/bmj.315.7120.1426; Violato C, 1997, ACAD MED, V72, pS82, DOI 10.1097/00001888-199710001-00028; Wensing M, 1998, BRIT J GEN PRACT, V48, P991; Wensing M, 1994, Int J Qual Health Care, V6, P115; WINKENS RAG, 1992, BRIT MED J, V304, P1093, DOI 10.1136/bmj.304.6834.1093	45	160	169	0	3	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	MAY 8	1999	318	7193					1276	1279						4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	195XT	10231265				2022-12-28	WOS:000080278000034
J	Present, DH; Rutgeerts, P; Targan, S; Hanauer, SB; Mayer, L; van Hogezand, RA; Podolsky, DK; Sands, BE; Braakman, T; DeWoody, KL; Schaible, TF; van Deventer, SJH				Present, DH; Rutgeerts, P; Targan, S; Hanauer, SB; Mayer, L; van Hogezand, RA; Podolsky, DK; Sands, BE; Braakman, T; DeWoody, KL; Schaible, TF; van Deventer, SJH			Infliximab for the treatment of fistulas in patients with Crohn's disease	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							MONOCLONAL-ANTIBODY CA2; TUMOR-NECROSIS-FACTOR; INFLAMMATORY BOWEL-DISEASE; FACTOR-ALPHA; ULCERATIVE-COLITIS; ACTIVITY INDEX; METRONIDAZOLE; 6-MERCAPTOPURINE; CYCLOSPORINE; THERAPY	Background Enterocutaneous fistulas are a serious complication of Crohn's disease and are difficult to treat. Infliximab, a chimeric monoclonal antibody to tumor necrosis factor a, has recently been developed as a treatment for Crohn's disease. We conducted a randomized, multicenter, double-blind, placebo-controlled trial of infliximab for the treatment of fistulas in patients with Crohn's disease. Methods The study included 94 adult patients who had draining abdominal or perianal fistulas of at least three months' duration as a complication of Crohn's disease. Patients were randomly assigned to receive one of three treatments: placebo (31 patients), 5 mg of infliximab per kilogram of body weight (31 patients), or 10 mg of infliximab per kilogram (32 patients); all three were to be administered intravenously at weeks 0, 2, and 6. The primary end point was a reduction of 50 percent or more from base line in the number of draining fistulas observed at two or more consecutive study visits. A secondary end point was the closure of all fistulas. Results Sixty-eight percent of the patients who received 5 mg of infliximab per kilogram and 56 percent of those who received 10 mg per kilogram achieved the primary end point as compared with 26 percent of the patients in the placebo group (P=0.002 and P=0.02, respectively). In addition, 55 percent of the patients assigned to receive 5 mg of infliximab per kilogram and 38 percent of those assigned to 10 mg per kilogram had closure of all fistulas, as compared with 13 percent of the patients assigned to placebo (P=0.001 and P=0.04, respectively). The median length of time during which the fistulas remained closed was three months. More than 60 percent of patients in ail the groups had adverse events. For patients treated with infliximab, the most common were headache, abscess, upper respiratory tract infection, and fatigue. Conclusions Infliximab is an efficacious treatment for fistulas in patients with Crohn's disease. (N Engl J Med 1999;340:1398-405.) (C) 1999, Massachusetts Medical Society.	Mt Sinai Med Ctr, New York, NY 10029 USA; Katholieke Univ Leuven Hosp, Louvain, Belgium; Cedars Sinai Med Ctr, Los Angeles, CA 90048 USA; Univ Chicago, Chicago, IL 60637 USA; Leiden Univ, Med Ctr, Leiden, Netherlands; Massachusetts Gen Hosp, Gastrointestinal Unit, Boston, MA 02114 USA; Massachusetts Gen Hosp, Ctr Inflammatory Bowel Dis, Boston, MA 02114 USA; Harvard Univ, Sch Med, Boston, MA USA; Centocor, Malvern, PA USA; Univ Amsterdam, Acad Med Ctr, NL-1105 AZ Amsterdam, Netherlands	Icahn School of Medicine at Mount Sinai; Flanders Institute for Biotechnology (VIB); KU Leuven; University Hospital Leuven; Cedars Sinai Medical Center; University of Chicago; Leiden University; Leiden University Medical Center (LUMC); Leiden University - Excl LUMC; Harvard University; Massachusetts General Hospital; Harvard University; Massachusetts General Hospital; Harvard University; Harvard Medical School; Johnson & Johnson; Johnson & Johnson USA; Janssen Biotech Inc; University of Amsterdam; Academic Medical Center Amsterdam	Present, DH (corresponding author), 12 E 86th St, New York, NY 10028 USA.		Sands, Bruce/R-7887-2019	Sands, Bruce/0000-0001-5762-5042				BERNSTEIN LH, 1980, GASTROENTEROLOGY, V79, P357; BEST WR, 1976, GASTROENTEROLOGY, V70, P439; BRAEGGER CP, 1992, LANCET, V339, P89, DOI 10.1016/0140-6736(92)90999-J; BRANDT LJ, 1982, GASTROENTEROLOGY, V83, P383; BREESE EJ, 1994, GASTROENTEROLOGY, V106, P1455, DOI 10.1016/0016-5085(94)90398-0; BRYNSKOV J, 1994, DIGEST DIS, V12, P290, DOI 10.1159/000171464; BUYSE ME, 1984, CANC CLIN TRIALS MET, P267; Feldmann M, 1996, CELL, V85, P307, DOI 10.1016/S0092-8674(00)81109-5; GREENSTEIN AJ, 1992, CANCER-AM CANCER SOC, V69, P1119; HANAUER SB, 1993, AM J GASTROENTEROL, V88, P646; IRVINE EJ, 1995, J CLIN GASTROENTEROL, V20, P27; KNIGHT DM, 1993, MOL IMMUNOL, V30, P1443, DOI 10.1016/0161-5890(93)90106-L; Mahadevan U, 1997, GASTROENTEROLOGY, V112, pA1031; McCabe RP, 1996, GASTROENTEROLOGY, V110, pA962; PEARSON DC, 1995, ANN INTERN MED, V123, P132, DOI 10.7326/0003-4819-123-2-199507150-00009; PRESENT DH, 1980, NEW ENGL J MED, V302, P981, DOI 10.1056/NEJM198005013021801; PRESENT DH, 1994, DIGEST DIS SCI, V39, P374, DOI 10.1007/BF02090211; Reimund JM, 1996, J CLIN IMMUNOL, V16, P144, DOI 10.1007/BF01540912; Rutgeerts P, 1997, GASTROENTEROLOGY, V112, pA1078; SCALLON BJ, 1995, CYTOKINE, V7, P251, DOI 10.1006/cyto.1995.0029; SIEGEL SA, 1995, CYTOKINE, V7, P15, DOI 10.1006/cyto.1995.1003; SOLOMON MJ, 1993, CAN J GASTROENTEROL, V7, P571, DOI 10.1155/1993/610272; Targan SR, 1997, NEW ENGL J MED, V337, P1029, DOI 10.1056/NEJM199710093371502; VanDeventer SJH, 1997, GUT, V40, P443, DOI 10.1136/gut.40.4.443; VANDULLEMEN HM, 1995, GASTROENTEROLOGY, V109, P129, DOI 10.1016/0016-5085(95)90277-5; WILLIAMS DR, 1981, DIS COLON RECTUM, V24, P22, DOI 10.1007/BF02603444	26	2019	2110	3	76	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	MAY 6	1999	340	18					1398	1405		10.1056/NEJM199905063401804	http://dx.doi.org/10.1056/NEJM199905063401804			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	192QN	10228190	Green Published			2022-12-28	WOS:000080090600004
J	Roche, H; Delagnes, A; Brugal, JP; Feibel, C; Kibunjia, M; Mourre, V; Texier, PJ				Roche, H; Delagnes, A; Brugal, JP; Feibel, C; Kibunjia, M; Mourre, V; Texier, PJ			Early hominid stone tool production and technical skill 2.34 Myr ago in west Turkana, Kenya	NATURE			English	Article							LAKE TURKANA; ETHIOPIA; SITES	Well-documented Pliocene archaeological sites are exceptional. At present they are known only in East Africa, in the Hadar(1,2) and Shungura(3) formations of Ethiopia and in the Nachukui formation of Kenya. Intensive archeological survey and a series of test excavations conducted in the Nachukui formation since 1987 have led to the discovery of more than 25 archaeological sites whose ages range from 2.34 to 0.7 million years before present (Myr)(4,5), and to the extensive excavation of two 2.34-Myr sites, Lokalalei 1 in 1991 (refs 6, 7) and Lokalalei 2C in 1997. Lokalalei 2C yielded nearly 3,000 archaeological finds from a context of such good preservation that it was possible to reconstitute more than 60 sets of complementary matching stone artefacts. These refits, predating the Koobi Fora refits by 500 Kyr (ref. 8), are the oldest ever studied. Here we describe a technological analysis of the core reduction sequences, based on these refits, which allows unprecedented accuracy in the understanding of flake production processes. We can thus demonstrate greater cognitive capacity and motor skill than previously assumed for early hominids, and highlight the diversity of Pliocene technical behaviour.	CNRS, F-92023 Nanterre, France; MMSH, CNRS, UMR 6636, F-13094 Aix En Provence, France; Rutgers State Univ, Dept Anthropol, New Brunswick, NJ 08903 USA; Natl Museum Kenya, Nairobi, Kenya; CNRS, CRA, F-06565 Valbonne, France	Centre National de la Recherche Scientifique (CNRS); Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Aix-Marseille Universite; Rutgers State University New Brunswick; Centre National de la Recherche Scientifique (CNRS)	Roche, H (corresponding author), CNRS, MAE Boite 3,Allee Univ, F-92023 Nanterre, France.			Mourre, Vincent/0000-0002-3089-1866; Brugal, Jean-Philip/0000-0002-5138-3545				BROWN FH, 1985, ANCESTORS HARD EVIDE, P82; Feibel C.S., 1991, P321; FEIBEL CS, 1989, AM J PHYS ANTHROPOL, V78, P595, DOI 10.1002/ajpa.1330780412; Harris J.M., 1988, CONTRIBUTIONS SCI, V399, P1; HOWELL FC, 1987, J HUM EVOL, V16, P643; Isaac G.L., 1997, KOOBI FORA RES PROJE, V5; KIBUNJIA M, 1992, J HUM EVOL, V23, P431, DOI 10.1016/0047-2484(92)90091-M; KIBUNJIA M, 1994, J HUM EVOL, V27, P157; KIBUNJIA M, 1998, THESIS U RUTGERS; ROCHE H, 1994, CR ACAD SCI II, V318, P1145; ROCHE H, 1996, 13 INT C PREH PROT S, V4, P55; ROCHE H, 1980, P 7 PAN C PREH QUAT, P194; Semaw S, 1997, NATURE, V385, P333, DOI 10.1038/385333a0	13	226	231	0	23	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	MAY 6	1999	399	6731					57	60		10.1038/19959	http://dx.doi.org/10.1038/19959			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	194BK	10331389				2022-12-28	WOS:000080172100053
J	Levin, TR; Palitz, A; Grossman, S; Conell, C; Finkler, L; Ackerson, L; Rumore, G; Selby, JV				Levin, TR; Palitz, A; Grossman, S; Conell, C; Finkler, L; Ackerson, L; Rumore, G; Selby, JV			Predicting advanced proximal colonic neoplasia with screening sigmoidoscopy	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							FECAL OCCULT BLOOD; COLORECTAL-CANCER; FLEXIBLE SIGMOIDOSCOPY; PATIENT PREFERENCES; HYPERPLASTIC POLYPS; COLONOSCOPY; ADENOMAS; RISK; MORTALITY; HISTORY	Context Indications are not well defined for follow-up colonoscopy for all patients with distal colonic tubular adenomas (TAs) found at screening sigmoidoscopy, Objective To determine whether distal adenoma size, number, and villous histology, along with family history and age, are predictors of advanced proximal colonic neoplasia, Design Cross-sectional analysis conducted between January 1, 1994, and December 31, 1995. Setting Large group-model hearth maintenance organization in northern California. Patients A total of 2972 asymptomatic subjects aged 50 years or older undergoing colonoscopy as follow-up to a screening sigmoidoscopy. Main Outcome Measure Based on sigmoidoscopy, colonoscopy, and pathology reports, occurrence of advanced proximal neoplasia, defined as adenocarcinoma or TAs 1 cm or larger or with villous features or severe dysplasia located beyond sigmoidoscopic view. Results The prevalence of advanced proximal neoplasia was similar among patients with no TAs at sigmoidoscopy, those with TAs less than 1 cm in diameter, and those with TAs 1 cm in diameter or larger (prevalence, 5.3%, 5.5%, and 5.6%, respectively). Of patients with a distal tubulovillous or villous adenoma, 12.1% had advanced proximal neoplasia. In multivariate analyses, having a distal tubulovillous adenoma or villous adenoma was the strongest predictor of advanced proximal neoplasia (odds ratio, 2.30; 95% confidence interval, 1.69-3.14). Age of 65 years or older, having more than 1 adenoma, and a positive family history of colorectal cancer were also significant predictors. Distal adenoma size was not a significant predictor in any multivariate analyses. Conclusions Advanced proximal neoplasia is not uncommon in subjects with or without distal TAs, but subjects with advanced distal histology and those older than 65 years are at increased risk. Age-specific screening using sigmoidoscopy starting at ages 50 to 55 years and colonoscopy after age 65 years may be justified.	Univ Calif San Francisco, Sch Med, GI Unit, Dept Med,Div Gastroenterol, San Francisco, CA 94143 USA; Kaiser Permanente Med Care Program, Div Res, Oakland, CA 94611 USA; Kaiser Permanente Med Ctr, Dept Pathol, Oakland, CA USA; Kaiser Permanente Med Ctr, Dept Med Gastroenterol, Martinez, CA USA	University of California System; University of California San Francisco; Kaiser Permanente; Kaiser Permanente; Kaiser Permanente	Levin, TR (corresponding author), Univ Calif San Francisco, Sch Med, GI Unit, Dept Med,Div Gastroenterol, Room S-357,Box 0538, San Francisco, CA 94143 USA.							ACHKAR E, 1988, ANN INTERN MED, V109, P880, DOI 10.7326/0003-4819-109-11-880; ATKIN WS, 1992, NEW ENGL J MED, V326, P658, DOI 10.1056/NEJM199203053261002; BRADY PG, 1993, GASTROINTEST ENDOSC, V39, P481, DOI 10.1016/S0016-5107(93)70155-8; CHURCH JM, 1988, DIS COLON RECTUM, V31, P50, DOI 10.1007/BF02552570; COOPER GS, 1995, CANCER, V75, P775, DOI 10.1002/1097-0142(19950201)75:3<775::AID-CNCR2820750305>3.0.CO;2-D; DINNING JP, 1994, ARCH INTERN MED, V154, P853, DOI 10.1001/archinte.154.8.853; Dominitz JA, 1997, AM J GASTROENTEROL, V92, P2171; Gopalswamy N, 1997, GASTROINTEST ENDOSC, V46, P497, DOI 10.1016/S0016-5107(97)70003-8; GROSSMAN S, 1989, GASTROENTEROLOGY, V96, P299, DOI 10.1016/0016-5085(89)91551-5; Jass JR, 1989, WHO INT HISTOLOGICAL, V2nd; KORETZ RL, 1993, ANN INTERN MED, V118, P63, DOI 10.7326/0003-4819-118-1-199301010-00011; Leard LE, 1997, J FAM PRACTICE, V45, P211; LIEBERMAN DA, 1991, AM J GASTROENTEROL, V86, P946; Marshall JR, 1996, GASTROENTEROLOGY, V111, P1411, DOI 10.1016/S0016-5085(96)70001-X; Mueller Astrid D., 1995, Archives of Internal Medicine, V155, P1741; NEWCOMB PA, 1992, JNCI-J NATL CANCER I, V84, P1572, DOI 10.1093/jnci/84.20.1572; Palitz A M, 1997, HMO Pract, V11, P5; PROVENZALE D, 1990, ANN INTERN MED, V113, P760, DOI 10.7326/0003-4819-113-10-760; Read TE, 1997, NEW ENGL J MED, V336, P8, DOI 10.1056/NEJM199701023360102; REX DK, 1991, GASTROENTEROLOGY, V100, P64, DOI 10.1016/0016-5085(91)90583-7; Schoen RE, 1997, GASTROINTEST ENDOSC, V46, P492, DOI 10.1016/S0016-5107(97)70002-6; Schoen RE, 1998, GASTROENTEROLOGY, V115, P533, DOI 10.1016/S0016-5085(98)70132-5; Sciallero S, 1997, GASTROINTEST ENDOSC, V46, P124, DOI 10.1016/S0016-5107(97)70059-2; SELBY JV, 1992, NEW ENGL J MED, V326, P653, DOI 10.1056/NEJM199203053261001; SIMON JB, 1993, ANN INTERN MED, V118, P71, DOI 10.7326/0003-4819-118-1-199301010-00013; Slattery ML, 1996, CANCER, V78, P1666, DOI 10.1002/(SICI)1097-0142(19961015)78:8<1666::AID-CNCR5>3.0.CO;2-C; Steinberg D., 1995, CART TREE STRUCTURED; STRYKER SJ, 1987, GASTROENTEROLOGY, V93, P1009, DOI 10.1016/0016-5085(87)90563-4; Wagner JL, 1996, PREVENTION EARLY DET, P321; Wallace MB, 1998, ANN INTERN MED, V129, P273, DOI 10.7326/0003-4819-129-4-199808150-00002; Winawer SJ, 1997, GASTROENTEROLOGY, V112, P594, DOI 10.1053/gast.1997.v112.agast970594; WOLF SH, 1996, US PREVENTIVE SERVIC, P89; ZARCHY TM, 1994, GASTROENTEROLOGY, V106, P1501, DOI 10.1016/0016-5085(94)90403-0	33	145	149	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAY 5	1999	281	17					1611	1617		10.1001/jama.281.17.1611	http://dx.doi.org/10.1001/jama.281.17.1611			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	191MJ	10235154	Bronze			2022-12-28	WOS:000080025900025
J	Macfarlane, PW				Macfarlane, PW			Renaissance in electrocardiography	LANCET			English	Editorial Material							HEART-RATE-VARIABILITY; MYOCARDIAL-INFARCTION; CARDIAC MORTALITY; QTC DISPERSION; ASSOCIATION; PREDICTION; RISK		Univ Glasgow, Royal Infirm, Dept Med Cardiol, Glasgow G31 2ER, Lanark, Scotland	Royal Infirmary of Edinburgh; University of Glasgow	Macfarlane, PW (corresponding author), Univ Glasgow, Royal Infirm, Dept Med Cardiol, Glasgow G31 2ER, Lanark, Scotland.							[Anonymous], 1997, Am J Cardiol, V79, P756; BREITHARDT G, 1991, EUR HEART J, V12, P473, DOI 10.1093/oxfordjournals.eurheartj.a059926; Camm AJ, 1996, EUR HEART J, V17, P354; Campbell R, 1996, BRIT MED J, V312, P878; DAY CP, 1990, BRIT HEART J, V63, P342; de Bruyne MC, 1999, EUR HEART J, V20, P278, DOI 10.1053/euhj.1998.1276; de Bruyne MC, 1998, CIRCULATION, V97, P467; DEBRUYNE MC, 1997, THESIS ERASMUS U ROT, P117; Elming H, 1998, EUR HEART J, V19, P1391, DOI 10.1053/euhj.1998.1094; KLEIGER RE, 1987, AM J CARDIOL, V59, P256, DOI 10.1016/0002-9149(87)90795-8; La Rovere MT, 1998, LANCET, V351, P478; Little CJL, 1999, AM J PHYSIOL-HEART C, V276, pH758, DOI 10.1152/ajpheart.1999.276.2.H758; Macfarlane PW, 1998, CIRCULATION, V98, P81; MALIK M, 1989, EUR HEART J, V10, P1060, DOI 10.1093/oxfordjournals.eurheartj.a059428; Puljevic D, 1997, EUR HEART J, V18, P1343; Savard P, 1997, CIRCULATION, V96, P202; Shepherd J, 1996, LANCET, V348, P1339; SIMSON MB, 1981, CIRCULATION, V64, P235, DOI 10.1161/01.CIR.64.2.235; Zabel M, 1998, CIRCULATION, V97, P2543, DOI 10.1161/01.CIR.97.25.2543	19	8	8	0	2	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	APR 24	1999	353	9162					1377	1379		10.1016/S0140-6736(98)00406-1	http://dx.doi.org/10.1016/S0140-6736(98)00406-1			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	191KD	10227214				2022-12-28	WOS:000080020800005
J	Schmidt, G; Malik, M; Barthel, P; Schneider, R; Ulm, K; Rolnitzky, L; Camm, AJ; Bigger, JT; Schomig, A				Schmidt, G; Malik, M; Barthel, P; Schneider, R; Ulm, K; Rolnitzky, L; Camm, AJ; Bigger, JT; Schomig, A			Heart-rate turbulence after ventricular premature beats as a predictor of mortality after acute myocardial infarction	LANCET			English	Article							RATE-VARIABILITY; EJECTION FRACTION; ARRHYTHMIC EVENTS; RISK; DYSFUNCTION; SURVIVORS	Background Identification of high-risk patients after acute myocardial infarction is essential for successful prophylactic therapy. The predictive accuracy of currently used risk predictors is modest even when several factors are combined. Thus, establishment of a new powerful method for risk prediction independent of the available stratifiers is of considerable practical value, Methods The study investigated fluctuations of sinus-rhythm cycle length after a single ventricular premature beat recorded in Holter electrocardiograms, and characterised the fluctuations (termed heart-rate turbulence) by two numerical parameters, termed turbulence onset and slope. The method was developed on a population of 100 patients with coronary heart disease and blindly applied to the population of the Multicentre Post-Infarction Program (MPIP; 577 survivors of acute infarction, 75 deaths during a median follow-up of 22 months) and to the placebo population of the European Myocardial Amiodarone Trial (EMIAT; 614 survivors of acute myocardial infarction, 87 deaths during median follow-up of 21 months). Multivariate risk stratification was done with the new parameters and conventional risk factors. Findings One of the new parameters (turbulence slope) was the most powerful stratifier of follow-up mortality in EMIAT and the second most powerful stratifier in MPIP: MPIP risk ratio 3.5 (95% CI 2.2-5.5, p<0.0001), EMIAT risk ratio 2.7 1.8-4.2, p<0.0001), In the multivariate analysis, low left-ventricular ejection fraction and turbulence slope were the only independent variables for mortality prediction in MPIP (p<0.001), whereas in EMIAT, five variables were independent mortality predictors: abnormal turbulence onset, abnormal turbulence slope, history of previous infarction, low left-ventricular ejection fraction, and high mean heart rate (p<0.001). In both MPIP and EMIAT, the combination of abnormal onset and slope was the most powerful multivariate risk stratifier: MPIP risk ratio 3.2 (1.7-6.0, p<0.0001), EMIAT risk ratio 3.2 (1.8-5.6, p<0.0001). Interpretation The absence of the heart rate turbulence after ventricular premature beats is a very potent postinfarction risk stratifier that is independent of other known risk factors and which is stronger than other presently available risk predictors.	Tech Univ Munich, Erste Med Klin, D-81675 Munich, Germany; Tech Univ Munich, Inst Med Stat & Epidemiol, D-81675 Munich, Germany; St George Hosp, Sch Med, Dept Cardiol Sci, London, England; Columbia Univ, Dept Med, Div Cardiol, New York, NY USA	Technical University of Munich; Technical University of Munich; St Georges University London; Columbia University	Schmidt, G (corresponding author), Tech Univ Munich, Erste Med Klin, Ismaniger Str 22, D-81675 Munich, Germany.	gschmidt@med1.med.tu-muenchen.de	Schmidt, Georg/D-3711-2009; Schneider, Raphaël/K-5446-2013	Schmidt, Georg/0000-0003-3692-5243; Schneider, Raphaël/0000-0002-6870-6902; Schneider, Raphael/0000-0001-7754-5840				[Anonymous], 1997, Ann Intern Med, V126, P556; BIGGER JT, 1984, CIRCULATION, V69, P250, DOI 10.1161/01.CIR.69.2.250; BREIMANN L, 1984, CLASSIFICATION REGRE; Camm AJ, 1996, CIRCULATION, V93, P1043; CHUNG EK, 1970, CARDIOLOGY, V55, P65, DOI 10.1159/000169268; Copie X, 1996, J AM COLL CARDIOL, V27, P270, DOI 10.1016/0735-1097(95)00454-8; Corr PB, 1986, HEART CARDIOVASCULAR, P1343; COX DR, 1972, J R STAT SOC B, V34, P187; DOHLEMANN C, 1979, Z KARDIOL, V68, P557; ERLANGER J, 1909, HEART, V1, P177; HASHIMOTO K, 1967, CIRC RES, V21, P297, DOI 10.1161/01.RES.21.3.297; HECHT AF, 1914, WIEN MED WCHNSCHR, V64, P178; JEDLICKA J, 1987, EUR HEART J, V8, P762, DOI 10.1093/eurheartj/8.7.762; Julian DG, 1997, LANCET, V349, P667, DOI 10.1016/S0140-6736(96)09145-3; KAPPAGODA CT, 1972, J PHYSIOL-LONDON, V225, P705, DOI 10.1113/jphysiol.1972.sp009965; KAPPAGODA CT, 1972, J PHYSIOL-LONDON, V220, P177, DOI 10.1113/jphysiol.1972.sp009700; KLEIGER RE, 1987, AM J CARDIOL, V59, P256, DOI 10.1016/0002-9149(87)90795-8; LEBLANC M, 1992, BIOMETRICS, V48, P411, DOI 10.2307/2532300; LOWN B, 1976, NEW ENGL J MED, V294, P1165; MOSS AJ, 1983, NEW ENGL J MED, V309, P331, DOI 10.1056/nejm198308113090602; Moss AJ, 1996, NEW ENGL J MED, V335, P1933, DOI 10.1056/NEJM199612263352601; MOSS AJ, 1977, AM J CARDIOL, V39, P635, DOI 10.1016/S0002-9149(77)80122-7; ODEMUYIWA O, 1991, AM J CARDIOL, V68, P434, DOI 10.1016/0002-9149(91)90774-F; Parsonnet AE, 1944, AM HEART J, V27, P676, DOI 10.1016/S0002-8703(44)90923-3; Redwood SR, 1997, EUR HEART J, V18, P1278; ROSENBAUM MB, 1955, CIRCULATION, V11, P240, DOI 10.1161/01.CIR.11.2.240; ROTH IR, 1948, AM HEART J, V36, P257, DOI 10.1016/0002-8703(48)90405-0; SANZ G, 1982, NEW ENGL J MED, V306, P1065, DOI 10.1056/NEJM198205063061801; Schmidt G, 1996, PACE, V19, P976; SIMSON MB, 1981, CIRCULATION, V64, P235, DOI 10.1161/01.CIR.64.2.235; Skanes AC, 1998, CIRCULATION, V97, P2245, DOI 10.1161/01.CIR.97.22.2245; Wenckebach KF., 1927, UNREGELMASSIGE HERZT	32	567	642	1	17	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	APR 24	1999	353	9162					1390	1396		10.1016/S0140-6736(98)08428-1	http://dx.doi.org/10.1016/S0140-6736(98)08428-1			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	191KD	10227219				2022-12-28	WOS:000080020800011
J	Wallace, EM; Baker, LS				Wallace, EM; Baker, LS			Effect of antenatal betamethasone administration on placental vascular resistance	LANCET			English	Article							CORTICOTROPIN-RELEASING HORMONE; DOPPLER WAVE-FORMS; UMBILICAL ARTERY; FLOW VELOCITY; FETAL SHEEP; PLASMA; PREGNANCY	Background High placental vascular resistance is an important cause of fetal growth restriction and subsequent perinatal mortality. Identification of affected pregnancies allows appropriate fetal surveillance and delivery, but there are no known therapeutic strategies to decrease resistance and improve blood flow. However, placental corticotropin-releasing hormone (CRH) is thought to be a potent fetoplacental vasodilator, and exogenous corticosteroids can increase placental CRH secretion. Therefore, we examined whether corticosteroids could improve fetoplacental blood flow in pregnancies with increased vascular resistance. Methods A retrospective review of umbilical-artery flow-velocity waveforms (FVWs) before and after betamethasone administration was undertaken in pregnancies with increased placental vascular resistance, as shown by umbilical-artery absent end-diastolic flow (AEDF). FVWs were obtained by pulsed-wave doppler ultrasonography. We studied all 28 pregnancies monitored at the maternal-fetal medicine unit of a university teaching hospital since 1995. Findings The median duration of gestation at presentation with AEDF was 27 weeks (range 23-33). In 19 (68% [95% CI 49-86]) pregnancies, umbilical-artery diastolic flow returned within 24 h after betamethasone administration, consistent with decreased resistance. The median duration of this effect was 3 days (range 2-7). There were no differences in duration of gestation at diagnosis or delivery, or in birthweight between fetuses showing a return of flow after betamethasone and those not showing a return of flow. Interpretation In pregnancies with umbilical-artery AEDF, betamethasone treatment is associated with decreased placental vascular resistance, possibly induced via increased placental CRH secretion. This study does not provide insights into whether this effect would be beneficial or harmful to the fetus.	Monash Univ, Dept Obstet & Gynaecol, Clayton, Vic 3168, Australia; Monash Med Ctr, Maternal Fetal Med Unit, Clayton, Vic 3168, Australia	Monash University; Monash University	Wallace, EM (corresponding author), Monash Univ, Dept Obstet & Gynaecol, Clayton, Vic 3168, Australia.		Wallace, Euan M/K-6774-2015	Wallace, Euan M/0000-0002-4506-5233				BEATTIE RB, 1989, BRIT MED J, V298, P631, DOI 10.1136/bmj.298.6674.631; Bisits A, 1998, AM J OBSTET GYNECOL, V178, P862; Burns PN, 1987, DOPPLER ULTRASOUND M, P43; CHALLIS JRG, 1995, PLACENTA, V16, P481, DOI 10.1016/S0143-4004(05)80001-3; CLIFTON VL, 1995, J CLIN ENDOCR METAB, V80, P2888, DOI 10.1210/jc.80.10.2888; CLIFTON VL, 1994, J CLIN ENDOCR METAB, V79, P666, DOI 10.1210/jc.79.2.666; Cohlen BJ, 1996, ULTRASOUND OBST GYN, V8, P252, DOI 10.1046/j.1469-0705.1996.08040252.x; Derks JB, 1997, J PHYSIOL-LONDON, V499, P217, DOI 10.1113/jphysiol.1997.sp021922; Giles W, 1997, OBSTET GYNECOL, V89, P49, DOI 10.1016/S0029-7844(96)00371-7; GILES W, 1992, LANCET, V340, P856, DOI 10.1016/0140-6736(92)92737-Z; Giles WB, 1996, OBSTET GYNECOL, V87, P107, DOI 10.1016/0029-7844(95)00338-X; GILES WB, 1985, BRIT J OBSTET GYNAEC, V92, P31, DOI 10.1111/j.1471-0528.1985.tb01045.x; GOLAND RS, 1993, J CLIN ENDOCR METAB, V77, P1174, DOI 10.1210/jc.77.5.1174; GUARAN RL, 1994, AUST NZ J OBSTET GYN, V34, P39, DOI 10.1111/j.1479-828X.1994.tb01037.x; HARPER A, 1991, BRIT J OBSTET GYNAEC, V98, P453, DOI 10.1111/j.1471-0528.1991.tb10339.x; KARI MA, 1994, PEDIATRICS, V93, P730; KARSDORP VHM, 1994, LANCET, V344, P1164; Kingdom JCP, 1997, ULTRASOUND OBST GYN, V9, P271, DOI 10.1046/j.1469-0705.1997.09040271.x; Korebrits C, 1998, BRIT J OBSTET GYNAEC, V105, P556, DOI 10.1111/j.1471-0528.1998.tb10158.x; Krebs C, 1996, AM J OBSTET GYNECOL, V175, P1534, DOI 10.1016/S0002-9378(96)70103-5; Marinoni E, 1998, AM J OBSTET GYNECOL, V178, P770, DOI 10.1016/S0002-9378(98)70490-9; MCCOWAN LM, 1987, AM J OBSTET GYNECOL, V157, P900, DOI 10.1016/S0002-9378(87)80082-0; MORROW RJ, 1989, AM J OBSTET GYNECOL, V161, P1055, DOI 10.1016/0002-9378(89)90783-7; NEILSON JP, 1998, PREGNANCY CHILDBIRTH; NICOLAIDES KH, 1988, BRIT MED J, V297, P1026, DOI 10.1136/bmj.297.6655.1026; ROBINSON BG, 1988, P NATL ACAD SCI USA, V85, P5244, DOI 10.1073/pnas.85.14.5244; THOMPSON RS, 1988, BRIT J OBSTET GYNAEC, V95, P581, DOI 10.1111/j.1471-0528.1988.tb09487.x; WOLFE CDA, 1988, BRIT J OBSTET GYNAEC, V95, P1003, DOI 10.1111/j.1471-0528.1988.tb06504.x	28	93	94	0	1	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	APR 24	1999	353	9162					1404	1407		10.1016/S0140-6736(98)08229-4	http://dx.doi.org/10.1016/S0140-6736(98)08229-4			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	191KD	10227222				2022-12-28	WOS:000080020800014
J	Wilde, A; Zheng, YX				Wilde, A; Zheng, YX			Stimulation of microtubule aster formation and spindle assembly by the small GTPase Ran	SCIENCE			English	Article							XENOPUS EGG EXTRACTS; GAMMA-TUBULIN; SELF-ORGANIZATION; RING COMPLEX; PROTEIN; CHROMOSOMES; CENTROSOMES; MUTATIONS; NUCLEATION; DYNAMICS	Ran, a small guanosine triphosphatase, is suggested to have additional functions beyond its well-characterized role in nuclear trafficking, Guanosine triphosphate-bound Ran, but not guanosine biphosphate-bound Ran, stimulated polymerization of astral microtubules from centrosomes assembled on Xenopus sperm, Moreover, a Ran allele with a mutation in the effector domain (RanL43E) induced the formation of microtubule asters and spindle assembly, in the absence of sperm nuclei, in a gamma TuRC (gamma-tubulin ring complex)- and XMAP215 (Xenopus microtubule associated protein)-dependent manner. Therefore, Ran could be a key signaling molecule regulating microtubule polymerization during mitosis.	Carnegie Inst Washington, Dept Embryol, Baltimore, MD 21210 USA	Carnegie Institution for Science	Zheng, YX (corresponding author), Carnegie Inst Washington, Dept Embryol, 115 W Univ Pkwy, Baltimore, MD 21210 USA.			Wilde, Andrew/0000-0002-9812-3847	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM056312] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM56312-01] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Dasso M, 1995, Prog Cell Cycle Res, V1, P163; DASSO M, 1994, EMBO J, V13, P5732, DOI 10.1002/j.1460-2075.1994.tb06911.x; Dogterom M, 1996, J CELL BIOL, V133, P125, DOI 10.1083/jcb.133.1.125; EVAN GI, 1985, MOL CELL BIOL, V5, P3610, DOI 10.1128/MCB.5.12.3610; GARD DL, 1987, J CELL BIOL, V105, P2203, DOI 10.1083/jcb.105.5.2203; Heald R, 1997, J CELL BIOL, V138, P615, DOI 10.1083/jcb.138.3.615; Heald R, 1996, NATURE, V382, P420, DOI 10.1038/382420a0; KARSENTI E, 1984, J CELL BIOL, V98, P1730, DOI 10.1083/jcb.98.5.1730; KIRKPATRICK D, 1994, GENETICS, V137, P381; Lounsbury KM, 1996, J BIOL CHEM, V271, P32834, DOI 10.1074/jbc.271.51.32834; Martin OC, 1998, J CELL BIOL, V141, P675, DOI 10.1083/jcb.141.3.675; Matunis MJ, 1996, J CELL BIOL, V135, P1457, DOI 10.1083/jcb.135.6.1457; Merdes A, 1996, CELL, V87, P447, DOI 10.1016/S0092-8674(00)81365-3; Moore MS, 1998, J BIOL CHEM, V273, P22857, DOI 10.1074/jbc.273.36.22857; MURRAY AW, 1991, METHOD CELL BIOL, V36, P581; Nakamura M, 1998, J CELL BIOL, V143, P1041, DOI 10.1083/jcb.143.4.1041; OUSPENSKI II, 1995, J BIOL CHEM, V270, P1975, DOI 10.1074/jbc.270.5.1975; SAWIN KE, 1994, MOL BIOL CELL, V5, P217, DOI 10.1091/mbc.5.2.217; SAWIN KE, 1991, J CELL BIOL, V112, P925, DOI 10.1083/jcb.112.5.925; THEURKAUF WE, 1992, J CELL BIOL, V116, P1167, DOI 10.1083/jcb.116.5.1167; VERDE F, 1992, J CELL BIOL, V118, P1097, DOI 10.1083/jcb.118.5.1097; VERDE F, 1990, NATURE, V343, P233, DOI 10.1038/343233a0; WILDE A, UNPUB; ZHANG DH, 1995, J CELL BIOL, V131, P1125, DOI 10.1083/jcb.131.5.1125; ZHENG YX, 1995, NATURE, V378, P578, DOI 10.1038/378578a0	25	318	323	0	10	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	MAY 21	1999	284	5418					1359	1362		10.1126/science.284.5418.1359	http://dx.doi.org/10.1126/science.284.5418.1359			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	198NN	10334991				2022-12-28	WOS:000080430600054
J	Schmidt, MI; Duncan, BB; Sharrett, AR; Lindberg, G; Savage, PJ; Offenbacher, S; Azambuja, MI; Tracy, RP; Heiss, G				Schmidt, MI; Duncan, BB; Sharrett, AR; Lindberg, G; Savage, PJ; Offenbacher, S; Azambuja, MI; Tracy, RP; Heiss, G		ARIC Investigators	Markers of inflammation and prediction of diabetes mellitus in adults (Atherosclerosis Risk in Communities study): a cohort study	LANCET			English	Article							INDUCED INSULIN-RESISTANCE; NECROSIS-FACTOR-ALPHA; INNATE IMMUNE-SYSTEM; CARDIOVASCULAR-DISEASE; OBESITY; ASSOCIATION; EXPRESSION; LEPTIN; NIDDM	Background Type 2 diabetes mellitus and atherosclerotic cardiovascular disease have common antecedents. Since markers of inflammation predict coronary heart disease and are raised in patients with type 2 diabetes, we investigated whether they predict whether people will develop type 2 diabetes. Methods 12 330 men and women, aged 45-64 years, were followed up for a mean of 7 years. We analysed the association between different markers of acute inflammation and subsequent diagnosis of diabetes. In a subgroup of 610 individuals selected originally for an unrelated atherosclerosis case-control study, we also investigated diabetes associations with total sialic acid and orosomucoid, haptoglobin, and alpha(1)-antitrypsin. Findings 1335 individuals had a new diagnosis of diabetes. Adjusted odds ratios for developing diabetes for quartile extremes were 1.9 (95% CI 1.6-2.3) for raised white-cell count, 1.3 (1.0-1.5) for low serum albumin, and 1.2 (1.0-1.5) for raised fibrinogen. In the subgroup analysis, individuals with concentrations of orosomucoid and sialic acid of more than the median had odds ratios of 7.9 (2.6-23.7) and 3.7 (1.4-9.8), respectively. Adjustment for body-mass index and waist-to-hip ratio lessened the associations; those for white-cell count (1.5 [1.3-1.8]), orosomucoid (7.1 [2.1-23.7]), and sialic acid (2.8 [1.0-8.1]) remained significant. Interpretation Markers of inflammation are associated with the development of diabetes in middle-aged adults. Although autoimmunity may partly explain these associations, they probably reflect the pathogenesis of type 2 diabetes.	UFRGS, Sch Med, Dept Social Med, BR-90035003 Porto Alegre, RS, Brazil; Univ N Carolina, Sch Publ Hlth, Dept Epidemiol, Chapel Hill, NC USA; Univ N Carolina, Sch Dent, Dent Res Ctr, Chapel Hill, NC USA; NHLBI, Div Epidemiol & Clin Applicat, Bethesda, MD 20892 USA; Malmo Hosp, NEPI Fdn, Malmo, Sweden; Univ Vermont, Dept Pathol & Biochem, Colchester, VT USA	Universidade Federal do Rio Grande do Sul; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill; National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI); University of Vermont	Schmidt, MI (corresponding author), UFRGS, Sch Med, Dept Social Med, Rua Barcelos 2600-414, BR-90035003 Porto Alegre, RS, Brazil.		Schmidt, Maria Inês/AGT-5691-2022; Duncan, Bruce B/L-4140-2016; Schmidt, Maria/V-3196-2019; Schmidt, Maria Inês/AGP-6441-2022	Duncan, Bruce B/0000-0002-7491-2630; Schmidt, Maria Inês/0000-0002-3837-0731	DIVISION OF EPIDEMIOLOGY AND CLINICAL APPLICATIONS [N01HC055016, N01HC055018, N01HC055015] Funding Source: NIH RePORTER; NHLBI NIH HHS [N01-HC-55016, N01-HC-55018, N01-HC-55015] Funding Source: Medline	DIVISION OF EPIDEMIOLOGY AND CLINICAL APPLICATIONS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		CAMPOS SP, 1992, MOL CELL BIOL, V12, P1789, DOI 10.1128/MCB.12.4.1789; Chambless L E, 1992, Ann Epidemiol, V2, P723; Corbett J, 1997, DIABETOLOGIA, V40, pB27, DOI 10.1007/BF03168183; Gavin JR, 1997, DIABETES CARE, V20, P1183; Girard J, 1997, DIABETES METAB, V23, P16; HEISS G, 1991, AM J EPIDEMIOL, V134, P250, DOI 10.1093/oxfordjournals.aje.a116078; Hotamisligil GS, 1996, SCIENCE, V271, P665, DOI 10.1126/science.271.5249.665; HOTAMISLIGIL GS, 1995, J CLIN INVEST, V95, P2409, DOI 10.1172/JCI117936; JARRETT RJ, 1988, DIABETOLOGIA, V31, P737, DOI 10.1007/BF00274775; JOURDIAN GW, 1971, J BIOL CHEM, V246, P430; Kushner I, 1993, ACUTE PHASE PROTEINS, P4; LINDBERG G, 1993, ATHEROSCLEROSIS, V103, P123, DOI 10.1016/0021-9150(93)90255-S; Loffreda S, 1998, FASEB J, V12, P57, DOI 10.1096/fasebj.12.1.57; Matson C.A., 1996, DIABETES REV, V4, P488; Memon RA, 1997, CYTOKINES HLTH DIS, P381; *NAT HEART LUNG BL, 1987, ATH RISK COMM ARIC S, P1; NIETO FJ, 1992, AM J EPIDEMIOL, V136, P525, DOI 10.1093/oxfordjournals.aje.a116530; Nilsson J, 1998, ARTERIOSCL THROM VAS, V18, P1199, DOI 10.1161/01.ATV.18.8.1199; Pickup JC, 1997, DIABETOLOGIA, V40, P1286, DOI 10.1007/s001250050822; Pickup JC, 1998, DIABETOLOGIA, V41, P1241, DOI 10.1007/s001250051058; Ross R, 1999, NEW ENGL J MED, V340, P115, DOI 10.1056/NEJM199901143400207; SALHANICK AI, 1988, AM J PHYSIOL, V255, P173; Schmidt MI, 1996, METABOLISM, V45, P699, DOI 10.1016/S0026-0495(96)90134-1; SIM E, 1993, HUMORAL FACTORS, P1; STERN MP, 1995, DIABETES, V44, P369, DOI 10.2337/diabetes.44.4.369; UNGER RH, 1995, DIABETES, V44, P863, DOI 10.2337/diabetes.44.8.863; Uysal KT, 1997, NATURE, V389, P610, DOI 10.1038/39335; VANDERPOLL T, 1998, AM J PHYSIOL, V24, pE457; WILLIAMS OD, 1989, AM J EPIDEMIOL, V129, P687, DOI 10.1093/oxfordjournals.aje.a115184; Yudkin JS, 1997, DIABETOLOGIA, V40, pS140	30	790	820	2	44	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	MAY 15	1999	353	9165					1649	1652		10.1016/S0140-6736(99)01046-6	http://dx.doi.org/10.1016/S0140-6736(99)01046-6			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	198DT	10335783				2022-12-28	WOS:000080408000008
J	Sury, MRJ; Hatch, DJ; Deeley, T; Dicks-Mireaux, C; Chong, WK				Sury, MRJ; Hatch, DJ; Deeley, T; Dicks-Mireaux, C; Chong, WK			Development of a nurse-led sedation service for paediatric magnetic resonance imaging	LANCET			English	Article							CHLORAL HYDRATE; ADVERSE EVENTS; PEDIATRIC MRI; CHILDREN; PROPOFOL; GUIDELINES; TOMOGRAPHY; ANESTHESIA; PROGRAM; SAFETY	Background Children generally lie still enough for magnetic resonance imaging (MRI) only if they are asleep, either under sedation, which is deeper than conscious sedation, or under anaesthesia. Anaesthesia resources, however, are limited, and non-anaesthetists must use sedation frequently. Demand for MRI has increased and the failure of our sedation regimen led to an impractical demand for anaesthesia and unacceptable waiting times for scanning. We have therefore developed a nurse-led sedation service in a designated unit next to the scanner. This study assessed the safety and efficacy of this approach. Methods Children who required MRI were sedated in the unit by designated sedationist nurses, who used an oral drug regimen (according to weight and age from conception: weight <5 hg, 50 mg/kg chloral hydrate; 5-10 kg, 100 mg/hg chloral hydrate; 10-20 hg, 1 mg/kg temazepam plus 0.25 mg/kg droperidol; >20 kg temazepam and droperidol as directed by radiologist; maximum doses 20 mg and 5 mg respectively). Nurses checked patients for their suitability, charted and administered the drugs according to a protocol, and monitored the children throughout the sedation. We prospectively audited failure and complications of sedation. Findings During the 30 month study, there were 1155 sedations. 61 (5%) were unsuccessful, and there were no adverse events relating to the airway or breathing. After scanning had finished all children, in response to gently pinching the nose, could open their mouths to maintain their airway. Interpretation This study suggests that it is possible to have a nurse-led sedation service for MRI of children that is both successful and safe.	Great Ormond St Hosp Children NHS Trust, Dept Anaesthesia, London WC1N 3JH, England; Great Ormond St Hosp Children NHS Trust, Dept Radiol, London WC1N 3JH, England; Inst Child Hlth, London, England	University of London; University College London; Great Ormond Street Hospital for Children NHS Foundation Trust; University of London; University College London; Great Ormond Street Hospital for Children NHS Foundation Trust; University of London; University College London	Sury, MRJ (corresponding author), Great Ormond St Hosp Children NHS Trust, Dept Anaesthesia, Great Ormond St, London WC1N 3JH, England.							BARST SM, 1994, PAEDIATR ANAESTH, V4, P243; BLOOMFIELD EL, 1993, RADIOLOGY, V186, P93, DOI 10.1148/radiology.186.1.8416594; COTE CJ, 1995, AM J ROENTGENOL, V165, P910, DOI 10.2214/ajr.165.4.7676991; Egelhoff JC, 1997, AM J ROENTGENOL, V168, P1259, DOI 10.2214/ajr.168.5.9129423; FRUSH DP, 1995, AM J ROENTGENOL, V165, P913, DOI 10.2214/ajr.165.4.7676992; GLAISIER CM, 1995, AM J NEURORADIOL, V16, P111; HOLLMAN GA, 1995, CLIN PEDIATR, V34, P300, DOI 10.1177/000992289503400602; KAUFFMAN RE, 1992, PEDIATRICS, V89, P1110; Malviya S, 1997, ANESTH ANALG, V85, P1207, DOI 10.1097/00000539-199712000-00005; MartiBonmati L, 1995, NEURORADIOLOGY, V37, P687; MEROLA C, 1995, PAEDIATR ANAESTH, V5, P375, DOI 10.1111/j.1460-9592.1995.tb00330.x; Murphy MS, 1997, ARCH DIS CHILD, V77, P281, DOI 10.1136/adc.77.4.281; NEUMAN GG, 1992, ANESTH ANALG, V74, P931; *ROY COLL AN ROY C, 1992, SED AN RAD REP JOINT; SHEPHERD JK, 1990, BRIT J RADIOL, V63, P794, DOI 10.1259/0007-1285-63-754-794; SPEAR RM, 1993, PAEDIATR ANAESTH, V3, P325; SURY MRJ, 1994, ANAESTHESIA, V49, P174, DOI 10.1111/j.1365-2044.1994.tb03394.x; SURY MRJ, 1993, PAEDIATR ANAESTH, V3, P329; VADE A, 1995, AM J ROENTGENOL, V165, P905, DOI 10.2214/ajr.165.4.7676990; VALTONEN M, 1989, ACTA ANAESTH SCAND, V33, P170, DOI 10.1111/j.1399-6576.1989.tb02884.x; VANGERVEN M, 1992, ANAESTHESIA, V47, P706, DOI 10.1111/j.1365-2044.1992.tb02397.x; Wouters PF, 1997, EUR J ANAESTH, V14, P236, DOI 10.1046/j.1365-2346.1997.00071.x	22	84	85	0	2	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	MAY 15	1999	353	9165					1667	1671		10.1016/S0140-6736(98)08383-4	http://dx.doi.org/10.1016/S0140-6736(98)08383-4			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	198DT	10335787				2022-12-28	WOS:000080408000012
J	Winceslaus, SJ; Schofield, J				Winceslaus, SJ; Schofield, J			A sore anus for 6 months	LANCET			English	Article									Kent & Sussex Hosp, Dept Genitourinary Med, Tunbridge Wells TN4 8AT, Kent, England; Maidstone Gen Hosp, Dept Histopathol, Maidstone, Kent, England		Winceslaus, SJ (corresponding author), Kent & Sussex Hosp, Dept Genitourinary Med, Tunbridge Wells TN4 8AT, Kent, England.			Winceslaus, SJ/0000-0002-9757-1007				MINDEL A, 1994, HERPES, V1, P39; *PREV HIV ENGL WAL, 1998, UNL AN HIV PREV MON; Winceslaus J, 1997, J ROY COLL SURG EDIN, V42, P276	3	1	1	0	1	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	MAY 15	1999	353	9165					1672	1672		10.1016/S0140-6736(99)01384-7	http://dx.doi.org/10.1016/S0140-6736(99)01384-7			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	198DT	10335788				2022-12-28	WOS:000080408000013
J	Lee, SH; Blake, R				Lee, SH; Blake, R			Visual form created solely from temporal structure	SCIENCE			English	Article							MOTION PERCEPTION; DISCRIMINATION; SEGMENTATION; INFORMATION; FIGURE; CORTEX; COHERENCE; PATTERNS; NEURONS; CONNECTIVITY	In several experiments, it was found that global perception of spatial form can arise exclusively from unpredictable but synchronized changes among Local features. Within an array of nonoverlapping apertures, contours move in one of two directions, with direction reversing randomly over time. When contours within a region of the array reverse directions in synchrony, they stand out conspicuously from the rest of the array where direction reversals are unsynchronized. Clarity of spatial structure from synchronized change depends on the rate of motion reversal and on the proportion of elements reversing direction in synchrony. Evidently, human vision is sensitive to the rich temporal structure in these stochastic events.	Vanderbilt Univ, Vanderbilt Vis Res Ctr, Nashville, TN 37240 USA	Vanderbilt University	Blake, R (corresponding author), Vanderbilt Univ, Vanderbilt Vis Res Ctr, 221 Kirkland Hall, Nashville, TN 37240 USA.		Lee, Sang-Hun/B-9898-2008		NATIONAL EYE INSTITUTE [R01EY007760] Funding Source: NIH RePORTER; NEI NIH HHS [EY07760, EY01826] Funding Source: Medline	NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		ANSTIS SM, 1995, ARTFUL EYE, P232; BIALEK W, 1992, TRENDS NEUROSCI, V15, P428, DOI 10.1016/0166-2236(92)90005-S; BIEDERMAN I, 1987, PSYCHOL REV, V94, P115, DOI 10.1037/0033-295X.94.2.115; Brainard D. H., 1997, SPATIAL VISION, V10, P443, DOI DOI 10.1163/156856897X00357; BRAVO MJ, 1992, VISION RES, V32, P1793, DOI 10.1016/0042-6989(92)90174-H; BRILLINGER DR, 1994, CAN J STAT, V22, P177, DOI 10.2307/3315583; Buracas GT, 1998, NEURON, V20, P959, DOI 10.1016/S0896-6273(00)80477-8; CAVANAGH P, 1992, SCIENCE, V257, P1563, DOI 10.1126/science.1523411; Chey J, 1997, J OPT SOC AM A, V14, P2570, DOI 10.1364/JOSAA.14.002570; CHUBB C, 1988, J OPT SOC AM A, V5, P1986, DOI 10.1364/JOSAA.5.001986; ECKHORN R, 1988, BIOL CYBERN, V60, P121, DOI 10.1007/BF00202899; FAHLE M, 1995, VISION RES, V35, P491, DOI 10.1016/0042-6989(94)00126-7; FAHLE M, 1993, P ROY SOC B-BIOL SCI, V254, P199, DOI 10.1098/rspb.1993.0146; FIELD DJ, 1993, VISION RES, V33, P173, DOI 10.1016/0042-6989(93)90156-Q; Garner WR., 1962, UNCERTAINTY STRUCTUR; GILDEN D, 1995, PSYCHOL SCI, V6, P235, DOI 10.1111/j.1467-9280.1995.tb00598.x; GROSSBERG S, 1993, NEURAL NETWORKS, V6, P463, DOI 10.1016/S0893-6080(05)80052-8; GRZYWACZ NM, 1995, VISION RES, V35, P3183, DOI 10.1016/0042-6989(95)00102-6; JULESZ B, 1976, BIOL CYBERN, V23, P25, DOI 10.1007/BF00344148; Julesz B., 1971, FDN CYCLOPEAN PERCEP; Kiper DC, 1996, VISION RES, V36, P539, DOI 10.1016/0042-6989(95)00135-2; Koffka K, 1935, PRINCIPLES GESTALT P; Lee SH, 1999, INVEST OPHTH VIS SCI, V40, pS45; Leonards U, 1996, VISION RES, V36, P2689, DOI 10.1016/0042-6989(96)86829-5; LU ZL, 1995, NATURE, V377, P237, DOI 10.1038/377237a0; Mozer M., 1991, PERCEPTION MULTIPLE; PALMER SE, 1992, COGNITIVE PSYCHOL, V24, P436, DOI 10.1016/0010-0285(92)90014-S; PALMER SE, 1998, 39 ANN M PSYCH SOC D; RAMACHANDRAN VS, 1991, B PSYCHONOMIC SOC, V29, P391; REGAN D, 1991, PERCEPTION, V20, P315, DOI 10.1068/p200315; REGAN D, 1989, VISION RES, V29, P1389, DOI 10.1016/0042-6989(89)90194-6; Reiss R.D., 1993, COURSE POINT PROCESS; RICHMOND BJ, 1990, J NEUROPHYSIOL, V64, P351, DOI 10.1152/jn.1990.64.2.351; ROCK I, 1986, HDB PERCEPTION HUMAN, V2; Shadlen MN, 1998, J NEUROSCI, V18, P3870; Shannon C. E., 1949, MATH THEORY COMMUNIC; SINGER W, 1995, ANNU REV NEUROSCI, V18, P555, DOI 10.1146/annurev.neuro.18.1.555; Snider RK, 1998, J NEUROPHYSIOL, V80, P730, DOI 10.1152/jn.1998.80.2.730; THOMPSON WB, 1992, BIOL CYBERN, V66, P327, DOI 10.1007/BF00203669; Usher M, 1998, NATURE, V394, P179, DOI 10.1038/28166; Vecera SP, 1998, J EXP PSYCHOL HUMAN, V24, P441, DOI 10.1037/0096-1523.24.2.441; WILSON HR, 1994, VISUAL NEUROSCI, V11, P1205, DOI 10.1017/S0952523800007008	42	122	123	0	5	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	MAY 14	1999	284	5417					1165	1168		10.1126/science.284.5417.1165	http://dx.doi.org/10.1126/science.284.5417.1165			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	197HJ	10325226				2022-12-28	WOS:000080359100036
J	Fender, GRK; Prentice, A; Gorst, T; Nixon, RM; Duffy, SW; Day, NE; Smith, SK				Fender, GRK; Prentice, A; Gorst, T; Nixon, RM; Duffy, SW; Day, NE; Smith, SK			Randomised controlled trial of educational package on management of menorrhagia in primary care: the Anglia menorrhagia education study	BRITISH MEDICAL JOURNAL			English	Article							MYOCARDIAL-INFARCTION; TRANEXAMIC ACID; MEFENAMIC-ACID; OUTREACH; NORETHISTERONE; GUIDELINES	Objective To determine whether an educational package could influence the management of menorrhagia, increase the appropriateness of choice of non-hormonal treatment, and reduce referral rates hom primary to secondary care. Design Randomised controlled trial. Setting General practices in East Anglia Subjects 100 practices (348 doctors) in primary care were recruited and randomised to intervention(54) and control (46). Interventions An educational package based on principles of "academic detailing" with independent academics was given in small practice based interactive groups with a visual presentation, a printed evidence based summary, a graphic management flow Chart, and a follow up meeting at 6 months. Outcome measures All practices recorded consultation details, treatments offered, and outcomes for women with regular heavy menstrual loss (menorrhagia) over 1 year. Results 1001 consultation data sheets for menorrhagia were returned. There were significantly fewer referrals (20% v 29%; odds ratio 0.64; 95% confidence interval 0.41 to 0.99) and a significantly higher use of tranexamic acid (odds ratio 2.38; 1.61 to 3.49) in the intervention group but no overall difference in norethisterone treatment compared with controls. There were more referrals when tranexamic acid was given with norethisterone than when it was given alone. Those practices reporting fewer than 10 cases showed the highest increase in prescribing of tranexamic acid. Conclusions The educational package positively influenced referral for menorrhagia and treatment with appropriate non-hormonal drugs.	Univ Cambridge, Sch Clin Med, Dept Obstet & Gynaecol, Rosie Matern Hosp, Cambridge CB2 2SW, England; Inst Publ Hlth, MRC, Biostat Unit, Cambridge CB2 2SR, England	University of Cambridge; MRC Biostatistics Unit; University of Cambridge	Fender, GRK (corresponding author), Univ Cambridge, Sch Clin Med, Dept Obstet & Gynaecol, Rosie Matern Hosp, Box 223, Cambridge CB2 2SW, England.		Smith, Stephen K/F-6938-2012	Nixon, Richard/0000-0002-9991-7833; Smith, Stephen/0000-0003-1912-3935				ANTMAN EM, 1992, JAMA-J AM MED ASSOC, V268, P240, DOI 10.1001/jama.268.2.240; AVORN J, 1983, NEW ENGL J MED, V308, P1457, DOI 10.1056/NEJM198306163082406; Bonnar J, 1996, BRIT MED J, V313, P579; CAMERON I, 1987, PROSTAGLANDINS, V43, P99; CAMERON IT, 1989, BAILLIERE CLIN OB GY, V3, P315, DOI 10.1016/S0950-3552(89)80024-0; CAMERON IT, 1990, OBSTET GYNECOL, V76, P85; *CONS ASS, 1990, DRUG THER B, V28, P17; COULTER A, 1991, BRIT J OBSTET GYNAEC, V98, P789, DOI 10.1111/j.1471-0528.1991.tb13484.x; DELAMOTHE T, 1993, BRIT MED J, V307, P218, DOI 10.1136/bmj.307.6898.218; DICKER RC, 1982, AM J OBSTET GYNECOL, V144, P841, DOI 10.1016/0002-9378(82)90362-3; Dowie J, 1996, HEALTH CARE ANAL, V4, P5, DOI 10.1007/BF02251141; FAHEY T, 1994, BRIT J GEN PRACT, V44, P446; Goldberg D., 1983, INT J REHABIL RES, V6, P127, DOI [10.1097/00004356-198303000-00021, DOI 10.1097/00004356-198303000-00021]; Grimshaw J, 1993, Qual Health Care, V2, P243, DOI 10.1136/qshc.2.4.243; Grimshaw J M, 1994, Qual Health Care, V3, P45, DOI 10.1136/qshc.3.1.45; GRIMSHAW JM, 1993, LANCET, V342, P1317, DOI 10.1016/0140-6736(93)92244-N; HAINES A, 1994, BMJ-BRIT MED J, V308, P1488, DOI 10.1136/bmj.308.6942.1488; HALLBERG L, 1966, ACTA OBSTET GYN SCAN, V45, P320, DOI 10.3109/00016346609158455; *INT MED STAT, 1994, REP UK IR; KETLEY D, 1993, LANCET, V342, P891, DOI 10.1016/0140-6736(93)91945-I; *MORI, 1990, WOM HLTH 1990; *OFF PUBL CENS SUR, 1995, HOSP INP ENQ; OXMAN AD, 1995, CAN MED ASSOC J, V153, P1423; PETO V, 1993, FAM PRACT, V10, P207, DOI 10.1093/fampra/10.2.207; PRESTON JT, 1995, BRIT J OBSTET GYNAEC, V102, P401, DOI 10.1111/j.1471-0528.1995.tb11293.x; *ROYAL COLL GEN PR, 1994, ED TRAIN GEN PRACT; RUSSELL IT, 1992, BRIT MED J, V304, P1480; SOUMERAI SB, 1986, MED CARE, V24, P313, DOI 10.1097/00005650-198604000-00003; SOUMERAI SB, 1993, JAMA-J AM MED ASSOC, V270, P961, DOI 10.1001/jama.270.8.961; SOUMERAI SB, 1990, JAMA-J AM MED ASSOC, V263, P549, DOI 10.1001/jama.263.4.549; SOUMERAI SB, 1987, MED CARE, V25, P210, DOI 10.1097/00005650-198703000-00005; *U LEEDS NUFF I HL, 1995, EFFECTIVE HLTH C AUG; Weingarten S, 1992, QRB Qual Rev Bull, V18, P449; WINGO P, 1984, AM J OBSTET GYNECOL, V152, P807	34	45	46	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	MAY 8	1999	318	7193					1246	1250						5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	195XT	10231255				2022-12-28	WOS:000080278000026
J	Shortt, S				Shortt, S			Pseudo-EBM-ers have their own lexicon	BRITISH MEDICAL JOURNAL			English	Letter									Queens Univ, Kingston, ON, Canada	Queens University - Canada	Shortt, S (corresponding author), Queens Univ, Kingston, ON, Canada.							Molesworth N, 1998, BRIT MED J, V317, P1720, DOI 10.1136/bmj.317.7174.1720a	1	0	0	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	MAY 8	1999	318	7193					1286	1286						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	195XT	10231272	Green Published			2022-12-28	WOS:000080278000042
J	Van der Stuyft, P; Gianella, A; Pirard, M; Cespedes, J; Lora, J; Peredo, C; Pelegrino, JL; Vorndam, V; Boelaert, M				Van der Stuyft, P; Gianella, A; Pirard, M; Cespedes, J; Lora, J; Peredo, C; Pelegrino, JL; Vorndam, V; Boelaert, M			Urbanisation of yellow fever in Santa Cruz, Bolivia	LANCET			English	Article							COST-EFFECTIVENESS; ENCEPHALITIS; INFECTIONS; DENGUE	Background Reinvasion by Aedes aegypti of cities in the Americas poses a threat of urbanisation of yellow fever. After detection of yellow-fever infection in a resident of the city of Santa Cruz, Bolivia, in December, 1997, we investigated all subsequent suspected cases. Methods We introduced active surveillance of yellow fever in the Santa Cruz area. Hospitals and selected urban and rural health centres reported all suspected cases. Patients were serologically screened for yellow fever, dengue, hepatitis A and B, and leptospirosis. We collected clinical and epidemiological information from patients' records and through interviews. We also carried out a population-based serosurvey in the neighbourhood of one case. Findings Between December, 1997, and June, 1998, symptomatic yellow-fever infection was confirmed in six residents of Santa Cruz, five of whom died. Five lived in the southern sector of the city. Two had not left the city during the incubation period, and one had visited only an area in which sylvatic transmission was deemed impossible. Of the 281 people covered in the serosurvey 16 (6%) were positive for IgM antibody to yellow fever. Among five people for whom this result could not be explained by recent vaccination, there were two pairs of neighbours. Interpretation Urban transmission of yellow fever in Santa Cruz was limited in space and time. Low yellow-fever immunisation coverage and high infestation with A aegypti in the city, and the existence of endemic areas in the region present a risk for future urban outbreaks. We recommend immediate large-scale immunisation of the urban population, as well as tightened surveillance and appropriate vector control.	Inst Trop Med, Epidemiol Unit, B-2000 Antwerp 1, Belgium; Ctr Nacl Enfermedades Trop, Santa Cruz, Bolivia; Belgian Agcy Dev Cooperat, CENETROP Project, Santa Cruz, Bolivia; Direcc Dept Salud, Secc Control Vectores, Santa Cruz, Bolivia; Inst Med Trop Pedro Kouri, La Havana, Cuba; Ctr Dis Control & Prevent, San Juan, PR USA	Institute of Tropical Medicine (ITM); Centers for Disease Control & Prevention - USA	Van der Stuyft, P (corresponding author), Inst Trop Med, Epidemiol Unit, B-2000 Antwerp 1, Belgium.		Boelaert, Marleen/E-2698-2012; Pelegrino Martinez de la Cotera, Jose Luis/F-9040-2016	Boelaert, Marleen/0000-0001-8051-6776; Pelegrino Martinez de la Cotera, Jose Luis/0000-0003-0833-653X				BRES PLJ, 1986, B WORLD HEALTH ORGAN, V64, P775; CHIPPAUX A, 1993, B SOC PATHOL EXOT, V86, P460; INNIS BL, 1989, AM J TROP MED HYG, V40, P418, DOI 10.4269/ajtmh.1989.40.418; MONATH TP, 1993, AM J TROP MED HYG, V48, P274, DOI 10.4269/ajtmh.1993.48.274; MONATH TP, 1991, AM J TROP MED HYG, V45, P1; Pan American Health Organization, 1994, SCI PUBL, P1; PINHEIRO FP, 1986, B WORLD HEALTH ORGAN, V64, P511; ROBERTSON RL, 1992, HEALTH POLICY PLANN, V7, P111, DOI 10.1093/heapol/7.2.111; Robertson SE, 1996, JAMA-J AM MED ASSOC, V276, P1157, DOI 10.1001/jama.276.14.1157; SAGARNAGA RV, 1983, B CIENT CENETROP, V9, P13; SCHOFIELD CJ, 1984, B CIENTIFICO CENETRO, V10, P22; SOPER FL, 1952, AM J TROP MED HYG, V1, P361, DOI 10.4269/ajtmh.1952.1.361; Van der Stuyft P, 1998, TROP MED INT HEALTH, V3, P857; Watts DM, 1997, AM J TROP MED HYG, V56, P661, DOI 10.4269/ajtmh.1997.56.661; WHO Emerging and Other Communicable Diseases, 1998, WHOEPIGEN9809; 1998, WKLY EPIDEMIOL REC, V73, P370; 1998, WKLY EPIDEMIOL REC, V73, P354; 1999, LANCET, V353, P648; 1999, WKLY EPIDEMIOL REC, V74, P56; 1999, WKLY EPIDEMIOL REC, V74, P80	20	66	71	0	19	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	MAY 8	1999	353	9164					1558	1562		10.1016/S0140-6736(99)03291-2	http://dx.doi.org/10.1016/S0140-6736(99)03291-2			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	195XW	10334253				2022-12-28	WOS:000080278300010
J	Breen, TL; Tien, J; Oliver, SRJ; Hadzic, T; Whitesides, GM				Breen, TL; Tien, J; Oliver, SRJ; Hadzic, T; Whitesides, GM			Design and self-assembly of open, regular, 3D mesostructures	SCIENCE			English	Article							CRYSTALLIZATION; MICROSCOPY; OBJECTS	Self-assembly provides the basis for a procedure used to organize millimeter-scale objects into regular, three-dimensional arrays ("crystals") with open structures. The individual components are designed and fabricated of polyurethane by molding; selected faces are coated with a thin film of liquid, metallic alloy. Under mild agitation in warm, aqueous potassium bromide solution, capillary forces between the films of alloy cause self-assembly. The structures of the resulting, self-assembled arrays are determined by structural features of the component parts: the three-dimensional shape of the components, the pattern of alloy on their surfaces, and the shape of the alloy-coated surfaces. Self-assembly of appropriately designed chiral pieces generates helices.	Harvard Univ, Dept Chem & Biol Chem, Cambridge, MA 02138 USA	Harvard University	Whitesides, GM (corresponding author), Harvard Univ, Dept Chem & Biol Chem, 12 Oxford St, Cambridge, MA 02138 USA.			Carmichael, Tricia/0000-0002-0847-437X				Bowden N, 1997, SCIENCE, V276, P233, DOI 10.1126/science.276.5310.233; BOWDEN N, IN PRESS J AM CHEMS; CARROLL MA, 1987, MATER SCI TECH SER, V3, P1040, DOI 10.1179/026708387790329423; CARROLL MA, 1990, HDB CHEM PHYSICS, P4; Green PW, 1995, J MICROELECTROMECH S, V4, P170, DOI 10.1109/84.475543; HOWIE FH, 1982, J MATER SCI, V17, P1434, DOI 10.1007/BF00752257; Murray CA, 1996, ANNU REV PHYS CHEM, V47, P421, DOI 10.1146/annurev.physchem.47.1.421; SCHOBER T, 1992, J APPL PHYS, V71, P2206, DOI 10.1063/1.351118; SIMPSON AW, 1972, NATURE, V237, P320, DOI 10.1038/237320a0; Terfort A, 1997, NATURE, V386, P162, DOI 10.1038/386162a0; Terfort A, 1998, ADV MATER, V10, P470, DOI 10.1002/(SICI)1521-4095(199804)10:6<470::AID-ADMA470>3.0.CO;2-1; Tien J, 1998, J AM CHEM SOC, V120, P12670, DOI 10.1021/ja982246y; vanBlaaderen A, 1997, NATURE, V385, P321, DOI 10.1038/385321a0; WHITESIDES GM, 1995, SCI AM, V273, P146	14	269	284	7	107	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	MAY 7	1999	284	5416					948	951		10.1126/science.284.5416.948	http://dx.doi.org/10.1126/science.284.5416.948			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	194MU	10320372				2022-12-28	WOS:000080198800041
J	Cheetham, GMT; Jeruzalmi, D; Steitz, TA				Cheetham, GMT; Jeruzalmi, D; Steitz, TA			Structural basis for initiation of transcription from an RNA polymerase-promoter complex	NATURE			English	Article							CRYSTAL-STRUCTURE; DNA RECOGNITION; ANGSTROM RESOLUTION; BACTERIOPHAGE-T7; SUBSTITUTION; BINDING	Although the single-polypeptide-chain RNA polymerase from bacteriophage T7 (T7RNAP), like other RNA polymerases, uses the same mechanism of polymerization as the DNA polymerases, it can also recognize a specific promoter sequence, initiate new RNA chains from a single nucleotide, abortively cycle the synthesis of short transcripts, be regulated by a transcription inhibitor, and terminate transcription(1-3), As T7RNAP is homologous to the Pol I family of DNA polymerases(4), the differences between the structure of T7RNAP complexed to substrates and that of the corresponding DNA polymerase complex provides a structural basis for understanding many of these functional differences. T7RNAP initiates RNA synthesis at promoter sequences that are conserved from positions -17 to +6 relative to the start site of transcription. The crystal structure at 2.4 Angstrom resolution of T7RNAP complexed with a 17-base-pair promoter shows that the four base pairs closest to the catalytic active site have melted to form a transcription bubble. The T7 promoter sequence is recognized by interactions in the major groove between an antiparallel B-loop and bases. The amino-terminal domain is involved in promoter recognition and DNA melting. We have also used homology modelling of the priming and incoming nucleoside triphosphates from the T7 DNA-polymerase ternary complex structure to explain the specificity of T7RNAP for ribonucleotides, its ability to initiate from a single nucleotide, and the abortive cycling at the initiation of transcription.	Yale Univ, Dept Mol Biophys & Biochem, New Haven, CT 06520 USA; Yale Univ, Dept Chem, New Haven, CT 06520 USA; Yale Univ, Howard Hughes Med Inst, New Haven, CT 06520 USA	Yale University; Yale University; Howard Hughes Medical Institute; Yale University	Steitz, TA (corresponding author), Yale Univ, Dept Mol Biophys & Biochem, 266 Whitney Ave, New Haven, CT 06520 USA.		Steitz, Thomas A./C-6559-2009					Abrahams JP, 1996, ACTA CRYSTALLOGR D, V52, P30, DOI 10.1107/S0907444995008754; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; CARPOUSIS AJ, 1980, BIOCHEMISTRY-US, V19, P3245, DOI 10.1021/bi00555a023; DAVANLOO P, 1984, P NATL ACAD SCI-BIOL, V81, P2035, DOI 10.1073/pnas.81.7.2035; DELARUE M, 1990, PROTEIN ENG, V3, P461, DOI 10.1093/protein/3.6.461; Doublie S, 1998, NATURE, V391, P251, DOI 10.1038/34593; Eom SH, 1996, NATURE, V382, P278, DOI 10.1038/382278a0; Gao GX, 1997, P NATL ACAD SCI USA, V94, P407, DOI 10.1073/pnas.94.2.407; IKEDA RA, 1986, P NATL ACAD SCI USA, V83, P3614, DOI 10.1073/pnas.83.11.3614; Jeruzalmi D, 1998, EMBO J, V17, P4101, DOI 10.1093/emboj/17.14.4101; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KIM JL, 1993, NATURE, V365, P520, DOI 10.1038/365520a0; KIM YC, 1993, NATURE, V365, P512, DOI 10.1038/365512a0; LEE SS, 1992, BIOCHEM INT, V26, P1; Leslie AGW, 1992, JOINT CCP4 ESF EACMB; MASTERS BS, 1987, CELL, V51, P89, DOI 10.1016/0092-8674(87)90013-4; MCALLISTER WT, 1978, P NATL ACAD SCI USA, V75, P804, DOI 10.1073/pnas.75.2.804; OSUMIDAVIS PA, 1992, J MOL BIOL, V226, P37, DOI 10.1016/0022-2836(92)90122-Z; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; RASKIN CA, 1992, J MOL BIOL, V228, P506, DOI 10.1016/0022-2836(92)90838-B; RAUMANN BE, 1994, NATURE, V367, P754, DOI 10.1038/367754a0; Rice PA, 1996, CELL, V87, P1295, DOI 10.1016/S0092-8674(00)81824-3; ROULD MA, 1992, NUCLEIC ACIDS MOL BI, V6, P225; SOMERS WS, 1992, NATURE, V359, P387, DOI 10.1038/359387a0; SOUSA R, 1993, NATURE, V364, P593, DOI 10.1038/364593a0; STEITZ TA, 1994, SCIENCE, V266, P2022, DOI 10.1126/science.7528445; STEITZ TA, 1993, CURR OPIN STRUC BIOL, V3, P31, DOI 10.1016/0959-440X(93)90198-T; STEITZ TA, 1990, Q REV BIOPHYS, V23, P205, DOI 10.1017/S0033583500005552; SUZUKI M, 1995, PROTEIN ENG, V8, P1, DOI 10.1093/protein/8.1.1	30	259	276	0	26	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	MAY 6	1999	399	6731					80	83		10.1038/19999	http://dx.doi.org/10.1038/19999			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	194BK	10331394				2022-12-28	WOS:000080172100059
J	Diermayer, M; Hedberg, K; Hoesly, F; Fischer, M; Perkins, B; Reeves, M; Fleming, D				Diermayer, M; Hedberg, K; Hoesly, F; Fischer, M; Perkins, B; Reeves, M; Fleming, D			Epidemic serogroup B meningococcal disease in Oregon - The evolving epidemiology of the ET-5 strain	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							MULTILOCUS ENZYME ELECTROPHORESIS; NEISSERIA-MENINGITIDIS; POPULATION-GENETICS; SAO-PAULO; INFLUENZA; OUTBREAK; CARRIAGE; VACCINE; COMPLEX; SMOKING	Context In 1993, Oregon's incidence of serogroup B meningococcal disease began to rise because of a highly clonal group of strains designated enzyme type 5 (ET-5), the first such increase observed in the United States. Objective To evaluate the impact that the ET-5 strain has had on the epidemiology of meningococcal disease in Oregon. Design and Setting Epidemiologic analysis of surveillance data on Oregon meningococcal disease cases from 1987 through 1996 and multilocus enzyme electrophoresis typing of serogroup B isolates from June 1993 through April 1995 and from April through June 1996. Patients A total of 836 persons with invasive meningococcal disease. Main Outcome Measures Disease frequency and clonality of strains. Results Serogroup B disease incidence rates more than doubled from the preepidemic period in 1987-1992 (1.0 case per 100 000 population) to the recent epidemic period in 1995-1996 (2.2 cases per 100 000), The age-specific incidence rate of serogroup B disease among those 15 through 19 years old increased 13-fold between the preepidemic period (0.5 case per 100 000) and 1995-1996 (6.4 cases per 100 000), However, the proportion of cases with meningococcemia and the case-fatality rate did not change. Of 99 Neisseria meningitidis isolates obtained from 1993-1995, 88 (89%) belonged to the ET-5 complex, Of these, 69 (78%) were a single clone, designated 301, Of 20 serogroup B isolates from 1996, 18 (90%) belonged to the ET-5 complex; 17 (94%) were the 301 clone. Conclusion Serogroup B meningococcal disease incidence continues at high levels in Oregon with increasing predominance of the ET-5 clonal strains.	Oregon Hlth Div, Portland, OR USA; Ctr Dis Control & Prevent, Div Field Epidemiol, Epidemiol Program Off, Atlanta, GA USA; Ctr Dis Control & Prevent, Meningitis & Special Pathogens Branch, Div Bacterial & Mycot Dis, Atlanta, GA USA	Oregon Health & Science University; Centers for Disease Control & Prevention - USA; Centers for Disease Control & Prevention - USA	Hedberg, K (corresponding author), 800 NE Oregon St,Suite 772, Portland, OR 97232 USA.	katrina.hedberg@state.or.us			PHS HHS [U50/CCU011184] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		CARBONARE SB, 1995, PEDIATR INFECT DIS J, V14, P797, DOI 10.1097/00006454-199509000-00013; CARTWRIGHT KAV, 1991, LANCET, V338, P554, DOI 10.1016/0140-6736(91)91112-8; CAUGANT DA, 1986, P NATL ACAD SCI USA, V83, P4927, DOI 10.1073/pnas.83.13.4927; *CDCP, 1996, MMWR-MORBID MORTAL W, V45, P1010; DEAN A, 1995, EPI INFO VERSION 6 W; DEMORAES JC, 1992, LANCET, V340, P1074; Fischer M, 1997, PEDIATR INFECT DIS J, V16, P979, DOI 10.1097/00006454-199710000-00015; FROHOLM L O, 1983, NIPH (National Institute of Public Health) Annals (Oslo), V6, P133; HARRISON LH, 1991, ARCH INTERN MED, V151, P1005, DOI 10.1001/archinte.151.5.1005; Jackson LA, 1996, PEDIATR INFECT DIS J, V15, P992, DOI 10.1097/00006454-199611000-00012; JACKSON LA, 1995, JAMA-J AM MED ASSOC, V273, P383, DOI 10.1001/jama.273.5.383; Jackson Lisa A., 1993, Morbidity and Mortality Weekly Report, V42, P21; KRASINSKI K, 1987, AM J EPIDEMIOL, V125, P499, DOI 10.1093/oxfordjournals.aje.a114556; KREMASTINOU J, 1994, SCAND J INFECT DIS, V26, P719, DOI 10.3109/00365549409008641; LYSTAD A, 1991, NIPH (National Institute of Public Health) Annals (Oslo), V14, P57; MORROW HW, 1990, PEDIATR INFECT DIS J, V9, P394, DOI 10.1097/00006454-199006000-00005; PELTOLA H, 1982, LANCET, V2, P595; POOLMAN JT, 1986, LANCET, V2, P555; Racoosin JA, 1998, JAMA-J AM MED ASSOC, V280, P2094, DOI 10.1001/jama.280.24.2094; REEVES MW, 1995, EMERG INFECT DIS, V1, P53, DOI 10.3201/eid0102.950203; SACCHI CT, 1992, J CLIN MICROBIOL, V30, P1734, DOI 10.1128/JCM.30.7.1734-1738.1992; SCHWARTZ B, 1989, CLIN MICROBIOL REV, V2, pS118, DOI 10.1128/CMR.2.Suppl.S118-S124.1989; SELANDER RK, 1986, APPL ENVIRON MICROB, V51, P873, DOI 10.1128/AEM.51.5.873-884.1986; SELANDER RK, 1987, MICROB PATHOGENESIS, V3, P1, DOI 10.1016/0882-4010(87)90032-5; STUART JM, 1989, LANCET, V2, P723, DOI 10.1016/S0140-6736(89)90781-2; WHALEN CM, 1995, JAMA-J AM MED ASSOC, V273, P390, DOI 10.1001/jama.273.5.390; WYLE FA, 1972, J INFECT DIS, V126, P514, DOI 10.1093/infdis/126.5.514	27	79	82	0	2	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	APR 28	1999	281	16					1493	1497		10.1001/jama.281.16.1493	http://dx.doi.org/10.1001/jama.281.16.1493			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	188PP	10227318	Bronze			2022-12-28	WOS:000079857400030
J	Appleby, L; Dennehy, JA; Thomas, CS; Faragher, EB; Lewis, G				Appleby, L; Dennehy, JA; Thomas, CS; Faragher, EB; Lewis, G			Aftercare and clinical characteristics of people with mental illness who commit suicide: a case-control study	LANCET			English	Article							PSYCHIATRIC-PATIENTS	Background Suicide prevention is now a health priority in many countries. In the UK, there are specific targets for reducing the suicide rate in the general population and in people with mental illness. However, there is almost no evidence for the effectiveness of health services in reducing suicide, and little evidence linking suicide to any aspect of health-service care. Method We conducted a case-control study of people who committed suicide after discharge from psychiatric inpatient care. Cases were a 30-month sample of 149 people who had received an inquest verdict of suicide or open verdict in Greater Manchester, and who had a history of psychiatric admission in the 5 years before death. Controls were surviving psychiatric patients individually matched for age, sex, diagnosis, and date of last admission. Cases and controls were compared on aspects of psychiatric care, and on clinical and social variables, information being obtained from case notes. Findings Those who took their own lives were more likely to have had their care reduced (odds ratio 3.7 [95% CI 1.8-7.6]) at the final appointment in the community before death. Suicide was also associated with a history of self harm (3.1[1.7-5.7]), suicidal thoughts during aftercare (1.9 [1.0-3.5]) and the most recent admission as the first illness (2.0 [1.1-3.6]). The associations reported above took account of a number of confounding factors, including the predictable risk of suicide judged from case notes. Only 34% of suicides had an identifiable key worker, the essence of the Care Programme Approach. This frequency was no higher than that for controls, reflecting the difficulty of identifying those likely to commit suicide. Interpretation Reductions in care are strongly associated with suicide by people with mental illness, and may be contributory. The implication is that maintaining care beyond the point of clinical recovery is important in protecting high-risk individuals. Several clinical variables indicate high risk but greater risk is not generally addressed in health service provisions.	Univ S Manchester Hosp, Sch Psychiat & Behav Sci, Manchester M20 8LR, Lancs, England; Univ Wales, Coll Med, Cardiff CF1 3NS, S Glam, Wales; Sch Med, Res Support Unit, Manchester, Lancs, England	University of Manchester; Wythenshawe Hospital NHS Foundation Trust; Wythenshawe Hospital; Cardiff University; University of Manchester	Appleby, L (corresponding author), Univ S Manchester Hosp, Sch Psychiat & Behav Sci, Manchester M20 8LR, Lancs, England.		Lewis, Glyn/E-9944-2012	Lewis, Glyn/0000-0001-5205-8245				ALLEBECK P, 1988, BRIT MED J, V297, P176, DOI 10.1136/bmj.297.6642.176; APPLEBY L, 1992, BRIT J PSYCHIAT, V161, P749, DOI 10.1192/bjp.161.6.749; BARRACLOUGH B, 1974, BRIT J PSYCHIAT, V125, P355, DOI 10.1192/bjp.125.4.355; Dennehy JA, 1996, BRIT MED J, V312, P1580, DOI 10.1136/bmj.312.7046.1580; *DEP HLTH, 1992, HLTH NAT; GOLDACRE M, 1993, LANCET, V342, P283, DOI 10.1016/0140-6736(93)91822-4; Kataria, 2016, SAUDI J SPORTS MED, V16, P139; KING E, 1990, BRIT J PSYCHIAT, V156, P714, DOI 10.1192/bjp.156.5.714; Last J., 1988, DICT EPIDEMIOLOGY	9	123	125	1	9	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	APR 24	1999	353	9162					1397	1400		10.1016/S0140-6736(98)10014-4	http://dx.doi.org/10.1016/S0140-6736(98)10014-4			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	191KD	10227220				2022-12-28	WOS:000080020800012
J	Brahams, D				Brahams, D			Truth, bias, and the medical "expert"	LANCET			English	Editorial Material											Brahams, D (corresponding author), Old Sq Chambers,Grays Inn, London WC1R 5LQ, England.								0	3	3	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	APR 24	1999	353	9162					1380	1380		10.1016/S0140-6736(99)00143-9	http://dx.doi.org/10.1016/S0140-6736(99)00143-9			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	191KD	10227216				2022-12-28	WOS:000080020800007
J	Dawson, C				Dawson, C			Flies and the elimination of blinding trachoma	LANCET			English	Editorial Material							SINGLE-DOSE AZITHROMYCIN; BLINDNESS; IMPACT		Univ Calif San Francisco, Francis I Proctor Fdn, San Francisco, CA 94143 USA; Univ Calif San Francisco, Dept Ophthalmol, San Francisco, CA 94143 USA	University of California System; University of California San Francisco; University of California System; University of California San Francisco	Dawson, C (corresponding author), Univ Calif San Francisco, Francis I Proctor Fdn, San Francisco, CA 94143 USA.							BAILEY RL, 1993, LANCET, V342, P453, DOI 10.1016/0140-6736(93)91591-9; BOBO L, 1995, LANCET, V338, P84; Dawson CR, 1997, CLIN INFECT DIS, V24, P363, DOI 10.1093/clinids/24.3.363; Dolin PJ, 1997, LANCET, V349, P1511, DOI 10.1016/S0140-6736(97)01355-X; JONES BR, 1975, T OPHTHAL SOC UK, V95, P16; Leach AJ, 1997, CLIN INFECT DIS, V24, P356, DOI 10.1093/clinids/24.3.356; MAXWELLLYONS F, 1949, B OPHTHAL SOC EGYPT, V42, P116; MCGUIRE C, 1957, AM J TROP MED HYG, V6, P56; SCHACHTER J, 1998, CHLAMYDIAL INFECTION, P247; Sharp D, 1998, LANCET, V352, P1609, DOI 10.1016/S0140-6736(05)61067-7; Tabbara KF, 1996, OPHTHALMOLOGY, V103, P842; THYLEFORS B, 1987, B WORLD HEALTH ORGAN, V65, P477; THYLEFORS B, 1995, B WORLD HEALTH ORGAN, V73, P115; WEST S, 1995, LANCET, V345, P155, DOI 10.1016/S0140-6736(95)90167-1; *WHO, 1996, GLOB SCI M GEN JUN 1	15	1	1	0	1	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	APR 24	1999	353	9162					1376	1377		10.1016/S0140-6736(99)90037-5	http://dx.doi.org/10.1016/S0140-6736(99)90037-5			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	191KD	10227213				2022-12-28	WOS:000080020800004
J	Ramsay, S				Ramsay, S			Getting the chemistry right in trials	LANCET			English	Editorial Material									Lancet, London WC1B 3SL, England		Ramsay, S (corresponding author), Lancet, London WC1B 3SL, England.							*U LEEDS, 1998, REP IND GROUP EST RE	1	4	4	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON WC1B 3SL, ENGLAND	0140-6736			LANCET	Lancet	MAY 23	1998	351	9115					1528	1528		10.1016/S0140-6736(05)61118-X	http://dx.doi.org/10.1016/S0140-6736(05)61118-X			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZQ497	10326533				2022-12-28	WOS:000073868000006
J	Edwards, SJL; Braunholtz, DA; Lilford, RJ; Stevens, AJ				Edwards, SJL; Braunholtz, DA; Lilford, RJ; Stevens, AJ			Ethical issues in the design and conduct of cluster randomised controlled trials	BMJ-BRITISH MEDICAL JOURNAL			English	Article									Univ Birmingham, Dept Publ Hlth Med, Birmingham B15 2TT, W Midlands, England	University of Birmingham	Edwards, SJL (corresponding author), Univ Birmingham, Dept Publ Hlth Med, Birmingham B15 2TT, W Midlands, England.	S.J.Edwards@bham.ac.uk						ASHCROFT R, 1997, HLTH TECHNOL ASSESS, V1; DIAMOND A, 1994, J ROY COLL PHYS LOND, V28, P439; Donner A, 1998, J R STAT SOC C-APPL, V47, P95, DOI 10.1111/1467-9876.00100; EDWARDS SJL, 1998, HLTH TECHNOL ASSESS, V2; KIRKWOOD BR, 1989, J BIOSOC SCI, P79	5	170	170	0	8	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	MAY 22	1999	318	7195					1407	1409		10.1136/bmj.318.7195.1407	http://dx.doi.org/10.1136/bmj.318.7195.1407			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	200DQ	10334756	Green Published			2022-12-28	WOS:000080524700034
J	Kee, F; Wilson, RH; Harper, C; Patterson, CC; McCallion, K; Houston, RF; Moorehead, RJ; Sloan, JM; Rowlands, BJ				Kee, F; Wilson, RH; Harper, C; Patterson, CC; McCallion, K; Houston, RF; Moorehead, RJ; Sloan, JM; Rowlands, BJ			Influence of hospital and clinician workload on survival from colorectal cancer: cohort study	BRITISH MEDICAL JOURNAL			English	Article							SURGICAL-PROCEDURES; VOLUME; MORTALITY; SURGEONS; CARE; RISK	Objective To determine whether clinician or hospital caseload affects mortality from colorectal cancer. Design Cohort study of cases ascertained between 1990 and 1994 by a region-wide colorectal cancer register. Outcome measures Mortality within a median follow up period of 54 months after diagnosis. Results Of the 3217 new patients registered over the period, 1512 (48%) died before 31 December 1996. Strong predictors of survival both in a logistic repression (fixed follow up) and in a Cox's proportional hazards model (variable follow up) were Duke's stage, the degree of tumour differentiation, whether the liver was deemed clear of cancer by the surgeon at operation, and the type of intervention (elective or emergency and curative or palliative intent). In a multilevel model, surgeon's caseload had no significant effect on mortality at 2 years. Hospital workload, however, had a significant impact on survival. The odds ratio for death within 2 years for cases managed in a hospital with a caseload of between 33 and 46 cases per year, 47 and 54 cases per year, and greater than or equal to 55 cases per year (compared to one with less than or equal to 23 cases per year) were respectively 1.48 (95% confidence interval 1.03 to 2.13), 1.52 (1.08 to 2.19), and 1.18 (0.83 to 1.68). Conclusions There was no detectable caseload effect for surgeons managing colorectal cancer, but survival of patients treated in hospitals with caseloads above 33 cases per year was slightly worse than for those treated in hospitals With fewer caseloads. Imprecise measurement of clinician specific "events rates" and the lack of routinely collected case mix data present major challenges for clinical audit and governance in the years ahead.	Queens Univ Belfast, Dept Epidemiol & Publ Hlth, Belfast BT12 6BJ, Antrim, North Ireland; Belvoir Pk Hosp, No Ireland Ctr Clin Oncol, Belfast BT8 8JR, Antrim, North Ireland; Belvoir Pk Hosp, No Ireland Canc Register, Belfast BT8 8JR, Antrim, North Ireland; Queens Univ Belfast, Dept Surg, Belfast BT12 6BJ, Antrim, North Ireland; N Down & Ards Hlth & Social Serv Trust, Belfast BT16 1RH, Antrim, North Ireland; Queens Univ Belfast, Dept Pathol, Belfast BT12 6BJ, Antrim, North Ireland; Queens Med Ctr, Dept Surg, Nottingham NG7 2UH, England	Queens University Belfast; Queens University Belfast; Queens University Belfast; University of Nottingham	Kee, F (corresponding author), Queens Univ Belfast, Dept Epidemiol & Publ Hlth, Belfast BT12 6BJ, Antrim, North Ireland.							Christiansen CL, 1997, ANN INTERN MED, V127, P764, DOI 10.7326/0003-4819-127-8_Part_2-199710151-00065; *DEP HLTH, 1997, GUID PURCH IMPR OUTC; *EXP ADV GROUP CAN, 1994, CONSULTATIVE DOCUMEN; FIELDING LP, 1978, LANCET, V2, P778; GOLDSTEIN H, 1996, J ROY STAT SOC A STA, V159, P1; GOLDSTEIN H, 1998, USERS GUIDE MLWINN; Hakama M, 1989, Int J Technol Assess Health Care, V5, P619; HANNAN EL, 1989, JAMA-J AM MED ASSOC, V262, P503, DOI 10.1001/jama.262.4.503; Holm T, 1997, BRIT J SURG, V84, P657, DOI 10.1046/j.1365-2168.1997.02745.x; HOUGHTON A, 1994, BRIT J SURG, V81, P653, DOI 10.1002/bjs.1800810508; HUGHES RG, 1987, MED CARE, V25, P489, DOI 10.1097/00005650-198706000-00004; Kee F, 1996, J EPIDEMIOL COMMUN H, V50, P640, DOI 10.1136/jech.50.6.640; KEE F, 1992, BRIT MED J, V305, P158, DOI 10.1136/bmj.305.6846.158; Lovegrove J, 1997, LANCET, V350, P1128, DOI 10.1016/S0140-6736(97)06507-0; LUFT HS, 1979, NEW ENGL J MED, V301, P1364, DOI 10.1056/NEJM197912203012503; Machin D., 1987, STAT TABLES DESIGN C; MCARDLE CS, 1991, BRIT MED J, V302, P1501, DOI 10.1136/bmj.302.6791.1501; *NHS, 1997, EFFECTIVE HLTH CARE, V13, P11; PEARCE K, 1997, REV COLORECTAL CANC; *ROYAL COLL SURG E, 1996, GUID MAN COL CANC; Sagar PM, 1996, DIS COLON RECTUM, V39, P654, DOI 10.1007/BF02056945; SAINSBURY R, 1995, LANCET, V345, P1265, DOI 10.1016/S0140-6736(95)90924-9; Taylor I, 1996, EUR J SURG ONCOL, V22, P205, DOI 10.1016/S0748-7983(96)80001-1	23	86	87	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	MAY 22	1999	318	7195					1381	1385		10.1136/bmj.318.7195.1381	http://dx.doi.org/10.1136/bmj.318.7195.1381			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	200DQ	10334746	Green Published, Green Submitted, Bronze			2022-12-28	WOS:000080524700023
J	Ezekowitz, MD; Levine, JA				Ezekowitz, MD; Levine, JA			Preventing stroke in patients with atrial fibrillation	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							TRANSESOPHAGEAL ECHOCARDIOGRAPHY; ELDERLY PATIENTS; RISK FACTOR; ANTICOAGULATION; WARFARIN; CARDIOVERSION; POPULATION; DISEASE; COMPLICATIONS; INFARCTION	Context Atrial fibrillation, a common disorder that affects nearly one sixth of the population aged 75 years and older, is a major risk factor for stroke. Objectives To review and evaluate the evidence supporting the use of warfarin and/or aspirin for stroke prevention in patients with atrial fibrillation. Data Sources Prospective, randomized trials of patients with atrial fibrillation evaluating either warfarin or aspirin or both, from MEDLINE from January 1, 1966, to February 23, 1999. Study Selection Five primary prevention placebo-controlled studies, which had been formally pooled, 1 study evaluating secondary prevention of stroke, 1 study comparing warfarin with aspirin, and 3 studies of warfarin in combination with aspirin were identified. Data Synthesis The risk of developing stroke is heterogeneous and increases with each decade above 65 years; history of high blood pressure, diabetes mellitus, previous transient ischemic attack, or stroke; poor ventricular function; and in women older than 75 years. For patients younger than 65 years, without risk factors, and not receiving antithrombotic therapy, the risk of stroke is 1%/y; those without risk factors between the ages of 65 and 75 years have a risk of 1.1%/y if taking warfarin and 1.4%/y if taking aspirin. For all other patients, stroke risk is reduced from an untreated rate of between 4.3%/y and more than 12%/y to a rate of 1.2%/y to 4%/y with warfarin use. Conclusion The protection afforded by warfarin is most pronounced in patients at the highest risk for stroke, while aspirin treatment seems adequate in low-risk populations.	Yale Univ, Sch Med, Yale Clin Trials Off, New Haven, CT 06511 USA; Vet Affairs Med Ctr, W Haven, CT USA	Yale University; US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Connecticut Healthcare System	Ezekowitz, MD (corresponding author), Yale Univ, Sch Med, Yale Clin Trials Off, 47 Coll Pl,Suite 202, New Haven, CT 06511 USA.		Ezekowitz, Michael/AAJ-2543-2021					Anderson DC, 1998, JAMA-J AM MED ASSOC, V279, P1273; Blackshear JL, 1996, LANCET, V348, P633; Brugada R, 1997, NEW ENGL J MED, V336, P905, DOI 10.1056/NEJM199703273361302; CONNOLLY SJ, 1991, J AM COLL CARDIOL, V18, P349, DOI 10.1016/0735-1097(91)90585-W; Einthoven W., 1906, ARCH INT PHYSIOL, V4, P132; Ezekowitz M, 1998, ARCH INTERN MED, V158, P1316; EZEKOWITZ MD, 1992, NEW ENGL J MED, V327, P1406, DOI 10.1056/NEJM199211123272002; EZEKOWITZ MD, 1995, CIRCULATION, V92, P2178, DOI 10.1161/01.CIR.92.8.2178; EZEKOWITZ MD, 1999, J CARDIOVASC PHARM, P43; Fatkin D, 1996, PROG CARDIOVASC DIS, V39, P57, DOI 10.1016/S0033-0620(96)80041-7; Fuster V, 1997, LANCET, V350, P389; GAJEWSKI J, 1981, JAMA-J AM MED ASSOC, V245, P1540; Gullov AL, 1998, ARCH INTERN MED, V158, P1513, DOI 10.1001/archinte.158.14.1513; Hylek EM, 1996, NEW ENGL J MED, V335, P540, DOI 10.1056/NEJM199608223350802; KAATZ SS, 1995, ARCH INTERN MED, V155, P1861, DOI 10.1001/archinte.155.17.1861; KANNEL WB, 1983, AM HEART J, V106, P389, DOI 10.1016/0002-8703(83)90208-9; KANNEL WB, 1982, NEW ENGL J MED, V306, P1018, DOI 10.1056/NEJM198204293061703; KISTLER JP, 1990, NEW ENGL J MED, V323, P1505; Klein AL, 1997, ANN INTERN MED, V126, P200, DOI 10.7326/0003-4819-126-3-199702010-00004; KOPECKY SL, 1987, NEW ENGL J MED, V317, P669, DOI 10.1056/NEJM198709103171104; KOPECKY SL, 1992, HOSP PRACT, V27, P135; KOUDSTAAL PJ, 1993, LANCET, V342, P1255; Langenberg M, 1996, BRIT MED J, V313, P1534, DOI 10.1136/bmj.313.7071.1534; Larrue V, 1997, STROKE, V28, P957, DOI 10.1161/01.STR.28.5.957; LAUPACIS A, 1994, ARCH INTERN MED, V154, P1449; Lewis T, 1909, Br Med J, V2, P1528; Lewis T., 1909, HEART, V1, P306; MANNING WJ, 1993, NEW ENGL J MED, V328, P750, DOI 10.1056/NEJM199303183281102; MASSICOTTE P, 1995, J PEDIATR-US, V127, P389, DOI 10.1016/S0022-3476(95)70069-2; MCBRIDE R, 1994, LANCET, V343, P687; MCBRIDE R, 1990, STROKE, V21, P538; Mikkola KM, 1997, AM HEART J, V134, P69, DOI 10.1016/S0002-8703(97)70108-X; Ott A, 1997, STROKE, V28, P316, DOI 10.1161/01.STR.28.2.316; Pengo V, 1998, AM J CARDIOL, V82, P433, DOI 10.1016/S0002-9149(98)00357-9; PETERSEN P, 1989, LANCET, V1, P175; PHILLIPS SJ, 1990, MAYO CLIN PROC, V65, P344, DOI 10.1016/S0025-6196(12)62535-X; Rothberger C, 1909, WIEN KLIN WOCHENSCHR, V22, P839; Rothberger C.J., 1909, WIEN KLIN WOCHENSCHR, V22, P1792; Sawicki PT, 1999, JAMA-J AM MED ASSOC, V281, P145, DOI 10.1001/jama.281.2.145; SILVERMAN ME, 1994, AM J CARDIOL, V73, P384, DOI 10.1016/0002-9149(94)90013-2; STODDARD MF, 1995, AM HEART J, V129, P1204, DOI 10.1016/0002-8703(95)90405-0; Wijffels MCEF, 1997, CIRCULATION, V96, P3710; WOLF PA, 1991, STROKE, V22, P983, DOI 10.1161/01.STR.22.8.983; Yamanouchi H, 1997, NEUROLOGY, V48, P1593, DOI 10.1212/WNL.48.6.1593; Zito M, 1996, AGING-CLIN EXP RES, V8, P341, DOI 10.1007/BF03339591	45	111	118	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAY 19	1999	281	19					1830	1835		10.1001/jama.281.19.1830	http://dx.doi.org/10.1001/jama.281.19.1830			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	196BH	10340371	Bronze			2022-12-28	WOS:000080288800037
J	Lawrence, RAAR				Lawrence, RAAR			Rosentyl Griffiths - Obituary	BRITISH MEDICAL JOURNAL			English	Biographical-Item																			0	0	0	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	MAY 15	1999	318	7194					1357	1357		10.1136/bmj.318.7194.1357	http://dx.doi.org/10.1136/bmj.318.7194.1357			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	198HR	10323842	Green Published			2022-12-28	WOS:000080418400065
J	Overgaard, M; Jensen, MB; Overgaard, J; Hansen, PS; Rose, C; Andersson, M; Kamby, C; Kjaer, M; Gadeberg, CC; Rasmussen, BB; Blichert-Toft, M; Mouridsen, HT				Overgaard, M; Jensen, MB; Overgaard, J; Hansen, PS; Rose, C; Andersson, M; Kamby, C; Kjaer, M; Gadeberg, CC; Rasmussen, BB; Blichert-Toft, M; Mouridsen, HT			Postoperative radiotherapy in high-risk postmenopausal breast-cancer patients given adjuvant tamoxifen: Danish Breast Cancer Cooperative Group DBCG 82c randomised trial	LANCET			English	Article							POSTMASTECTOMY RADIOTHERAPY; FOLLOW-UP; PREMENOPAUSAL WOMEN; RADICAL-MASTECTOMY; THERAPY; CHEMOTHERAPY; IRRADIATION	Background Postmastectomy radiotherapy is associated with a lower locoregional recurrence rate and improved disease-free and overall survival when combined with chemotherapy in premenopausal high-risk breast-cancer patients. However, whether the same benefits apply also in postmenopausal women treated with adjuvant tamoxifen for similar high-risk cancer is unclear. In a randomised trial among postmenopausal women who had undergone mastectomy, we compared adjuvant tamoxifen alone with tamoxifen plus postoperative radiotherapy. Methods Between 1982 and 1990, postmenopausal women with high-risk breast cancer (stage II or III) were randomly assigned adjuvant tamoxifen (30 mg daily for 1 year) alone (689) or with postoperative radiotherapy to the chest wall and regional lymph nodes (686). Median follow-up was 123 months. The endpoints were first site of recurrence (locoregional recurrence, distant metastases, or both), and disease-free and overall metastases, survival. Findings Locoregional recurrence occurred in 52 (8%) of the radiotherapy plus tamoxifen group and 242 (35%) of the tamoxifen only group (p<0.001). In total there were 321 (47%) and 411 (60%) recurrences, respectively. Disease-free survival was 36% in the radiotherapy plus tamoxifen group and 24% in the tamoxifen alone group (p<0.001). Overall survival was also higher in the radiotherapy group (385 vs 434 deaths; survival 45 vs 36% at 10 years, p=0.03). Interpretation Postoperative radiotherapy decreased the risk of locoregional recurrence and was associated with improved survival in high-risk postmenopausal breast-cancer patients after mastectomy and limited axillary dissection, with 1 year of adjuvant tamoxifen treatment. Improved survival in high-risk breast cancer can best be achieved by a strategy of both locoregional and systemic tumour control.	Aarhus Univ Hosp, Dept Oncol, DK-8000 Aarhus C, Denmark; Aarhus Univ Hosp, Danish Canc Soc Dept Expt Clin Oncol, DK-8000 Aarhus, Denmark; Rigshosp, Danish Breast Canc Cooperat Grp Secretariat, DK-2100 Copenhagen, Denmark; Rigshosp, Dept Oncol, DK-2100 Copenhagen, Denmark; Rigshosp, Dept Surg, DK-2100 Copenhagen, Denmark; Viborg Cty Hosp, Dept Med, Viborg, Denmark; Odense Univ Hosp, Dept Oncol, Odense, Denmark; Copenhagen Univ Hosp, Dept Oncol, Herlev, Denmark; Aalborg Cty Hosp, Dept Oncol, Aalborg, Denmark; Vejle Cty Hosp, Dept Oncol, Vejle, Denmark; Roskilde Cty Hosp, Dept Pathol, Roskilde, Denmark	Aarhus University; Aarhus University; Danish Cancer Society; Danish Breast Cancer Cooperative Group (DBCG); Rigshospitalet; University of Copenhagen; Rigshospitalet; University of Copenhagen; Rigshospitalet; University of Copenhagen; Aarhus University; University of Southern Denmark; Odense University Hospital; University of Copenhagen; Aalborg University; Aalborg University Hospital; University of Southern Denmark; Lillebaelt Hospital	Overgaard, M (corresponding author), Aarhus Univ Hosp, Dept Oncol, Norrebrogade 44,Bldg 5, DK-8000 Aarhus C, Denmark.							ABE O, 1992, LANCET, V339, P71; ABE O, 1995, NEW ENGL J MED, V333, P1444; ANDERSEN KW, 1988, ACTA ONCOL, V27, P627, DOI 10.3109/02841868809091763; ARRIAGADA R, 1995, J CLIN ONCOL, V13, P2869, DOI 10.1200/JCO.1995.13.12.2869; Bentzen SM, 1996, J NATL CANCER I, V88, P918, DOI 10.1093/jnci/88.13.918; BONADONNA G, 1995, NEW ENGL J MED, V332, P901, DOI 10.1056/NEJM199504063321401; Clarke M, 1998, LANCET, V351, P1451; CUZICK J, 1987, CANCER TREAT REP, V71, P15; CUZICK J, 1994, J CLIN ONCOL, V12, P447, DOI 10.1200/JCO.1994.12.3.447; CUZICK J, 1987, CANCER TREAT REP, V71, P7; DOMBERNOWSKY P, 1988, ACTA ONCOL, V27, P691, DOI 10.3109/02841868809091771; GELMAN R, 1990, J CLIN ONCOL, V8, P548, DOI 10.1200/JCO.1990.8.3.548; Hansen PS, 1997, ACTA ONCOL, V36, P711, DOI 10.3109/02841869709001342; Harris JR, 1996, INT J RADIAT ONCOL, V35, P641, DOI 10.1016/0360-3016(96)00215-5; HARRIS JR, 1995, DISEASES BREAST, P485; HOJRIS I, 1998, RADIOTHER ONCOL S1, V48, P475; JOHANSEN H, 1990, ACTA ONCOL, V29, P709, DOI 10.3109/02841869009092988; MOURIDSEN HT, 1988, ACTA ONCOL, V27, P699, DOI 10.3109/02841868809091772; OVERGAARD M, 1988, ACTA ONCOL, V27, P707, DOI 10.3109/02841868809091773; Overgaard M, 1997, NEW ENGL J MED, V337, P949, DOI 10.1056/NEJM199710023371401; Overgaard M, 1998, NEW ENGL J MED, V338, P331; Ragaz J, 1997, NEW ENGL J MED, V337, P956, DOI 10.1056/NEJM199710023371402; RECHT A, 1995, J CLIN ONCOL, V13, P2861, DOI 10.1200/JCO.1995.13.12.2861; Recht A, 1998, J CLIN ONCOL, V16, P2886, DOI 10.1200/JCO.1998.16.8.2886; ROSE C, 1994, EUR J CANCER, V30, pS28; RUTQVIST LE, 1993, RADIOTHER ONCOL, V26, P104, DOI 10.1016/0167-8140(93)90090-U; Rutqvist LE, 1996, J NATL CANCER I, V88, P1543; Willsher PC, 1997, BREAST, V6, P150, DOI 10.1016/S0960-9776(97)90557-9; Yarnold J, 1997, LANCET, V350, P1415, DOI 10.1016/S0140-6736(05)64204-3	29	1251	1306	1	13	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	MAY 15	1999	353	9165					1641	1648		10.1016/S0140-6736(98)09201-0	http://dx.doi.org/10.1016/S0140-6736(98)09201-0			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	198DT	10335782				2022-12-28	WOS:000080408000007
J	Koepp, DM; Harper, JW; Elledge, SJ				Koepp, DM; Harper, JW; Elledge, SJ			How the cyclin became a cyclin: Regulated proteolysis in the cell cycle	CELL			English	Review							ANAPHASE-PROMOTING COMPLEX; F-BOX; SACCHAROMYCES-CEREVISIAE; DROSOPHILA FIZZY; S-PHASE; YEAST; UBIQUITINATION; DEGRADATION; MITOSIS; FAMILY		Baylor Coll Med, Howard Hughes Med Inst, Houston, TX 77030 USA; Baylor Coll Med, Dept Biochem, Houston, TX 77030 USA; Baylor Coll Med, Dept Mol & Human Genet, Houston, TX 77030 USA	Baylor College of Medicine; Howard Hughes Medical Institute; Baylor College of Medicine; Baylor College of Medicine	Elledge, SJ (corresponding author), Baylor Coll Med, Howard Hughes Med Inst, Houston, TX 77030 USA.			Harper, Jeffrey/0000-0002-6944-7236				Bai C, 1996, CELL, V86, P263, DOI 10.1016/S0092-8674(00)80098-7; Bastians H, 1998, P NATL ACAD SCI USA, V95, P15374, DOI 10.1073/pnas.95.26.15374; Chu S, 1998, SCIENCE, V282, P699, DOI 10.1126/science.282.5389.699; ELLEDGE SJ, 1998, BIOCHIM BIOPHYS ACTA, V1377, P61; Fang GW, 1998, MOL CELL, V2, P163, DOI 10.1016/S1097-2765(00)80126-4; Feldman RMR, 1997, CELL, V91, P221, DOI 10.1016/S0092-8674(00)80404-3; Jaspersen SL, 1999, CURR BIOL, V9, P227, DOI 10.1016/S0960-9822(99)80111-0; Jaspersen SL, 1998, MOL BIOL CELL, V9, P2803, DOI 10.1091/mbc.9.10.2803; Kaiser P, 1998, GENE DEV, V12, P2587, DOI 10.1101/gad.12.16.2587; KAISER P, 1999, IN PRESS GENES DEV; Kamura T, 1999, SCIENCE, V284, P657, DOI 10.1126/science.284.5414.657; Kamura T, 1998, GENE DEV, V12, P3872, DOI 10.1101/gad.12.24.3872; Kramer ER, 1998, CURR BIOL, V8, P1207, DOI 10.1016/S0960-9822(07)00510-6; Li FN, 1997, EMBO J, V16, P5629, DOI 10.1093/emboj/16.18.5629; Marti A, 1999, NAT CELL BIOL, V1, P14, DOI 10.1038/8984; Michael WM, 1998, SCIENCE, V282, P1886, DOI 10.1126/science.282.5395.1886; Ohta T, 1999, MOL CELL, V3, P535, DOI 10.1016/S1097-2765(00)80482-7; Schwab M, 1997, CELL, V90, P683, DOI 10.1016/S0092-8674(00)80529-2; Shou WY, 1999, CELL, V97, P233, DOI 10.1016/S0092-8674(00)80733-3; SIGRIST S, 1995, EMBO J, V14, P4827, DOI 10.1002/j.1460-2075.1995.tb00164.x; Sigrist SJ, 1997, CELL, V90, P671, DOI 10.1016/S0092-8674(00)80528-0; Skowyra D, 1997, CELL, V91, P209, DOI 10.1016/S0092-8674(00)80403-1; Skowyra D, 1999, SCIENCE, V284, P662, DOI 10.1126/science.284.5414.662; Stebbins CE, 1999, SCIENCE, V284, P455, DOI 10.1126/science.284.5413.455; Tan PL, 1999, MOL CELL, V3, P527, DOI 10.1016/S1097-2765(00)80481-5; Visintin R, 1999, NATURE, V398, P818, DOI 10.1038/19775; Visintin R, 1997, SCIENCE, V278, P460, DOI 10.1126/science.278.5337.460; Yanagida M, 1998, TRENDS CELL BIOL, V8, P144, DOI 10.1016/S0962-8924(98)01236-7; Yu HT, 1998, SCIENCE, V279, P1219, DOI 10.1126/science.279.5354.1219; Zachariae W, 1998, SCIENCE, V282, P1721, DOI 10.1126/science.282.5394.1721; Zachariae W, 1998, SCIENCE, V279, P1216, DOI 10.1126/science.279.5354.1216; ZHANG H, 1995, CELL, V82, P915, DOI 10.1016/0092-8674(95)90271-6; Zhou PB, 1998, MOL CELL, V2, P571, DOI 10.1016/S1097-2765(00)80156-2	33	372	387	0	17	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	MAY 14	1999	97	4					431	434		10.1016/S0092-8674(00)80753-9	http://dx.doi.org/10.1016/S0092-8674(00)80753-9			4	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	196FV	10338207	Bronze			2022-12-28	WOS:000080299100004
J	Feliciani, C; Amerio, P				Feliciani, C; Amerio, P			Madelung's disease: Inherited from an ancient Mediterranean population?	NEW ENGLAND JOURNAL OF MEDICINE			English	Article									Univ G DAnnunzio, I-66013 Chieti, Italy; Univ Catania, I-00100 Rome, Italy	G d'Annunzio University of Chieti-Pescara; University of Catania	Feliciani, C (corresponding author), Univ G DAnnunzio, I-66013 Chieti, Italy.		Amerio, Paolo/F-4573-2010	Amerio, Paolo/0000-0003-1589-9672; feliciani, claudio/0000-0003-0883-3210					0	14	16	0	0	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	MAY 13	1999	340	19					1481	1481		10.1056/NEJM199905133401906	http://dx.doi.org/10.1056/NEJM199905133401906			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	194MT	10320387				2022-12-28	WOS:000080198700006
J	Weissman, MM; Wolk, S; Goldstein, RB; Moreau, D; Adams, P; Greenwald, S; Klier, CM; Ryan, ND; Dahl, RE; Wickramaratne, P				Weissman, MM; Wolk, S; Goldstein, RB; Moreau, D; Adams, P; Greenwald, S; Klier, CM; Ryan, ND; Dahl, RE; Wickramaratne, P			Depressed adolescents grown up	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							AFFECTIVE-DISORDERS; MAJOR DEPRESSION; PUBERTAL STATUS; CHILDHOOD; CHILDREN; SCHIZOPHRENIA; SCHEDULE; ANXIETY; RISK; AGE	Context Major depressive disorder (MDD) that arises in adolescence impairs functioning and is associated with suicide risk, but little is known about its continuity into adulthood. Objective To describe the clinical course of adolescent-onset MDD into adulthood. Design and Participants Prospective case-control study. Seventy-three subjects had onset of MDD based on systematic clinical assessment during adolescence (Tanner stage III-V) and 37 controls had no evidence of past or current psychiatric disorders, and also were assessed in adolescence (assessment years: 1977-1985). Follow-up was conducted 10 to 15 years after the initial assessment by an independent team without knowledge of initial diagnosis (follow-up years: 1992-1996). Setting Cases were identified at Columbia Presbyterian Hospital, New York City, NY; controls were recruited from the community. Main Outcome Measures Suicide and suicide attempts, psychiatric diagnoses, treatment utilization, and social functioning. Results Clinical outcomes of adolescent-onset MDD into adulthood compared with control subjects without psychiatric illness include a high rate of suicide (7.7%); a 5-fold increased risk for first suicide attempt; a 2-fold increased risk of MDD, but not other psychiatric disorders; an increased occurrence of psychiatric and medical hospitalization; and impaired functioning in work, social, and family life. Thirty-seven percent of those with adolescent MDD survived without an episode of MDD in adulthood vs 69% of the control participants (relative risk, 2.2 [95% confidence interval, 1.0-4.7; P<.05]), Conclusion There is substantial continuity, specificity, morbidity, and potential mortality from suicide into adulthood in adolescent-onset MDD patients. Now that empirically based guides to their treatment are becoming available, early identification and treatment seems warranted.	Columbia Univ Coll Phys & Surg, New York State Psychiat Inst, Div Clin & Genet Epidemiol, New York, NY 10032 USA; Columbia Univ, Dept Psychiat, New York, NY USA; Columbia Univ, Sch Publ Hlth, New York, NY USA; New York State Psychiat Inst, New York, NY USA; Virginia Commonwealth Univ, Dept Psychiat, Richmond, VA USA; Univ Vienna, Dept Psychiat, A-1010 Vienna, Austria; Univ Pittsburgh, Dept Psychiat, Pittsburgh, PA USA	Columbia University; New York State Psychiatry Institute; Columbia University; Columbia University; New York State Psychiatry Institute; Virginia Commonwealth University; University of Vienna; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	Weissman, MM (corresponding author), Columbia Univ Coll Phys & Surg, New York State Psychiat Inst, Div Clin & Genet Epidemiol, 1051 Riverside Dr,Unit 24, New York, NY 10032 USA.		Dahl, Ronald/AAW-8714-2021	Goldstein, Rise/0000-0002-9603-9473; dahl, ronald/0000-0002-1794-7132; Klier, Claudia/0000-0003-0696-8904; Weissman, Myrna/0000-0003-3490-3075	NIMH NIH HHS [MH50666] Funding Source: Medline; NATIONAL INSTITUTE OF MENTAL HEALTH [R01MH050666] Funding Source: NIH RePORTER	NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		ANDREWS JA, 1992, J AM ACAD CHILD PSY, V31, P655, DOI 10.1097/00004583-199207000-00012; ANGOLD A, 1992, DEV PSYCHOPATHOL, V4, P5, DOI 10.1017/S0954579400005538; Angold A, 1998, PSYCHOL MED, V28, P51, DOI 10.1017/S003329179700593X; ASAMOW JR, 1988, J AFFECT DISORDERS, V15, P245; Bardone AM, 1998, J AM ACAD CHILD PSY, V37, P594, DOI 10.1097/00004583-199806000-00009; BILLINGS AG, 1985, J ABNORMAL CHILD PSY, V14, P149; Brent DA, 1999, J AM ACAD CHILD PSY, V38, P263, DOI 10.1097/00004583-199903000-00012; Brent DA, 1997, ARCH GEN PSYCHIAT, V54, P877; BRENT DA, 1990, J AM ACAD CHILD PSY, V29, P586, DOI 10.1097/00004583-199007000-00012; CHAMBERS WJ, 1985, ARCH GEN PSYCHIAT, V42, P696; CHRISTIE KA, 1988, AM J PSYCHIAT, V145, P971; Clarke GN, 1999, J AM ACAD CHILD PSY, V38, P272, DOI 10.1097/00004583-199903000-00014; Cox D. R., 1984, ANAL SURVIVAL DATA; Emslie GJ, 1997, ARCH GEN PSYCHIAT, V54, P1031; ENDICOTT J, 1978, ARCH GEN PSYCHIAT, V35, P837; FENDRICH M, 1991, J AM ACAD CHILD ADOL, V30, P67; FLEMING JE, 1990, J AM ACAD CHILD PSY, V29, P571, DOI 10.1097/00004583-199007000-00010; GARBER J, 1988, J AM ACAD CHILD PSY, V27, P49, DOI 10.1097/00004583-198801000-00008; GOETZ RR, 1987, ARCH GEN PSYCHIAT, V44, P61; GOODYER IM, 1995, EPIDEMIOLOGY CHILD A, P210; Hankin BL, 1998, J ABNORM PSYCHOL, V107, P128, DOI 10.1037/0021-843X.107.1.128; Harrington R, 1998, BRIT J PSYCHIAT, V173, P291, DOI 10.1192/bjp.173.4.291; HARRINGTON R, 1990, ARCH GEN PSYCHIAT, V47, P465; Hollingshead A.B., 1975, 4 FACTOR INDEX SOCIA; HOSMER DW, 1989, APPL LOGISTIC REGRES; KAPLAN EL, 1958, J AM STAT ASSOC, V53, P457, DOI 10.2307/2281868; KESSLER RC, 1994, J AFFECT DISORDERS, V30, P15, DOI 10.1016/0165-0327(94)90147-3; KING L J, 1970, Archives of General Psychiatry, V22, P230; KOVACS M, 1993, J AM ACAD CHILD PSY, V32, P8, DOI 10.1097/00004583-199301000-00003; KOVACS M, 1984, ARCH GEN PSYCHIAT, V41, P229; Kramer RA, 1998, J AM ACAD CHILD PSY, V37, P602, DOI 10.1097/00004583-199806000-00010; Lahey BB, 1996, J AM ACAD CHILD PSY, V35, P855, DOI 10.1097/00004583-199607000-00011; LECKMAN JF, 1982, ARCH GEN PSYCHIAT, V39, P879; LEWINSOHN PM, 1994, J CONSULT CLIN PSYCH, V62, P297, DOI 10.1037/0022-006X.62.2.297; MANNUZZA S, 1986, J PSYCHIAT RES, V20, P317, DOI 10.1016/0022-3956(86)90034-8; MERIKANGAS KR, 1994, BRIT J PSYCHIAT, V164, P342, DOI 10.1192/bjp.164.3.342; MUFSON L, IN PRESS ARCH GEN PS; Olfson M, 1998, ARCH GEN PSYCHIAT, V55, P310, DOI 10.1001/archpsyc.55.4.310; ORVASCHEL H, 1995, J AM ACAD CHILD PSY, V34, P1525, DOI 10.1097/00004583-199511000-00020; Pine DS, 1998, ARCH GEN PSYCHIAT, V55, P56, DOI 10.1001/archpsyc.55.1.56; PUIGANTICH J, 1993, J AM ACAD CHILD PSY, V32, P244, DOI 10.1097/00004583-199303000-00003; RAO U, 1993, J AM ACAD CHILD PSY, V32, P21, DOI 10.1097/00004583-199301000-00004; RAO U, 1995, J AM ACAD CHILD PSY, V34, P566, DOI 10.1097/00004583-199505000-00009; ROHDE P, 1991, J ABNORM PSYCHOL, V100, P214, DOI 10.1037/0021-843X.100.2.214; RYAN ND, 1987, ARCH GEN PSYCHIAT, V44, P854; SAS Institute Inc, 1989, SAS STAT US GUID VER; SIEGEL S, 1956, NONPARAMETRIC STRATE; SPITZER RL, 1978, ARCH GEN PSYCHIAT, V35, P773, DOI 10.1001/archpsyc.1978.01770300115013; STROBER M, 1981, J AFFECT DISORDERS, V3, P281, DOI 10.1016/0165-0327(81)90029-X; Tanner JM, 1962, GROWTH ADOLESCENCE G; Weissman MM, 1997, ARCH GEN PSYCHIAT, V54, P932; WEISSMAN MM, 1976, ARCH GEN PSYCHIAT, V33, P1111; WEISSMAN MM, 1992, JAMA-J AM MED ASSOC, V268, P3098, DOI 10.1001/jama.1992.03490210080039; Weissman MM, 1996, JAMA-J AM MED ASSOC, V276, P293, DOI 10.1001/jama.276.4.293; Wickramaratne PJ, 1998, J AM ACAD CHILD PSY, V37, P933, DOI 10.1097/00004583-199809000-00013	55	629	641	1	39	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAY 12	1999	281	18					1707	1713		10.1001/jama.281.18.1707	http://dx.doi.org/10.1001/jama.281.18.1707			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	193WR	10328070	Bronze			2022-12-28	WOS:000080161200027
J	Studd, J; Pornel, B; Marton, I; Bringer, J; Varin, C; Tsouderos, Y; Christiansen, C				Studd, J; Pornel, B; Marton, I; Bringer, J; Varin, C; Tsouderos, Y; Christiansen, C		Aerodiol Study Grp	Efficacy and acceptability of intranasal 17 beta-oestradiol for menopausal symptoms: randomised dose-response study	LANCET			English	Article							ESTROGEN REPLACEMENT THERAPY; POSTMENOPAUSAL WOMEN; DOUBLE-BLIND; ESTRADIOL; PHARMACOKINETICS; TOLERABILITY; DELIVERY; 2-YEAR	Background The benefit of oestrogen therapy for menopause symptoms is well recognised. However, the means of delivery currently available have disadvantages, including variable bioavailability, intestinal and hepatic first-pass effects, and dermatological reactions. An intranasal 17 beta-oestradiol spray, S21400, which bypasses such drawbacks, has been developed. We studied the efficacy and tolerability of S21400 in the treatment of postmenopausal symptoms. Methods In this double-blind study, 420 postmenopausal women were randomly allocated to receive intranasal placebo or S21400 in doses of 100 mu g, 200 mu g, 300 mu g, or 400 mu g, or oral oestradiol valerate in doses of 1 mg or 2 mg, daily for 12 weeks. The primary outcomes were the Kupperman Index (KI) and the incidence of hot flushes. Tolerability assessments included rhinoscopy and ciliary function tests. Findings S21400 dose-dependently decreased KI (p<0.001), with a lowest effective dose of 300 mu g/day at 4 weeks (p<0.05) and 200 mu g/day at 12 weeks (p<0.01). The incidence of hot flushes decreased by a maximum of 75% (S21400 lowest effective dose 200 mu g/day at 4 weeks and 100 mu g/day at 12 weeks). S21400 increased serum oestradiol exposure dose-dependently, to concentrations similar to those achieved with oral oestradiol 1-2 mg, with lower intra-patient and inter-patient variability. There was no significant difference in ear, nose, and throat function or adverse events between the S21400 and the placebo or oral oestradiol groups, except for a greater incidence of sneezing and application site reaction (99% mild or moderate) in the S21400 groups. S21400 was thought to be effective and convenient by the patients, and compliance was high. Interpretation Intranasally administered 17 beta-oestradiol is significantly better than placebo; its effectiveness at reducing menopausal symptoms is similar to that of oral oestradiol and is also well-tolerated. Intranasal administration avoids first-pass metabolism and provides a reproducible, easily adjustable dosing mechanism that represents a new option for hormone replacement therapy.	Chelsea & Westminster Hosp, London SW10 9HN, England; Brussels Menopause Ctr, Brussels, Belgium; MAV Hosp, Budapest, Hungary; Hop Lapeyronie, Montpellier, France; IRIS, Courbevole, France; CCBR, Ballerup, Denmark	Imperial College London; Universite de Montpellier; CHU de Montpellier; Center Clinical & Basic Research; Synarc	Studd, J (corresponding author), Chelsea & Westminster Hosp, 369 Fulham Rd, London SW10 9HN, England.							AMY JJ, 1993, INT J FERTIL, V38, P5; BacchiModena A, 1997, MATURITAS, V27, P285, DOI 10.1016/S0378-5122(97)00039-X; CAULEY JA, 1995, ANN INTERN MED, V122, P9, DOI 10.7326/0003-4819-122-1-199501010-00002; CHRISTIANSEN C, 1980, EUR J CLIN INVEST, V10, P273, DOI 10.1111/j.1365-2362.1980.tb00033.x; DELIGNIERES B, 1986, J CLIN ENDOCR METAB, V62, P536, DOI 10.1210/jcem-62-3-536; FRENKEL Y, 1994, MATURITAS, V20, P31, DOI 10.1016/0378-5122(94)90098-1; GREBE SKG, 1993, ARCH DERMATOL, V129, P379, DOI 10.1001/archderm.1993.01680240125023; Grodstein F, 1997, NEW ENGL J MED, V336, P1769, DOI 10.1056/NEJM199706193362501; HERMENS WAJJ, 1991, EUR J OBSTET GYN R B, V40, P35, DOI 10.1016/0028-2243(91)90042-J; Jones NS, 1997, INT J CLIN PRACT, V51, P308; KUPPERMAN HS, 1953, J CLIN ENDOCR METAB, V13, P688, DOI 10.1210/jcem-13-6-688; LIEVERTZ RW, 1987, AM J OBSTET GYNECOL, V156, P1289, DOI 10.1016/0002-9378(87)90166-9; NOGRADI M, 1984, Drugs of the Future, V9, P577; OCONNELL MB, 1995, J CLIN PHARMACOL, V35, pS18, DOI 10.1002/j.1552-4604.1995.tb04143.x; OVERGAARD K, 1995, CLIN THER, V17, P680, DOI 10.1016/0149-2918(95)80044-1; Robinson John A., 1997, P43; SCOTT RT, 1991, OBSTET GYNECOL, V77, P758; STANCZYK FZ, 1988, AM J OBSTET GYNECOL, V159, P1540, DOI 10.1016/0002-9378(88)90591-1; STEINGOLD KA, 1985, J CLIN ENDOCR METAB, V61, P627, DOI 10.1210/jcem-61-4-627; STUDD JWW, 1995, MATURITAS, V22, P105, DOI 10.1016/0378-5122(95)00910-D; Thacker HL, 1997, PRIMARY CARE, V24, P205; WIKLUND I, 1993, AM J OBSTET GYNECOL, V168, P824, DOI 10.1016/S0002-9378(12)90828-5	22	81	82	0	5	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	MAY 8	1999	353	9164					1574	1578		10.1016/S0140-6736(98)06196-0	http://dx.doi.org/10.1016/S0140-6736(98)06196-0			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	195XW	10334256				2022-12-28	WOS:000080278300013
J	Wilkes, M; Bligh, J				Wilkes, M; Bligh, J			Evaluating educational interventions	BRITISH MEDICAL JOURNAL			English	Article							MEDICAL CURRICULUM; PRIMARY-CARE; STUDENTS; COMPETENCE; ATTITUDES; SCHOOLS		Univ Calif Los Angeles, Sch Med, Off Dean, Los Angeles, CA 90095 USA; Univ Liverpool, Sch Med, Dept Hlth Care Educ, Liverpool L69 3GA, Merseyside, England	University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of Liverpool	Wilkes, M (corresponding author), Univ Calif Los Angeles, Sch Med, Off Dean, Los Angeles, CA 90095 USA.							Abrahams MB, 1996, ACAD MED, V71, P371, DOI 10.1097/00001888-199604000-00015; ALSHEHRI A, 1993, ED GEN PRACT, V5, P135; BARNSLEY L, 1994, TEACH LEARN MED, V6, P179; Brookfield S., 1986, UNDERSTANDING FACILI; BROOMFIELD D, 1998, MED EDUC, P32; Clack GB, 1997, MED TEACH, V19, P32, DOI 10.3109/01421599709019344; DesMarchais JE, 1996, ACAD MED, V71, P274, DOI 10.1097/00001888-199603000-00021; Distlehorst LH, 1998, TEACH LEARN MED, V10, P131, DOI 10.1207/S15328015TLM1003_2; Dolmans DHJM, 1996, ACAD MED, V71, P1008, DOI 10.1097/00001888-199609000-00017; Donald J.G., 1996, ASSESS EVAL HIGH EDU, V21, P23; EDWARDS J, 1991, EV AD FURTH ED; ELNICKI MD, 1998, TEACH LEARN MED, V10, P223; FRIEDMAN CP, 1990, ACAD MED, V65, P8, DOI 10.1097/00001888-199001000-00002; Gask L, 1998, MED EDUC, V32, P190, DOI 10.1046/j.1365-2923.1998.00195.x; General Medical Council, 1993, TOM DOCT; HOJAT M, 1995, ACAD MED, V70, pS17, DOI 10.1097/00001888-199501000-00020; JONES GL, 1999, MED EDUC, V33, P8; Kaufman DM, 1996, ACAD MED, V71, P1096, DOI 10.1097/00001888-199610000-00018; Mennin SP, 1996, ACAD MED, V71, P1079, DOI 10.1097/00001888-199610000-00015; MENNIN SP, 1998, ACAD MED S, V9, P73; Morrison J, 1999, MED EDUC, V33, P163, DOI 10.1046/j.1365-2923.1999.0389b.x; Pabst R, 1996, MED TEACH, V18, P288, DOI 10.3109/01421599609034179; POPHAM WJ, 1993, ED EV; POWELL AM, 1997, ASSESS EVAL HIGH EDU, V22, P397; Remmen R, 1998, MED TEACH, V20, P428; ROLFE I, 1997, IMPERATIVES MED ED N; Rolfe IE, 1996, TEACH LEARN MED, V8, P77, DOI 10.1080/10401339609539771; ROLFE IE, 1995, MED EDUC, V29, P225, DOI 10.1111/j.1365-2923.1995.tb02835.x; Schmidt HG, 1996, ACAD MED, V71, P658, DOI 10.1097/00001888-199606000-00021; Slavin SJ, 1995, ACAD MED, V70, P1091; Tamblyn R, 1998, JAMA-J AM MED ASSOC, V280, P989, DOI 10.1001/jama.280.11.989; Treloar CJ, 1998, MED EDUC, V32, P70, DOI 10.1046/j.1365-2923.1998.00168.x	32	112	113	0	19	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	MAY 8	1999	318	7193					1269	1272						4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	195XT	10231263				2022-12-28	WOS:000080278000032
J	Meyer, JE; Smith, DN; Lester, SC; Kaelin, C; DiPiro, PJ; Denison, CM; Christian, RL; Harvey, SC; Selland, DLG; Durfee, SM				Meyer, JE; Smith, DN; Lester, SC; Kaelin, C; DiPiro, PJ; Denison, CM; Christian, RL; Harvey, SC; Selland, DLG; Durfee, SM			Large-core needle biopsy of nonpalpable breast lesions	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							ATYPICAL DUCTAL HYPERPLASIA; VACUUM-ASSISTED BIOPSY; MAMMOGRAPHIC FINDINGS; SURGICAL BIOPSY; 14-GAUGE; ABNORMALITIES; PLACEMENT; ACCURACY; IMPACT; CLIP	Context An increasing number of nonpalpable abnormalities requiring breast biopsy are being identified due to the widespread use of screening mammography, Large-cole needle biopsy (LCNB) has become an alternative to surgical excision, Objective To determine whether LCNB is a safe and accurate technique to evaluate nonpalpable abnormalities found on breast imaging studies. Design and Setting Case series at an institutional referral center from August 1, 1991, to December 31, 1997. Patients A total of 1643 women with 1 or more suspicious breast abnormalities received LCNBs (n = 1836 lesions). Intervention The LCNB of the breast uses a 14- or 11-gauge needle with stereotactic localization or ultrasound guidance, Main Outcome Measure Utility and potential limitations of LCNB compared with the criterion standard, surgical excision after wire localization. Results Of the 1836 breast lesions sampled, 444 (24%) were found to be malignant. a total of 412 (22%) were found to be malignant on the initial LCNB and 202 repeat biopsies yielded 32 additional malignancies, Complications were infrequent: 1 patient experienced a superficial infection and 1 developed a pneumothorax after LCNB. Conclusion Image-guided LCNB is a reliable diagnostic alternative to surgical excision of suspicious nonpalpable breast abnormalities.	Brigham & Womens Hosp, Dept Radiol, Boston, MA 02115 USA; Brigham & Womens Hosp, Dept Surg, Boston, MA 02115 USA; Brigham & Womens Hosp, Dept Pathol, Boston, MA 02115 USA	Harvard University; Brigham & Women's Hospital; Harvard University; Brigham & Women's Hospital; Harvard University; Brigham & Women's Hospital	Meyer, JE (corresponding author), Brigham & Womens Hosp, Dept Radiol, 75 Francis St, Boston, MA 02115 USA.							Burbank F, 1997, RADIOLOGY, V204, P153, DOI 10.1148/radiology.204.1.9205238; Burbank F, 1996, AM SURGEON, V62, P738; Burbank F, 1997, RADIOLOGY, V202, P843, DOI 10.1148/radiology.202.3.9051043; Burbank F, 1997, RADIOLOGY, V205, P407, DOI 10.1148/radiology.205.2.9356621; ELVECROG EL, 1993, RADIOLOGY, V188, P453, DOI 10.1148/radiology.188.2.8327696; Jackman RJ, 1997, RADIOLOGY, V204, P485, DOI 10.1148/radiology.204.2.9240540; Jackman RJ, 1997, RADIOLOGY, V204, P677, DOI 10.1148/radiology.204.3.9280243; JACKMAN RJ, 1994, RADIOLOGY, V193, P91, DOI 10.1148/radiology.193.1.8090927; KOPANS DB, 1992, AM J ROENTGENOL, V158, P521, DOI 10.2214/ajr.158.3.1310825; Lee CH, 1997, RADIOLOGY, V202, P849, DOI 10.1148/radiology.202.3.9051045; LIBERMAN L, 1995, RADIOLOGY, V195, P633, DOI 10.1148/radiology.195.3.7753986; LIBERMAN L, 1995, AM J ROENTGENOL, V164, P1111, DOI 10.2214/ajr.164.5.7717215; Liberman L, 1997, RADIOLOGY, V203, P343, DOI 10.1148/radiology.203.2.9114086; Liberman L, 1998, RADIOLOGY, V208, P251, DOI 10.1148/radiology.208.1.9646821; Liberman L, 1997, RADIOLOGY, V205, P417, DOI 10.1148/radiology.205.2.9356622; MEYER JE, 1993, RADIOLOGY, V188, P581, DOI 10.1148/radiology.188.2.8327720; Meyer JE, 1997, RADIOLOGY, V204, P575, DOI 10.1148/radiology.204.2.9240556; Meyer JE, 1996, AM J ROENTGENOL, V167, P179, DOI 10.2214/ajr.167.1.8659367; Meyer JE, 1998, RADIOLOGY, V206, P717, DOI 10.1148/radiology.206.3.9494490; MEYER JE, 1990, JAMA-J AM MED ASSOC, V263, P2341, DOI 10.1001/jama.263.17.2341; PARKER SH, 1991, RADIOLOGY, V180, P403, DOI 10.1148/radiology.180.2.1648757; SICKLES EA, 1991, RADIOLOGY, V179, P463, DOI 10.1148/radiology.179.2.2014293; Smith DN, 1997, ARCH SURG-CHICAGO, V132, P256	23	187	192	0	2	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAY 5	1999	281	17					1638	1641		10.1001/jama.281.17.1638	http://dx.doi.org/10.1001/jama.281.17.1638			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	191MJ	10235159				2022-12-28	WOS:000080025900030
J	Gonzales, R; Steiner, JF; Lum, A; Barrett, PH				Gonzales, R; Steiner, JF; Lum, A; Barrett, PH			Decreasing antibiotic use in ambulatory practice - Impact of a multidimensional intervention on the treatment of uncomplicated acute bronchitis in adults	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							RESISTANT STREPTOCOCCUS-PNEUMONIAE; RANDOMIZED CONTROLLED TRIAL; UNITED-STATES; EDUCATIONAL INTERVENTION; DRUG-RESISTANCE; PHYSICIANS; CARE; HEALTH; INFECTIONS; EMERGENCE	Context The emergence and spread of antibiotic-resistant Streptococcus pneumoniae in US communities is due, in part, to the excessive use of antibiotics for acute respiratory tract infections. Objective To decrease total antibiotic use for uncomplicated acute bronchitis in adults. Design Prospective, nonrandomized controlled trial, including baseline (November 1996-February 1997) and study (November 1997-February 1998) periods. Setting Four selected primary care practices belonging to a group-model health maintenance organization in the Denver, Cole, metropolitan area, Participants Consecutive adults diagnosed as having uncomplicated acute bronchitis. A total of 2462 adults were included at baseline and 2027 adults were included in the study. Clinicians included 56 physicians, 28 physician assistants or nurse practitioners, and 9 registered nurses. Intervention The full intervention site received household and office-based patient educational materials, as well as a clinician intervention consisting of education, practice-profiling, and academic detailing, A limited intervention site received only office-based educational materials, and control sites provided usual care. Main Outcome Measure Antibiotic prescriptions for uncomplicated acute bronchitis during baseline and study periods. Results Antibiotic prescription rates for uncomplicated acute bronchitis were similar at all 4 sites during the baseline period. During the study period, there was a substantial decline in antibiotic prescription rates at the full intervention site (from 74% to 48% [P=.003]), but not at the control and limited intervention sites (78% to 76% [P=.81] and 82% to 77% [P=.68], respectively). Compared with control sites, changes in nonantibiotic prescriptions (inhaled bronchodilators, cough suppressants, and analgesics) were not significantly different for intervention sites. Return office visits (within 30 days of the incident visit) for bronchitis or pneumonia did not change significantly for any of the sites. Conclusions Antibiotic treatment of adults diagnosed as having uncomplicated acute bronchitis can be safely reduced using a combination of patient and clinician interventions.	Univ Colorado, Hlth Sci Ctr, Div Gen Internal Med, Dept Med, Denver, CO 80262 USA; Kaiser Permanente, Denver, CO USA	University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; Kaiser Permanente	Gonzales, R (corresponding author), Univ Colorado, Hlth Sci Ctr, Div Gen Internal Med, Dept Med, Box B-180,4200 E 9th Ave, Denver, CO 80262 USA.							*AM SOC HLTH SYST, 1997, AM HOSP FORM SERV DR; Arason VA, 1996, BMJ-BRIT MED J, V313, P387; AVORN J, 1983, NEW ENGL J MED, V308, P1457, DOI 10.1056/NEJM198306163082406; Bexell A, 1996, J CLIN EPIDEMIOL, V49, P355, DOI 10.1016/0895-4356(95)00059-3; BOLDY DAR, 1990, RESP MED, V84, P377, DOI 10.1016/S0954-6111(08)80072-8; BREIMAN RF, 1994, JAMA-J AM MED ASSOC, V271, P1831, DOI 10.1001/jama.271.23.1831; BROWNER WS, 1994, WESTERN J MED, V161, P572; Butler JC, 1996, J INFECT DIS, V174, P986, DOI 10.1093/infdis/174.5.986; Campbell D. T., 1963, EXPT QUASIEXPERIMENT, P171; COHEN ML, 1992, SCIENCE, V257, P1050, DOI 10.1126/science.257.5073.1050; DESANTIS G, 1994, MED J AUSTRALIA, V160, P502; DIVINE GW, 1992, J GEN INTERN MED, V7, P623, DOI 10.1007/BF02599201; Dowell SF, 1997, AM FAM PHYSICIAN, V55, P1647; EISENBERG JM, 1981, JAMA-J AM MED ASSOC, V246, P2195, DOI 10.1001/jama.246.19.2195; EVANS AS, 1967, MED CLIN N AM, V51, P803, DOI 10.1016/S0025-7125(16)33048-6; FOXMAN B, 1987, J CHRON DIS, V40, P429, DOI 10.1016/0021-9681(87)90176-7; Gold HS, 1996, NEW ENGL J MED, V335, P1445, DOI 10.1056/NEJM199611073351907; Gonzales R, 1998, J GEN INTERN MED, V13, P541, DOI 10.1046/j.1525-1497.1998.00165.x; Gonzales R, 1997, JAMA-J AM MED ASSOC, V278, P901, DOI 10.1001/jama.278.11.901; Gonzales R., 1998, JGIM, V13, P29; Hamm RM, 1996, J FAM PRACTICE, V43, P56; HOFMANN J, 1995, NEW ENGL J MED, V333, P481, DOI 10.1056/NEJM199508243330803; HOSMER DW, 1989, APPL LOGISTIC REGRES; Hueston WJ, 1997, J FAM PRACTICE, V44, P261; HUESTON WJ, 1991, J FAM PRACTICE, V33, P476; HUESTON WJ, 1994, J FAM PRACTICE, V39, P437; HUTCHINSON JM, 1997, 37 INT C ANT AG CHEM; IVES TJ, 1987, ARCH INTERN MED, V147, P44, DOI 10.1001/archinte.147.1.44; Jernigan DB, 1996, JAMA-J AM MED ASSOC, V275, P206, DOI 10.1001/jama.275.3.206; KOSECOFF J, 1987, JAMA-J AM MED ASSOC, V258, P2708, DOI 10.1001/jama.258.19.2708; KUNIN CM, 1993, ANN INTERN MED, V118, P557, DOI 10.7326/0003-4819-118-7-199304010-00011; Lederberg J, 1996, JAMA-J AM MED ASSOC, V276, P417, DOI 10.1001/jama.276.5.417; LOHR KN, 1979, MED CARE, V18, P1; LOMAS J, 1991, ANNU REV PUBL HEALTH, V12, P41, DOI 10.1146/annurev.pu.12.050191.000353; LOMAS J, 1989, NEW ENGL J MED, V321, P1306, DOI 10.1056/NEJM198911093211906; Mainous AG, 1997, LANCET, V350, P1077, DOI 10.1016/S0140-6736(05)70457-8; MCCAIG LF, 1995, JAMA-J AM MED ASSOC, V273, P214, DOI 10.1001/jama.273.3.214; MCKAY DN, 1996, J GEN INTERN MED, V11, P557; Melbye Hasse, 1994, Tidsskrift for den Norske Laegeforening, V114, P814; MULBYE H, 1991, FAM PRACT, V8, P216; MUSHER DM, 1995, PRINCIPLES PRACTICE, P1811; NEU HC, 1992, SCIENCE, V257, P1064, DOI 10.1126/science.257.5073.1064; POOLE PM, 1973, POSTGRAD MED J, V49, P778, DOI 10.1136/pgmj.49.577.778; POSES RM, 1995, MED DECIS MAKING, V15, P65, DOI 10.1177/0272989X9501500110; RAZ R, 1995, ISRAEL J MED SCI, V31, P432; Santoso B, 1996, SOC SCI MED, V42, P1163, DOI 10.1016/0277-9536(95)00390-8; SCHAFFNER W, 1983, JAMA-J AM MED ASSOC, V250, P1728, DOI 10.1001/jama.250.13.1728; SCHAPPERT SM, 1997, VITAL HLTH STAT 13, V129, P1; SCHECTMAN JM, 1995, MED CARE, V33, P139; Schwartz B, 1997, JAMA-J AM MED ASSOC, V278, P944, DOI 10.1001/jama.278.11.944; Seppala H, 1997, NEW ENGL J MED, V337, P441, DOI 10.1056/NEJM199708143370701; SOUMERAI SB, 1990, JAMA-J AM MED ASSOC, V263, P549, DOI 10.1001/jama.263.4.549; Stephenson J, 1996, JAMA-J AM MED ASSOC, V275, P175, DOI 10.1001/jama.275.3.175; 1996, AM MED NEWS, V39, P34	54	289	296	0	8	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	APR 28	1999	281	16					1512	1519		10.1001/jama.281.16.1512	http://dx.doi.org/10.1001/jama.281.16.1512			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	188PP	10227321	Bronze			2022-12-28	WOS:000079857400033
J	May, MJ; Ghosh, S				May, MJ; Ghosh, S			Signal transduction - I kappa B kinases: Kinsmen with different crafts	SCIENCE			English	Editorial Material							COMPLEX; TWIST; LIMB		Yale Univ, Sch Med, Howard Hughes Med Inst, Immunobiol Sect, New Haven, CT 06520 USA; Yale Univ, Sch Med, Howard Hughes Med Inst, Dept Mol Biophys & Biochem, New Haven, CT 06520 USA	Howard Hughes Medical Institute; Yale University; Howard Hughes Medical Institute; Yale University	May, MJ (corresponding author), Yale Univ, Sch Med, Howard Hughes Med Inst, Immunobiol Sect, 333 Cedar St, New Haven, CT 06520 USA.			May, Michael/0000-0002-2485-3716				Bushdid PB, 1998, NATURE, V392, P615, DOI 10.1038/33435; Cohen L, 1998, NATURE, V395, P292, DOI 10.1038/26254; Delhase M, 1999, SCIENCE, V284, P309, DOI 10.1126/science.284.5412.309; Ghosh S, 1998, ANNU REV IMMUNOL, V16, P225, DOI 10.1146/annurev.immunol.16.1.225; GHOUZZI VE, 1997, NAT GENET, V15, P42; Howard TD, 1997, NAT GENET, V15, P36, DOI 10.1038/ng0197-36; Hu YL, 1999, SCIENCE, V284, P316, DOI 10.1126/science.284.5412.316; JIANG J, 1991, GENE DEV, V5, P1881, DOI 10.1101/gad.5.10.1881; Kanegae Y, 1998, NATURE, V392, P611, DOI 10.1038/33429; Li QT, 1999, SCIENCE, V284, P321, DOI 10.1126/science.284.5412.321; Maniatis T, 1999, GENE DEV, V13, P505, DOI 10.1101/gad.13.5.505; May MJ, 1998, IMMUNOL TODAY, V19, P80, DOI 10.1016/S0167-5699(97)01197-3; Mercurio F, 1999, MOL CELL BIOL, V19, P1526; Regnier CH, 1997, CELL, V90, P373, DOI 10.1016/S0092-8674(00)80344-X; Rothwarf DM, 1998, NATURE, V395, P297, DOI 10.1038/26261; Seitz CS, 1998, P NATL ACAD SCI USA, V95, P2307, DOI 10.1073/pnas.95.5.2307; Takeda K, 1999, SCIENCE, V284, P313, DOI 10.1126/science.284.5412.313; Yamaoka S, 1998, CELL, V93, P1231, DOI 10.1016/S0092-8674(00)81466-X; Yin MJ, 1998, NATURE, V396, P77, DOI 10.1038/23948	19	117	129	0	1	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	APR 9	1999	284	5412					271	+		10.1126/science.284.5412.271	http://dx.doi.org/10.1126/science.284.5412.271			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	184WH	10232975				2022-12-28	WOS:000079636400028
J	Hollingsworth, SJ; Barker, SGE				Hollingsworth, SJ; Barker, SGE			Gene therapy: into the future of surgery	LANCET			English	Article									UCL Royal Free & UCL Med Sch, Middlesex Hosp, Dept Surg, Acad Vasc Unit, London W1N 8AA, England	University of London; University College London	Hollingsworth, SJ (corresponding author), UCL Royal Free & UCL Med Sch, Middlesex Hosp, Dept Surg, Acad Vasc Unit, London W1N 8AA, England.							BLAESE RM, 1995, SCIENCE, V270, P475, DOI 10.1126/science.270.5235.475; BLAUMGARTNER I, 1998, CIRCULATION, V97, P1114; Habib NA, 1996, CANCER DETECT PREV, V20, P103; HABIB NA, 1995, TUMOR TARGET, V1, P295; ISNER JM, 1995, CIRCULATION, V91, P2687, DOI 10.1161/01.CIR.91.11.2687; MARSHALL E, 1995, SCIENCE, V269, P1050, DOI 10.1126/science.7652552; Roth JA, 1997, J NATL CANCER I, V89, P21, DOI 10.1093/jnci/89.1.21; Shears LL, 1998, J AM COLL SURGEONS, V187, P295, DOI 10.1016/S1072-7515(98)00163-X; YlaHerttuala S, 1996, ANN MED, V28, P89, DOI 10.3109/07853899609092931	9	2	2	0	0	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736			LANCET	Lancet	APR	1999	353			1			SL19	SL20						2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	192NH	10319927				2022-12-28	WOS:000080084900008
J	Nicoll, A; Catchpole, M; Cliffe, S; Hughes, G; Simms, I; Thomas, D				Nicoll, A; Catchpole, M; Cliffe, S; Hughes, G; Simms, I; Thomas, D			Sexual health of teenagers in England and Wales: analysis of national data	BRITISH MEDICAL JOURNAL			English	Article									Publ Hlth Lab Serv, Ctr Communicable Dis Surveillance, HIV & Sexually Transmitted Dis Div, London NW9 5EQ, England; Ctr Communicable Dis Surveillance, Lab Serv, Welsh Unit, Cardiff CF4 3QX, S Glam, Wales	Public Health England	Nicoll, A (corresponding author), Publ Hlth Lab Serv, Ctr Communicable Dis Surveillance, HIV & Sexually Transmitted Dis Div, London NW9 5EQ, England.		Simms, Ian/P-1454-2019; Simms, Ian/AAA-8740-2019	Simms, Ian/0000-0003-4519-5684; Hughes, Gwenda/0000-0003-2090-7702				COWAN FM, 1993, GENITOURIN MED, V69, P141; DICKSON R, 1997, EFFECTIVE HLTH CARE, V3, P1; HUGHES G, 1997, NEW CASES GENITOURIN; Simms I., 1998, CDR Weekly, V8, pS1; 1998, MMWR, V47, P749	5	52	53	0	2	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	MAY 15	1999	318	7194					1321	1322		10.1136/bmj.318.7194.1321	http://dx.doi.org/10.1136/bmj.318.7194.1321			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	198HR	10323816	Bronze, Green Published, Green Submitted			2022-12-28	WOS:000080418400025
J	Glasser, SP				Glasser, SP			Prospects for therapy of nitrate tolerance	LANCET			English	Editorial Material							CONVERTING ENZYME-INHIBITORS; DOUBLE-BLIND; PREVENTION; CARVEDILOL		Univ S Florida, Dept Clin Pharmacol, Tampa, FL 33163 USA; Univ Minnesota, Div Epidemiol, Minneapolis, MN 55455 USA	State University System of Florida; University of South Florida; University of Minnesota System; University of Minnesota Twin Cities	Glasser, SP (corresponding author), Univ S Florida, Dept Clin Pharmacol, Tampa, FL 33163 USA.		Glasser, Stephen P/S-5996-2019	Glasser, Stephen P/0000-0001-9620-6406				Abrams J, 1998, AM J CARDIOL, V81, p3A, DOI 10.1016/S0002-9149(97)00992-2; Boesgaard S, 1998, AM J CARDIOL, V81, p21A, DOI 10.1016/S0002-9149(97)00994-6; KATZ RJ, 1991, CIRCULATION, V83, P1271, DOI 10.1161/01.CIR.83.4.1271; MANGIONE NJ, 1994, AM HEART J, V128, P137, DOI 10.1016/0002-8703(94)90020-5; MUIESAN ML, 1993, EUR HEART J, V14, P1701, DOI 10.1093/eurheartj/14.12.1701; Munzel T, 1998, AM J CARDIOL, V81, p30A, DOI 10.1016/S0002-9149(97)00995-8; Watanabe H, 1998, J AM COLL CARDIOL, V32, P1201, DOI 10.1016/S0735-1097(98)00398-2; Watanabe H, 1998, J AM COLL CARDIOL, V32, P1194, DOI 10.1016/S0735-1097(98)00392-1	8	21	21	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	MAY 8	1999	353	9164					1545	1546		10.1016/S0140-6736(98)00373-0	http://dx.doi.org/10.1016/S0140-6736(98)00373-0			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	195XW	10334251				2022-12-28	WOS:000080278300007
J	Huang, F; Buschman, LL; Higgins, RA; McGaughey, WH				Huang, F; Buschman, LL; Higgins, RA; McGaughey, WH			Inheritance of resistance to Bacillus thuringiensis toxin (Dipel ES) in the European corn borer	SCIENCE			English	Article							DIAMONDBACK MOTH LEPIDOPTERA; HELIOTHIS-VIRESCENS; PLUTELLA-XYLOSTELLA; INSECT RESISTANCE; DELTA-ENDOTOXIN; NOCTUIDAE; SELECTION; STABILITY; KURSTAKI	Resistance in the European com borer, Ostrinia nubilalis (Hubner), to a commercial formulation of Bacillus thuringiensis (Bt)Berliner toxin, Dipel ES, appears to be inherited as an incompletely dominant autosomal gene. This contrasts with the inheritance of resistance to St in other insects, where it has usually been characterized as a recessive trait. The proposed high-dose/refuge strategy for resistance management in St maize depends on resistance being recessive or partially recessive, if field resistance turns out to be similar to this Laboratory resistance, the usefulness of the high-dose/refuge strategy for resistance management in Bt maize may be diminished.	Kansas State Univ, Dept Entomol, Manhattan, KS 66506 USA; ARS, USDA, Grain Mkt & Prod Res Ctr, Manhattan, KS 66502 USA	Kansas State University; United States Department of Agriculture (USDA)	Higgins, RA (corresponding author), Kansas State Univ, Dept Entomol, Manhattan, KS 66506 USA.							ANDOW DA, 1998, NOW NEVER SERIOUS NE, P19; BEERNAN RW, 1988, J ECON ENTOMOL, V81, P28; Chaufaux J, 1997, J ECON ENTOMOL, V90, P873, DOI 10.1093/jee/90.4.873; GEORGHIOU GP, 1969, EXP PARASITOL, V26, P224, DOI 10.1016/0014-4894(69)90116-7; GOULD F, 1995, J ECON ENTOMOL, V88, P1545, DOI 10.1093/jee/88.6.1545; GOULD F, 1992, P NATL ACAD SCI USA, V89, P7986, DOI 10.1073/pnas.89.17.7986; HAMA H, 1992, APPL ENTOMOL ZOOL, V27, P355, DOI 10.1303/aez.27.355; Huang F.-T., UNPUB; Huang FN, 1997, J ECON ENTOMOL, V90, P1137, DOI 10.1093/jee/90.5.1137; LANDE R, 1981, GENETICS, V99, P541; MARTINEZRAMIREZ AC, 1995, PESTIC SCI, V43, P115, DOI 10.1002/ps.2780430204; MCGAUGHEY WH, 1985, SCIENCE, V229, P193, DOI 10.1126/science.229.4709.193; MCGAUGHEY WH, 1992, SCIENCE, V258, P1451, DOI 10.1126/science.258.5087.1451; Ostlie K. R., 1997, NCR PUBLICATION, V602; RAHARDJA U, 1995, J ECON ENTOMOL, V88, P21, DOI 10.1093/jee/88.1.21; Roush RT., 1990, PESTICIDE RESISTANCE, P97, DOI DOI 10.1007/978-1-4684-6429-0_5; SIMS SR, 1991, J INVERTEBR PATHOL, V57, P206, DOI 10.1016/0022-2011(91)90118-A; STONE BF, 1968, B WORLD HEALTH ORGAN, V38, P325; TABASHNIK BE, 1991, J ECON ENTOMOL, V84, P703, DOI 10.1093/jee/84.3.703; TABASHNIK BE, 1994, ANNU REV ENTOMOL, V39, P47, DOI 10.1146/annurev.en.39.010194.000403; TABASHNIK BE, 1992, J ECON ENTOMOL, V85, P1046, DOI 10.1093/jee/85.4.1046; Tang JD, 1997, J ECON ENTOMOL, V90, P732, DOI 10.1093/jee/90.3.732	22	146	174	0	20	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	MAY 7	1999	284	5416					965	967		10.1126/science.284.5416.965	http://dx.doi.org/10.1126/science.284.5416.965			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	194MU	10320377				2022-12-28	WOS:000080198800046
J	Ren, JH; Kachel, K; Kim, H; Malenbaum, SE; Collier, RJ; London, E				Ren, JH; Kachel, K; Kim, H; Malenbaum, SE; Collier, RJ; London, E			Interaction of diphtheria toxin T domain with molten globule-like proteins and its implications for translocation	SCIENCE			English	Article							PARTIALLY FOLDED STATE; MEMBRANE TRANSLOCATION; SERUM-ALBUMIN; A-FRAGMENT; CONFORMATIONS; APOMYOGLOBIN; INTERMEDIATE; BILAYERS; MUTANTS; PH	The transmembrane (T) domain of diphtheria toxin has a critical role in the Low pH-induced translocation of the catalytic domain (A chain) of the toxin across membranes. Here it is shown that at Low pH, addition of proteins in a partly unfolded, molten globule-like conformation converted the T domain from a shallow membrane-inserted form to its transmembrane form. Fluorescence energy transfer demonstrated that molten globule-like proteins bound to the T domain. Thus, the T domain recognizes proteins that are partly unfolded and may function in translocation of the A chain as a transmembrane chaperone.	SUNY Stony Brook, Dept Biochem & Cell Biol, Stony Brook, NY 11794 USA; SUNY Stony Brook, Dept Chem, Stony Brook, NY 11794 USA; Harvard Univ, Sch Med, Dept Microbiol & Mol Genet, Boston, MA 02115 USA	State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook; State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook; Harvard University; Harvard Medical School	London, E (corresponding author), SUNY Stony Brook, Dept Biochem & Cell Biol, Stony Brook, NY 11794 USA.		Ibrahim, Essam Hassan/G-1960-2018	Ibrahim, Essam Hassan/0000-0003-0130-2257; Collier, R John/0000-0002-2427-4239	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI022021, R37AI022021] Funding Source: NIH RePORTER; NIAID NIH HHS [AI 22021] Funding Source: Medline; NIGMS NIH HHS [GM 39186] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AHMAD F, 1979, BIOCHIM BIOPHYS ACTA, V576, P333, DOI 10.1016/0005-2795(79)90408-2; BANUELOS S, 1995, J BIOL CHEM, V270, P29910, DOI 10.1074/jbc.270.50.29910; CHOE S, 1992, NATURE, V357, P216, DOI 10.1038/357216a0; EWBANK JJ, 1991, NATURE, V350, P518, DOI 10.1038/350518a0; FALNES PO, 1995, J BIOL CHEM, V270, P20787, DOI 10.1074/jbc.270.35.20787; FALNES PO, 1994, J BIOL CHEM, V269, P8402; HAEZEBROUCK P, 1995, J MOL BIOL, V246, P382, DOI 10.1006/jmbi.1994.0093; HUGHSON FM, 1991, BIOCHEMISTRY-US, V30, P4113, DOI 10.1021/bi00231a001; KACHEL K, 1998, NATURE, V273, P22950; LEE JW, 1992, ARCH BIOCHEM BIOPHYS, V297, P354, DOI 10.1016/0003-9861(92)90684-O; LEE JY, 1992, J BIOL CHEM, V267, P14753; Liu LP, 1996, BIOPOLYMERS, V39, P465, DOI 10.1002/(SICI)1097-0282(199609)39:3<465::AID-BIP17>3.0.CO;2-A; LONDON E, 1992, BIOCHIM BIOPHYS ACTA, V1113, P25, DOI 10.1016/0304-4157(92)90033-7; Oh KJ, 1996, SCIENCE, V273, P810, DOI 10.1126/science.273.5276.810; PAPINI E, 1987, EUR J BIOCHEM, V169, P637, DOI 10.1111/j.1432-1033.1987.tb13655.x; Reed JC, 1997, NATURE, V387, P773, DOI 10.1038/42867; Ren JH, 1999, BIOCHEMISTRY-US, V38, P976, DOI 10.1021/bi981576s; Ren JH, 1997, BIOCHEMISTRY-US, V36, P10213, DOI 10.1021/bi9709295; SADLER PJ, 1993, EUR J BIOCHEM, V212, P811, DOI 10.1111/j.1432-1033.1993.tb17722.x; Wang Y, 1997, J BIOL CHEM, V272, P25091, DOI 10.1074/jbc.272.40.25091; WEIDLOCHA A, 1992, EMBO J, V11, P4835; ZHAO JM, 1988, J BIOL CHEM, V263, P15369	22	105	107	0	6	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	MAY 7	1999	284	5416					955	957		10.1126/science.284.5416.955	http://dx.doi.org/10.1126/science.284.5416.955			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	194MU	10320374				2022-12-28	WOS:000080198800043
J	Weatherbee, SD; Carroll, SB				Weatherbee, SD; Carroll, SB			Selector genes and limb identity in arthropods and vertebrates	CELL			English	Review							T-BOX GENES; SPECIFICATION; FAMILY; TBX5		Univ Wisconsin, Howard Hughes Med Inst, Madison, WI 53706 USA; Univ Wisconsin, Mol Biol Lab, Madison, WI 53706 USA	Howard Hughes Medical Institute; University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison	Carroll, SB (corresponding author), Univ Wisconsin, Howard Hughes Med Inst, Madison, WI 53706 USA.	sbcarrol@facstaff.wisc.edu		Weatherbee, Scott/0000-0002-0915-1329				CARROLL SB, 1995, NATURE, V376, P479, DOI 10.1038/376479a0; Gibson-Brown JJ, 1998, DEVELOPMENT, V125, P2499; Johnson RL, 1997, CELL, V90, P979, DOI 10.1016/S0092-8674(00)80364-5; Lanctot C, 1999, DEVELOPMENT, V126, P1805; Lanctot C, 1997, DEVELOPMENT, V124, P2807; Li QY, 1997, NAT GENET, V15, P21; Logan M, 1999, SCIENCE, V283, P1736, DOI 10.1126/science.283.5408.1736; Logan M, 1998, DEVELOPMENT, V125, P2825; Ohuchi H, 1998, DEVELOPMENT, V125, P51; RODRIGUEZESTEBA.C, 1999, IN PRESS NATURE; Simon HG, 1997, DEVELOPMENT, V124, P1355; STRUHL G, 1982, P NATL ACAD SCI-BIOL, V79, P7380, DOI 10.1073/pnas.79.23.7380; Szeto DP, 1999, GENE DEV, V13, P484, DOI 10.1101/gad.13.4.484; TAKEUCHI JK, 1999, IN PRESS NATURE; Weatherbee SD, 1998, GENE DEV, V12, P1474, DOI 10.1101/gad.12.10.1474; Weatherbee SD, 1999, CURR BIOL, V9, P109, DOI 10.1016/S0960-9822(99)80064-5	16	44	44	1	8	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	APR 30	1999	97	3					283	286		10.1016/S0092-8674(00)80737-0	http://dx.doi.org/10.1016/S0092-8674(00)80737-0			4	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	192VP	10319808	Bronze			2022-12-28	WOS:000080100500001
J	Mills, AA; Zheng, BH; Wang, XJ; Vogel, H; Roop, DR; Bradley, A				Mills, AA; Zheng, BH; Wang, XJ; Vogel, H; Roop, DR; Bradley, A			p63 is a p53 homologue required for limb and epidermal morphogenesis	NATURE			English	Article							GENE-EXPRESSION; CHICK; MICE; DIFFERENTIATION; PATTERN; DEATH; BUD	The p53 tumour suppressor is a transcription factor that regulates the progression of the cell through its cycle and cell death (apoptosis) in response to environmental stimuli such as DNA damage and hypoxia(1,2). Even though p53 modulates these critical cellular processes, mice that lack p53 are developmentally normal(3), suggesting that p53-related proteins might compensate for the functions of p53 during embryogenesis. Two p53 homologues, p63 and p73, are known(4,5) and here we describe the function of p63 in vivo. Mice lacking p63 are born alive but have striking developmental defects. Their limbs are absent or truncated, defects that are caused by a failure of the apical ectodermal ridge to differentiate. The skin of p63-deficient mice does not progress past an early developmental stage: it lacks stratification and does not express differentiation markers. Structures dependent upon epidermal-mesenchymal interactions during embryonic development, such as hair follicles, teeth and mammary glands, are absent in p63-deficient mice. Thus, in contrast to p53, p63 is essential for several aspects of ectodermal differentiation during embryogenesis.	Baylor Coll Med, Howard Hughes Med Inst, Houston, TX 77030 USA; Baylor Coll Med, Dept Mol & Human Genet, Houston, TX 77030 USA; Baylor Coll Med, Dept Cell Biol, Houston, TX 77030 USA; Baylor Coll Med, Dept Dermatol, Houston, TX 77030 USA; Texas Childrens Hosp, Dept Pathol, Houston, TX 77030 USA	Baylor College of Medicine; Howard Hughes Medical Institute; Baylor College of Medicine; Baylor College of Medicine; Baylor College of Medicine; Baylor College of Medicine	Bradley, A (corresponding author), Baylor Coll Med, Howard Hughes Med Inst, 1 Baylor Plaza, Houston, TX 77030 USA.	abradley@bcm.tmc.edu		Vogel, Otto Hannes/0000-0002-0960-3508; Bradley, Allan/0000-0002-2349-8839				BICKENBACH JR, 1995, J INVEST DERMATOL, V104, P405, DOI 10.1111/1523-1747.ep12665896; Bradley A, 1987, TERATOCARCINOMAS EMB, P113; BYRNE C, 1994, DEVELOPMENT, V120, P2369; Cygan JA, 1997, DEVELOPMENT, V124, P5021; DONEHOWER LA, 1992, NATURE, V356, P215, DOI 10.1038/356215a0; Grieshammer U, 1996, DEVELOPMENT, V122, P3851; Hardy MH, 1996, ACTA ANAT, V157, P169; HINCHLIFFE JR, 1973, J EMBRYOL EXP MORPH, V30, P753; Kaghad M, 1997, CELL, V90, P809, DOI 10.1016/S0092-8674(00)80540-1; Liu PT, 1998, GENETICS, V150, P1155; LIVINGSTONE LR, 1992, CELL, V70, P923, DOI 10.1016/0092-8674(92)90243-6; LOWE SW, 1993, NATURE, V362, P847, DOI 10.1038/362847a0; MCNEISH JD, 1988, SCIENCE, V241, P837, DOI 10.1126/science.3406741; MEHREL T, 1990, CELL, V61, P1103, DOI 10.1016/0092-8674(90)90073-N; Osada M, 1998, NAT MED, V4, P839, DOI 10.1038/nm0798-839; Osoegawa K, 1998, GENOMICS, V52, P1, DOI 10.1006/geno.1998.5423; PRAHLAD KV, 1979, J EXP ZOOL, V209, P427, DOI 10.1002/jez.1402090308; RAMIREZSOLIS R, 1995, NATURE, V378, P720, DOI 10.1038/378720a0; ROOP DR, 1988, CANCER RES, V48, P3245; ROTHNAGEL JA, 1987, J BIOL CHEM, V262, P15643; Schmale H, 1997, ONCOGENE, V15, P1363, DOI 10.1038/sj.onc.1201500; SUMMERBELL D, 1973, NATURE, V244, P492, DOI 10.1038/244492a0; Trink B, 1998, NAT MED, V4, P747, DOI 10.1038/nm0798-747; VALANCIUS V, 1991, MOL CELL BIOL, V11, P4389, DOI 10.1128/MCB.11.9.4389; Vogel A, 1996, DEVELOPMENT, V122, P1737; WANG XJ, 1995, ONCOGENE, V10, P279; WANG YQ, 1995, DEV BIOL, V168, P374, DOI 10.1006/dbio.1995.1087; Wilkinson DG, 1992, SITU HYBRIDIZATION P; Yang AN, 1998, MOL CELL, V2, P305, DOI 10.1016/S1097-2765(00)80275-0; ZHENG B, IN PRESS NUCL ACIDS; ZHOU PB, 1995, GENE DEV, V9, P700, DOI 10.1101/gad.9.6.700	31	1647	1691	1	75	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	APR 22	1999	398	6729					708	713		10.1038/19531	http://dx.doi.org/10.1038/19531			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	189RP	10227293				2022-12-28	WOS:000079920100051
J	Van Dyck, E; Stasiak, AZ; Stasiak, A; West, SC				Van Dyck, E; Stasiak, AZ; Stasiak, A; West, SC			Binding of double-strand breaks in DNA by human Rad52 protein	NATURE			English	Article							HOMOLOGOUS RECOMBINATION; IONIZING-RADIATION; VERTEBRATE CELLS; MAMMALIAN-CELLS; REPAIR; YEAST; SACCHAROMYCES; RESISTANCE; COMPLEXES; EXCHANGE	Double-strand breaks (DSBs) in DNA are caused by ionizing radiation. These chromosomal breaks can kill the cell unless repaired efficiently, and inefficient or inappropriate repair can lead to mutation, gene translocation and cancer(1), Two proteins that participate in the repair of DSBs are Rad52 and Ku: in lower eukaryotes such as yeast, DSBs are repaired by Rad52-dependent homologous recombination, whereas vertebrates repair DSBs primarily by Ku-dependent non-homologous end-joining(2). The contribution of homologous recombination to vertebrate DSB repair, however, is important(3,4). Biochemical studies indicate that Ku binds to DNA ends and facilitates end-joining(5). Here we show that human Rad52, like Ku, binds directly to DSBs, protects them from exonuclease attack and facilitates end-to-end interactions. A model for repair is proposed in which either Ku or Rad52 binds the DSB. Ku directs DSBs into the non-homologous end-joining repair pathway, whereas Rad52 initiates repair by homologous recombination. Ku and Rad52, therefore, direct entry into alternative pathways for the repair of DNA breaks.	Imperial Canc Res Fund, Clare Hall Labs, S Mimms EN6 3LD, Herts, England; Univ Lausanne, Lab Anal Ultrastruct, CH-1015 Lausanne, Switzerland	University of Lausanne	West, SC (corresponding author), Imperial Canc Res Fund, Clare Hall Labs, S Mimms EN6 3LD, Herts, England.		Stasiak, Andrzej/E-5551-2010	Stasiak, Andrzej/0000-0002-0398-1989; West, Stephen/0000-0001-8848-9418; Van Dyck, Eric/0000-0001-8614-2402				ANDERSON CW, 1996, MOL ANAL DNA REARRAN, P91; Baumann P, 1996, CELL, V87, P757, DOI 10.1016/S0092-8674(00)81394-X; Benson FE, 1998, NATURE, V391, P401, DOI 10.1038/34937; Critchlow SE, 1998, TRENDS BIOCHEM SCI, V23, P394, DOI 10.1016/S0968-0004(98)01284-5; FRIEDBERG EC, 1995, DNA REPAIR MUTAGENES; GAME JC, 1993, SEMIN CANCER BIOL, V4, P73; Gasior SL, 1998, GENE DEV, V12, P2208, DOI 10.1101/gad.12.14.2208; Johnson BL, 1996, MUTAT RES-DNA REPAIR, V363, P179, DOI 10.1016/0921-8777(96)00007-9; Kanaar R, 1998, TRENDS CELL BIOL, V8, P483, DOI 10.1016/S0962-8924(98)01383-X; Liang F, 1998, P NATL ACAD SCI USA, V95, P5172, DOI 10.1073/pnas.95.9.5172; Mortensen UH, 1996, P NATL ACAD SCI USA, V93, P10729, DOI 10.1073/pnas.93.20.10729; New JH, 1998, NATURE, V391, P407, DOI 10.1038/34950; Nussenzweig A, 1996, NATURE, V382, P551, DOI 10.1038/382551a0; Nussenzweig A, 1997, P NATL ACAD SCI USA, V94, P13588, DOI 10.1073/pnas.94.25.13588; PARK MS, 1995, J BIOL CHEM, V270, P15467, DOI 10.1074/jbc.270.26.15467; Petes T. D., 1991, MOL CELLULAR BIOL YE, P407; Reddy MP, 1997, GERIATRICS, V52, P59; Rijkers T, 1998, MOL CELL BIOL, V18, P6423, DOI 10.1128/MCB.18.11.6423; Shen ZY, 1996, MUTAT RES-DNA REPAIR, V364, P81, DOI 10.1016/0921-8777(96)00025-0; Shinohara A, 1998, NATURE, V391, P404, DOI 10.1038/34943; Shinohara A, 1998, GENES CELLS, V3, P145, DOI 10.1046/j.1365-2443.1998.00176.x; SUBRAMANI S, 1988, GENETIC RECOMBINATIO, P549; SUGAWARA N, 1992, MOL CELL BIOL, V12, P563, DOI 10.1128/MCB.12.2.563; Sugiyama T, 1998, P NATL ACAD SCI USA, V95, P6049, DOI 10.1073/pnas.95.11.6049; SUN H, 1991, CELL, V64, P1155, DOI 10.1016/0092-8674(91)90270-9; Sung P, 1997, GENE DEV, V11, P1111, DOI 10.1101/gad.11.9.1111; Sung P, 1997, J BIOL CHEM, V272, P28194, DOI 10.1074/jbc.272.45.28194; Takata M, 1998, EMBO J, V17, P5497, DOI 10.1093/emboj/17.18.5497; Van Dyck E, 1998, J MOL BIOL, V284, P1027, DOI 10.1006/jmbi.1998.2203; Yamaguchi-Iwai Y, 1998, MOL CELL BIOL, V18, P6430, DOI 10.1128/MCB.18.11.6430	30	253	259	0	11	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	APR 22	1999	398	6729					728	731		10.1038/43942	http://dx.doi.org/10.1038/43942			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	189RP	10227297	Bronze			2022-12-28	WOS:000079920100055
J	Walsh, C				Walsh, C			Microbiology - Deconstructing vancomycin	SCIENCE			English	Editorial Material							RESISTANCE; STORY		Harvard Univ, Sch Med, Dept Biol Chem & Mol Pharmacol, Boston, MA 02115 USA	Harvard University; Harvard Medical School	Walsh, C (corresponding author), Harvard Univ, Sch Med, Dept Biol Chem & Mol Pharmacol, Boston, MA 02115 USA.	walsh@walsh.med.harvard.edu						BUGG TDH, 1991, BIOCHEMISTRY-US, V30, P10408, DOI 10.1021/bi00107a007; Evans DA, 1998, ANGEW CHEM INT EDIT, V37, P2700, DOI 10.1002/(SICI)1521-3773(19981016)37:19<2700::AID-ANIE2700>3.0.CO;2-P; EVANS DA, 1998, ANGEW CHEM INT EDIT, V37, P2717; Ge M, 1999, SCIENCE, V284, P507, DOI 10.1126/science.284.5413.507; Sieradzki K, 1999, NEW ENGL J MED, V340, P517, DOI 10.1056/NEJM199902183400704; Smith TL, 1999, NEW ENGL J MED, V340, P493, DOI 10.1056/NEJM199902183400701; Thompson C, 1999, J AM CHEM SOC, V121, P1237, DOI 10.1021/ja983504u; Waldvogel FA, 1999, NEW ENGL J MED, V340, P556, DOI 10.1056/NEJM199902183400709; Walsh CT, 1996, CHEM BIOL, V3, P21, DOI 10.1016/S1074-5521(96)90079-4; Williams DH, 1996, NAT PROD REP, V13, P469, DOI 10.1039/np9961300469	10	93	96	1	20	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	APR 16	1999	284	5413					442	443		10.1126/science.284.5413.442	http://dx.doi.org/10.1126/science.284.5413.442			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	187NE	10232990				2022-12-28	WOS:000079792200029
J	Summerfield, DA				Summerfield, DA			"Trauma" and the experience of war: a reply	LANCET			English	Article									Med Fdn Care Victims Torture, London NW5 3EJ, England		Summerfield, DA (corresponding author), Med Fdn Care Victims Torture, 96-98 Grafton Rd, London NW5 3EJ, England.							AGGER I, 1995, THEORY PRACTICE PSYC; Boyden J., 1996, VULNERABILITY RESILI; Bracken P., 1997, Journal of Refugee Studies, V10, P431, DOI 10.1093/jrs/10.4.431; JONES LW, 1997, COMMUNICATION; Mandela N., 1995, LONG WALK FREEDOM AU; *UNICEF, 1996, CFDOIPR199608 UNICEF; Young A., 1995, HARMONY ILLUSIONS	7	12	12	0	2	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON WC1B 3SL, ENGLAND	0140-6736			LANCET	Lancet	MAY 23	1998	351	9115					1580	1581		10.1016/S0140-6736(98)02001-7	http://dx.doi.org/10.1016/S0140-6736(98)02001-7			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZQ497	10326558				2022-12-28	WOS:000073868000050
J	Binder, S; Levitt, AM; Sacks, JJ; Hughes, JM				Binder, S; Levitt, AM; Sacks, JJ; Hughes, JM			Emerging infectious diseases: Public health issues for the 21st century	SCIENCE			English	Editorial Material							VACCINE; SURVEILLANCE; BIOSENSOR; INFLUENZA	Infectious diseases are the third leading cause of death in the United States and the Leading cause worldwide. As the new millennium approaches, the public health community must replenish capacity depleted during years of inadequate funding while simultaneously incorporating new technologies and planning for the Longer term. Among the challenges facing the public health community is the need for coordinated, global, multisectoral approaches to preventing and controlling complex infectious disease problems.	Ctr Dis Control & Prevent, Div Parasit Dis, Natl Ctr Infect Dis, Atlanta, GA 30341 USA; Ctr Dis Control & Prevent, Off Director, Natl Ctr Infect Dis, Brooklyn, NY 11215 USA; Ctr Dis Control & Prevent, Natl Ctr Injury Prevent & Control, Atlanta, GA 30341 USA; Ctr Dis Control & Prevent, Natl Ctr Infect Dis, Atlanta, GA 30333 USA	Centers for Disease Control & Prevention - USA; Centers for Disease Control & Prevention - USA; Centers for Disease Control & Prevention - USA; Centers for Disease Control & Prevention - USA	Binder, S (corresponding author), Ctr Dis Control & Prevent, Div Parasit Dis, Natl Ctr Infect Dis, F-22,4770 Buford Highway NE, Atlanta, GA 30341 USA.	scb1@cdc.gov						AACH RD, 1980, ANN INTERN MED, V92, P539, DOI 10.7326/0003-4819-92-4-539; [Anonymous], PREV EM INF DIS STRA; Armstrong GL, 1999, JAMA-J AM MED ASSOC, V281, P61, DOI 10.1001/jama.281.1.61; Arntzen CJ, 1997, PUBLIC HEALTH REP, V112, P190; Balaban N, 1998, SCIENCE, V280, P438, DOI 10.1126/science.280.5362.438; Bauchner H, 1999, PEDIATRICS, V103, P395, DOI 10.1542/peds.103.2.395; BERKELMAN RL, 1994, SCIENCE, V264, P368, DOI 10.1126/science.8153621; Busch DF, 1997, CLIN INFECT DIS, V25, P34, DOI 10.1086/514511; CDC, 1997, MMWR-MORBID MORTAL W, V46, P741; *CDC, 1997, MMWR-MORBID MORTAL W, V46, P777; *CDC, 1999, MMWR-MORBID MORTAL W, V48, P285; *CDC, 1997, TRANSL ADV HUM GEN P; Centers for Disease Control, 1994, MORBIDITY MORTALITY, V43, P1; Centers for Disease Control and Prevention (CDC), 1998, MMWR Morb Mortal Wkly Rep, V46, P1245; Centers for Disease Control and Prevention (CDC), 1998, MMWR Morb Mortal Wkly Rep, V47, P665; Centers for Disease Control and Prevention (CDC), 1998, MMWR Morb Mortal Wkly Rep, V47, P1085; *COMM INT SCI ENG, 1995, INF DIS GLOB HLTH TH; Cornell BA, 1997, NATURE, V387, P580, DOI 10.1038/42432; Corrier DE, 1999, SALMONELLA ENTERICA SEROVAR ENTERITIDIS IN HUMANS AND ANIMALS: EPIDEMIOLOGY, PATHOGENESIS AND CONTROL, P391; Dagan R, 1996, J INFECT DIS, V174, P1271, DOI 10.1093/infdis/174.6.1271; FRICKE W, 1992, TRANSFUSION, V32, P707, DOI 10.1046/j.1537-2995.1992.32893032095.x; Henderson DA, 1999, SCIENCE, V283, P1279, DOI 10.1126/science.283.5406.1279; Institute of Medicine, 1997, AM VIT INT GLOB HLTH; Institute of Medicine, 1992, EM INF MICR THREATS; Lipshutz RJ, 1999, NAT GENET, V21, P20, DOI 10.1038/4447; McNicholl JM, 1999, AM J PREV MED, V16, P141, DOI 10.1016/S0749-3797(98)00143-3; MOFFAT AS, 1995, SCIENCE, V268, P658, DOI 10.1126/science.7732373; Ostroff SM, 1998, INFECT DIS CLIN N AM, V12, P231, DOI 10.1016/S0891-5520(05)70420-7; Pestotnik SL, 1996, ANN INTERN MED, V124, P884, DOI 10.7326/0003-4819-124-10-199605150-00004; Pinner RW, 1996, JAMA-J AM MED ASSOC, V275, P189, DOI 10.1001/jama.275.3.189; Poste G, 1998, Nat Biotechnol, V16 Suppl, P19, DOI 10.1038/5403; Reichman LB, 1996, LANCET, V347, P175, DOI 10.1016/S0140-6736(96)90348-7; Relman DA, 1999, SCIENCE, V284, P1308, DOI 10.1126/science.284.5418.1308; Robinson HL, 1997, VACCINE, V15, P785, DOI 10.1016/S0264-410X(96)00249-6; Sisk JE, 1997, JAMA-J AM MED ASSOC, V278, P1333, DOI 10.1001/jama.278.16.1333; Snow RW, 1999, PARASITOL TODAY, V15, P99, DOI 10.1016/S0169-4758(99)01395-2; Southern E, 1999, NAT GENET, V21, P5, DOI 10.1038/4429; Subbarao K, 1998, SCIENCE, V279, P393, DOI 10.1126/science.279.5349.393; Talan DA, 1998, ANN EMERG MED, V32, P703, DOI 10.1016/S0196-0644(98)70071-X; Troesch A, 1999, J CLIN MICROBIOL, V37, P49, DOI 10.1128/JCM.37.1.49-55.1999; Turner APF, 1997, NATURE, V387, P555, DOI 10.1038/42365; Webster RG, 1998, EMERG INFECT DIS, V4, P436, DOI 10.3201/eid0403.980325; WHO, 1996, WORLD HLTH REP 1996; Witte W, 1998, SCIENCE, V279, P996, DOI 10.1126/science.279.5353.996; Ziegler C, 1998, CURR OPIN CHEM BIOL, V2, P585, DOI 10.1016/S1367-5931(98)80087-2	45	178	197	3	46	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAY 21	1999	284	5418					1311	1313		10.1126/science.284.5418.1311	http://dx.doi.org/10.1126/science.284.5418.1311			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	198NN	10334978				2022-12-28	WOS:000080430600041
J	Fan, S; Wang, JA; Yuan, R; Ma, Y; Meng, Q; Erdos, MR; Pestell, RG; Yuan, F; Auborn, KJ; Goldberg, ID; Rosen, EM				Fan, S; Wang, JA; Yuan, R; Ma, Y; Meng, Q; Erdos, MR; Pestell, RG; Yuan, F; Auborn, KJ; Goldberg, ID; Rosen, EM			BRCA1 inhibition of estrogen receptor signaling in transfected cells	SCIENCE			English	Article							TUMOR-SUPPRESSOR; TRANSCRIPTIONAL ACTIVATION; NUCLEAR RECEPTORS; DNA-DAMAGE; GENE BRCA1; PROLIFERATION; CANCER; DIFFERENTIATION; EXPRESSION; BREAST	Mutations of the breast cancer susceptibility gene BRCA1 confer increased risk for breast, ovarian, and prostatic cancers, but it is not clear why the mutations are associated with these particular tumor types. In transient transfection assays, BRCA1 was found to inhibit signaling by the Ligand-activated estrogen receptor (ER-alpha) through the estrogen-responsive enhancer element and to block the transcriptional activation function AF-2 of ER-alpha. These results raise the possibility that wild-type BRCA1 suppresses estrogen-dependent transcriptional pathways related to mammary epithelial cell proliferation and that Loss of this ability contributes to tumorigenesis.	Albert Einstein Coll Med, Long Isl Jewish Med Ctr, Dept Radiat Oncol, New Hyde Park, NY 11040 USA; Albert Einstein Coll Med, Long Isl Jewish Med Ctr, Dept Otolaryngol, New Hyde Park, NY 11040 USA; N Shore Univ Hosp, NSUH LIJ Hlth Syst, Dept Radiat Oncol, Manhasset, NY 11030 USA; NIH, Genet & Mol Biol Branch, Natl Human Genome Res Inst, Bethesda, MD 20892 USA; Yeshiva Univ Albert Einstein Coll Med, Dept Dev, Bronx, NY 10461 USA; Yeshiva Univ Albert Einstein Coll Med, Dept Mol Biol, Bronx, NY 10461 USA; Yeshiva Univ Albert Einstein Coll Med, Dept Med, Bronx, NY 10461 USA	Northwell Health; Yeshiva University; Northwell Health; Yeshiva University; Northwell Health; North Shore University Hospital; National Institutes of Health (NIH) - USA; NIH National Human Genome Research Institute (NHGRI); Yeshiva University; Albert Einstein College of Medicine; Yeshiva University; Albert Einstein College of Medicine; Yeshiva University; Albert Einstein College of Medicine	Fan, S (corresponding author), Albert Einstein Coll Med, Long Isl Jewish Med Ctr, Dept Radiat Oncol, Long Isl Campus,270-05 76th Ave, New Hyde Park, NY 11040 USA.				NCI NIH HHS [R01-CA75503] Funding Source: Medline; NIEHS NIH HHS [R01-ES09169] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA075503] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES009169] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		BAICHWAL VR, 1991, NATURE, V352, P165, DOI 10.1038/352165a0; Chapman MS, 1996, NATURE, V382, P678, DOI 10.1038/382678a0; Chen YM, 1996, CANCER RES, V56, P3168; Fan SJ, 1998, ONCOGENE, V16, P3069, DOI 10.1038/sj.onc.1202116; Ferguson AT, 1997, CRIT REV ONCOGENESIS, V8, P29, DOI 10.1615/CritRevOncog.v8.i1.20; FLEMINGTON EK, 1993, P NATL ACAD SCI USA, V90, P6914, DOI 10.1073/pnas.90.15.6914; FORD D, 1994, LANCET, V343, P692, DOI 10.1016/S0140-6736(94)91578-4; Gowen LC, 1998, SCIENCE, V281, P1009, DOI 10.1126/science.281.5379.1009; Hakem R, 1996, CELL, V85, P1009, DOI 10.1016/S0092-8674(00)81302-1; Henttu PMA, 1997, MOL CELL BIOL, V17, P1832, DOI 10.1128/MCB.17.4.1832; Holt JT, 1996, NAT GENET, V12, P298, DOI 10.1038/ng0396-298; Katzenellenbogen BS, 1996, BIOL REPROD, V54, P287, DOI 10.1095/biolreprod54.2.287; MIKI Y, 1994, SCIENCE, V266, P66, DOI 10.1126/science.7545954; Monteiro ANA, 1996, P NATL ACAD SCI USA, V93, P13595, DOI 10.1073/pnas.93.24.13595; Perlmann T, 1997, CELL, V90, P391, DOI 10.1016/S0092-8674(00)80498-5; Rajan JV, 1997, DEV BIOL, V184, P385, DOI 10.1006/dbio.1997.8526; Rajan JV, 1996, P NATL ACAD SCI USA, V93, P13078, DOI 10.1073/pnas.93.23.13078; Scully R, 1997, CELL, V90, P425, DOI 10.1016/S0092-8674(00)80503-6; Shao NS, 1996, ONCOGENE, V13, P1; Somasundaram K, 1997, NATURE, V389, P187, DOI 10.1038/38291; STREUWING JP, 1997, NEW ENGL J MED, V336, P1401; Watanabe G, 1998, MOL CELL BIOL, V18, P3212, DOI 10.1128/MCB.18.6.3212	22	390	421	0	8	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	MAY 21	1999	284	5418					1354	1356		10.1126/science.284.5418.1354	http://dx.doi.org/10.1126/science.284.5418.1354			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	198NN	10334989				2022-12-28	WOS:000080430600052
J	Srinivasan, G; Goswami, JN; Bhandari, N				Srinivasan, G; Goswami, JN; Bhandari, N			Al-26 in eucrite Piplia Kalan: Plausible heat source and formation chronology	SCIENCE			English	Article							EARLY SOLAR-SYSTEM; ORDINARY CHONDRITE; ASTEROID-4 VESTA; METEORITES; DIFFERENTIATION; CONSTRAINTS; ACCRETION; PLANETS; BODY; TIME	Aluminum-magnesium isotopic analysis of plagioclase in the eucrite Piplia Kalan, with (27)A1/Mg-24 ratio between 2000 to 7000, reveals the presence of excess magnesium-26 resulting from in situ decay of the short-lived nuclide aluminum-26. This observation confirms aluminum-26 as a plausible heat source for melting and differentiation of the eucrite parent body in particular and for planetesimals in general. The inferred initial abundance of Al-26/Al-27 Of (7.5 +/- 0.9) x 10(-7) indicates that melting, differentiation, and crust formation in the parent body of Piplia Kalan was complete within 5 million years of the formation of the solar system.	Phys Res Lab, Ahmadabad 380009, Gujarat, India	Department of Space (DoS), Government of India; Physical Research Laboratory - India	Srinivasan, G (corresponding author), Phys Res Lab, Ahmadabad 380009, Gujarat, India.	srini@pri.ernet.in						Basaltic Volcanism Study Project, 1981, BAS VOLC TERR PLAN; BERNIUS MT, 1991, LUNAR PLANET SCI, V22, P93; Bhandari N, 1998, METEORIT PLANET SCI, V33, P455, DOI 10.1111/j.1945-5100.1998.tb01650.x; BINZEL RP, 1993, SCIENCE, V260, P186, DOI 10.1126/science.260.5105.186; Buchanan PC, 1997, METEORIT PLANET SCI, V32, pA22; BUCHANAN PC, 1997, LPS, V28, P167; CATANZAR.EJ, 1966, J RES NBS A PHYS CH, VA 70, P453, DOI 10.6028/jres.070A.037; CHEN JH, 1990, GEOCHIM COSMOCHIM AC, V54, P1729, DOI 10.1016/0016-7037(90)90404-9; DAVIS AM, 1988, LUNAR PLANET SCI, V29, P251; Drake M. J., 1979, ASTEROIDS, P765; Ghosh A, 1998, ICARUS, V134, P187, DOI 10.1006/icar.1998.5956; GOPEL C, 1991, METEORITICS, V26, P338; GOSWAMI JN, 1994, GEOCHIM COSMOCHIM AC, V58, P431, DOI 10.1016/0016-7037(94)90475-8; HERBERT F, 1979, ICARUS, V40, P484, DOI 10.1016/0019-1035(79)90041-1; Hsu WB, 1996, GEOCHIM COSMOCHIM AC, V60, P4571, DOI 10.1016/S0016-7037(96)00277-3; HUTCHEON ID, 1989, NATURE, V337, P238, DOI 10.1038/337238a0; KENNEDY AK, 1992, EARTH PLANET SC LETT, V113, P191, DOI 10.1016/0012-821X(92)90219-L; KUMAR A, UNPUB GEOCHIM COSMOC; KUMAR A, 1998, CHINESE SCI B S, V43, P70; KUMAR A, 1997, C IS SOL SYST, P11; Lee DC, 1996, SCIENCE, V274, P1876, DOI 10.1126/science.274.5294.1876; LEE T, 1976, GEOPHYS RES LETT, V3, P109, DOI 10.1029/GL003i002p00109; Lugmair GW, 1998, GEOCHIM COSMOCHIM AC, V62, P2863, DOI 10.1016/S0016-7037(98)00189-6; LUGMAIR GW, 1992, GEOCHIM COSMOCHIM AC, V56, P1673, DOI 10.1016/0016-7037(92)90234-A; LUGMAIR GW, 1995, NUCL COSMOS, V3, P591; LUGMAIR GW, 1975, METEORITICS, V9, P369; MACPHERSON GJ, 1995, METEORITICS, V30, P365, DOI 10.1111/j.1945-5100.1995.tb01141.x; MANHES G, 1988, ATP PLANETOL, P323; Russell SS, 1996, SCIENCE, V273, P757, DOI 10.1126/science.273.5276.757; Sahijpal S, 1995, P INDIAN AS-EARTH, V104, P555; SAHIJPAL S, 1997, THESIS PHYSICAL RES; Schramm D. N., 1970, Earth and Planetary Science Letters, V10, P44, DOI 10.1016/0012-821X(70)90063-4; Shukla AD, 1997, METEORIT PLANET SCI, V32, P611, DOI 10.1111/j.1945-5100.1997.tb01546.x; SHUKOLYUKOV A, 1993, SCIENCE, V259, P1138, DOI 10.1126/science.259.5098.1138; SHUKOLYUKOV A, 1993, EARTH PLANET SC LETT, V119, P159, DOI 10.1016/0012-821X(93)90013-Y; SONETT CP, 1968, NATURE, V219, P924, DOI 10.1038/219924a0; UREY HC, 1955, P NATL ACAD SCI USA, V41, P127, DOI 10.1073/pnas.41.3.127; Vaya VK, 1996, CURR SCI INDIA, V71, P253; Wadhwa M., 1995, LUNAR PLANET SCI, VXXVI, P1453; WOOD JA, 1992, SUN TIME, P740; YOMOGIDA K, 1983, J GEOPHYS RES, V88, P9513, DOI 10.1029/JB088iB11p09513	41	135	136	1	13	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAY 21	1999	284	5418					1348	1350		10.1126/science.284.5418.1348	http://dx.doi.org/10.1126/science.284.5418.1348			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	198NN	10334987				2022-12-28	WOS:000080430600050
J	Wang, RF; Wang, X; Atwood, AC; Topalian, SL; Rosenberg, SA				Wang, RF; Wang, X; Atwood, AC; Topalian, SL; Rosenberg, SA			Cloning genes encoding MHC class II-restricted antigens: Mutated CDC27 as a tumor antigen	SCIENCE			English	Article							T-CELL RESPONSES; HLA-DM; INFILTRATING LYMPHOCYTES; HUMAN-MELANOMA; HUMAN HOMOLOG; BETA-CATENIN; KAPPA-B; IDENTIFICATION; PROTEINS; COMPLEX	In an effort to identify tumor-specific antigens recognized by CD4(+) T cells, an approach was developed that allows the screening of an invariant chain-complementary DNA fusion library in a genetically engineered cell line expressing the essential components of the major histocompatibility complex (MHC) class II processing and presentation pathway. This Led to the identification of a mutated form of human CDC27, which gave rise to an HLA-DR4-restricted melanoma antigen, A mutated form of triosephosphate isomerase, isolated by a biochemical method, was also identified as an HLA-DR1-restricted antigen. Thus, this approach may be generally applicable to the identification of antigens recognized by CD4(+) T cells, which could aid the development of strategies for the treatment of patients with cancer, autoimmune diseases, or infectious diseases.	NCI, Surg Branch, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Wang, RF (corresponding author), NCI, Surg Branch, NIH, Bldg 10-2B42,9000 Rockville Pike, Bethesda, MD 20892 USA.				DIVISION OF CLINICAL SCIENCES - NCI [Z01SC006664] Funding Source: NIH RePORTER	DIVISION OF CLINICAL SCIENCES - NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Baldwin AS, 1996, ANNU REV IMMUNOL, V14, P649, DOI 10.1146/annurev.immunol.14.1.649; Bona CA, 1998, IMMUNOL TODAY, V19, P126, DOI 10.1016/S0167-5699(97)01218-8; BRASH DE, 1991, P NATL ACAD SCI USA, V88, P10124, DOI 10.1073/pnas.88.22.10124; CHEN PL, 1995, CELL GROWTH DIFFER, V6, P199; Ciechanover A, 1998, EMBO J, V17, P7151, DOI 10.1093/emboj/17.24.7151; CLAUSER KR, 1995, P NATL ACAD SCI USA, V92, P5072, DOI 10.1073/pnas.92.11.5072; CRESSWELL P, 1994, ANNU REV IMMUNOL, V12, P259, DOI 10.1146/annurev.immunol.12.1.259; Cresswell P, 1996, CELL, V84, P505, DOI 10.1016/S0092-8674(00)81025-9; DENZIN LK, 1995, CELL, V82, P155, DOI 10.1016/0092-8674(95)90061-6; Enari M, 1998, NATURE, V391, P43, DOI 10.1038/34112; FLING SP, 1994, NATURE, V368, P554, DOI 10.1038/368554a0; GERMAIN RN, 1994, CELL, V76, P287, DOI 10.1016/0092-8674(94)90336-0; Halder T, 1997, CANCER RES, V57, P3238; Hershko A, 1998, ANNU REV BIOCHEM, V67, P425, DOI 10.1146/annurev.biochem.67.1.425; Ji H, 1997, ELECTROPHORESIS, V18, P605, DOI 10.1002/elps.1150180344; Kalams SA, 1998, J EXP MED, V188, P2199, DOI 10.1084/jem.188.12.2199; KATZ JD, 1995, SCIENCE, V268, P1185, DOI 10.1126/science.7761837; KEMP BE, 1990, TRENDS BIOCHEM SCI, V15, P342, DOI 10.1016/0968-0004(90)90073-K; KING RW, 1995, CELL, V81, P279, DOI 10.1016/0092-8674(95)90338-0; KNOWLES JR, 1977, ACCOUNTS CHEM RES, V10, P105, DOI 10.1021/ar50112a001; Kouskoff V, 1996, CELL, V87, P811, DOI 10.1016/S0092-8674(00)81989-3; MONACH PA, 1995, IMMUNITY, V2, P45, DOI 10.1016/1074-7613(95)90078-0; MORRIS P, 1994, NATURE, V368, P551, DOI 10.1038/368551a0; Nakano N, 1997, SCIENCE, V275, P678, DOI 10.1126/science.275.5300.678; O'Garra A, 1997, CURR OPIN IMMUNOL, V9, P872, DOI 10.1016/S0952-7915(97)80192-6; OSTRANDROSENBERG S, 1994, CURR OPIN IMMUNOL, V6, P722, DOI 10.1016/0952-7915(94)90075-2; Pardoll DM, 1998, CURR OPIN IMMUNOL, V10, P588, DOI 10.1016/S0952-7915(98)80228-8; Pieper R, 1999, J EXP MED, V189, P757, DOI 10.1084/jem.189.5.757; RAMMENSEE HG, 1995, IMMUNOGENETICS, V41, P178, DOI 10.1007/BF00172063; RIDDELL SR, 1995, ANNU REV IMMUNOL, V13, P545; Robbins PF, 1996, J EXP MED, V183, P1185, DOI 10.1084/jem.183.3.1185; ROCHE PA, 1995, IMMUNITY, V3, P259, DOI 10.1016/1074-7613(95)90111-6; Rubinfeld B, 1997, SCIENCE, V275, P1790, DOI 10.1126/science.275.5307.1790; SANDERSON S, 1995, P NATL ACAD SCI USA, V92, P7217, DOI 10.1073/pnas.92.16.7217; Southwood S, 1998, J IMMUNOL, V160, P3363; Tisch R, 1996, CELL, V85, P291, DOI 10.1016/S0092-8674(00)81106-X; Topalian SL, 1996, J EXP MED, V183, P1965, DOI 10.1084/jem.183.5.1965; TOPALIAN SL, 1994, P NATL ACAD SCI USA, V91, P9461, DOI 10.1073/pnas.91.20.9461; TUGENDREICH S, 1995, CELL, V81, P261, DOI 10.1016/0092-8674(95)90336-4; TUGENDREICH S, 1993, P NATL ACAD SCI USA, V90, P10031, DOI 10.1073/pnas.90.21.10031; VERMA IM, 1995, GENE DEV, V9, P2723, DOI 10.1101/gad.9.22.2723; WALTER EA, 1995, NEW ENGL J MED, V333, P1038, DOI 10.1056/NEJM199510193331603; Wang R., UNPUB; WANG RF, 1995, J EXP MED, V181, P799, DOI 10.1084/jem.181.2.799; Wang RF, 1996, J EXP MED, V184, P2207, DOI 10.1084/jem.184.6.2207; Wang RF, 1998, J IMMUNOL, V161, P3596; WOLFEL T, 1995, SCIENCE, V269, P1281, DOI 10.1126/science.7652577	47	233	266	2	7	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	MAY 21	1999	284	5418					1351	1354		10.1126/science.284.5418.1351	http://dx.doi.org/10.1126/science.284.5418.1351			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	198NN	10334988				2022-12-28	WOS:000080430600051
J	Smith, KE; Besser, JM; Hedberg, CW; Leano, FT; Bender, JB; Wicklund, JH; Johnson, BP; Moore, KA; Osterholm, MT				Smith, KE; Besser, JM; Hedberg, CW; Leano, FT; Bender, JB; Wicklund, JH; Johnson, BP; Moore, KA; Osterholm, MT		Invest Team	Quinolone-resistant Campylobacter jejuni infections in Minnesota, 1992-1998	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							CIPROFLOXACIN-RESISTANT; ANTIMICROBIAL SUSCEPTIBILITIES; VETERINARY-MEDICINE; EMERGENCE; COLI; FLUOROQUINOLONES; TYPHIMURIUM; NORFLOXACIN; SPECTRUM; DIARRHEA	Background Increasing resistance to quinolones among campylobacter isolates from humans has been reported in Europe and Asia, but not in the United States. We evaluated resistance to quinolones among campylobacter isolates from Minnesota residents during the period from 1992 through 1998. Methods All 4953 campylobacter isolates from humans received by the Minnesota Department of Health were tested for resistance to nalidixic acid. Resistant isolates and selected sensitive isolates were tested for resistance to ciprofloxacin. We conducted a case-comparison study of patients with ciprofloxacin-resistant Campylobacter jejuni isolated during 1996 and 1997. Domestic chicken was evaluated as a potential source of quinolone-resistant campylobacter. Results The proportion of quinolone-resistant C. jejuni isolates from humans increased from 1.3 percent in 1992 to 10.2 percent in 1998 (P<0.001). During 1996 and 1997, infection with quinolone-resistant C. jejuni was associated with foreign travel and with the use of a quinolone before the collection of stool specimens. However, quinolone use could account for no more than 15 percent of the cases from 1996 through 1998. The number of quinolone-resistant infections that were acquired domestically also increased during the period from 1996 through 1998. Ciprofloxacin-resistant C. jejuni was isolated from 14 percent of 91 domestic chicken products obtained from retail markets in 1997. Molecular subtyping showed an association between resistant C. jejuni strains from chicken products and domestically acquired infections in Minnesota residents. Conclusions The increase in quinolone-resistant C. jejuni infections in Minnesota is largely due to infections acquired during foreign travel. However, the number of quinolone-resistant infections acquired domestically has also increased, largely because of the acquisition of resistant strains from poultry. The use of fluoroquinolones in poultry, which began in the United States in 1995, has created a reservoir of resistant C, jejuni. (N Engl J Med 1999;340:1525-32.) (C)1999, Massachusetts Medical Society.	Minnesota Dept Hlth, Acute Dis Epidemiol Sect, Minneapolis, MN 55440 USA; Minnesota Dept Hlth, Div Publ Hlth Labs, Minneapolis, MN 55440 USA; Ctr Dis Control & Prevent, Epidem Intelligence Serv, Epidemiol Program Off, Atlanta, GA USA	Minnesota Department of Health (MHD); Minnesota Department of Health (MHD); Centers for Disease Control & Prevention - USA	Smith, KE (corresponding author), Minnesota Dept Hlth, Acute Dis Epidemiol Sect, 717 Delaware St SE, Minneapolis, MN 55440 USA.			Bender, Jeffrey/0000-0003-4645-9936	PHS HHS [U50/CCU511190] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		ALLOS BM, 1995, CLIN INFECT DIS, V20, P1092, DOI 10.1093/clinids/20.5.1092; BLASER MJ, 1995, MANDELL DOUGLAS BENN, P1948; BOWLER I, 1992, LANCET, V340, P245, DOI 10.1016/0140-6736(92)90517-7; DEAN A, 1995, EPI INFO VERSION 6 W; ENDTZ HP, 1991, J ANTIMICROB CHEMOTH, V27, P199, DOI 10.1093/jac/27.2.199; *FAO UN, 1993, FAO YB 1992 1997; *FOODB DIS ACT SUR, 1997, MMWR-MORBID MORTAL W, V46, P258; Gaunt PN, 1996, J ANTIMICROB CHEMOTH, V37, P747, DOI 10.1093/jac/37.4.747; Glynn MK, 1998, NEW ENGL J MED, V338, P1333, DOI 10.1056/NEJM199805073381901; GOODMAN LJ, 1990, ARCH INTERN MED, V150, P541, DOI 10.1001/archinte.150.3.541; GUERRANT RL, 1995, MANDELL DOUGLAS BENN, P987; HOOPER DC, 1991, NEW ENGL J MED, V324, P384, DOI 10.1056/NEJM199102073240606; HUANG MB, 1992, J CLIN MICROBIOL, V30, P3243, DOI 10.1128/JCM.30.12.3243-3248.1992; HUNT JM, 1992, BACTERIOLOGICAL ANAL, P77; JACOBSREITSMA WF, 1994, LETT APPL MICROBIOL, V19, P228, DOI 10.1111/j.1472-765X.1994.tb00950.x; LEUCHTERFIELD NW, 1981, LAB MED, V12, P481; Li CC, 1998, SCAND J INFECT DIS, V30, P39, DOI 10.1080/003655498750002286; *MERC EST, 1994, COL MIN; *MN DEP HLTH CTR H, 1996, MINN HLTH STAT 1994; Murphy GS, 1996, CLIN INFECT DIS, V22, P868, DOI 10.1093/clinids/22.5.868; MURRAY PR, 1995, MANUAL CLIN MICROBIO, P485; NACHAMKIN I, 1993, J CLIN MICROBIOL, V31, P1531, DOI 10.1128/JCM.31.6.1531-1536.1993; National Committee for Clinical Laboratory Standards, 1997, M2A6 NCCLS CLIN LAB, V6th; National Committee for Clinical Laboratory Standards, 1998, M100S8 NAT COMM CLIN; PEREZTRALLERO E, 1993, LANCET, V342, P1371, DOI 10.1016/0140-6736(93)92285-2; Piddock LJV, 1995, J ANTIMICROB CHEMOTH, V36, P891, DOI 10.1093/jac/36.6.891; RAUTELIN H, 1991, ANTIMICROB AGENTS CH, V35, P2065, DOI 10.1128/AAC.35.10.2065; REINA J, 1992, EUR J CLIN MICROBIOL, V11, P1163, DOI 10.1007/BF01961137; SANCHEZ R, 1994, ANTIMICROB AGENTS CH, V38, P1879, DOI 10.1128/AAC.38.9.1879; SAS Institute, 1990, SAS PROC GUID VERS 6; Sjogren E, 1997, J ANTIMICROB CHEMOTH, V40, P257, DOI 10.1093/jac/40.2.257; Slavin MA, 1996, EUR J CLIN MICROBIOL, V15, P348, DOI 10.1007/BF01695672; TAUXE RV, 1992, CAMPLYLOBACTER JEJUNI, P9; Threlfall EJ, 1996, LANCET, V347, P1053, DOI 10.1016/S0140-6736(96)90199-3; VELAZQUEZ JB, 1995, J ANTIMICROB CHEMOTH, V35, P173, DOI 10.1093/jac/35.1.173; WISTROM J, 1992, ANN INTERN MED, V117, P202, DOI 10.7326/0003-4819-117-3-202; 1998, MED LETT DRUGS THER, V40, P33	37	442	458	0	21	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	MAY 20	1999	340	20					1525	1532		10.1056/NEJM199905203402001	http://dx.doi.org/10.1056/NEJM199905203402001			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	197HG	10332013				2022-12-28	WOS:000080358900001
J	Sandford, JJ				Sandford, JJ			Public health psychiatry and crime prevention - Preventive detention of mentally ill people is already widespread	BRITISH MEDICAL JOURNAL			English	Letter									Landon Hosp, Butler Clin, Forens Psychiat Serv, Dawlish EX7 0NR, Devon, England		Sandford, JJ (corresponding author), Landon Hosp, Butler Clin, Forens Psychiat Serv, Dawlish EX7 0NR, Devon, England.							Eastman N, 1999, BRIT MED J, V318, P549, DOI 10.1136/bmj.318.7183.549; Hollander E., 1995, IMPULSIVITY AGGRESSI	2	3	3	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	MAY 15	1999	318	7194					1354	1354		10.1136/bmj.318.7194.1354b	http://dx.doi.org/10.1136/bmj.318.7194.1354b			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	198HR	10323839	Green Published			2022-12-28	WOS:000080418400057
J	Holvoet, P; Collen, D; Van de Werf, F				Holvoet, P; Collen, D; Van de Werf, F			Malondialdehyde-modified LBL as a marker of acute coronary syndromes	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							CARDIAC TROPONIN-I; ARTERY DISEASE; PROTEIN; RISK	Context Release of circulating malondialdehyde (MDA)-modified low-density lipoprotein (LDL) may reflect endothelial injury or plaque instability. Objective To determine the usefulness of MDA-modified LDL for identifying patients with unstable angina and acute myocardial infarction (AMI). Design Blinded comparison of MDA-modified LDL, C-reactive protein, and troponin I followed by multiple receiver operating curve analysis. Setting University hospital. Participants A total of 104 consecutive patients with acute coronary syndromes (42 with unstable angina and 62 with AMI), and 64 patients with stable coronary artery disease (CAD) without evidence of ischemia. Main Outcome Measures Ability of MDA-modified LDL, C-reactive protein, and troponin I to discriminate patients with stable CAD, unstable angina, or AMI, Results Malondialdehyde-modified LDL (chi(2) = 10.2; P = .001), but not troponin I or C-reactive protein, discriminated between stable CAD and unstable angina. Troponin I (chi(2) = 14.5; P<.001), but not MDA-modified LDL or C-reactive protein, discriminated between unstable angina and AMI. Both MDA-modified LDL and troponin I (chi(2) = 14.5; P<.001 and chi(2) = 5.3; P = .02, respectively) but not C-reactive protein discriminated between stable CAD and AMI. The sensitivity of MDA-modified LDL was 95% for unstable angina and 95% for AMI, with a specificity of 95%. Values for troponin I were 38% and 90%, respectively, with a specificity of 95%. The combination of MDA-modified LDL and troponin I had a sensitivity of 98% for unstable angina and 100% for AMI, with a specificity of 99%. Conclusion The combination of MDA-modified LDL, which may reflect endothelial injury or plaque instability, and troponin I, which reflects myocardial cell injury, allows better discrimination between stable CAD and acute coronary syndromes than troponin I alone.	Catholic Univ Louvain, Ctr Mol & Vasc Biol, B-3000 Louvain, Belgium; Catholic Univ Louvain, Dept Cardiol, B-3000 Louvain, Belgium	Universite Catholique Louvain; Universite Catholique Louvain	Holvoet, P (corresponding author), Catholic Univ Louvain, Ctr Mol & Vasc Biol, Campus Gasthuisberg,O&N,Herestr 49, B-3000 Louvain, Belgium.		HOLVOET, PAUL/T-8434-2017	HOLVOET, PAUL/0000-0001-9201-0772				ADAMS JE, 1993, CIRCULATION, V88, P101, DOI 10.1161/01.CIR.88.1.101; Antman EM, 1996, NEW ENGL J MED, V335, P1342, DOI 10.1056/NEJM199610313351802; FARBER HW, 1991, CIRC RES, V68, P1446, DOI 10.1161/01.RES.68.5.1446; Galvani M, 1997, CIRCULATION, V95, P2053, DOI 10.1161/01.CIR.95.8.2053; HABERLAND ME, 1988, SCIENCE, V241, P215, DOI 10.1126/science.2455346; Hamm CW, 1997, NEW ENGL J MED, V337, P1648, DOI 10.1056/NEJM199712043372302; Holvoet P, 1998, CIRCULATION, V98, P1487, DOI 10.1161/01.CIR.98.15.1487; HOLVOET P, 1995, J CLIN INVEST, V95, P2611, DOI 10.1172/JCI117963; Holvoet P, 1998, ARTERIOSCL THROM VAS, V18, P100, DOI 10.1161/01.ATV.18.1.100; LYNCH SM, 1994, J CLIN INVEST, V93, P998, DOI 10.1172/JCI117107; Mach F, 1997, EUR HEART J, V18, P1897; MORROW JD, 1992, P NATL ACAD SCI USA, V89, P10721, DOI 10.1073/pnas.89.22.10721; Ohman EM, 1996, NEW ENGL J MED, V335, P1333, DOI 10.1056/NEJM199610313351801; OLTRONA L, 1995, NEW ENGL J MED, V332, P399; VandeWerf F, 1996, NEW ENGL J MED, V335, P1388, DOI 10.1056/NEJM199610313351809; ZWEIG MH, 1992, CLIN CHEM, V38, P1425	16	94	104	0	3	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAY 12	1999	281	18					1718	1721		10.1001/jama.281.18.1718	http://dx.doi.org/10.1001/jama.281.18.1718			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	193WR	10328072	Bronze			2022-12-28	WOS:000080161200029
J	Hutchinson, L				Hutchinson, L			Evaluating and researching the effectiveness of educational interventions	BRITISH MEDICAL JOURNAL			English	Article									St George Hosp, Sch Med, Dept Child Hlth, London SW17 0RE, England	St Georges University London	Hutchinson, L (corresponding author), St George Hosp, Sch Med, Dept Child Hlth, London SW17 0RE, England.							Buckley G, 1998, MED EDUC, V32, P1, DOI 10.1046/j.1365-2923.1998.00187.x; CALDER J, 1994, PROGRAMME EVALUATION; Edwards J., 1991, EVALUATION ADULT FUR; Green J, 1998, BMJ-BRIT MED J, V316, P1064; Green J, 1998, BMJ-BRIT MED J, V316, P1230, DOI 10.1136/bmj.316.7139.1230; Kirk J., 1986, RELIABILITY VALIDITY; Kirkpatrick DL, 1967, TRAINING DEV HDB; Patton M.Q., 1987, USE QUALITATIVE METH; Robson C., 2011, REAL WORLD RES, V3rd Edn; *UPD SOFTW, 1998, COCHR COLL COCHR LIB; Vandenbroucke JP, 1999, J ROY SOC MED, V92, P159, DOI 10.1177/014107689909200401	11	156	158	0	9	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	MAY 8	1999	318	7193					1267	1269						3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	195XT	10231262				2022-12-28	WOS:000080278000031
J	Rodriguez-Esteban, C; Tsukui, T; Yonei, S; Magallon, J; Tamura, K; Belmonte, JCI				Rodriguez-Esteban, C; Tsukui, T; Yonei, S; Magallon, J; Tamura, K; Belmonte, JCI			The T-box genes Tbx4 and Tbx5 regulate limb outgrowth and identity	NATURE			English	Article							PROGRAMMED CELL-DEATH; VERTEBRATE LIMB; CHICK LIMB; BRACHYURY; SPECIFICATION; MESODERM; BMP-2; SHAPE; FGF	During embryonic development, initially similar fields can develop into distinct structures, such as the vertebrate fore- and hindlimbs, Although considerable progress has been made in our understanding of the genetic control underlying the establishment of the different Limb axes(1-3), the molecular cues that specify the differential development of the fore- and hindlimbs are unknown. Possible candidates for genes determining limb identity are PitxI, a gene whose transcripts are detected in the early hind- but not forelimb bud, and two members of the T-box (Tbx) gene family, Tbx4 and Tbx5, which are specifically expressed in the hindlimb and forelimb buds, respectively(4-6). Here we show that Tbx4 and Tbx5 are essential regulators of limb outgrowth whose roles seem to be tightly linked to the activity of three signalling proteins that are required for limb outgrowth and patterning: fibroblast growth factor (FGF), bone morphogenetic protein (BMP) and Wnt. In addition, we provide evidence that Tbx4 and Tbx5 are involved in controlling limb identity. Our findings provide insight into how similar developmental fields can evolve into homologous but distinct structures.	Salk Inst Biol Studies, Gene Express Lab, La Jolla, CA 92037 USA	Salk Institute	Belmonte, JCI (corresponding author), Salk Inst Biol Studies, Gene Express Lab, 10010 N Torrey Pines Rd, La Jolla, CA 92037 USA.	belmonte@salk.edu						Cohn MJ, 1997, NATURE, V387, P97, DOI 10.1038/387097a0; COHN MJ, 1995, CELL, V80, P739, DOI 10.1016/0092-8674(95)90352-6; Duprez D, 1996, MECH DEVELOP, V57, P145, DOI 10.1016/0925-4773(96)00540-0; Gibson-Brown JJ, 1998, DEVELOPMENT, V125, P2499; GibsonBrown JJ, 1996, MECH DEVELOP, V56, P93, DOI 10.1016/0925-4773(96)00514-X; Hadorn E., 1978, P556; HAMBURGER V, 1951, J MORPHOL, V88, P49, DOI 10.1002/jmor.1050880104; Isaac A, 1998, DEVELOPMENT, V125, P1867; Johnson RL, 1997, CELL, V90, P979, DOI 10.1016/S0092-8674(00)80364-5; Kanegae Y, 1998, NATURE, V392, P611, DOI 10.1038/33429; Kawakami Y, 1996, DEVELOPMENT, V122, P3557; Kengaku M, 1998, SCIENCE, V280, P1274, DOI 10.1126/science.280.5367.1274; Li QY, 1997, NAT GENET, V15, P21; Logan M, 1999, SCIENCE, V283, P1736, DOI 10.1126/science.283.5408.1736; Logan M, 1998, DEVELOPMENT, V125, P2825; Macias D, 1997, DEVELOPMENT, V124, P1109; MACNICOL AM, 1993, CELL, V73, P571, DOI 10.1016/0092-8674(93)90143-E; Martin GR, 1998, GENE DEV, V12, P1571, DOI 10.1101/gad.12.11.1571; MAVES L, 1995, DEVELOPMENT, V121, P1263; Muller CW, 1997, NATURE, V389, P884, DOI 10.1038/39929; Ohuchi H, 1998, DEVELOPMENT, V125, P51; SAUNDERS JW, 1948, J EXP ZOOL, V108, P363, DOI 10.1002/jez.1401080304; Schwabe JWR, 1998, TRENDS GENET, V14, P229, DOI 10.1016/S0168-9525(98)01477-2; Sekine K, 1999, NAT GENET, V21, P138, DOI 10.1038/5096; Smith JC, 1997, COLD SPRING HARB SYM, V62, P337; STEPHENS TD, 1989, DEV BIOL, V133, P1, DOI 10.1016/0012-1606(89)90290-X; Szeto DP, 1999, GENE DEV, V13, P484, DOI 10.1101/gad.13.4.484; Weatherbee SD, 1998, GENE DEV, V12, P1474, DOI 10.1101/gad.12.10.1474; Yokouchi Y, 1996, DEVELOPMENT, V122, P3725; Zou HY, 1996, SCIENCE, V272, P738, DOI 10.1126/science.272.5262.738	30	225	232	0	21	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	APR 29	1999	398	6730					814	818		10.1038/19769	http://dx.doi.org/10.1038/19769			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	192BL	10235264				2022-12-28	WOS:000080058100060
J	Yang, A; Schweitzer, R; Sun, DQ; Kaghad, M; Walker, N; Bronson, RT; Tabin, C; Sharpe, A; Caput, D; Crum, C; McKeon, F				Yang, A; Schweitzer, R; Sun, DQ; Kaghad, M; Walker, N; Bronson, RT; Tabin, C; Sharpe, A; Caput, D; Crum, C; McKeon, F			p63 is essential for regenerative proliferation in limb, craniofacial and epithelial development	NATURE			English	Article							VERTEBRATE LIMB; P53 HOMOLOG; MICE; DIFFERENTIATION; KERATINOCYTE; INVOLVEMENT; EXPRESSION; INITIATION; INDUCTION; CELLS	The p63 gene, a homologue of the tumour-suppressor p53 (refs 1-5), is highly expressed in the basal or progenitor layers of many epithelial tissues(1). Here we report that mice homozygous for a disrupted p63 gene have major defects in their limb, craniofacial and epithelial development. p63 is expressed in the ectodermal surfaces of the limb buds, branchial arches and epidermal appendages, which are all sites of reciprocal signalling that direct morphogenetic patterning of the underlying mesoderm. The limb truncations are due to a failure to maintain the apical ectodermal ridge, a stratified epithelium, essential for Limb development The embryonic epidermis of p63(-/-) mice undergoes an unusual process of non-regenerative differentiation, culminating in a striking absence of all squamous epithelia and their derivatives, including mammary, lacrymal and salivary glands. Taken together, our results indicate that p63 is critical for maintaining the progenitor-cell populations that are necessary to sustain epithelial development and morphogenesis.	Harvard Univ, Sch Med, Dept Cell Biol, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Genet, Boston, MA 02115 USA; Harvard Univ, Sch Med, Massachusetts Gen Hosp, Div Immunol Res, Boston, MA 02115 USA; Harvard Univ, Sch Med, Massachusetts Gen Hosp, Dept Pathol, Boston, MA 02115 USA; Sanofi Biorech, F-31676 Labege, France; Tufts Univ, Sch Vet Med, USDA, Human Nutr Res Ctr Aging, Boston, MA 02111 USA; Tufts Univ, Sch Vet Med, Dept Pathol, Boston, MA 02111 USA	Harvard University; Harvard Medical School; Harvard University; Harvard Medical School; Harvard University; Harvard Medical School; Massachusetts General Hospital; Harvard University; Harvard Medical School; Massachusetts General Hospital; Sanofi-Aventis; Sanofi France; Tufts University; United States Department of Agriculture (USDA); Tufts University	McKeon, F (corresponding author), Harvard Univ, Sch Med, Dept Cell Biol, Boston, MA 02115 USA.		Schweitzer, Ronen/AAY-2127-2020	Schweitzer, Ronen/0000-0002-7425-5028				Augustin M, 1998, MAMM GENOME, V9, P899, DOI 10.1007/s003359900891; BARRANDON Y, 1987, P NATL ACAD SCI USA, V84, P2302, DOI 10.1073/pnas.84.8.2302; BARRANDON Y, 1993, DEV BIOL, V4, P209; BYRNE C, 1994, DEVELOPMENT, V120, P2369; CALAUTTI E, 1995, GENE DEV, V9, P2279, DOI 10.1101/gad.9.18.2279; Chen H, 1998, NAT GENET, V19, P51, DOI 10.1038/ng0598-51; Crossley PH, 1996, CELL, V84, P127, DOI 10.1016/S0092-8674(00)80999-X; DONEHOWER LA, 1992, NATURE, V356, P215, DOI 10.1038/356215a0; Francis-West P, 1998, MECH DEVELOP, V75, P3, DOI 10.1016/S0925-4773(98)00082-3; GREER J, 1991, J INVEST DERMATOL, V96, P553; JACKS T, 1994, CURR BIOL, V4, P1, DOI 10.1016/S0960-9822(00)00002-6; Jan YN, 1998, NATURE, V392, P775, DOI 10.1038/33854; Johnson RL, 1997, CELL, V90, P979, DOI 10.1016/S0092-8674(00)80364-5; Kaghad M, 1997, CELL, V90, P809, DOI 10.1016/S0092-8674(00)80540-1; KELLEY RO, 1976, DEV BIOL, V51, P241, DOI 10.1016/0012-1606(76)90141-X; Ko LJ, 1996, GENE DEV, V10, P1054, DOI 10.1101/gad.10.9.1054; Loomis CA, 1998, DEVELOPMENT, V125, P1137; MANSOUR SL, 1988, NATURE, V336, P348, DOI 10.1038/336348a0; Osada M, 1998, NAT MED, V4, P839, DOI 10.1038/nm0798-839; PARR BA, 1995, NATURE, V374, P350, DOI 10.1038/374350a0; PELLEGRINI G, IN PRESS J CELL BIOL; RHEINWALD JG, 1975, CELL, V6, P331, DOI 10.1016/S0092-8674(75)80001-8; RIDDLE RD, 1995, CELL, V83, P631, DOI 10.1016/0092-8674(95)90103-5; ROBERTS AJ, 1991, J SWIM RES, V7, P5; TICKLE C, 1995, CURR OPIN GENET DEV, V5, P478, DOI 10.1016/0959-437X(95)90052-I; Trink B, 1998, NAT MED, V4, P747, DOI 10.1038/nm0798-747; Vogel A, 1996, DEVELOPMENT, V122, P1737; WANG YQ, 1995, DEV BIOL, V168, P374, DOI 10.1006/dbio.1995.1087; WATT FM, 1991, PHIL T R SOC LOND B, V358, P553; Yang AN, 1998, MOL CELL, V2, P305, DOI 10.1016/S1097-2765(00)80275-0	30	1821	1887	3	80	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	APR 22	1999	398	6729					714	718		10.1038/19539	http://dx.doi.org/10.1038/19539			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	189RP	10227294				2022-12-28	WOS:000079920100052
J	Charatan, F				Charatan, F			Fluid intake affects the risk of bladder cancer in men	BRITISH MEDICAL JOURNAL			English	News Item																		Michaud DS, 1999, NEW ENGL J MED, V340, P1390, DOI 10.1056/NEJM199905063401803	1	3	3	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	MAY 22	1999	318	7195					1372	1372		10.1136/bmj.318.7195.1372	http://dx.doi.org/10.1136/bmj.318.7195.1372			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	200DQ	10334737	Green Published			2022-12-28	WOS:000080524700014
J	Cherry, N				Cherry, N			Recent advances - Occupational disease	BMJ-BRITISH MEDICAL JOURNAL			English	Review							ACID ANHYDRIDES; INDUCED ASTHMA; EXPOSURE; SYMPTOMS; WORKERS; RISK; SENSITIZATION; ASSOCIATION; ALLERGY; COHORT		Univ Manchester, Ctr Occupat Hlth, Manchester M13 9PT, Lancs, England	University of Manchester	Cherry, N (corresponding author), Univ Manchester, Ctr Occupat Hlth, Stopford Bldg, Manchester M13 9PT, Lancs, England.	nicola.cherry@man.ac.uk						Balboni A, 1996, EUR RESPIR J, V9, P207, DOI 10.1183/09031936.96.09020207; Barker RD, 1998, OCCUP ENVIRON MED, V55, P684, DOI 10.1136/oem.55.10.684; BIGNON JS, 1994, AM J RESP CRIT CARE, V149, P71, DOI 10.1164/ajrccm.149.1.8111601; Bosma H, 1997, BRIT MED J, V314, P558, DOI 10.1136/bmj.314.7080.558; CARTER JT, 1991, BRIT J IND MED, V48, P289; Cherry Nicola, 1995, P413; CHERRY NM, 1994, P 9 INT S EP OCC HLT; *COMM MED ASP RAD, 1996, 4 COMARE DEP HLTH; CROFT P, 1994, ANN RHEUM DIS, V53, P525, DOI 10.1136/ard.53.8.525; CULLINAN P, 1994, OCCUP ENVIRON MED, V51, P589, DOI 10.1136/oem.51.9.589; Donaldson K, 1998, J AEROSOL SCI, V29, P553, DOI 10.1016/S0021-8502(97)00464-3; FARROW S, 1994, BRIT MED J, V309, P1; GARDNER MJ, 1990, BRIT MED J, V300, P429, DOI 10.1136/bmj.300.6722.429; Griffin MJ, 1997, OCCUP ENVIRON MED, V54, P73, DOI 10.1136/oem.54.2.73; HARRINGTON JM, 1998, OCCUP ENVIRON MED, V55, P1; HODGSON JT, 1993, SELF REPORTED WORK R; *INT AG RES CANC, 1997, MON EV CARC RISK CHE, V68; Irgens A, 1998, AM J IND MED, V34, P431, DOI 10.1002/(SICI)1097-0274(199811)34:5<431::AID-AJIM3>3.0.CO;2-T; JONES AD, 1997, ANN OCCUP HYG     S1, V41, P244; KIMBER I, 1995, HUM EXP TOXICOL, V14, P735, DOI 10.1177/096032719501400907; Krause N, 1997, SCAND J WORK ENV HEA, V23, P179, DOI 10.5271/sjweh.196; Lin S, 1998, AM J EPIDEMIOL, V148, P173; Liss GM, 1997, OCCUP ENVIRON MED, V54, P335, DOI 10.1136/oem.54.5.335; LYMPANY PA, 1997, AM J RESP CRIT CARE, V155, P1335; McDonald JC, 1997, ANN OCCUP HYG, V41, P699, DOI 10.1093/annhyg/41.6.699; MEREDITH SK, 1989, BR J IND MED, V48, P292; PETO J, 1995, LANCET, V345, P535, DOI 10.1016/S0140-6736(95)90462-X; Punnett L, 1998, OCCUP ENVIRON MED, V55, P414, DOI 10.1136/oem.55.6.414; Richeldi L, 1997, AM J IND MED, V32, P337, DOI 10.1002/(SICI)1097-0274(199710)32:4<337::AID-AJIM3>3.3.CO;2-H; Ross DJ, 1996, ANN OCCUP HYG, V40, P645, DOI 10.1093/annhyg/40.6.645; SEATON A, 1995, LANCET, V345, P176, DOI 10.1016/S0140-6736(95)90173-6; Sjogren B, 1997, OCCUP ENVIRON MED, V54, P466, DOI 10.1136/oem.54.7.466; Sobti A, 1997, AM J IND MED, V32, P76, DOI 10.1002/(SICI)1097-0274(199707)32:1<76::AID-AJIM9>3.0.CO;2-P; Tas S, 1996, CRIT REV TOXICOL, V26, P261, DOI 10.3109/10408449609012525; van der Beek AJ, 1998, OCCUP ENVIRON MED, V55, P291, DOI 10.1136/oem.55.5.291; van Poppel MNM, 1997, OCCUP ENVIRON MED, V54, P841, DOI 10.1136/oem.54.12.841; Werner RA, 1997, OCCUP ENVIRON MED, V54, P96, DOI 10.1136/oem.54.2.96; WHORTON D, 1977, LANCET, V2, P1259; YOUNG RP, 1995, AM J RESP CRIT CARE, V151, P219, DOI 10.1164/ajrccm.151.1.7812558	39	25	26	0	1	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	MAY 22	1999	318	7195					1397	1399		10.1136/bmj.318.7195.1397	http://dx.doi.org/10.1136/bmj.318.7195.1397			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	200DQ	10334753	Green Published			2022-12-28	WOS:000080524700031
J	Cody, SH; Abbott, SL; Marfin, AA; Schulz, B; Wagner, P; Robbins, K; Mohle-Boetani, JC; Vugia, DJ				Cody, SH; Abbott, SL; Marfin, AA; Schulz, B; Wagner, P; Robbins, K; Mohle-Boetani, JC; Vugia, DJ			Two outbreaks of multidrug-resistant Salmonella serotype Typhimurium DT104 infections linked to raw-milk cheese in northern California	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article; Proceedings Paper	35th Annual Meeting of the Infectious-Diseases-Society-of-America	SEP 07-16, 1997	SAN FRANCISCO, CALIFORNIA	Infect Dis Soc Amer			UNITED-STATES	Context Salmonella serotype Typhimurium definitive type 104 (DT104), with resistance to 5 drugs (ampicillin, chloramphenicol, streptomycin, sulfonamides, and tetracycline), has emerged as the most common multidrug-resistant Salmonella strain in the United States, However, illnesses resulting from this strain have not been associated definitively with a source in this country. Objective To determine the source of 2 outbreaks of Salmonella Typhimurium DT104. Design Matched case-control study conducted between March 24 and April 5, 1997 (outbreak 1), enhanced surveillance for new cases dating from February 1, 1997 (outbreak 2), and environmental and laboratory investigations. Setting and Participants The case-control study included residents of 2 adjacent counties in northern California infected with the outbreak strain of Salmonella Typhimurium var Copenhagen and age-matched controls. For enhanced surveillance, a case was defined as Salmonella Typhimurium infection in a person exposed to fresh Mexican-style cheese. Main Outcome Measures Risk factors for infection and source of implicated food. Results Outbreak 1 peaked in February 1997; 31 patients were confirmed by culture as' having Salmonella Typhimurium var Copenhagen infection, isolates of which showed indistinguishable pulsed-field gel electrophoresis (PFGE) patterns. The outbreak strain was phage type DT104 with the 5-drug resistance pattern. Sixteen cases and 25 controls were enrolled in the case-control study; 15 of 16 Salmonella Typhimurium var Copenhagen cases compared with 14 of 24 matched controls reported eating unpasteurized Mexican-style cheese, (matched odds ratio, 7.9; 95% confidence interval, 1.1-354.9). Enhanced surveillance uncovered outbreak 2, which peaked in April 1997 and was caused by a non-Copenhagen variant of Salmonella Typhimurium. During outbreak 2, Salmonella Typhimurium was isolated from 79 persons who ate fresh Mexican-style cheese from street vendors and from cheese samples and raw milk. The PFGE pattern of the milk isolate matched 1 of the 3 patterns recovered from patients; all strains were phage type DT104b with the 5-drug resistance pattern. Conclusion Raw-milk products pose a risk for multidrug-resistant Salmonella Typhimurium DT104 infections.	Calif Dept Hlth Serv, Div Communicable Dis Control, Berkeley, CA 94704 USA; Ctr Dis Control & Prevent, Epidem Intelligence Serv, Epidemiol Program Off, Atlanta, GA USA; Ctr Dis Control & Prevent, Foodborne & Diarrheal Dis Branch, Atlanta, GA USA; Santa Clara Valley Hlth & Hosp Syst, Dept Publ Hlth, San Jose, CA USA; San Mateo Cty Dept Hlth, San Mateo, CA USA; Calif Dept Food & Agr, Milk & Dairy Branch, Sacramento, CA 95814 USA	California Department of Health Care Services; Centers for Disease Control & Prevention - USA; Centers for Disease Control & Prevention - USA; California Department of Food & Agriculture	Cody, SH (corresponding author), Santa Clara Cty Dept Publ Hlth, 2220 Moorpark Ave 115, San Jose, CA 95128 USA.		Mohle-Boetani, Janet/AAH-4221-2019					ANDERSON ES, 1977, J HYG-CAMBRIDGE, V78, P297, DOI 10.1017/S0022172400056187; *CDCP, 1995, SALM SURV ANN TAB SU; Cooke, 1996, COMMUN DIS REP CDR R, V6, P159; Dean A.G., 1994, EPI INFO VERSION 6 W; Fone D. L., 1994, COMMUNICAB DIS REP, V4, P136; FRIEDMAN CR, 1998, INT C EM INF DIS MAR; Glynn MK, 1998, NEW ENGL J MED, V338, P1333, DOI 10.1056/NEJM199805073381901; Headrick ML, 1998, AM J PUBLIC HEALTH, V88, P1219, DOI 10.2105/AJPH.88.8.1219; Headrick ML, 1997, PUBLIC HEALTH REP, V112, P418; HELMICK CG, 1994, NIH PUBLICATION, P85; HICKMANBRENNER FW, 1991, J CLIN MICROBIOL, V29, P2817, DOI 10.1128/JCM.29.12.2817-2823.1991; Keene WE, 1997, J INFECT DIS, V176, P815, DOI 10.1086/517310; LINNAN MJ, 1988, NEW ENGL J MED, V319, P823, DOI 10.1056/NEJM198809293191303; Murthy G.K., 1992, STANDARD METHODS EXA, P413; POTTER ME, 1984, JAMA-J AM MED ASSOC, V252, P2048, DOI 10.1001/jama.252.15.2048; Threlfall EJ, 1996, LANCET, V347, P1053, DOI 10.1016/S0140-6736(96)90199-3; Villar RG, 1999, JAMA-J AM MED ASSOC, V281, P1811, DOI 10.1001/jama.281.19.1811; Wall P G, 1994, Commun Dis Rep CDR Rev, V4, pR130; WOOD RC, 1992, JAMA-J AM MED ASSOC, V268, P3228, DOI 10.1001/jama.268.22.3228	19	126	128	0	6	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAY 19	1999	281	19					1805	1810		10.1001/jama.281.19.1805	http://dx.doi.org/10.1001/jama.281.19.1805			6	Medicine, General & Internal	Conference Proceedings Citation Index - Science (CPCI-S); Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	196BH	10340367	Bronze			2022-12-28	WOS:000080288800033
J	Turner, RB; Wecker, MT; Pohl, G; Witek, TJ; McNally, E; St George, R; Winther, B; Hayden, FG				Turner, RB; Wecker, MT; Pohl, G; Witek, TJ; McNally, E; St George, R; Winther, B; Hayden, FG			Efficacy of tremacamra, a soluble intercellular adhesion molecule 1, for experimental rhinovirus infection - A randomized clinical trial	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							IN-VITRO; INTRANASAL ALPHA-2-INTERFERON; COLDS; INTERLEUKIN-8; RECEPTOR; PROPHYLAXIS; PREVENTION; VOLUNTEERS; INVITRO; ICAM-1	Context Attachment of most rhinovirus subtypes to cells depends on a cellular receptor, the intercellular adhesion molecule 1 (ICAM-1). A recombinant soluble ICAM-1 (tremacamra, formerly BIRR 4) has shown possible efficacy in early studies. Objective To determine the efficacy and safety of intranasal administration of tremacamra in experimental rhinovirus colds in humans. Design Four randomized, double-blind, placebo-controlled trials conducted in January to March 1996, Setting and Subjects Volunteers between the ages of 18 and 60 years who had an antibody titer of 1:4 or less to the challenge virus. Subjects were isolated in a hotel room during study days 0 to 8; symptoms were recorded through day 14, A total of 198 subjects were randomized, of whom 196 received drug or placebo and were included in the safety analysis. A total of 177 subjects were included in the efficacy analysis. Interventions Tremacamra or placebo was given beginning 7 hours before inoculation with rhinovirus type 39 (preinoculation studies) or 12 hours after (postinoculation studies). Tremacamra as an inhaled solution or as a powder (each given preinoculation and postinoculation for a total of 4 studies) and placebo were given in 6 doses at 3-hour intervals daily during days 1 through 7, Recipients of active treatment received 367 mu g of tremacamra per nostril per dose for a total of 4.4 mg/d. Main Outcome Measures Effect of tremacamra on infection, as determined by virus isolation and seroconversion, and on illness, as determined by symptom scores, clinical colds, and nasal mucus weights. Treatment-by-study interaction was not significant, so results were pooled for the main analysis. Results A total of 88 (92%) of the 96 subjects in the placebo groups and 69 (85%) of the 81 subjects in the active treatment groups were infected (P=.19). For placebo vs tremacamra, respectively, the total symptom score (+/- 95% confidence interval [CI]) was 17.6 (+/- 2.7) vs 9.6 (+/- 2.9), the proportion of clinical colds was 64/96 (67% +/- 9%) vs 36/81 (44% +/- 11%), and the nasal mucus weight was 32.9 (+/- 8.8) g vs 14.5 (+/- 9.4) g (P<.001 for all comparisons). Tremacamra was not associated with adverse effects or evidence of absorption through the nasal mucosa and did not interfere with development of neutralizing antibody. Conclusion Tremacamra reduced the severity of experimental rhinovirus colds. Whether tremacamra will be useful clinically will require further study.	Med Univ S Carolina, Dept Pediat, Charleston, SC 29425 USA; Med Univ S Carolina, Dept Lab Med, Charleston, SC 29425 USA; Boehringer Ingelheim Pharmaceut Inc, Ridgefield, CT 06877 USA; Univ Virginia, Hlth Sci Ctr, Dept Otolaryngol, Charlottesville, VA USA; Univ Virginia, Hlth Sci Ctr, Dept Internal Med, Charlottesville, VA USA; Univ Virginia, Hlth Sci Ctr, Dept Pathol, Charlottesville, VA USA	Medical University of South Carolina; Medical University of South Carolina; Boehringer Ingelheim; University of Virginia; University of Virginia; University of Virginia	Turner, RB (corresponding author), Med Univ S Carolina, Dept Pediat, Clin Sci Bldg,Room 312,171 Ashley Ave, Charleston, SC 29425 USA.	turnerr@musc.edu						ABRAHAM G, 1984, J VIROL, V51, P340, DOI 10.1128/JVI.51.2.340-345.1984; ANDRIES K, 1992, ANTIMICROB AGENTS CH, V36, P100, DOI 10.1128/AAC.36.1.100; Arruda E, 1996, J CLIN MICROBIOL, V34, P1277, DOI 10.1128/JCM.34.5.1277-1279.1996; Barrow GI, 1990, ANTIVIR CHEM CHEMOTH, V1, P279, DOI 10.1177/095632029000100501; CAME PE, 1976, J INFECT DIS, V133, pA136, DOI 10.1093/infdis/133.Supplement_2.A136; CRUMP CE, 1993, ANTIVIR CHEM CHEMOTH, V4, P323, DOI 10.1177/095632029300400603; DELONG DC, 1980, J INFECT DIS, V141, P87, DOI 10.1093/infdis/141.1.87; DOUGLAS RM, 1986, NEW ENGL J MED, V314, P65, DOI 10.1056/NEJM198601093140201; GREVE JM, 1989, CELL, V56, P839, DOI 10.1016/0092-8674(89)90688-0; Grunberg K, 1997, CLIN EXP ALLERGY, V27, P36, DOI 10.1111/j.1365-2222.1997.tb00670.x; Gwaltney J.M., 1989, DIAGNOSTIC PROCEDURE, P579; GWALTNEY JM, 1992, PROG MED VIROL, V39, P256; Harris JM, 1996, CLIN INFECT DIS, V23, P1287, DOI 10.1093/clinids/23.6.1287; HAYDEN FG, 1986, NEW ENGL J MED, V314, P71, DOI 10.1056/NEJM198601093140202; HAYDEN FG, 1988, ANTIVIR RES, V9, P233, DOI 10.1016/0166-3542(88)90055-1; HAYDEN FG, 1984, J INFECT DIS, V150, P174, DOI 10.1093/infdis/150.2.174; HAYDEN FG, 1992, ANTIMICROB AGENTS CH, V36, P727, DOI 10.1128/AAC.36.4.727; HAYDEN FG, 1983, J INFECT DIS, V148, P543, DOI 10.1093/infdis/148.3.543; HENDLEY JO, 1972, J INFECT DIS, V125, P243, DOI 10.1093/infdis/125.3.243; HIGGINS PG, 1986, J INTERFERON RES, V6, P153, DOI 10.1089/jir.1986.6.153; Huguenel ED, 1997, AM J RESP CRIT CARE, V155, P1206, DOI 10.1164/ajrccm.155.4.9105055; ISHITSUKA H, 1982, ANTIMICROB AGENTS CH, V22, P617, DOI 10.1128/AAC.22.4.617; JACKSON GG, 1958, ARCH INTERN MED, V101, P267, DOI 10.1001/archinte.1958.00260140099015; KENNY MT, 1985, ANTIMICROB AGENTS CH, V28, P745, DOI 10.1128/AAC.28.6.745; MARLIN SD, 1990, NATURE, V344, P70, DOI 10.1038/344070a0; MONTO AS, 1986, J INFECT DIS, V154, P128, DOI 10.1093/infdis/154.1.128; ROZHON E, 1993, ANTIVIR RES, V21, P15, DOI 10.1016/0166-3542(93)90064-P; STAUNTON DE, 1989, CELL, V56, P849, DOI 10.1016/0092-8674(89)90689-2; Teran LM, 1997, AM J RESP CRIT CARE, V155, P1362, DOI 10.1164/ajrccm.155.4.9105080; Turner RB, 1998, CLIN INFECT DIS, V26, P840, DOI 10.1086/513922; WOODS MG, 1989, ANTIMICROB AGENTS CH, V33, P2069, DOI 10.1128/AAC.33.12.2069; ZERIAL A, 1985, ANTIMICROB AGENTS CH, V27, P846, DOI 10.1128/AAC.27.5.846; Zhu Z, 1996, J CLIN INVEST, V97, P421, DOI 10.1172/JCI118431; Zhu Z, 1997, AM J PHYSIOL-LUNG C, V273, pL814, DOI 10.1152/ajplung.1997.273.4.L814	34	132	140	0	5	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAY 19	1999	281	19					1797	1804		10.1001/jama.281.19.1797	http://dx.doi.org/10.1001/jama.281.19.1797			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	196BH	10340366	Bronze			2022-12-28	WOS:000080288800032
J	Davies, HTO; Marshall, MN				Davies, HTO; Marshall, MN			Public disclosure of performance data: does the public get what the public wants?	LANCET			English	Editorial Material							CONSUMERS; QUALITY		Univ Exeter, Inst Gen Practice, Exeter, Devon, England; Univ St Andrews, Dept Management, St Andrews KY16 9AL, Fife, Scotland	University of Exeter; University of St Andrews	Davies, HTO (corresponding author), Univ Calif San Francisco, Inst Hlth Policy Studies, San Francisco, CA 94143 USA.							Chassin MR, 1996, NEW ENGL J MED, V335, P1060, DOI 10.1056/NEJM199610033351413; Davies H T, 1997, J Eval Clin Pract, V3, P187, DOI 10.1046/j.1365-2753.1997.00003.x; EdgmanLevitan S, 1996, HEALTH AFFAIR, V15, P42, DOI 10.1377/hlthaff.15.4.42; Gabel JR, 1998, EMPLOYERS CHOOSE HLT; HANNAN EL, 1995, JAMA-J AM MED ASSOC, V273, P209, DOI 10.1001/jama.273.3.209; Hibbard JH, 1997, HEALTH AFFAIR, V16, P218, DOI 10.1377/hlthaff.16.3.218; Hibbard JH, 1997, HEALTH AFFAIR, V16, P172, DOI 10.1377/hlthaff.16.6.172; LONGO DR, 1997, JAMA-J AM MED ASSOC, V178, P1579; Nutley S, 1998, J Health Serv Res Policy, V3, P50; Smith P., 1995, INT J PUBLIC ADMIN, V18, P277, DOI DOI 10.1080/01900699508525011; Smith R, 1998, BMJ-BRIT MED J, V316, P1917, DOI 10.1136/bmj.316.7149.1917	11	38	39	1	6	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	MAY 15	1999	353	9165					1639	1640		10.1016/S0140-6736(99)90047-8	http://dx.doi.org/10.1016/S0140-6736(99)90047-8			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	198DT	10335781				2022-12-28	WOS:000080408000006
J	Des Jarlais, DC; Paone, D; Milliken, J; Turner, CF; Miller, H; Gribble, J; Shi, QH; Hagan, H; Friedman, SR				Des Jarlais, DC; Paone, D; Milliken, J; Turner, CF; Miller, H; Gribble, J; Shi, QH; Hagan, H; Friedman, SR			Audio-computer interviewing to measure risk behaviour for HIV among injecting drug users: a quasi-randomised trial	LANCET			English	Article								Background We aimed to assess audio-computer-assisted self-interviewing (audio-CASI) as a method of reducing underreporting of HIV risk behaviour among injecting drug users. Methods Injecting drug users were interviewed at syringe exchange programmes in four US cities. Potential respondents were randomly selected from participants in the syringe exchanges, with weekly alternate assignment to either traditional face-to-face interviews or audio-CASI. The questionnaire included items on sociodemographic characteristics, drug use, and HIV risk behaviours for 30 days preceding the interview. We calculated odds ratios for the difference in reporting of HIV risk behaviours between interview methods. Findings 757 respondents were interviewed face-to-face, and 724 were interviewed by audio-CASI. More respondents reported HIV risk behaviours and other sensitive behaviours in audio-CASI than in face-to-face interviews (odds ratios for reporting of rented or bought used injection equipment in audio-CASI vs face-to-face interview 2.1 [95% CI 1.4-3.3] p=0.001; for injection with borrowed used injection equipment 1.5 [1.1-2.2] p=0.02; for renting or selling used equipment 2.3 [1.3-4.0] p=0.003). Interpretation Although validation of these self-reported behaviours was not possible, we propose that audio-CASI enables substantially more complete reporting of HIV risk behaviour. More complete reporting might increase understanding of the dynamics of HIV transmission and make the assessment of HIV-prevention efforts easier.	Beth Israel Deaconess Med Ctr, Inst Chem Dependency, New York, NY 10003 USA; Res Triangle Inst, Washington, DC USA; Seattle King Cty Dept Publ Hlth, Seattle, WA USA; Natl Dev & Res Inst Inc, New York, NY USA	Harvard University; Beth Israel Deaconess Medical Center; Research Triangle Institute; National Development & Research Institutes, Inc	Des Jarlais, DC (corresponding author), Beth Israel Deaconess Med Ctr, Inst Chem Dependency, 1st Ave & 16th St, New York, NY 10003 USA.				NATIONAL INSTITUTE ON DRUG ABUSE [R01DA009536] Funding Source: NIH RePORTER; NIDA NIH HHS [R01 DA 09536] Funding Source: Medline	NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission); NIDA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA))		BLOWER SM, 1991, PHILOS T R SOC B, V331, P171, DOI 10.1098/rstb.1991.0006; COYLE SL, 1991, EVALUATING AIDS PREV; CROFTS N, 1996, HCV INJECTIONG DRUG; DESJARIAIS DC, 1996, P 21 INT C AIDS VANC, P244; DesJarlais DC, 1996, AM J PUBLIC HEALTH, V86, P1780, DOI 10.2105/AJPH.86.12.1780; DESJARLAIS DC, 1994, AM J PUBLIC HEALTH, V84, P452, DOI 10.2105/AJPH.84.3.452; FRIEDMAN SR, 1998, AIDS SOC, V11, P12; GERBERDING JL, 1995, NEW ENGL J MED, V332, P444, DOI 10.1056/NEJM199502163320707; HAGAN H, 1992, P 8 INT C AIDS AMST, pC292; HAGAN H, 1996, P 10 INT C AIDS VANC, P232; Jarlais DCD, 1996, LANCET, V348, P987, DOI 10.1016/S0140-6736(96)02536-6; JONES EF, 1992, DEMOGRAPHY, V29, P113, DOI 10.2307/2061366; Kretzschmar M, 1998, AIDS, V12, P801, DOI 10.1097/00002030-199807000-00017; LURIE P, 1993, PUBLIC HLTH IMPACT N, V1; MILLER HG, 1990, 2 DECADE; MILLER HG, 1998, SCI SELF REPORT; NORMAND J, 1995, PREVENTING HIV TRANS; PETERSON D, 1990, J ACQ IMMUN DEF SYND, V3, P1086; Turner C. F., 1992, SURVEY MEASUREMENT D; Turner CF, 1998, SCIENCE, V280, P867, DOI 10.1126/science.280.5365.867; TURNER CF, 1989, AIDS SEXUAL BEHAV IN; TURNER CF, 1998, COMPUTER ASSISTED SU	22	339	342	0	5	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	MAY 15	1999	353	9165					1657	1661						5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	198DT	10335785				2022-12-28	WOS:000080408000010
J	Palmer, S; Byford, S; Raftery, J				Palmer, S; Byford, S; Raftery, J			Economic notes - Types of economic evaluation	BRITISH MEDICAL JOURNAL			English	Article							HEALTH		Univ York, Ctr Hlth Econ, York YO1 5DD, N Yorkshire, England; Univ Birmingham, Hlth Serv Management Ctr, Hlth Econ Facil, Birmingham B15 2RT, W Midlands, England	University of York - UK; University of Birmingham	Palmer, S (corresponding author), Univ York, Ctr Hlth Econ, York YO1 5DD, N Yorkshire, England.		Byford, Sarah/D-1699-2010	Byford, Sarah/0000-0001-7084-1495				BIRCH S, 1992, J HEALTH ECON, V11, P279, DOI 10.1016/0167-6296(92)90004-K; Byford S, 1998, BRIT MED J, V316, P1529, DOI 10.1136/bmj.316.7143.1529; Phelps C E, 1991, Int J Technol Assess Health Care, V7, P12; ROBINSON R, 1993, BRIT MED J, V307, P859, DOI 10.1136/bmj.307.6908.859; TORRANCE GW, 1986, J HEALTH ECON, V5, P1, DOI 10.1016/0167-6296(86)90020-2; Torrance GW, 1987, METHODS EC EVALUATIO; Weinstein M., 1973, J PUBLIC ECON, V2, P147, DOI DOI 10.1016/0047-2727(73)90002-9; WEINSTEIN MC, 1977, NEW ENGL J MED, V296, P716, DOI 10.1056/NEJM197703312961304	8	48	52	0	10	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	MAY 15	1999	318	7194					1349	1349		10.1136/bmj.318.7194.1349	http://dx.doi.org/10.1136/bmj.318.7194.1349			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	198HR	10323827	Green Published			2022-12-28	WOS:000080418400043
J	Portenoy, RK; Lesage, P				Portenoy, RK; Lesage, P			Management of cancer pain	LANCET			English	Article							QUALITY-OF-LIFE; THERAPY; MORPHINE	Patients with cancer have diverse symptoms, impairments In physical and psychological functioning, and other difficulties that can undermine their quality of life. If inadequately controlled, pain can have a profoundly adverse impact on the patient and his or her family. The critical importance of pain management as part of routine cancer care has been forcefully advanced by WHO, international and national professional organisations, and governmental agencies. The prevalence of chronic pain is about 30-50% among patients with cancer who are undergoing active treatment for a solid tumour and 70-90% among those with advanced disease. Prospective surveys indicate that as many as 90% of patients could attain adequate relief with simple drug therapies, but this success rate is not achieved in routine practice. Inadequate management of pain is the result of various issues that include: undertreatment by clinicians with insufficient knowledge of pain assessment and therapy; inappropriate concerns about opioid side-effects and addiction; a tendency to give lower priority to symptom control than to disease management; patients under-reporting of pain and non-compliance with therapy; and impediments to optimum analgesic therapy in the healthcare system. To improve the management of cancer pain, every practitioner involved in the care of these patients must ensure that his or her medical information is current and that patients receive appropriate education.	Beth Israel Deaconess Med Ctr, Dept Pain Med & Palliat Care, New York, NY 10003 USA	Harvard University; Beth Israel Deaconess Medical Center	Portenoy, RK (corresponding author), Beth Israel Deaconess Med Ctr, Dept Pain Med & Palliat Care, New York, NY 10003 USA.	Rportenoy@bethisraelny.org						Ahmedzai S, 1997, J PAIN SYMPTOM MANAG, V13, P254, DOI 10.1016/S0885-3924(97)00082-1; *AM PAIN SOC, 1992, PRINC AN US TREATM A; Bloomfield DJ, 1998, J CLIN ONCOL, V16, P1218, DOI 10.1200/JCO.1998.16.3.1218; BRUERA E, 1990, ADV PAIN RES THER, V16, P203; Bruera E, 1996, CANCER, V78, P852, DOI 10.1002/(SICI)1097-0142(19960815)78:4<852::AID-CNCR23>3.0.CO;2-T; Burris HA, 1997, J CLIN ONCOL, V15, P2403, DOI 10.1200/JCO.1997.15.6.2403; CASSEL EJ, 1982, NEW ENGL J MED, V306, P639, DOI 10.1056/NEJM198203183061104; CELLA DF, 1994, J PAIN SYMPTOM MANAG, V9, P186, DOI 10.1016/0885-3924(94)90129-5; Cherny N I, 1994, J Palliat Care, V10, P57; CHERNY NI, IN PRESS TXB PAIN; Curtis E B, 1991, J Palliat Care, V7, P25; Derby S, 1998, CNS DRUGS, V9, P99, DOI 10.2165/00023210-199809020-00003; DERBY S, 1997, T PALLIAT CARE, V1, P95; DOYLE E, 1998, OXFORD TXB PALLIATIV; Ingham JM, 1993, CURR OPIN ANAESTH, V6, P838; Jacox A, 1994, AHCPR PUBLICATION; Portenoy R. K., 1994, Annals Academy of Medicine Singapore, V23, P160; PORTENOY RK, 1990, PAIN, V43, P273, DOI 10.1016/0304-3959(90)90025-9; Portenoy RK, 1999, PAIN, V79, P303, DOI 10.1016/S0304-3959(98)00179-1; PORTENOY RK, 1994, QUAL LIFE RES, V3, P183, DOI 10.1007/BF00435383; PORTENOY RK, 1992, LANCET, V339, P1026, DOI 10.1016/0140-6736(92)90545-E; PORTENOY RK, 1998, CONT DIAGNOSIS MANAG, P40; PORTENOY RK, 1998, OXFORD TXB PALLIATIV, P361; RIPAMONTI C, 1994, J PAIN SYMPTOM MANAG, V9, P193, DOI 10.1016/0885-3924(94)90130-9; Saunders C, 1984, MANAGEMENT TERMINAL, P232; Vane JR, 1998, ANNU REV PHARMACOL, V38, P97, DOI 10.1146/annurev.pharmtox.38.1.97; VENTAFRIDDA V, 1990, ANN ONCOL, V1, P415, DOI 10.1093/oxfordjournals.annonc.a057794; Waldman Steven D., 1993, P285; World Health Organization, 1996, CANC PAIN REL PALL C	29	452	478	3	20	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	MAY 15	1999	353	9165					1695	1700		10.1016/S0140-6736(99)01310-0	http://dx.doi.org/10.1016/S0140-6736(99)01310-0			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	198DT	10335806				2022-12-28	WOS:000080408000047
J	Ragnarsson, G				Ragnarsson, G			Opposition to the Icelandic database is based on false information	BRITISH MEDICAL JOURNAL			English	Letter									Fjolbrautaskolinn Gardabae, IS-210 Gardabae, Iceland		Ragnarsson, G (corresponding author), Fjolbrautaskolinn Gardabae, IS-210 Gardabae, Iceland.		Ragnarsson, Gisli/B-6668-2008	Ragnarsson, Gisli/0000-0002-2943-4377				Duncan N, 1999, BRIT MED J, V318, P1096, DOI 10.1136/bmj.318.7191.1096a	1	3	3	0	5	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	MAY 15	1999	318	7194					1354	1354		10.1136/bmj.318.7194.1354	http://dx.doi.org/10.1136/bmj.318.7194.1354			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	198HR	10323837	Green Published			2022-12-28	WOS:000080418400055
J	Selby, M				Selby, M			How to drive away teenagers	BRITISH MEDICAL JOURNAL			English	Article														lowth, mary/0000-0002-0058-8591					0	0	0	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	MAY 15	1999	318	7194					1323	1323		10.1136/bmj.318.7194.1323	http://dx.doi.org/10.1136/bmj.318.7194.1323			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	198HR	10323819	Green Published			2022-12-28	WOS:000080418400027
J	Tonnesen, H; Rosenberg, J; Nielsen, HJ; Rasmussen, V; Hauge, C; Pedersen, IK; Kehlet, H				Tonnesen, H; Rosenberg, J; Nielsen, HJ; Rasmussen, V; Hauge, C; Pedersen, IK; Kehlet, H			Effect of preoperative abstinence on poor postoperative outcome in alcohol misusers: randomised controlled trial	BMJ-BRITISH MEDICAL JOURNAL			English	Article							MORBIDITY; RESECTION; PARAMETERS; DISEASE; SEPSIS; RISK	Objective To evaluate the influence of preoperative abstinence on postoperative outcome in alcohol misusers with no symptoms who were drinking the equivalent of at least 60 g ethanol/day. Design Randomised controlled trial. Setting Copenhagen, Denmark. Subjects 42 alcoholic patients without liver disease admitted for elective colorectal surgery. Interventions Withdrawal from alcohol consumption for 1 month before operation (disulfiram controlled) compared with continuous drinking. Main outcome measures Postoperative complications requiring treatment within the first month after surgery. Perioperative immunosuppression measured by delayed type hypersensitivity; myocardial ischaemia and arrhythmias measured by Holter tape recording; episodes of hypoxaemia measured by pulse oximetry. Response to stress during the operation were assessed by heart rate, blood pressure, serum concentration of cortisol, and plasma concentrations of glucose, interleukin 6, and catecholamines. Results The intervention group developed significantly fewer postoperative complications than the continuous drinkers (31% v 74%, P = 0.02). Delayed type hypersensitivity responses were better in the intervention group before (37 mm(2) v 12 mm(2), P = 0.04), but not after surgery (3 mm(2) v 3 mm(2)). Development of postoperative myocardial ischaemia (23% v 85%) and arrhythmias (33% v 86%) on the second postoperative day as well as nightly hypoxaemic episodes (4 v 18 on the second postoperative night) occurred significantly less often in the intervention group. Surgical stress responses were lower in the intervention group (P less than or equal to 0.05). Conclusions One month of preoperative abstinence reduces postoperative morbidity in alcohol abusers. The mechanism is probably reduced preclinical organ dysfunction and reduction of the exaggerated response to surgical stress.	Univ Copenhagen, Hvidovre Hosp, Dept Surg Gastroenterol, DK-2650 Hvidovre, Denmark; Univ Copenhagen, Hvidovre Hosp, Dept Cardiol, Holter Lab, DK-2650 Hvidovre, Denmark; Univ Copenhagen, Bispebjerg Hosp, Dept Surg Gastroenterol, DK-2400 Copenhagen NV, Denmark; Univ Copenhagen, Herlev Hosp, Dept Surg, DK-2730 Herlev, Denmark	University of Copenhagen; University of Copenhagen; University of Copenhagen; Bispebjerg Hospital; University of Copenhagen; Herlev & Gentofte Hospital	Tonnesen, H (corresponding author), Bispebjerg Hosp, Clin Unit Prevent Med & Hlth Promot, Bispebjerg Bakke 24, DK-2400 Copenhagen NV, Denmark.	ht02@bbh.hosp.dk		Tonnesen, Hanne/0000-0002-7161-3416; Nielsen, Hans Jorgen/0000-0003-2619-4379				*AM SOC AN, 1965, ANESTHESIOLOGY, V24, P111; [Anonymous], 1996, Am J Public Health, V86, P948; APPEL E, 1981, N-S ARCH PHARMACOL, V315, P233, DOI 10.1007/BF00499840; BOKEY EL, 1995, DIS COLON RECTUM, V38, P480, DOI 10.1007/BF02148847; CHRISTOU NV, 1985, CAN J SURG, V28, P39; DAMAS P, 1992, ANN SURG, V215, P356, DOI 10.1097/00000658-199204000-00009; FELDING C, 1992, AM J OBSTET GYNECOL, V166, P667, DOI 10.1016/0002-9378(92)91695-7; GOLDMAN L, 1977, NEW ENGL J MED, V297, P845, DOI 10.1056/NEJM197710202971601; KELBAEK H, 1987, BRIT HEART J, V58, P352; LaVecchia L, 1996, CLIN CARDIOL, V19, P45; LeBon O, 1997, J STUD ALCOHOL, V58, P30, DOI 10.15288/jsa.1997.58.30; Mangano DT, 1995, NEW ENGL J MED, V333, P1750, DOI 10.1056/NEJM199512283332607; Marchesi C, 1997, PSYCHIAT RES, V72, P187, DOI 10.1016/S0165-1781(97)00101-7; MARTIN PR, 1995, ALCOHOL CLIN EXP RES, V19, P1078, DOI 10.1111/j.1530-0277.1995.tb00992.x; POPHAM RE, 1981, J STUD ALCOHOL, V42, P355, DOI 10.15288/jsa.1981.42.355; ROSENBERG J, 1990, BRIT J ANAESTH, V65, P684, DOI 10.1093/bja/65.5.684; ROSENBERG J, 1997, PHYSL STRESS MALNUTR; Simms J M, 1982, Clin Nutr, V1, P71, DOI 10.1016/0261-5614(82)90007-3; Spies CD, 1996, ACTA ANAESTH SCAND, V40, P649, DOI 10.1111/j.1399-6576.1996.tb04505.x; Stage JG, 1997, BRIT J SURG, V84, P391, DOI 10.1046/j.1365-2168.1997.02516.x; TONNESEN H, 1992, BRIT J ADDICT, V87, P1025; TONNESEN H, 1987, DIS COLON RECTUM, V30, P549, DOI 10.1007/BF02554788; TONNESEN H, 1992, LANCET, V340, P334; TONNESEN H, IN PRESS ALCOHOL ALC; Vignali A, 1997, J AM COLL SURGEONS, V185, P105, DOI 10.1016/S1072-7515(01)00891-2; WILLIAMS HL, 1981, ALCOHOL CLIN EXP RES, V5, P318, DOI 10.1111/j.1530-0277.1981.tb04905.x	26	158	165	0	8	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	MAY 15	1999	318	7194					1311	1316		10.1136/bmj.318.7194.1311	http://dx.doi.org/10.1136/bmj.318.7194.1311			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	198HR	10323814	Green Submitted, Bronze, Green Published			2022-12-28	WOS:000080418400023
J	Horwitz, GD; Newsome, WT				Horwitz, GD; Newsome, WT			Separate signals for target selection and movement specification in the superior colliculus	SCIENCE			English	Article							NEURONAL-ACTIVITY; EYE-MOVEMENTS; MONKEY; DISSOCIATION; RESPONSES; MACAQUES; MOTION; MEMORY; CELLS	At any given instant, multiple potential targets for saccades are present in the: visual world, implying that a "selection process" within the brain determines: the target of the next eye movement, Some superior colliculus (SC) neurons: begin discharging seconds before saccade initiation, suggesting involvement in target selection or, alternatively, in postselectional saccade preparation. SC neurons were recorded in monkeys who selected saccade targets on the basis of motion direction in a visual display. Some neurons carried a direction- selective visual signal, consistent with a role in target selection in this task, whereas other SC neurons appeared to be more involved in postselection specification of saccade parameters.	Stanford Univ, Sch Med, Howard Hughes Med Inst, Stanford, CA 94305 USA; Stanford Univ, Sch Med, Dept Neurobiol, Stanford, CA 94305 USA	Howard Hughes Medical Institute; Stanford University; Stanford University	Newsome, WT (corresponding author), Stanford Univ, Sch Med, Howard Hughes Med Inst, Stanford, CA 94305 USA.	bill@monkeybiz.stanford.edu	Newsome, William T./W-7171-2019	Horwitz, Gregory/0000-0001-5130-5259	NIH HHS [5T32NH17047-17] Funding Source: Medline	NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA)		Basso MA, 1998, J NEUROSCI, V18, P7519; Bichot NP, 1996, NATURE, V381, P697, DOI 10.1038/381697a0; BRITTEN KH, 1992, J NEUROSCI, V12, P4745; GLIMCHER PW, 1992, NATURE, V355, P542, DOI 10.1038/355542a0; GNADT JW, 1988, EXP BRAIN RES, V70, P216; Green DM, 1966, SIGNAL DETECTION THE; Kim JN, 1999, NAT NEUROSCI, V2, P176, DOI 10.1038/5739; MAYS LE, 1980, J NEUROPHYSIOL, V43, P207, DOI 10.1152/jn.1980.43.1.207; Mazzoni P, 1996, J NEUROPHYSIOL, V76, P1439, DOI 10.1152/jn.1996.76.3.1439; MUNOZ DP, 1995, J NEUROPHYSIOL, V73, P2313, DOI 10.1152/jn.1995.73.6.2313; ROBINSON DA, 1963, IEEE T BIO-MED ENG, VBM10, P137, DOI 10.1109/TBMEL.1963.4322822; Roitman J. D., 1998, Society for Neuroscience Abstracts, V24, P262; SCHALL JD, 1993, NATURE, V366, P467, DOI 10.1038/366467a0; SCHILLER PH, 1971, J NEUROPHYSIOL, V34, P920, DOI 10.1152/jn.1971.34.5.920; Shadlen MN, 1996, P NATL ACAD SCI USA, V93, P628, DOI 10.1073/pnas.93.2.628; SPARKS DL, 1978, BRAIN RES, V156, P1, DOI 10.1016/0006-8993(78)90075-6; WURTZ RH, 1971, SCIENCE, V171, P82, DOI 10.1126/science.171.3966.82; WURTZ RH, 1972, J NEUROPHYSIOL, V35, P575, DOI 10.1152/jn.1972.35.4.575	18	247	248	0	7	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAY 14	1999	284	5417					1158	1161		10.1126/science.284.5417.1158	http://dx.doi.org/10.1126/science.284.5417.1158			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	197HJ	10325224				2022-12-28	WOS:000080359100034
J	Laney, JD; Hochstrasser, M				Laney, JD; Hochstrasser, M			Substrate targeting in the ubiquitin system	CELL			English	Review							NF-KAPPA-B; DEPENDENT PROTEOLYSIS; PROTEASOME PATHWAY; BETA-CATENIN; DEGRADATION; PROTEIN; INHIBITION; SIGNALS; LIGASE; MOTIF		Univ Chicago, Dept Biochem & Mol Biol, Chicago, IL 60637 USA	University of Chicago	Hochstrasser, M (corresponding author), Univ Chicago, Dept Biochem & Mol Biol, 920 E 58Th St, Chicago, IL 60637 USA.			Hochstrasser, Mark/0000-0002-1131-5484				Aberle H, 1997, EMBO J, V16, P3797, DOI 10.1093/emboj/16.13.3797; FUCHS SY, 1999, IN PRESS ONCOGENE; Ghosh S, 1998, ANNU REV IMMUNOL, V16, P225, DOI 10.1146/annurev.immunol.16.1.225; Gilon T, 1998, EMBO J, V17, P2759, DOI 10.1093/emboj/17.10.2759; Goulet CC, 1998, J BIOL CHEM, V273, P30012, DOI 10.1074/jbc.273.45.30012; Harrison SC, 1996, CELL, V86, P341, DOI 10.1016/S0092-8674(00)80105-1; Hart M, 1999, CURR BIOL, V9, P207, DOI 10.1016/S0960-9822(99)80091-8; Hershko A, 1998, ANNU REV BIOCHEM, V67, P425, DOI 10.1146/annurev.biochem.67.1.425; Jiang J, 1998, NATURE, V391, P493, DOI 10.1038/35154; Johnson PR, 1998, CELL, V94, P217, DOI 10.1016/S0092-8674(00)81421-X; Koepp DM, 1999, CELL, V97, P431, DOI 10.1016/S0092-8674(00)80753-9; Latres E, 1999, ONCOGENE, V18, P849, DOI 10.1038/sj.onc.1202653; Lu PJ, 1999, SCIENCE, V283, P1325, DOI 10.1126/science.283.5406.1325; Margottin F, 1998, MOL CELL, V1, P565, DOI 10.1016/S1097-2765(00)80056-8; Marikawa Y, 1998, MECH DEVELOP, V77, P75, DOI 10.1016/S0925-4773(98)00134-8; Patton EE, 1998, TRENDS GENET, V14, P236, DOI 10.1016/S0168-9525(98)01473-5; Rubinfeld B, 1997, SCIENCE, V275, P1790, DOI 10.1126/science.275.5307.1790; SADIS S, 1995, MOL CELL BIOL, V15, P4086; Sommer T, 1997, FASEB J, V11, P1227, DOI 10.1096/fasebj.11.14.9409541; Spencer E, 1999, GENE DEV, V13, P284, DOI 10.1101/gad.13.3.284; Varshavsky A, 1997, GENES CELLS, V2, P13, DOI 10.1046/j.1365-2443.1997.1020301.x; Wang GL, 1999, MOL CELL BIOL, V19, P342; Winston JT, 1999, GENE DEV, V13, P270, DOI 10.1101/gad.13.3.270; Yaron A, 1997, EMBO J, V16, P6486, DOI 10.1093/emboj/16.21.6486; Yaron A, 1998, NATURE, V396, P590, DOI 10.1038/25159	25	374	396	0	21	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	MAY 14	1999	97	4					427	430		10.1016/S0092-8674(00)80752-7	http://dx.doi.org/10.1016/S0092-8674(00)80752-7			4	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	196FV	10338206	Bronze			2022-12-28	WOS:000080299100003
J	Perry, ACF; Wakayama, T; Kishikawa, H; Kasai, T; Okabe, M; Toyoda, Y; Yanagimachi, R				Perry, ACF; Wakayama, T; Kishikawa, H; Kasai, T; Okabe, M; Toyoda, Y; Yanagimachi, R			Mammalian transgenesis by intracytoplasmic sperm injection	SCIENCE			English	Article							GREEN FLUORESCENT PROTEIN; MEDIATED GENE-TRANSFER; GERM-LINE; MOUSE EMBRYOS; EXOGENOUS DNA; FOREIGN DNA; MICE; SPERMATOZOA; OOCYTES; CELLS	Coinjection of-unfertilized mouse oocytes with sperm heads and exogenous DNA encoding either a green fluorescent protein (GFP) or beta-galactosidase reporter produced 64 to 94 percent transgene-expressing embryos, reflecting DNA-sperm head association before coinjection. Nonselective transfer to surrogate mothers of embryos in the GFP series generated about 20 percent offspring expressing the integrated transgene. These data indicate that exogenous DNA can reproducibly be delivered into an oocyte by microinjected spermatozoa and suggest an adaptable method of transgenesis.	Univ Hawaii, John A Burns Sch Med, Dept Anat & Reprod Biol, Honolulu, HI 96822 USA; Osaka Univ, Genome Informat Res Ctr, Osaka 5650871, Japan; Obihiro Univ Agr & Vet Med, Res Ctr Protozoan Mol Immunol, Obihiro, Hokkaido 080, Japan	University of Hawaii System; Osaka University; Obihiro University of Agriculture & Veterinary Medicine	Perry, ACF (corresponding author), Univ Hawaii, John A Burns Sch Med, Dept Anat & Reprod Biol, Honolulu, HI 96822 USA.	perry@hawaii.edu	Okabe, Masaru/B-6917-2015	Okabe, Masaru/0000-0002-0803-9044; Perry, Tony/0000-0003-3136-5355	NICHD NIH HHS [HD-34362] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD034362] Funding Source: NIH RePORTER	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		BosMikich A, 1997, DEV BIOL, V182, P172, DOI 10.1006/dbio.1996.8468; BRINSTER RL, 1989, CELL, V59, P239, DOI 10.1016/0092-8674(89)90282-1; Chan AWS, 1998, P NATL ACAD SCI USA, V95, P14028, DOI 10.1073/pnas.95.24.14028; CHATOT CL, 1990, BIOL REPROD, V42, P432, DOI 10.1095/biolreprod42.3.432; EVANS MJ, 1981, NATURE, V292, P154, DOI 10.1038/292154a0; GORDON JW, 1989, INT REV CYTOL, V115, P171; GORDON JW, 1980, P NATL ACAD SCI-BIOL, V77, P7380, DOI 10.1073/pnas.77.12.7380; GORDON JW, 1981, SCIENCE, V214, P1244, DOI 10.1126/science.6272397; GOTO K, 1990, VET REC, V127, P517; Huguet E, 1998, MOL REPROD DEV, V51, P42, DOI 10.1002/(SICI)1098-2795(199809)51:1&lt;42::AID-MRD5&gt;3.0.CO;2-W; JAHNER D, 1985, P NATL ACAD SCI USA, V82, P6927, DOI 10.1073/pnas.82.20.6927; KANEGAE Y, 1995, NUCLEIC ACIDS RES, V23, P3816, DOI 10.1093/nar/23.19.3816; Kim NH, 1998, MOL REPROD DEV, V51, P436, DOI 10.1002/(SICI)1098-2795(199812)51:4&lt;436::AID-MRD11&gt;3.0.CO;2-Q; KIMURA Y, 1995, BIOL REPROD, V52, P709, DOI 10.1095/biolreprod52.4.709; Kimura Y, 1998, BIOL REPROD, V58, P1407, DOI 10.1095/biolreprod58.6.1407; Kroll KL, 1996, DEVELOPMENT, V122, P3173; KUEHN MR, 1987, NATURE, V326, P295, DOI 10.1038/326295a0; Kuretake S, 1996, BIOL REPROD, V55, P789, DOI 10.1095/biolreprod55.4.789; Ladha S, 1997, J CELL SCI, V110, P1041; LAVITRANO M, 1989, CELL, V57, P717, DOI 10.1016/0092-8674(89)90787-3; LAVITRANO M, 1992, MOL REPROD DEV, V31, P161, DOI 10.1002/mrd.1080310302; LONGO FJ, 1987, J CELL BIOL, V105, P1105, DOI 10.1083/jcb.105.3.1105; Maione B, 1997, DNA CELL BIOL, V16, P1087, DOI 10.1089/dna.1997.16.1087; Maione B, 1998, MOL REPROD DEV, V50, P406, DOI 10.1002/(SICI)1098-2795(199808)50:4&lt;406::AID-MRD4&gt;3.0.CO;2-M; NIWA H, 1991, GENE, V108, P193, DOI 10.1016/0378-1119(91)90434-D; OKABE M, UNPUB; PALMITER RD, 1986, ANNU REV GENET, V20, P465, DOI 10.1146/annurev.ge.20.120186.002341; Takada T, 1997, NAT BIOTECHNOL, V15, P458, DOI 10.1038/nbt0597-458; Toyoda Y., UNPUB; Tsien RY, 1998, ANNU REV BIOCHEM, V67, P509, DOI 10.1146/annurev.biochem.67.1.509; Tsukui T, 1996, NAT BIOTECHNOL, V14, P982, DOI 10.1038/nbt0896-982; Wakayama T, 1998, J REPROD FERTIL, V112, P11, DOI 10.1530/jrf.0.1120011; Wakayama T, 1998, NAT BIOTECHNOL, V16, P639, DOI 10.1038/nbt0798-639; WAKAYAMA T, UNPUB; Yanagimachi R., 1994, P189; Zhang GH, 1996, BIOCHEM BIOPH RES CO, V227, P707, DOI 10.1006/bbrc.1996.1573	36	341	392	0	20	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAY 14	1999	284	5417					1180	1183		10.1126/science.284.5417.1180	http://dx.doi.org/10.1126/science.284.5417.1180			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	197HJ	10325231				2022-12-28	WOS:000080359100041
J	de Jong, K; Ford, N; Kleber, R				de Jong, K; Ford, N; Kleber, R			Mental health care for refugees from Kosovo: the experience of Medecins Sans Frontieres	LANCET			English	Article									Med Sans Frontieres, NL-1001 EA Amsterdam, Netherlands; Univ Utrecht, Inst Psychotrauma, Utrecht, Netherlands	Doctors Without Borders; Utrecht University	de Jong, K (corresponding author), Med Sans Frontieres, POB 10014, NL-1001 EA Amsterdam, Netherlands.								0	17	17	0	4	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	MAY 8	1999	353	9164					1616	1617		10.1016/S0140-6736(99)00084-7	http://dx.doi.org/10.1016/S0140-6736(99)00084-7			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	195XW	10334275				2022-12-28	WOS:000080278300046
J	Niggebrugge, AHP; Trimbos, JB; Hermans, J; Steup, WH; Van de Velde, CJH				Niggebrugge, AHP; Trimbos, JB; Hermans, J; Steup, WH; Van de Velde, CJH			Influence of abdominal-wound closure technique on complications after surgery: a randomised study	LANCET			English	Article							ELEVATED INTRAABDOMINAL PRESSURE; COMPARTMENT SYNDROME; MIDLINE LAPAROTOMY; MECHANICAL FACTORS; BLOOD-FLOW; SUTURE; DEHISCENCE; PERFORMANCE; INFECTION; REPAIR	Background Wound complications that occur after closure of midline laparotomy remain challenging. A new continuous double-loop closure (CDLC) technique was developed to avoid wound rupture through resistance to high intra-abdominal pressure and continued approximation of wound edges. We investigated the efficacy of this technique. Methods We randomly assigned 390 patients undergoing midline laparotomy-wound closure with the commonly used continuous running suture (CRS) technique (n=204) or with the CDLC technique (n=186). We assessed the influence of closure technique on the rate of wound and other complications, with emphasis on wound dehiscence, pulmonary complications, and death. Findings The rate of wound complications did not differ significantly between groups. Pulmonary complications were seen in 11 patients (5.4%) in the CRS group, and in 32 patients (17.2%) in the CDLC group (p=0.0002). In the CRS group, 17 (8.3%) patients died, compared with 39 (21.0%) patients in the CDLC group (p=0.0004). Interpretation The CDLC technique should not be used. The lessened compliance of the abdominal wall,which raises intra-abdominal pressure for long periods, may increase the risk of postoperative pulmonary complications and death. The ideal closure technique should combine strength to prevent wound rupture with elasticity to adapt to increased intra-abdominal pressure.	Bronovo Hosp, Dept Surg, NL-2597 AX The Hague, Netherlands; Univ Leiden Hosp, Dept Gynaecol, NL-2300 RC Leiden, Netherlands; Leiden Univ, Dept Med Stat, NL-2300 RA Leiden, Netherlands; Leyenburg Hosp, Dept Surg, The Hague, Netherlands; Univ Leiden Hosp, Dept Surg, NL-2300 RC Leiden, Netherlands	Haaglanden Medical Center; Bronovo Hospital; Leiden University; Leiden University Medical Center (LUMC); Leiden University; Leiden University - Excl LUMC; Leiden University; Leiden University Medical Center (LUMC)	Niggebrugge, AHP (corresponding author), Bronovo Hosp, Dept Surg, Bronovolaan 5, NL-2597 AX The Hague, Netherlands.	sbadal@worldonline.nl						BAGGOT M G, 1951, Curr Res Anesth Analg, V30, P295; BENDAHAN J, 1995, J TRAUMA, V38, P152, DOI 10.1097/00005373-199501000-00034; Bloomfield GL, 1997, J TRAUMA, V42, P997, DOI 10.1097/00005373-199706000-00002; Burch JM, 1996, SURG CLIN N AM, V76, P833, DOI 10.1016/S0039-6109(05)70483-7; BURLESON RL, 1978, SURG GYNECOL OBSTET, V147, P414; CAHALANE MJ, 1989, LANCET, V1, P146; CRUSE PJE, 1980, SURG CLIN N AM, V60, P27; CULLEN DJ, 1989, CRIT CARE MED, V17, P118, DOI 10.1097/00003246-198902000-00002; DALY JW, 1988, CLIN OBSTET GYNECOL, V31, P754, DOI 10.1097/00003081-198809000-00023; DIEBEL L, 1992, AM SURGEON, V58, P573; DIEBEL LN, 1992, J TRAUMA, V33, P45, DOI 10.1097/00005373-199207000-00010; EDLICH RF, 1973, ANN SURG, V177, P679, DOI 10.1097/00000658-197306000-00006; EFRON G, 1965, LANCET, V1, P1287; GREENBURG AG, 1979, ARCH SURG-CHICAGO, V114, P143; HESSELINK VJ, 1993, SURG GYNECOL OBSTET, V176, P228; HOLL DD, 1974, AM J SURG, V127, P716, DOI 10.1016/0002-9610(74)90355-9; HUGH TB, 1990, AUST NZ J SURG, V60, P153, DOI 10.1111/ans.1990.60.3.153; HUGH TB, 1990, WORLD J SURG, V14, P231, DOI 10.1007/BF01664878; HUSKISSON EC, 1974, LANCET, V2, P1127, DOI 10.1016/S0140-6736(74)90884-8; ISRAELSSON LA, 1993, BRIT J SURG, V80, P1284, DOI 10.1002/bjs.1800801020; KIRK RM, 1972, LANCET, V2, P352; KRON IL, 1984, ANN SURG, V199, P28, DOI 10.1097/00000658-198401000-00005; MAYO CW, 1951, AMA ARCH SURG, V62, P883, DOI 10.1001/archsurg.1951.01250030894016; Niggebrugge AHP, 1997, BRIT J SURG, V84, P258, DOI 10.1002/bjs.1800840233; NIGGEBRUGGE AHP, 1995, EUR J SURG, V161, P655; POLLOCK AV, 1997, CRUCIAL CONTROVERSIE; POOLE GV, 1984, AM SURGEON, V50, P569; POOLE GV, 1985, SURGERY, V97, P631; RICHARDS PC, 1983, ANN SURG, V197, P238, DOI 10.1097/00000658-198302000-00018; RIOU JPA, 1992, AM J SURG, V163, P324, DOI 10.1016/0002-9610(92)90014-I; RODEHEAVER GT, 1986, ANN SURG, V204, P193, DOI 10.1097/00000658-198608000-00015; RODEHEAVER GT, 1981, SURG GYNECOL OBSTET, V153, P835; SCHEIN M, 1995, J AM COLL SURGEONS, V180, P745; SUGRUE M, 1995, BRIT J SURG, V82, P235, DOI 10.1002/bjs.1800820234; TRIMBOS JB, 1986, OBSTET GYNECOL, V68, P425, DOI 10.1097/00006250-198609000-00029; WISSING J, 1987, BRIT J SURG, V74, P738, DOI 10.1002/bjs.1800740831	36	45	49	0	0	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	MAY 8	1999	353	9164					1563	1567		10.1016/S0140-6736(98)10181-2	http://dx.doi.org/10.1016/S0140-6736(98)10181-2			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	195XW	10334254				2022-12-28	WOS:000080278300011
J	Baron, TH; Morgan, DE				Baron, TH; Morgan, DE			Current concepts - Acute necrotizing pancreatitis	NEW ENGLAND JOURNAL OF MEDICINE			English	Review							ACUTE BILIARY PANCREATITIS; ACTIVATING-FACTOR ANTAGONIST; CONTROLLED CLINICAL-TRIAL; SELECTIVE DECONTAMINATION; ANTIBIOTIC-PROPHYLAXIS; CONSERVATIVE TREATMENT; SURGICAL DEBRIDEMENT; PARENTERAL-NUTRITION; COMPUTED-TOMOGRAPHY; INFECTED NECROSIS		Mayo Clin & Mayo Fdn, Div Gastroenterol & Hepatol, Dept Med, Rochester, MN 55905 USA; Univ Alabama, Dept Med, Div Gastroenterol & Hepatol, Birmingham, AL 35294 USA; Univ Alabama, Dept Radiol, Birmingham, AL 35294 USA	Mayo Clinic; University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham	Baron, TH (corresponding author), Mayo Clin & Mayo Fdn, Div Gastroenterol & Hepatol, Dept Med, 200 1st St SW, Rochester, MN 55905 USA.							ANGELINI G, 1993, DIGESTION, V54, P143, DOI 10.1159/000201028; ANGELINI G, 1984, DIGESTION, V30, P131, DOI 10.1159/000199097; Baillie J, 1997, NEW ENGL J MED, V336, P286, DOI 10.1056/NEJM199701233360409; BALTHAZAR EJ, 1990, RADIOLOGY, V174, P331, DOI 10.1148/radiology.174.2.2296641; BALTHAZAR EJ, 1994, RADIOLOGY, V193, P297, DOI 10.1148/radiology.193.2.7972730; Banks PA, 1997, AM J GASTROENTEROL, V92, P377; BANKS PA, 1991, HEPATO-GASTROENTEROL, V38, P116; BANKS PA, 1994, AM J GASTROENTEROL, V89, P78; Baron TH, 1996, GASTROENTEROLOGY, V111, P755, DOI 10.1053/gast.1996.v111.pm8780582; Bassi C, 1998, GASTROENTEROLOGY, V115, P1513, DOI 10.1016/S0016-5085(98)70030-7; Beger HG, 1997, WORLD J SURG, V21, P130, DOI 10.1007/s002689900204; BOZKURT T, 1995, HEPATO-GASTROENTEROL, V42, P55; Bradley Edward L. Iii, 1994, P105; BRADLEY EL, 1993, ARCH SURG-CHICAGO, V128, P586; DABROWSKI A, 1995, INT J PANCREATOL, V17, P173; Echenique AM, 1998, J VASC INTERV RADIOL, V9, P565, DOI 10.1016/S1051-0443(98)70323-9; FAN ST, 1993, NEW ENGL J MED, V328, P228, DOI 10.1056/NEJM199301283280402; FENTONLEE D, 1993, BRIT J SURG, V80, P1579, DOI 10.1002/bjs.1800801228; FernandezCruz L, 1997, WORLD J SURG, V21, P169, DOI 10.1007/s002689900210; FOITZIK T, 1995, EUR J SURG, V161, P187; FOITZIK T, 1995, ANN SURG, V222, P179, DOI 10.1097/00000658-199508000-00010; Folsch UR, 1997, NEW ENGL J MED, V336, P237, DOI 10.1056/NEJM199701233360401; Freeny PC, 1998, AM J ROENTGENOL, V170, P969, DOI 10.2214/ajr.170.4.9530046; GERZOF SG, 1987, GASTROENTEROLOGY, V93, P1315, DOI 10.1016/0016-5085(87)90261-7; Ho HS, 1997, ARCH SURG-CHICAGO, V132, P487; HO HS, 1995, ARCH SURG-CHICAGO, V130, P817; IMRIE CW, 1997, ADV ACUTE PANCREATIT, V1, P3; Kalfarentzos F, 1997, BRIT J SURG, V84, P1665, DOI 10.1002/bjs.1800841207; KARIMGANI I, 1992, GASTROENTEROLOGY, V103, P1636, DOI 10.1016/0016-5085(92)91189-B; Kingsnorth AN, 1997, GASTROENTEROLOGY, V112, pA453; KINGSNORTH AN, 1995, BRIT J SURG, V82, P1414, DOI 10.1002/bjs.1800821039; Luiten EJT, 1997, CLIN INFECT DIS, V25, P811, DOI 10.1086/515545; LUITEN EJT, 1995, ANN SURG, V222, P57, DOI 10.1097/00000658-199507000-00010; Marotta F, 1996, DIGESTION, V57, P446, DOI 10.1159/000201373; McClave SA, 1997, DIGEST DIS SCI, V42, P2035, DOI 10.1023/A:1018806131924; Mier J, 1997, AM J SURG, V173, P71, DOI 10.1016/S0002-9610(96)00425-4; Mithofer K, 1996, GASTROENTEROLOGY, V110, P232, DOI 10.1053/gast.1996.v110.pm8536862; NEOPTOLEMOS JP, 1988, LANCET, V2, P979, DOI 10.1016/S0140-6736(88)90740-4; NEOPTOLEMOS JP, 1993, BRIT J SURG, V80, P94, DOI 10.1002/bjs.1800800131; NORDBACK IH, 1985, BRIT J SURG, V72, P687, DOI 10.1002/bjs.1800720905; NUUTINEN P, 1988, PANCREAS, V3, P53, DOI 10.1097/00006676-198802000-00010; PEDERZOLI P, 1993, SURG GYNECOL OBSTET, V176, P480; RATTNER DW, 1992, AM J SURG, V163, P105, DOI 10.1016/0002-9610(92)90261-O; Rau B, 1997, WORLD J SURG, V21, P155, DOI 10.1007/s002689900208; Rau B, 1998, BRIT J SURG, V85, P179; RAU B, 1995, J AM COLL SURGEONS, V181, P279; SAINIO V, 1995, LANCET, V346, P663, DOI 10.1016/S0140-6736(95)92280-6; STEINBERG W, 1994, NEW ENGL J MED, V330, P1198, DOI 10.1056/NEJM199404283301706; Tenner S, 1997, WORLD J SURG, V21, P143, DOI 10.1007/s002689900206; TSIOTOS GG, 1995, ARCH SURG-CHICAGO, V130, P48, DOI 10.1001/archsurg.1995.01430010050010; Windsor ACJ, 1998, GUT, V42, P431, DOI 10.1136/gut.42.3.431	51	317	344	0	3	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	MAY 6	1999	340	18					1412	1417		10.1056/NEJM199905063401807	http://dx.doi.org/10.1056/NEJM199905063401807			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	192QN	10228193				2022-12-28	WOS:000080090600007
J	Engert, F; Bonhoeffer, T				Engert, F; Bonhoeffer, T			Dendritic spine changes associated with hippocampal long-term synaptic plasticity	NATURE			English	Article							POTENTIATION; SYNAPSES; DENSITY; LTP; SPECIFICITY; INDUCTION; CULTURES; NEURONS; SLICE; CA1	Long-term enhancement of synaptic efficacy in the hippocampus is an important model for studying the cellular mechanisms of neuronal plasticity, circuit reorganization, and even learning and memory(1). Although these long-lasting functional changes are easy to induce, it has been very difficult to demonstrate that they are accompanied or even caused by morphological changes on the subcellular level Here we combined a local superfusion technique(2,3) with two-photon imaging(4), which allowed us to scrutinize specific regions of the postsynaptic dendrite where we knew that the synaptic changes had to occur. We show that after induction of long-lasting (but not short-lasting) functional enhancement of synapses in area CAI, new spines appear on the postsynaptic dendrite, whereas in control regions on the same dendrite or in slices where long-term potentiation was blocked, no significant spine growth occurred.	Max Planck Inst Neurobiol, D-82152 Munich, Germany	Max Planck Society	Bonhoeffer, T (corresponding author), Max Planck Inst Neurobiol, Klopferspitz 18A, D-82152 Munich, Germany.		Bonhoeffer, Tobias/B-9481-2009	Bonhoeffer, Tobias/0000-0001-7897-6634				BIENENSTOCK EL, 1982, J NEUROSCI, V2, P32, DOI 10.1523/jneurosci.02-01-00032.1982; BLISS TVP, 1993, NATURE, V361, P31, DOI 10.1038/361031a0; Bolshakov VY, 1997, NEURON, V19, P635, DOI 10.1016/S0896-6273(00)80377-3; BONHOEFFER T, 1989, P NATL ACAD SCI USA, V86, P8113, DOI 10.1073/pnas.86.20.8113; Buchs PA, 1996, P NATL ACAD SCI USA, V93, P8040, DOI 10.1073/pnas.93.15.8040; Collin C, 1997, J NEUROPHYSIOL, V77, P1614, DOI 10.1152/jn.1997.77.3.1614; CRICK F, 1982, TRENDS NEUROSCI, V5, P44, DOI 10.1016/0166-2236(82)90020-0; DENK W, 1990, SCIENCE, V248, P73, DOI 10.1126/science.2321027; DESMOND NL, 1990, SYNAPSE, V5, P139, DOI 10.1002/syn.890050208; DUNAEVSKY A, 1998, SOC NEUR ABSTR, V24; Engert F, 1997, NATURE, V388, P279, DOI 10.1038/40870; Fischer M, 1998, NEURON, V20, P847, DOI 10.1016/S0896-6273(00)80467-5; GAHWILER BH, 1981, J NEUROSCI METH, V4, P329, DOI 10.1016/0165-0270(81)90003-0; GRAY EG, 1959, NATURE, V183, P1592, DOI 10.1038/1831592a0; HOSOKAWA T, 1995, J NEUROSCI, V15, P5560; McKinney RA, 1999, NAT NEUROSCI, V2, P44, DOI 10.1038/4548; MILLER KD, 1994, NEURAL COMPUT, V6, P100, DOI 10.1162/neco.1994.6.1.100; MOSER MB, 1994, P NATL ACAD SCI USA, V91, P12673, DOI 10.1073/pnas.91.26.12673; Sorra KE, 1998, J NEUROSCI, V18, P658; Svoboda K, 1996, SCIENCE, V272, P716, DOI 10.1126/science.272.5262.716; Turrigiano GG, 1998, NATURE, V391, P892, DOI 10.1038/36103; Veselovsky NS, 1996, PFLUG ARCH EUR J PHY, V432, P351, DOI 10.1007/s004240050143; WOOLLEY CS, 1990, J NEUROSCI, V10, P4035, DOI 10.1523/JNEUROSCI.10-12-04035.1990	23	1284	1306	2	125	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	MAY 6	1999	399	6731					66	70		10.1038/19978	http://dx.doi.org/10.1038/19978			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	194BK	10331391				2022-12-28	WOS:000080172100056
J	Lerman, C; Hughes, C; Trock, BJ; Myers, RE; Main, D; Bonney, A; Abbaszadegan, MR; Harty, AE; Franklin, BA; Lynch, JF; Lynch, HT				Lerman, C; Hughes, C; Trock, BJ; Myers, RE; Main, D; Bonney, A; Abbaszadegan, MR; Harty, AE; Franklin, BA; Lynch, JF; Lynch, HT			Genetic testing in families with hereditary nonpolyposis colon cancer	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							COLORECTAL-CANCER; BREAST-CANCER; PSYCHOLOGICAL DISTRESS; SEX-DIFFERENCES; RISK; SUSCEPTIBILITY; PARTICIPATION; ADHERENCE; OUTCOMES; LINKAGE	Context Genetic testing for hereditary nonpolyposis colon cancer (HNPCC) is available, but the rates of acceptance of testing or barriers to participation are not known. Objective To investigate rates and predictors of utilization of genetic testing for HNPCC. Design Cohort study conducted between July 1996 and July 1998, Setting Hereditary nonpolyposis colon cancer family registry, Participants Adult male and female members (n = 208) of 4 extended HNPCC families contacted for a baseline telephone interview. Interventions Family education and individual genetic counseling. Main Outcome Measure Participant acceptance of HNPCC test results. Results Of the 208 family members, 90 (43%) received test results and 118 (57%) declined. Of 139 subjects (67%) who completed a baseline telephone interview, 84 (60%) received test results and 55 (40%) declined. Of the 84 subjects who received test results, 35 (42%) received information indicating that they had HNPCC-associated mutations and 49 (58%) that they did not. Test acceptors had higher education levels (odds ratio [OR], 3.74; 95% confidence interval [CI], 2.49-5.61) and were more likely to have participated in a previous genetic linkage study (OR, 4.30; 95% CI, 1.84-10.10). The presence of depression symptoms significantly reduced rates of HNPCC test use (OR, 0.34; 95% CI, 0.17-0.66). Although rates of test use were identical among men and women, the presence of depression symptoms resulted in a 4-fold decrease in test use among women (OR, 0.25; 95% CI, 0.08-0.80) and a smaller, nonsignificant reduction among men (OR, 0.49; 95% CI, 0.19-1.27). Conclusions Despite having significantly elevated risks of developing colon cancer, a relatively small proportion of HNPCC family members are likely to use genetic testing. Barriers to test acceptance may include less formal education and the presence of depression symptoms, especially among women. Additional research is needed to generalize these findings to different clinical settings and racially diverse populations.	Georgetown Univ, Med Ctr, Vincent T Lombardi Canc Res Ctr, Washington, DC 20007 USA; Thomas Jefferson Univ, Dept Med, Philadelphia, PA 19107 USA; Creighton Univ, Hereditary Canc Inst, Omaha, NE 68178 USA	Georgetown University; Jefferson University; Creighton University	Lerman, C (corresponding author), Georgetown Univ, Med Ctr, Vincent T Lombardi Canc Res Ctr, 2233 Wisconsin Ave NW,Suite 317, Washington, DC 20007 USA.		Lerman, Caryn/AHC-5180-2022	Myers, Ronald E./0000-0002-8059-7390	NATIONAL CANCER INSTITUTE [R01CA074684] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA74684] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Aaltonen LA, 1998, NEW ENGL J MED, V338, P1481, DOI 10.1056/NEJM199805213382101; ANDERSON LM, 1995, AM J PUBLIC HEALTH, V85, P840, DOI 10.2105/AJPH.85.6.840; Belle D., 1990, HDB STRESS; BLALOCK SJ, 1987, PREV MED, V16, P9, DOI 10.1016/0091-7435(87)90002-8; BROWN ML, 1990, PREV MED, V19, P562, DOI 10.1016/0091-7435(90)90054-N; *CDCP, 1996, JAMA-J AM MED ASSOC, V275, P830; CROYLE RT, 1993, PREV MED, V22, P284, DOI 10.1006/pmed.1993.1023; Ginsberg, 1975, LIFE SPAN DEV PSYCH, P191; HOROWITZ M, 1979, PSYCHOSOM MED, V41, P209, DOI 10.1097/00006842-197905000-00004; JARVINEN HJ, 1995, GASTROENTEROLOGY, V108, P1405, DOI 10.1016/0016-5085(95)90688-6; KESSLER RC, 1984, AM SOCIOL REV, V49, P620, DOI 10.2307/2095420; Kunkel EJS, 1997, PSYCHO-ONCOL, V6, P139, DOI 10.1002/(SICI)1099-1611(199706)6:2<139::AID-PON256>3.0.CO;2-O; Lerman C, 1996, JAMA-J AM MED ASSOC, V275, P1885, DOI 10.1001/jama.275.24.1885; Lerman C, 1997, J CONSULT CLIN PSYCH, V65, P414, DOI 10.1037/0022-006X.65.3.414; LERMAN C, 1995, J NATL CANCER I, V87, P286, DOI 10.1093/jnci/87.4.286; Lerman C, 1996, INT J CANCER, V69, P58, DOI 10.1002/(SICI)1097-0215(19960220)69:1<58::AID-IJC15>3.0.CO;2-G; LERMAN C, 1993, J NATL CANCER I, V85, P1074, DOI 10.1093/jnci/85.13.1074; LINDBLOM A, 1993, NAT GENET, V5, P279, DOI 10.1038/ng1193-279; Lynch Henry T., 1998, Current Opinion in Oncology, V10, P349, DOI 10.1097/00001622-199807000-00012; LYNCH HT, 1993, GASTROENTEROLOGY, V104, P1535, DOI 10.1016/0016-5085(93)90368-M; Lynch HT, 1997, CANCER GENET CYTOGEN, V93, P84, DOI 10.1016/S0165-4608(96)00290-7; MYERS RE, 1994, PREV MED, V23, P142, DOI 10.1006/pmed.1994.1020; NICOLAIDES NC, 1994, NATURE, V371, P75, DOI 10.1038/371075a0; NYSTROMLAHTI M, 1994, AM J HUM GENET, V55, P659; Pearlin L.I., 1979, RES COMMUNITY MENTAL, VVol. 1, P217; PEARLIN LI, 1978, J HEALTH SOC BEHAV, V19, P2, DOI 10.2307/2136319; PELTOMAKI P, 1993, SCIENCE, V260, P810, DOI 10.1126/science.8484120; RADLOFF L, 1975, SEX ROLES, V1, P249; RADLOFF L S, 1977, Applied Psychological Measurement, V1, P385, DOI 10.1177/014662167700100306; Vasen HFA, 1998, CANCER, V82, P1632, DOI 10.1002/(SICI)1097-0142(19980501)82:9<1632::AID-CNCR6>3.3.CO;2-X; Vernon SW, 1997, HEALTH PSYCHOL, V16, P73, DOI 10.1037/0278-6133.16.1.73; Vernon SW, 1997, JNCI-J NATL CANCER I, V89, P1406, DOI 10.1093/jnci/89.19.1406; Watson M, 1996, PSYCHO-ONCOL, V5, P233; ZEGER SL, 1986, BIOMETRICS, V42, P121, DOI 10.2307/2531248	34	193	193	0	7	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAY 5	1999	281	17					1618	1622		10.1001/jama.281.17.1618	http://dx.doi.org/10.1001/jama.281.17.1618			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	191MJ	10235155	Bronze			2022-12-28	WOS:000080025900026
J	Ellis, H; Moran, BJ; Thompson, JN; Parker, MC; Wilson, MS; Menzies, D; McGuire, A; Lower, AM; Hawthorn, RJS; O'Brien, F; Buchan, S; Crowe, AM				Ellis, H; Moran, BJ; Thompson, JN; Parker, MC; Wilson, MS; Menzies, D; McGuire, A; Lower, AM; Hawthorn, RJS; O'Brien, F; Buchan, S; Crowe, AM			Adhesion-related hospital readmissions after abdominal and pelvic surgery: a retrospective cohort study	LANCET			English	Article							INTESTINAL-OBSTRUCTION	Background Adhesions after abdominal and pelvic surgery are important complications, although their basic epidemiology is unclear. We investigated the frequency of such complications in the general population to provide a basis for the targeting and assessment of new adhesion-prevention measures. Methods We used validated data from the Scottish National Health Service medical record linkage database to identify patients undergoing open abdominal or pelvic surgery in 1986, who had no record of such surgery in the preceding 5 years; Patients were followed up for 10 years and subsequent readmissions were:reviewed and outcomes classified by the degree of adhesion. We also assessed the rate of adhesion-related admissions in 1994 for the population of 5 million people. Findings 1209 (5.7%) of all readmissions (21 347) were classified as being directly related to adhesions, with 1169 (3.8%) managed operatively. Overall, 34.6% of the 29 790 patients who underwent open abdominal or pelvic surgery in 1986 were readmitted a mean of 2.1 times over 10 years for a disorder directly or possibly related to adhesions, or for abdominal or pelvic surgery that could be potentially complicated by adhesions. 22.1% of all outcome readmissions occurred in the first year after initial:surgery, but readmissions continued steadily throughout the 10-year period. In 1994, 4199 admissions were directly related to adhesions. Interpretation Postoperative adhesions have important consequences to patients, surgeons, and the health system. Surgical procedures with a high risk of adhesion-related complications need to be identified and adhesion prevention carefully assessed.	Guys Kings Coll & St Thomass, Sch Biomed Sci, Div Anat Cell & Human Biol, London SE1 9RT, England; N Hampshire Hosp, Dept Surg, Basingstoke, Hants, England; Chelsea & Westminster Hosp, Dept Surg, London, England; Joyce Green Hosp, Dept Surg, Dartford, England; Macclesfield Hosp, Dept Surg, Macclesfield, Cheshire, England; Stepping Hill Hosp, Stockport, England; Colchester Dist Gen Hosp, Dept Surg, Colchester, Essex, England; City Univ London, Sch Social Sci, London EC1V 0HB, England; Univ Oxford, Inst Hlth Sci, Oxford Hlth Econ Grp, Oxford, England; St Bartholomews Hosp, Fertil Ctr, London, England; So Gen Hosp NHS Trust, Dept Gynecol, Glasgow, Lanark, Scotland; Natl Hlth Serv Scotland, Informat & Stat Div, Edinburgh, Midlothian, Scotland; Strategan Dis & Therapy Management, Basingstoke, Hants, England	University of London; King's College London; Imperial College London; City University London; University of Greenwich; University of Oxford; University of London; Queen Mary University London; NHS National Services Scotland	Ellis, H (corresponding author), Guys Kings Coll & St Thomass, Sch Biomed Sci, Div Anat Cell & Human Biol, Guys Campus, London SE1 9RT, England.							*CENTR STAT OFF, 1995, SOC TRENDS, V25; Ellis H, 1997, EUR J SURG, V163, P5; Ellis H, 1998, ANN CHIR GYNAECOL FE, V87, P9; FAZIO VW, 1995, ANN SURG, V222, P120, DOI 10.1097/00000658-199508000-00003; Harley K, 1996, Health Bull (Edinb), V54, P410; HERSHLAG A, 1991, CLIN OBSTET GYNECOL, V34, P395, DOI 10.1097/00003081-199106000-00023; Kendrick Stephen, 1993, Health Bulletin (Edinburgh), V51, P72; KROOK S, 1947, ACTA CHIR SCAND    S, V95, P1; MENZIES D, 1993, ANN ROY COLL SURG, V75, P147; MENZIES D, 1990, ANN ROY COLL SURG, V72, P60; *NAT HLTH SERV SCO, 1996, SCOTT HLTH STAT 1996, V38, P50; Ray NF, 1998, J AM COLL SURGEONS, V186, P1, DOI 10.1016/S1072-7515(97)00127-0	12	661	691	4	34	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	MAY 1	1999	353	9163					1476	1480		10.1016/S0140-6736(98)09337-4	http://dx.doi.org/10.1016/S0140-6736(98)09337-4			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	195XV	10232313				2022-12-28	WOS:000080278200010
J	Kekki, M; Kurki, T; Paavonen, J; Rutanen, EM				Kekki, M; Kurki, T; Paavonen, J; Rutanen, EM			Insulin-like growth factor binding protein-1 in cervix as a marker of infectious complications in pregnant women with bacterial vaginosis	LANCET			English	Article									Univ Helsinki, Cent Hosp, Dept Obstet & Gynaecol, Helsinki 00029, Finland	University of Helsinki; Helsinki University Central Hospital	Kekki, M (corresponding author), Univ Helsinki, Cent Hosp, Dept Obstet & Gynaecol, POB 140, Helsinki 00029, Finland.							Goldenberg RL, 1996, OBSTET GYNECOL, V87, P656, DOI 10.1016/0029-7844(96)00034-S; HAY PE, 1994, BRIT MED J, V308, P295, DOI 10.1136/bmj.308.6924.295; KURKI T, 1992, OBSTET GYNECOL, V80, P172; Martina NA, 1997, J CLIN ENDOCR METAB, V82, P1894, DOI 10.1210/jc.82.6.1894; RUTANEN EM, 1988, BIOCHEM BIOPH RES CO, V152, P208, DOI 10.1016/S0006-291X(88)80701-0	5	24	25	0	2	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	MAY 1	1999	353	9163					1494	1494		10.1016/S0140-6736(99)00400-6	http://dx.doi.org/10.1016/S0140-6736(99)00400-6			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	195XV	10232319				2022-12-28	WOS:000080278200016
J	Detwiler, PB				Detwiler, PB			Sir Alan Hodgkin (1914-1998)	SCIENCE			English	Biographical-Item									Univ Washington, Dept Physiol & Biophys, Seattle, WA 98195 USA	University of Washington; University of Washington Seattle	Detwiler, PB (corresponding author), Univ Washington, Dept Physiol & Biophys, Seattle, WA 98195 USA.			Detwiler, Peter/0000-0003-3910-2023					0	0	0	0	3	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	APR 30	1999	284	5415					753	753		10.1126/science.284.5415.753	http://dx.doi.org/10.1126/science.284.5415.753			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	192AW	10336399				2022-12-28	WOS:000080056200030
J	Ellaway, CJ; Bennetts, B; Tuck, RR; Wilcken, B				Ellaway, CJ; Bennetts, B; Tuck, RR; Wilcken, B			Clumsiness, confusion, coma, and valproate	LANCET			English	Article							ORNITHINE TRANSCARBAMYLASE DEFICIENCY		New Childrens Hosp, Dept Biochem Genet, Parramatta, NSW 2124, Australia; New Childrens Hosp, Dept Mol Genet, Westmead, NSW, Australia	University of Sydney	Wilcken, B (corresponding author), New Childrens Hosp, Dept Biochem Genet, Parramatta, NSW 2124, Australia.							Brusilow SW HA., 1995, METABOLIC MOL BASES, P1187; HATA A, 1988, J BIOCHEM-TOKYO, V103, P302, DOI 10.1093/oxfordjournals.jbchem.a122265; HONEYCUTT D, 1992, NEUROLOGY, V42, P666, DOI 10.1212/WNL.42.3.666; KAY JDS, 1986, LANCET, V2, P1283; Tuchman M, 1997, J INHERIT METAB DIS, V20, P525, DOI 10.1023/A:1005301513465	5	16	16	0	1	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	APR 24	1999	353	9162					1408	1408		10.1016/S0140-6736(99)01433-6	http://dx.doi.org/10.1016/S0140-6736(99)01433-6			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	191KD	10227223				2022-12-28	WOS:000080020800015
J	Kreuger, FA; van Ballegooijen, M; Doornewaard, H				Kreuger, FA; van Ballegooijen, M; Doornewaard, H			Is PAPNET suitable for primary screening?	LANCET			English	Editorial Material									Municipal Hlth Serv Rotterdam, Dept Hlth Promot, NL-3000 LP Rotterdam, Netherlands; Erasmus Univ, Dept Publ Hlth, Rotterdam, Netherlands; Univ Utrecht, Dept Pathol, NL-3508 TC Utrecht, Netherlands	Erasmus University Rotterdam; Utrecht University	Kreuger, FA (corresponding author), Municipal Hlth Serv Rotterdam, Dept Hlth Promot, POB 70032, NL-3000 LP Rotterdam, Netherlands.							DOORNEWARD H, 1998, EVALUATION SEMIAUTOM; Raffle AE, 1998, LANCET, V351, P297, DOI 10.1016/S0140-6736(05)78229-5; Solomon HM, 1998, ACTA CYTOL, V42, P253, DOI 10.1159/000331554; 1998, LANCET, V351, P459	4	6	6	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	APR 24	1999	353	9162					1374	1375		10.1016/S0140-6736(99)90070-3	http://dx.doi.org/10.1016/S0140-6736(99)90070-3			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	191KD	10227211				2022-12-28	WOS:000080020800002
J	Eastell, R				Eastell, R			Commentary: Bone density can be used to assess fracture risk	BRITISH MEDICAL JOURNAL			English	Editorial Material							POSTMENOPAUSAL OSTEOPOROSIS; ALENDRONATE		Univ Sheffield, No Gen Hosp, Div Clin Sci, Med Sect, Sheffield S5 7AU, S Yorkshire, England	Northern General Hospital; University of Sheffield	Eastell, R (corresponding author), Univ Sheffield, No Gen Hosp, Div Clin Sci, Med Sect, Sheffield S5 7AU, S Yorkshire, England.	r.eastell@sheffield.ac.uk	Eastell, Richard/G-5851-2011	Eastell, Richard/0000-0002-0323-3366				Blumsohn A, 1997, ANN CLIN BIOCHEM, V34, P449, DOI 10.1177/000456329703400501; Chavassieux PM, 1997, J CLIN INVEST, V100, P1475, DOI 10.1172/JCI119668; Eastell R, 1998, NEW ENGL J MED, V338, P736, DOI 10.1056/NEJM199803123381107; Eddy D. M., 1998, OSTEOPOROS INT S4, V8, pS7; LIBERMAN UA, 1995, NEW ENGL J MED, V333, P1437, DOI 10.1056/NEJM199511303332201; Lindsay R, 1997, LANCET, V350, P550, DOI 10.1016/S0140-6736(97)02342-8; Marshall D, 1996, BRIT MED J, V312, P1254, DOI 10.1136/bmj.312.7041.1254; PARFITT AM, 1993, OSTEOPOROSIS, P164; RIGGS BL, 1996, BONE, V18, P197	9	5	5	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	MAR 27	1999	318	7187					864	+						2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	185DM	10223796				2022-12-28	WOS:000079652900039
J	Foudraine, NA; Hoetelmans, RMW; Lange, JMA; de Wolf, F; van Benthem, BHB; Mass, JJ; Keet, IPM; Portegies, P				Foudraine, NA; Hoetelmans, RMW; Lange, JMA; de Wolf, F; van Benthem, BHB; Mass, JJ; Keet, IPM; Portegies, P			Cerebrospinal-fluid HIV-1 RNA and drug concentrations after treatment with lamivudine plus zidovudine or stavudine	LANCET			English	Article							IMMUNODEFICIENCY-VIRUS INFECTION; AIDS DEMENTIA COMPLEX; PHASE I/II; PHARMACOKINETICS; CHILDREN; ANTIGEN; RESISTANCE; DIAGNOSIS; DISEASES; PLASMA	Background Treatment and prevention of HIV-l-related central-nervous-system disease may be dependent on penetration of antiretroviral drugs into the central nervous system. Few data are available about cerebrospinal-fluid penetration and concomitant changes of HIV-1-RNA concentrations during treatment with antiretroviral agents. We investigated these effects in HIV-1-infected people. Methods 28 antiretroviral-naive individuals with CD4 cell counts of 200/mu L or more and plasma HIV-1-RNA concentrations of 10000 or more copies/mL who were free of neurological symptoms were randomly assigned lamivudine plus either stavudine (n=17) or zidovudine (n=11). We did lumbar punctures on 28 individuals before and 22 individuals after 12 weeks of treatment to assess HIV-1-RNA and drug concentrations in cerebrospinal fluid. Findings All 28 individuals had detectable HIV-1-RNA concentrations in the cerebrospinal fluid (median 4.64 log(20) copies/mL and 4.20 log(10) copies/mL in the lamivudine plus zidovudine and lamivudine plus stavudine groups, respectively). There was no correlation between plasma and cerebrospinal-fluid HIV-1-RNA concentrations (r=0.18, p=0.35). After 12 weeks of treatment none of the individuals had detectable HIV-1-RNA concentrations in the cerebrospinal fluid. The highest drug concentration in the cerebrospinal fluid was for lamivudine followed by stavudine and zidovudine. Concentrations were consistent over time, unlike plasma concentrations. Therefore, we found time-dependent cerebrospinal-fluid to plasma drug-penetration ratios, which were highest for zidovudine followed by stavudine and lamivudine. Interpretation The two drug combinations were equally effective in the decrease of cerebrospinal fluid HIV-1-RNA concentrations. All drugs penetrated the cerebrospinal fluid. Antiretroviral drugs other than zidovudine might be useful in the prevention of AIDS dementia complex.	Univ Amsterdam, Acad Med Ctr, Dept Neurol, NL-1105 AZ Amsterdam, Netherlands; Dept Publ Hlth & Environm, Municipal Hlth Serv, Amsterdam, Netherlands; Slotervaart Hosp, Dept Pharm & Pharmacol, Amsterdam, Netherlands; Univ Amsterdam, Acad Med Ctr, Natl AIDS Therapy Evaluat Ctr, NL-1105 AZ Amsterdam, Netherlands; Univ Amsterdam, Acad Med Ctr, Dept Internal Med, Div Infect Dis Trop Med & AIDS, NL-1105 AZ Amsterdam, Netherlands; Univ Amsterdam, Acad Med Ctr, Dept Human Retrovirol, NL-1105 AZ Amsterdam, Netherlands	University of Amsterdam; Academic Medical Center Amsterdam; Slotervaart Hospital; University of Amsterdam; Academic Medical Center Amsterdam; University of Amsterdam; Academic Medical Center Amsterdam; University of Amsterdam; Academic Medical Center Amsterdam	Portegies, P (corresponding author), Univ Amsterdam, Acad Med Ctr, Dept Neurol, Meibergdreef 9, NL-1105 AZ Amsterdam, Netherlands.		Foudraine, Norbert/P-7753-2017	Foudraine, Norbert/0000-0003-1353-4434				BACELLAR H, 1994, NEUROLOGY, V44, P1892, DOI 10.1212/WNL.44.10.1892; Brew BJ, 1996, AIDS, V10, P1357, DOI 10.1097/00002030-199610000-00007; BREW BJ, 1990, ANN NEUROL, V28, P556, DOI 10.1002/ana.410280413; BREW BJ, 1992, AIDS, V6, P461, DOI 10.1097/00002030-199205000-00004; BURGER DM, 1993, AIDS, V7, P1581, DOI 10.1097/00002030-199312000-00006; BURGER DM, 1992, J CHROMATOGR-BIOMED, V584, P239, DOI 10.1016/0378-4347(92)80581-A; Burger DM, 1996, J DRUG DEV CLIN PR, V7, P313; Chiesi A, 1996, J ACQ IMMUN DEF SYND, V11, P39, DOI 10.1097/00042560-199601010-00005; CINQUE P, 1992, J INFECT DIS, V166, P1408, DOI 10.1093/infdis/166.6.1408; DAVIS LE, 1992, NEUROLOGY, V42, P1736, DOI 10.1212/WNL.42.9.1736; DUDLEY MN, 1992, J INFECT DIS, V166, P480, DOI 10.1093/infdis/166.3.480; Gisslen M, 1997, J INFECT DIS, V175, P434, DOI 10.1093/infdis/175.2.434; GOUDSMIT J, 1986, LANCET, V2, P177; HAGBERG L, 1991, SCAND J INFECT DIS, V23, P681, DOI 10.3109/00365549109024293; HARKER AJ, 1994, J CHROMATOGR B, V657, P227, DOI 10.1016/0378-4347(94)80092-8; HITCHCOCK M J M, 1991, Antiviral Chemistry and Chemotherapy, V2, P125; HO DD, 1985, ANN INTERN MED, V103, P880, DOI 10.7326/0003-4819-103-6-880; Jeffery KJM, 1997, LANCET, V349, P313, DOI 10.1016/S0140-6736(96)08107-X; Jellinger RM, 1997, J INFECT DIS, V175, P561, DOI 10.1093/infdis/175.3.561; KLECKER RW, 1987, CLIN PHARMACOL THER, V41, P407, DOI 10.1038/clpt.1987.49; KLINE MW, 1995, PEDIATRICS, V96, P247; Kuritzkes DR, 1996, AIDS, V10, P975, DOI 10.1097/00002030-199610090-00007; LAKEMAN FD, 1995, J INFECT DIS, V171, P857, DOI 10.1093/infdis/171.4.857; Lea AP, 1996, DRUGS, V51, P846, DOI 10.2165/00003495-199651050-00009; Lewis LL, 1996, J INFECT DIS, V174, P16, DOI 10.1093/infdis/174.1.16; LUPIA RH, 1993, ANTIMICROB AGENTS CH, V37, P818, DOI 10.1128/AAC.37.4.818; PORTEGIES P, 1989, ARCH NEUROL-CHICAGO, V46, P261, DOI 10.1001/archneur.1989.00520390027010; PORTEGIES P, 1993, AIDS, V7, P669, DOI 10.1097/00002030-199305000-00010; POWER C, 1995, J ACQ IMMUN DEF SYND, V8, P273, DOI 10.1097/00042560-199503010-00008; ROYAL W, 1994, ANN NEUROL, V36, P32, DOI 10.1002/ana.410360109; Sei S, 1996, J INFECT DIS, V174, P1200, DOI 10.1093/infdis/174.6.1200	31	143	148	0	3	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON WC1B 3SL, ENGLAND	0140-6736			LANCET	Lancet	MAY 23	1998	351	9115					1547	1551		10.1016/S0140-6736(98)07333-4	http://dx.doi.org/10.1016/S0140-6736(98)07333-4			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZQ497	10326538				2022-12-28	WOS:000073868000011
J	Webb, CM; Rosano, GMC; Collins, P				Webb, CM; Rosano, GMC; Collins, P			Oestrogen improves exercise-induced myocardial ischaemia in women	LANCET			English	Article							POSTMENOPAUSAL WOMEN; ESTROGEN; DISEASE		Natl Heart & Lung Inst, Imperial Coll Sch Med, Div Cardiac Med, London SW3 6LY, England; Royal Brompton Hosp, London SW3 6LY, England; Osped San Raffaele, Dept Cardiol, Rome, Italy	Imperial College London; Royal Brompton Hospital; Vita-Salute San Raffaele University; IRCCS Ospedale San Raffaele	Collins, P (corresponding author), Natl Heart & Lung Inst, Imperial Coll Sch Med, Div Cardiac Med, Dovehouse St, London SW3 6LY, England.		Rosano, Giuseppe M. C./K-8718-2018	Rosano, Giuseppe M. C./0000-0003-4023-2263; Webb, Carolyn/0000-0002-2538-6953				COLLINS P, 1995, CIRCULATION, V92, P24, DOI 10.1161/01.CIR.92.1.24; GILLIGAN DM, 1994, CIRCULATION, V89, P2545, DOI 10.1161/01.CIR.89.6.2545; HERRINGTON DM, 1994, AM J CARDIOL, V73, P951, DOI 10.1016/0002-9149(94)90136-8; Rosano GMC, 1997, CIRCULATION, V96, P2837, DOI 10.1161/01.CIR.96.9.2837; ROSANO GMC, 1993, LANCET, V342, P133, DOI 10.1016/0140-6736(93)91343-K	5	43	43	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON WC1B 3SL, ENGLAND	0140-6736			LANCET	Lancet	MAY 23	1998	351	9115					1556	1557		10.1016/S0140-6736(05)61121-X	http://dx.doi.org/10.1016/S0140-6736(05)61121-X			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZQ497	10326543				2022-12-28	WOS:000073868000016
J	Yang, FY; Liu, K; Hong, KM; Reich, DH; Searson, PC; Chien, CL				Yang, FY; Liu, K; Hong, KM; Reich, DH; Searson, PC; Chien, CL			Large magnetoresistance of electrodeposited single-crystal bismuth thin films	SCIENCE			English	Article							GIANT MAGNETORESISTANCE	Single-crystal bismuth thin films 1 to 20 micrometers thick were fabricated by electrodeposition and suitable annealing. Magnetoresistance up to 250 percent at 300 kelvin and 380,000 percent at 5 kelvin as well as clean Shubnikov-de Haas oscillations were observed, indicative of the high quality of these films. A hybrid structure was also made that showed a large magnetoresistive effect of 30 percent at 200 oersted and a field sensitivity of 0.2 percent magnetoresistance per oersted at room temperature.	Johns Hopkins Univ, Dept Phys & Astron, Baltimore, MD 21218 USA; Johns Hopkins Univ, Dept Mat Sci & Engn, Baltimore, MD 21218 USA	Johns Hopkins University; Johns Hopkins University	Chien, CL (corresponding author), Johns Hopkins Univ, Dept Phys & Astron, Baltimore, MD 21218 USA.		Searson, Peter C/A-3311-2010; Liu, Kai/B-1163-2008	Liu, Kai/0000-0001-9413-6782; Searson, Peter/0000-0002-5417-0828; Hong, Kimin/0000-0001-5962-1897				ANTHONY TC, 1994, IEEE T MAGN, V30, P3816; Ashcroft N W, 1976, SOLID STATE PHYS; BEUTLER DE, 1988, PHYS REV B, V38, P8, DOI 10.1103/PhysRevB.38.8; DIENY B, 1991, PHYS REV B, V43, P1297, DOI 10.1103/PhysRevB.43.1297; KOMNIK YF, 1971, ZH EKSP TEOR FIZ, V33, P364; Liu K, 1998, APPL PHYS LETT, V73, P1436, DOI 10.1063/1.122378; Lu M, 1996, PHYS REV B, V53, P1609, DOI 10.1103/PhysRevB.53.1609; MANGEZ JH, 1976, PHYS REV B, V14, P4381, DOI 10.1103/PhysRevB.14.4381; PARTIN DL, 1988, PHYS REV B, V38, P3818, DOI 10.1103/PhysRevB.38.3818; Prinz GA, 1998, SCIENCE, V282, P1660, DOI 10.1126/science.282.5394.1660; SCHAD R, 1994, APPL PHYS LETT, V64, P3500, DOI 10.1063/1.111253; SMITH GE, 1964, PHYS REV, V135, P1118, DOI 10.1103/PhysRev.135.A1118; YANG F, UNPUB; Zhang ZB, 1998, APPL PHYS LETT, V73, P1589, DOI 10.1063/1.122213	14	463	475	6	191	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	MAY 21	1999	284	5418					1335	1337		10.1126/science.284.5418.1335	http://dx.doi.org/10.1126/science.284.5418.1335			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	198NN	10334983				2022-12-28	WOS:000080430600046
J	Pineiro, DJ; Bellido, CA				Pineiro, DJ; Bellido, CA			Circumferential dissection of the aorta	NEW ENGLAND JOURNAL OF MEDICINE			English	Article									Univ Buenos Aires, RA-1195 Buenos Aires, DF, Argentina	University of Buenos Aires	Pineiro, DJ (corresponding author), Univ Buenos Aires, RA-1195 Buenos Aires, DF, Argentina.								0	2	2	0	0	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	MAY 20	1999	340	20					1553	1553		10.1056/NEJM199905203402005	http://dx.doi.org/10.1056/NEJM199905203402005			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	197HG	10332017				2022-12-28	WOS:000080358900005
J	Kmietowicz, Z				Kmietowicz, Z			Heart disease mortality declining with fewer and less deadly attacks	BRITISH MEDICAL JOURNAL			English	News Item																		1999, BRIT MED J, V353, P1547	1	0	0	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	MAY 15	1999	318	7194					1307	1307		10.1136/bmj.318.7194.1307	http://dx.doi.org/10.1136/bmj.318.7194.1307			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	198HR	10323802	Green Published			2022-12-28	WOS:000080418400011
J	Monath, TP				Monath, TP			Facing up to re-emergence of urban yellow fever	LANCET			English	Editorial Material									OraVax Inc, Res & Med Affairs, Cambridge, MA 02139 USA		Monath, TP (corresponding author), OraVax Inc, Res & Med Affairs, 230 Albany St, Cambridge, MA 02139 USA.							MONATH TP, 1993, AM J TROP MED HYG, V48, P274, DOI 10.4269/ajtmh.1993.48.274; Soper F.L., 1935, Q B HLTH ORGAN LEAGU, V5, P1	2	25	27	0	4	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	MAY 8	1999	353	9164					1541	1541		10.1016/S0140-6736(99)00155-5	http://dx.doi.org/10.1016/S0140-6736(99)00155-5			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	195XW	10334247				2022-12-28	WOS:000080278300003
J	O'Brien, E; Staessen, JA				O'Brien, E; Staessen, JA			What is "hypertension"?	LANCET			English	Editorial Material							AMBULATORY BLOOD-PRESSURE; NORMALITY; PAMELA		Beaumont Hosp, Blood Pressure Unit, Dublin 9, Ireland; Katholieke Univ Leuven, Hypertensie & Cardiovasc Revalidatie Eenheld, Louvain, Belgium	KU Leuven	O'Brien, E (corresponding author), Beaumont Hosp, Blood Pressure Unit, Dublin 9, Ireland.		Staessen, Jan A/A-1065-2011	Staessen, Jan A/0000-0002-3026-1637				Chalmers J, 1999, J HYPERTENS, V17, P151; IMAI Y, 1993, HYPERTENSION, V22, P990; *JOINT NAT COMM PR, 1997, ARCH INTERN MED, V157, P2443; Mancia G, 1995, J HYPERTENS, V13, P1377; Nielsen PE, 1995, AM J HYPERTENS, V8, P978; O'Brien, 1998, Blood Press Monit, V3, P131; OBRIEN E, 1991, J HYPERTENS, V9, P355, DOI 10.1097/00004872-199104000-00007; OBRIEN F, 1995, BLOOD PRESSURE, V4, P256; PICKERING T, 1995, AM J HYPERTENS, V9, P1; Sega R, 1997, HYPERTENSION, V30, P1; Staessen, 1996, Blood Press Monit, V1, P13; Staessen JA, 1996, NEPHROL DIAL TRANSPL, V11, P241, DOI 10.1093/oxfordjournals.ndt.a027247; STAESSEN JA, 1994, J HYPERTENS, V12, pS1; Staessen JA, 1997, HYPERTENSION, V29, P30, DOI 10.1161/01.HYP.29.1.30	14	25	25	0	1	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	MAY 8	1999	353	9164					1541	1543		10.1016/S0140-6736(99)00157-9	http://dx.doi.org/10.1016/S0140-6736(99)00157-9			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	195XW	10334248				2022-12-28	WOS:000080278300004
J	Strachan, DP				Strachan, DP			Lifestyle and atopy	LANCET			English	Editorial Material							HAY-FEVER; PREVALENCE; CHILDREN; SIZE		St Georges Hosp, Sch Med, Dept Publ Hlth Sci, London SW17 0RE, England	St Georges University London	Strachan, DP (corresponding author), St Georges Hosp, Sch Med, Dept Publ Hlth Sci, London SW17 0RE, England.							Bjorksten B, 1999, LANCET, V353, P167, DOI 10.1016/S0140-6736(05)77212-3; Braun-Fahrlander C, 1999, CLIN EXP ALLERGY, V29, P28, DOI 10.1046/j.1365-2222.1999.00479.x; Heinrich J, 1998, AM J PUBLIC HEALTH, V88, P1319, DOI 10.2105/AJPH.88.9.1319; Kramer U, 1999, LANCET, V353, P450, DOI 10.1016/S0140-6736(98)06329-6; Matricardi PM, 1997, ALLERGY, V52, P879, DOI 10.1111/j.1398-9995.1997.tb01246.x; STRACHAN DP, 1989, BRIT MED J, V299, P1259, DOI 10.1136/bmj.299.6710.1259; Strachan DP, 1997, J ALLERGY CLIN IMMUN, V99, P6, DOI 10.1016/S0091-6749(97)81038-X; Strachan DP, 1997, CLIN EXP ALLERGY, V27, P235; von Mutius E, 1998, LANCET, V351, P862, DOI 10.1016/S0140-6736(97)10100-3; Yobo EODA, 1997, THORAX, V52, P161, DOI 10.1136/thx.52.2.161	10	30	31	0	2	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	MAY 1	1999	353	9163					1457	1458		10.1016/S0140-6736(99)90038-7	http://dx.doi.org/10.1016/S0140-6736(99)90038-7			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	195XV	10232306				2022-12-28	WOS:000080278200003
J	Gerszten, RE; Garcia-Zepeda, EA; Lim, YC; Yoshida, M; Ding, HA; Gimbrone, MA; Luster, AD; Luscinskas, FW; Rosenzweig, A				Gerszten, RE; Garcia-Zepeda, EA; Lim, YC; Yoshida, M; Ding, HA; Gimbrone, MA; Luster, AD; Luscinskas, FW; Rosenzweig, A			MCP-1 and IL-8 trigger firm adhesion of monocytes to vascular endothelium under flow conditions	NATURE			English	Article							LEUKOCYTE ADHESION; CHEMOATTRACTANT PROTEIN-1; CHEMOTACTIC CYTOKINES; APOLIPOPROTEIN-E; CC CHEMOKINES; IN-VITRO; CELLS; ATHEROSCLEROSIS; MICE; ALPHA-4-BETA-1	Monocytes contribute to the development of atherosclerotic lesions in mouse models(1-3), The chemoattractant proteins (chemokines), monocyte chemoattractant protein-1 (MCP-1) and interleukin-8 (IL-8), are found in human atheroma(4,5), and mice lacking receptors for these chemokines are less susceptible to atherosclerosis and have fewer monocytes in vascular lesions(6,7). Although MCP-1 has a powerful effect on monocytes, IL-8 is thought to act predominantly on neutrophils and it is unclear how it could recruit monocytes(6,8). Here we investigate the ability of chemokines to control the interaction of monocytes under now conditions with vascular endothelium that has been transduced to express specific leukocyte-adherence receptors. We find that MCP-I and IL-8 can each rapidly cause rolling monocytes to adhere firmly onto monolayers expressing E-selectin, whereas related chemokines do not. These effects do not correlate with either the induction of a calcium transient or chemotaxis. We conclude that chemokines are important modulators of monocyte-endothelial interactions under now conditions. Moreover, our finding that IL-8 is a powerful trigger for firm adhesion of monocytes to vascular endothelium reveals an unexpected role for this chemokine in monocyte recruitment.	Massachusetts Gen Hosp, Cardiovasc Res Ctr, Boston, MA 02114 USA; Massachusetts Gen Hosp, Div Cardiol, Boston, MA 02114 USA; Harvard Univ, Sch Med, Boston, MA 02114 USA; Massachusetts Gen Hosp, Infect Dis Unit, Boston, MA 02114 USA; Brigham & Womens Hosp, Dept Pathol, Div Vasc Res, Boston, MA 02115 USA; Tokyo Med & Dent Univ, Med Res Inst, Tokyo, Japan	Harvard University; Massachusetts General Hospital; Harvard University; Massachusetts General Hospital; Harvard University; Harvard Medical School; Harvard University; Massachusetts General Hospital; Harvard University; Brigham & Women's Hospital; Tokyo Medical & Dental University (TMDU)	Rosenzweig, A (corresponding author), Massachusetts Gen Hosp, Cardiovasc Res Ctr, Boston, MA 02114 USA.		Rosenzweig, Anthony/AAD-7893-2019; Luster, Andrew/ABE-6504-2020	Luster, Andrew/0000-0001-9679-7912				BAGGIOLINI M, 1994, ADV IMMUNOL, V55, P97; Berkhout TA, 1997, J BIOL CHEM, V272, P16404, DOI 10.1074/jbc.272.26.16404; BEVILACQUA MP, 1987, P NATL ACAD SCI USA, V84, P9238, DOI 10.1073/pnas.84.24.9238; Boisvert WA, 1998, J CLIN INVEST, V101, P353, DOI 10.1172/JCI1195; Boring L, 1998, NATURE, V394, P894, DOI 10.1038/29788; CHUNTHARAPAI A, 1994, J IMMUNOL, V153, P5682; FALK W, 1980, J IMMUNOL METHODS, V33, P239, DOI 10.1016/S0022-1759(80)80014-7; Fazio S, 1997, P NATL ACAD SCI USA, V94, P4647, DOI 10.1073/pnas.94.9.4647; Gerszten RE, 1998, CIRC RES, V82, P871; Gerszten RE, 1996, CIRC RES, V79, P1205, DOI 10.1161/01.RES.79.6.1205; GRABER N, 1990, J IMMUNOL, V145, P819; Jones KA, 1998, NATURE, V396, P674, DOI 10.1038/25348; KOCH AE, 1993, AM J PATHOL, V142, P1423; LUSCINSKAS FW, 1991, J IMMUNOL, V146, P1617; LUSCINSKAS FW, 1994, J CELL BIOL, V125, P1417, DOI 10.1083/jcb.125.6.1417; LUSCINSKAS FW, 1996, J IMMUNOL, V156, P326; NELKEN NA, 1991, J CLIN INVEST, V88, P1121, DOI 10.1172/JCI115411; Premack BA, 1996, NAT MED, V2, P1174, DOI 10.1038/nm1196-1174; SCHRODER JM, 1987, J IMMUNOL, V139, P3474; SHEN J, 1992, AM J PHYSIOL, V262, pC384, DOI 10.1152/ajpcell.1992.262.2.C384; SMITH JD, 1995, P NATL ACAD SCI USA, V92, P8264, DOI 10.1073/pnas.92.18.8264; SPRINGER TA, 1994, CELL, V76, P301, DOI 10.1016/0092-8674(94)90337-9; Suzuki H, 1997, NATURE, V386, P292, DOI 10.1038/386292a0; TAICHMAN DB, 1991, CELL REGUL, V2, P347, DOI 10.1091/mbc.2.5.347; Weber C, 1996, J CELL BIOL, V134, P1063, DOI 10.1083/jcb.134.4.1063; WHEELER ME, 1988, J CLIN INVEST, V82, P1211, DOI 10.1172/JCI113718; WOLDEMARCARR M, 1996, IMMUNITY, V4, P179; Yoshida M, 1998, J IMMUNOL, V161, P933; YOSHIMURA T, 1987, P NATL ACAD SCI USA, V84, P9233, DOI 10.1073/pnas.84.24.9233	29	1016	1059	1	60	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	APR 22	1999	398	6729					718	723		10.1038/19546	http://dx.doi.org/10.1038/19546			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	189RP	10227295				2022-12-28	WOS:000079920100053
J	Nightingale, SL				Nightingale, SL			Electronic "Orange book"	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	News Item									US FDA, Off Hlth Affairs, Rockville, MD 20857 USA	US Food & Drug Administration (FDA)	Nightingale, SL (corresponding author), US FDA, Off Hlth Affairs, Parklawn Bldg,5600 Fishers Ln, Rockville, MD 20857 USA.								0	0	0	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAY 5	1999	281	17					1580	1580		10.1001/jama.281.17.1580	http://dx.doi.org/10.1001/jama.281.17.1580			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	191MJ	10235141				2022-12-28	WOS:000080025900008
J	Nightingale, SL				Nightingale, SL			Dietary supplement labeling more informative	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	News Item									US FDA, Off Hlth Affairs, Rockville, MD 20857 USA	US Food & Drug Administration (FDA)	Nightingale, SL (corresponding author), US FDA, Off Hlth Affairs, Parklawn Bldg,5600 Fishers Ln, Rockville, MD 20857 USA.								0	0	0	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAY 5	1999	281	17					1580	1580		10.1001/jama.281.17.1580	http://dx.doi.org/10.1001/jama.281.17.1580			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	191MJ	10235141				2022-12-28	WOS:000080025900009
J	Raju, TNK				Raju, TNK			The Nobel chronicles - 1952: Selman Abraham Waksman (1888-1973)	LANCET			English	Article									Univ Illinois, Chicago, IL 60680 USA	University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital	Raju, TNK (corresponding author), Univ Illinois, Chicago, IL 60680 USA.								0	4	4	0	3	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	MAY 1	1999	353	9163					1536	1536		10.1016/S0140-6736(05)67238-8	http://dx.doi.org/10.1016/S0140-6736(05)67238-8			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	195XV	10232360				2022-12-28	WOS:000080278200072
